<SEC-DOCUMENT>0001659617-19-000169.txt : 20191112
<SEC-HEADER>0001659617-19-000169.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112063149
ACCESSION NUMBER:		0001659617-19-000169
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		191205906

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mbx-20190930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2019 Workiva--><!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286,d:a5bb90565baf434aa9785421b07d4d24--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:mbx="http://www.moleculin.com/20190930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMC0xLTEtMS0w_8b8cf685-1f5f-42be-a997-c033603a190b">2019</ix:nonNumeric><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMS0xLTEtMS0w_39651c65-69c6-43ad-9f92-90b656740229">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMi0xLTEtMS0w_16c42b14-49e4-439a-b131-b3e54839f4cd">false</ix:nonNumeric><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGV4dHJlZ2lvbjpmMzZhZmFlNWE5Yjc0YWEwOWVkOWI0MWYzZjU3YTgyMF84Mg_66f10d07-fd36-4354-90a2-2284a3340239">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGV4dHJlZ2lvbjpmMzZhZmFlNWE5Yjc0YWEwOWVkOWI0MWYzZjU3YTgyMF84Mw_c0218a15-4c47-4958-9224-bbd106ec48b3">0001659617</ix:nonNumeric><ix:nonNumeric contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY0OTI2NzQ1NjEzNg_c203f143-78a7-490e-b73e-32b489147d7d">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="if6aba8c1ca904a9bbabe93cdea1880d0_D20170729-20170729" name="mbx:ClassofWarrantorRightAgreementPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzcyMQ_9e5789a7-6205-4556-8350-0fb32f1e123d">P12M</ix:nonNumeric><ix:nonNumeric contextRef="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729" name="mbx:ClassofWarrantorRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODM2NQ_0243ffb2-eae1-40d2-9343-bc1cb403c4d5">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i06a1277d53a849948a8725927997052c_D20190708-20190708" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTE4MQ_bd9f0e14-58b3-4547-8588-62c23121c211">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" name="mbx:ClassOfWarrantOrRightInitialExercisePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAzNTE_dc4c3f39-7e46-4a6e-916d-e8c0623716e3">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA1NTQ_b2561df1-708d-4b79-82bd-4bfa1c75f45e">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i816a05948bde4ad3ab07190983382b45_D20160501-20160531" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjk1NQ_b57729a6-ddb3-4566-b0b4-be41f4b8b523">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502" name="mbx:LicensingAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgxOQ_a802d1b7-06a0-4544-aeec-9aa89cbf575a">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mbx-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7c85ac00e67c48559bae7aff48334e41_I20191108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i658888d65697477c8bdf7f277240e630_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ab107b4fc145aa9e410c1077fc257f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i114bd5e9a8244f23bea013dccf03d439_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a5d43efb884dd483ae1a865e745eba_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd2efefa5274aa1a8f2a55f0852dd1a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f67e63bde64896b6be0cd287af8360_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74fa480b48548fcb3f47ebd9af912da_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e191fc355f64d22a595d839903d46d5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c767c50b21430cbcb5d42f9d4fd136_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb8fc5d43ae43fca34bb33ecfcdf46c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a8d3d8b10b4b7e8f4bd5b548ead03e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie983009200a54629a89ffbfa2cb7f380_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc0d29d80ec4048ad2f652630bde7da_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbdd2af8e4d642e1b38acd3209e7555d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0ff7a1031f4a39b51e586b6cd222d6_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ded679e60bf43f8a1f4e944669f3068_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if283467953714adaa4dbed6b2b274c45_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaafa1f6602348a5b935698ec678c979_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b4e969450c437790071f03f750f80e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d0afcd4335499d9e893ac0fe43a745_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acb7f4d36654d6aaa455805fd5c6315_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978af72bda7f4cdd9be415879b75924c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia243c08879a44b0faf74e1d1174ed227_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0247f93d3c7f48b79cc2f61f28823bc3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d99b3bb92ec4d6ba3098d7f73a6bceb_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e90206e9605402a8453b05d60c725f1_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb6cf7dac114e15b0924f118be98bfc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10dbdf0540504f7ab8fc60ae4a1261b0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d43a3d31a684c7898dc1177b7e32f2c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f0a67ae93e4a0fbe9ed5c48e3b8c58_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6b42302d064af99a04ff7719b2ffe4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5d1f7a1ea941aeb1aebd6c4114bfb5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0b19ebdcf34ae2bd120ba45f2990ba_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a013c63ce649f6adc0f00d0053d9e8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i511e28680ebf4b96856998ec784196c8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c10695ca664bf5ba8f73db1e940f69_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6198e1f6f1d940ba8beb2aa6c66ee4ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66751d7b8a8046c5870329c2d7f9b432_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i698da61e696241338dc1d0d51f6ee26f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b54a748ee7147f8960b4e3c01fda1b5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f912538dc243708b1c08523fce0322_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3883a699ce4e02b970417d508d4ad7_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca2487f82e44a2d874e72ac389555e3_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb5c9e8ad114039be905d2ce6a2f928_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1499fe2de067467d92d06bf6af15d71f_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1a22242df74771b68a9b7d49a044ea_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993b33833a034e6287f0b8bca653f504_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019f3c2995584a11884f6a959327107e_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if668eee949014fecb89a24b65ff223a8_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e84c009114a45de864360cb755f97d2_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d7cce25b87468db25b99f7b4ec4a5f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11fd7e524cb4871884958f022962fd8_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74298b670ca4645ae764781cf988f36_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58e6bb80ae84986b925d657b40bd986_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf298971c424b638760ec464c4f3e3b_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f19c66cce8b4632acc641adacd87dc5_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a55ef48475e4201bc338d2dca5da777_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773749c5e55246028373864551af9e8d_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87044ed8d26543a698744dcd07920f10_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c13ec668974c76b242c324030b9a8d_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5aeb81499c4d30a2c9a5f3456dba46_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475cf3e6dd1a4bc68203346a5e4ddd00_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59c9518ea0244de9d05ecac711dafd4_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6dc0cbeab3aa44b48883e4da0862b3bf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mbx:AnimalLifeScienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="technology"><xbrli:measure>mbx:technology</xbrli:measure></xbrli:unit><xbrli:unit id="candidate"><xbrli:measure>mbx:candidate</xbrli:measure></xbrli:unit><xbrli:unit id="drug"><xbrli:measure>mbx:drug</xbrli:measure></xbrli:unit><xbrli:unit id="clinicaltrial"><xbrli:measure>mbx:clinicalTrial</xbrli:measure></xbrli:unit><xbrli:unit id="project"><xbrli:measure>mbx:project</xbrli:measure></xbrli:unit><xbrli:context id="ibaa5d1878a8449bbbfb93f6bcb30609b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ec7928d44f45ea880ca27fb60483ae_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mbx:AuthorityAxis">mbx:FoodAndDrugAdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mbx:segment</xbrli:measure></xbrli:unit><xbrli:context id="id7d483fa5b8b4a508aa8033181369c0b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb53084bb5d5439da0fc3b7ce0bac811_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd7f29a819443ba880b572c77f75db8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ba623e5dc34281830bac2c5b222d0b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d184260db97490785df4ce8f01a87f4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb96a49c87b43728767fc948cbd81a0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e02f1d5e0b843aa9cefaba9fe3c4bd4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010c1a26c61e446aadddfcdda2856af2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbd36b98aa84664bebd964e031364e7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285e6798fd8943ccb8ce51b198c79b4c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ffd58e0885541359bfea5e4d56a4af2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3707bb56148497495ea24016f264a35_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib34e1490cda548bdaab67ad8ede83e51_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833cbb966fe54a1dbf89b625b300e6a7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57abc24e231945ddb977a7587f1bc971_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7f1136ba8448bfa401f14716d6bdc5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i219719edc1b9438090dbeae77bf96672_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdda18b689c40d8a99d07a7fce046cd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8704f5f266694aa9b6f1e5fc38343f5f_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0764deeff02e4de2af7c0933afdb419b_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828883bbb66748609912c14fccab2dc0_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7679c4528b848609353c11a6dc439fd_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fdd5e53f5094aada2975171e573b157_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca157a098ae4304a258adc86a04a5b6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cab3276359415a9615b407edca1b58_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id58152a5a8294f01b352ea46be89ca0e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3468782c8cf7406292dddbcdcb10f2e6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b3edd6398a45bfa280974c3f953e3e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdddec1576174893ac672d9353477c60_I20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e01f1ab9534250ba00bf6fed63b50e_D20190425-20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-25</xbrli:startDate><xbrli:endDate>2019-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca03e3808584abfb0298f0b407b56ac_I20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwitersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04057d9a2fc47f59c529617eb6148da_I20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff20b788d224ad3a44277ae0c89865e_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa81cbdf3044194a501897570de6f30_I20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwitersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic650d629ddbe42bba07cd7284425b9cb_D20181004-20181004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-04</xbrli:startDate><xbrli:endDate>2018-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b95e4a080574cb187b7baa5845b5bc7_D20181004-20181004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-04</xbrli:startDate><xbrli:endDate>2018-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-04</xbrli:startDate><xbrli:endDate>2018-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0294ca4bdf04a0a9eca45bd94dea472_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38daafc04f49458db341d48f10e1fbe3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af2bc87c2d14e3faa7aa256386e955c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6670a76fcc104cb499360b871805a581_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b480bb73120461ead91f6bfb97297dc_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5395f33565804b6db870e49ee1f42631_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OppenheimerCoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbdedafb3e34aa6ae001a6d102bb5ea_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OppenheimerCoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944e3ebf4e3447758b5f5ad06e16b8d3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mbx:StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11172b4c23840729a0c55b50453ef6b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c80993834594538b743751a71aac719_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c39d2de985d4affbdbb368f73d64943_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80a49b1ac35464ca409df350165e50c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c2d53697dc4799b0f1c3663013ed3f_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7f681b9d1a4c9a9ea32d44511a7e37_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic732ea1178074f47a9dc97cb065ced73_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0f11dd922044268e807fecd4317991_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13547ca083ed457da93a472804befa90_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d423e14ef8484ca70b7db69ffb12f3_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3d37009bad40bcbbe66bfb5272cfd4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie587b47ea845420dab0c9acddca354f8_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cfe79a8ccc44f1a1b37b902e2066fa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e6f95a02bb48c59456c43de158162f_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bbd1cc266d4e28b55786247b4551ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6aba8c1ca904a9bbabe93cdea1880d0_D20170729-20170729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-29</xbrli:startDate><xbrli:endDate>2017-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9663d77efe491f97c917d37bd60486_I20170729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd06781e67be410c92ac95aa2495a7db_I20170729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:GSKConsultingAgreementWarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e838cce41cb48e980a2b72acf45b359_I20170729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:GSKConsultingAgreementWarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-29</xbrli:startDate><xbrli:endDate>2017-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia621ad5cb56b4f519b43b8d05d571153_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:ConsultingAgreementWarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice90c9c153c9457994fb3428ae482f66_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:ConsultingAgreementWarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a1277d53a849948a8725927997052c_D20190708-20190708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-08</xbrli:startDate><xbrli:endDate>2019-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3cdb4704f2241f7bf6422f7e0974142_I20190708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1792812536944689b19b7c33818e27e0_I20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743b8f15d1954cd1977b8bf32aa43aa0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8aa13f97f5742a3afa1fb7e64d1af57_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbda1bd25cd4cd7ab24c983a3515b9e_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11095fb1fa8d4f1a99847b1a8454b970_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63863dee744943d8b707c78817d930ed_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1617ea995ee541e797427260cfd1509c_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31991190cd3e40a2857e50efaa21c859_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db6bce61f314f58ae7094418825cba1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5f752a87a043319ef30dc7b1278714_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676b8255b2e542be8196edfc27042486_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816a05948bde4ad3ab07190983382b45_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3b7c28de3e409ab196587e0ef6e3b9_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife26a4e6c9db456586eec4fb4d9b4058_I20180322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cccf3548364065976506f8bb9f0ce0_D20180322-20180322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-22</xbrli:startDate><xbrli:endDate>2018-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2aeadcc3b7480899be3e16b8a13854_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b329d2fb15249cbabe0efe9cfb5aa8a_D20190831-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-31</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia823a60ecb104dedb9bf6190868e582c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c8d7aea62b452da49a9315e073e07a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i664f42f1665c485c853202fc74ba4d18_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d94dee648346efb077db14d8fbd8ec_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c55769a2d6349beb36762d47f51c0ae_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbx:SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3bb46bfb304e42ab171f7dfca58b9c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec29135c33746a293feac556994b9e6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490694ff28c945c0970bd1b5b00026d8_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f36e65608b4660897d32d69ff25cdb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb689274badf4dc5ba81def9e3ba4777_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-02</xbrli:startDate><xbrli:endDate>2016-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2399e296e4074ad8812022575df5b89e_D20190430-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea85e97e50094e9d81434a25899adfb3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie435b286972e4f7ea765d0391fbceef7_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03cfdc63ce24474c9076a3ed88c23973_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf0e3597d934e9c84c3d513f1c63b8c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921f1f39a083428c9445130e7d4459eb_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442d97ffc8c34dfdb6c0f85109bcfe82_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4177a6893406483a97433eb0e53c41da_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd4d78cf6204458b1ee511c741627f6_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84dd43168aa14c0ba971eed3e33aab51_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aabb04846bf431c9fecd7123d274260_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b81d0dea25642c59af5126ab6197c98_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1546f03b3854c86bdcc7ffe18a533ef_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb95c8a4307d477fb7b1a627137efc1d_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic028dc6b564848f8a736e7c1a222fe61_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213f24715e7642f782c9022686a24919_I20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13dfe851934d44768ccba995e1db6556_D20190219-20190219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892ca0d0325349b29aa4133a6747e7f1_I20190219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mbx:PeriodAxis">mbx:PeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c05bdb824e4b5aa9eb2f176d9c0de9_I20190219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mbx:PeriodAxis">mbx:PeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV84NA_51db8a03-7574-493e-a6e8-bf33350edd0b">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;<ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8xMDk5NTExNjMwMDg4_9ff240c7-d7f6-44b2-8dd8-380a52c008df">&#9746;</ix:nonNumeric>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:80%;">For the quarterly period ended <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDk_4b1e23dc-e843-4249-8ef3-8ac01d60f825">September 30, 2019</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:80%;">&#160;or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE4_a241b419-26e1-448d-843e-d11197e809ce">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEy_22618a2c-3a08-43ac-87db-943ddf54dc45">001-37758</ix:nonNumeric></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><img src="mbx-20190930_g1.jpg" alt="mbx-20190930_g1.jpg" style="height:62px;width:228px;"/></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:31.480176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.452276%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.599119%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:14pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8wLTAtMS0xLTA_05bd9c02-f985-44a4-9b1a-46831c81bd7e">MOLECULIN BIOTECH, INC.</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Exact name of registrant as specified in its charter)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8yLTAtMS0xLTA_0df36d13-6075-4cc4-be7e-5dce95f11484">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2834</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8yLTQtMS0xLTA_3e62de46-b0d4-4720-9acd-1d94ad7f1d4e">47-4671997</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Primary Standard Industrial</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Classification Code Number)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(IRS Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl80LTAtMS0xLTA_d5bfba2b-8831-42a6-ae52-61171c6b4714">5300 Memorial Drive,</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl80LTItMS0xLTA_3d1b2a0b-e379-4f66-aafd-1ad2ba183ea6">Suite 950</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTAtMS0xLTA_fed3e04b-4cca-42dc-96e4-445a3f892294">Houston</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTItMS0xLTA_edd679b5-2e36-43b2-96fa-31a9df03c2ba">TX</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTQtMS0xLTA_8565cd85-de73-4762-89c9-28d062b427d4">77007</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Address of principal executive offices)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Zip Code)</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDA3_4bd96ad6-e583-401e-80e8-90dbd118daeb">713</ix:nonNumeric>-<ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE5_bddac13f-dfed-4896-9175-30ad73312d2d">300-5160</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEz_dac009d8-9408-426e-99ba-ff44bd392db7">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9746; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDA5_8376303d-e954-494a-afdd-b658126264be">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9746; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:31.627019%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.298091%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.074890%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Large accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Smaller reporting company <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8wLTItMS0xLTAvdGV4dHJlZ2lvbjplYWEyNDAzYjNhMDY0NjYxYmUwYjEyZjk5OGYyZGYxYl8zMQ_5350472c-e4c5-4fee-abe7-463bafebb1f9">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8xLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTJiMGIxYTZiOTg0NmNmODhmZTMyZjRjZmZlMjk5Zl81_9e94e928-ba5b-415f-bfb7-4873d478881b">Non-accelerated filer</ix:nonNumeric>   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Emerging growth company <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8xLTItMS0xLTAvdGV4dHJlZ2lvbjoxMzM2ZmY3MTdjNjE0MmE1YmZiMDUxNDhlMjAzYjA0MF8yOQ_bc0b8982-0164-4e8f-83f3-e4808c207afd">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEx_b96bc152-3c8c-4cce-9276-ce3b9ebcc7cc">&#9746;</ix:nonNumeric></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE0_47ebc022-1d04-4631-b751-f945666e1c30">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:33.233918%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.584795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.181287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol (s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTAtMS0xLTA_9aea3db1-fadd-47b6-a404-dfcf98594068">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTEtMS0xLTA_6696516f-f362-46fb-b5d2-bde7e8db8846">MBRX</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTItMS0xLTA_2d2b8033-d3d4-4225-bb42-67b74b87ffc4">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The registrant had <ix:nonFraction unitRef="shares" contextRef="i7c85ac00e67c48559bae7aff48334e41_I20191108" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8xOTUw_ca759fb7-62aa-4ff8-8663-32ff1845b923">45,727,700</ix:nonFraction> shares of common stock outstanding at November 8, 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_7"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:6.040936%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:77.239766%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Page</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_10">PART I &#8211; FINANCIAL INFORMATION </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Condensed Consolidated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Condensed Consolidated Statements of Stockholders'</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Equity for the Three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> Months Ended September 30, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55">M</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55">anagement's</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55"> D</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55">iscussion</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55">and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_55">24</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_70">Q</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_70">uantitati</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_70">ve and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_70">36</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">C</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">ontrols and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">37</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_76">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_76">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_79">L</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_79">egal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_79">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_82">R</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_82">isk </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_82">Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_82">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">U</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">nregistered sales of Equity Secur</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">ities and Uses of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">D</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">efaults </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">M</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">ine Saf</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">ety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">O</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">ther Info</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">rmation</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94"> </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">E</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">xhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">40</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">S</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">ignatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">41</a></span></div></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART 1 FINANCIAL INFORMATION</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div id="i_0_13"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item 1. Financial Statements</span></div><div id="i_0_16"></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except for share and per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:66.567251%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.350877%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.350877%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNC0xLTEtMS0w_bfdadb76-b532-4377-9f5c-f7b26aadbaa7">15,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNC0zLTEtMS0w_921ff6d5-40e8-4f7e-8772-1dfd6395d45d">7,134</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNS0xLTEtMS0w_b187c732-6008-4a9e-9efa-b3a3679dd696">3,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNS0zLTEtMS0w_dcf4f5ef-dee7-4ce4-b045-a87c586cd4d4">840</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNi0xLTEtMS0w_24bf3997-e60d-4e5a-b0fb-4e4835d10bcf">18,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNi0zLTEtMS0w_0e411368-71f6-41cd-92f5-46a715bf85fb">7,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNy0xLTEtMS0w_d52a189b-880f-499d-8993-73d0d507d70b">358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNy0zLTEtMS0w_262ec169-1ca6-4553-90dc-d8c6037cea04">463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOC0xLTEtMS0w_6ee8bf7b-bb9d-4816-b910-a8ad6917b0f5">11,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOC0zLTEtMS0w_0be550f6-53e9-4b32-b72e-3c1e3455fe18">11,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOS0xLTEtMS0w_29305dc8-13f9-42ad-85ce-dfa20b9e9942">306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTAtMS0xLTEtMA_66056f2a-a960-42fe-8790-e726d1d30db0">30,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTAtMy0xLTEtMA_516666cf-37eb-47fe-a311-198f28c9b0ef">19,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTMtMS0xLTEtMA_f8a44b18-aaf3-46c1-a72e-d9b30f81fd93">3,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTMtMy0xLTEtMA_d242a3bb-1eb6-49d8-b372-60de37156f00">1,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTQtMS0xLTEtMA_2fffdae7-dba2-42bf-a177-4f9ae4c728ad">1,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTQtMy0xLTEtMA_7b1c59f8-7117-494d-804b-efec9e2bc0c7">2,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Warrant liability - current</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTUtMS0xLTEtMA_81364296-ed9a-4d73-af08-46fdae9fe7b9">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTUtMy0xLTEtMA_84fbe966-230b-4d89-8bae-8312ca446da6">180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTYtMS0xLTEtMA_0c0dbee5-53f9-40a0-ac3f-c4fcbde5e577">11,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTYtMy0xLTEtMA_382b6959-f8c6-4afe-b15a-01bce7c86088">3,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability - long-term, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTctMS0xLTEtMA_4ad26483-656a-4f58-88e0-de2fcecf8f98">304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Deferred rent - long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTgtMy0xLTEtMA_e879e2a0-0239-4ef8-be60-6a05b1951aa7">107</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Warrant liability - long-term</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTktMS0xLTEtMA_f3db1de0-b39f-488e-8074-2f062ceecbb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTktMy0xLTEtMA_c1a65b8e-bb7d-4fe6-aa7a-c531f9279a2b">1,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjAtMS0xLTEtMA_6d8e8d44-4d07-4fa5-80ea-292c96153bfc">11,423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjAtMy0xLTEtMA_04036a8e-233a-4021-a727-9576664bd68f">5,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjEtMS0xLTEtMA_5e6153b5-6cbf-4141-9875-9dfedcc8422a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjEtMy0xLTEtMA_8787a052-a933-48a1-8c0a-f3de38afa233"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzIx_65dffff2-bf22-4d47-9f03-2fb2c307a846"><ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzIx_fd20fa64-fcc7-4f39-a3a5-bdf8722ab934">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzM1_835eea53-16a3-48de-a73c-7a467dae2882"><ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzM1_ee2b9a3a-ef92-44ac-8183-dacbf4291f67">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_0cae8c65-9a15-4a05-9d19-ef460fbc24e3"><ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_256c39fd-3dca-448e-9337-bd7035ab90b3"><ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_65669ebf-28d5-4404-8853-fdd52a54787f"><ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_de1ad32e-ecf7-4fa6-86a2-daed3aceaee5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMS0xLTEtMA_6d0e40a3-c15b-42b8-9944-b8919db0ffce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMy0xLTEtMA_63a8733a-1ddb-40fc-b41e-72f6f0300833">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzE4_25c8af86-1f2e-474f-860a-01104d8b8405"><ix:nonFraction unitRef="usdPerShare" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzE4_60de7885-8a7c-44d5-997b-1f2d7bc64dac">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzMy_68963527-bb77-4d48-98e3-95133ac2d940">100,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzQw_9ca7ff38-b7f8-4e1b-8bb2-d45c8ea3151b">75,000,000</ix:nonFraction> shares authorized as of September 30, 2019 and December 31, 2018, <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzEwNA_6bdc7fe5-7a60-4849-85de-667b642a4e76"><ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzEwNA_d0031ee2-7a63-46d1-bde8-6f81b8510eac">45,727,700</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzExMQ_074101d4-b584-43b3-8d52-41e1a7b167c7"><ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzExMQ_309f6b66-04ee-40dd-8154-a8a11f1d0e9f">28,528,663</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMS0xLTEtMA_43f3e35d-97b6-4d9b-9bb3-aef7774f9882">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMy0xLTEtMA_f65e7900-2b81-4801-8773-e39fa12babaf">29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-60pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Additional paid-in capital</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjUtMS0xLTEtMA_f5b591e3-1e30-4428-8a52-f62687565e5b">54,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjUtMy0xLTEtMA_037d54bf-2377-4a12-bca9-baab9f57f830">40,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-66pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:AociBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjYtMS0xLTEtMA_cb3921a2-f83a-4749-949d-41b7872e2f7d">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:AociBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjYtMy0xLTEtMA_4ea8cb48-ca05-45d0-b246-bbf9d454aef3">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjctMS0xLTEtMA_9cd7fecb-3f06-4c6e-8658-198444e0720b">35,763</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjctMy0xLTEtMA_878986ac-dff7-4b01-af84-58f28a6548fc">26,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjgtMS0xLTEtMA_a1f8a2fb-fede-4755-8055-9f4c5687627c">18,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjgtMy0xLTEtMA_43dae111-fe73-452b-93e7-3aa53c173f5e">14,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjktMS0xLTEtMA_de97cbf3-23c0-4cbd-ba2b-8875cfd54530">30,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjktMy0xLTEtMA_d4e22bae-cc2c-4acd-a6d8-bff997593f1a">19,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_19"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514620%;"><tr><td style="width:1.0%;"></td><td style="width:42.527736%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.043478%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.849475%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.043478%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.999400%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.043478%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.849475%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.043478%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi0xLTEtMS0w_d217009e-a06c-425b-9dfd-f76aea83ca5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi0zLTEtMS0w_ba27d546-d724-42ba-97e7-fce2b0b1c194">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi01LTEtMS0w_27cab1a1-1377-4405-835f-0709a33cfcd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi03LTEtMS0w_d2cac3c1-c633-474f-ae8c-7f64c410a38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS0xLTEtMS0w_745615d6-6ef0-46ba-a78c-3060c2d79a20">2,785</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS0zLTEtMS0w_28bb8126-7660-4ccd-8383-7c84c116902c">1,332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS01LTEtMS0w_6c8fe3c7-6155-4296-b7ee-a790442b45fe">7,816</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS03LTEtMS0w_cee52483-678a-4041-9c28-a70a4df56e9e">6,801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi0xLTEtMS0w_9f027db7-1a66-4934-b322-4e382eea4426">1,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi0zLTEtMS0w_d91fddad-b640-4691-b6e3-0f1631e7f1f3">1,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi01LTEtMS0w_eed3716b-d197-4914-ab16-7df453791c12">4,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi03LTEtMS0w_21ccb9e0-ba58-47a7-9ff8-8b28bae6a31c">3,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy0xLTEtMS0w_8b0695df-550b-49c2-b2c5-0db7ec5421e8">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy0zLTEtMS0w_0e4c9a97-c416-473d-ab7b-b25e10fd0765">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy01LTEtMS0w_5abc7b89-e58d-4ffd-b43b-a1f5436106f9">147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy03LTEtMS0w_979c6f8b-95f5-4c85-85a7-16c1648dc9cc">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total operating expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC0xLTEtMS0w_c9eea410-f66d-4414-8ba3-4bac18c0c84c">4,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC0zLTEtMS0w_530a783e-a5c4-4163-94f3-3ceb20568bbb">2,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC01LTEtMS0w_73b7a3a5-e801-4515-a4a6-71eb5b78322f">12,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC03LTEtMS0w_05379d23-acf8-4ec1-853a-04c9b7eb5179">10,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS0xLTEtMS0w_da491248-8b7b-4bf4-bf73-eb718e7c0983">4,508</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS0zLTEtMS0w_66618bea-a633-4806-8499-9fa0ba294fc2">2,591</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS01LTEtMS0w_4a308744-fe4d-4872-b908-b807772de980">12,711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS03LTEtMS0w_05193aae-7d65-4d68-b73e-45baf9e64381">10,687</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Gain from change in fair value of warrant liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtMS0xLTEtMA_e08c2f33-3ea9-43d4-8570-e39fcd46d0a7">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtMy0xLTEtMA_490d0078-7f4e-411e-a81d-c6f59e1422fe">573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtNS0xLTEtMA_5c4614a2-ffaa-4a5e-9f44-ca343e0c1414">3,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtNy0xLTEtMA_b49c76ae-7c27-48a6-a825-6a6f7ed6db9f">1,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItMS0xLTEtMA_39c37b5c-6c22-4b3d-90de-0e400dbd59a4">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItMy0xLTEtMA_a66ee6bd-d5ba-4984-8404-21b87dd42710">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItNS0xLTEtMA_cee12729-2e64-45b3-bc39-949024eeb5f6">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItNy0xLTEtMA_412d9899-f455-4e09-b5db-e07273ebf7d5">23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtMS0xLTEtMA_5dc1f2bd-07e5-45e2-b270-76a914ef2192">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtMy0xLTEtMA_fc3d4086-284d-443b-b175-efe27a1c45b4">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtNS0xLTEtMA_78e6d44a-2e40-4b97-8efe-7e86ae240353">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtNy0xLTEtMA_c764b98b-77bc-4847-9c02-4f4731c77bdb">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss before taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtMS0xLTEtMA_4930c734-5974-4939-b8c6-f2e169e280d0">4,374</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtMy0xLTEtMA_0930947e-733a-430c-b407-27c61a8e3ee0">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtNS0xLTEtMA_a366fb4f-2a9c-4472-8312-4e43f1932f06">9,637</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtNy0xLTEtMA_5e763ed4-7234-4350-b08d-5f50d479d0c4">9,091</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtMS0xLTEtMTEzNA_94e512dc-bbaa-4239-b451-0f451c773b91">229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtMy0xLTEtMTEzNw_c0bca9b9-b84e-4adf-9758-c2ad487aa194">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtNS0xLTEtMTE0OQ_8e0afe20-a2b3-41e7-ab8b-3b2eb9506231">229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtNy0xLTEtMTE0OQ_2971d1cf-3bf6-41e9-b2a3-883d70c77098">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMS0xLTEtMTE1Mw_04ec1ae3-b2cb-4d4e-ac86-dbc9d44b72ce">4,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMy0xLTEtMTE1Mw_9a6b1abe-148f-4f32-a4ca-4b1bf06a0907">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNS0xLTEtMTE1Ng_beea93ea-dad0-4878-8733-8b5b7cace53d">9,408</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNy0xLTEtMTE1Ng_a19f63ae-f36f-4f25-b9e1-9c4fba698d8f">9,091</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share - basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMS0xLTEtMA_5342f74d-4d0f-44a6-8ed5-081d52ef992c">0.09</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMy0xLTEtMA_bcec5026-7c5c-46ce-b21c-9ccbd5be1352">0.08</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNS0xLTEtMA_0b9bb060-2dbc-4116-a62e-8fb1643a393d">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNy0xLTEtMA_c18324bb-f2d0-4afd-9cef-c949f7a14cd5">0.36</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding:                Basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctMS0xLTEtMA_59bb526b-0ffe-413c-b81e-03ee791a0f70">45,464,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctMy0xLTEtMA_1ea6f21e-008f-4ee9-82b6-9d84b0871b06">26,861,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctNS0xLTEtMA_8fe15be2-bca0-4bc1-9b3c-26a8096179b7">39,034,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctNy0xLTEtMA_6b7cac4a-e38c-4585-b85e-60e9734bb3a2">25,373,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktMS0xLTEtMA_2aa8e154-12a6-4b58-957b-8faf64fd9076">4,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktMy0xLTEtMA_2519b77b-073c-4037-8f7c-16c64a62b8fe">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktNS0xLTEtMA_3c16bfc8-4daa-43f8-935a-3d60c04309a3">9,408</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktNy0xLTEtMA_f3671904-63f3-4dec-9b00-0e1fe9ab0def">9,091</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Foreign currency translation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtMS0xLTEtMA_d198c995-8795-4db5-870a-a766868a1ee8">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtMy0xLTEtMA_6f033a20-86c4-4631-82fb-5c98b6951b99">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtNS0xLTEtMA_4df5161f-5bf5-460a-950e-c238d98d078f">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtNy0xLTEtMA_2bc63cb8-96ca-44ef-836d-0f89f5b1d0be">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItMS0xLTEtMA_1ffcdf0a-d886-4b32-ba72-ef0cd1b9232a">4,148</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItMy0xLTEtMA_da9de453-836b-41cc-9b37-8d0fccee3b4e">2,023</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItNS0xLTEtMA_aa3a975c-6bfa-4ada-860f-3ae8f5231b17">9,424</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItNy0xLTEtMA_33e367db-7dcd-4821-b908-7b9a8622da3b">9,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div id="i_0_22"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">  Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391813%;"><tr><td style="width:1.0%;"></td><td style="width:67.390788%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.007429%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542942%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.858841%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMy0xLTEtMS0w_1f314181-c1e0-4840-8340-708b94b2b3df">9,408</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMy0zLTEtMS0w_d152d318-e6cd-4eb6-b2ad-7999a6d8ca50">9,091</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNS0xLTEtMS0w_fcd5dbff-aeaf-4ffe-9b95-8852b3a024b8">147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNS0zLTEtMS0w_3c36b8dd-00f0-4f85-8d3b-643837f98a6e">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNi0xLTEtMS0w_0b490bc4-f71e-4c80-87c3-aa088d60e67b">1,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNi0zLTEtMS0w_c4112504-b9b8-412a-8da9-b1e56aa28ba2">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">License rights expense settled in stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0xLTEtMS0xODY3_737abdb6-976f-49ef-ab73-2dba3f5a8f8a">490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0zLTEtMS0xODY3_43a05ee3-0475-4758-a11a-a172c564c077">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Gain from change in fair value of warrant liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0xLTEtMS0w_9e07e719-30e9-4e03-a0d2-12940ad105c6">3,059</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0zLTEtMS0w_baffe250-d133-4784-9957-1067c58c2bdb">1,614</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="mbx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOC0xLTEtMS0w_d2cc7ae1-a533-4b52-ab3e-4917d6daa5f9">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on foreign currency transactions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOS0xLTEtMS0w_3f3c8e0f-09a1-4b43-ad5e-36b44a5e255f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOS0zLTEtMS0w_e19bc3bb-5eec-4b00-a180-97fba9b7bd8a">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTEtMS0xLTEtMA_458dca0d-130c-42d7-8736-93b1f1f66a62">2,337</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTEtMy0xLTEtMA_2f4ee905-d352-4504-89ff-22846c4cec3b">172</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-42pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#160;Accounts payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTItMS0xLTEtMA_af16d70a-61df-4265-bf83-f9c35e0363a8">1,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTItMy0xLTEtMA_a65eee03-1963-441b-ae5e-c43eff34d12d">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTMtMS0xLTEtMA_228e8cd4-002c-4d18-b29e-d5e784188805">1,441</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTMtMy0xLTEtMA_810f1869-1edf-4ba9-b355-ac2d038f6b88">923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMS0xLTEtNDM_23b5fb2d-c1cf-4e49-9e81-4a64d3ec2c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMy0xLTEtNDY_119697d5-bbe7-418a-8ff0-820f65e921cc">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMS0xLTEtMA_5e479839-e4a0-4947-a98b-1359c6e3e17f">12,521</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMy0xLTEtMA_41fe94b9-a6c9-4095-8592-f73b85c66675">9,093</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-48pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Purchase of fixed assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTYtMS0xLTEtMA_71763491-f503-435c-94cb-688f99eab92d">42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTYtMy0xLTEtMA_6df56daf-f9ed-4e82-a978-00dd034a30b0">303</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTctMS0xLTEtMA_8795d44f-af35-4a8c-9480-1accfff14c4b">42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTctMy0xLTEtMA_446afb47-04c7-426a-a659-39217f66b071">303</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTktMS0xLTEtMA_89fa5ff5-7f31-4d3d-861d-26ec6f5a405f">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTktMy0xLTEtMA_3c296ab0-27fc-4b2e-a85e-7b00c64601d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Proceeds from exercise of warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjAtMS0xLTEtMA_e18f46d4-bf5d-4833-bd92-233ae2e499cc">1,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjAtMy0xLTEtMA_136de8d6-5178-414b-9846-60d7fd6e99ef">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-60pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Proceeds from sale of common stock, net of issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjEtMS0xLTEtMA_d5df2e3c-57ad-46e2-87fd-fa990c9cd793">19,292</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjEtMy0xLTEtMA_c428d56b-a894-4c39-b0d8-6860aee48460">10,269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjItMS0xLTEtMA_04279288-edc7-4b4a-93aa-95f7d721dc69">20,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjItMy0xLTEtMA_c22b7fe0-b132-4d84-b6af-83f36e6f4074">10,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjMtMS0xLTEtMA_70c5a8dc-a928-46ba-97f5-dcc823c1a41e">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjMtMy0xLTEtMA_958980f7-5c83-4423-8706-085c11cf9469">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjQtMS0xLTEtMA_e67f362f-5593-46fc-a998-7fdd4f0dd6b7">8,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjQtMy0xLTEtMA_bd5494f7-71d3-4b20-a4e4-a9e2696476f8">886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjUtMS0xLTEtMA_ac61df52-c752-4651-a6cb-68392e1a0b5e">7,134</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i114bd5e9a8244f23bea013dccf03d439_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjUtMy0xLTEtMA_a9d21113-00c7-4b66-a9cd-e95a8c3f6f35">7,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjYtMS0xLTEtMA_3e53c638-7557-45e2-949b-9feb641fcc3d">15,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjYtMy0xLTEtMA_42233f76-f877-4e25-be5d-9d361593de70">8,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-66pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash paid for interest</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjktMS0xLTEtMA_f9bd3236-296e-436a-8a82-9e19410849e3">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjktMy0xLTEtMA_b9d4f7da-78f2-40c3-8d1c-e8658656ce58">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash paid for taxes</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzAtMS0xLTEtMA_1b8612d3-4a48-47f1-9edd-f0f222a8bb0f">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzAtMy0xLTEtMA_91b905d3-97d2-49cc-890c-dc7784b2de4c">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment in accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzEtMS0xLTEtMA_22d1a78d-3028-47c1-a3b3-6efe438e637d">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzEtMy0xLTEtMA_3f5920a3-0f9f-44d0-8bdd-afed004ebcdc">136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements paid by landlord</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mbx:LeaseholdImprovementsPaidByLandlord" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzMtMS0xLTEtNTE_49e2bbf3-d335-4630-946f-8adba3ff8145">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="mbx:LeaseholdImprovementsPaidByLandlord" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzMtMy0xLTEtNTQ_996f27be-767b-471c-ba10-21a1dbc69ba5">82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense settled in stock</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="mbx:SharesIssuedInLeiuOfCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzUtMS0xLTEtNTE2OA_ce942445-f96a-435c-ab2d-c8e1ba787e51">490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="mbx:SharesIssuedInLeiuOfCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzUtMy0xLTEtNTE2OA_943a3786-9075-489d-87b1-870e95864158">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div id="i_0_25"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except for shares)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:25.046784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134503%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549708%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Shares&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Amount&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' Equity&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i50a5d43efb884dd483ae1a865e745eba_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0xLTEtMS0w_6ab66d33-2d2c-41e6-83b0-8e629f79a13e">28,528,663</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50a5d43efb884dd483ae1a865e745eba_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0zLTEtMS0w_f4d5dbea-6923-4ec1-9007-caa1ffa5f7a6">29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dd2efefa5274aa1a8f2a55f0852dd1a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi01LTEtMS0w_782ae4bd-4424-488c-a893-1addd75b0c3d">40,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67f67e63bde64896b6be0cd287af8360_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi03LTEtMS0w_17f223f9-32d6-46fb-9a41-b181dc0e8312">26,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic74fa480b48548fcb3f47ebd9af912da_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi05LTEtMS0w_cbfe6190-2c22-4233-9bed-fe3825cb7beb">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0xMS0xLTEtMA_78c23f2c-0861-4d6e-8c00-28648b86884d">14,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Issued for cash - sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0wLTEtMS0wL3RleHRyZWdpb246Nzc1MDY5NWEyZDliNGQ0ZmFlMmUyOWE1ZGVmOWI0YTJfNzA_bf7c4487-a497-4667-a0ae-eb49feb99420">617</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0xLTEtMS0w_98683cca-f817-4f9b-9a5b-6b13f720935b">5,250,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0zLTEtMS0w_5b8497b8-720a-4f7e-901b-05fb05ab346e">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e191fc355f64d22a595d839903d46d5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy01LTEtMS0w_1a80f534-da81-4fc7-96d8-f5c6b4ab9eb9">3,221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2c767c50b21430cbcb5d42f9d4fd136_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0xMS0xLTEtMA_d45725ab-4fd8-4ab8-8661-ef9fd7e5e2e5">3,226</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issued to Lincoln Park - sale of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaeb8fc5d43ae43fca34bb33ecfcdf46c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC0xLTEtMS0w_4612647c-e800-486d-aeef-cc616bee5782">605,367</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31a8d3d8b10b4b7e8f4bd5b548ead03e_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC01LTEtMS0w_0dfd5129-fbdc-49f7-96b0-1c6098150c07">883</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC0xMS0xLTEtMA_14ec95d5-0f07-4238-a477-f7e118ba0edd">883</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie983009200a54629a89ffbfa2cb7f380_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS0xLTEtMS0w_274bb8d9-faea-4afa-8c93-ca8068405ddb">25,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS01LTEtMS0w_bf6ae3fd-05f6-4069-a929-f3472fc01eef">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS0xMS0xLTEtMA_60fd7e71-f34e-4ba7-86b7-8f3f5b2b2b24">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNi01LTEtMS0w_10e6f41f-d8d5-40a4-9c94-3305d9662123">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNi0xMS0xLTEtMA_48f60c85-e429-4d5c-8286-0264987db45e">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9dc0d29d80ec4048ad2f652630bde7da_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNy03LTEtMS0w_10d33265-5f92-4990-a7f7-d411b159162f">4,041</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNy0xMS0xLTEtMA_0cc27704-b508-488f-95a8-c370104e8fdb">4,041</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifbdd2af8e4d642e1b38acd3209e7555d_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOC05LTEtMS0w_28f6a83f-ad2e-435c-81b8-9e8cda1ec54e">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOC0xMS0xLTEtMA_81864199-d9fb-413e-84ee-c854e71108a3">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0xLTEtMS0w_f90683d0-193e-49c0-b1fc-1c9c7c07efa7">34,409,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0zLTEtMS0w_e751c004-6772-4341-8b33-a9bb6a331b82">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd0ff7a1031f4a39b51e586b6cd222d6_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS01LTEtMS0w_303edd35-d204-4709-a0f3-991968901f51">45,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5ded679e60bf43f8a1f4e944669f3068_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS03LTEtMS0w_a817f4a5-7531-49bc-9833-00f92091a5fd">30,397</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if283467953714adaa4dbed6b2b274c45_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS05LTEtMS0w_dd0a78a6-6d7d-49b8-ae06-9406ec7a1842">24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifaafa1f6602348a5b935698ec678c979_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0xMS0xLTEtMA_7714d3bc-b0c8-405f-a9af-49b3ecc7fdd2">14,682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Issued for cash - sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjhjODY0NmNhYTk0YTQzZTFiOGJjYmU2NWJlMGVmMDllXzcw_122fea4f-4f51-4644-9d6d-94fc443be4e8">1,300</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMS0xLTEtMA_64907066-c48a-4107-a449-24ab971a01a2">9,375,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMy0xLTEtMA_c14537b0-886e-42d4-a93d-a6832f229d78">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6b4e969450c437790071f03f750f80e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtNS0xLTEtMA_7e0409c6-1687-4725-a3e1-fd78e8a0e4fa">3,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0d0afcd4335499d9e893ac0fe43a745_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMTEtMS0xLTA_14abe4b3-da0e-4cfe-8628-39fa9037cf26">3,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="mbx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMS0xLTEtMA_ff116d1e-3627-4c71-bca3-48eb501ca82c">1,413,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630" decimals="-3" name="mbx:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMy0xLTEtMA_7f61e38f-8421-4a39-b89e-b8a8b2874e98">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="mbx:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtNS0xLTEtMA_b3dccf49-e86f-4156-a1c4-af0db683b457">4,729</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="mbx:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMTEtMS0xLTA_fd7e23f0-678d-4ed6-a46a-0bbd60af0f4e">4,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTItNS0xLTEtMA_5c1f4cd6-eae9-4426-bded-bf9f825113ab">318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTItMTEtMS0xLTA_450b9127-ec37-4135-8900-cad13a70d17d">318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7acb7f4d36654d6aaa455805fd5c6315_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTMtNy0xLTEtMA_563683d7-4741-4869-9cd9-d542b688e82e">1,221</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTMtMTEtMS0xLTA_99e25877-1c84-45aa-83f6-f21942a234fc">1,221</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i978af72bda7f4cdd9be415879b75924c_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTQtOS0xLTEtMA_55222ba2-4e62-4b9d-be53-ea94941fa495">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTQtMTEtMS0xLTA_6b392f93-824a-41c0-ab49-5bca89918774">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMS0xLTEtMA_7fbebc40-7343-4d66-9dcf-b43f1dd22839">45,197,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMy0xLTEtMA_51d62d43-3774-4c56-a41b-c1a227f8532d">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia243c08879a44b0faf74e1d1174ed227_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtNS0xLTEtMA_d31d745b-4140-4ab1-b860-92be1f4311b3">53,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0247f93d3c7f48b79cc2f61f28823bc3_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtNy0xLTEtMA_27f9faea-1cf1-4bab-8240-1a53c60fe360">31,618</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d99b3bb92ec4d6ba3098d7f73a6bceb_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtOS0xLTEtMA_b54d658a-d620-4d93-9fd5-a92d1b2fe25e">22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e90206e9605402a8453b05d60c725f1_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMTEtMS0xLTA_67b6f9a9-09e5-47bd-913b-88f156ac9b2c">22,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Issued to Lincoln Park - sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMC0xLTEtMjgwMC90ZXh0cmVnaW9uOjZlZmZiZDI0NDNkMTQ4YmE5ODhhM2Q5ZmI4YjFiYTM5XzM4NDgyOTA2OTcyOTg_813546ce-ab53-4b1b-a5fb-12ada9064d65">59</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifcb6cf7dac114e15b0924f118be98bfc_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMS0xLTEtMTI3_f9a42c07-cbdb-40a2-b128-499a9d7ed651">100,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10dbdf0540504f7ab8fc60ae4a1261b0_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtNS0xLTEtMTMz_a8171316-6476-473d-93b8-93e2c73b4f1c">52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMTEtMS0xLTEzOQ_4954223c-9e9b-4856-98f5-5520864cd33e">52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued for license rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMS0xLTEtMjA0Mw_511b6fa7-cb2c-4f8c-9b78-4251472641e7">429,978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMy0xLTEtMjA0Mw_4f01dc52-bbf1-4551-b3f4-dc46ec83198d">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d43a3d31a684c7898dc1177b7e32f2c_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMjA0Mw_cb9c123d-d8f3-47b7-823e-ae2adc02e8fd">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5f0a67ae93e4a0fbe9ed5c48e3b8c58_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTIwNDM_93499856-c6ee-4e97-8982-53dfb21a90bd">490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea6b42302d064af99a04ff7719b2ffe4_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMTQz_857b92a3-0765-4467-bbff-fdc4043960ec">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTE0Mw_e0d0a6c4-e67f-4d00-9edf-c3ef2f852134">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a5d1f7a1ea941aeb1aebd6c4114bfb5_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtNy0xLTEtMTQ2_a04b9765-937f-4087-87a6-80f4be171436">4,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMTEtMS0xLTE0Ng_7338f545-ca45-42e2-84db-9fa04addbba6">4,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a0b19ebdcf34ae2bd120ba45f2990ba_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktOS0xLTEtMTQ5_4ff72de4-f026-4461-8d61-f2ed3e320ef0">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMTEtMS0xLTE0OQ_8d93108f-d98e-4f09-baca-8eba5e4c7fc5">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i85a013c63ce649f6adc0f00d0053d9e8_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMS0xLTEtMTcy_1e2cae39-3869-4f03-b853-4751d87f4dd1">45,727,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85a013c63ce649f6adc0f00d0053d9e8_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMy0xLTEtMTcy_5a5fe7b0-081c-4b62-820d-9bf0f9d1aaa0">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i511e28680ebf4b96856998ec784196c8_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNS0xLTEtMTcy_30052a31-66cc-47cb-8d2d-b3ea16b2946d">54,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib5c10695ca664bf5ba8f73db1e940f69_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNy0xLTEtMTcy_318f023b-3071-4392-b5b1-d6f7e41dc9ec">35,763</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6198e1f6f1d940ba8beb2aa6c66ee4ba_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtOS0xLTEtMTcy_47ecb8ac-a44c-4116-ae89-b12945315397">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMTEtMS0xLTE3Mg_4b06fc07-20d1-4369-bee0-874a3f1a83b9">18,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="36" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">See accompanying notes to unaudited condensed consolidated financial statements.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:25.046784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134503%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549708%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="36" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Moleculin Biotech, Inc.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="35" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Statements of Stockholders&#8217; Equity (Continued)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="36" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for shares)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="36" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Shares&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Amount&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' Equity&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i66751d7b8a8046c5870329c2d7f9b432_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMS0xLTEtMA_60895e09-aa80-4768-816c-fc88e1bb4579">21,469,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66751d7b8a8046c5870329c2d7f9b432_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMy0xLTEtMA_8eb985c1-9aa1-4385-a151-de7dcde4774b">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i698da61e696241338dc1d0d51f6ee26f_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMA_c7c5877c-36ad-44c5-871b-2dea1fca7f02">31,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b54a748ee7147f8960b4e3c01fda1b5_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNy0xLTEtMA_fe190316-1277-45e9-abd6-a22e3397189d">14,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i114bd5e9a8244f23bea013dccf03d439_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTA_a7bef673-9706-4ca0-8ec4-77682aa6bed7">17,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="mbx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMS0xLTEtMA_fcf0a5f9-6655-4d7e-a75a-426cff1409d8">9,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331" decimals="-3" name="mbx:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtNS0xLTEtMA_a7046c27-9123-41a5-b2c9-f22d23de7131">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331" decimals="-3" name="mbx:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMTEtMS0xLTA_ad686866-b344-4272-9881-74db533b0aaf">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Issued for cash - sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMC0xLTEtMC90ZXh0cmVnaW9uOmQ0YzVjZTg0N2ZkNjQxZTQ4MjM5NzVkYjI5ZTI2OGRmXzcw_735c42c3-c157-453f-9f6d-1b18101f4ae4">809</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMS0xLTEtMA_078c66d7-d98d-4a29-9eb3-3413dc580ceb">4,290,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMy0xLTEtMA_53447451-b69b-4379-825a-9b0968fe093a">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktNS0xLTEtMA_88dfa92c-7883-4444-bb38-331467347ca2">5,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMTEtMS0xLTA_d6b1621d-b918-4b62-9b1e-0b4081b141af">5,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNS0xLTEtMA_fe2c37fd-6036-4e4e-a027-1d43878bc272">242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMTEtMS0xLTA_11ccc61a-354a-43bf-bd73-2250e150670f">242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7f3883a699ce4e02b970417d508d4ad7_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjEtNy0xLTEtMA_6a76cfeb-5223-4f42-ada6-5d05086e78dc">1,927</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjEtMTEtMS0xLTA_cf350ca7-f9b5-4fde-a624-9090a6c6629f">1,927</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ca2487f82e44a2d874e72ac389555e3_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMS0xLTEtMA_592b4062-76fa-49e7-9a3b-e4045ff9c794">25,768,861</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ca2487f82e44a2d874e72ac389555e3_I20180331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMy0xLTEtMA_8925d30f-1e97-40e7-b226-695be4541a68">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bb5c9e8ad114039be905d2ce6a2f928_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItNS0xLTEtMA_94b2c04f-e9bf-4505-a672-04864a7db3c6">36,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1499fe2de067467d92d06bf6af15d71f_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItNy0xLTEtMA_f70ecbc0-0106-4208-b366-4d8c6b9aed03">16,407</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c1a22242df74771b68a9b7d49a044ea_I20180331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItOS0xLTEtMA_f6f9546e-d6c3-427e-b396-77dcf074df09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i993b33833a034e6287f0b8bca653f504_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMTEtMS0xLTA_3139b5e4-02ca-4dd1-a293-e55d61f9c95a">20,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Issued for cash - sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmMzY2NiYjhkYTFhOTQwN2RiZjg1YmIxYzE3ZWMzOGNhXzcw_7465cabb-4291-487e-8440-9e75195b8a7a">232</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMS0xLTEtMA_ebf3e46e-2a38-4f2b-9a70-2fb5dba6e8eb">1,092,636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMy0xLTEtMA_65e5ca51-68d4-4e83-b085-ee45a390492e">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i019f3c2995584a11884f6a959327107e_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtNS0xLTEtMA_04e0cbcd-1649-48a3-963c-52a9b783e83f">957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if668eee949014fecb89a24b65ff223a8_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMTEtMS0xLTA_be92fc59-3feb-4e86-92e1-c66221a51afc">958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e84c009114a45de864360cb755f97d2_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjQtNS0xLTEtMA_54518611-cd73-4ea3-a248-c05a15869d13">339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjQtMTEtMS0xLTA_64aa0360-9ced-47e0-895a-607bac1a27c8">339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i81d7cce25b87468db25b99f7b4ec4a5f_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjUtNy0xLTEtMA_90488d8c-1f98-4f84-a6fd-2aebeb64f354">5,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjUtMTEtMS0xLTA_06c404de-9b29-48c2-8b49-9cd2c2a7da7f">5,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib11fd7e524cb4871884958f022962fd8_D20180401-20180630" decimals="-3" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjYtOS0xLTEtMA_ca5d9800-e45b-4ff3-8805-246c30b905df">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630" decimals="-3" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjYtMTEtMS0xLTA_3995dc95-4c33-4443-8283-bf1ae51b3980">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic74298b670ca4645ae764781cf988f36_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMS0xLTEtMA_314879f1-056e-4b02-b7f0-21eafd22ba58">26,861,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic74298b670ca4645ae764781cf988f36_I20180630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMy0xLTEtMA_ddd0e5b1-697f-44f9-ba8f-7fc737fd5199">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie58e6bb80ae84986b925d657b40bd986_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctNS0xLTEtMA_073e7365-2ba4-4f6a-a969-e93084bbc2ad">38,247</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iccf298971c424b638760ec464c4f3e3b_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctNy0xLTEtMA_c59ef3c3-e20f-4c0d-bb70-d145c2cdc2ae">21,532</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f19c66cce8b4632acc641adacd87dc5_I20180630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctOS0xLTEtMA_febb7138-dd50-4a95-8d2d-7adab24f2887">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a55ef48475e4201bc338d2dca5da777_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMTEtMS0xLTA_43fc8376-7692-4b5e-873a-94c53f996800">16,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i773749c5e55246028373864551af9e8d_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDctNS0xLTEtMTk1_3ad0b0a9-ad18-49a9-86af-283f4fc12aac">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDctMTEtMS0xLTE5NQ_dd9f5251-59ea-48fb-b4eb-b6ba1966c7cb">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i87044ed8d26543a698744dcd07920f10_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDgtNy0xLTEtMTk1_333d9596-cf3b-41ab-9f42-6d80bb02efbc">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDgtMTEtMS0xLTE5NQ_fd2c53b5-a6e4-4c2f-ac0b-5dbdf8bed530">2,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia7c13ec668974c76b242c324030b9a8d_D20180701-20180930" decimals="-3" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDktOS0xLTEtMTk1_5a5a2d08-15dd-4255-b3ed-d28ac4deaa3d">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDktMTEtMS0xLTE5NQ_11f69c6b-4d5c-40a7-8dd6-eccc4b1160e3">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMS0xLTEtMTk1_a68d4a54-a0da-41ca-9d22-020bec0e622b">26,861,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMy0xLTEtMTk1_d57f31c2-a0c5-4856-9fc9-952365935e77">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5aeb81499c4d30a2c9a5f3456dba46_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtNS0xLTEtMTk1_8d9fb31b-b46c-4fe9-99a1-2b10bc04ab57">38,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i475cf3e6dd1a4bc68203346a5e4ddd00_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtNy0xLTEtMTk1_98a8ea9d-3b39-4291-bad6-0dcef3145206">23,570</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia59c9518ea0244de9d05ecac711dafd4_I20180930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtOS0xLTEtMTk1_d5a40fd7-76ca-46d5-a4cd-2f11bd01083e">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMTEtMS0xLTE5NQ_e3d106a7-d9a9-4d89-bc58-43add290724a">14,969</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_28"></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to the Unaudited Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_31"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="mbx:NatureOfBusinessAndLiquidityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfOTUxMQ_c5d64820-0a1b-40f1-8921-408a90c1e91c" continuedAt="ia57d1398e4214f4793c254384762ec2c" escape="true">Nature of Business and Liquidity</ix:nonNumeric></span></div><ix:continuation id="ia57d1398e4214f4793c254384762ec2c" continuedAt="i91368c774e1a4a9e96649f6cd30bd298"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, with its focus on the treatment of highly resistant cancers via the development of its oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI formed Moleculin Australia Pty. Ltd., (MAPL), a wholly owned subsidiary in June 2018, to begin preclinical development in Australia for WP1732, an analog of WP1066. This enables the Company to enjoy the benefits of certain research and development tax credits in Australia. In February 2019, the Company entered into an agreement with Animal Life Sciences, LLC ("ALI"), where the Company has granted a sublicense to ALI to research, develop, make, have made, use, offer to sell, sell, export or import and commercialize certain licensed products for non-human use and share development data. ALI issued to the Company a <ix:nonFraction unitRef="number" contextRef="i6dc0cbeab3aa44b48883e4da0862b3bf_I20190930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTE1MA_122c485e-9ae4-43b3-b4bf-761f56c76112">10</ix:nonFraction>% interest in ALI. ALI converted into a corporation and became Animal Life Sciences, Inc. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Core Technologies - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">MBI has <ix:nonFraction unitRef="technology" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="mbx:NumberOfDrugTechnologies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTI3MQ_6bbd69f3-24e9-4925-bb28-29c7fa3fa12b">three</ix:nonFraction> core technologies with <ix:nonFraction unitRef="candidate" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="mbx:NumberofDrugCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTI5Nw_b6c1a425-1860-450d-ae3e-50932dfd963f">six</ix:nonFraction> drug candidates, all of which are based on discoveries made at MD Anderson. These core technologies are 1) Annamycin, 2) its STAT3 Immune/Transcription Modulators, or simply "Immune/Transcription Modulators" WP1066 portfolio and 3) its Metabolism/Glycosylation Inhibitor portfolio, WP1122. The Company&#8217;s clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We have completed full enrollment and begun treating patients with WP1220, an analog of WP1066, for the topical treatment of cutaneous T-cell lymphoma ("CTCL"), a form of skin cancer, in a clinical trial approved by Polish regulators in January 2019. MBI is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors. With the approval of the Polish clinical trial in January 2019 for WP1220 for the treatment of CTCL, the Company now has <ix:nonFraction unitRef="drug" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="mbx:NumberofDrugsinClinicalTrials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMjM4Ng_2a41b68c-435b-4d66-9ac9-089cb69db38c">three</ix:nonFraction> drugs in <ix:nonFraction unitRef="clinicaltrial" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="mbx:NumberofClinicalTrials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMjM5OA_35bfea61-4075-423f-80b9-54dbde8ceb6e">four</ix:nonFraction> clinical trials.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company believes Annamycin is a "Next Generation Anthracycline" since it is designed to avoid the multidrug resistance mechanisms that typically defeat currently approved anthracyclines, as well as to be non-cardiotoxic, which is the dose limiting toxicity of all currently approved anthracyclines. Annamycin is currently in two Phase I/II clinical trials, and preliminary clinical data suggests that it may have the potential to become the first therapy suitable for the majority of relapsed or refractory AML patients regardless of gene mutations. Additionally, preclinical research in animal models at MD Anderson demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs. Coupled with research demonstrating that Annamycin is capable of accumulating in the lungs at very high levels, this suggests that Annamycin may be well suited to become a treatment for lung-localized tumors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">WP1066 is one of several Immune/Transcription Modulators that appear capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells ("TRegs") while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1&#945;. These transcription factors are widely sought targets that may also play a role in the lack of efficacy of immune checkpoint inhibitors in certain resistant tumors.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis and glycosylation. Its lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy ("2-DG") within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Drug Candidates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - Within the Company's core technologies, it currently has six drug candidates representing three substantially different approaches to treating cancer. Annamycin is a chemotherapy designed to inhibit the replication of DNA of rapidly dividing cells and is the Company's most mature drug candidate. Annamycin had been in clinical trials pursuant to an investigational new drug application or IND that had been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, the Company resubmitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which the FDA allowed to go into effect in September 2017. The Company has trials open in the US and Poland and is actively recruiting in both countries.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has <ix:nonFraction unitRef="project" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="mbx:NumberOfOtherDrugDevelopmentProjects" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfNDgwMw_70379a2c-4749-4c92-ab06-f4e01b53be34">five</ix:nonFraction> other drug development projects, two of which are also in clinical trials:</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i91368c774e1a4a9e96649f6cd30bd298"><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1066 has an approved physician-sponsored clinical trial open for enrollment and dosing patients for the treatment of brain tumors and is also being evaluated for another physician-sponsored clinical trial for the potential treatment of pediatric brain tumors, as well as AML and pancreatic cancer,</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1220 is an analog of WP1066 for which Polish authorities in January 2019 approved the Company's Clinical Trial Application ("CTA") to study the topical treatment of CTCL, which study reached full enrollment in August 2019,</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1732, another analog of WP1066, is being evaluated along with WP1066 for the potential treatment of AML, pancreatic and other cancers, and MBI has begun pre-clinical work that it expects to generate sufficient data for an IND for an intravenous formulation of one of its STAT3 inhibitors, which filing is expected to be submitted in 2021, and </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1122 and WP1234 are being evaluated for their potential to treat brain tumors and pancreatic cancer via their ability to inhibit glycolysis.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Clinical Trials - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that patient recruitment for its Annamycin clinical trial in the US has been slow due to the high number of competitive clinical trials, combined with the FDA&#8217;s requirement to set the initial dose level relatively low in comparison with previous Annamycin clinical trials. Additionally, the Company believes that patient recruitment for its clinical trial in Poland has been more successful than in the US due to a comparatively lower number of competitive clinical trials and the protocol there being approved to start at a significantly higher dose than in the US with fewer enrollment screening limitations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the physician sponsored WP1066 Phase I clinical trial for the treatment of glioblastoma and melanoma metastasized to the brain, which opened for recruitment in July 2018, began treating patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company completed full enrollment in a proof-of-concept clinical trial in Poland to study WP1220, a part of the WP1066 portfolio, for the treatment of CTCL. Polish authorities approved the Company's CTA  for this use in January 2019, and the trial began enrolling patients in March 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Licenses - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company has been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of MBI's drug technologies, as these intellectual property rights are owned in part or entirely by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, the Company filed new patent applications in July 2019 for formulation, synthetic process and reconstitution related to MBI's Annamycin drug product candidate, although there is no assurance that the Company will be successful in obtaining such patent protection. Such technology is also licensed from MD Anderson. Independently from potential patent protection, MBI has received Orphan Drug designation ("ODD") from the FDA for Annamycin for the treatment of AML and for WP1066 for the treatment of glioblastoma. ODD may provide tax and other benefits during product development, and if either product is approved, may lead to a grant of seven-year market exclusivity. Under that exclusivity, which runs from the date of the approval of the New Drug Application ("NDA") in the United States, the FDA generally (there are important exceptions) could not approve another product containing the same drug for the designated indication. The Company also intends to apply for similar status in the European Union ("EU") where market exclusivity could extend to <ix:nonNumeric contextRef="ibaa5d1878a8449bbbfb93f6bcb30609b_D20190101-20190930" format="ixt-sec:duryear" name="mbx:MarketExclusivityExtensionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfODg3MQ_cd7766b0-b4a5-40d5-989f-e9eb979144e4">10</ix:nonNumeric> years from the date of Marketing Authorization Application ("MAA") approval. Separately, the FDA may also grant market exclusivity of <ix:nonNumeric contextRef="id4ec7928d44f45ea880ca27fb60483ae_D20190101-20190930" format="ixt-sec:duryear" name="mbx:MarketExclusivityExtensionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfOTAwOA_f0ce6c19-c850-4edc-a093-34922276a625">5</ix:nonNumeric> years for newly approved new chemical entities (which the Company believes Annamycin would be one), which would preclude approval of any other annamycin product, but there can be no assurance that such exclusivity will be granted. In April 2019, FDA approved the Company's request for Fast Track Designation for Annamycin for the treatment of relapsed or refractory AML. Fast Track Designation, the purpose of which is to expedite drug development and approval, is granted to drugs intended to treat serious conditions and where data demonstrate the potential to address an unmet medical need.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Moleculin, LLC -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> Prior to MBI's initial public offering, the Company acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.</span></div></ix:continuation><div id="i_0_34"></div><div><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODg_b58526b6-6816-4f68-9704-5e887f96f74e" continuedAt="i5da2f8b9f5a74cb59c1e0dfdcee800c7" escape="true">Basis of presentation, principles of consolidation and significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i5da2f8b9f5a74cb59c1e0dfdcee800c7" continuedAt="i4a07af2bfa5f4f389d05cda6f4f081e6"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODk_add1d734-ab6d-4e43-b294-ce93fb0755be" continuedAt="iea9ce3f2a97040498f4b9705b6529020" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Basis of Presentation &#8211; Unaudited Interim Condensed Consolidated Financial Information -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a </span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i4a07af2bfa5f4f389d05cda6f4f081e6" continuedAt="ifd62c08f70744866b7fbb6830f67e9a3"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="iea9ce3f2a97040498f4b9705b6529020">fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These interim condensed unaudited consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December&#160;31, 2018 and December&#160;31, 2017 and notes thereto contained in the Form 10-K filed with the SEC on February&#160;21, 2019.</ix:continuation> </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTc_8a4b8ba1-b3f3-403c-bac6-99cf526e80e8" continuedAt="ic3402cd23bec47bcbd66b267dbe5d324" escape="true">Principles of consolidation</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic3402cd23bec47bcbd66b267dbe5d324"> - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTczNw_993f9a7d-f190-4d4d-a2eb-b247997ef3ce">one</ix:nonFraction> operating segment. All long-lived assets of the Company reside in the United States.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDE_7fd54a10-b5c7-4b80-a3ae-f654685cfbac" continuedAt="ied1c8e9a608548dd8498308fb309bfe6" escape="true">Use of Estimates -</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ied1c8e9a608548dd8498308fb309bfe6"> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.</ix:continuation> </span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="mbx:GoingConcernPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDc_522f9b86-418d-49fc-8baf-ac600d978214" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Going Concern -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of September&#160;30, 2019, the Company has incurred an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzc2OA_f7e7be28-103a-478c-9174-4f2225363aa5">35.8</ix:nonFraction> million since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of September&#160;30, 2019, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</span></ix:nonNumeric></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDI_04924ac0-04b6-4f65-bb3e-160ef951cddb" continuedAt="i22a2de8ccd824338a49e6cc339808680" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i22a2de8ccd824338a49e6cc339808680"> - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the Federally insured limits of $250,000.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0NjI2MA_68adf6dc-a406-4fb4-9772-b27ddec74153" continuedAt="ia0e267a938ff4efda8b6949de40eaf0c" escape="true">Prepaid expenses and other current assets consist of the following (in thousands):</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><ix:continuation id="ia0e267a938ff4efda8b6949de40eaf0c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:57.064327%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vendor prepayments and deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="mbx:VendorPrepaymentAndDeposits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMS0xLTEtMS0zMTY2_d4b70bcc-1a61-4790-8084-f39368a71e82">1,994</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="mbx:VendorPrepaymentAndDeposits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMS0zLTEtMS0zMTY2_9c2d92b2-a791-4219-bef9-0d5ac590e773">238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMi0xLTEtMS0zMTY2_1950ab60-5072-4934-8dfd-bb0f6a794aed">560</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMi0zLTEtMS0zMTY2_cf27aa1e-3563-481f-80b4-82f53e7c3fd7">171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-trade receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMy0xLTEtMS0zMTY2_2d31ac5f-e9e5-44c3-9189-9e9f04ed1a5c">316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMy0zLTEtMS0zMTY2_a12e65da-4aa9-41af-b8d2-1f80919167e7">56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNC0xLTEtMS0zMTY2_371aea54-8f2b-440f-a47f-0e705290c09a">307</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNC0zLTEtMS0zMTY2_be727b30-175d-4b03-a971-ab234b60c134">375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNS0xLTEtMS0zMTY2_7bc7bf62-7965-46fb-bb5b-168f434d28f3">3,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNS0zLTEtMS0zMTY2_11041d5f-28ad-480b-bd2a-6e0f76839bbf">840</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Vendor prepayments includes approximately $<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="mbx:VendorPrepaymentAndDepositsExpansionOfProductionCommitments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMjE5OTAyMzI3Mzk0OQ_ff40f08f-2f5e-4410-a945-34c0ea60cc02">1.7</ix:nonFraction> million for the expansion of Annamycin production commitments on a commercial scale to be delivered in 2020, which will be used in clinical trials. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMTE_565430ba-5ee9-4d73-9432-dcf032ff4fea" continuedAt="i94e36230569742ee867f525df3e1a35f" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Intangible Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development ("IPR&amp;D") asset, then no </span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ifd62c08f70744866b7fbb6830f67e9a3" continuedAt="i72ed0397543b4d5b8a835787672f29d8"><ix:continuation id="i94e36230569742ee867f525df3e1a35f"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, if any, the IPR&amp;D assets will be amortized over their estimated useful lives.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if the Company believes indicators of potential impairment exist, using a fair-value-based approach.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTQ_1f444ccd-8b1c-4e99-ba14-3a41cedbaf40" continuedAt="ifae9f9b2c2054113b12426f383576af0" escape="true">Property and Equipment, net - </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ifae9f9b2c2054113b12426f383576af0">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</ix:continuation> Accumulated depreciation on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfNjYzNA_17b915b0-efcb-40c2-b56d-c644ac029aae">0.2</ix:nonFraction> million at September&#160;30, 2019, and $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfNjY1OQ_11ffe4dd-c509-425d-b960-ab95d1cd4fe6">0.1</ix:nonFraction> million at December&#160;31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:LessorLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0NTMyOQ_cde06d67-c5b8-4301-8089-6e77279dee20" continuedAt="id96543aba97e49eb81ce9124584df002" escape="true">Operating Lease Right-of-Use Asset - </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id96543aba97e49eb81ce9124584df002">The Company determines if an arrangement is a lease at contract inception or during modifications or renewal of an existing lease. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company's operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheet. The Company has elected the practical expedient and will not separate lease components from nonlease components for its leases. The Company's operating leases are reflected in operating lease right-of-use asset ("ROU"), accrued expenses and current liabilities, and operating lease liability - long-term in the Company's condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 7 - Commitments and Contingencies - Lease Obligations Payable for additional information related to the Company&#8217;s operating leases.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> &#160;<ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:CostMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0ODE5Mg_3cea42ca-6cac-4323-9ffe-ccc5ef7ea0b0" continuedAt="if56224008e4840a992791749ba474b5f" escape="true">Cost Method Investment - </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if56224008e4840a992791749ba474b5f">Our cost method investment consists of an investment in a private company in which we do not have the ability to exercise significant influence over its operating and financial activities. The investment is tested for impairment quarterly.</ix:continuation></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTU_ad884856-71e0-4728-9f02-7c935fa5edc2" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments consist primarily of non-trade receivables, account payables, accrued expenses and a warrant liability. The carrying amount of non-trade receivables, accounts payables, and accrued expenses approximates their fair value because of the short-term maturity of such.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8211; Unobservable inputs for the asset or liability.</span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. In the accompanying interim condensed consolidated financial statements as of September&#160;30, 2019, the fair value of this warrant liability is included in current liabilities for the February 2017 Issuance of Warrants, the February 2018 Issuance of Warrants, the June 2018 Issuance of Warrants, the March 2019 Issuance of Warrants, and the April 2019 Issuance of Warrants. Warrant liabilities will be shown as a current liability on the balance sheet when it is deemed more probable than not by management to be exercised within one year.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i72ed0397543b4d5b8a835787672f29d8" continuedAt="i693c1dc1bf0f4f7c8be046c5c095904c"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTY_1b837f42-2a9d-41e2-94d3-9987170c2f2f" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September&#160;30, 2019 and at December 31, 2018 (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:23.000000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.882353%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.117647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.235294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.823529%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liabilities</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Measured at Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">in Active</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Assets (Level 1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unobservable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 3)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7d483fa5b8b4a508aa8033181369c0b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS0yLTEtMS0w_67e85c7a-d2ac-4ae3-9618-7584f27073c5">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb53084bb5d5439da0fc3b7ce0bac811_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS00LTEtMS0w_60071136-fe4c-4940-8414-1635e8882f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd7f29a819443ba880b572c77f75db8_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS02LTEtMS0w_633d31d1-0044-4e3d-a667-de460d75bdb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43ba623e5dc34281830bac2c5b222d0b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS04LTEtMS0w_7f01128e-e3ed-48cb-bccf-e95eb9fe814e">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of December 31, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d184260db97490785df4ce8f01a87f4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi0yLTEtMS0w_d8bfc1c4-fc73-45ab-a627-df2e885cc4cf">1,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bb96a49c87b43728767fc948cbd81a0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi00LTEtMS0w_2682d1cc-6f30-4a31-9b2c-19fc4027788e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e02f1d5e0b843aa9cefaba9fe3c4bd4_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi02LTEtMS0w_ada82002-ba19-46bb-8281-1365b8a0827f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i010c1a26c61e446aadddfcdda2856af2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi04LTEtMS0w_78a44e99-762c-45f9-89a9-7d08f572219e">1,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTE_fec61090-a0f4-4750-b620-8c262fa78cb9" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The table below (in thousands) of Level 3 liabilities begins with the valuation as of the beginning of the third quarter and then is adjusted for the issuances and exercises that occurred during the third quarter of 2019 and adjusts for balances for changes in fair value that occurred during the current quarter. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:56.918129%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Long-Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iacbd36b98aa84664bebd964e031364e7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS0xLTEtMS0w_9bf9fded-51b3-4981-ad56-655c7b25a236">6,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i285e6798fd8943ccb8ce51b198c79b4c_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS0zLTEtMS0w_6f5b9981-82ae-4a97-af20-351e793c26fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ffd58e0885541359bfea5e4d56a4af2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS01LTEtMS0w_117ac911-9b26-43b4-b1f0-aa6c5d938416">6,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi0xLTEtMS0w_0791ed9f-0b41-42ce-9c50-855f26aca53d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi0zLTEtMS0w_0c421e47-a2dd-4bf1-b178-99ad4aef39b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi01LTEtMS0w_5de005ea-248c-435d-97d5-b3d1c9f0adaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy0xLTEtMS0w_846a4254-f6ba-4a84-9cd5-2d1eaf6318c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy0zLTEtMS0w_1cfbd901-0b40-4e14-81e0-7145f36d7f9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy01LTEtMS0w_79b8a9a0-1162-4191-b1c9-2d0dd5fad4c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC0xLTEtMS0w_8a7de3c0-2046-4472-98c0-0b1da8b30698">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC0zLTEtMS0w_fa0a9c34-bc87-40df-9f56-48c1fad837b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC01LTEtMS0w_d89c5ce8-6cfe-4f4d-b9b5-7ca864228306">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value - net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS0xLTEtMS0w_780c0545-c9d9-4557-b030-9ac654323f03">124</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS0zLTEtMS0w_33f00c7a-b317-424d-a171-592387698ded">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS01LTEtMS0w_b3cbc043-6cdf-411d-92c5-283eb14c6428">124</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3707bb56148497495ea24016f264a35_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi0xLTEtMS0w_3456624b-1dac-4557-8f4c-14e9e02f0172">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi0zLTEtMS0w_d2dfc163-52fd-4caa-9caf-937021701d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib34e1490cda548bdaab67ad8ede83e51_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi01LTEtMS0w_9bca2b47-bebb-46f4-a98f-42986ce96f84">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;The table below (in thousands) of Level 3 liabilities begins with the valuation as of December&#160;31, 2018 and then is adjusted for the issuances and exercises, and changes in fair value that occurred during the nine months ended September&#160;30, 2019. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:54.140351%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Long-Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i833cbb966fe54a1dbf89b625b300e6a7_I20181231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS0xLTEtMS0w_f048c58d-bbb6-4d5e-8e0c-314f4af4b19c">180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57abc24e231945ddb977a7587f1bc971_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS0zLTEtMS0w_76e85b3e-1531-4e13-905c-f7363ea6502e">1,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a7f1136ba8448bfa401f14716d6bdc5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS01LTEtMS0w_9f432bfb-43e1-4697-adea-6bd06cfdd0d5">1,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi0xLTEtMS0w_4d75c5cb-e263-4ef8-b14f-b8114adda6ba">1,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi0zLTEtMS0w_ddee387f-e716-41ac-a410-0273fcb0526f">1,328</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi01LTEtMS0w_af8ee37b-d506-44e0-bedc-0dc8272fbbd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy0xLTEtMS0w_a529a237-9b61-44bd-a9f8-2ef2ea545113">3,174</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy0zLTEtMS0w_d1284a5b-d7e2-4771-a0e1-c9c6cf550890">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy01LTEtMS0w_33cb4b78-06e5-47ae-9344-f3ec2a5ed3c7">3,174</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC0xLTEtMS0w_d5e08aa8-b979-490e-977a-6d16ea7da705">11,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC0zLTEtMS0w_deea7493-4404-46b1-ae3e-23ddc52c5c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC01LTEtMS0w_6e7bd3ac-0bbc-49e2-b493-4289c3f0bb7b">11,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value -  net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS0xLTEtMS0w_6ffab8cb-ac47-4ad5-9c51-4bf7b46b5919">3,059</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS0zLTEtMS0w_0ff7f07b-593f-4286-9f50-66779ffec1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS01LTEtMS0w_4bf40078-acd0-4be8-915d-8128741464fd">3,059</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3707bb56148497495ea24016f264a35_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi0xLTEtMS0w_4478bb38-b4de-44fe-bd22-10c22d243784">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi0zLTEtMS0w_947c3bf8-aacf-4e12-a113-5581d3357156">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib34e1490cda548bdaab67ad8ede83e51_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi01LTEtMS0w_213a7507-0e42-4088-b196-46b6ff7bdc32">6,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMTI_3b78ff77-1203-46af-bc8b-da1a7e5c7d1d" continuedAt="i39c0fff5eddd4f0fb680df88ed38663f" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Loss Per Common Share</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting and warrants to purchase common stock were considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be antidilutive. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">For the three months ended September 30, 2019 and 2018, </span></ix:nonNumeric></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i693c1dc1bf0f4f7c8be046c5c095904c"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i39c0fff5eddd4f0fb680df88ed38663f">approximately <ix:nonFraction unitRef="shares" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY1MQ_847448d7-943d-4cf2-addb-1832e1524767">14.7</ix:nonFraction> million and approximately <ix:nonFraction unitRef="shares" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY2Nw_26add7b7-1077-42e2-abb8-1a00544539da">6.5</ix:nonFraction> million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2019 and 2018, approximately <ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY4NA_f0a287f4-91c7-46ac-bd64-ce842e8a71aa">11.3</ix:nonFraction> million and approximately <ix:nonFraction unitRef="shares" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzcwMA_37246a4c-490b-43b5-8f45-8be41f65d62f">5.0</ix:nonFraction> million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect.</ix:continuation></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODc_0ecaebd1-722b-420a-ad2d-0ac2e4a15e26" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Reclassifications - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Subsequent Events -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The Company&#8217;s management reviewed all material events through the date these unaudited condensed consolidated financial statements were issued for subsequent events disclosure consideration, see Note 8 - "Subsequent Events".</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTk_2fbb4593-ee14-417d-ba96-315458ca16ca" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;In July 2018, the FASB issued ASU No. 2018-11, Leases Targeted Improvements ("ASU 2018-11"). In March 2019, the FASB issued ASU. No. 2019-01, Leases ("ASU 2019-01"). ASU 2019-01 and 2018-11 assists stakeholders with implementation questions and issues as organizations prepare to adopt the new leases standard. The Company adopted this standard on January 1, 2019 and used the effective date of initial application using the modified retrospective transition method. Upon adoption there was no cumulative-effect adjustment to the opening balance of retained earnings as of January 1, 2019. Therefore, prior period financial information has not been adjusted and continues to be reflected in accordance with the Company's historical accounting policy. The standard establishes a ROU asset model that requires the lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. (see Note 7. Commitments and Contingencies - Lease Obligations Payable).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718) Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 affects all entities that enter into share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption permitted, but no earlier than an entity's adoption date of Topic 606. The adoption of this pronouncement did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) ("ASU 2018-13"). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  Early adoption is permitted upon issuance of this ASU. The Company is currently evaluating the impact that this standard will have, if any, on its financial statements.</span></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;</span></div><div id="i_0_37"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RleHRyZWdpb246MGRjMGIyYzY5MGU4NDg5MTk2ZDU2ZjVjOWFjZWUzMmFfMTU5_d5e4666e-d3d3-474d-a4e3-f61583187a5f" continuedAt="i8257e70424ee4eaf905e747f1930308a" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i8257e70424ee4eaf905e747f1930308a" continuedAt="i8468aa28b0ba4967b1b0bd54e53ac9aa"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RleHRyZWdpb246MGRjMGIyYzY5MGU4NDg5MTk2ZDU2ZjVjOWFjZWUzMmFfMTYw_52f00c15-6cfd-4b38-a840-e4e248ac5afe" continuedAt="ica28217cb1ea44a6b514914b336dfc92" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following components (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="i8468aa28b0ba4967b1b0bd54e53ac9aa"><ix:continuation id="ica28217cb1ea44a6b514914b336dfc92"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:57.649123%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical testing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="mbx:AccruedClinicalTestingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMS0yLTEtMS0w_5ec0acd2-4aee-44fb-8f93-d9bd5fcdb675">349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="mbx:AccruedClinicalTestingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMS00LTEtMS0w_c867688a-b586-4c6c-a14a-0289a5110a75">95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and bonuses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMi0yLTEtMS0w_e4c03694-c8ab-4654-ba11-2bdce7fc22f0">249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMi00LTEtMS0w_e2608865-c90d-493d-9633-31c0a97d2fb5">492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMy0yLTEtMS0w_2941f871-5c13-4c09-8206-0bc6568465c0">144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMy00LTEtMS0w_475126d1-8971-4413-9ed8-7f713bb8436c">227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal and professional fees</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNC0yLTEtMS0w_f65613bd-f60c-43e6-8fcb-197a3b6116c4">137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNC00LTEtMS0w_cabef318-a4f9-48fa-b1c4-a7058b543dfa">91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNS0yLTEtMS0w_50e59df6-de08-4ca5-9456-86bca9e8be97">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued license fees and sponsored research agreements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="mbx:AccruedLicenseFeesAndSRACurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNi0yLTEtMS0w_1690ef76-d97d-4ccf-ade0-8a0961362226">91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="mbx:AccruedLicenseFeesAndSRACurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNi00LTEtMS0w_2cdb7517-4429-427f-a042-44555c0046b6">1,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued drug manufacturing costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="mbx:AccruedDrugManufacturingCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNy0yLTEtMS0w_7019f678-6947-48e6-8e11-04c94e4d52c3">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="mbx:AccruedDrugManufacturingCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNy00LTEtMS0w_5240925b-afcc-4680-b743-9de284dcda2d">400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfOC0yLTEtMS0w_1f3a51ae-8c2e-4185-a303-9bf53e579be0">1,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfOC00LTEtMS0w_de18db47-ea84-413c-84ae-122bd8bf3e4b">2,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div id="i_0_40"></div><div><span><br/></span></div><div><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:ProductWarrantyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzMw_e924f407-b0ee-4a13-a072-9313bb85d082" continuedAt="i79f1aea2b42444f8853808acf421f1f8" escape="true">Warrant Liability </ix:nonNumeric></span></div><ix:continuation id="i79f1aea2b42444f8853808acf421f1f8" continuedAt="i96a6babe744a4a51bb2288c96bde3549"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As of September&#160;30, 2019, the Company had <ix:nonFraction unitRef="shares" contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjg_644a6eea-0c6a-4185-a26f-bef52d539353">10,256,193</ix:nonFraction> warrants outstanding consisting of <ix:nonFraction unitRef="shares" contextRef="i8704f5f266694aa9b6f1e5fc38343f5f_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTA2_1c770beb-f6c7-4753-a0ce-fc8790dce0ca">5,250,000</ix:nonFraction> warrants issued in April 2019; <ix:nonFraction unitRef="shares" contextRef="i0764deeff02e4de2af7c0933afdb419b_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQw_196b86a9-a873-45e0-a0e4-074b2f49b7b4">1,585,500</ix:nonFraction> warrants issued in March 2019; <ix:nonFraction unitRef="shares" contextRef="i828883bbb66748609912c14fccab2dc0_D20180601-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTc0_20ec4d2a-8ff2-4bee-b91d-64fdbe9e028c">742,991</ix:nonFraction> warrants issued in June 2018; <ix:nonFraction unitRef="shares" contextRef="ic7679c4528b848609353c11a6dc439fd_D20180201-20180228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjA3_70df5fcb-ee02-4533-8fd7-c4086df8e89c">2,273,700</ix:nonFraction> warrants issued in February 2018; and <ix:nonFraction unitRef="shares" contextRef="i8fdd5e53f5094aada2975171e573b157_D20170201-20170228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjQ4_333707c8-418f-479d-a7af-9d4298d32b35">404,002</ix:nonFraction> warrants issued in February 2017.</span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="mbx:ScheduleOfWarrantActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzNg_4fa5c035-39f7-4578-b336-67754df6e687" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">A summary of the Company's warrant activity during the nine months ended September&#160;30, 2019 and related information follows:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:37.035088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.011696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.602339%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964912%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.105263%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares Under Warrant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Range of Warrant Exercise Price per Share</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ca157a098ae4304a258adc86a04a5b6_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS0xLTEtMS0w_bb8d8a1e-f185-42a6-8f6a-f64157797caf">3,426,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i08cab3276359415a9615b407edca1b58_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS0zLTEtMS0w_a65345ba-b835-4b9e-9fa3-28a997c7563f">1.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id58152a5a8294f01b352ea46be89ca0e_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS01LTEtMS0w_0cc6fee5-2973-4b22-9826-283d2d5a56f3">2.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ca157a098ae4304a258adc86a04a5b6_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS03LTEtMS0w_316ad337-f770-4168-8742-9d8e81403d22">2.48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS05LTEtMS0w_1c3df4cd-edab-489a-8e29-ddc01d1bd381">4.53</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi0xLTEtMS0w_c3e5ace2-4ab0-41c2-a9bd-cd8d38b1c0d6">8,242,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi0zLTEtMS0w_0a39974c-b5b3-4b66-8024-aaaeceafbda9">1.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi01LTEtMS0w_6a225edf-89d5-48b5-83da-dad72f8e656e">1.75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi03LTEtMS0w_b53a0530-caa6-45f5-a1db-6671bf99238f">1.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy0xLTEtMS0w_bb1b7be8-0242-4b91-8397-54af29a0f6b2">1,413,018</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy0zLTEtMS0w_0d299f51-86ce-4c1c-8d21-6f3483530bd7">1.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930" decimals="INF" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy01LTEtMS0w_3ca0a61c-c71b-4f4e-88ca-f698cb27f3bf">1.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy03LTEtMS0w_6509a437-1f33-4e7d-8fe1-e71d5a69389e">1.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNC0xLTEtMS0w_7a6928ad-688e-4693-91d2-e760278ca4c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS0xLTEtMS0w_644a6eea-0c6a-4185-a26f-bef52d539353">10,256,193</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3468782c8cf7406292dddbcdcb10f2e6_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS0zLTEtMS0w_c79d56a0-3262-4f1f-a6a6-dcc6ee45efb0">1.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b3edd6398a45bfa280974c3f953e3e_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS01LTEtMS0w_18c33f36-1ef6-47cb-b569-be573ca776ec">2.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS03LTEtMS0w_d7773755-ee43-4514-acb8-57a1b7e5dcc5">1.89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS05LTEtMS0w_f0897920-49fb-439b-bc4d-25153273c507">4.29</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Exercisable at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930" decimals="INF" format="ixt:numdotdecimal" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy0xLTEtMS0w_3eab78cb-f96a-4362-b60d-a37ee655727c">10,256,193</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3468782c8cf7406292dddbcdcb10f2e6_I20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy0zLTEtMS0w_0d7d5a55-6417-472a-8c0a-163a1bd16f30">1.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b3edd6398a45bfa280974c3f953e3e_I20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy01LTEtMS0w_9ff3576e-6e59-4125-b661-54006e241fc6">2.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy03LTEtMS0w_c57f1a9f-9c84-4bd0-b722-7f6f6e0e3aae">1.89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" format="ixt-sec:duryear" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy05LTEtMS0w_3969e362-96a9-4fce-9f4f-b402fa4659c7">4.29</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 5, in connection with the offering that closed on April 25, 2019, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ibdddec1576174893ac672d9353477c60_I20190425" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNTM2_c43eec6e-a61e-4d41-a7b9-5d11794a4c7c">4,687,500</ix:nonFraction> shares of its common stock (each a "Warrant"). The warrants are immediately exercisable at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjQx_2d492476-07e6-4bb3-9e81-793a2647da93">1.75</ix:nonFraction> per share and expire <ix:nonNumeric contextRef="ic4e01f1ab9534250ba00bf6fed63b50e_D20190425-20190425" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjY1_b0ce45d6-61ce-428a-b343-734bf267ff2d">five years</ix:nonNumeric> from the date of issuance. In connection with the offering, the Company issued Oppenheimer &amp; Co. Inc. a warrant (the "Underwriter Warrant") to purchase up to <ix:nonFraction unitRef="shares" contextRef="ifca03e3808584abfb0298f0b407b56ac_I20190425" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfODI2_30e5c267-a1a1-455f-bcc9-344efedc9c68">562,500</ix:nonFraction> shares of its common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfODgy_828dcb41-cb2e-465f-90e5-e2a0841429dd">1.75</ix:nonFraction> per share. The Underwriter Warrant expires on April 23, 2024.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 5, in connection with the offering that closed on March 29, 2019, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ia04057d9a2fc47f59c529617eb6148da_I20190329" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTA3NQ_4eda6415-a263-4c8b-80a4-1a049a8ec135">2,625,000</ix:nonFraction> shares of its common stock (each a &#8220;Warrant&#8221;).  The warrants are immediately exercisable at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia04057d9a2fc47f59c529617eb6148da_I20190329" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTE4MQ_685531ad-184e-4965-8567-a92acbbf1fc6">1.10</ix:nonFraction> per share, subject to adjustment in certain circumstances, and expire <ix:nonNumeric contextRef="i0ff20b788d224ad3a44277ae0c89865e_D20190329-20190329" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTI1NA_f68b5139-1b0a-44b8-ab5f-65d113f4a294">five years</ix:nonNumeric> from the date of issuance.  In connection with the offering, the Company issued Oppenheimer &amp; Co. Inc. a warrant (the &#8220;Underwriter Warrant&#8221;) to purchase up to <ix:nonFraction unitRef="shares" contextRef="idfa81cbdf3044194a501897570de6f30_I20190329" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQxNg_ee3896fe-a390-4ea9-b477-075670fa4b35">367,500</ix:nonFraction> shares of its common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idfa81cbdf3044194a501897570de6f30_I20190329" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQ3Mg_63bb5f75-a4b6-438f-b5b5-156357cac85a">1.10</ix:nonFraction> per share. The Underwriter Warrant expires on March 27, 2024. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The basis of value of the warrant liability is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. The Company uses the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of its remaining warrants outstanding. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The risk-free interest rate </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Where appropriate, the Company used the historical volatility of peer entities combined with the Company's due to the lack of sufficient historical data of its stock price during the years 2017 to 2019. </span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i96a6babe744a4a51bb2288c96bde3549"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="mbx:ScheduleOfAssumptionsUsed1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzNw_9b129ab7-901e-418c-b0fa-c09ea4ec5e49" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The assumptions used in the BSM models for its outstanding warrants are as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:51.362573%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.380117%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.070175%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918129%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.380117%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.723977%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526316%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS0xLTEtMS0w_611a391a-920d-493b-b0ca-6bbd2390a8e4">1.55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS0zLTEtMS0w_ee48606e-2088-4c1d-81fa-01ceb2229080">1.60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS01LTEtMS0w_05e6189b-65ae-4036-9347-5ff5cbcf13d3">2.46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS03LTEtMS0w_a8be3209-c348-46d5-8e63-7bfd30f5c6ae">2.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi0xLTEtMS0w_bbfe08cb-71d4-47d4-8826-cba762be5db9">90.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi0zLTEtMS0w_ead403c0-efb1-4158-83ae-da70b2e3c0b8">97.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi01LTEtMS0w_7c5cd16c-1a57-48a9-ba2b-14ad5186b747">75.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi03LTEtMS0w_70080488-06ae-4383-9045-71d00b3e10f7">80.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy0xLTEtMS0w_170c7bcb-5360-46de-97d2-66f391dc6873">2.37</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy0zLTEtMS0w_74ef8038-60c2-40dc-93e1-f04235e76592">4.57</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy01LTEtMS0w_6cd9b405-1e87-463e-95ef-012efb9074db">3.12</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy03LTEtMS0w_0afe54a3-b507-43ef-ba17-0339b10dff53">4.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfNC0xLTEtMS0w_bcfddeb2-5256-4746-80c8-09c15db7ab53">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfNC01LTEtMS0w_0a068492-310d-4d6f-91c1-84f928d9421f">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_43"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNzA_c90f3c4c-8910-4af5-a0e3-8c7c4e6948e4" continuedAt="ia0924bc9a86949988bbbf47f588fc2f7" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="ia0924bc9a86949988bbbf47f588fc2f7" continuedAt="i1c5a88508cd340f8a48cf935e06ef04d"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="mbx:SharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTI_3034bf95-3538-4ecb-97ac-727d1ca15e18">105,000,000</ix:nonFraction> shares of which <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzE_b1b81a3c-c986-4178-864c-7f66692e8828">5,000,000</ix:nonFraction> shares of preferred stock are authorized and <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE5_8488c425-bcac-4dfc-8aa7-716b92c4f549">100,000,000</ix:nonFraction> shares of common stock are authorized.</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjIz_3f79a171-ef70-41a6-a294-a0fa5dcff5f9">5,000,000</ix:nonFraction> shares of preferred stock. Its certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of September&#160;30, 2019, there was <ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODAx_6cb067ca-c2ae-4d6f-becc-81523f93e2b5">no</ix:nonFraction> preferred stock issued.</span></div><div style="text-indent:19pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Lincoln Park Transaction</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On October 4, 2018, the Company entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"). Pursuant to the terms of the Purchase Agreement, Lincoln Park has agreed to purchase from the Company up to $<ix:nonFraction unitRef="usd" contextRef="ic650d629ddbe42bba07cd7284425b9cb_D20181004-20181004" decimals="INF" format="ixt:numdotdecimal" name="mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE4OQ_13c9bcb0-a78e-4c34-86f2-79b8d983b80c">20.0</ix:nonFraction> million of our common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, the Company filed with the SEC a registration statement to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, at the time the Company signed the Purchase Agreement and the Registration Rights Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i2b95e4a080574cb187b7baa5845b5bc7_D20181004-20181004" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY5Mw_3bd42837-d5bd-493b-886e-53db65fe4f9e">243,013</ix:nonFraction> shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement and the Company may issue an additional <ix:nonFraction unitRef="shares" contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTg2Nw_f203be41-8670-44b8-b633-813d3591eb3d">121,507</ix:nonFraction> commitment shares pro-rata when and if Lincoln Park purchases (at the Company's discretion) the $<ix:nonFraction unitRef="usd" contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004" decimals="INF" format="ixt:numdotdecimal" name="mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTk2Ng_76abfbdc-18ed-4b89-9c70-47f23aa01270">20.0</ix:nonFraction> million aggregate commitment. The commitment shares were valued at $<ix:nonFraction unitRef="usd" contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjAyOA_67995a5e-ea0c-4add-8611-e19fa41d4bd4">337,788</ix:nonFraction>, recorded as an addition to equity for the issuance of common stock and treated as a reduction to equity as a cost of capital to be raised under the Purchase Agreement. During the three months ended December 31, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie0294ca4bdf04a0a9eca45bd94dea472_D20181001-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjI2OA_c2fcbcc7-c1f8-4909-bea9-9ecfe82dddf1">1,399,153</ix:nonFraction> shares to Lincoln Park which included <ix:nonFraction unitRef="shares" contextRef="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjMwOQ_5b98320d-8f08-4688-9c83-13fe1ce3c588">10,918</ix:nonFraction> commitment shares, for $<ix:nonFraction unitRef="usd" contextRef="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjMzNA_f90c0846-a30f-4d0e-bb8a-7d16695b1e48">1.8</ix:nonFraction> million. During the first quarter of 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjM5MQ_8a1a5594-29d3-4ea8-a52b-bbe00f74ff1f">605,367</ix:nonFraction> shares, which included <ix:nonFraction unitRef="shares" contextRef="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQxNw_a71c05fe-48f7-492b-982c-d58e7c32cc5c">5,367</ix:nonFraction> commitment shares for $<ix:nonFraction unitRef="usd" contextRef="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQ0Mg_c9ba130a-e1b5-4af0-95b2-cfbd274dd1cc">0.9</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="i38daafc04f49458db341d48f10e1fbe3_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjM_5d4097af-7fc9-4aa1-b75c-e5ab04fb49fd"><ix:nonFraction unitRef="shares" contextRef="i2af2bc87c2d14e3faa7aa256386e955c_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQ0Ng_6f9b2482-4fbe-4ae5-bec7-87f53496ad35">No</ix:nonFraction></ix:nonFraction> shares were issued to Lincoln Park during the second quarter of 2019. During the third quarter of 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgwMA_03779b62-dd3e-451f-82e7-4e4ea248aaec">100,674</ix:nonFraction> shares to Lincoln Park which included <ix:nonFraction unitRef="shares" contextRef="i6670a76fcc104cb499360b871805a581_D20190701-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgwNQ_b4c49231-d9ea-44c1-ab32-7cfd3a323559">674</ix:nonFraction> commitment shares, for $<ix:nonFraction unitRef="usd" contextRef="i6670a76fcc104cb499360b871805a581_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgxOQ_825c3710-a055-4972-b305-0b69d4b3fd62">0.1</ix:nonFraction> million.</span></div><div style="text-indent:19pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:174%;">At Market Issuance Sales Agreements ("ATM")</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> In September 2017, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with Roth Capital Partners, LLC ("Roth") and National Securities Corporation ("National") (collectively, the &#8220;Agents&#8221;). Pursuant to the terms of the ATM Agreement, the Company was permitted to sell from time to time through the Agents shares of the Company&#8217;s common stock with an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i9b480bb73120461ead91f6bfb97297dc_I20170930" decimals="-6" format="ixt:numdotdecimal" name="mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjk4Ng_61f67473-90ea-48ff-9128-88ffb1717455">13</ix:nonFraction> million.  The Company agreed to pay a commission to the Agents of <ix:nonFraction unitRef="number" contextRef="i5395f33565804b6db870e49ee1f42631_D20170901-20170930" decimals="3" name="mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzA0Nw_5bf6903f-8ed8-434d-81b0-03e7aa9418fd">3.0</ix:nonFraction>% of the gross proceeds of the sale of the shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company also provided the Agents with customary indemnification rights. In June 2019, the Company canceled the ATM Agreement. The Company did not sell any shares under this ATM Agreement in 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Subsequent to canceling the ATM Agreement with Roth and National, the Company entered into an At Market Issuance Sales Agreement (the &#8220;Opco Agreement&#8221;) with Oppenheimer &amp; Co. Inc. (the &#8220;Agent&#8221;) on July 23, 2019. Pursuant to </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1c5a88508cd340f8a48cf935e06ef04d" continuedAt="iafa54978c01743aaa2c5bafa5838de15"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">the terms of the Opco Agreement, the Company may sell from time to time through the Agent shares of the Company&#8217;s common stock, with an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723" decimals="-6" format="ixt:numdotdecimal" name="mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzgzMA_5109b0f0-c6af-4000-9fd5-dc0f98f32c71">15</ix:nonFraction> million (the &#8220;Shares&#8221;). Any sales of Shares pursuant to the Opco Agreement will be made under the Company&#8217;s effective &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-3 (File No. 333-219434), which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the Opco Agreement, the Company may sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended. Sales of the Shares, if any, may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company&#8217;s Board of Directors or a duly authorized committee thereof. The Company or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to $<ix:nonFraction unitRef="usd" contextRef="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723" decimals="-6" format="ixt:numdotdecimal" name="mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTAwOQ_55cf87cc-a1b2-4594-9c4b-fa9b2d6344d5">15</ix:nonFraction> million, or sooner if either the Company or the Agent terminate the Agreement pursuant to its terms. The Company will pay a commission to the Agent of <ix:nonFraction unitRef="number" contextRef="i4bbdedafb3e34aa6ae001a6d102bb5ea_D20190723-20190723" decimals="3" name="mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTE1NQ_e844fe51-3a52-47f7-ba85-4f442c8a9887">3.0</ix:nonFraction>% of the gross proceeds of the sale of the Shares sold under the Agreement and reimburse the Agent for certain expenses. The Company has also provided the Agent with customary indemnification rights. The Company has not sold any shares under the Opco Agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Adoption of 2015 Stock Plan</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In 2015, the Board of Directors of the Company approved the Company&#8217;s 2015 Stock Plan, which was amended in 2017 and 2018. The expiration date of the plan is December&#160;5, 2025 and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants under the plan is currently <ix:nonFraction unitRef="shares" contextRef="i944e3ebf4e3447758b5f5ad06e16b8d3_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTc4NQ_d1dbdd31-3c06-4db4-a33f-6c7f580d40c3">4,500,000</ix:nonFraction> shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards, stock unit awards or stock appreciation rights. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjQ_66b8ee6b-ca19-4abf-9aee-85a91cbe4cce" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for the nine months ended September&#160;30, 2019:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:34.818851%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.782032%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.929308%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.929308%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.929308%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.929308%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Stock Options Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted Average Grant Date Fair Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS0yLTEtMS0w_63a17ada-46bd-4943-aa71-a668505b0457">2,794,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS00LTEtMS0w_27357532-f54c-4e45-b699-0a65bc0367d7">1.78</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS02LTEtMS0w_3dcda4ff-dd39-4262-851b-6fd471a48e89">2.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic11172b4c23840729a0c55b50453ef6b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS04LTEtMS0w_b525a23a-7ecb-4fa4-89a0-6586b98f7c49">9.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS0xMC0xLTEtMA_6de67049-5a4e-4bd8-b80b-201e8d1fad7c">21,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi0yLTEtMS0w_56e31a05-49d0-430b-9801-9cb940655609">1,115,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi00LTEtMS0w_d2e15d98-0b16-4ed4-8172-40e26ba2a1c6">1.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi02LTEtMS0w_115077b1-c40d-460d-b06e-02cdf8680a69">1.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy0yLTEtMS0w_72d9afc4-12e8-43f7-9121-0e118d45860f">25,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy00LTEtMS0w_340d981e-5b04-471e-9aef-7103c5dee657">0.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy02LTEtMS0w_29a489c9-6927-4b01-97d9-fd8108796f53">0.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0yLTEtMS04NjQ_0aa100d2-440e-404e-8082-667f25f02d9d">103,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC00LTEtMS04NjQ_4503a6a3-76f4-4b6d-bbaa-2335c0343ed5">1.29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC02LTEtMS04NjQ_302fadcd-14f0-4cba-b0df-551ace73292d">1.82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0yLTEtMS0w_76fc9ffb-a676-44c1-9288-ef2c29ae601e">3,781,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC00LTEtMS0w_d76e33ef-a362-4c7a-ba17-ef5d6bb6d8f9">1.60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC02LTEtMS0w_007aafac-ff40-4fcc-a541-db309a04b02f">2.28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC04LTEtMS0w_747456af-c76e-44c9-b22c-afaa925756b5">8.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0xMC0xLTEtMA_57149de2-f1a6-41d4-a3fa-43c874c1b2a3">900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi0yLTEtMS0w_ca683c5d-18ce-45ab-95de-2e600fea3c1d">993,083</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="2" name="mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi00LTEtMS0w_6e7fe95c-9749-41bb-b0b9-80217e0417b7">2.28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi02LTEtMS0w_c77af90c-1b9a-456a-bc6a-58d6e00049d8">3.42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi04LTEtMS0w_c9fdbcf4-7f44-4d03-b525-967e246800a4">7.79</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi0xMC0xLTEtMA_5e7c7998-bd0d-4619-a496-c6ef91b9cdfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjc_fbf29108-7b4e-4dba-870f-2d8a3fdeadfc" escape="true"><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of the option grants has been estimated, with the following assumptions:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:59.549708%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.040936%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.577778%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.040936%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.040936%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.577778%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.040936%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi0xLTEtMS0w_5a5df09f-4130-46c9-921b-59bff2eab9b2">1.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi0zLTEtMS0w_8e0defc1-beda-4140-82fb-60ef2298e80b">1.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi01LTEtMS0w_9dc72285-9c09-4e6d-953e-cec6ba932436">0.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi03LTEtMS0w_9ceb1755-ac14-4ae6-9f82-b0747429a1d5">2.24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy0xLTEtMS0w_468eb76a-6515-44bc-b093-1b18f3db0e63">85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy0zLTEtMS0w_eba71353-501f-4cdb-a5ba-986833dcc898">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy01LTEtMS0w_3ef986f4-ad8f-441e-a537-6bb9ecf7447a">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy03LTEtMS0w_240a8cd2-4a33-4171-acbc-c464862656ad">89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2c39d2de985d4affbdbb368f73d64943_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC0xLTEtMS0w_e02929df-e96f-4d0f-b35a-02c432418b23">5.31</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if80a49b1ac35464ca409df350165e50c_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC0zLTEtMS0w_2ed5381e-4854-4805-bac2-6d4627044843">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i84c2d53697dc4799b0f1c3663013ed3f_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC01LTEtMS0w_81479427-e74e-437d-a809-5a1532f7051b">5</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9a7f681b9d1a4c9a9ea32d44511a7e37_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC03LTEtMS0w_ca3076d0-ed59-4d67-9463-6a8251528270">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNS0xLTEtMS0w_6be61682-5b57-4925-9e67-a8d7cbcbc21c">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNS01LTEtMS0w_d21330e8-4e39-47a2-9b77-81c261f2eac0">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iafa54978c01743aaa2c5bafa5838de15" continuedAt="ie3b6a2b2b19143aabb54ecf0d55c6647"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="mbx:ComponentsofShareBasedCompensationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjI_f13616ab-82f1-4ed9-97b3-8e9fb40c7456" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation for the three and nine months ended September&#160;30, 2019 and 2018, are as follows (in thousands):</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.684211%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549708%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic732ea1178074f47a9dc97cb065ced73_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi0xLTEtMS0w_2f819c2c-2b7a-44fd-bf2c-aefb972902d4">430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac0f11dd922044268e807fecd4317991_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi0zLTEtMS0w_ae73970a-8671-4bde-a13d-7b66ca941bf9">207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13547ca083ed457da93a472804befa90_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi01LTEtMS0w_a3162880-0a7a-4413-8d0c-94fe2a9953be">1,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47d423e14ef8484ca70b7db69ffb12f3_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi03LTEtMS0w_41c68b62-dfbc-4764-80e8-28d617c49490">709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a3d37009bad40bcbbe66bfb5272cfd4_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy0xLTEtMS0w_800c35ae-30ff-4509-85f6-d5548377b13d">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie587b47ea845420dab0c9acddca354f8_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy0zLTEtMS0w_afe79969-c9f2-4cdf-8089-6b680db90271">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76cfe79a8ccc44f1a1b37b902e2066fa_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy01LTEtMS0w_3ac2fe1e-6844-4e9d-8df4-da4f6cc4b5db">152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i29e6f95a02bb48c59456c43de158162f_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy03LTEtMS0w_4d90d726-fe17-4e20-a4a8-d62af910d316">116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC0xLTEtMS0w_a6421e91-ab9f-4952-ac74-ec4a04b05be9">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC0zLTEtMS0w_5bcea531-c4f4-4d1a-9787-a4fba5e35d39">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC01LTEtMS0w_53ddb249-3095-456d-8e49-782f11c24242">1,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC03LTEtMS0w_6ee7280d-606f-4c8d-ba60-901fde98edc2">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2019, <ix:nonFraction unitRef="shares" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjM3MQ_b2e5ed09-7017-45a4-8b94-65a2e2e98107">1,115,000</ix:nonFraction> stock options were granted. Options granted during 2019 have an aggregated fair value of $<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-5" format="ixt:numdotdecimal" name="mbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjQ5NA_bd99cf39-3f15-4c4c-991c-41a50c549e10">1.2</ix:nonFraction> million which was calculated using the Black-Scholes option-pricing model. As of September&#160;30, 2019, total compensation cost not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjYyMQ_e64e62b1-a2af-485b-8119-94d68d8ff991">3.2</ix:nonFraction> million and the weighted average period over which this amount is expected to be recognized is <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjcxMQ_d7d2cea8-2d73-40e0-b86a-ac02127f93ba">2.51</ix:nonNumeric> years. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the "plain vanilla" method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because the Company does not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies combined with the Company's due to the lack of sufficient historical data of its stock price. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">During the nine months ended September 30, 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc1Mg_9006b442-6c34-4bff-ad3e-ecbb01c4b835">316,907</ix:nonFraction> restricted stock units, which vest annually in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY0OTI2NzQ1NjEzNg_c203f143-78a7-490e-b73e-32b489147d7d">four</span> equal installments. The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc1OQ_ffd1d6af-4a53-4f8c-a94f-09047092a7ef">1.31</ix:nonFraction> per unit. As of September&#160;30, 2019, total compensation cost not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="id6bbd1cc266d4e28b55786247b4551ba_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc3Mw_c23cfe4b-0c62-4907-90b9-2ca6b6f0318f">0.4</ix:nonFraction> million and the weighted average period over which this amount is expected to be recognized is <ix:nonNumeric contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc4Nw_4c25915b-5e1f-4282-8ae6-162252747fe8">3.8</ix:nonNumeric> years. No restricted stock units were vested as of September 30, 2019 and no units were granted prior to 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Consulting Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company entered into a consulting agreement for its investor relations operations. The consulting agreement initially covered a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzcyMQ_9e5789a7-6205-4556-8350-0fb32f1e123d">twelve</span> months from the commencement date of July 29, 2017 and was extended in April 2018 until March 31, 2019. Pursuant to the original consulting agreement, in exchange for the consulting services, the Company issued <ix:nonFraction unitRef="technology" contextRef="i7b9663d77efe491f97c917d37bd60486_I20170729" decimals="INF" format="ixt-sec:numwordsen" name="mbx:ClassofWarrantorRightNumberofWarrantsIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzkzMg_afecfcb9-2b01-48a7-9530-6b0021bbafe2">two</ix:nonFraction> warrants (collectively, the &#8220;Warrants&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="icd06781e67be410c92ac95aa2495a7db_I20170729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzk4Nw_2d17e100-629b-46da-b625-12192820c296">100,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2e838cce41cb48e980a2b72acf45b359_I20170729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzk5NA_4322fd5d-9721-4262-a6d1-19a156610449">50,000</ix:nonFraction> shares of common stock at exercise prices of $<ix:nonFraction unitRef="usdPerShare" contextRef="icd06781e67be410c92ac95aa2495a7db_I20170729" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA0Mg_998e87ba-da41-4db3-9c71-33dfc509fdb6">2.41</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e838cce41cb48e980a2b72acf45b359_I20170729" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA0OQ_9737a9d0-4a1a-4f1d-9e71-4e6d2a470293">3.00</ix:nonFraction> per share. Each of the Warrants vested over a <ix:nonNumeric contextRef="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729" format="ixt-sec:durmonth" name="mbx:ClassofWarrantorRightVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA5OA_c8295b92-9135-4253-a03c-40329a6c38c2">12</ix:nonNumeric>-month period in equal monthly installments starting July 29, 2017, provided that the consultant was providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017 and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODM2NQ_0243ffb2-eae1-40d2-9343-bc1cb403c4d5">five</span> years from the initial exercise date. In connection with the first extension of the consulting agreement, the Company issued the consultant a <ix:nonNumeric contextRef="ia621ad5cb56b4f519b43b8d05d571153_D20180401-20180430" format="ixt-sec:duryear" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODc0Nw_6efdd43b-5286-4fb2-b930-14ddf294605d">3</ix:nonNumeric>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ice90c9c153c9457994fb3428ae482f66_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODc3NQ_0c88831e-4aee-48de-9807-7ea759c3205c">100,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ice90c9c153c9457994fb3428ae482f66_I20180430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODgyNQ_b8e32b5a-2994-4b6f-bad0-f3c7f9eb18e3">3.00</ix:nonFraction> per share vesting in four quarterly installments. In addition, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="mbx:ConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODkwOA_59a78e52-eb2f-4641-8965-9e3d50997f1a">20,000</ix:nonFraction> to the consultant per quarter pursuant to the first amendment to the consulting agreement. On July 8, 2019, the Company amended the existing consulting agreement for additional cash payments, with a right to cease cash payments by issuing the consultant a fully vested <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTE4MQ_bd9f0e14-58b3-4547-8588-62c23121c211">three</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="id3cdb4704f2241f7bf6422f7e0974142_I20190708" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTIwOQ_ebf79d52-a023-47bf-9c07-cdf7cd379c5a">150,000</ix:nonFraction> shares of Company common stock, subject to NASDAQ listing of additional shares approval. On August 8, 2019, the Company elected to issue such warrant with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1792812536944689b19b7c33818e27e0_I20190808" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTYzMg_25f26e2b-4514-4039-96d9-850911c3138b">1.64</ix:nonFraction>. The Company recorded stock compensation expense for the non-employee consulting agreement of $<ix:nonFraction unitRef="usd" contextRef="i743b8f15d1954cd1977b8bf32aa43aa0_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjc0ODc3OTA4ODkwNQ_3e9d6106-2100-49e3-bfab-1d2e862c3467">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8aa13f97f5742a3afa1fb7e64d1af57_D20180701-20180930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjE5OTAyMzI3NTA2MQ_d580eae6-2fca-406b-a6e0-fe633f715e62">0.04</ix:nonFraction> million for the three months ended September 30, 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjE5OTAyMzI3NTA3MQ_c1b7894c-9e14-4c72-811d-02da795399fe">0.1</ix:nonFraction> million for both the nine months ended September 30, 2019 and 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTYzNw_c824f425-3fd7-44f1-a9aa-d80307808ece">9</ix:nonFraction> million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale of <ix:nonFraction unitRef="shares" contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTc5Ng_6c07d966-0a5a-462d-b528-6931d07e1a55">4,290,000</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTg1Mg_960b5a9c-064f-4add-a821-c54ee822988b">2.10</ix:nonFraction> per share. Concurrently with the sale of the common stock, pursuant to the Purchase Agreement, the Company also sold warrants to purchase <ix:nonFraction unitRef="shares" contextRef="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTk5Mw_37e5c33d-b8e5-42a2-a4e4-8cc1ecc56c6d">2,145,000</ix:nonFraction> shares of common stock. The Company sold the common stock and warrants for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAxMTM_84a312f8-b669-4f69-a0bb-369aaaf70a1e">9.0</ix:nonFraction> million. The net proceeds from the transactions was approximately $<ix:nonFraction unitRef="usd" contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAxNzQ_8ac43c1d-106b-439b-9f6f-185aac38e8c7">8.2</ix:nonFraction> million after deducting certain fees due to the placement agent and transaction expenses. Subject to certain beneficial ownership limitations, the warrants became exercisable on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAzNTE_dc4c3f39-7e46-4a6e-916d-e8c0623716e3">six</span>-month anniversary of the issuance date at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6cbda1bd25cd4cd7ab24c983a3515b9e_I20180228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA0MjM_38044303-1233-4d0e-8b78-472eda2ea34a">2.80</ix:nonFraction> per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA1NTQ_b2561df1-708d-4b79-82bd-4bfa1c75f45e">five</span> years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018. </span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ie3b6a2b2b19143aabb54ecf0d55c6647"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA3MDI_ae62ecb8-2ed1-4007-819d-6cd2c860b73c">2.3</ix:nonFraction> million Registered Direct Offering</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA5MDg_2d704eb4-8dda-4576-96ae-cfdea2c9d08b">2.3</ix:nonFraction> million. In connection with the offering, the Company issued <ix:nonFraction unitRef="shares" contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA5NjQ_7484a3c7-6903-4a53-a9e3-c55930c9108c">1,092,636</ix:nonFraction> registered shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEwMjQ_907edb7a-9b38-440f-a770-82bf8bdd444d">2.105</ix:nonFraction> per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEyMDg_11ff64dc-a596-4859-8281-1e099740a0a9">0.65</ix:nonFraction> of a share of common stock. The warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEyNzg_7479e095-da05-4c0f-9dd5-5e6c4636abe8">2.02</ix:nonFraction> per share, became exercisable <ix:nonNumeric contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630" format="ixt-sec:durwordsen" name="mbx:ClassOfWarrantOrRightInitialExercisePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEzMTE_e0102772-7817-4855-8c6a-b5181b632f27">six months</ix:nonNumeric> from the date of issuance, and will expire <ix:nonNumeric contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630" format="ixt-sec:durwordsen" name="mbx:ClassofWarrantorRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEzNTc_f682ca5e-3d9b-4ef1-9aeb-81656e5d9a6f">five years</ix:nonNumeric> from the initial exercise date. Roth Capital Partners LLC served as sole placement agent for the offering.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE0NzA_c0b779b2-4f2a-4bcb-8cf9-a6846e4749c8">5.25</ix:nonFraction> million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with Oppenheimer &amp; Co. Inc. (the "Underwriter") relating to an underwritten offering (the "Offering") of <ix:nonFraction unitRef="shares" contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="mbx:UnitsSoldInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE3MDM_45080fb9-e93e-484d-8cbb-09b26a8208e6">5,250,000</ix:nonFraction> units (each a "Unit"), each unit consisting of (i) <ix:nonFraction unitRef="shares" contextRef="i1617ea995ee541e797427260cfd1509c_D20190301-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE3NTc_89f86af0-7ef2-4e16-be2f-0e5227eb35db">one</ix:nonFraction> share of the Company's common stock, and (ii) <ix:nonFraction unitRef="shares" contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE4MDY_27dd6eb5-e6c7-456f-9dd5-e4c54f636dcd">0.5</ix:nonFraction> of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $<ix:nonFraction unitRef="usdPerShare" contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331" decimals="INF" name="mbx:UnitOfferingUnitPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE5MjM_75869fd4-0f7f-47c3-8d25-81d145b30dc3">1.00</ix:nonFraction> per Unit, and the Underwriter agreed to purchase the Units from the Company pursuant to the Underwriting Agreement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0db6bce61f314f58ae7094418825cba1_I20190331" decimals="INF" name="mbx:UnitOfferingUnitPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIwNTU_2e637a66-be3e-4c23-a07b-5ab618299322">0.93</ix:nonFraction> per Unit. The Warrants included in the Units are immediately exercisable at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIxNDU_247363ac-4bbb-4011-a40e-91c6387f94c9">1.10</ix:nonFraction> per share, subject to adjustments in certain circumstances, and will expire <ix:nonNumeric contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331" format="ixt-sec:durwordsen" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIyMjQ_19a77926-2dcb-4ba4-9d13-513a16931add">five years</ix:nonNumeric> from the date of issuance. The net proceeds from the transaction was approximately $<ix:nonFraction unitRef="usd" contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIzMTA_179e2aa1-77bf-4498-8d13-f2b1701a191f">4.7</ix:nonFraction> million after deducting the underwriting discount and estimated offering expenses payable by the Company.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI0MTI_d63e1a62-eda6-4e12-9625-f98e29b044ae">15</ix:nonFraction> million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company entered into subscription agreements (each a "Subscription Agreement") with certain institutional investors (the "Investors") for the sale by the Company of <ix:nonFraction unitRef="shares" contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI2Mjc_78ab277a-cc2b-46ce-b771-c8ec6a598de0">9,375,000</ix:nonFraction> units (each a "Unit"), each Unit consisting of (i) <ix:nonFraction unitRef="shares" contextRef="ied5f752a87a043319ef30dc7b1278714_D20190401-20190430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI2ODE_0d86d30f-ca9c-4069-ab34-8154954505ab">one</ix:nonFraction> share of the Company's common stock, and (ii) <ix:nonFraction unitRef="shares" contextRef="i676b8255b2e542be8196edfc27042486_I20190430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI3MzA_29f64d95-1857-4d64-90f1-b5d6f658f512">0.5</ix:nonFraction> of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $<ix:nonFraction unitRef="usdPerShare" contextRef="i676b8255b2e542be8196edfc27042486_I20190430" decimals="INF" name="mbx:UnitOfferingUnitPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI4NDc_d899d073-b912-49f6-8da7-ff6166a92e0e">1.60</ix:nonFraction> per Unit. The Warrants included in the Units are immediately exercisable at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i676b8255b2e542be8196edfc27042486_I20190430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI5NDE_c46c9b9a-0e92-4483-84d0-9e46374158cb">1.75</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430" format="ixt-sec:durwordsen" name="mbx:ClassOfWarrantOrRightTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI5NzA_9a87f490-8de6-4ce6-9f67-c89316a6dac2">five years</ix:nonNumeric> from the date of issuance. The net proceeds from the transaction was approximately $<ix:nonFraction unitRef="usd" contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMwNTY_1414ec7a-dfcf-402d-95d9-e6e5e406d325">13.7</ix:nonFraction> million after deducting the placement agent fees and estimated offering expenses payable by the Company.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Initial Public Offering Warrants</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Company's initial public offering completed in May 2016, the Company issued its underwriter a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjk1NQ_b57729a6-ddb3-4566-b0b4-be41f4b8b523">five</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i816a05948bde4ad3ab07190983382b45_D20160501-20160531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjE4Mw_8ccb4d36-f30c-43ba-b8be-87b25d9f0929">107,802</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4d3b7c28de3e409ab196587e0ef6e3b9_I20160531" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjE5MA_73bf81d8-2e1e-4d0d-b12e-923d0a6bd264">7.50</ix:nonFraction> per share.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">    &#160;</span></div><div id="i_0_46"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMTYzMA_8b746fbb-ee38-4f5d-99c1-b5638a759828" continuedAt="ibc6f9c34132f468784a5dcda0172114f" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ibc6f9c34132f468784a5dcda0172114f"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not expect to pay any significant federal, state, or foreign income taxes in 2019 as a result of the losses recorded during the three and nine months ended September&#160;30, 2019 and the additional losses expected for the remainder of 2019 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of September&#160;30, 2019, the Company maintained a full valuation allowance for all deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded an income tax benefit for the three and nine months ended September 30, 2019 of $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwMA_e279321c-16c0-4ce2-a2d5-ec6fde8374dd"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwMA_fddf56b4-3374-41db-bec9-dfcbd88dc80c">0.2</ix:nonFraction></ix:nonFraction> million resulting in a quarterly effective tax rate of <ix:nonFraction unitRef="number" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwNw_49a50be4-cd64-4b48-ada7-e2ddc22421d3">5.2</ix:nonFraction>% and an annual effective rate of <ix:nonFraction unitRef="number" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYxMw_8463779a-984b-48da-a23e-f28603489144">1.4</ix:nonFraction>%. The total income tax benefit is comprised of research and development tax credits recoverable, associated with Moleculin Australia Pty Ltd., (MAPL), a wholly owned subsidiary formed in June 2018, related to preclinical development in Australia for WP1732, an analog of WP1066. Aside from the Australia tax credit, the Company has recorded <ix:nonFraction unitRef="usd" contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfOTI0_f8e96955-b19b-463b-8232-18965ae28665"><ix:nonFraction unitRef="usd" contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfOTI0_fffdc90c-a033-4d18-83cb-78925c49d39e">no</ix:nonFraction></ix:nonFraction> income taxes for the three and nine months ended September&#160;30, 2019 and 2018. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants and valuation allowances on the Company&#8217;s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i_0_49"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTQyOTM2NTExODE5Nzg_668d6f58-2154-4ec0-a612-b1786d36023e" continuedAt="ic20f63b42f774b7cbbb5e397f0524d21" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic20f63b42f774b7cbbb5e397f0524d21" continuedAt="i81985915ee134013b668d2124bc6e02d"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the commitments and contingencies elsewhere in these notes, see below for a discussion of our commitments and contingencies as of September&#160;30, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Lease Obligations Payable</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of use asset and a lease liability for all leases at the commencement date based on the present value of the lease payment over the lease term. In March 2018, the Company entered into a Lease Agreement (the &#8220;Lease&#8221;) which it uses for its corporate office space and headquarters. The term of the Lease began in August 2018 and will continue for an initial term of <ix:nonNumeric contextRef="ife26a4e6c9db456586eec4fb4d9b4058_I20180322" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzkz_5c490bec-eb6f-4567-8492-e0d16f78580a">66</ix:nonNumeric> months, which may be renewed for an additional <ix:nonNumeric contextRef="ife26a4e6c9db456586eec4fb4d9b4058_I20180322" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODM2_7e8fcb56-a8fe-49a0-8db8-f44480cb5d67">5</ix:nonNumeric> years. The Company is required to remit base monthly rent which will increase at an average approximate rate of <ix:nonFraction unitRef="number" contextRef="i32cccf3548364065976506f8bb9f0ce0_D20180322-20180322" decimals="2" name="mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTY1_96e0d1a4-cd91-4526-a0f1-de0cad8eb3c6">3</ix:nonFraction>% each year. The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the Landlord. The leased space is located in Houston, Texas. The corporate office lease is classified as an operating lease.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company entered into an Amended Lease Agreement (the "Lab Lease") which it uses for lab space. The term of the Lease began in September 2019 and will continue for an initial term of <ix:nonNumeric contextRef="i7d2aeadcc3b7480899be3e16b8a13854_I20190831" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0MTY3NQ_a5c522d6-d0eb-4780-89c3-3972fac9c181">35</ix:nonNumeric> months, with no further right or option to renew. The Company is required to remit base monthly rent which will increase at an average approximate rate of <ix:nonFraction unitRef="number" contextRef="i5b329d2fb15249cbabe0efe9cfb5aa8a_D20190831-20190831" decimals="2" name="mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0MjY0NQ_0fc4347b-b90a-4000-ad84-5dca127ad181">3</ix:nonFraction>% each year.  The Lab Lease is classified as an operating lease. In August 2019, the Company entered into a sublease with Houston Pharmaceuticals, Inc. ("HPI"). The Company has granted HPI access to all of its Lab Lease space and HPI has agreed to pay the Company <ix:nonFraction unitRef="number" contextRef="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831" decimals="2" name="mbx:PercentageOfRentPayableByCoLessee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTM0Mw_935aa486-4604-4321-aff0-7995fb1bad41">50</ix:nonFraction>% of the Company's rent payable under the Lab Lease less <ix:nonFraction unitRef="number" contextRef="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831" decimals="2" name="mbx:PercentageOfSubLeaseIncomeAllocableToCoLessee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTA5OTUxMTY1NzcwMw_81360027-a6de-4bd7-ad83-0250eddfb598">50</ix:nonFraction>% of any benefits from any sublease or other lab service agreement the Company may receive from its Lab Lease. Although HPI has access to the Company's Lab Lease space, it is the intent of the parties that they equally share the Lab Lease space for research purposes. The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTMzOA_afab2e73-f751-46f0-b07f-b83e158a0e32"><ix:nonFraction unitRef="usd" contextRef="ia823a60ecb104dedb9bf6190868e582c_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTMzOA_da9e588a-20ac-480b-9da8-633364e9d6ce">3,400</ix:nonFraction></ix:nonFraction> in sublease income from the related party for the three and nine months ended September 30, 2019, respectively. Sublease income is recorded as other income on the Company's condensed consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded lease costs of $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI3MA_59d0d5df-8d6d-4791-b759-0f9249fd144e">0.02</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI3Nw_49350868-4e32-4974-8bae-4589368c967c">0.03</ix:nonFraction> million for the three and nine months ended September&#160;30, 2019, respectively. The Company made an accounting policy election not to apply the recognition requirements to short-term leases. The Company recognizes the lease payments for short-term leases in profit or loss on a straight-line basis over the lease term, and variable lease payments in the period in which the obligation for those payments is incurred. The Company recorded total expenses for its short-term leases of $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTc0Ng_64464334-9372-440a-adb4-e75c94c573fa">0.01</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTc1Mw_16009917-a0fa-46e9-aa07-87c127766ce9">0.04</ix:nonFraction> million for the three and nine months ended September&#160;30, 2019, respectively. The Company recorded lease costs for variable lease payments of $<ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTg4NA_45d852b1-a0b9-423d-981c-263493ce75b2">0.01</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTg5MQ_db7dc8dd-c0db-4ae2-a0eb-c47de6e87405">0.02</ix:nonFraction> million for the three and nine months ended September&#160;30, 2019, respectively.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i81985915ee134013b668d2124bc6e02d" continuedAt="i7e646eaf7f604936b42ab5a555772b17"><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTA5OTUxMTY1ODE0Ng_eaea5745-01f3-4f30-81b1-2b533fec3be7" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other supplemental cash flow information for operating leases is as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:57.064327%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfMy0xLTEtMS00NjQ1_45c451b6-726c-4c20-93f8-da78e6e0322f">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfMy0zLTEtMS00NjUw_641cb1c8-31ae-4db7-8e5e-a1f63c814704">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfNS0xLTEtMS00NjQ1_0bf3de8f-645e-439a-8509-38fb41abedcb">212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfNS0zLTEtMS00NjUw_840ed9d6-6d19-49ca-af2e-f9c9f42af7e8">321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTU3MDE_7c7a0708-ecef-4209-a3ef-afdf785a5d80" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The minimum lease payments are expected to be as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:74.023392%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.245614%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMS0yLTEtMS0w_374045b7-15c2-4588-8120-e17d1c89cd6d">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMi0yLTEtMS0w_157b08c8-90dc-4924-b74c-524f09609d62">135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMy0yLTEtMS0w_c03cbed8-adc7-4318-bb63-3bcf80529eb8">138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNC0yLTEtMS0w_efbdec72-6390-407f-857e-b65ace55ac5a">105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNS0yLTEtMS0w_8d2e536b-e63b-4f09-80db-f6bd5c64f092">57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNi0yLTEtMS0w_fa735311-8516-4d9b-b953-3dd0f3c99a23">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNy0yLTEtMS0w_1c5a357a-a171-4cfe-b0a4-2453db1260e0">478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfOC0yLTEtMS0w_7a36d74e-7fc4-4157-9e45-7d4d9b33be53">74</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfOS0yLTEtMS0w_a4410f03-63d1-473b-8959-d9c668225de0">404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the prior lease guidance, future minimum lease payments at December 31, 2018 under long-term leases for the five years ending December 31, 2019 through 2023 and thereafter are as follows (in thousands): $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIxNA_d85449fe-63ab-4877-8353-566fadc56af1">48</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIxOA_9e1d7d62-5ded-41ed-90bb-5ebb4cbfcc0a">53</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIyMg_984616ed-ca27-498a-a917-4c8ca51627ec">54</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIyNg_aaf274e3-5a93-47c4-9c9e-4af28aa7f446">55</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIzMA_a0929542-ff0a-492e-9cd8-fb40eae583af">56</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIzOA_5518dac4-b5bb-43e2-8346-305d40c3d60e">5</ix:nonFraction>, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the weighted average remaining lease term is <ix:nonNumeric contextRef="i658888d65697477c8bdf7f277240e630_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjMyNA_591dbf99-44f7-4091-a13f-c78ebd78f622">4.42</ix:nonNumeric> and <ix:nonNumeric contextRef="i86c8d7aea62b452da49a9315e073e07a_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzAzODI1OQ_4717493d-b748-4a99-b63e-95a6843b1e92">2.84</ix:nonNumeric> for the Lease and Lab Lease, respectively, and the weighted average discount rate is <ix:nonFraction unitRef="number" contextRef="i658888d65697477c8bdf7f277240e630_I20190930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjM3MA_c8f69f08-f7d2-4ba8-94a2-35c1220b563f">9.6</ix:nonFraction>%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses an incremental borrowing rate based on a peer analysis using information available at the commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. During the nine months ended September&#160;30, 2019, in addition to the initial adoption of the lease standard, the Company amended its Lab Lease which required additional right of use assets and liabilities to be recorded.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MD Anderson</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under agreements associated with Annamycin, the WP1122 Portfolio, and the WP1066 Portfolio, which includes WP1732, all described below, the Company is responsible for certain license, milestone and royalty payments over the course of the agreements. Annual license fees can cost as high as $<ix:nonFraction unitRef="usd" contextRef="i664f42f1665c485c853202fc74ba4d18_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mbx:LicenseAgreementAnnualLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzM1MA_7e4eb228-826c-42cf-814c-a84f562715e1">0.1</ix:nonFraction> million depending upon the anniversary. Milestone payments for the commencement of phase II and phase III clinical trials can cost as high as $<ix:nonFraction unitRef="usd" contextRef="if1d94dee648346efb077db14d8fbd8ec_I20190930" decimals="-5" format="ixt:numdotdecimal" name="mbx:MilestonePaymentsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzQ4Nw_7535b724-21b1-4387-bc71-eb6d4271a523">0.5</ix:nonFraction> million. Other milestone payments for submission of an NDA to the FDA and receipt of first marketing approval for sale of a license product can be as high as $<ix:nonFraction unitRef="usd" contextRef="i0c55769a2d6349beb36762d47f51c0ae_I20190930" decimals="-5" format="ixt:numdotdecimal" name="mbx:MilestonePaymentsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzY0MA_b6015420-57d1-4d0b-86c6-4c313511b300">0.6</ix:nonFraction> million.  Royalty payments can range in the single digits as a percent of net sales on drug products or flat fees as high as $<ix:nonFraction unitRef="usd" contextRef="i6a3bb46bfb304e42ab171f7dfca58b9c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzc2MA_d8f2cffc-d786-4187-a89a-f7e65ae69a58">0.6</ix:nonFraction> million, depending upon certain terms and conditions. Not all of these payments are applicable to every drug. Total expenses under these agreements were $<ix:nonFraction unitRef="usd" contextRef="i0ec29135c33746a293feac556994b9e6_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzkwOA_1725b81b-88dd-413a-bb1a-3084befc5005">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i490694ff28c945c0970bd1b5b00026d8_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzkxNQ_f76b9f59-28fb-4c4c-a8f4-c3a6fbf45a5d">0.1</ix:nonFraction> million for the three months ended September&#160;30, 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia0f36e65608b4660897d32d69ff25cdb_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzk4Nw_dbfd2740-a598-4e4a-9c4f-347190f5fa56">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icb689274badf4dc5ba81def9e3ba4777_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzk5NA_1c3a70b4-357e-4d56-ab61-f5d5852c9b24">0.2</ix:nonFraction> million during the nine months ended September&#160;30, 2019 and 2018, respectively. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WP1122 Portfolio</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#8220;IntertechBio Agreement&#8221;) have been assigned to MBI. Therefore, MBI has obtained a </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7e646eaf7f604936b42ab5a555772b17" continuedAt="i48d39b9d6e964953b3095ca6fddec8b0"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WP1066 Portfolio</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#8220;Moleculin Agreement&#8221;) have been assigned to MBI. Therefore, MBI has obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, MBI must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement.  Annual Maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights the Company has obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">MBI entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), pursuant to which it granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#8220;HPI Out-Licensing Agreement&#8221;). Under the HPI Out-Licensing Agreement the Company was required to make quarterly sponsored research payments totaling $<ix:nonFraction unitRef="usd" contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjM4MA_5b7ac80f-0937-4e18-bc98-8dbf1abf6d15">0.75</ix:nonFraction> million for the first twelve quarters following the effective date, of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding the Company's obligation to make the foregoing payments, the HPI Out-Licensing Agreement did not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgwMg_78cd4663-63f1-4585-a3a5-6bb6ddf6d4e9">1.0</ix:nonFraction> million to HPI within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgxOQ_a802d1b7-06a0-4544-aeec-9aa89cbf575a">three</span> years of the effective date of the HPI Out-Licensing Agreement ("HPI Option Repurchase Payment") MBI regained all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly sponsored research payments. The option repurchase payment was paid on April 30, 2019 for $<ix:nonFraction unitRef="usd" contextRef="i2399e296e4074ad8812022575df5b89e_D20190430-20190430" decimals="-5" format="ixt:numdotdecimal" name="mbx:OptionRepurchasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzMwMQ_a3f80335-87db-4026-8f42-c6103f1f15a9">1.0</ix:nonFraction> million and, accordingly, the HPI Out-Licensing Agreement was terminated. The $<ix:nonFraction unitRef="usd" contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzM3NA_8fe8feea-bc19-4dc1-9163-0274a6306485">1.0</ix:nonFraction> million payment was accrued and expensed under "Research and development" in the second quarter of 2018. Total expenses related to HPI were $<ix:nonFraction unitRef="usd" contextRef="iea85e97e50094e9d81434a25899adfb3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzUwOQ_6c7f039b-210f-44d3-a747-d21f087931c2">0.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie435b286972e4f7ea765d0391fbceef7_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzUxNg_b1a7fe4f-f35c-4d6c-9da1-9cceb0496275">0.1</ix:nonFraction> million for the three months ended September&#160;30, 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i03cfdc63ce24474c9076a3ed88c23973_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzU4OA_f8a18537-8220-4b11-81c9-b7e7e9af2abd">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4cf0e3597d934e9c84c3d513f1c63b8c_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzU5NQ_abad0fca-e29d-4f8f-bb37-15fb3d26aa58">1.2</ix:nonFraction> million for the nine months ended September&#160;30, 2019 and 2018, respectively. </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, MBI entered into a license agreement with MD Anderson covering a new group of molecules recently discovered in connection with research it has been sponsoring there called WP1732, a part of the WP1066 Portfolio. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sponsored Research Agreements with MD Anderson</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2017, MBI amended its Sponsored Laboratory Study Agreement with MD Anderson where it was extended to the end of October 2018. In December 2017, MBI extended this Agreement until the end of October 2019 for total payment amount of $<ix:nonFraction unitRef="usd" contextRef="i921f1f39a083428c9445130e7d4459eb_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODIxMw_4836eac3-3540-4873-93ec-38e320b8f065">0.3</ix:nonFraction> million spread over that period of time. In September 2018, the Company extended this Agreement until the end of October 2020 for total payment amount of $<ix:nonFraction unitRef="usd" contextRef="i442d97ffc8c34dfdb6c0f85109bcfe82_D20180901-20180930" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODQ4NA_0dd9333d-4025-4c7e-a446-446bd494ef04">0.4</ix:nonFraction> million spread over that period of time. In June 2019, the Company amended the Agreement to support the continuation of the project for total payment amount of $<ix:nonFraction unitRef="usd" contextRef="i4177a6893406483a97433eb0e53c41da_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc2OQ_4a2485f6-96a3-4405-ba9a-16a2cb95afcc">0.4</ix:nonFraction> million. In October 2019, the Company amended the agreement until the end of October 2021 for a total additional payment amount of $<ix:nonFraction unitRef="usd" contextRef="i5fd4d78cf6204458b1ee511c741627f6_D20191001-20191031" decimals="-5" format="ixt:numdotdecimal" name="mbx:PaymentsForResearchAndDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0NDE4Mg_3ccf8923-3597-4027-872d-8b5156e94f4d">0.4</ix:nonFraction> million. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were $<ix:nonFraction unitRef="usd" contextRef="i84dd43168aa14c0ba971eed3e33aab51_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTAzOA_1ed951b1-c582-4fff-a1f8-ecf67e403b1c">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4aabb04846bf431c9fecd7123d274260_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTA0NQ_dc5c957e-d4ac-46d6-b6ae-186ba6c903d3">0.1</ix:nonFraction> million for the three months ended September&#160;30, 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7b81d0dea25642c59af5126ab6197c98_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTExNw_4ff54d2d-6912-441a-8e3b-4ce5939a87d2">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1546f03b3854c86bdcc7ffe18a533ef_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTEyNA_a091d0ff-b96e-455e-9c81-40252a0200ca">0.3</ix:nonFraction> million, for the nine months ended September&#160;30, 2019 and 2018, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Other Licenses</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Dermin</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In 2015, the Company obtained the rights and obligations for certain patent and technology development and license agreements with Dermin sp. z o.o. (&#8220;Dermin&#8221;). In connection with such agreements, certain intellectual property rights related to Annamycin, our WP1122 portfolio, and the Company's WP1066 portfolio were licensed to Dermin and Dermin was granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property. With respect to Annamycin, the license is limited to the </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i48d39b9d6e964953b3095ca6fddec8b0" continuedAt="id94ec8cf4ab0488b8f013c218382ee7c"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany; provided that the Company has the right to remove Germany from the list of covered territories with a $<ix:nonFraction unitRef="usd" contextRef="idb95c8a4307d477fb7b1a627137efc1d_D20150101-20151231" decimals="INF" format="ixt:numdotdecimal" name="mbx:LicensedTechnologyFuturePaymentToRemoveCountry" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTAyNjE_691da09f-31f1-40a4-9b1c-5c4db2e8aaaf">0.5</ix:nonFraction> million payment. With respect to WP1122, the license is limited to the countries of Belarus, Russia, Kazakhstan, Uzbekistan, Turkmenistan, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. With respect to WP1066, the license is limited to the countries of Belarus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. In each case, Dermin agreed to pay a royalty for the sale of any licensed product in the licensed territories and agreed to pay all out-of-pocket expenses incurred in filing, prosecuting and maintaining the licensed patents for which the license has been granted in the licensed territories. Dermin also agreed to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In July 2019, Dermin assigned its rights under the foregoing license agreements to an affiliated entity, Exploration Invest Pte Ltd. (&#8220;Exploration&#8221;). On July 30, 2019, the Company and Exploration entered into a License Modification Agreement pursuant to which the Company agreed to issue Exploration shares of Company common stock valued at $<ix:nonFraction unitRef="usd" contextRef="ic028dc6b564848f8a736e7c1a222fe61_I20190730" decimals="-5" format="ixt:numdotdecimal" name="mbx:EquityDistributionCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTE0MTM_9576b8f9-7691-4dca-8476-3ef1bc8ac52b">0.5</ix:nonFraction> million (based on the greater of the closing price of the common stock on the date of the agreement or the 10-day average closing price prior to the date of the agreement) in exchange for the modifying the license agreements to: (i) limit the licensed territory solely to Poland; and (ii) limit the patent rights and technology rights licensed to Exploration to the patent rights and technology rights that existed on the date the original license agreements were entered into with Dermin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">. On August 8, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i213f24715e7642f782c9022686a24919_I20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzI5ODUzNDkwNjQ4MA_38ce5429-9efb-46c4-a36b-ad5e6d3fdd83">429,978</ix:nonFraction> shares of Company common stock to Exploration to satisfy this commitment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">WPD Pharmaceuticals</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio to WPD Pharmaceuticals sp. z o.o. (&#8220;WPD&#8221;) (the &#8220;WPD Agreement&#8221;). WPD is affiliated with Dr. Waldemar Priebe, one of the Company's founders and largest shareholder. Under the WPD Agreement, the Company granted WPD a royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Germany, Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Armenia, Azerbaijan, Georgia, Slovakia, Czech Republic, Hungary, Uzbekistan, Kazakhstan, Greece, Austria, Russia, Netherlands, Turkey, Belgium, Switzerland, Sweden, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland (&#8220;licensed territories&#8221;), provided that the Company has the right to buyback Germany from the licensed territories by making a payment $<ix:nonFraction unitRef="usd" contextRef="i13dfe851934d44768ccba995e1db6556_D20190219-20190219" decimals="INF" format="ixt:numdotdecimal" name="mbx:LicensedTechnologyFuturePaymentToRemoveCountry" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI5NjU_ffffa5b3-df95-4b4d-8711-b024e4e4d8b4">0.5</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On July 30, 2019, the Company entered into the aforementioned July 30, 2019 agreement with Dermin that satisfied the foregoing buyback right, and as such, Germany is no longer considered part of the licensed territories.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In consideration for entering into the WPD Agreement, WPD agreed that it must use Commercially Reasonable Development Efforts to develop and commercialize products in the licensed territories. For purposes of the WPD Agreement, the term &#8220;Commercially Reasonable Development Efforts&#8221; means the expenditure by or on behalf of WPD or any of its affiliates of at least: (i) $<ix:nonFraction unitRef="usd" contextRef="i892ca0d0325349b29aa4133a6747e7f1_I20190219" decimals="-5" format="ixt:numdotdecimal" name="mbx:ResearchAndDevelopmentCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTM1MTk_eaf66c27-37d1-4a2c-8934-3c9a3e51264d">2.0</ix:nonFraction>&#160;million during the first two years of the agreement on the research, development and commercialization of products in the licensed territories; and (ii) $<ix:nonFraction unitRef="usd" contextRef="i73c05bdb824e4b5aa9eb2f176d9c0de9_I20190219" decimals="-5" format="ixt:numdotdecimal" name="mbx:ResearchAndDevelopmentCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTM2Njc_31315e48-544c-43e5-9cd0-41297de34070">1.0</ix:nonFraction>&#160;million annually for the two years thereafter on the research and development of products in the licensed territories. This license is subject to the terms in the prior agreements entered into by the Company with Dermin and MDA.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">WPD is actively seeking Polish government grants for research involving licensed drug candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prior to approval of the WPD Agreement, the Company's board of directors received a fairness opinion from Roth Capital Partners, LLC that stated that it was their opinion that the consideration the Company will receive from WPD pursuant to the WPD Agreement is fair, from a financial point of view, to the Company.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Animal Life Sciences</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio in the field of non-human animals to ALI (the &#8220;ALI Agreement&#8221;). ALI is affiliated with Dr. Waldemar Priebe, one of its founders and its largest shareholder. Under the ALI Agreement, the Company granted ALI a worldwide royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of non-human animals under the licensed intellectual property. This license is subject to the terms in the prior agreements entered into by the Company and MDA. Under the ALI Agreement, the Company has the right to name an observer to ALI's board of directors.  On August 8, 2019, the Company named its Chairman and CEO Walter V. Klemp to that position.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id94ec8cf4ab0488b8f013c218382ee7c"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since ALI and WPD are beginning the process to develop and commercialize products using the sublicensed intellectual property rights, the Company is currently unable to predict whether ALI and WPD will be successful in developing such products or when the Company may recognize royalty revenues related to such products.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employment Agreements</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with certain employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately $<ix:nonFraction unitRef="usd" contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mbx:EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTU2NDA_0517f6f6-a890-4810-a115-d7287082a246">0.9</ix:nonFraction> million using the rate of compensation in effect at September 30, 2019.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i_0_52"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF81Mi9mcmFnOjRlNWUwOGRjNjEwYjQzMDJiMTRhNmJiNjcyYjcwZWRmL3RleHRyZWdpb246NGU1ZTA4ZGM2MTBiNDMwMmIxNGE2YmI2NzJiNzBlZGZfMTI1_fa32cfd1-592b-466a-b0fe-3d368e014592" continuedAt="i61d67c8c951645a384934d79e5207913" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i61d67c8c951645a384934d79e5207913">In addition to the subsequent events discussed elsewhere in these notes, no other events occurred.</ix:continuation> </span></div><div id="i_0_55"></div><div style="text-align:justify;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Forward-looking statements include, but are not limited to, statements about:</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to obtain additional funding to fund operations and develop our drug candidates;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to satisfy any requirements imposed by the FDA (or its foreign equivalents) as a condition of our clinical trials proceeding;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The success, including the ability to recruit patients, of our clinical trials through all phases of clinical development;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Poland;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to complete our clinical trials in a timely fashion and within our expected budget;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Compliance with obligations under intellectual property licenses with third parties;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Any delays in regulatory review and approval of drug candidates in clinical development;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to commercialize our drug candidates;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Market acceptance of our drug candidates;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Competition from existing therapies or new therapies that may emerge;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Potential product liability claims;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our drug candidates for our preclinical work and our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to establish or maintain collaborations, licensing or other arrangements;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The ability of our sublicense partners to successfully develop our product candidates in accordance with our sublicense agreements;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The effects of future government shutdowns on our ability to raise financing;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability and third parties&#8217; abilities to protect intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to adequately support future growth; and</span></div><div style="text-indent:-18pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to attract and retain key personnel to manage our business effectively.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moleculin Biotech, Inc., a Delaware corporation, is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center ("MD Anderson"). We have three drugs in four clinical trials in the US and Poland. Our clinical stage drugs are Annamycin, believed by management to be a &#8220;Next Generation&#8221; Anthracycline, being studied in the US and Poland for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. Additionally, a third drug, WP1220 (a molecule similar to WP1066), was approved for a clinical trial in January 2019 in Poland for the topical treatment of cutaneous T-cell lymphoma and for which patient treatments have begun, and the trial has achieved full enrollment. We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that our Next Generation Anthracycline, Annamycin, is unlike currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms and has little to no cardiotoxicity (two problems common to all currently approved anthracyclines) &#8212; hence the use of the term "Next Generation." Annamycin is currently in two Phase I/II clinical trials and preliminary clinical data suggest it may have the potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">WP1066 is one of several STAT3 Immune/Transcription Modulators designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells ("TRegs") while also inhibiting key oncogenic transcription </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">factors, including p-STAT3, c-Myc and HIF-1&#945;. These transcription factors are widely sought targets that may also play a role in the lack of efficacy of immune checkpoint inhibitors in certain resistant tumors.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are also developing new compounds designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (&#8220;2-DG&#8221;), which we believe may provide an opportunity to cut off the fuel supply of tumors by taking advantage of their high level of dependence on glucose in comparison to healthy cells. A key drawback to 2-DG is its lack of drug-like properties, including a short circulation time and poor tissue/organ distribution characteristics. Our lead Metabolism/Glycosylation Inhibitor, WP1122, is a prodrug of 2-DG that appears to improve the drug-like properties of 2-DG by increasing its circulation time and improving tissue/organ distribution. New research also points to the potential for 2-DG to be capable of enhancing the usefulness of checkpoint inhibitors. Considering that 2-DG lacks sufficient drug-like properties to be practical in a clinical setting, we believe WP1122 may also become an important drug to potentiate checkpoint inhibitors.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mission and Strategy</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moleculin is focused on developing treatments for highly resistant cancers. These include AML, glioblastoma, cutaneous t-cell lymphoma, pancreatic cancer, and others. Our diverse pipeline of technologies was built around the recognition that many highly resistant tumors tend to have a common set of traits, including an increase in multidrug resistant mechanisms, an evasion of the natural immune system, a marked upregulation of certain key oncogenic transcription factors and an increased dependence on glycolysis for energy production. We believe each of these elements may be addressed by the unique and innovative mechanisms introduced by one or more of our three core technologies.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe this approach not only provides the opportunity to help the many patients in need of alternative therapies, but also to work in combination with numerous existing technologies that often fail as tumors present immediate or acquired resistance. We believe showing even modest improvements in highly resistant cancers may lead to accelerated approval pathways, potentially reducing the time and capital required to ultimately realize success.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Corporate Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We were founded in 2015 in order to combine and consolidate the development efforts involving several oncology technologies, based on license agreements with MD Anderson. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, on behalf of Moleculin, LLC, we entered into a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, which culminated with the merger of Moleculin, LLC into MBI coincident with our initial public offering allowing us to gain control of the WP1066 Portfolio.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moleculin, LLC was formed in 2006 and was working to develop the WP1066 Portfolio it licensed from MD Anderson. On May 2, 2016, Moleculin, LLC was merged with and into MBI. As a result of the merger, we issued the holders of Moleculin, LLC equity interests and convertible notes representing in the aggregate 999,931 shares of our common stock. Since Moleculin, LLC commenced operations in 2006, substantially all of its efforts had been focused on research, development and the advancement of the WP1066 Portfolio. Moleculin, LLC did not generate any revenue from product sales and, as a result, incurred significant losses.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we formed Moleculin Australia Pty. Ltd., a wholly owned subsidiary to oversee pre-clinical development in Australia. The Australian government provides an aggressive incentive for research and development carried out in their country. We believe having an Australian subsidiary could provide an opportunity to speed up pre-clinical development and reduce the overall cost of our continued drug development efforts.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We do not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Technology Overview </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, but on July 10, 2019, we submitted patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate. If these patent applications are approved, of which we can provide no assurance, this would provide potentially 20 years of protection for our drug. Independently from potential patent protection, in 2018 we have received Orphan Drug designation (&#8220;ODD&#8221;) from the FDA for Annamycin for the treatment </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">of AML and, in 2019 we received ODD for WP1066 for the treatment of glioblastoma. This may enable market exclusivity of 7 years from the date of approval of a New Drug Application (&#8220;NDA&#8221;) in the United States. During that period, the FDA generally could not approve another product containing the same drug for the designated indication. We also intend to apply for similar status in the European Union (&#8220;EU&#8221;) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (&#8220;MAA&#8221;). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), which would preclude approval of any other annamycin product, but there can be no assurance that such exclusivity will be granted. Furthermore, in April 2019, the FDA approved the Company's request for Fast Track Designation for Annamycin for the treatment of relapsed or refractory AML. Fast Track Designation, the purpose of which is to expedite drug development and approval, is granted to drugs intended to treat serious conditions and where data demonstrate the potential to address an unmet medical need.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Next Generation Anthracycline</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Chemotherapy continues to be a cornerstone of cancer therapy. Despite the progress made with immunotherapy and precision medicine, the first-line treatment for many cancers continues to include chemotherapy. And, in part because of the emphasis placed on alternatives to chemotherapy, we believe that not enough has been done to improve chemotherapeutic agents to make them safer and more effective. Anthracyclines are a class of chemotherapy drugs designed to destroy the DNA of targeted cancer cells. Acute leukemia is one of a number of cancers that are usually treated with anthracyclines. In the case of acute leukemia, anthracyclines are typically used in &#8220;induction therapy,&#8221; where the goal is to induce sufficient remission of patients&#8217; blood-born tumor cells to allow for a curative bone marrow transplant.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Two key factors limit the safety and effectiveness of anthracyclines: cardiotoxicity (potential to damage the heart) and multidrug resistance. We believe Annamycin may overcome these two factors; if preliminary data are borne out, Annamycin may ultimately provide clinically meaningful benefits over currently approved anthracyclines in treating certain cancers. Preliminary data from very early-stage clinical trials suggest acute leukemia as a potentially opportune indication in which to further study Annamycin.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">One of the key dose-limiting toxicities associated with currently available anthracyclines (including the anthracycline in the approved drug, Vyxeos) is the propensity to induce life-threatening heart damage (also known as cardiotoxity). This is a particularly significant risk for pediatric leukemia patients, whose life spans can be severely shortened by the induction therapy intended to cure them of acute leukemia. In the animal model recommended by the FDA as an indicator of human cardiotoxicity, the non-liposomal (free) form of Annamycin has been shown to be significantly less likely than doxorubicin to create heart lesions in mice, and the liposomal formulation ("L-Annamycin") has been shown in these same models to have reduced cardiotoxicity to the point where it is unlikely to cause harm to human patients. If this characteristic is shown to be the same in humans, it may allow L-Annamycin to be used more aggressively to help patients achieve remission. This would be especially valuable in the case of pediatric acute leukemia (both AML and ALL) because of the potential impact of cardiotoxicity on long-term survival. In our current Phase I/II trial for Annamycin, we are collecting data to further validate the design intent of Annamycin to have little or no cardiotoxicity. Unless otherwise noted, all of our references to Annamycin refer to the liposomal form or L-Annamycin.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, the effectiveness of currently approved anthracyclines is limited by their propensity for succumbing to &#8220;multidrug resistance.&#8221; This can occur where, as a natural defense mechanism, transmembrane proteins acting as transporters (one type of which is referred to as a &#8220;P-glycoprotein pump&#8221; or &#8220;ABCB1 transporter&#8221;) develop on the outer surface of cells to expel perceived threats like anthracyclines. In many instances, the likelihood of cardiotoxicity (and other serious side effects) prevents increasing the dosing of current therapies in order to overcome multidrug resistance. As a result, most patients cannot receive current anthracyclines in doses that are adequate to produce lasting remission and thereby qualify for a bone marrow transplant. A laboratory study has suggested that Annamycin may resist being expelled by P-glycoprotein pumps and similar multidrug resistance transporters, which may mean the drug circumvents multidrug resistance. This characteristic has been shown in pre-clinical testing to allow for higher drug uptake in diseased cells, which we believe could allow for more effective induction therapy with less risk to the patient.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Additionally, preclinical research in animal models at MD Anderson demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models. Coupled with research demonstrating that Annamycin is capable of accumulating in the lungs at very high levels, this suggests that Annamycin may be well suited to become a treatment for lung-localized tumors.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">STAT3 Immune/Transcription Modulators: Enabling Immune Response and Inhibiting p-STAT3 and other Oncogenic Transcription Factors &#8211;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe our WP1066 Portfolio (including lead drugs WP1066, WP1220 and WP1732) represents a novel class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. A substantial body of published research has identified STAT3 as a master regulator of a wide range of tumors and has linked the activated form, p-STAT3, with the survival and progression of these tumors. For this reason, it is widely believed that targeted inhibition of p-STAT3 may be an effective way to reduce or eliminate the progression of these diseases.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The high level of anticancer activity demonstrated in multiple tumors in animal models by WP1066 and WP1732 is potentially related to their ability to also inhibit such important key oncogenic transcription factors like c-Myc and HIF-1&#945;. In addition to direct anticancer effects not related to the function of the immune system, our lead drug WP1066 has also been shown to boost immune response in animals, in part by inhibiting activity of Regulatory T cells ("Tregs"), which are coopted by tumors to evade the immune system. We believe the dual effect of (1) directly inhibiting tumor growth and inducing tumor cell death and (2) separately boosting and directing the natural immune response to tumors is therapeutically highly promising. If additional preclinical and clinical data validate the two avenues of apparent activity, this class of drugs may be well-suited to treat a wide range of tumors, both as single agents and as critical elements of successful combination therapies targeting even some of the most difficult-to-treat cancers.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The recent oncology drug landscape has been dominated by immunotherapy, specifically including checkpoint inhibitors. In just the last 5 years, checkpoint inhibitors (such as Opdivo and Keytruda) have reached over $10 billion in annual revenues. To summarize checkpoint blockade therapy, the T-Cells within an individual&#8217;s own immune systems should be capable of identifying tumor cells and destroying them before they destroy the individual. Unfortunately, tumors develop the ability to prevent this natural immune response by regulating the expression of certain receptors referred to as &#8220;immune checkpoints&#8221; that then bind to T-Cells and prevent them from attacking the tumor. Immune checkpoint inhibitors are antibodies that block these receptor mechanisms and allow the T-Cells to act normally and attack the tumor.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In certain types of tumors, like melanoma, checkpoint inhibitors work well, and the results can be impressive, creating durable suppression of tumors where no other therapy had succeeded. However, despite the outstanding results in select patients, checkpoint inhibitors benefit only a limited number of patients in certain cancers, and they are essentially not effective in what are called &#8220;non-responsive&#8221; tumors like glioblastoma and pancreatic cancer, among others. As a result, companies are now focusing heavily on combination therapies, combining immune checkpoint inhibitors with chemotherapy, as well as other agents. We believe there is a clear need for new chemotherapeutic agents that, by their specific mechanism of action, would produce potent combination effects with immune checkpoint inhibitors, and that additionally can boost immune system response on their own. In this regard, there is early nonclinical evidence that WP1066, as a single agent, has the ability to reverse immune tolerance in brain tumor patients (Cancer Res, 67(20), 9630, 2007), and preliminary data in animal models that suggests WP1066 may have a potential for combination use with checkpoint inhibitors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Recently published research papers have presented several findings that may point to major new opportunities for Moleculin&#8217;s WP1066 class of drugs. One such article suggested that our STAT3 inhibitor WP1066 abrogated PD-L1/2 expression in cancer cells and may be a useful agent in addition to checkpoint inhibitor immunotherapy in cancer patients (J Clin Exp Hematop, 57(1), 21-25, 2017). Other published results show that CTLA4-induced immune suppression occurs primarily via an intrinsic STAT3 pathway, suggesting that, through its inhibition of activated STAT3, WP1066 might work well in combination with this checkpoint inhibitor (Cancer Res, 77(18), 5118&#8211;28, 2017).</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A separate paper presents selected key transcription factors as being responsible for the upregulation of an often-targeted checkpoint actor in tumors known as PD-L1. Some of the most important transcription factors identified were HIF-1&#945;, c-Myc and STAT3, the very targets for which WP1066 was designed (Front Pharmacol, 2018 May 22, 9:536, doi: 10.3389/ fphar.2018.00536, eCollection 2018). In summary, although much of the data is nonclinical and all of it is preliminary, we are optimistic that administration of WP1066 could lead to improved treatment results in many patients receiving checkpoint inhibitor therapy.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Metabolism/Glycosylation Inhibitors: Using the Warburg Effect to Starve Tumor Cells to Death &#8211; </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Science has recognized that many types of cancer cells have a unique metabolism, distinct from that of normal cells. Cancer cells&#8217; dependence on glycolysis (a specific way of converting glucose into energy) to proliferate and metastasize has been described as the &#8220;sweet tooth of cancer&#8221; and is a classic example of how the metabolism of cancer cells and normal cells differ. Glycolysis is a glucose-intensive means of producing energy that is used by normal cells only if oxygen levels are low.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">However, many types of tumor cells are essentially addicted to glycolysis even in the presence of abundant oxygen. This is known as the &#8220;Warburg Effect&#8221; after its discoverer, Dr. Otto Warburg, and such tumors are said to be highly &#8220;glycolytic.&#8221;</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">This phenomenon of tumors relying preferentially on glycolysis and the resulting dramatic increase of glucose uptake to fulfill their metabolic demands has already been utilized very effectively in cancer diagnostics. It is the Warburg Effect that enables imaging of actively growing tumors by positron emission tomography (&#8220;PET scans&#8221;). This diagnostic test uses a fluorine-18 radiolabeled glucose decoy called F18DG that accumulates disproportionately in tumors, using the same process that increases glucose uptake and retention in cancer cells.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The success of PET scanning points to the potential therapeutic benefit of the tumor-specific inhibition of glycolysis that would block energy (adenosine triphosphate (&#8220;ATP&#8221;)) production and could potentially &#8220;starve tumor cells to death&#8221; and/or make them sensitive to other existing therapies, including radiotherapy. Unsuccessful attempts to realize this therapeutic potential have been made in the past, using a glucose decoy known as &#8220;2-deoxy-D-glucose&#8221; ("2-DG"). Those attempts to target the metabolism of tumor cells have failed, we believe, because of 2-DG&#8217;s lack of drug-like properties that include rapid metabolism, short half-life and limited tissue-organ distribution. Essentially, not enough 2-DG could be delivered to its intended target.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have designed and are studying a novel and patented prodrug of 2-DG (WP1122). We believe WP1122 has the potential for developing into a technology platform for enabling increased cellular uptake, increased drug half-life and, importantly, enabling greater uptake and retention in organs where the most resistant and glycolytic tumors are localized, including the brain and pancreas.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Altering Glycosylation to Enhance Immune Checkpoint Therapy &#8211;</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A recently published study (Am J Cancer Res, 8(9), 1837-1846, 2018) focused on the analysis of tumor resistance to immune checkpoint therapy. The study found that a process known as glycosylation plays an important role in the ability of checkpoint receptors to suppress immune activity and thereby protect tumors from attack. The researchers discovered that an alteration of the glycosylation of these receptor mechanisms could effectively prevent this evasion of the immune system. This study found that 2-deoxyglucose, or 2-DG, was capable of making this alteration. Although the data are preliminary, the findings suggest that 2-DG could act as an effective anticancer agent in combination with checkpoint inhibitors and potentially with other anticancer therapies.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Attempting to use 2-DG as a drug, however, faces the same problems discussed above. 2-DG&#8217;s short circulation time and lack of other drug-like properties mean the drug does not stay in the system long enough or concentrate sufficiently in targeted organs, which severely limits its effectiveness. This suggests a possible role for our drug candidate, WP1122. WP1122 is a prodrug of 2-DG, meaning it is a molecule that may be able to be converted into pharmacologically active 2-DG within the body of the patient. The design of WP1122 is intended to allow for a longer circulation time and improved organ distribution, which should provide it a greater opportunity to become an effective drug.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We intend to study WP1122 for both its ability to directly inhibit tumor activity and to potentiate existing therapies via an inhibition of tumor metabolism and to improve the performance of checkpoint inhibitors by reducing the effect of glycosylation and have begun the necessary preclinical work required to file an IND.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Clinical Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Annamycin had previously been in clinical trials with a prior drug developer pursuant to an application for Investigational New Drug status (&#8220;IND&#8221;) that had been filed with the FDA. Due to a lack of development activity by the prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. Patient treatment began in the US in March 2018. In March 2019, we announced that the first cohort in the US was completed and announced top-line results.  We are now in the second cohort in our Phase I portion of the US trial.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With regard to additional Annamycin clinical activity, we received Polish National Office approval in June 2018 for a Clinical Trial authorization (&#8220;CTA&#8221;) in Poland, which enabled us to begin a Phase I/II clinical trial there to study Annamycin for the treatment of relapsed or refractory AML. During the first half of 2019, we began screening and treating patients in Poland. We have now completed the first two cohorts and are now treating patients in the third cohort.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We continue to recruit and contract with clinics both in the United States and Poland. We can provide no assurance of additional recruitment or that treatments will occur in the near term and on a timely basis, if at all.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With the additional preclinical research on Annamycin's impact on lung localized tumors, we expect to announce a related clinical trial in 2020. In October 2019, we announced the expansion of Annamycin production to supply the above-mentioned AML clinical trials, as they continue, and a trial for the treatment of lung localized tumors. </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. In July 2018, this trial opened for recruitment in the US. This trial is now in its fourth cohort of the Phase I portion of the planned protocol. Because this trial is physician led, we are limited in our ability to manage the trial. We expect to transfer the IND for this trial from MD Anderson to Moleculin in 2020.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">With regard to additional clinical activity on other drugs, we initiated a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the topical treatment of cutaneous T-cell lymphoma (&#8220;CTCL&#8221;). In August 2019, we completed full enrollment in a proof-of-concept clinical trial in Poland to study WP1220, a part of the WP1066 portfolio, for the treatment of CTCL. Polish authorities approved our CTA for this use in January 2019, and the trial began enrolling patients in March 2019 In August 2019, we completed full enrollment in a proof-of-concept clinical trial in Poland to study WP1220, a part of the WP1066 portfolio, for the treatment of CTCL. Polish authorities approved our CTA for this use in January 2019, and the trial began enrolling patients in March 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We have begun planning and performing the necessary pre-clinical work required to submit an IND or its foreign equivalent for WP1732 or another intravenous formulation of WP1066, as well as WP1122. We expect to submit these INDs in 2021. In June 2018, we entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732. This agreement marked the beginning of creating a preclinical package to submit to the FDA in order to request Investigational New Drug status. We have now completed initial formulation development, and our IND-enabling toxicology work will be progressing via our Australian subsidiary, Moleculin Australia. As a result of our preclinical work to date, we are investigating improvements to the formulation of WP1732. Furthermore, we are investigating additional methods of making WP1066 deliverable intravenously.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_58"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Business Developments </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Below are recent business developments.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">New Preclinical Data Further Suggests Anti-tumor Efficacy of Annamycin in Both Human and Murine AML models</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On October 29, 2019, we announced the presentation of a poster at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, MA.  The poster, entitled &#8220;Dose and Schedule-Dependent Efficacy of Liposomal Annamycin in Pre-clinical Models of Acute Myeloid Leukemia,&#8221; presents preclinical data documenting the high activity of Annamycin against AML, including in vitro studies in a panel of human AML cell lines, as well as in vivo studies in both human and murine AML models developed under the Company&#8217;s sponsored research agreement with MD Anderson.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Comments from the FDA Regarding our US AML Trial with Annamycin</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">During September and October 2019, we received comments from the FDA related to the proposed, revised protocol of our US trial with Annamycin treating relapse and refractory AML patients. Management believes that it has implemented all changes suggested or requested by the FDA in a revised protocol submitted to the FDA. We do not anticipate any material impact on the timing of conducting the study. Details of this trial are available on www.clinical trials.gov (NCT03315039).</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Increases Annamycin Production</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On October 22, 2019, we announced the expansion of Annamycin production commitments in response to management's assessment of positive AML clinical trial activity and the potential expansion of indications for use to include lung-localized tumors. The purchase commitment arranged through Davos Pharmaceuticals includes moving final production of Annamycin to a larger-scale suite within BSP Pharmaceuticals S.p.A. ("BSP") in Latina, Italy. Until now, BSP has been producing the clinical supplies of Annamycin in a smaller pilot-scale suite. In connection with this work, we have also </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">contracted with BSP and the maker of the Annamycin active pharmaceutical ingredient (API) to develop methods for eventual commercial scale production.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Filing of Patent Protection for New Discovery</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 16, 2019, we announced our sponsored research at MD Anderson Cancer Center has resulted in the filing of a new patent on behalf of MD Anderson Cancer Center covering the combination of our immune-stimulating/transcriptional-modulator, WP1066, with well-known immune checkpoint inhibitors.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">CTRC Approval of WP1066 Pediatric Brain Tumor Trial</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On August 20, 2019, we announced approval by the Emory University Clinical Trial Review Committee (CTRC) to move forward with an investigator initiated clinical trial of our immune-stimulating/transcriptional-modulator, WP1066, for the treatment of pediatric brain tumors. The trial will take place at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Completion of Lymphoma Trial Enrollment</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On August 13, 2019, we announced that we had reached full enrollment in our proof of concept clinical trial to evaluate our p-STAT3 inhibitor, WP1220, for the topical treatment of CTCL. If successful, this study could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor. We believe showing activity with one of our STAT3 inhibitors could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On August 6, 2019, we announced that a paper entitled "Immunological Reprogramming in the CNS Tumor Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade" would be presented at the Inaugural Conference on Brain Metastases, in New York City, August 16-17, 2019. Dr. Martina Ott, of MD Anderson Cancer Center, will be presented the findings of research she conducted in collaboration with Dr. Amy Heimberger (the Principle Investigator of the current investigator-initiated clinical trial of WP1066 for brain tumors) in combining WP1066 with radiation therapy in glioblastoma animal models.  One of the findings of her research that is especially encouraging is that immune-competent mice treated with both radiation and WP1066 developed an immunological memory that enabled them to prevent regrowth of the tumor after these tumor cells were reintroduced. The result was the development of long-term survivors, leading to an increase in overall survival in these models. Of note was that mice with a compromised immune system did not show this effect. We believe that these findings may have a profound impact on understanding the role of STAT3 inhibition, and it will help focus our continued development of WP1066 in this disease.  This study was also particularly interesting because it showed the most robust immunological responses were located in the CNS (Central Nervous System) tumor microenvironment rather than peripheral non-tumor tissue.  Importantly, the study indicated that the combination of STAT3 inhibition with whole brain radiotherapy may have the capacity to enhance the therapeutic effect against established tumors based on immunological competence.  There remains much work to be done to follow up on these data, of course. In that regard, we plan to explore this potential in human clinical trials.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">At Market Issuance Sales Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We entered into an At Market Issuance Sales Agreement with Oppenheimer &amp; Co. Inc. on July 23, 2019 (the "Opco Agreement"). Pursuant to the terms of the Opco Agreement, we may sell from time to time through the Agent shares of our common stock with an aggregate sales price of up to $15 million. Any sales of shares pursuant to the Opco Agreement will be made under our effective &#8220;shelf&#8221; registration statement on Form S-3 (File No. 333-219434), which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission. Under the Opco Agreement, we may sell shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended. Sales of the shares, if any, may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by our Board of Directors or a duly authorized committee thereof. We or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the shares under the Agreement. The offering of the shares pursuant to the Agreement will terminate upon the sale of shares in an aggregate offering amount equal to $15 million, or sooner if either we or the Agent terminate the Opco Agreement pursuant to its terms. We will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the shares sold under the Opco Agreement and reimburse the Agent for </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">certain expenses. We have also provided the Agent with customary indemnification rights. We have not sold any shares under the Opco Agreement.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On July 18, 2019, we announced additional interim safety and efficacy data from our ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. Three patients were treated at a dose level of 150 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2 </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">with no drug-related adverse events, including no signs of cardiotoxicity. The results for all three patients were reviewed by the Drug Safety Review Committee, which determined that the trial could progress to the next higher dose level of 180 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. To date in Poland, one patient receiving the higher dose experienced grade 2 mucositis (which resolved to grade 1 within 2 days) and no other adverse events related to Annamycin have been reported. One patient has completed treatment in the 120 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (second) cohort in our parallel US clinical trial (the US trial started at a lower initial dose of 100 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">).</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">New Patents for Annamycin </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On July 10, 2019, we announced we have filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory AML. If these patent applications are approved, which cannot be assured, it would potentially give us 20 years of protection for a finished drug product incorporating those characteristics.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Europe</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, we announced additional interim safety and efficacy data from our ongoing open label, single arm Phase 1/2 study of Annamycin in Poland.  After receiving a single starting dose of 120 mg/m2 in the first cohort of the dose escalation phase of the trial, 2 of 3 patients treated responded sufficiently to qualify for a potentially curative bone marrow transplant.  The results for all 3 patients were reviewed by the Safety Review Committee, which determined that no drug-related adverse events were observed that would prevent advancing the trial to the next higher dose level of 150 mg/m2.  To date in the European trial, one patient experienced grade 2 mucositis (which resolved to grade 1 within 2 days) and no other adverse events related to Annamycin have been reported. No signs of cardiotoxicity have been reported in either trial.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">$15.0 Million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2019, we entered into definitive agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. Each unit was comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock resulting in gross proceeds of $15.0 million. Each warrant has an exercise price of $1.75 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. The offering closed on April 25, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">FDA Approval of Fast Track Designation for Annamycin</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 18, 2019, we announced that the FDA approved our request for Fast Track Designation for Annamycin for the treatment of AML. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Annamycin Found to be Active Against Metastatic Lung Cancer in Pre-Clinical Testing</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 17, 2019, we announced that the ongoing sponsored research at the University of Texas MD Anderson Cancer Center has now demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Agreement with Emory University to Conduct Pediatric Brain Tumor Trial</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 11, 2019, we announced that we have entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. The study will be conducted at the Aflac Cancer &amp; Blood Disorders Center at Children's Healthcare of Atlanta.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Underwritten Public Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On March 29, 2019, we completed an underwritten public offering of an aggregate of 5,250,000 units at a public offering price of $1.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 5,250,000 shares of common stock and warrants to purchase 2,625,000 shares of common stock. Each warrant has an exercise price of $1.10 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. The gross proceeds of the offering were $5.25 million, prior to deducting the underwriting discount and other estimated offering expenses. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Europe</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On March 26, 2019, we announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin. In the first study, being conducted in the US, four patients have completed treatment at 100 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> with no significant adverse events related to Annamycin, and the study will now proceed to the next higher dose of 120 mg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  No signs of cardiotoxicity have been reported in either trial. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">First Patients Enrolled in Lymphoma Clinical Trial</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On March 19, 2019, we announced that the first two patients have been enrolled in our European clinical trial of WP1220 for the topical treatment of CTCL.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On March 18, 2019, we announced that Dr. Martin Tallman, Chief of Leukemia for Memorial Sloan Kettering Cancer Center joined the Company's Science Advisory Board. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_61"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth, for the periods indicated, data derived from our statement of operations (in thousands) and such changes in the periods are discussed below in approximate amounts:</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Moleculin Biotech, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#160;&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.783626%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.011696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.011696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549708%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.304094%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,332&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,816&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total operating expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,508)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,591)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10,687)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Other income (expense):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Gain from change in fair value of warrant liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-48pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Interest income, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,374)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,038)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9,637)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9,091)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Three Months Ended September 30, 2019 Compared to Three Months Ended September 30, 2018</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Research and Development Expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Research and development ("R&amp;D") expense was $2.8 million and $1.3 million for the three months ended September&#160;30, 2019 and 2018, respectively. The increase of $1.5 million is mainly related to increased clinical activity due to an increase in clinical trials (2 drugs in 3 clinical trials in 2018, versus 3 drugs in 4 clinical trials in 2019), as well as the issuance of common stock to Exploration Invest Pte Ltd for $0.5 million, related to the exercise of the option to reacquire certain license rights in Germany under the Dermin License Agreements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">General and Administrative Expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> General and administrative expense was $1.7 million and $1.2 million for the three months ended September&#160;30, 2019 and 2018, respectively. The increase of $0.5&#160;million was mainly attributable to increase in payroll costs for an additional finance and office staff and stock-based compensation expense for vested warrants issued to a consultant and annual employee stock options.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Gain from Change in Fair Value of Warrant Liability.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We recorded a net gain of $0.1 million in the third quarter of 2019 as compared to a net gain of $0.6 million in the third quarter of 2018, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with our stock offerings. We are required to revalue certain of the warrants at the time of each warrant exercise and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nine Months Ended September&#160;30, 2019 Compared to Nine Months Ended September&#160;30, 2018</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Research and Development Expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> R&amp;D expense was $7.8 million and $6.8 million for the nine months ended September 30, 2019 and 2018, respectively. The increase of $1.0&#160;million is mainly related to increased clinical trial activity in 2019 as compared to 2018 (2 drugs in 3 clinical trials in 2018, versus 3 drugs in 4 clinical trials in 2019), as well as the issuance of common stock to Exploration Invest Pte Ltd for $0.5 million, as discussed above.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">General and Administrative Expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> General and administrative expense was $4.7 million and $3.9 million for the nine months ended September&#160;30, 2019 and 2018, respectively. The increase of $0.8&#160;million was mainly attributable to increase </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">in payroll costs for an additional finance and office staff, stock-based compensation expense for vested warrants issued to a consultant and annual employee stock options.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Gain from Change in Fair Value of Warrant Liability.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We recorded a net gain of $3.1 million in the nine months ended September&#160;30, 2019, as compared to a net gain of $1.6 million in 2018, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with our stock offerings. We are required to revalue certain of the warrants at the time of each warrant exercise and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i_0_64"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our primary sources and uses of cash for the period indicated (in thousands):&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:66.081991%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.226940%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.226940%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net cash used in operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12,521)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9,093)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net cash used in investing activities</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net cash provided by financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,284&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net increase in cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:55pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, there was no cash on hand in Australia however there was a local tax receivable of $0.2 million which was collected in October 2019. We maintain a bank account in Australia and know of no related limitations impacting our liquidity there.</span></div><div style="text-indent:55pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash used in operating activities</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cash used in operations was $12.5 million f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">r the nine months ended September&#160;30, 2019. This $3.4 million increase over the prior year o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">f </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">$9.1 million was mainly due to: 1) payments for developing, manufacturing and testing drug product as we prepared for clinical trials; 2) an increase in R&amp;D employee and contractor headcount and associated payroll costs; 3) an increase in paid sponsored research and related expenses; and 4) an increase in license fees. These are all a reflection of the ongoing clinical and pre-clinical activity and the associated increase in G&amp;A support for our three core drug technologies. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash used in investing activities</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities was $0.04 million for the nine months ended September&#160;30, 2019 compared to $0.3 million for the nine months ended September&#160;30, 2018. The decrease relates to purchases in 2018 related to furniture and fixtures and leasehold improvements on the new office location, as well as the installation of a new accounting system in 2018.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash provided in financing activities</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we completed subscription agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. Each unit was comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock resulting in gross proceeds of $15.0 million. Each warrant has an exercise price of $1.75 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Additionally, during the second quarter of 2019, 1,413,018 shares were issued due to the exercise of various warrants related to past public offerings. Gross proceeds received due to these exercises approximated $1.6 million. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In March 2019, we completed an underwritten offering of 5,250,000 units, each unit consisting of (i) one share of common stock and (ii) 0.5 of a warrant to purchase one share of common stock. The public offering price of the units was $1.00 per unit, and the underwriter agreed to purchase the units from us at a price of $0.93 per Unit. The warrants included in the units are immediately exercisable at a price of $1.10 per share, subject to adjustments in certain circumstances, and will expire </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">five years from the date of issuance. The net proceeds from the transaction was $4.7 million after deducting the underwriting discount and estimated offering expenses.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we entered into an agreement with institutional investors for a registered direct offering of securities for the sale of 1,092,636 shares of our common stock, at a purchase price of $2.105 per share. Concurrently with the sale of the common shares, we also sold warrants to purchase 710,212 shares of common stock. We sold the common shares and warrants for net proceeds of $2.1 million after deducting certain fees due to the placement agent and transaction expenses. Subject to certain beneficial ownership limitations, the warrants became initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.02 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for five years from the initial exercise date.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we entered into a securities purchase agreement with certain institutional investors for the sale by us of 4,290,000 shares of our common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common shares, we also sold warrants to purchase 2,145,000 shares of common stock. We sold the common shares and warrants for net proceeds of $8.2 million after deducting certain fees due to the placement agent and transaction expenses. Subject to certain beneficial ownership limitations, the warrants became exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.80 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for five years from the initial exercise date.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that our existing cash and cash equivalents as of September 30, 2019, will be sufficient to fund our planned operations into the second quarter of 2020, without the issuance of additional equity for cash. Such issuances should extend the funding of our planned operations beyond the second quarter of 2020.  Such plans are subject to our stock price, market conditions, changes in planned expenses depending on clinical enrollment progress, the use of drug product or a combination thereof.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will not generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly, we anticipate that we will need to raise additional capital to fund our future operations. Until such time that we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings and debt financings, and we may seek to raise additional capital through strategic collaborations. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations, which may cause dilution to our existing stockholders.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i_0_67"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition and Creation of a Subsidiary</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We acquired Moleculin, LLC on May 2, 2016, and, since such date our consolidated financial statements have included the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. We obtained input from third-parties regarding our tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. In June 2018, MBI formed Moleculin Australia Pty. Ltd., ("MAPL"), a wholly owned subsidiary, to begin preclinical development in Australia for WP1732. This may enable us to enjoy the benefits of certain research and development tax credits in Australia. In February 2019, the Company entered into an agreement with Animal Life Sciences, LLC ("ALI"), where the Company has granted a sublicense to ALI to research, develop, make, have made, use, offer to sell, sell, export or import and commercialize certain licensed products and share development data. ALI issued to the Company a 10% membership interest in ALI. In June 2019 ALI became Animal Life Sciences, Inc., incorporated in Nevada. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We record accrued expenses for estimated costs of our research and development activities conducted by third-party service providers, which include the conducting of pre-clinical studies and the preparation for clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and we include these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Warrant Liability</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The basis of value of the warrant liability is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. The Company uses the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of its remaining warrants outstanding. </span></div><div style="text-align:justify;"><span><br/></span></div><div id="i_0_70"></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Not applicable to us, as we are a smaller reporting company.</span></div><div id="i_0_73"></div><div style="-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We maintain disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were not effective as disclosed below.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In light of the material weakness described below, we performed additional procedures during the quarter and additional analysis and procedures post-closing to ensure our unaudited consolidated condensed financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the consolidated financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board Auditing Standard 1305) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the last quarter of fiscal 2016, and as our operational activities increased, management determined that it does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and has concluded that the control deficiency represents a material weakness. In 2018, management added two accounting positions, added additional fraud controls with regards to our banking systems, and replaced the accounting system with a more robust accounting system that should assist in mitigating this material weakness. Along with these improvements, changes were made in our authorization processes to improve segregation of duties. Certain improvements in segregation of duties are currently being acted upon and addressed, mainly as to the controls on information technology systems. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. During the second quarter of 2019, we began scoping and planning the implementation of required internal controls, utilizing outside consultants. In the third quarter of 2019, management increased its accounting staff and added an IT consultant to assist in management's efforts to improve the internal control structure.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_76"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_79"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div id="i_0_82"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A. RISK FACTORS</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled &#8220;Risk Factors&#8221; in Part I, Item 1A in our annual report on Form 10-K for the year ended December 31, 2018. Except as updated below, there have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2018 as filed with the SEC. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The timeliness of our clinical trials may be impacted by numerous factors and any delays may adversely affect our ability to execute our current business strategy. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all. If initiation or completion of any of our clinical trials for our product candidates are delayed for any reason, our development costs may increase, our approval process could be delayed, any periods after commercial launch and before expiration of patent protection may be reduced and our competitors may have more time to bring products to market before we do. Any of these events could impair the commercial potential of our product candidates and could have a material adverse effect on our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.&#8232;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Clinical testing is expensive, takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our product candidates are subject to the risks of failure inherent in biologic drug development. Success in early clinical trials does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing, even at statistically significant levels. We will be required to demonstrate through clinical trials that our product candidates are safe and effective for use in the target indication before we can obtain regulatory approvals for commercial sale. Companies frequently suffer significant setbacks in late-stage clinical trials, even after earlier clinical trials have shown promising results and most product candidates that commence clinical trials are never approved as products. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates fail to demonstrate sufficient safety or efficacy, we would experience potentially significant delays in, or be required to abandon our development of the product candidate, which would have a material and adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and even if we obtain approval for a product candidate in one country or jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we and our collaborators must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for a product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. Seeking regulatory </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">approval could result in difficulties and costs for us and require additional nonclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business and operations would suffer in the event of third-party computer system failures, cyber-attacks on third-party systems or deficiency in our cyber security.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We rely on information technology (&#8220;IT&#8221;) systems, including third-party &#8220;cloud based&#8221; service providers, to keep financial records, maintain laboratory data, clinical data, and corporate records, to communicate with staff and external parties and to operate other critical functions. This includes critical systems such as email, other communication tools, electronic document repositories and archives. If any of these third-party information technology providers are compromised due to computer viruses, unauthorized access, malware, natural disasters, fire, terrorism, war and telecommunication failures, electrical failures, cyber-attacks or cyber-intrusions over the internet, then sensitive emails or documents could be exposed or deleted. Similarly, we could incur business disruption if our access to the internet is compromised and we are unable to connect with third-party IT providers. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, we rely on those third parties to safeguard important confidential personal data regarding our employees and patients enrolled in our clinical trials. If a disruption event were to occur and cause interruptions in a third-party IT provider&#8217;s operation, it could result in a disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and development of our product candidates could be delayed, or could fail.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i_0_85"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On July 30, 2019, we entered into a License Modification Agreement with Exploration Invest Pte Ltd pursuant to which we agreed to issue Exploration shares of our common stock valued at $0.5 million (based on the greater of the closing price of the common stock on the date of the agreement or the 10-day average closing price prior to the date of the agreement) in exchange for the modifying certain license agreements. On August 8, 2019, we issued 429,978 shares of common stock to Exploration to satisfy this commitment. The common stock was issued pursuant to Section 4(a)(2) of the Securities Act.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i_0_88"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_91"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. MINE SAFETY DISCLOSURE</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_94"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 5. OTHER INFORMATION.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">None.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_97"></div><div style="-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 6. EXHIBITS</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:12.076246%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:83.190616%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Exhibit No.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420419035673/tv525752_ex1-1.htm">At Market Issuance Sales Agreement, dated July 23, 2019, by and among the Company and Oppenheimer &amp; Co. Inc. (incorporated by reference to Exhibit 1.1 of the Form 8-K filed July 24, 2019)</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">31.1*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q3ex311-xnextgen.htm">Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">31.2*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q3ex312-xnextgen.htm">Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">32.1*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q3ex321-xnextgen.htm">Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">32.2*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q3ex322-xnextgen.htm">Certification of Principal Accounting and Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.INS*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.SCH*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.CAL*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.DEF*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.LAB*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">101.PRE*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">* Filed herewith.</span></div><div><span><br/></span></div><div id="i_0_100"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.973607%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.692082%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.334311%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">MOLECULIN BIOTECH, INC.</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date:&#160;November 12, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">/s/ Walter V. Klemp</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Walter V. Klemp,</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer and Chairman</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date:&#160;November 12, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">/s/ Jonathan P. Foster</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Jonathan P. Foster,</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Executive Vice President &amp; Chief Financial Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2019q3ex311-xnextgen.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-indent:36pt;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000033;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Walter V. Klemp, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">November 12, 2019 </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.912281%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#47;s&#47; Walter V. Klemp</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Walter V. Klemp</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-indent:36pt;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2019q3ex312-xnextgen.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-indent:36pt;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000033;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Jonathan P. Foster, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">November 12, 2019</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.912281%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#47;s&#47; Jonathan P. Foster</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Jonathan P. Foster</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Executive Vice President and Chief Financial Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2019q3ex321-xnextgen.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Walter Klemp, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d))&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November 12, 2019 </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.912281%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#47;s&#47; Walter V. Klemp</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Walter V. Klemp</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2019q3ex322-xnextgen.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Annual Report on Form 10-Q for the quarter ended September 30, 2019 of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jonathan Foster, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d))&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November 12, 2019 </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.912281%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#47;s&#47; Jonathan P. Foster</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Jonathan P. Foster</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Executive Vice President and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mbx-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:mbx="http://www.moleculin.com/20190930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.moleculin.com/20190930">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="mbx_AccruedDrugManufacturingCost" abstract="false" name="AccruedDrugManufacturingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_LeaseAgreementForCorporateOfficeSpaceMember" abstract="true" name="LeaseAgreementForCorporateOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mbx_NumberOfDrugTechnologies" abstract="false" name="NumberOfDrugTechnologies" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_AtMarketIssuanceSalesAgreementMember" abstract="true" name="AtMarketIssuanceSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" abstract="false" name="OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mbx_LincolnParkSaleMember" abstract="true" name="LincolnParkSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_IPXMemorialDriveInvestorsLLCMember" abstract="true" name="IPXMemorialDriveInvestorsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_ClassofWarrantorRightExpirationPeriod" abstract="false" name="ClassofWarrantorRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_OptionRepurchasePayments" abstract="false" name="OptionRepurchasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_DerminMember" abstract="true" name="DerminMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_UnitsSoldInPeriod" abstract="false" name="UnitsSoldInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_GSKConsultingAgreementWarrantTwoMember" abstract="true" name="GSKConsultingAgreementWarrantTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_MarketExclusivityExtensionPeriod" abstract="false" name="MarketExclusivityExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_ConsultingFees" abstract="false" name="ConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_OppenheimerCoIncMember" abstract="true" name="OppenheimerCoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_ClassofWarrantorRightAgreementPeriod" abstract="false" name="ClassofWarrantorRightAgreementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_WarrantLiabiltyMember" abstract="true" name="WarrantLiabiltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mbx_LicenseAgreementAnnualLicenseFee" abstract="false" name="LicenseAgreementAnnualLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_UnitOfferingUnitPricePerShare" abstract="false" name="UnitOfferingUnitPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mbx_PeriodTwoMember" abstract="true" name="PeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" abstract="false" name="SaleOfStockFeesPaidPercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mbx_June2018RegisteredDirectOfferingMember" abstract="true" name="June2018RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_TheWarrantsMember" abstract="true" name="TheWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_HoustonPharmaceuticalsIncMember" abstract="true" name="HoustonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" abstract="false" name="PercentageOfSubLeaseIncomeAllocableToCoLessee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" abstract="false" name="SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" abstract="false" name="VendorPrepaymentAndDepositsExpansionOfProductionCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_ClassofWarrantorRightVestingPeriod" abstract="false" name="ClassofWarrantorRightVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_ScheduleOfWarrantActivityTableTextBlock" abstract="false" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mbx_LicensingAgreementTerm" abstract="false" name="LicensingAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_SharesAuthorized" abstract="false" name="SharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_NumberofDrugCandidates" abstract="false" name="NumberofDrugCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_PeriodOneMember" abstract="true" name="PeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_WarrantLiabilityLongtermMember" abstract="true" name="WarrantLiabilityLongtermMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_WPDPharmaceuticalsMember" abstract="true" name="WPDPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_LeaseholdImprovementsPaidByLandlord" abstract="false" name="LeaseholdImprovementsPaidByLandlord" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_FoodAndDrugAdministrationMember" abstract="true" name="FoodAndDrugAdministrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_June2018IssuanceMember" abstract="true" name="June2018IssuanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_AuthorityAxis" abstract="true" name="AuthorityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mbx_NatureOfBusinessAndLiquidityTextBlock" abstract="false" name="NatureOfBusinessAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mbx_UnderwitersMember" abstract="true" name="UnderwitersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_OlympiaDriveWBellfortLLCMember" abstract="true" name="OlympiaDriveWBellfortLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_StockPlanMember" abstract="true" name="StockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_AnimalLifeScienceMember" abstract="true" name="AnimalLifeScienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_March2019IssuanceMember" abstract="true" name="March2019IssuanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_CommitmentSharesMember" abstract="true" name="CommitmentSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_NumberofDrugsinClinicalTrials" abstract="false" name="NumberofDrugsinClinicalTrials" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mbx_ResearchAndDevelopmentCommitment" abstract="false" name="ResearchAndDevelopmentCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_MdAndersonMember" abstract="true" name="MdAndersonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_NumberofClinicalTrials" abstract="false" name="NumberofClinicalTrials" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" abstract="false" name="EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_AprilOfferingsMember" abstract="true" name="AprilOfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_GoingConcernPolicyPolicyTextBlock" abstract="false" name="GoingConcernPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mbx_PeriodDomain" abstract="true" name="PeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_VendorPrepaymentAndDeposits" abstract="false" name="VendorPrepaymentAndDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" abstract="true" name="RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_ScheduleOfAssumptionsUsed1TableTextBlock" abstract="false" name="ScheduleOfAssumptionsUsed1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mbx_WarrantLiabilityAbstract" abstract="true" name="WarrantLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mbx_WarrantLiabilityCurrentMember" abstract="true" name="WarrantLiabilityCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_AuthorityDomain" abstract="true" name="AuthorityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_ClassOfWarrantOrRightInitialExercisePeriod" abstract="false" name="ClassOfWarrantOrRightInitialExercisePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_UnderwriterMember" abstract="true" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_GSKConsultingAgreementWarrantOneMember" abstract="true" name="GSKConsultingAgreementWarrantOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" abstract="false" name="CommonStockIssuedForLicenceRightsUnderLicenceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_SharesIssuedInLeiuOfCash" abstract="false" name="SharesIssuedInLeiuOfCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_March2019RegisteredDirectOfferingsMember" abstract="true" name="March2019RegisteredDirectOfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_LicensedTechnologyFuturePaymentToRemoveCountry" abstract="false" name="LicensedTechnologyFuturePaymentToRemoveCountry" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_AccruedLicenseFeesAndSRACurrent" abstract="false" name="AccruedLicenseFeesAndSRACurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_NumberOfOtherDrugDevelopmentProjects" abstract="false" name="NumberOfOtherDrugDevelopmentProjects" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" abstract="true" name="SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_ConsultingAgreementWarrantThreeMember" abstract="true" name="ConsultingAgreementWarrantThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_ComponentsofShareBasedCompensationTableTextBlock" abstract="false" name="ComponentsofShareBasedCompensationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mbx_ClassofWarrantorRightNumberofWarrantsIssued" abstract="false" name="ClassofWarrantorRightNumberofWarrantsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mbx_PaymentsForResearchAndDevelopmentAgreement" abstract="false" name="PaymentsForResearchAndDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_MilestonePaymentsLiabilities" abstract="false" name="MilestonePaymentsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_AccruedClinicalTestingCurrent" abstract="false" name="AccruedClinicalTestingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_ClassOfWarrantOrRightTerm" abstract="false" name="ClassOfWarrantOrRightTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mbx_EquityDistributionCommitment" abstract="false" name="EquityDistributionCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mbx_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mbx_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_LicenceRightsMember" abstract="true" name="LicenceRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mbx_PeriodAxis" abstract="true" name="PeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mbx_PercentageOfRentPayableByCoLessee" abstract="false" name="PercentageOfRentPayableByCoLessee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbx-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbx-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbx-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbx-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.moleculin.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandLiquidity" roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidity">
        <link:definition>2101101 - Disclosure - Nature of Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandLiquidityDetails" roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" roleURI="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies">
        <link:definition>2103102 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails">
        <link:definition>2406402 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2407403 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails">
        <link:definition>2408404 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails">
        <link:definition>2409405 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>2110103 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>2311302 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2412406 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiability" roleURI="http://www.moleculin.com/role/WarrantLiability">
        <link:definition>2113104 - Disclosure - Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityTables" roleURI="http://www.moleculin.com/role/WarrantLiabilityTables">
        <link:definition>2314303 - Disclosure - Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityNarrativeDetails" roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails">
        <link:definition>2415407 - Disclosure - Warrant Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" roleURI="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails">
        <link:definition>2416408 - Disclosure - Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.moleculin.com/role/Equity">
        <link:definition>2117105 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.moleculin.com/role/EquityTables">
        <link:definition>2318304 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.moleculin.com/role/EquityNarrativeDetails">
        <link:definition>2419409 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofOptionActivitiesDetails" roleURI="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails">
        <link:definition>2420410 - Disclosure - Equity - Summary of Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofAssumptionsUsedDetails" roleURI="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails">
        <link:definition>2421411 - Disclosure - Equity - Summary of Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityComponentsofStockBasedCompensationDetails" roleURI="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails">
        <link:definition>2422412 - Disclosure - Equity - Components of Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.moleculin.com/role/IncomeTaxes">
        <link:definition>2123106 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesDetails">
        <link:definition>2424413 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.moleculin.com/role/CommitmentsandContingencies">
        <link:definition>2125107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.moleculin.com/role/CommitmentandContingenciesTables">
        <link:definition>2326305 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" roleURI="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails">
        <link:definition>2428415 - Disclosure - Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMinimumLeasePaymentsDetails" roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails">
        <link:definition>2429416 - Disclosure - Commitments and Contingencies - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMinimumLeasePaymentsDetails_1" roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1">
        <link:definition>2429416 - Disclosure - Commitments and Contingencies - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.moleculin.com/role/SubsequentEvents">
        <link:definition>2130108 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mbx-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.moleculin.com/role/Cover" xlink:type="simple" xlink:href="mbx-20190930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e7502978-cacc-4643-ba8b-02c974ea791f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b9513cfe-0258-4148-898f-4c4aa44313d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e7502978-cacc-4643-ba8b-02c974ea791f" xlink:to="loc_us-gaap_AccountsPayableCurrent_b9513cfe-0258-4148-898f-4c4aa44313d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ce5c7c18-8e83-4858-b240-b06c07d33a30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e7502978-cacc-4643-ba8b-02c974ea791f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ce5c7c18-8e83-4858-b240-b06c07d33a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_8ddc20b6-0d39-4c10-a0b8-97f51b84c464" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e7502978-cacc-4643-ba8b-02c974ea791f" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_8ddc20b6-0d39-4c10-a0b8-97f51b84c464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_65733e04-b286-4938-8f47-2b1226fd29c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_821e79f4-8ed0-44b8-8d15-0a209143785a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65733e04-b286-4938-8f47-2b1226fd29c4" xlink:to="loc_us-gaap_LiabilitiesCurrent_821e79f4-8ed0-44b8-8d15-0a209143785a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_4bf6ec71-15e4-472f-90b6-dcc490a7cab7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65733e04-b286-4938-8f47-2b1226fd29c4" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_4bf6ec71-15e4-472f-90b6-dcc490a7cab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_88d0c0a5-88e7-4a49-aa4f-7a88a562a241" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65733e04-b286-4938-8f47-2b1226fd29c4" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_88d0c0a5-88e7-4a49-aa4f-7a88a562a241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_88174f2c-60f7-44cc-bd42-d797cd1b90a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65733e04-b286-4938-8f47-2b1226fd29c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_88174f2c-60f7-44cc-bd42-d797cd1b90a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7209ded9-281e-4a0d-b6ae-3d1d602679ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fdc33a06-f525-442a-a6c3-2ba5ffe179dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7209ded9-281e-4a0d-b6ae-3d1d602679ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fdc33a06-f525-442a-a6c3-2ba5ffe179dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6aeca34f-62b9-4ad3-9cd4-5417854a6d38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7209ded9-281e-4a0d-b6ae-3d1d602679ce" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6aeca34f-62b9-4ad3-9cd4-5417854a6d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0829733e-24e6-42c3-81a0-0243b8fb9705" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_be60b4b5-3d39-4b2e-ae69-a5e82011ac00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0829733e-24e6-42c3-81a0-0243b8fb9705" xlink:to="loc_us-gaap_AssetsCurrent_be60b4b5-3d39-4b2e-ae69-a5e82011ac00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_979ad6b5-8e6d-4906-9b3a-0fec019ea7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0829733e-24e6-42c3-81a0-0243b8fb9705" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_979ad6b5-8e6d-4906-9b3a-0fec019ea7ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e5bddd73-4150-467b-a762-eb71aa6125f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0829733e-24e6-42c3-81a0-0243b8fb9705" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e5bddd73-4150-467b-a762-eb71aa6125f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f75b651f-1e01-40bd-93b9-ac42e41a63b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0829733e-24e6-42c3-81a0-0243b8fb9705" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f75b651f-1e01-40bd-93b9-ac42e41a63b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_76dfc696-ca77-4b0e-ac39-5464c6dd2096" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_30629ead-65e0-4b5c-b578-704a55efe252" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_76dfc696-ca77-4b0e-ac39-5464c6dd2096" xlink:to="loc_us-gaap_Liabilities_30629ead-65e0-4b5c-b578-704a55efe252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e53f4f2-d386-49dc-bac6-e5b456c9e6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_76dfc696-ca77-4b0e-ac39-5464c6dd2096" xlink:to="loc_us-gaap_StockholdersEquity_7e53f4f2-d386-49dc-bac6-e5b456c9e6ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_07507a83-e4fe-4f13-b6d9-e0fe445af7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_76dfc696-ca77-4b0e-ac39-5464c6dd2096" xlink:to="loc_us-gaap_CommitmentsAndContingencies_07507a83-e4fe-4f13-b6d9-e0fe445af7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_105eff8f-d94a-478f-ac3c-723bf8d749ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:to="loc_us-gaap_PreferredStockValue_105eff8f-d94a-478f-ac3c-723bf8d749ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4de56396-63cd-496d-8968-a3bf2027033e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:to="loc_us-gaap_CommonStockValue_4de56396-63cd-496d-8968-a3bf2027033e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1616018-a863-40e9-a716-e44d058a608f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1616018-a863-40e9-a716-e44d058a608f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7beac12c-49b0-49b5-8c4d-5c24a5478a20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7beac12c-49b0-49b5-8c4d-5c24a5478a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociBeforeTaxAttributableToParent_901fd995-7d7f-418a-bc5c-49e80bc3003f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociBeforeTaxAttributableToParent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_601320ef-cac3-4648-870c-4e998bf4e0ee" xlink:to="loc_us-gaap_AociBeforeTaxAttributableToParent_901fd995-7d7f-418a-bc5c-49e80bc3003f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9c9a9886-b694-45d4-ba57-b67aa4cc7210" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79335127-a693-4f84-b77a-f859af048ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c9a9886-b694-45d4-ba57-b67aa4cc7210" xlink:to="loc_us-gaap_OperatingIncomeLoss_79335127-a693-4f84-b77a-f859af048ba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6f638a4b-e671-45b6-a989-b51cc52a3606" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c9a9886-b694-45d4-ba57-b67aa4cc7210" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6f638a4b-e671-45b6-a989-b51cc52a3606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3fb493bc-bde2-4566-9fbe-f3a28f96d36e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c9a9886-b694-45d4-ba57-b67aa4cc7210" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3fb493bc-bde2-4566-9fbe-f3a28f96d36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_35763aa6-10c5-4160-906c-bb050ecba8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c9a9886-b694-45d4-ba57-b67aa4cc7210" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_35763aa6-10c5-4160-906c-bb050ecba8e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7bdf7932-0293-4f30-900b-93e4f7a295d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4c71e3ad-b292-4445-a73a-792861b18c66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7bdf7932-0293-4f30-900b-93e4f7a295d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4c71e3ad-b292-4445-a73a-792861b18c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2678ff1f-2634-43ee-9156-350c4f7f0b74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7bdf7932-0293-4f30-900b-93e4f7a295d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2678ff1f-2634-43ee-9156-350c4f7f0b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9e007e1d-a691-48d7-80bf-090f5c6553c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7bdf7932-0293-4f30-900b-93e4f7a295d1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9e007e1d-a691-48d7-80bf-090f5c6553c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9619b949-74e4-4656-b40b-397a52ef3fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_614e1ef1-d392-452e-9698-f18d95e4aaba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9619b949-74e4-4656-b40b-397a52ef3fd3" xlink:to="loc_us-gaap_Revenues_614e1ef1-d392-452e-9698-f18d95e4aaba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_825fd526-5a33-4e24-9353-6b02a3842c29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9619b949-74e4-4656-b40b-397a52ef3fd3" xlink:to="loc_us-gaap_OperatingExpenses_825fd526-5a33-4e24-9353-6b02a3842c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_463bf131-5379-4a29-8ecd-30229246cf8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bf148959-0008-4be3-8e78-df31dcd24d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_463bf131-5379-4a29-8ecd-30229246cf8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bf148959-0008-4be3-8e78-df31dcd24d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9161816-0987-4b07-9883-2bccb9f8feae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_463bf131-5379-4a29-8ecd-30229246cf8e" xlink:to="loc_us-gaap_NetIncomeLoss_d9161816-0987-4b07-9883-2bccb9f8feae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81c59505-4700-4d14-8e6a-6f048c5d6c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1e825e3b-3483-41ae-9802-1609a5142dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_81c59505-4700-4d14-8e6a-6f048c5d6c8d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1e825e3b-3483-41ae-9802-1609a5142dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_10552977-d70b-4dcc-9672-fbb84d1e9057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_81c59505-4700-4d14-8e6a-6f048c5d6c8d" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_10552977-d70b-4dcc-9672-fbb84d1e9057" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12daef68-a3ed-4cd3-8224-2d4231e3f47a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02770f92-7db9-49fd-a5ad-59f90a0eeb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12daef68-a3ed-4cd3-8224-2d4231e3f47a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02770f92-7db9-49fd-a5ad-59f90a0eeb4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25780e2c-7812-4dd4-b954-493c5321e73f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0540e680-fc49-41fb-b21e-f5b50affd5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25780e2c-7812-4dd4-b954-493c5321e73f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0540e680-fc49-41fb-b21e-f5b50affd5c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_429e4aa8-7309-4d5c-981d-56eb1c9950da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25780e2c-7812-4dd4-b954-493c5321e73f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_429e4aa8-7309-4d5c-981d-56eb1c9950da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ed3ba577-f223-4913-bd1f-bfdcaba372eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25780e2c-7812-4dd4-b954-493c5321e73f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ed3ba577-f223-4913-bd1f-bfdcaba372eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f81ad5d7-24ca-4f5a-8034-936a3cb14196" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a908cce-c0ed-4317-ba94-49ff2fd88743" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f81ad5d7-24ca-4f5a-8034-936a3cb14196" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a908cce-c0ed-4317-ba94-49ff2fd88743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e715ade8-b755-473b-9f08-1e625eb3631a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f81ad5d7-24ca-4f5a-8034-936a3cb14196" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e715ade8-b755-473b-9f08-1e625eb3631a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6fcceb6-4e92-4c87-b3ac-389d7541b428" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f81ad5d7-24ca-4f5a-8034-936a3cb14196" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6fcceb6-4e92-4c87-b3ac-389d7541b428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf40d7e9-93d3-46c5-9c2d-666c76eb76e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f81ad5d7-24ca-4f5a-8034-936a3cb14196" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf40d7e9-93d3-46c5-9c2d-666c76eb76e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_da524646-c623-42aa-b359-ae1342539be3" xlink:href="mbx-20190930.xsd#mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_da524646-c623-42aa-b359-ae1342539be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_fde78e56-c1bd-4569-91ec-c97057fcdbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_fde78e56-c1bd-4569-91ec-c97057fcdbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9946ed8f-fb0e-412d-8e9e-ecd829511930" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_NetIncomeLoss_9946ed8f-fb0e-412d-8e9e-ecd829511930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2e09af19-9015-4f8f-a867-b4c09f11b960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2e09af19-9015-4f8f-a867-b4c09f11b960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_fbffa779-ac75-4f88-a0bc-939731dc4158" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_fbffa779-ac75-4f88-a0bc-939731dc4158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_aa6eebf7-f3ee-4af7-81e3-6fc76fac381b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_aa6eebf7-f3ee-4af7-81e3-6fc76fac381b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_066d897a-2b23-4df1-81e6-03b1ec482de5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_066d897a-2b23-4df1-81e6-03b1ec482de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bd2dec74-cacb-460b-8151-5b2b8c7aa670" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_ShareBasedCompensation_bd2dec74-cacb-460b-8151-5b2b8c7aa670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8d55f37e-5905-4e44-abf6-2c96fff7d89e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8d55f37e-5905-4e44-abf6-2c96fff7d89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2cb2a2a8-e00f-4c7e-b11b-bbd76933e2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2cb2a2a8-e00f-4c7e-b11b-bbd76933e2e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_626a2440-b8c7-499e-8bc8-b9cfc9313caf" xlink:href="mbx-20190930.xsd#mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfc7e036-50af-4989-a07d-2e38a91d1554" xlink:to="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_626a2440-b8c7-499e-8bc8-b9cfc9313caf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidity"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidityDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_259d892d-ff4b-4ed1-b687-9f055ed8cc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_558c5f84-e206-40b0-b013-5731f4d4401a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_259d892d-ff4b-4ed1-b687-9f055ed8cc8a" xlink:to="loc_us-gaap_PrepaidInsurance_558c5f84-e206-40b0-b013-5731f4d4401a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_VendorPrepaymentAndDeposits_22f7e59a-31f2-4147-9b3b-1de729e0f069" xlink:href="mbx-20190930.xsd#mbx_VendorPrepaymentAndDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_259d892d-ff4b-4ed1-b687-9f055ed8cc8a" xlink:to="loc_mbx_VendorPrepaymentAndDeposits_22f7e59a-31f2-4147-9b3b-1de729e0f069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_7bd61fd4-a34a-45f4-afd8-587f0b2c9bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_259d892d-ff4b-4ed1-b687-9f055ed8cc8a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_7bd61fd4-a34a-45f4-afd8-587f0b2c9bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3ab8aa2b-3128-4484-abdf-376326725349" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_259d892d-ff4b-4ed1-b687-9f055ed8cc8a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3ab8aa2b-3128-4484-abdf-376326725349" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbf4a0b5-d30c-423b-be9a-5cb49bc67766" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbf4a0b5-d30c-423b-be9a-5cb49bc67766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedDrugManufacturingCost_a97dc043-1aa1-4234-9164-af9297f87916" xlink:href="mbx-20190930.xsd#mbx_AccruedDrugManufacturingCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_mbx_AccruedDrugManufacturingCost_a97dc043-1aa1-4234-9164-af9297f87916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedClinicalTestingCurrent_99b33c20-9bb1-4247-aea4-1eeafc04eabc" xlink:href="mbx-20190930.xsd#mbx_AccruedClinicalTestingCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_mbx_AccruedClinicalTestingCurrent_99b33c20-9bb1-4247-aea4-1eeafc04eabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f87dcd97-2f82-41fe-8f98-4e80156273ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f87dcd97-2f82-41fe-8f98-4e80156273ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_bd01072e-b05b-4e8f-b15a-90873d7daa83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_bd01072e-b05b-4e8f-b15a-90873d7daa83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cc84bb2d-4d9d-4221-954a-3c92d51d5f52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cc84bb2d-4d9d-4221-954a-3c92d51d5f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedLicenseFeesAndSRACurrent_40d3c144-9ebe-4db5-ab7a-fe978a92fdf1" xlink:href="mbx-20190930.xsd#mbx_AccruedLicenseFeesAndSRACurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f58f5a10-4ead-4ec6-a548-2ac4f98cf994" xlink:to="loc_mbx_AccruedLicenseFeesAndSRACurrent_40d3c144-9ebe-4db5-ab7a-fe978a92fdf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiability"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityTables"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:type="simple" xlink:href="mbx-20190930.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesAuthorized_163be13b-2db4-4675-b1a1-b50f8b9e16a0" xlink:href="mbx-20190930.xsd#mbx_SharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7920c140-6f06-4485-b598-0ec3d65d63c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mbx_SharesAuthorized_163be13b-2db4-4675-b1a1-b50f8b9e16a0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7920c140-6f06-4485-b598-0ec3d65d63c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b0af3b06-d39f-4b0d-904f-22f933b1a6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mbx_SharesAuthorized_163be13b-2db4-4675-b1a1-b50f8b9e16a0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b0af3b06-d39f-4b0d-904f-22f933b1a6a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofOptionActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofAssumptionsUsedDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityComponentsofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e46ff85a-d6a2-4c0e-859d-0d9712857546" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e46ff85a-d6a2-4c0e-859d-0d9712857546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8beeccac-9800-445a-a4d4-84895a686b62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8beeccac-9800-445a-a4d4-84895a686b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e88c890-6542-4ac6-b4b4-b54422b62731" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e88c890-6542-4ac6-b4b4-b54422b62731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54bb630c-7b0e-48bc-a35b-6d48279bd43e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54bb630c-7b0e-48bc-a35b-6d48279bd43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_555b2da3-57d1-473d-9393-66235b3f1a05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_555b2da3-57d1-473d-9393-66235b3f1a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1fc95b01-7d57-438f-8874-2c98ee87e1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cbe7bed2-2b41-43f1-b256-72da13f0b370" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1fc95b01-7d57-438f-8874-2c98ee87e1b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b873bb6-f718-4bb5-abfd-1b50a86c7885" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7bd753a5-095c-4276-b0d0-075ebecc8ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b873bb6-f718-4bb5-abfd-1b50a86c7885" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7bd753a5-095c-4276-b0d0-075ebecc8ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_580cc39d-c765-4112-8591-27faf744736d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b873bb6-f718-4bb5-abfd-1b50a86c7885" xlink:to="loc_us-gaap_OperatingLeaseLiability_580cc39d-c765-4112-8591-27faf744736d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mbx-20190930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mbx-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/Cover" xlink:type="simple" xlink:href="mbx-20190930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/Cover" xlink:type="extended" id="i9ced26e11da34f58a3b401eb31b193a6_8f72b520-d8ac-4577-8c8f-39944f9b31c3"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i884221b7076040e7a805ba4c3441b985_2a546e3e-2a61-402a-b74e-c634c19dff0f"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i2ac665b527ed41c9a622df642af071e0_37108e6d-c690-49b9-9b9a-d7a4ec2443c2"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i453fcfd0802a4bc4b62dd37704bc3152_46cab1d4-29f9-4120-bf37-48395ef8e30e"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i44a90a7333244c439e9065e327d802bf_d0eea301-14a7-41ac-9c07-8a1bcba9f896"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i117fbe0725ee49858d6dcb489ac3fdf5_f1146eef-7b23-468b-a422-8f2896e15e64">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e25fe320-83e4-4af9-ae54-c75301b4d966" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockholdersEquity_e25fe320-83e4-4af9-ae54-c75301b4d966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1590759c-b2c8-4b21-930b-b6f1c9a9602e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_SharesOutstanding_1590759c-b2c8-4b21-930b-b6f1c9a9602e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b42158f5-41cd-4213-ba08-4fffb4776485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b42158f5-41cd-4213-ba08-4fffb4776485" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f36e2be-0db9-45ab-b6d3-2c59b254b0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f36e2be-0db9-45ab-b6d3-2c59b254b0a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27a518f9-758a-40c3-897b-2ea4264a6b22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27a518f9-758a-40c3-897b-2ea4264a6b22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52ea275-06d3-4b58-92e4-7af4a2042145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52ea275-06d3-4b58-92e4-7af4a2042145" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40403b99-c701-4735-87a2-17cb545e8039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40403b99-c701-4735-87a2-17cb545e8039" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cbb05997-ebde-41af-9f1d-96855862a3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_NetIncomeLoss_cbb05997-ebde-41af-9f1d-96855862a3bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_658bfc18-9855-4e8f-bb9d-5229a36c3e70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_658bfc18-9855-4e8f-bb9d-5229a36c3e70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_3110d769-0993-4bb1-9a78-eed3d640fdcf" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_3110d769-0993-4bb1-9a78-eed3d640fdcf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_14f56972-3aa4-4d81-95bb-666de11431b2" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_14f56972-3aa4-4d81-95bb-666de11431b2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef4e3002-f08c-44b3-888e-3f470034bb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4960d88b-5ccb-46a6-b325-68d00c87347e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:to="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5fddd2d-09c9-40f1-84e7-3015542ad7b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:to="loc_us-gaap_EquityComponentDomain_f5fddd2d-09c9-40f1-84e7-3015542ad7b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:to="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_713a16e1-a4f1-4989-bc7d-5bb4745ef8be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_CommonStockMember_713a16e1-a4f1-4989-bc7d-5bb4745ef8be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_39db7a28-fcdb-43f4-8f32-8d5545aee09b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_39db7a28-fcdb-43f4-8f32-8d5545aee09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f688320-fd3c-46ba-acb7-b1fc34721b47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_RetainedEarningsMember_4f688320-fd3c-46ba-acb7-b1fc34721b47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_456c2b4e-b257-4a18-9736-a5324c6ba7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_456c2b4e-b257-4a18-9736-a5324c6ba7dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019IssuanceMember_4dc32f6f-6526-43e1-940e-43d98bc312c6" xlink:href="mbx-20190930.xsd#mbx_March2019IssuanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_March2019IssuanceMember_4dc32f6f-6526-43e1-940e-43d98bc312c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LincolnParkSaleMember_835174d1-de9c-4b91-97d7-b1bec480c878" xlink:href="mbx-20190930.xsd#mbx_LincolnParkSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_LincolnParkSaleMember_835174d1-de9c-4b91-97d7-b1bec480c878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_a01e21cc-f1f0-48d7-8cd9-1963b9acfef8" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_AprilOfferingsMember_a01e21cc-f1f0-48d7-8cd9-1963b9acfef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018IssuanceMember_4ba87168-9616-4120-b675-dc087d874d27" xlink:href="mbx-20190930.xsd#mbx_June2018IssuanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_June2018IssuanceMember_4ba87168-9616-4120-b675-dc087d874d27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenceRightsMember_476e5ba0-9c14-417a-ba68-b31b9cac942e" xlink:href="mbx-20190930.xsd#mbx_LicenceRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_LicenceRightsMember_476e5ba0-9c14-417a-ba68-b31b9cac942e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i5ad0636e1bd04d22bf4b6087c39bb4dc_749f4e4c-dac2-4ea6-8a97-5a7dd4924372"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidity"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="extended" id="i90a311b42f6543778ce19535714c87ce_eef6c056-9bcf-4aec-a069-4bc2f4f75d8c"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="extended" id="i4da1e57d5a604876852135cf8d22c862_4a7f31f6-f5a4-4ffd-a908-b0b3f0a795d1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ac684ec-6c04-4064-8b73-aaaa1d4041e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ac684ec-6c04-4064-8b73-aaaa1d4041e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfDrugTechnologies_985898b2-b168-474b-a947-956b62634725" xlink:href="mbx-20190930.xsd#mbx_NumberOfDrugTechnologies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberOfDrugTechnologies_985898b2-b168-474b-a947-956b62634725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugCandidates_6f3f4400-de91-49d4-ba3c-30e5b9b2c171" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofDrugCandidates_6f3f4400-de91-49d4-ba3c-30e5b9b2c171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugsinClinicalTrials_df9151e4-16ca-49f8-9728-f74d4d2bebfa" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugsinClinicalTrials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofDrugsinClinicalTrials_df9151e4-16ca-49f8-9728-f74d4d2bebfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofClinicalTrials_ee50b5b6-8d04-4a94-93f2-089d1aea735f" xlink:href="mbx-20190930.xsd#mbx_NumberofClinicalTrials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofClinicalTrials_ee50b5b6-8d04-4a94-93f2-089d1aea735f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfOtherDrugDevelopmentProjects_697dba7e-1a69-49cb-b92a-307408553c81" xlink:href="mbx-20190930.xsd#mbx_NumberOfOtherDrugDevelopmentProjects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberOfOtherDrugDevelopmentProjects_697dba7e-1a69-49cb-b92a-307408553c81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MarketExclusivityExtensionPeriod_3e222180-b7e7-4d48-af8b-32deae3f2b1b" xlink:href="mbx-20190930.xsd#mbx_MarketExclusivityExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_MarketExclusivityExtensionPeriod_3e222180-b7e7-4d48-af8b-32deae3f2b1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cdca327d-034a-45d1-98e2-1cead83a8b47_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cdca327d-034a-45d1-98e2-1cead83a8b47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AnimalLifeScienceMember_e5927a61-b48c-4b74-ba18-8601850f8f04" xlink:href="mbx-20190930.xsd#mbx_AnimalLifeScienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:to="loc_mbx_AnimalLifeScienceMember_e5927a61-b48c-4b74-ba18-8601850f8f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_689217a5-109a-40f9-b9fc-a1d254b7eb8f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:to="loc_srt_SegmentGeographicalDomain_689217a5-109a-40f9-b9fc-a1d254b7eb8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:to="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_4ddcb6e0-1ee2-4f1e-a9f5-12ff938daddf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:to="loc_us-gaap_EuropeanUnionMember_4ddcb6e0-1ee2-4f1e-a9f5-12ff938daddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:href="mbx-20190930.xsd#mbx_AuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityDomain_5ae7764a-a862-4ac7-b133-d32e6e42769b_default" xlink:href="mbx-20190930.xsd#mbx_AuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:to="loc_mbx_AuthorityDomain_5ae7764a-a862-4ac7-b133-d32e6e42769b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:href="mbx-20190930.xsd#mbx_AuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:to="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FoodAndDrugAdministrationMember_a83d605d-2cec-4d78-b3a8-cc4c8eca0e12" xlink:href="mbx-20190930.xsd#mbx_FoodAndDrugAdministrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:to="loc_mbx_FoodAndDrugAdministrationMember_a83d605d-2cec-4d78-b3a8-cc4c8eca0e12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="extended" id="if8a7fd20008e4a7183768526740ba0a3_53243216-4610-46b4-b91f-b5944806ac05"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="extended" id="i03c66afa9a024e3d93f9562a7e85c437_a542d69c-43cc-49c5-9035-3012741d8f2c"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="extended" id="ie80b05005df04f13a899ec431c719aa5_55593971-eb8e-4445-8f9c-c591063ebbda"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="extended" id="i0b776a560aa64572be3cafa043dba7a0_88114edc-844a-42ac-941c-bf88efedbc32"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="iedd4ccbab85340deb590c44d99f48ae3_20a75724-127b-4ffa-9834-fc002be619cf"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="extended" id="i062db9cc927a4adcbbebbb018816222b_bff149a5-b652-4806-b750-3a3423014bce">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_09b84b37-f81a-4bca-98d7-6f6b6c3929da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_09b84b37-f81a-4bca-98d7-6f6b6c3929da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b30f7801-2087-43a5-aa91-ece0a71bd905_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b30f7801-2087-43a5-aa91-ece0a71bd905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfc310a1-5be1-4d2a-9615-13876b1b8d27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfc310a1-5be1-4d2a-9615-13876b1b8d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e4982f14-581b-48e6-8a01-f4b3b797343d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e4982f14-581b-48e6-8a01-f4b3b797343d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75b2a286-8b63-4ae9-8706-8e2d9dec5326" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75b2a286-8b63-4ae9-8706-8e2d9dec5326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac38f83b-af02-463d-a1e5-cbb0dd85e7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac38f83b-af02-463d-a1e5-cbb0dd85e7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b1c3f8b1-41e4-4a90-931d-b177fae7710d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b1c3f8b1-41e4-4a90-931d-b177fae7710d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="extended" id="i59e358177e464636a4f25426c57c0302_3d16c9d0-c60c-43e9-bf57-88f529e0c27d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618f8d64-1933-4571-9721-97a02552f202" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618f8d64-1933-4571-9721-97a02552f202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_e0b05852-3748-4212-acab-5ca3e055383f" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_e0b05852-3748-4212-acab-5ca3e055383f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_96d1befb-9654-4be3-acf5-f2899d126219" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_96d1befb-9654-4be3-acf5-f2899d126219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_cee8fa9e-89a0-46d9-8d92-6e30dac08a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_cee8fa9e-89a0-46d9-8d92-6e30dac08a2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_0336ca2e-3c42-4e3a-a4c8-e81fc2032608" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_0336ca2e-3c42-4e3a-a4c8-e81fc2032608" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2728908-fa4e-44eb-89ae-c4096a8ebd01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3911331-5f5a-4d11-9c68-6721ff6606b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3911331-5f5a-4d11-9c68-6721ff6606b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e81fb93a-42c4-4fb8-a60a-eeecb2ed070a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e81fb93a-42c4-4fb8-a60a-eeecb2ed070a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_75916638-d19c-4159-b337-ace98097e5ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_75916638-d19c-4159-b337-ace98097e5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityCurrentMember_d4f9ce0c-16f2-4359-b3fb-cc89e820f603" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabilityCurrentMember_d4f9ce0c-16f2-4359-b3fb-cc89e820f603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityLongtermMember_1043a20c-2d0d-4803-b21c-f78a93cc1b6f" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityLongtermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabilityLongtermMember_1043a20c-2d0d-4803-b21c-f78a93cc1b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabiltyMember_90ae52e6-9edf-4083-b382-318192da4c5d" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabiltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabiltyMember_90ae52e6-9edf-4083-b382-318192da4c5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended" id="i9e5a33b3aaec45219d69400570f64df2_ba3f7651-1530-46ad-bf5a-c1a59f7663b8"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended" id="i078a399cd0c34d179527c1558e3bfb17_40598424-e182-4c15-acf4-73bf473b289e"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="i666928a8a9854ae7b6205958c9c1707a_dd049cee-01a3-4289-8a6a-b940d16f09df"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiability"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended" id="i7506c94077af45d89486211fb70d1f0b_9a1664c8-aa07-49ce-8577-253eadb5fdd6"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityTables"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended" id="i2b871d4d9bb5498597beada8f5d9140f_b8df46b6-c3c7-48f9-9b13-7069201a6427"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended" id="i3c3a2f9440af47579611eb0b78555c17_0332f684-16e8-4edc-863c-6b6c412b9641">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c82ad31-23b1-43b6-9a2f-69f665b58071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c82ad31-23b1-43b6-9a2f-69f665b58071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ec021c4-ae39-4c54-9e65-73cda29f36aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ec021c4-ae39-4c54-9e65-73cda29f36aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5412bad3-332f-4637-bfc7-9eccf6875085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5412bad3-332f-4637-bfc7-9eccf6875085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f70bb21-5d6f-4efb-aad8-fe7a31bd37f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f70bb21-5d6f-4efb-aad8-fe7a31bd37f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b08b02e5-2dd8-4349-9c6d-d69e5ab1e90f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b08b02e5-2dd8-4349-9c6d-d69e5ab1e90f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3796752c-8014-4d0b-93a7-070cd58543c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3796752c-8014-4d0b-93a7-070cd58543c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_8484b831-879a-4053-b744-4a50397f5833" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:to="loc_mbx_AprilOfferingsMember_8484b831-879a-4053-b744-4a50397f5833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019RegisteredDirectOfferingsMember_334e3be9-ab93-4ef8-8980-91b49caf11c7" xlink:href="mbx-20190930.xsd#mbx_March2019RegisteredDirectOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:to="loc_mbx_March2019RegisteredDirectOfferingsMember_334e3be9-ab93-4ef8-8980-91b49caf11c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25be4e38-6eeb-443e-97db-a478f02c7544_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:to="loc_us-gaap_EquityComponentDomain_25be4e38-6eeb-443e-97db-a478f02c7544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:to="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_932f1611-03f2-427f-912e-c2ee41769e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:to="loc_us-gaap_WarrantMember_932f1611-03f2-427f-912e-c2ee41769e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8fdecb52-f958-4ea6-942b-34e97b21c064" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:to="loc_us-gaap_CommonStockMember_8fdecb52-f958-4ea6-942b-34e97b21c064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_138a8ad1-a991-45b3-8ba3-493f47219c8d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_138a8ad1-a991-45b3-8ba3-493f47219c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwitersMember_ea3225f3-80a8-4c98-a4c4-2b8a8b7917be" xlink:href="mbx-20190930.xsd#mbx_UnderwitersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:to="loc_mbx_UnderwitersMember_ea3225f3-80a8-4c98-a4c4-2b8a8b7917be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="extended" id="i4e8112b0e1814ebbb30de0712619e877_21c439d0-d06a-4476-8763-70659b80e33d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b35da78-c919-4864-a10f-fcd2c58c1d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b35da78-c919-4864-a10f-fcd2c58c1d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5757a27e-0311-445a-98da-f8237f1b9ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5757a27e-0311-445a-98da-f8237f1b9ea1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_a1fe134e-952a-46a7-9844-09bc932c61dc" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_a1fe134e-952a-46a7-9844-09bc932c61dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_8f42dff3-282d-493d-a44d-63374834e5f4" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_8f42dff3-282d-493d-a44d-63374834e5f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65fc4eff-2bcb-406a-8d4b-4d58187db50e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_05284b44-3a30-4997-a4b5-217c4f3bfce6" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_05284b44-3a30-4997-a4b5-217c4f3bfce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7858dfb9-ed00-4fbc-a7f4-981d979e0b73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7858dfb9-ed00-4fbc-a7f4-981d979e0b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_831cf080-ad98-4cc9-9545-8ce0ac670e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_831cf080-ad98-4cc9-9545-8ce0ac670e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_fd48d358-81ba-47a6-ae9e-da3a748a8410" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_fd48d358-81ba-47a6-ae9e-da3a748a8410" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a95abe70-d2f1-4982-bc1b-b0cbe7af358a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_8429deb7-ef08-4851-bee9-5b50367ca2d5" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_8429deb7-ef08-4851-bee9-5b50367ca2d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_eefc59d6-69a9-47e4-b9b0-6f78de903165" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_eefc59d6-69a9-47e4-b9b0-6f78de903165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4ee44b32-9c3e-49fd-959d-20545794332f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_1e666b10-2b31-48f7-85ad-3880edd122e1" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_1e666b10-2b31-48f7-85ad-3880edd122e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8f82f9f8-ee82-4b80-b202-e70d390766ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8f82f9f8-ee82-4b80-b202-e70d390766ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_749aeffd-b5e5-4b6d-8fea-df9cbb4f3acc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_749aeffd-b5e5-4b6d-8fea-df9cbb4f3acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a345630c-2a34-41bb-8456-16a8976e290c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a345630c-2a34-41bb-8456-16a8976e290c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed254dc8-55be-494c-9591-f3cad039c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed254dc8-55be-494c-9591-f3cad039c3fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_744ce802-103f-439a-9591-41ee8d224e0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:to="loc_us-gaap_EquityComponentDomain_744ce802-103f-439a-9591-41ee8d224e0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:to="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_710d31e3-0297-4bce-989c-16b1aabe8688" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:to="loc_us-gaap_WarrantMember_710d31e3-0297-4bce-989c-16b1aabe8688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:to="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:to="loc_srt_RangeMember_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:to="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4da9bb43-3049-45c6-bba9-6385ce2855ce" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:to="loc_srt_MinimumMember_4da9bb43-3049-45c6-bba9-6385ce2855ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99bd64f9-8768-4d7c-9101-e569917437e7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:to="loc_srt_MaximumMember_99bd64f9-8768-4d7c-9101-e569917437e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:type="simple" xlink:href="mbx-20190930.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended" id="i592bd9b2744540e78275b1bb828cf3d2_e56387d1-94d5-4ad9-a6ec-f95a3e022539"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended" id="i488bf61b02ff4a7e97c4ff5e61084eae_e6f825a8-d832-4edd-aa86-46911adfe4f5"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended" id="i09ef43cd89ed4269bd8f99dd60c16e6b_00e0eadc-2cb3-4958-8092-be3b22cbd2df">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesAuthorized_b1af8c65-5533-4e50-92a5-0b09033bc91a" xlink:href="mbx-20190930.xsd#mbx_SharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SharesAuthorized_b1af8c65-5533-4e50-92a5-0b09033bc91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c89efa6d-179d-4164-b534-035d0608c153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c89efa6d-179d-4164-b534-035d0608c153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c2b9cc99-0160-469c-873e-3614b43bb192" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c2b9cc99-0160-469c-873e-3614b43bb192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d85f6a0f-004c-43c8-ada5-de1adbd476d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d85f6a0f-004c-43c8-ada5-de1adbd476d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_d6bbdb3d-3b32-477a-8cf6-4330e40923f1" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_d6bbdb3d-3b32-477a-8cf6-4330e40923f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3a88aa0-2152-4dd1-b96c-f22ef891214b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3a88aa0-2152-4dd1-b96c-f22ef891214b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_84dbdbc7-8b35-4050-94c5-b28e6890f0df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_84dbdbc7-8b35-4050-94c5-b28e6890f0df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_56c0b9ae-15c1-4650-a89f-d260239e923c" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_56c0b9ae-15c1-4650-a89f-d260239e923c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_29c39285-ea3c-404c-83d4-d295aeb567d3" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_29c39285-ea3c-404c-83d4-d295aeb567d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5d175249-2e22-4dfe-9a6c-6a3d6990d279" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5d175249-2e22-4dfe-9a6c-6a3d6990d279" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7112bc97-391b-4674-a003-3518aa95b97b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7112bc97-391b-4674-a003-3518aa95b97b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_cc1d79ab-8eb7-455c-98d6-bb845f1b261b" xlink:href="mbx-20190930.xsd#mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_cc1d79ab-8eb7-455c-98d6-bb845f1b261b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef508d11-4ef7-4750-b800-d4fd131213ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef508d11-4ef7-4750-b800-d4fd131213ce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_25c7d578-d737-48d0-a07e-7b1e37f0e059" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_25c7d578-d737-48d0-a07e-7b1e37f0e059" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_114dfb61-56ac-4a94-b00a-50e5f1478f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_114dfb61-56ac-4a94-b00a-50e5f1478f8b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adad86d9-8712-412d-9d71-3fcb04d151e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adad86d9-8712-412d-9d71-3fcb04d151e7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4bf4f03-2dfb-4f58-9d08-2b613b3677fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4bf4f03-2dfb-4f58-9d08-2b613b3677fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65008a68-7aff-45a1-abc8-3c0d650ef41f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65008a68-7aff-45a1-abc8-3c0d650ef41f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d28cdb66-c31b-42b5-9f41-223abe4bc94f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d28cdb66-c31b-42b5-9f41-223abe4bc94f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ba9695a-3b20-4586-a62b-452f7706f5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ba9695a-3b20-4586-a62b-452f7706f5bd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightAgreementPeriod_df2f1649-618f-4ecf-89f6-663e2f285bd8" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightAgreementPeriod_df2f1649-618f-4ecf-89f6-663e2f285bd8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued_249607f9-0638-40d6-b9ae-621060092a3c" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightNumberofWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued_249607f9-0638-40d6-b9ae-621060092a3c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16277442-4249-4951-9336-e10ea087484f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16277442-4249-4951-9336-e10ea087484f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_49fc172c-5a15-4e9a-b96c-5fc71ce0e569" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_49fc172c-5a15-4e9a-b96c-5fc71ce0e569" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightVestingPeriod_aaf83513-2281-4669-9641-67eb19c0f479" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightVestingPeriod_aaf83513-2281-4669-9641-67eb19c0f479" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightExpirationPeriod_bcb177af-7238-4d23-be0a-245335aca1a2" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightExpirationPeriod_bcb177af-7238-4d23-be0a-245335aca1a2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d42871a5-14b1-4f67-a4d7-eb19f0ff1181" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d42871a5-14b1-4f67-a4d7-eb19f0ff1181" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightTerm_c0115c22-85d6-436f-952c-b95f63014c90" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassOfWarrantOrRightTerm_c0115c22-85d6-436f-952c-b95f63014c90" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingFees_9c79a7cc-3dd2-4479-861d-20bb18fd479b" xlink:href="mbx-20190930.xsd#mbx_ConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ConsultingFees_9c79a7cc-3dd2-4479-861d-20bb18fd479b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ec18e6f-0297-465c-bae0-3907e744ecd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ec18e6f-0297-465c-bae0-3907e744ecd3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6d0311dc-1949-427f-9fd4-1f302c59ede9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6d0311dc-1949-427f-9fd4-1f302c59ede9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c11f9c54-c9d6-4f3e-a45c-b7993e1d3e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c11f9c54-c9d6-4f3e-a45c-b7993e1d3e4a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a349d383-014c-4fe1-9657-d207cf3cf45c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a349d383-014c-4fe1-9657-d207cf3cf45c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod_407603a8-96a5-4836-a8f6-a62ae5003ff6" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightInitialExercisePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod_407603a8-96a5-4836-a8f6-a62ae5003ff6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitsSoldInPeriod_2f5c7efd-c2fa-435e-bee4-b902c7f9352b" xlink:href="mbx-20190930.xsd#mbx_UnitsSoldInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_UnitsSoldInPeriod_2f5c7efd-c2fa-435e-bee4-b902c7f9352b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ba811902-bf85-4923-85b8-9f615b6af618" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ba811902-bf85-4923-85b8-9f615b6af618" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitOfferingUnitPricePerShare_4efd9698-f492-4b5a-8441-3ae0c36ee172" xlink:href="mbx-20190930.xsd#mbx_UnitOfferingUnitPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_UnitOfferingUnitPricePerShare_4efd9698-f492-4b5a-8441-3ae0c36ee172" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db22c07-824f-45bc-81db-3f81ac727e9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db22c07-824f-45bc-81db-3f81ac727e9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LincolnParkSaleMember_a6149849-215e-40df-9da4-39b0c1e23863" xlink:href="mbx-20190930.xsd#mbx_LincolnParkSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_LincolnParkSaleMember_a6149849-215e-40df-9da4-39b0c1e23863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AtMarketIssuanceSalesAgreementMember_4a7b8264-fe30-40ea-92c0-b3ee7bac1e84" xlink:href="mbx-20190930.xsd#mbx_AtMarketIssuanceSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_AtMarketIssuanceSalesAgreementMember_4a7b8264-fe30-40ea-92c0-b3ee7bac1e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SecuritiesPurchaseAgreementMember_915a4475-4590-4ed0-b3f3-9da511ddd50d" xlink:href="mbx-20190930.xsd#mbx_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_SecuritiesPurchaseAgreementMember_915a4475-4590-4ed0-b3f3-9da511ddd50d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018RegisteredDirectOfferingMember_8de348f6-0030-418a-8ffa-56d38947e194" xlink:href="mbx-20190930.xsd#mbx_June2018RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_June2018RegisteredDirectOfferingMember_8de348f6-0030-418a-8ffa-56d38947e194" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019RegisteredDirectOfferingsMember_f412c9ba-6c5e-4fb5-813e-602709614500" xlink:href="mbx-20190930.xsd#mbx_March2019RegisteredDirectOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_March2019RegisteredDirectOfferingsMember_f412c9ba-6c5e-4fb5-813e-602709614500" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_bf4ce24d-a8c2-41da-a665-89bbbe7c30b4" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_AprilOfferingsMember_bf4ce24d-a8c2-41da-a665-89bbbe7c30b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61e530cd-34c2-4b40-b5bd-d7ce999d50b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61e530cd-34c2-4b40-b5bd-d7ce999d50b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentSharesMember_104a5b21-d6fb-4d8c-bb7c-6ebc1d2a58f5" xlink:href="mbx-20190930.xsd#mbx_CommitmentSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:to="loc_mbx_CommitmentSharesMember_104a5b21-d6fb-4d8c-bb7c-6ebc1d2a58f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:href="mbx-20190930.xsd#mbx_TheWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:to="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantOneMember_eaa14e2b-f68c-4caf-bb67-16ff4d171108" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_GSKConsultingAgreementWarrantOneMember_eaa14e2b-f68c-4caf-bb67-16ff4d171108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantTwoMember_7e5ebe81-2016-4d90-87fd-361a35c7b657" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_GSKConsultingAgreementWarrantTwoMember_7e5ebe81-2016-4d90-87fd-361a35c7b657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingAgreementWarrantThreeMember_c23b6d31-1235-4c11-ad5a-35207e68f0b6" xlink:href="mbx-20190930.xsd#mbx_ConsultingAgreementWarrantThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_ConsultingAgreementWarrantThreeMember_c23b6d31-1235-4c11-ad5a-35207e68f0b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59e7043e-4dfd-4f78-a299-3115e7849746_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59e7043e-4dfd-4f78-a299-3115e7849746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_f0f9a6c2-8eae-457f-8437-0afe993bc1ba" xlink:href="mbx-20190930.xsd#mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_f0f9a6c2-8eae-457f-8437-0afe993bc1ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OppenheimerCoIncMember_d1eb75f2-3652-402e-869a-7721791c089a" xlink:href="mbx-20190930.xsd#mbx_OppenheimerCoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_OppenheimerCoIncMember_d1eb75f2-3652-402e-869a-7721791c089a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwriterMember_ade9c382-20ab-4cb8-807c-7bf5138ab3b3" xlink:href="mbx-20190930.xsd#mbx_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_UnderwriterMember_ade9c382-20ab-4cb8-807c-7bf5138ab3b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:to="loc_srt_RangeMember_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:to="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ec84724-c6b9-434a-97ed-779e58b5d8a1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:to="loc_srt_MaximumMember_0ec84724-c6b9-434a-97ed-779e58b5d8a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2dbe00c4-9b85-42b4-b39f-1c3b720a3888" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:to="loc_srt_MinimumMember_2dbe00c4-9b85-42b4-b39f-1c3b720a3888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_611685f1-610d-479a-b107-91d45bdf7c11_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:to="loc_us-gaap_EquityComponentDomain_611685f1-610d-479a-b107-91d45bdf7c11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:to="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8dab511b-b0aa-40f0-b43a-7fd371bbfc53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:to="loc_us-gaap_CommonStockMember_8dab511b-b0aa-40f0-b43a-7fd371bbfc53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a2b5289-b094-4422-999b-8df1e68f4f6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a2b5289-b094-4422-999b-8df1e68f4f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockPlanMember_9df7c5df-0a1b-4c71-80b2-881b21f90cfb" xlink:href="mbx-20190930.xsd#mbx_StockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_mbx_StockPlanMember_9df7c5df-0a1b-4c71-80b2-881b21f90cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f9b9870-89be-4870-a1e0-6444381cff52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f9b9870-89be-4870-a1e0-6444381cff52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4355a54f-590c-429d-9eee-89eb09f71a91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_us-gaap_WarrantMember_4355a54f-590c-429d-9eee-89eb09f71a91" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofOptionActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="extended" id="i22d57bf52cd74cdcb9333d885aee63e2_6c127939-09be-4770-94f3-7f1eb02d2a09"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="extended" id="i4ca760ded21e4b478856072311972bf2_238db036-7a64-480d-9b33-8e3717fcaf89">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ee15d429-4a49-4eda-a4ff-591a8f8fe2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ee15d429-4a49-4eda-a4ff-591a8f8fe2f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bb4b4b97-ea79-4b02-bacf-d2ce69f2de55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bb4b4b97-ea79-4b02-bacf-d2ce69f2de55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_716b56ea-c5d6-4b92-9ed8-f6da491765e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_716b56ea-c5d6-4b92-9ed8-f6da491765e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ebedf878-6c20-477e-aa52-b4bc93d72b19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ebedf878-6c20-477e-aa52-b4bc93d72b19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b74a55c-4142-4f92-a81c-ab0f50dd1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b74a55c-4142-4f92-a81c-ab0f50dd1cee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e897f3a7-46af-436b-ba88-e2a0c320af70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e897f3a7-46af-436b-ba88-e2a0c320af70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:to="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_243bb974-8b74-4ae4-88e3-7ce4864baea8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_243bb974-8b74-4ae4-88e3-7ce4864baea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49276244-2e7f-4fa4-aed2-3ffff4ac59ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49276244-2e7f-4fa4-aed2-3ffff4ac59ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:to="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05842ca7-9fbd-493d-bba2-e011aa022f9f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:to="loc_srt_RangeMember_05842ca7-9fbd-493d-bba2-e011aa022f9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:to="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5c27ab4-c7b3-49db-ab6f-1a9a9e080eb5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:to="loc_srt_MinimumMember_d5c27ab4-c7b3-49db-ab6f-1a9a9e080eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_224f58a7-61dc-44d5-a1df-87f4eacea9de" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:to="loc_srt_MaximumMember_224f58a7-61dc-44d5-a1df-87f4eacea9de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityComponentsofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="extended" id="ifac61cb60bd54fbaa838a28ac2893b76_53eeccd0-46f0-422d-93e5-30158f9d61b0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_081d4f9b-6894-4662-9052-d5455b0ed27f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_081d4f9b-6894-4662-9052-d5455b0ed27f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c540580-260a-4033-87c1-b4778e031668_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c540580-260a-4033-87c1-b4778e031668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e05b08-6f82-438d-8469-d308a60bd6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e05b08-6f82-438d-8469-d308a60bd6a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a1ef325-2777-4098-9bc9-64dc5e89c21c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a1ef325-2777-4098-9bc9-64dc5e89c21c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended" id="ie83f16ae15dc4721b986efbf42c71abf_6486a495-b8e7-44af-8497-1f9c09dbf96d"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="extended" id="i6abc018b38f842c68fdf7dc27f063ba3_33738c98-a429-4268-99ad-240bbaa2b8be"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="extended" id="i698411edfce94d8fa7604742c11890ab_18054832-a191-45e1-90ea-3b1f4cf876ae"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="extended" id="i213621a485ae4ca6ace85b69e50cc5e0_c8395d2a-a02b-4044-b2e8-6c1f12d1fa93"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i1801071b07694aafb9fff7f8df1534b7_cbb8b3bb-63c3-4eff-93fa-44dd1ef1d8d3">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_837fcc80-493b-47da-b6b5-51174b032ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_837fcc80-493b-47da-b6b5-51174b032ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_432101e6-9015-4b1b-8242-2614ef9311a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_432101e6-9015-4b1b-8242-2614ef9311a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_21ae1fad-64e8-40f3-83ab-89d96b0af1c9" xlink:href="mbx-20190930.xsd#mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_21ae1fad-64e8-40f3-83ab-89d96b0af1c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfRentPayableByCoLessee_d364e7bc-6a2a-4a14-8182-47855332ec24" xlink:href="mbx-20190930.xsd#mbx_PercentageOfRentPayableByCoLessee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PercentageOfRentPayableByCoLessee_d364e7bc-6a2a-4a14-8182-47855332ec24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_5a0912c2-d82e-4711-8722-d7081bdc2901" xlink:href="mbx-20190930.xsd#mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_5a0912c2-d82e-4711-8722-d7081bdc2901" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_06b0e312-fd2c-4c9b-8e0a-2b24e1fb45ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_SubleaseIncome_06b0e312-fd2c-4c9b-8e0a-2b24e1fb45ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f7e0cb0e-a896-49d7-a84e-f6161eb65c46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseCost_f7e0cb0e-a896-49d7-a84e-f6161eb65c46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_cc2b4c86-2d4e-471e-98c5-ca56ca2e6f00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_ShortTermLeaseCost_cc2b4c86-2d4e-471e-98c5-ca56ca2e6f00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8d329e08-41c6-427e-b2e1-068d2f6f5eff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_VariableLeaseCost_8d329e08-41c6-427e-b2e1-068d2f6f5eff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6914764d-5e89-4799-86ee-829537ae4076" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6914764d-5e89-4799-86ee-829537ae4076" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d6b6b650-7656-49ea-89a6-e247e0856c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d6b6b650-7656-49ea-89a6-e247e0856c9d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f36cbbd4-825e-443b-9ad9-a70ef40a53e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f36cbbd4-825e-443b-9ad9-a70ef40a53e7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_d75cceed-3bdf-4d6e-93e3-651b7aae349a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_d75cceed-3bdf-4d6e-93e3-651b7aae349a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_45d56406-b74f-4585-968b-a471765fb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_45d56406-b74f-4585-968b-a471765fb6d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_91a1d932-8d14-415e-8a1b-6239fd2e7834" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_91a1d932-8d14-415e-8a1b-6239fd2e7834" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_160dfad0-2759-49c0-b308-b1c62d4bc68d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_160dfad0-2759-49c0-b308-b1c62d4bc68d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3b1f4c8b-bd2d-4cff-adb3-239aad388442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3b1f4c8b-bd2d-4cff-adb3-239aad388442" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenseAgreementAnnualLicenseFee_cee16276-de12-4b06-8f53-c30c8789ef35" xlink:href="mbx-20190930.xsd#mbx_LicenseAgreementAnnualLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicenseAgreementAnnualLicenseFee_cee16276-de12-4b06-8f53-c30c8789ef35" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MilestonePaymentsLiabilities_496327e1-44ba-4048-ae50-bf0725af5b10" xlink:href="mbx-20190930.xsd#mbx_MilestonePaymentsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_MilestonePaymentsLiabilities_496327e1-44ba-4048-ae50-bf0725af5b10" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_512f4c43-8984-431a-b291-446eec9d6cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_PaymentsForRoyalties_512f4c43-8984-431a-b291-446eec9d6cef" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_041a5f46-164b-4e59-bcec-cc0cc274f1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_041a5f46-164b-4e59-bcec-cc0cc274f1d4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7078d3bc-90b6-4e64-a9c7-b2e7acf8d275" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7078d3bc-90b6-4e64-a9c7-b2e7acf8d275" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PaymentsForResearchAndDevelopmentAgreement_27b428bb-4b38-4939-aa17-356110b850e7" xlink:href="mbx-20190930.xsd#mbx_PaymentsForResearchAndDevelopmentAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PaymentsForResearchAndDevelopmentAgreement_27b428bb-4b38-4939-aa17-356110b850e7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensingAgreementTerm_241cc09b-813b-4f5a-8528-01c64174d2aa" xlink:href="mbx-20190930.xsd#mbx_LicensingAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicensingAgreementTerm_241cc09b-813b-4f5a-8528-01c64174d2aa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4a5a3a2-a266-4f1f-8ed4-9a967b0a80a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4a5a3a2-a266-4f1f-8ed4-9a967b0a80a3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OptionRepurchasePayments_a69e900f-3923-4cd4-ad28-e271b141dbbd" xlink:href="mbx-20190930.xsd#mbx_OptionRepurchasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_OptionRepurchasePayments_a69e900f-3923-4cd4-ad28-e271b141dbbd" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_e8c0dbc5-4fea-4569-a009-bf11e49f7f03" xlink:href="mbx-20190930.xsd#mbx_LicensedTechnologyFuturePaymentToRemoveCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_e8c0dbc5-4fea-4569-a009-bf11e49f7f03" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EquityDistributionCommitment_14cd3494-4761-4c28-bd92-77e01c49ad8b" xlink:href="mbx-20190930.xsd#mbx_EquityDistributionCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_EquityDistributionCommitment_14cd3494-4761-4c28-bd92-77e01c49ad8b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab534414-1f13-4877-a685-311e1f2b2ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab534414-1f13-4877-a685-311e1f2b2ee1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ResearchAndDevelopmentCommitment_b1ca97fd-62d4-4268-8e8d-227976279358" xlink:href="mbx-20190930.xsd#mbx_ResearchAndDevelopmentCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_ResearchAndDevelopmentCommitment_b1ca97fd-62d4-4268-8e8d-227976279358" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_0d578a50-71d5-469a-912b-d76480f3ccd6" xlink:href="mbx-20190930.xsd#mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_0d578a50-71d5-469a-912b-d76480f3ccd6" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87d897df-c5b7-40a6-870a-4a5c5704076c_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:to="loc_srt_RangeMember_87d897df-c5b7-40a6-870a-4a5c5704076c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:to="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5fa15689-0f9f-40eb-9c42-d6eb7dea27cf" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:to="loc_srt_MaximumMember_5fa15689-0f9f-40eb-9c42-d6eb7dea27cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_b0788c1b-a957-4de1-b61f-0271bedb71c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_b0788c1b-a957-4de1-b61f-0271bedb71c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember_469ebbff-dda1-4fe2-8e44-d5731533cd70" xlink:href="mbx-20190930.xsd#mbx_LeaseAgreementForCorporateOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:to="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember_469ebbff-dda1-4fe2-8e44-d5731533cd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IPXMemorialDriveInvestorsLLCMember_3df7c0da-62e5-42f6-95dc-95698b04ce15" xlink:href="mbx-20190930.xsd#mbx_IPXMemorialDriveInvestorsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_IPXMemorialDriveInvestorsLLCMember_3df7c0da-62e5-42f6-95dc-95698b04ce15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OlympiaDriveWBellfortLLCMember_10e51109-d1eb-401a-952a-40ee76404c3f" xlink:href="mbx-20190930.xsd#mbx_OlympiaDriveWBellfortLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_OlympiaDriveWBellfortLLCMember_10e51109-d1eb-401a-952a-40ee76404c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_HoustonPharmaceuticalsIncMember_bc6edb6e-1894-4dc5-880d-0a2718d3e7e5" xlink:href="mbx-20190930.xsd#mbx_HoustonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_HoustonPharmaceuticalsIncMember_bc6edb6e-1894-4dc5-880d-0a2718d3e7e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MdAndersonMember_479db02f-b4fb-42f2-b34c-825b96801c57" xlink:href="mbx-20190930.xsd#mbx_MdAndersonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_MdAndersonMember_479db02f-b4fb-42f2-b34c-825b96801c57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_DerminMember_6e46cb84-a4fa-4cb9-889b-89b480c0fd63" xlink:href="mbx-20190930.xsd#mbx_DerminMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_DerminMember_6e46cb84-a4fa-4cb9-889b-89b480c0fd63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WPDPharmaceuticalsMember_f94a7422-96b3-41fa-a950-46c89c5f1f8c" xlink:href="mbx-20190930.xsd#mbx_WPDPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_WPDPharmaceuticalsMember_f94a7422-96b3-41fa-a950-46c89c5f1f8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MdAndersonMember_d2355391-400c-45be-9b29-f26ca10fc819" xlink:href="mbx-20190930.xsd#mbx_MdAndersonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:to="loc_mbx_MdAndersonMember_d2355391-400c-45be-9b29-f26ca10fc819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_41feed4a-e776-48ca-855c-e7bf16a8aabf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:to="loc_us-gaap_ProjectMember_41feed4a-e776-48ca-855c-e7bf16a8aabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:to="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_fda2223c-2691-42cd-aecc-1e6a84d99a26" xlink:href="mbx-20190930.xsd#mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:to="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_fda2223c-2691-42cd-aecc-1e6a84d99a26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ed6dd52-341f-4c35-b89c-c36f5c927232_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:to="loc_srt_ProductsAndServicesDomain_6ed6dd52-341f-4c35-b89c-c36f5c927232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:to="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ae3373f1-f4f5-459a-ad2e-ac8320929123" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:to="loc_us-gaap_LicenseMember_ae3373f1-f4f5-459a-ad2e-ac8320929123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3d3fd9fa-53d6-4dcb-becf-203c8b709743" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:to="loc_us-gaap_SubsequentEventMember_3d3fd9fa-53d6-4dcb-becf-203c8b709743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_53462891-45c4-4585-94bb-02788ca1a566_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:to="loc_dei_EntityDomain_53462891-45c4-4585-94bb-02788ca1a566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:to="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WPDPharmaceuticalsMember_63c038b7-f515-443e-af84-d43cc43a1d35" xlink:href="mbx-20190930.xsd#mbx_WPDPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:to="loc_mbx_WPDPharmaceuticalsMember_63c038b7-f515-443e-af84-d43cc43a1d35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:href="mbx-20190930.xsd#mbx_PeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodDomain_d7f5b347-adf9-4f75-8bee-98340fa6eec5_default" xlink:href="mbx-20190930.xsd#mbx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:to="loc_mbx_PeriodDomain_d7f5b347-adf9-4f75-8bee-98340fa6eec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:href="mbx-20190930.xsd#mbx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:to="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodOneMember_de85db21-80b3-4092-93fb-a6d5fa655f16" xlink:href="mbx-20190930.xsd#mbx_PeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:to="loc_mbx_PeriodOneMember_de85db21-80b3-4092-93fb-a6d5fa655f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodTwoMember_91a2ec86-fb54-4579-b540-5b82032f3661" xlink:href="mbx-20190930.xsd#mbx_PeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:to="loc_mbx_PeriodTwoMember_91a2ec86-fb54-4579-b540-5b82032f3661" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="extended" id="i8a782a5594e344b1a7ee97ff25b979c0_a2fba14a-3fd1-4cc9-b2f9-84915d796108"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="extended" id="ib9ad4478846f4c4ab3b01634354453de_d5c3eba1-b47d-4bb0-97b1-579ac4cecd23"/>
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mbx-20190930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended" id="i2fb427b879dc401f91bd7aa7a6b8b072_c6e7d3f8-dfe3-486e-b741-8381504856c9"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mbx-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ee2f07c2-87cc-45fd-b416-d18897367dca_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_20c52848-d85c-4678-a149-52ca84949a5c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a67db735-d28f-47a2-94e7-e7a6c7f36e08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_DerminMember_505b1eb5-09ca-4607-aa4e-73083631d9ba_terseLabel_en-US" xlink:label="lab_mbx_DerminMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermin</link:label>
    <link:label id="lab_mbx_DerminMember_label_en-US" xlink:label="lab_mbx_DerminMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermin [Member]</link:label>
    <link:label id="lab_mbx_DerminMember_documentation_en-US" xlink:label="lab_mbx_DerminMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_DerminMember" xlink:href="mbx-20190930.xsd#mbx_DerminMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_DerminMember" xlink:to="lab_mbx_DerminMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_bf85b478-ed06-4a98-952f-d20052d55988_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation, principles of consolidation and significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_UnderwriterMember_0b62e573-4f49-4726-aa4d-83ddf38ac478_terseLabel_en-US" xlink:label="lab_mbx_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:label id="lab_mbx_UnderwriterMember_label_en-US" xlink:label="lab_mbx_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter [Member]</link:label>
    <link:label id="lab_mbx_UnderwriterMember_documentation_en-US" xlink:label="lab_mbx_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwriterMember" xlink:href="mbx-20190930.xsd#mbx_UnderwriterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_UnderwriterMember" xlink:to="lab_mbx_UnderwriterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1381032d-f611-42c4-9447-44dd25de5bbd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_89455520-f40f-472e-8510-4a1a27b20ea3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_f16f4c22-9611-4002-9af1-70597ece7704_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_19fe6cf2-d3a0-448d-919c-30e651bfae93_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassofWarrantorRightExpirationPeriod_d0d37f3b-73ba-4b5d-ade3-10f85110e988_terseLabel_en-US" xlink:label="lab_mbx_ClassofWarrantorRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_mbx_ClassofWarrantorRightExpirationPeriod_label_en-US" xlink:label="lab_mbx_ClassofWarrantorRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ClassofWarrantorRightExpirationPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightExpirationPeriod" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassofWarrantorRightExpirationPeriod" xlink:to="lab_mbx_ClassofWarrantorRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91da54fa-0b90-473e-87f1-c88d52a883ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7f3d16bf-1e11-4f25-a663-1d97409e8bf6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce353511-41d2-4b5e-88e0-16dbb707937f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_388c82a0-637a-4147-a8ee-06fd5e12770b_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aef9e7a7-f3af-4961-8c91-d35cb4e6d057_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrants, aggregate amounts (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_64ff4549-97cf-4b58-9f8f-e170f8ec4cc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AtMarketIssuanceSalesAgreementMember_62f0041c-3a16-4eef-91f4-862336b0c62d_terseLabel_en-US" xlink:label="lab_mbx_AtMarketIssuanceSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Issuance Sales Agreement</link:label>
    <link:label id="lab_mbx_AtMarketIssuanceSalesAgreementMember_label_en-US" xlink:label="lab_mbx_AtMarketIssuanceSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AtMarketIssuanceSalesAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AtMarketIssuanceSalesAgreementMember" xlink:href="mbx-20190930.xsd#mbx_AtMarketIssuanceSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AtMarketIssuanceSalesAgreementMember" xlink:to="lab_mbx_AtMarketIssuanceSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_647af442-2c48-443a-9ac9-787c6defbc3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_952099b8-aeb8-48e4-9ec8-2d648f40d198_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_e814f496-123a-4e83-a166-c7849ad38330_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b743ea1f-5e07-456c-a9a4-06cf9787b830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_f149e88d-5594-4589-82a7-e95b4de5d681_terseLabel_en-US" xlink:label="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, aggregate fair value</link:label>
    <link:label id="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_label_en-US" xlink:label="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregated Fair Value</link:label>
    <link:label id="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_documentation_en-US" xlink:label="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:href="mbx-20190930.xsd#mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:to="lab_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LincolnParkSaleMember_2dac8d04-862c-4bef-9601-1e4e55392f9b_terseLabel_en-US" xlink:label="lab_mbx_LincolnParkSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park</link:label>
    <link:label id="lab_mbx_LincolnParkSaleMember_label_en-US" xlink:label="lab_mbx_LincolnParkSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Sale [Member]</link:label>
    <link:label id="lab_mbx_LincolnParkSaleMember_documentation_en-US" xlink:label="lab_mbx_LincolnParkSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LincolnParkSaleMember" xlink:href="mbx-20190930.xsd#mbx_LincolnParkSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LincolnParkSaleMember" xlink:to="lab_mbx_LincolnParkSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_30eed81c-d9d4-46de-9c0c-327e40ff40e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_StockPlanMember_6118d602-15d2-4f4f-b3f4-69c4827935d4_verboseLabel_en-US" xlink:label="lab_mbx_StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Stock Plan</link:label>
    <link:label id="lab_mbx_StockPlanMember_label_en-US" xlink:label="lab_mbx_StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockPlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockPlanMember" xlink:href="mbx-20190930.xsd#mbx_StockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_StockPlanMember" xlink:to="lab_mbx_StockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_618b276a-4600-4e9d-a79c-aee41c09fa9b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_68cb8768-e2be-4c7d-95ab-e03190663451_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49702159-5614-4463-94f2-b3327b0e6c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0c71c779-d9d4-4f02-9e18-9011c1ec436b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant OtherObservable Inputs(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2b8020f0-0754-4192-aa05-d4812acf5b42_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AprilOfferingsMember_e7c7efc4-1295-426e-82ad-cba9da6c648b_terseLabel_en-US" xlink:label="lab_mbx_AprilOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April Offerings</link:label>
    <link:label id="lab_mbx_AprilOfferingsMember_label_en-US" xlink:label="lab_mbx_AprilOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April Offerings [Member]</link:label>
    <link:label id="lab_mbx_AprilOfferingsMember_documentation_en-US" xlink:label="lab_mbx_AprilOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AprilOfferingsMember" xlink:to="lab_mbx_AprilOfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_536b0e42-8e8c-4299-97f0-c68c32760d89_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments_fcb1e7a6-0a19-4511-82c8-6993a4afb7f0_verboseLabel_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor prepayment and deposits, expansion of production commitments</link:label>
    <link:label id="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments_label_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Prepayment And Deposits, Expansion Of Production Commitments</link:label>
    <link:label id="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments_documentation_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Prepayment And Deposits, Expansion Of Production Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:href="mbx-20190930.xsd#mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:to="lab_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca046e11-3c1f-4682-80ad-5da8b7ec911f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd583b70-8070-4e1a-9e01-b81a9ab824d6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8efbeb2f-6820-42b7-9ebc-a50c822b932e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1604d1d1-65bc-4112-ab75-9816ee3c0bc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af034f5d-d679-4dea-82b0-7a9c99e6970d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_91904cc0-d4f2-4dba-985b-b76fe0e803fe_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_611bb21b-0ab8-47a1-aadc-c73022599453_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0e2b5107-88c4-4d5a-8ba0-4b452ad61400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of underlying shares of common stock available under 2015 Stock Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4eb5ce85-137a-423c-b2e5-0f049dee3789_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a905fd34-e272-4f29-a369-d728c2a1ebe7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7445fb82-077d-4ef4-a928-ed87cddeb1a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_UnitsSoldInPeriod_ff7dd17d-0537-4889-b483-204c561db601_terseLabel_en-US" xlink:label="lab_mbx_UnitsSoldInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units sold in period (in units)</link:label>
    <link:label id="lab_mbx_UnitsSoldInPeriod_label_en-US" xlink:label="lab_mbx_UnitsSoldInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Sold In Period</link:label>
    <link:label id="lab_mbx_UnitsSoldInPeriod_documentation_en-US" xlink:label="lab_mbx_UnitsSoldInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Sold In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitsSoldInPeriod" xlink:href="mbx-20190930.xsd#mbx_UnitsSoldInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_UnitsSoldInPeriod" xlink:to="lab_mbx_UnitsSoldInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_36d81e54-18ae-4271-81a4-41d4d1822970_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_dea1674e-3101-494e-8e70-8bcafa935a6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7c200a8e-3190-4fa0-bc5f-57528385bfa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_36bedd5d-3db6-494c-bfb7-3353f504378d_terseLabel_en-US" xlink:label="lab_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_label_en-US" xlink:label="lab_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Number Of Shares Issued In Transaction Aggregate Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:to="lab_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2551294b-ca55-46e0-9444-ade4c5f66f6f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fded2003-a7b7-4103-893a-a339da2ed5eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PeriodAxis_1ebe0178-786b-481b-9716-bf8c7cd9e373_terseLabel_en-US" xlink:label="lab_mbx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Axis]</link:label>
    <link:label id="lab_mbx_PeriodAxis_label_en-US" xlink:label="lab_mbx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Axis]</link:label>
    <link:label id="lab_mbx_PeriodAxis_documentation_en-US" xlink:label="lab_mbx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodAxis" xlink:href="mbx-20190930.xsd#mbx_PeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PeriodAxis" xlink:to="lab_mbx_PeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_082826b9-8a92-49af-b9d1-abed8589365c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f6a9695e-eae0-4bb4-8b8e-3429118c6aa5_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_912ca370-99bc-452d-ae64-9d4af6656dc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c85c40d2-daff-4f99-a134-2b7f1378fc2c_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ResearchAndDevelopmentCommitment_1a10a91c-ddf5-43b0-b6f6-f00d8f84403d_terseLabel_en-US" xlink:label="lab_mbx_ResearchAndDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development commitment</link:label>
    <link:label id="lab_mbx_ResearchAndDevelopmentCommitment_label_en-US" xlink:label="lab_mbx_ResearchAndDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Commitment</link:label>
    <link:label id="lab_mbx_ResearchAndDevelopmentCommitment_documentation_en-US" xlink:label="lab_mbx_ResearchAndDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ResearchAndDevelopmentCommitment" xlink:href="mbx-20190930.xsd#mbx_ResearchAndDevelopmentCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ResearchAndDevelopmentCommitment" xlink:to="lab_mbx_ResearchAndDevelopmentCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1164b371-cefa-433d-ae27-8aae5b089458_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_44750e75-4f09-4981-951f-24e46a16bfeb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_048d6206-42ef-447e-9310-8d4539291bda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk fee interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f667703f-cdc6-48a9-adb2-33fbb39ff4b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AnimalLifeScienceMember_192859f8-bf34-4713-98c7-ddf259b75c8e_terseLabel_en-US" xlink:label="lab_mbx_AnimalLifeScienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Life Science</link:label>
    <link:label id="lab_mbx_AnimalLifeScienceMember_label_en-US" xlink:label="lab_mbx_AnimalLifeScienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Life Science [Member]</link:label>
    <link:label id="lab_mbx_AnimalLifeScienceMember_documentation_en-US" xlink:label="lab_mbx_AnimalLifeScienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Life Science</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AnimalLifeScienceMember" xlink:href="mbx-20190930.xsd#mbx_AnimalLifeScienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AnimalLifeScienceMember" xlink:to="lab_mbx_AnimalLifeScienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_OppenheimerCoIncMember_e513c925-7200-4a6d-b237-68e8da1245cb_terseLabel_en-US" xlink:label="lab_mbx_OppenheimerCoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oppenheimer &amp; Co. Inc.</link:label>
    <link:label id="lab_mbx_OppenheimerCoIncMember_label_en-US" xlink:label="lab_mbx_OppenheimerCoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oppenheimer &amp; Co. Inc. [Member]</link:label>
    <link:label id="lab_mbx_OppenheimerCoIncMember_documentation_en-US" xlink:label="lab_mbx_OppenheimerCoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oppenheimer &amp; Co. Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OppenheimerCoIncMember" xlink:href="mbx-20190930.xsd#mbx_OppenheimerCoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_OppenheimerCoIncMember" xlink:to="lab_mbx_OppenheimerCoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6eac2933-4eb7-49c1-8ba3-8d5c20ee4bd2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_e3304946-d424-46a9-9144-9cd2d669d140_negatedLabel_en-US" xlink:label="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_label_en-US" xlink:label="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exercises</link:label>
    <link:label id="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_documentation_en-US" xlink:label="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:to="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PercentageOfRentPayableByCoLessee_813844b3-2b56-42d7-b69e-ff9449aa1146_terseLabel_en-US" xlink:label="lab_mbx_PercentageOfRentPayableByCoLessee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of rents payable by co-lessee</link:label>
    <link:label id="lab_mbx_PercentageOfRentPayableByCoLessee_label_en-US" xlink:label="lab_mbx_PercentageOfRentPayableByCoLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Rent Payable By Co-Lessee</link:label>
    <link:label id="lab_mbx_PercentageOfRentPayableByCoLessee_documentation_en-US" xlink:label="lab_mbx_PercentageOfRentPayableByCoLessee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Rent Payable By Co-Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfRentPayableByCoLessee" xlink:href="mbx-20190930.xsd#mbx_PercentageOfRentPayableByCoLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PercentageOfRentPayableByCoLessee" xlink:to="lab_mbx_PercentageOfRentPayableByCoLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dfda9d35-e75e-48e1-907b-836cd8a60037_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - long-term, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8891f4b4-ac1b-488c-aa5e-fbf87b026c8d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f065acf1-16a6-4d97-866c-5124b2ca92b0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_696fc8c2-e679-4b9d-8718-b744518fa411_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NumberofClinicalTrials_87d18e33-f99d-4a81-bc4d-8b9a0e00c4cf_terseLabel_en-US" xlink:label="lab_mbx_NumberofClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical trials</link:label>
    <link:label id="lab_mbx_NumberofClinicalTrials_label_en-US" xlink:label="lab_mbx_NumberofClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberofClinicalTrials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofClinicalTrials" xlink:href="mbx-20190930.xsd#mbx_NumberofClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NumberofClinicalTrials" xlink:to="lab_mbx_NumberofClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_02f971c6-1848-4a16-b601-fb87051985c7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f8f4a64-3dca-4d06-b4ba-522ba41f9e1b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4ceb3677-3b3e-43d6-a576-835589c079f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5fb9c53e-585c-4691-9ecf-1b612acdaec4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3c53e2f9-a471-407d-be60-054d35227476_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AccruedLicenseFeesAndSRACurrent_931928f9-4b56-4f71-a321-3cfde3dcea4c_verboseLabel_en-US" xlink:label="lab_mbx_AccruedLicenseFeesAndSRACurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued license fees and sponsored research agreements</link:label>
    <link:label id="lab_mbx_AccruedLicenseFeesAndSRACurrent_label_en-US" xlink:label="lab_mbx_AccruedLicenseFeesAndSRACurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued License Fees And SRA Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedLicenseFeesAndSRACurrent" xlink:href="mbx-20190930.xsd#mbx_AccruedLicenseFeesAndSRACurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AccruedLicenseFeesAndSRACurrent" xlink:to="lab_mbx_AccruedLicenseFeesAndSRACurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ba835362-6df8-4d0a-8837-8a69adb17cb5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_06d48d93-4abe-4c16-9531-1ee6f0a70393_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions and Methodology</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0da7a160-8bcd-4ee3-999e-d0b24508051b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NumberOfDrugTechnologies_97e78a2d-d463-43dd-afb8-fa6983a1d214_terseLabel_en-US" xlink:label="lab_mbx_NumberOfDrugTechnologies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of core drug technologies</link:label>
    <link:label id="lab_mbx_NumberOfDrugTechnologies_label_en-US" xlink:label="lab_mbx_NumberOfDrugTechnologies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfDrugTechnologies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfDrugTechnologies" xlink:href="mbx-20190930.xsd#mbx_NumberOfDrugTechnologies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NumberOfDrugTechnologies" xlink:to="lab_mbx_NumberOfDrugTechnologies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8705aaad-74ab-46ea-aecd-5049f6c5595f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_8ad9705a-e833-4d1a-8d4f-88e947b0f76c_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_24e16d80-3265-4779-b0d0-97481d5cc237_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_beb96727-4cb6-4344-9b8c-be2949325b25_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7873342a-2eac-45a8-b1b6-cc537894f06d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NumberofDrugCandidates_c81eb154-df86-4f4f-9b65-b0cd171ea07c_terseLabel_en-US" xlink:label="lab_mbx_NumberofDrugCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of drug candidates</link:label>
    <link:label id="lab_mbx_NumberofDrugCandidates_label_en-US" xlink:label="lab_mbx_NumberofDrugCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberofDrugCandidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugCandidates" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NumberofDrugCandidates" xlink:to="lab_mbx_NumberofDrugCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_MilestonePaymentsLiabilities_a8939851-8428-4098-985c-344716c87318_terseLabel_en-US" xlink:label="lab_mbx_MilestonePaymentsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments liabilities</link:label>
    <link:label id="lab_mbx_MilestonePaymentsLiabilities_label_en-US" xlink:label="lab_mbx_MilestonePaymentsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilestonePaymentsLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MilestonePaymentsLiabilities" xlink:href="mbx-20190930.xsd#mbx_MilestonePaymentsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_MilestonePaymentsLiabilities" xlink:to="lab_mbx_MilestonePaymentsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_836d9ce0-9987-4fb0-adb7-817fbf5c91ec_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e0eef031-a889-47b6-b54b-200217092392_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_69ea3b6c-511d-4194-a85f-aad8b0bfce2c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent - long-term</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_94bded2d-804b-41fe-920e-2054682fcb0b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_87b8080a-d8f7-41ef-8af1-c5e922c00901_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5e168c3e-ff17-432e-82d9-7c4768bc7a3a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d296d3ca-0a79-4e79-8409-d24af464ce83_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_eef0bc5b-4e0b-4ab4-b047-32eb81a8f2f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_21ea03c2-f697-4bcc-b0c2-cf572dda2e07_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f1e33e33-e3b0-42d4-99e8-aee8ba98bc74_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e1915e06-5069-4bc2-9f65-b8b6de895e26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for cash - sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a0979841-81f1-41f6-84b5-4eb39d4676e9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0ee784b0-ff93-456f-8d81-c5701b8bc5f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_f6ba9963-b1c0-46a3-a3a6-77c66450fa96_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_WarrantLiabilityAbstract_label_en-US" xlink:label="lab_mbx_WarrantLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Abstract]</link:label>
    <link:label id="lab_mbx_WarrantLiabilityAbstract_documentation_en-US" xlink:label="lab_mbx_WarrantLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityAbstract" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_WarrantLiabilityAbstract" xlink:to="lab_mbx_WarrantLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociBeforeTaxAttributableToParent_ce571f24-6ce0-4df1-8218-6bb4ccff70e6_terseLabel_en-US" xlink:label="lab_us-gaap_AociBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AociBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_AociBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_AociBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_193fb879-75ac-4497-94f1-b07a6bd8a97f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5b6b5364-03a6-437f-9a23-cbce0eda2da2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a66a8222-a774-4ad8-8cf9-d5a8726ce75a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, net of estimated forfeitures, related to the Company's non-vested equity awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_049d323f-eba5-48ec-9772-8e08ce42e944_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, year one</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_GoingConcernPolicyPolicyTextBlock_3b85a826-5bd6-428f-9489-335037c3a094_terseLabel_en-US" xlink:label="lab_mbx_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_mbx_GoingConcernPolicyPolicyTextBlock_label_en-US" xlink:label="lab_mbx_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoingConcernPolicyPolicyTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GoingConcernPolicyPolicyTextBlock" xlink:href="mbx-20190930.xsd#mbx_GoingConcernPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_GoingConcernPolicyPolicyTextBlock" xlink:to="lab_mbx_GoingConcernPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_747b27a5-fe69-4f5d-9a6c-08de2b70c53c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c01b4a04-77a0-4dc0-8a96-a41e66ac8aa6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8c5a41b2-6930-486c-9da9-bd1cbbffdc73_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c7371ff4-370f-4f74-8984-29f61eaefe58_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of units sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1f13cbb-ac73-4ca1-b0ad-84b5dd71714e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_66405c76-f609-449e-ab3b-fa988311bb79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, year five</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_381f1065-55a7-4c47-84e3-196ab422e071_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cae95d8a-a962-4629-b200-cb4a6e7e9360_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7b0b3e0b-342b-48c2-81b1-50dd4275c44e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fd143410-f18a-4cf7-a488-bf68b1e507b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_30cc7e47-8a21-4006-92da-144fc4d23fa7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4a8b9098-5863-4fa7-95e6-8f6805c76b4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b5d75f8a-7db5-4d6c-9926-ade135231b11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_a5a4fc34-ee2f-48c2-8b88-10c2cfcc2bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_045b048d-3d2e-429b-b065-2566b2c8f758_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3c0419b8-27d9-4e0f-a15d-f21b19b3b314_verboseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, exercisable (in dollars per share)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_58c263f3-005e-45eb-ae93-be614d7bb3a5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_0ba414f5-ca3d-461a-be53-f532384ec6c3_terseLabel_en-US" xlink:label="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License rights expense settled in stock</link:label>
    <link:label id="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_label_en-US" xlink:label="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued For Licence Rights Under Licence Agreement</link:label>
    <link:label id="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_documentation_en-US" xlink:label="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued For Licence Rights Under Licence Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:href="mbx-20190930.xsd#mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:to="lab_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f16048c3-d85f-4684-aea2-91ccbe9b3d99_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Supplemental Cash Flow Information For Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4c29cee5-d3f0-4e97-9f18-ffa8bde63f25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c568b0bd-bf93-401b-8933-8240dcabc8c1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassofWarrantorRightAgreementPeriod_87a24aec-31e3-4c80-b26a-ad52fd58b912_terseLabel_en-US" xlink:label="lab_mbx_ClassofWarrantorRightAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of agreement</link:label>
    <link:label id="lab_mbx_ClassofWarrantorRightAgreementPeriod_label_en-US" xlink:label="lab_mbx_ClassofWarrantorRightAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ClassofWarrantorRightAgreementPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightAgreementPeriod" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightAgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassofWarrantorRightAgreementPeriod" xlink:to="lab_mbx_ClassofWarrantorRightAgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_293b4d34-d032-4ed4-8bf5-6289f966cc94_terseLabel_en-US" xlink:label="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Sub-lease income allocable to co-lessee</link:label>
    <link:label id="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_label_en-US" xlink:label="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sub-lease Income Allocable To Co-lessee</link:label>
    <link:label id="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_documentation_en-US" xlink:label="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sub-lease Income Allocable To Co-lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:href="mbx-20190930.xsd#mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:to="lab_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PeriodOneMember_8e9c78f6-8fbd-4acd-8b46-9f896d13a412_terseLabel_en-US" xlink:label="lab_mbx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Two Years</link:label>
    <link:label id="lab_mbx_PeriodOneMember_label_en-US" xlink:label="lab_mbx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One [Member]</link:label>
    <link:label id="lab_mbx_PeriodOneMember_documentation_en-US" xlink:label="lab_mbx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodOneMember" xlink:href="mbx-20190930.xsd#mbx_PeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PeriodOneMember" xlink:to="lab_mbx_PeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_WarrantLiabilityLongtermMember_5b241c74-0588-41b9-bad8-f11f3e0b1f3d_terseLabel_en-US" xlink:label="lab_mbx_WarrantLiabilityLongtermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability Long-Term</link:label>
    <link:label id="lab_mbx_WarrantLiabilityLongtermMember_label_en-US" xlink:label="lab_mbx_WarrantLiabilityLongtermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WarrantLiabilityLongtermMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityLongtermMember" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityLongtermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_WarrantLiabilityLongtermMember" xlink:to="lab_mbx_WarrantLiabilityLongtermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c5e23cec-6c88-481e-84a4-83f225480ccf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0dbb5a19-697b-4d3e-96a1-5a52cb998951_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed0948e3-b711-4b67-a22b-d4eea610b476_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bbf31213-7901-49bf-a1d1-0e138ec8e635_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d46daef-9843-4736-954a-a42db3cef312_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d973cab3-b51a-46e5-bbff-4f9306ea3251_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0681dad3-1c8c-44da-bad6-815ec4676dc2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_FoodAndDrugAdministrationMember_f01ac0ee-1c25-4da7-bc74-ef40aff3c6ed_terseLabel_en-US" xlink:label="lab_mbx_FoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Food and Drug Administration</link:label>
    <link:label id="lab_mbx_FoodAndDrugAdministrationMember_label_en-US" xlink:label="lab_mbx_FoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Food and Drug Administration [Member]</link:label>
    <link:label id="lab_mbx_FoodAndDrugAdministrationMember_documentation_en-US" xlink:label="lab_mbx_FoodAndDrugAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Food and Drug Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FoodAndDrugAdministrationMember" xlink:href="mbx-20190930.xsd#mbx_FoodAndDrugAdministrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_FoodAndDrugAdministrationMember" xlink:to="lab_mbx_FoodAndDrugAdministrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharesAuthorized_dfc68c13-5465-4327-9e93-4dda75179b3e_totalLabel_en-US" xlink:label="lab_mbx_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_mbx_SharesAuthorized_label_en-US" xlink:label="lab_mbx_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharesAuthorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesAuthorized" xlink:href="mbx-20190930.xsd#mbx_SharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharesAuthorized" xlink:to="lab_mbx_SharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2f1d1899-acbb-4028-8f7c-c8625a66785b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6da896b3-6561-42eb-af1a-8a25a8676ff7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (in years), outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassofWarrantorRightNumberofWarrantsIssued_afb0d7c9-3fe7-4c34-8dd9-e39aae792550_terseLabel_en-US" xlink:label="lab_mbx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants issued</link:label>
    <link:label id="lab_mbx_ClassofWarrantorRightNumberofWarrantsIssued_label_en-US" xlink:label="lab_mbx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ClassofWarrantorRightNumberofWarrantsIssued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightNumberofWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:to="lab_mbx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMethodInvestmentsPolicy_e33669fd-86e7-496a-a72c-dc91e12fd93e_terseLabel_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investments</link:label>
    <link:label id="lab_us-gaap_CostMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMethodInvestmentsPolicy" xlink:to="lab_us-gaap_CostMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e196a24b-b35b-4cb8-862f-e15b7688a068_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7a9a448a-0e86-4227-b5d4-5e0ac15344b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AuthorityAxis_e887cf67-a79f-4fb9-9b56-da5d194cd245_terseLabel_en-US" xlink:label="lab_mbx_AuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority [Axis]</link:label>
    <link:label id="lab_mbx_AuthorityAxis_label_en-US" xlink:label="lab_mbx_AuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority [Axis]</link:label>
    <link:label id="lab_mbx_AuthorityAxis_documentation_en-US" xlink:label="lab_mbx_AuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityAxis" xlink:href="mbx-20190930.xsd#mbx_AuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AuthorityAxis" xlink:to="lab_mbx_AuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1917af42-f20b-4f9f-87fa-b3e0f26f7d55_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_effa26ca-6e97-407a-bd41-e83ba990ab25_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_GSKConsultingAgreementWarrantOneMember_7a6ca3dd-ac3b-48e2-9bbd-96c23ece2288_terseLabel_en-US" xlink:label="lab_mbx_GSKConsultingAgreementWarrantOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK Consulting Agreement Warrant One</link:label>
    <link:label id="lab_mbx_GSKConsultingAgreementWarrantOneMember_label_en-US" xlink:label="lab_mbx_GSKConsultingAgreementWarrantOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSKConsultingAgreementWarrantOneMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantOneMember" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_GSKConsultingAgreementWarrantOneMember" xlink:to="lab_mbx_GSKConsultingAgreementWarrantOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_59bf431e-c84a-4879-85fb-91cc5dfcba7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bd751a2c-1a69-4885-9286-d03dc6554a9c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant OtherUnobservable Inputs(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_baa0545b-c163-46c7-929b-993522c67088_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b0d7ef05-5292-4f19-9d1e-e6970b777bdb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ab3dc7c9-1e4a-4de8-b234-688aaccfe5f1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9a6f4391-70e7-4140-af7f-ec51a491e311_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to HPI over three-year period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_27c4574d-2a74-48a5-9354-6df287537781_negatedLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares under warrant, expired (in shares)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LicensingAgreementTerm_9cca9893-e079-4366-a2ce-4579106e7eab_terseLabel_en-US" xlink:label="lab_mbx_LicensingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HPI out-licensing agreement term</link:label>
    <link:label id="lab_mbx_LicensingAgreementTerm_label_en-US" xlink:label="lab_mbx_LicensingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LicensingAgreementTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensingAgreementTerm" xlink:href="mbx-20190930.xsd#mbx_LicensingAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LicensingAgreementTerm" xlink:to="lab_mbx_LicensingAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_90e14d74-fded-47a9-b4e7-aa1a5571ae5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SecuritiesPurchaseAgreementMember_9a643872-9a9f-4e6f-8a83-0dcae6761ab3_terseLabel_en-US" xlink:label="lab_mbx_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_mbx_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_mbx_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SecuritiesPurchaseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SecuritiesPurchaseAgreementMember" xlink:href="mbx-20190930.xsd#mbx_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SecuritiesPurchaseAgreementMember" xlink:to="lab_mbx_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_48c63eb1-0237-4182-8388-d06b039047bc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b6e9f78b-dc09-4348-b90f-5886dcafe1e4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a0459928-d23b-4273-9ab3-38cad3a1e157_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9f9995cd-e4eb-4f87-adcf-0100cc4d185d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_780a1ed7-5295-402a-957a-782db4f80edf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_bc528b0b-2ac9-4010-9e04-f9c170e4636a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_4314dcd6-3bb9-4171-b867-30302f557d39_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offered for each warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_0f479c78-e560-48c9-a664-c68c5b70836d_terseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Warrant Price Per Share, Vested and Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassofWarrantorRightVestingPeriod_d87ffdf7-1bcd-4e51-a6c4-750722f25229_terseLabel_en-US" xlink:label="lab_mbx_ClassofWarrantorRightVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_mbx_ClassofWarrantorRightVestingPeriod_label_en-US" xlink:label="lab_mbx_ClassofWarrantorRightVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ClassofWarrantorRightVestingPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightVestingPeriod" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassofWarrantorRightVestingPeriod" xlink:to="lab_mbx_ClassofWarrantorRightVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_b8caeb93-3ba1-4330-9859-6be272c77f4c_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aed97cc5-5f1f-4c95-91fc-493a3ae9abdf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_932cca13-93b0-44cc-9d49-b65244f48349_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3b5c9eff-6556-4ca3-bbd6-1e93b82811e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_4567f9af-4e0f-4a80-b1d6-73889b619c5a_negatedLabel_en-US" xlink:label="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, net</link:label>
    <link:label id="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="mbx-20190930.xsd#mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_60541d01-a3c6-45e1-9983-df2506746f55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b7e71956-2645-41f8-b1c7-72b5cce056da_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_OptionRepurchasePayments_a3e9f620-c3bf-45a5-bcd9-66888f5195a1_terseLabel_en-US" xlink:label="lab_mbx_OptionRepurchasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option repurchase payment</link:label>
    <link:label id="lab_mbx_OptionRepurchasePayments_label_en-US" xlink:label="lab_mbx_OptionRepurchasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Repurchase Payments</link:label>
    <link:label id="lab_mbx_OptionRepurchasePayments_documentation_en-US" xlink:label="lab_mbx_OptionRepurchasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Repurchase Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OptionRepurchasePayments" xlink:href="mbx-20190930.xsd#mbx_OptionRepurchasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_OptionRepurchasePayments" xlink:to="lab_mbx_OptionRepurchasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d8a8b08f-2031-43a0-b28d-40ce10a1d2e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_93568b56-16b7-49da-97c8-3ca83a8c7c89_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_WarrantLiabilityCurrentMember_0b0b7c53-8ade-41e8-bd89-285ce603dbb8_terseLabel_en-US" xlink:label="lab_mbx_WarrantLiabilityCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability Current</link:label>
    <link:label id="lab_mbx_WarrantLiabilityCurrentMember_label_en-US" xlink:label="lab_mbx_WarrantLiabilityCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WarrantLiabilityCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityCurrentMember" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_WarrantLiabilityCurrentMember" xlink:to="lab_mbx_WarrantLiabilityCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5580b86c-bc78-47ae-877f-a379cc5786a5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding Basic and diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91519470-28f2-40d3-90a4-42eb23e1fd7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock_75437c6f-c613-4ea5-b726-2e9a2f1dd6c7_terseLabel_en-US" xlink:label="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock_label_en-US" xlink:label="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used 1 [Table Text Block]</link:label>
    <link:label id="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock_documentation_en-US" xlink:label="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:href="mbx-20190930.xsd#mbx_ScheduleOfAssumptionsUsed1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:to="lab_mbx_ScheduleOfAssumptionsUsed1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ebfaf097-838f-4afa-8a46-8d3c4ed02e1f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_d3dcfe86-606f-4568-bf76-53a380bd4038_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_7c537e37-15e3-4349-b676-e97e17c30072_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1cb329b0-653b-4f8d-80fc-71ec20f8fc57_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_f3ee6bfe-4c02-4da8-9462-4e723e76e379_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e4b8e4ac-e466-47fa-a42b-7f00500f4911_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b1ab0bfd-b233-47db-b184-576b90b80ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_47afef36-4113-46f6-b233-ecb817f67763_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_b08264be-206d-4bb2-872e-77cddab42d99_terseLabel_en-US" xlink:label="lab_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rent expense, annual increase in rent (as a percent)</link:label>
    <link:label id="lab_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_label_en-US" xlink:label="lab_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OperatingLeaseRentExpenseAnnualIncreaseInRentPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:href="mbx-20190930.xsd#mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:to="lab_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_6af170ad-8255-4b9a-86e8-81dc09b7415d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on foreign currency transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_MdAndersonMember_7564b710-9371-4b0c-82ec-d12370817d2a_terseLabel_en-US" xlink:label="lab_mbx_MdAndersonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MD Anderson</link:label>
    <link:label id="lab_mbx_MdAndersonMember_label_en-US" xlink:label="lab_mbx_MdAndersonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MdAndersonMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MdAndersonMember" xlink:href="mbx-20190930.xsd#mbx_MdAndersonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_MdAndersonMember" xlink:to="lab_mbx_MdAndersonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_e34da5dc-35ed-4b0f-98ad-e3833b371d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_March2019IssuanceMember_93dc2d54-c633-4d09-9868-65f1a585231c_terseLabel_en-US" xlink:label="lab_mbx_March2019IssuanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019</link:label>
    <link:label id="lab_mbx_March2019IssuanceMember_label_en-US" xlink:label="lab_mbx_March2019IssuanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Issuance [Member]</link:label>
    <link:label id="lab_mbx_March2019IssuanceMember_documentation_en-US" xlink:label="lab_mbx_March2019IssuanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019IssuanceMember" xlink:href="mbx-20190930.xsd#mbx_March2019IssuanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_March2019IssuanceMember" xlink:to="lab_mbx_March2019IssuanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_62edf25b-f62d-4f1e-ac63-162b670c9ac6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_afe786ba-2e61-4aee-bea1-a4b0ba1e4a84_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_455e7b96-9a24-4d94-8112-ea28707d5ac5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8686ea9f-3b96-477c-8ecc-b619c971fde5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LicenseAgreementAnnualLicenseFee_fa7e3f8a-8076-4188-acdc-f21b97d02fe4_terseLabel_en-US" xlink:label="lab_mbx_LicenseAgreementAnnualLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, annual license fee</link:label>
    <link:label id="lab_mbx_LicenseAgreementAnnualLicenseFee_label_en-US" xlink:label="lab_mbx_LicenseAgreementAnnualLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LicenseAgreementAnnualLicenseFee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenseAgreementAnnualLicenseFee" xlink:href="mbx-20190930.xsd#mbx_LicenseAgreementAnnualLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LicenseAgreementAnnualLicenseFee" xlink:to="lab_mbx_LicenseAgreementAnnualLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_June2018RegisteredDirectOfferingMember_15ebc34e-7a5c-4714-b5ad-2d1e4b333615_terseLabel_en-US" xlink:label="lab_mbx_June2018RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018 Registered Direct Offering</link:label>
    <link:label id="lab_mbx_June2018RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_mbx_June2018RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June2018RegisteredDirectOfferingMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018RegisteredDirectOfferingMember" xlink:href="mbx-20190930.xsd#mbx_June2018RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_June2018RegisteredDirectOfferingMember" xlink:to="lab_mbx_June2018RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6a08d291-00bc-4705-879c-10750784e95d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f189d799-8eef-4cea-8059-f18ced2b9bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2415b09f-4bb9-4d71-9ad3-043c9e3c5bdc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bdd5d065-cbf1-4a62-91df-011b2d4e8742_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ComponentsofShareBasedCompensationTableTextBlock_9a95d725-3bba-4f7a-b5a4-1b1e9ad5edf0_terseLabel_en-US" xlink:label="lab_mbx_ComponentsofShareBasedCompensationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Share-Based Compensation</link:label>
    <link:label id="lab_mbx_ComponentsofShareBasedCompensationTableTextBlock_label_en-US" xlink:label="lab_mbx_ComponentsofShareBasedCompensationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ComponentsofShareBasedCompensationTableTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ComponentsofShareBasedCompensationTableTextBlock" xlink:href="mbx-20190930.xsd#mbx_ComponentsofShareBasedCompensationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ComponentsofShareBasedCompensationTableTextBlock" xlink:to="lab_mbx_ComponentsofShareBasedCompensationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3ab364de-174c-4146-a78f-c3da116a4acb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_cd1cbfe4-b308-4ca9-bb61-ca433f7d66df_verboseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Under Warrant, Vested and Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_5a64abc7-14b5-40f9-9b8d-176452eba557_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0bb33dc6-94f6-462e-a8f7-4869446507e8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5bcc3ee2-bb6a-4112-9488-d6a9325cd3d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exercisable, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ea37a5fa-7f6d-4753-8918-3797c226a6bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_f7025fab-0456-4c6a-b6e5-2a5db71860d5_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2aa38f46-e4b0-4d96-8b0d-b850522307f9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_186770a3-642d-412a-8ed1-036b75061493_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_99c724d1-310b-4286-bb60-f57119961174_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b598ce8c-0551-4e29-8a29-d39c9209ef43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5dbc690e-1427-4373-8071-2a9917667223_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from registered offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6341d483-0544-43c1-9586-1868521d2b38_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Warrant Price Per Share, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26231b1c-3bc1-420d-aaee-6b48f5cf67b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value for equity investments granted other than options (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_aeff8373-65ab-4b82-beb0-11d33a081139_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_aef1aece-6576-4d88-9b33-e4614fa96138_terseLabel_en-US" xlink:label="lab_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions paid, percentage of gross proceeds (percent)</link:label>
    <link:label id="lab_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_label_en-US" xlink:label="lab_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SaleOfStockFeesPaidPercentageOfGrossProceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:to="lab_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1d876c5-39f7-4648-a746-824aa80ab00d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LeaseAgreementForCorporateOfficeSpaceMember_ecfe9be0-db1c-4e6e-9d3e-8b3941ce3133_terseLabel_en-US" xlink:label="lab_mbx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreement For Corporate Office Space</link:label>
    <link:label id="lab_mbx_LeaseAgreementForCorporateOfficeSpaceMember_label_en-US" xlink:label="lab_mbx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LeaseAgreementForCorporateOfficeSpaceMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:href="mbx-20190930.xsd#mbx_LeaseAgreementForCorporateOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:to="lab_mbx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0d7d0748-93c9-427f-b461-f92c6be5a09c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LicenceRightsMember_18539ab0-2b04-4775-99b2-1af2675624f3_terseLabel_en-US" xlink:label="lab_mbx_LicenceRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licence Rights</link:label>
    <link:label id="lab_mbx_LicenceRightsMember_label_en-US" xlink:label="lab_mbx_LicenceRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licence Rights [Member]</link:label>
    <link:label id="lab_mbx_LicenceRightsMember_documentation_en-US" xlink:label="lab_mbx_LicenceRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licence Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenceRightsMember" xlink:href="mbx-20190930.xsd#mbx_LicenceRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LicenceRightsMember" xlink:to="lab_mbx_LicenceRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6edd1d2-e404-4bbe-ac6a-7c1d8c7f93e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e89c4d31-7b7f-40a7-9e0e-66e4999fde64_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ConsultingFees_1f84b4d1-8b69-42e8-86c9-4976cb06ecce_terseLabel_en-US" xlink:label="lab_mbx_ConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting fees</link:label>
    <link:label id="lab_mbx_ConsultingFees_label_en-US" xlink:label="lab_mbx_ConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Fees</link:label>
    <link:label id="lab_mbx_ConsultingFees_documentation_en-US" xlink:label="lab_mbx_ConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingFees" xlink:href="mbx-20190930.xsd#mbx_ConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ConsultingFees" xlink:to="lab_mbx_ConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_897d8469-cf1d-4743-ad4a-6655470766f5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Pricesin ActiveMarkets forIdenticalAssets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_247358d5-0cdf-4816-ab93-c79385a3370f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_59141c66-6c8d-4eca-9a71-195bdce3108f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f7089111-137e-41fc-89fb-106805e493cb_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_14436366-1df7-4633-8518-3b030037894e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2cd9769f-8a0a-40aa-92e5-054bc8ea92d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_a99b5eb7-c771-43d2-b77d-836e7639552f_terseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Warrant Price Per Share, Exercised (in dollars per share)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options ExercisedI n Period</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_documentation_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options ExercisedI n Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NumberofDrugsinClinicalTrials_e66807a0-e09e-43c6-8757-4388d899994b_terseLabel_en-US" xlink:label="lab_mbx_NumberofDrugsinClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of drugs in clinical trials</link:label>
    <link:label id="lab_mbx_NumberofDrugsinClinicalTrials_label_en-US" xlink:label="lab_mbx_NumberofDrugsinClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberofDrugsinClinicalTrials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugsinClinicalTrials" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugsinClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NumberofDrugsinClinicalTrials" xlink:to="lab_mbx_NumberofDrugsinClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AccruedDrugManufacturingCost_0a8debf4-4db4-4dcf-ae92-107b0ced6a93_terseLabel_en-US" xlink:label="lab_mbx_AccruedDrugManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued drug manufacturing costs</link:label>
    <link:label id="lab_mbx_AccruedDrugManufacturingCost_label_en-US" xlink:label="lab_mbx_AccruedDrugManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Drug Manufacturing Cost</link:label>
    <link:label id="lab_mbx_AccruedDrugManufacturingCost_documentation_en-US" xlink:label="lab_mbx_AccruedDrugManufacturingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Drug Manufacturing Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedDrugManufacturingCost" xlink:href="mbx-20190930.xsd#mbx_AccruedDrugManufacturingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AccruedDrugManufacturingCost" xlink:to="lab_mbx_AccruedDrugManufacturingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_af44559f-9c9d-4acc-bdf6-37272cbdf570_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_2ba1d565-28db-4500-b028-371ec78e8972_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4724e59-6109-4e82-a4da-1b5279282684_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89358ed4-ae30-49ad-96a9-3fd451dee899_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3109bf6d-901b-40c4-b4e7-83212ef3cb08_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_65c6e1de-6767-47a0-bd2f-89c977872639_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_b0478903-7a9e-422b-b976-96092a130e29_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a0a38149-8378-4685-8b92-496c2dcf047e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f6cdc280-ab48-41c5-9948-247910d1b048_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_13892a7a-34c6-4def-9ba7-2dd262a5b62a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NatureOfBusinessAndLiquidityTextBlock_55586de7-2380-465f-87e7-cbf45795cd66_terseLabel_en-US" xlink:label="lab_mbx_NatureOfBusinessAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Liquidity</link:label>
    <link:label id="lab_mbx_NatureOfBusinessAndLiquidityTextBlock_label_en-US" xlink:label="lab_mbx_NatureOfBusinessAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NatureOfBusinessAndLiquidityTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NatureOfBusinessAndLiquidityTextBlock" xlink:href="mbx-20190930.xsd#mbx_NatureOfBusinessAndLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NatureOfBusinessAndLiquidityTextBlock" xlink:to="lab_mbx_NatureOfBusinessAndLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d5113cc9-8988-4df9-a871-45d93ec6fe43_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f10911d3-7670-4d31-a695-9fe028eac81c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_cd52fcaf-08a3-42b5-b892-2055c785cc59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value - net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharesIssuedInLeiuOfCash_18d94bf8-1a28-431e-a8db-0447254cfcaf_terseLabel_en-US" xlink:label="lab_mbx_SharesIssuedInLeiuOfCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense settled in stock</link:label>
    <link:label id="lab_mbx_SharesIssuedInLeiuOfCash_label_en-US" xlink:label="lab_mbx_SharesIssuedInLeiuOfCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued in Leiu Of Cash</link:label>
    <link:label id="lab_mbx_SharesIssuedInLeiuOfCash_documentation_en-US" xlink:label="lab_mbx_SharesIssuedInLeiuOfCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued in Leiu Of Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesIssuedInLeiuOfCash" xlink:href="mbx-20190930.xsd#mbx_SharesIssuedInLeiuOfCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharesIssuedInLeiuOfCash" xlink:to="lab_mbx_SharesIssuedInLeiuOfCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_b6519c71-29d2-4f7d-ba8e-e101715befe8_terseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, exercised (in dollars per share)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5601a12c-fbf6-4656-bf9a-f1ad5b619268_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d12b7f37-b68f-4592-b076-9598f77caaaf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of expected recognition of compensation cost (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9d4e3703-f8cc-43fa-8437-dfea8cc42583_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b152d02a-14a3-4ec6-81b2-4ee0c0fb2bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5f65b75b-e61c-46a2-966c-a151ce573cc4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Under Warrant, balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a63fe11-1cdd-4026-beb8-fdb5e89e0305_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Under Warrant, balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AuthorityDomain_67575306-6dc9-48dc-84e9-ca532a529802_terseLabel_en-US" xlink:label="lab_mbx_AuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority [Domain]</link:label>
    <link:label id="lab_mbx_AuthorityDomain_label_en-US" xlink:label="lab_mbx_AuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority [Domain]</link:label>
    <link:label id="lab_mbx_AuthorityDomain_documentation_en-US" xlink:label="lab_mbx_AuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityDomain" xlink:href="mbx-20190930.xsd#mbx_AuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AuthorityDomain" xlink:to="lab_mbx_AuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f3fb0fe9-c24a-4e8c-b645-81433cfc5f55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_8e030787-1ecf-4b5c-81e9-a9f12129b167_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_39f952a5-723f-430c-ac92-71f542961e43_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ce9cb48a-6b91-4b1f-b918-feea694f7f9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_aa5e8b0d-f080-401b-820d-506e3b7ed59c_terseLabel_en-US" xlink:label="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_mbx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_TheWarrantsMember_baf78f62-881f-4e6d-9bb9-646a53c86a6e_terseLabel_en-US" xlink:label="lab_mbx_TheWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Warrants</link:label>
    <link:label id="lab_mbx_TheWarrantsMember_label_en-US" xlink:label="lab_mbx_TheWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TheWarrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_TheWarrantsMember" xlink:href="mbx-20190930.xsd#mbx_TheWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_TheWarrantsMember" xlink:to="lab_mbx_TheWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_53cde83e-f8f6-408d-91f1-257e89d7211e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for cash - sale of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ecc7ba27-a172-4e65-9c86-908bcbf21367_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_925bc220-5502-4084-81f8-5b42b614ef84_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_UnitOfferingUnitPricePerShare_16c72192-bc3a-4394-8505-d9d5a7124699_terseLabel_en-US" xlink:label="lab_mbx_UnitOfferingUnitPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit offering (in dollars per unit)</link:label>
    <link:label id="lab_mbx_UnitOfferingUnitPricePerShare_label_en-US" xlink:label="lab_mbx_UnitOfferingUnitPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Offering Unit Price Per Share</link:label>
    <link:label id="lab_mbx_UnitOfferingUnitPricePerShare_documentation_en-US" xlink:label="lab_mbx_UnitOfferingUnitPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Offering Unit Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitOfferingUnitPricePerShare" xlink:href="mbx-20190930.xsd#mbx_UnitOfferingUnitPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_UnitOfferingUnitPricePerShare" xlink:to="lab_mbx_UnitOfferingUnitPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a2f6b093-8d90-4785-a07d-6ee1d579bb82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_12ca29d2-d170-46ed-b481-1d9e75f7e1d5_terseLabel_en-US" xlink:label="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payment to remove Germany</link:label>
    <link:label id="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_label_en-US" xlink:label="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Technology, Future Payment To Remove Country</link:label>
    <link:label id="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_documentation_en-US" xlink:label="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Technology, Future Payment To Remove Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:href="mbx-20190930.xsd#mbx_LicensedTechnologyFuturePaymentToRemoveCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:to="lab_mbx_LicensedTechnologyFuturePaymentToRemoveCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_GSKConsultingAgreementWarrantTwoMember_3477b742-bb8a-48d2-8b17-a7a80769629e_terseLabel_en-US" xlink:label="lab_mbx_GSKConsultingAgreementWarrantTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK Consulting Agreement Warrant Two</link:label>
    <link:label id="lab_mbx_GSKConsultingAgreementWarrantTwoMember_label_en-US" xlink:label="lab_mbx_GSKConsultingAgreementWarrantTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSKConsultingAgreementWarrantTwoMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantTwoMember" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_GSKConsultingAgreementWarrantTwoMember" xlink:to="lab_mbx_GSKConsultingAgreementWarrantTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5e02592e-2d25-44e0-8e1d-16f45f286914_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_3546f843-c419-43cb-8344-217691b20dba_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_UnderwitersMember_59d2106d-91fc-4bf8-abb4-9f130f0f4f72_terseLabel_en-US" xlink:label="lab_mbx_UnderwitersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwiters</link:label>
    <link:label id="lab_mbx_UnderwitersMember_label_en-US" xlink:label="lab_mbx_UnderwitersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwiters [Member]</link:label>
    <link:label id="lab_mbx_UnderwitersMember_documentation_en-US" xlink:label="lab_mbx_UnderwitersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwiters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwitersMember" xlink:href="mbx-20190930.xsd#mbx_UnderwitersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_UnderwitersMember" xlink:to="lab_mbx_UnderwitersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_f10afc9a-03b1-494e-9ed5-98f36974993c_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Right-of-Use Assets</link:label>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_213ba45c-f1a4-4be9-9d9f-5d3cadff7047_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_935123ec-80dd-42fc-9443-b4bbda964be4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, year three</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1caeff18-d900-430f-a7fe-50aa98db215c_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_NumberOfOtherDrugDevelopmentProjects_252e1f7a-7526-4d94-921a-0bf0e3e5998f_terseLabel_en-US" xlink:label="lab_mbx_NumberOfOtherDrugDevelopmentProjects" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other drug development projects</link:label>
    <link:label id="lab_mbx_NumberOfOtherDrugDevelopmentProjects_label_en-US" xlink:label="lab_mbx_NumberOfOtherDrugDevelopmentProjects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfOtherDrugDevelopmentProjects</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfOtherDrugDevelopmentProjects" xlink:href="mbx-20190930.xsd#mbx_NumberOfOtherDrugDevelopmentProjects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_NumberOfOtherDrugDevelopmentProjects" xlink:to="lab_mbx_NumberOfOtherDrugDevelopmentProjects" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_291a033c-3e03-4002-bd04-6fac6de5e8ee_verboseLabel_en-US" xlink:label="lab_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_label_en-US" xlink:label="lab_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodValueStockWarrantsExercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="lab_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_17f8babe-5777-4c88-8ef8-122a68057a5d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PaymentsForResearchAndDevelopmentAgreement_df0da310-e6a4-44a3-9160-4ab7076e4d55_terseLabel_en-US" xlink:label="lab_mbx_PaymentsForResearchAndDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for research and development agreement</link:label>
    <link:label id="lab_mbx_PaymentsForResearchAndDevelopmentAgreement_label_en-US" xlink:label="lab_mbx_PaymentsForResearchAndDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PaymentsForResearchAndDevelopmentAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PaymentsForResearchAndDevelopmentAgreement" xlink:href="mbx-20190930.xsd#mbx_PaymentsForResearchAndDevelopmentAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PaymentsForResearchAndDevelopmentAgreement" xlink:to="lab_mbx_PaymentsForResearchAndDevelopmentAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5027b36b-c55a-4477-9be1-c92e6fe22fbd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e3fb0008-58d2-4d28-8f09-2cd63cfa1a8d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edbb9d18-a8e4-4ab8-86c1-133786905891_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_60adf1ec-5359-43c1-b1d0-f662fe1c6f42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_b9f11b1f-54c1-44f8-9a06-2e38799b6c1e_terseLabel_en-US" xlink:label="lab_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roth Capital Partners and National Securities Corporation</link:label>
    <link:label id="lab_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_label_en-US" xlink:label="lab_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roth Capital Partners LLC and National Securities Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" xlink:href="mbx-20190930.xsd#mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" xlink:to="lab_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca12ed1c-b55c-42d3-b268-199a67ff8cb4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fafa750b-bc7b-45dd-bba9-234cbfdd4b3f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 and 75,000,000 shares authorized as of September 30, 2019 and December 31, 2018, 45,727,700 and 28,528,663 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_335cbfb0-a537-454c-b678-d6c30ca6db25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eb260102-6087-4206-beef-27b25a9ce82d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_b82b97a0-c9aa-4df2-83a8-a781138b9e9e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_VendorPrepaymentAndDeposits_adb614a8-9403-48ce-bfd1-bfac8ea32989_terseLabel_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor prepayments and deposits</link:label>
    <link:label id="lab_mbx_VendorPrepaymentAndDeposits_label_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Prepayment And Deposits</link:label>
    <link:label id="lab_mbx_VendorPrepaymentAndDeposits_documentation_en-US" xlink:label="lab_mbx_VendorPrepaymentAndDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Prepayment And Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_VendorPrepaymentAndDeposits" xlink:href="mbx-20190930.xsd#mbx_VendorPrepaymentAndDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_VendorPrepaymentAndDeposits" xlink:to="lab_mbx_VendorPrepaymentAndDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4acc8c15-27a6-42db-b5f9-5e492a08cb6b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b3e4499f-1de9-463a-a992-6327edf2b612_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_67378c4e-745f-4565-978f-01e0529a1168_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_WarrantLiabiltyMember_4369595c-73cf-4fcc-a23f-45dc82b717ad_terseLabel_en-US" xlink:label="lab_mbx_WarrantLiabiltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability Total</link:label>
    <link:label id="lab_mbx_WarrantLiabiltyMember_label_en-US" xlink:label="lab_mbx_WarrantLiabiltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WarrantLiabiltyMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabiltyMember" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabiltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_WarrantLiabiltyMember" xlink:to="lab_mbx_WarrantLiabiltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f21afb3b-4152-481d-af4c-576012d570cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_610885d5-fd16-4a6e-b6d4-6418693549a9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_185ab131-16fb-4996-947f-a2313fd45c6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_WPDPharmaceuticalsMember_24aad5ff-dddd-428c-b58c-1e20381692d3_terseLabel_en-US" xlink:label="lab_mbx_WPDPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WPD Pharmaceuticals</link:label>
    <link:label id="lab_mbx_WPDPharmaceuticalsMember_label_en-US" xlink:label="lab_mbx_WPDPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WPD Pharmaceuticals [Member]</link:label>
    <link:label id="lab_mbx_WPDPharmaceuticalsMember_documentation_en-US" xlink:label="lab_mbx_WPDPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WPD Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WPDPharmaceuticalsMember" xlink:href="mbx-20190930.xsd#mbx_WPDPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_WPDPharmaceuticalsMember" xlink:to="lab_mbx_WPDPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_3e19b9aa-a9c2-4e3a-95a5-72da78953ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_32e6de74-38a3-488c-942f-b90bc37d110a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (in years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_77e40333-445c-403d-bba0-bda73078bfc2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_da00d332-9b2b-4047-883f-30cbaa1c2a28_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_CommitmentsAndContingenciesLineItems_139d3879-f99e-46d0-b61e-2ce8d711d829_terseLabel_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_mbx_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_mbx_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesLineItems" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems" xlink:to="lab_mbx_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b47684da-2945-48e1-9c22-a5677850a3f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a20b9e7f-2516-43c3-aa54-ced7a46d36be_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_CommitmentsAndContingenciesTable_13743e30-0e74-4f1e-a4a6-bb7bba2d0a92_terseLabel_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_mbx_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_mbx_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_mbx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesTable" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_CommitmentsAndContingenciesTable" xlink:to="lab_mbx_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_30bf263a-08b1-4273-bf0f-77a330d259c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_a5ed44e1-b721-4ec3-bef1-b53a251fb188_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability - current</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_88899cb4-53aa-4331-a9c6-fc2423e525e7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_b2f2b65a-f866-4c60-824d-4a781933a220_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9a7a8b20-d6e9-48ea-93b2-b1d0d6f0843c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_aef3384e-9f8d-4c89-8627-e209ed99cfed_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_71ec5285-73fa-4a6d-9f90-b520d66b1ac2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7d26e255-1528-4e82-ade3-ceeb7f4f18c3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1b1d77fa-c8e7-4249-b60f-43e11768c5e8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_94265efb-b325-487d-9790-f1be8a9974d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_OlympiaDriveWBellfortLLCMember_e9135d45-6d55-4054-bf2e-67d90e4ee619_terseLabel_en-US" xlink:label="lab_mbx_OlympiaDriveWBellfortLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olympia Drive W Bellfort, LLC</link:label>
    <link:label id="lab_mbx_OlympiaDriveWBellfortLLCMember_label_en-US" xlink:label="lab_mbx_OlympiaDriveWBellfortLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olympia Drive W Bellfort, LLC [Member]</link:label>
    <link:label id="lab_mbx_OlympiaDriveWBellfortLLCMember_documentation_en-US" xlink:label="lab_mbx_OlympiaDriveWBellfortLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olympia Drive W Bellfort, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OlympiaDriveWBellfortLLCMember" xlink:href="mbx-20190930.xsd#mbx_OlympiaDriveWBellfortLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_OlympiaDriveWBellfortLLCMember" xlink:to="lab_mbx_OlympiaDriveWBellfortLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassOfWarrantOrRightTerm_152fd816-663e-4c3f-a2c9-9f1e9d12be32_terseLabel_en-US" xlink:label="lab_mbx_ClassOfWarrantOrRightTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_mbx_ClassOfWarrantOrRightTerm_label_en-US" xlink:label="lab_mbx_ClassOfWarrantOrRightTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightTerm" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassOfWarrantOrRightTerm" xlink:to="lab_mbx_ClassOfWarrantOrRightTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1843349-0dca-4106-b040-9d553b13f74c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fcab0040-4aac-453b-8318-9109b60847bc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_54341a8a-c237-40cc-bd6b-6aa22118fb71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4011daf-d2d1-429f-b1b0-c5ebf5e65b97_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_df0307ae-4630-4842-bd2e-b5b9fb94b9c8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_ed888a79-54d1-4e13-a92b-6a5bf96f9d62_terseLabel_en-US" xlink:label="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of shares to be sold in transaction</link:label>
    <link:label id="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_label_en-US" xlink:label="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction</link:label>
    <link:label id="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_documentation_en-US" xlink:label="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:to="lab_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_69cfc9aa-ff81-4302-b208-54b5e7f4d57e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9c4fb299-4217-45c6-ad0a-59f4b448d3fb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PeriodTwoMember_53e886ca-5a28-4209-82cc-ffd179204a88_terseLabel_en-US" xlink:label="lab_mbx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Two Years</link:label>
    <link:label id="lab_mbx_PeriodTwoMember_label_en-US" xlink:label="lab_mbx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two [Member]</link:label>
    <link:label id="lab_mbx_PeriodTwoMember_documentation_en-US" xlink:label="lab_mbx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodTwoMember" xlink:href="mbx-20190930.xsd#mbx_PeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PeriodTwoMember" xlink:to="lab_mbx_PeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f6bbf264-3a8e-4de5-b19b-e3bc896d0ee9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_84ce6c06-1386-4d73-9fa9-7c88803845fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_07305f81-dc66-44ac-8d34-405a7281ddda_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, year two</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a796e9ec-bc28-4bdb-b908-e39c12f1e049_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4d62f1c8-c6c8-444e-b6f1-7b69ddb06de0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9a13b377-9c34-4626-a563-2b9b4d44aeaf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ClassOfWarrantOrRightInitialExercisePeriod_04768a20-e627-46a2-b242-383052c82be3_terseLabel_en-US" xlink:label="lab_mbx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, initial exercise period</link:label>
    <link:label id="lab_mbx_ClassOfWarrantOrRightInitialExercisePeriod_label_en-US" xlink:label="lab_mbx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ClassOfWarrantOrRightInitialExercisePeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightInitialExercisePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:to="lab_mbx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20cd9841-c153-4d0a-9a27-247d74facdf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7bfbb337-472a-41a4-8816-5757c005fe69_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_CommitmentSharesMember_6ac592ef-f17c-4bdf-a855-60296a648049_terseLabel_en-US" xlink:label="lab_mbx_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:label id="lab_mbx_CommitmentSharesMember_label_en-US" xlink:label="lab_mbx_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares [Member]</link:label>
    <link:label id="lab_mbx_CommitmentSharesMember_documentation_en-US" xlink:label="lab_mbx_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentSharesMember" xlink:href="mbx-20190930.xsd#mbx_CommitmentSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_CommitmentSharesMember" xlink:to="lab_mbx_CommitmentSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0845563a-4268-4dab-ba4f-2529374664dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares under warrants granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9795a1a-b4e2-4b67-be7e-b79bae5f2af5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of equity investments granted in period other than options (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1d0157a2-fa93-41bb-abd4-3a7f15cf66e2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_AccruedClinicalTestingCurrent_56230bf8-2ed3-4760-8741-9ddc62c0c2a3_terseLabel_en-US" xlink:label="lab_mbx_AccruedClinicalTestingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical testing</link:label>
    <link:label id="lab_mbx_AccruedClinicalTestingCurrent_label_en-US" xlink:label="lab_mbx_AccruedClinicalTestingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Testing Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedClinicalTestingCurrent" xlink:href="mbx-20190930.xsd#mbx_AccruedClinicalTestingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_AccruedClinicalTestingCurrent" xlink:to="lab_mbx_AccruedClinicalTestingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_11f725ad-f7d0-41a8-964e-7b482b0ed60d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_bb98edac-9e70-4f49-9099-4ae0b20096ab_terseLabel_en-US" xlink:label="lab_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Submission Of NDA And Receipt Of First Marketing Approval For Sale Of A Licensed Product</link:label>
    <link:label id="lab_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_label_en-US" xlink:label="lab_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" xlink:href="mbx-20190930.xsd#mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" xlink:to="lab_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_IPXMemorialDriveInvestorsLLCMember_5343b636-57f6-4b99-b3df-22df3762d20b_terseLabel_en-US" xlink:label="lab_mbx_IPXMemorialDriveInvestorsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPX Memorial Drive Investors, LLC</link:label>
    <link:label id="lab_mbx_IPXMemorialDriveInvestorsLLCMember_label_en-US" xlink:label="lab_mbx_IPXMemorialDriveInvestorsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPXMemorialDriveInvestorsLLCMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IPXMemorialDriveInvestorsLLCMember" xlink:href="mbx-20190930.xsd#mbx_IPXMemorialDriveInvestorsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_IPXMemorialDriveInvestorsLLCMember" xlink:to="lab_mbx_IPXMemorialDriveInvestorsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4170ac0b-3a3b-4e9d-b18e-5be5b6db8208_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12e9ff16-89bb-4c3f-b7a7-9d1ea1507f7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised price per warrant (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_00d0efcd-74c3-4ba0-a30d-dba7e7f153cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_LeaseholdImprovementsPaidByLandlord_c1feb0d9-0792-4a50-bc03-7427671bab7e_terseLabel_en-US" xlink:label="lab_mbx_LeaseholdImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements paid by landlord</link:label>
    <link:label id="lab_mbx_LeaseholdImprovementsPaidByLandlord_label_en-US" xlink:label="lab_mbx_LeaseholdImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements Paid By Landlord</link:label>
    <link:label id="lab_mbx_LeaseholdImprovementsPaidByLandlord_documentation_en-US" xlink:label="lab_mbx_LeaseholdImprovementsPaidByLandlord" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements Paid By Landlord</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LeaseholdImprovementsPaidByLandlord" xlink:href="mbx-20190930.xsd#mbx_LeaseholdImprovementsPaidByLandlord"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_LeaseholdImprovementsPaidByLandlord" xlink:to="lab_mbx_LeaseholdImprovementsPaidByLandlord" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2c551e54-86b6-404d-8954-7d14bff48f26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6df9e8f5-eb89-4d6a-b895-7a630198704f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f0a78ff8-3a19-4b4c-aba5-82fd49f8845a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_91ba5a60-b70e-46e5-a755-7c8493e96d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Under Warrant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_77350738-7189-432e-b201-338265708606_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4fc5216b-9f3c-4712-92bb-66160b5152d7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c2ca5d05-4626-45c2-855f-8ead1988b283_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_47cdb190-6a41-4b81-a612-298639936a3b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1ed30d62-b782-4134-8717-1596336a3c02_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fa57d770-286d-4232-ab0f-c06d412cf6c3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b7e5d677-a61c-4574-8b35-a3698dc31614_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f5fe2e4f-19e5-4bb7-ae15-307d6636c7d0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_8fd0029a-4b3c-40e6-9c33-9a18b6cff58a_terseLabel_en-US" xlink:label="lab_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee agreements, termination benefits provided to key employees, aggregate amount</link:label>
    <link:label id="lab_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_label_en-US" xlink:label="lab_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:href="mbx-20190930.xsd#mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:to="lab_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ConsultingAgreementWarrantThreeMember_ec5cba02-7372-4563-8e4a-cdd0605905d0_terseLabel_en-US" xlink:label="lab_mbx_ConsultingAgreementWarrantThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement Warrant Three</link:label>
    <link:label id="lab_mbx_ConsultingAgreementWarrantThreeMember_label_en-US" xlink:label="lab_mbx_ConsultingAgreementWarrantThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ConsultingAgreementWarrantThreeMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingAgreementWarrantThreeMember" xlink:href="mbx-20190930.xsd#mbx_ConsultingAgreementWarrantThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ConsultingAgreementWarrantThreeMember" xlink:to="lab_mbx_ConsultingAgreementWarrantThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_2c7bff76-3ed2-4f2b-9ca8-15e7018cc46d_negatedLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares under warrant, exercised (in shares)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_PeriodDomain_127bc5de-be0d-488f-9f08-26ee6bedb556_terseLabel_en-US" xlink:label="lab_mbx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Domain]</link:label>
    <link:label id="lab_mbx_PeriodDomain_label_en-US" xlink:label="lab_mbx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Domain]</link:label>
    <link:label id="lab_mbx_PeriodDomain_documentation_en-US" xlink:label="lab_mbx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodDomain" xlink:href="mbx-20190930.xsd#mbx_PeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_PeriodDomain" xlink:to="lab_mbx_PeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53f0cec0-efa1-4094-a0b9-f8176347c7ee_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bf746e93-0e6f-4679-b7a9-7a94f8af7968_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_22c4059a-0d4b-417e-b3ef-3089dac8c20e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ec0240d9-17bd-4e9c-ad03-e7de66af9fd1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_db359bd8-859c-4c17-8dde-e5deb0843a10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_HoustonPharmaceuticalsIncMember_25b83171-c6a3-4246-967d-29c32e638de1_terseLabel_en-US" xlink:label="lab_mbx_HoustonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Houston Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_mbx_HoustonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_mbx_HoustonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HoustonPharmaceuticalsIncMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_HoustonPharmaceuticalsIncMember" xlink:href="mbx-20190930.xsd#mbx_HoustonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_HoustonPharmaceuticalsIncMember" xlink:to="lab_mbx_HoustonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_04e2d532-d375-4aa0-8450-b72a9ca471d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f18383c2-5ffe-4844-b782-a989be466d28_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2efd572d-2116-4ba8-abad-0a9be8759bc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_efd58b68-0dc9-44d1-97ab-2d88d100d684_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ef5427f5-4ed7-4752-a3c7-4e0b2fcaa0fb_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_d63986b7-7404-4639-8d69-fe481e71a8ee_negatedTerseLabel_en-US" xlink:label="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclass of liability from long-term to current</link:label>
    <link:label id="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_label_en-US" xlink:label="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis, Transfer of Liability From Long-term To Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:to="lab_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2ae9a67d-a74a-484b-9dee-e39c9947e055_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_45910e62-c93f-4a7f-9b99-2a628c5baed9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_16fa58c6-b438-4552-b23c-0c5af6183325_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_d7fa29a7-63eb-44a6-a5b8-1f8b319ffad9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_26733cbd-7d5f-4e4c-8f19-bf7341e6a194_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_ScheduleOfWarrantActivityTableTextBlock_6c190905-b7b5-4b25-80fa-ae4456a9c15c_terseLabel_en-US" xlink:label="lab_mbx_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_mbx_ScheduleOfWarrantActivityTableTextBlock_label_en-US" xlink:label="lab_mbx_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfWarrantActivityTableTextBlock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ScheduleOfWarrantActivityTableTextBlock" xlink:href="mbx-20190930.xsd#mbx_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_mbx_ScheduleOfWarrantActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_210f8249-a04b-4cde-aae9-19af46469a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4962df4b-9d0f-4f4c-9b41-749a572776dc_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0c35be2e-a875-4717-9103-255a75fd0874_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5e085fb5-515d-4c38-b66a-c711443f588c_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_EquityDistributionCommitment_57677d05-a89e-4161-97de-6c6649964375_terseLabel_en-US" xlink:label="lab_mbx_EquityDistributionCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity distribution commitment</link:label>
    <link:label id="lab_mbx_EquityDistributionCommitment_label_en-US" xlink:label="lab_mbx_EquityDistributionCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Commitment</link:label>
    <link:label id="lab_mbx_EquityDistributionCommitment_documentation_en-US" xlink:label="lab_mbx_EquityDistributionCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EquityDistributionCommitment" xlink:href="mbx-20190930.xsd#mbx_EquityDistributionCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_EquityDistributionCommitment" xlink:to="lab_mbx_EquityDistributionCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_99d02f10-5b51-416d-9e27-1d23854a2ca2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_6d4857ae-bb36-417d-8960-dcdf0fb118e9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for royalties</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_MarketExclusivityExtensionPeriod_babb0ac1-ce4b-4d89-9c90-4a909a04f69b_terseLabel_en-US" xlink:label="lab_mbx_MarketExclusivityExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market exclusivity extension period (years)</link:label>
    <link:label id="lab_mbx_MarketExclusivityExtensionPeriod_label_en-US" xlink:label="lab_mbx_MarketExclusivityExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Exclusivity Extension Period</link:label>
    <link:label id="lab_mbx_MarketExclusivityExtensionPeriod_documentation_en-US" xlink:label="lab_mbx_MarketExclusivityExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Exclusivity Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MarketExclusivityExtensionPeriod" xlink:href="mbx-20190930.xsd#mbx_MarketExclusivityExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_MarketExclusivityExtensionPeriod" xlink:to="lab_mbx_MarketExclusivityExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8be12bc8-91b6-4540-a3c1-463e316f8348_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cb130da2-3652-4478-820c-b85870f0e9f1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c79cfbb-f9b2-4e18-98f4-33a7f4606bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_04aa6ec1-4844-446c-b628-1839bbef582f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5e9d341a-4f73-4bad-92c8-41d4d222f919_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7d25359-5944-40c8-96e3-9be7976f17dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Warrant Price per Share, Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2bdb6160-011d-4963-a7be-092ebf972b36_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Warrant Price per Share, Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c422e569-5a30-4748-8b6a-a06aa67641c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23829dc8-5938-4a0b-b7fa-61ac469056f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9efaf2e6-8997-4f09-8777-7324f439b27f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_June2018IssuanceMember_8920dc71-0b35-46a0-8fd4-c2016aa13843_terseLabel_en-US" xlink:label="lab_mbx_June2018IssuanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018</link:label>
    <link:label id="lab_mbx_June2018IssuanceMember_label_en-US" xlink:label="lab_mbx_June2018IssuanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June2018IssuanceMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018IssuanceMember" xlink:href="mbx-20190930.xsd#mbx_June2018IssuanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_June2018IssuanceMember" xlink:to="lab_mbx_June2018IssuanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e0c492f1-ca24-4113-9028-9e35351a6758_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments, year four</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5fba0665-ee4b-4d44-89c0-8008b1e4dd74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of operating lease (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_27d25fe5-6007-4001-b72f-081e95b983f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5664ef40-5d24-42f2-98d6-2893491c94c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_85f12c44-7223-41e4-b5fc-89cf6ff7ad07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6d26df16-5bf8-43ae-83ac-27bef9b6e7ce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_72acbc81-100e-40bd-91b9-294724512973_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b2880f2-a699-46c1-b72c-334bf037ab16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ffd1e495-fae9-4b1c-86b3-690d15f033be_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2df2825a-eafd-408e-abff-3e837d3ce113_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5dc6a255-de9c-48df-8be1-c0edc9719654_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1dccd0d2-1ee6-457c-a6ff-22d62136cce2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_79c2c7a3-4bcc-4108-9603-04f9675fdf0a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Address</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_d4a06b7b-2b53-41fd-8e62-4f4c6e68b43f_verboseLabel_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Vested and Exercisable at end of period (in years)</link:label>
    <link:label id="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_37c77adf-8f91-4b56-8d56-6d117eff01ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d08a89de-af5d-401f-8ac4-17c839413c33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_04eb0efc-a077-4238-8134-d5eb2d89eefa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_681fb68b-dd75-450e-b3d9-ccb4340bed2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a09e40c6-1905-4d42-a026-b1dcb58c7cbf_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b752f8da-c88e-4676-b3b2-d4295b798fa0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mbx_March2019RegisteredDirectOfferingsMember_e393973c-d097-4ca8-9699-463692d5a302_terseLabel_en-US" xlink:label="lab_mbx_March2019RegisteredDirectOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Registered Direct Offerings</link:label>
    <link:label id="lab_mbx_March2019RegisteredDirectOfferingsMember_label_en-US" xlink:label="lab_mbx_March2019RegisteredDirectOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Registered Direct Offerings [Member]</link:label>
    <link:label id="lab_mbx_March2019RegisteredDirectOfferingsMember_documentation_en-US" xlink:label="lab_mbx_March2019RegisteredDirectOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Registered Direct Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019RegisteredDirectOfferingsMember" xlink:href="mbx-20190930.xsd#mbx_March2019RegisteredDirectOfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbx_March2019RegisteredDirectOfferingsMember" xlink:to="lab_mbx_March2019RegisteredDirectOfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_e4983559-7974-4702-bf0a-0e5514085d6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ad04011f-0e5b-4f5a-8109-ea952a9b442b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of expected recognition of compensation cost for equity investments other than options (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_31dfaa52-137c-400e-8f98-5a96bd293015_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance, beginning (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_18f574df-507a-46ce-89e9-fd1dc0cc4af3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance, ending (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e9f91290-30c4-4214-b695-74594b46031e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_ee3b07a2-08e6-4f0d-b346-999070252dae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability - long-term</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e690a87d-06c9-4fd7-8a39-808aebe178bd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mbx-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:3b12a6f2-291f-4e7c-8ccd-6c47e2630a4f,g:6bd5a6de-276a-4483-af29-c078c1068286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.moleculin.com/role/Cover" xlink:type="simple" xlink:href="mbx-20190930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8179ce7a-a27f-4465-a56a-d4af5b6f569e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentType_8179ce7a-a27f-4465-a56a-d4af5b6f569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8a086803-54c5-4fd9-b934-550c9c65342d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentQuarterlyReport_8a086803-54c5-4fd9-b934-550c9c65342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_444583da-8c76-499b-8ecd-cbcb0d53b4eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentPeriodEndDate_444583da-8c76-499b-8ecd-cbcb0d53b4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ec59e7ff-9e78-4612-87aa-da572b131526" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentTransitionReport_ec59e7ff-9e78-4612-87aa-da572b131526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_35b8db83-5d0d-4df6-b9f4-ef135c1fb3e7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityFileNumber_35b8db83-5d0d-4df6-b9f4-ef135c1fb3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e2213767-1068-430f-8228-9b49f92b5cf8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityRegistrantName_e2213767-1068-430f-8228-9b49f92b5cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a6c652f7-8f93-47c4-9e23-f0dee498b8ef" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a6c652f7-8f93-47c4-9e23-f0dee498b8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_964c9550-ea1a-49d6-ad9b-4fb9fddcaaa7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityTaxIdentificationNumber_964c9550-ea1a-49d6-ad9b-4fb9fddcaaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a7327a7e-266f-446c-ae26-d4103323fa8f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityAddressAddressLine1_a7327a7e-266f-446c-ae26-d4103323fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ca150dcb-cdb9-449d-a95b-169d8de3ec9e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityAddressAddressLine2_ca150dcb-cdb9-449d-a95b-169d8de3ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f3ae606-9977-4010-ae57-ee5a8dbff4e7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityAddressCityOrTown_8f3ae606-9977-4010-ae57-ee5a8dbff4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5a315a70-a65a-4e24-ae13-629bead17e80" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityAddressStateOrProvince_5a315a70-a65a-4e24-ae13-629bead17e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8dabe343-33f4-4652-b1d0-7755ea74d5c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityAddressPostalZipCode_8dabe343-33f4-4652-b1d0-7755ea74d5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06ef38f1-9aaf-4b8c-8c0c-9b30f3c7381b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_CityAreaCode_06ef38f1-9aaf-4b8c-8c0c-9b30f3c7381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e15cefb0-5db4-4098-b246-090a52167e7a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_LocalPhoneNumber_e15cefb0-5db4-4098-b246-090a52167e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_df4c4e38-4c6d-4661-84f0-ad8db204922e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityCurrentReportingStatus_df4c4e38-4c6d-4661-84f0-ad8db204922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a6b8f203-347f-4b21-b6e1-b9a8912516cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityInteractiveDataCurrent_a6b8f203-347f-4b21-b6e1-b9a8912516cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1a35b818-5c8b-4374-9fc2-ece2ff62cc19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityFilerCategory_1a35b818-5c8b-4374-9fc2-ece2ff62cc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a81ab975-2a20-4051-9671-389241dc261b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntitySmallBusiness_a81ab975-2a20-4051-9671-389241dc261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8c15da71-3b71-4fcb-8731-593728cf79d5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityEmergingGrowthCompany_8c15da71-3b71-4fcb-8731-593728cf79d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_b1a55e86-0fcd-46a9-83a0-9d7c91fc0f4b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityExTransitionPeriod_b1a55e86-0fcd-46a9-83a0-9d7c91fc0f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_322d9288-d305-410e-b272-9fb6de55eda2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityShellCompany_322d9288-d305-410e-b272-9fb6de55eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_30af52df-a698-4cf9-91b2-8a8aa87d5ed5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_Security12bTitle_30af52df-a698-4cf9-91b2-8a8aa87d5ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e654b98e-ab00-4c58-a350-811d48fda45f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_TradingSymbol_e654b98e-ab00-4c58-a350-811d48fda45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_60abd49b-4388-4519-9729-077b618f0c01" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_SecurityExchangeName_60abd49b-4388-4519-9729-077b618f0c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bef8892a-d885-44de-81cf-6c38276fe519" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bef8892a-d885-44de-81cf-6c38276fe519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_67f0197a-fee5-4677-a58b-0b225d03fb01" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_EntityCentralIndexKey_67f0197a-fee5-4677-a58b-0b225d03fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8cf0c8aa-dd8f-465f-8631-017c14346fb8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentFiscalYearFocus_8cf0c8aa-dd8f-465f-8631-017c14346fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e94b37f1-033d-41fb-809e-e5627698a263" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e94b37f1-033d-41fb-809e-e5627698a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cd535eda-55ba-4062-a224-88a3f6e1c44f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_AmendmentFlag_cd535eda-55ba-4062-a224-88a3f6e1c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f44a2557-a3a4-422e-8c8a-dcf1cb7e421d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9406cbc1-dfda-4b27-95ab-36d1eec37907" xlink:to="loc_dei_CurrentFiscalYearEndDate_f44a2557-a3a4-422e-8c8a-dcf1cb7e421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_22ac5ebc-a154-4e9e-8b56-c20efc249460" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22ac5ebc-a154-4e9e-8b56-c20efc249460" xlink:to="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_abced249-c337-46b5-9b77-2b4768c070d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:to="loc_us-gaap_AssetsCurrentAbstract_abced249-c337-46b5-9b77-2b4768c070d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96114afb-dc28-4dc3-85eb-5d5fc803d3d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_abced249-c337-46b5-9b77-2b4768c070d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96114afb-dc28-4dc3-85eb-5d5fc803d3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c9d3672-d5b3-4afb-b6c2-f177a5a1594d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_abced249-c337-46b5-9b77-2b4768c070d9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c9d3672-d5b3-4afb-b6c2-f177a5a1594d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bea24807-6ff8-4d31-9a91-b94030c85703" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_abced249-c337-46b5-9b77-2b4768c070d9" xlink:to="loc_us-gaap_AssetsCurrent_bea24807-6ff8-4d31-9a91-b94030c85703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cf4d2e32-1f62-4439-9046-1c88e69d4f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cf4d2e32-1f62-4439-9046-1c88e69d4f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e4754ba8-fcd5-424d-ba00-c033fb5d7a17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e4754ba8-fcd5-424d-ba00-c033fb5d7a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_73c6cbdd-665b-4aed-88f8-37d9fbffc819" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_73c6cbdd-665b-4aed-88f8-37d9fbffc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5a9b26c7-e3e5-45f1-ae85-ff36ca706444" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9fffea27-b60a-48a3-a009-03c8772f9359" xlink:to="loc_us-gaap_Assets_5a9b26c7-e3e5-45f1-ae85-ff36ca706444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22ac5ebc-a154-4e9e-8b56-c20efc249460" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_96155088-8389-4f88-8c84-51cfd44eef66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:to="loc_us-gaap_AccountsPayableCurrent_96155088-8389-4f88-8c84-51cfd44eef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c7d41aba-6888-485d-a4a0-1890679ba317" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c7d41aba-6888-485d-a4a0-1890679ba317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_d78be3a7-96ea-48d9-8b1a-574f3143af36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_d78be3a7-96ea-48d9-8b1a-574f3143af36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_47819b4b-a037-4f46-a922-3b2157691195" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbee7235-8e8c-4701-a652-2d77b1f6dcbc" xlink:to="loc_us-gaap_LiabilitiesCurrent_47819b4b-a037-4f46-a922-3b2157691195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9910231-8f08-40a6-a814-c3b951cddbe5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9910231-8f08-40a6-a814-c3b951cddbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_9b6f3cd9-2601-42ca-95cb-3e7311fc2d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_9b6f3cd9-2601-42ca-95cb-3e7311fc2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_aad14fb2-5943-4be2-81fa-998b2ca3072a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_aad14fb2-5943-4be2-81fa-998b2ca3072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_004472ec-af77-4050-994a-2c45ee3a8d78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_Liabilities_004472ec-af77-4050-994a-2c45ee3a8d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cbd5c79f-28ff-4166-8f31-aaad3d83e608" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cbd5c79f-28ff-4166-8f31-aaad3d83e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_30519cba-a6ea-435c-983c-c139437a1432" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_PreferredStockValue_30519cba-a6ea-435c-983c-c139437a1432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dcadb62e-bdcc-4382-af04-b3914ab6972f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_CommonStockValue_dcadb62e-bdcc-4382-af04-b3914ab6972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_69754563-bfe5-415b-8926-520d496d1dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_69754563-bfe5-415b-8926-520d496d1dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociBeforeTaxAttributableToParent_aa466e2b-b0c7-4b0d-84c3-0c6e4475c402" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociBeforeTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_AociBeforeTaxAttributableToParent_aa466e2b-b0c7-4b0d-84c3-0c6e4475c402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59dc5900-9285-42da-b676-8f68578b4b01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59dc5900-9285-42da-b676-8f68578b4b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_847cf7e2-83e1-4c51-b1a4-17562b3899e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15a30f35-230c-43cc-98ad-88099a441e9c" xlink:to="loc_us-gaap_StockholdersEquity_847cf7e2-83e1-4c51-b1a4-17562b3899e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f11918-36be-4d05-b2f2-6394a05f291b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9a6e0264-3810-41c3-9fe4-08126420b49d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_26f11918-36be-4d05-b2f2-6394a05f291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_678d9743-227e-4824-b61c-0ce7e318ec76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_678d9743-227e-4824-b61c-0ce7e318ec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_698d764f-7ea2-40ad-aab2-099dfbc4bd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_698d764f-7ea2-40ad-aab2-099dfbc4bd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_321b9ae3-ce09-4411-be28-1af87f523023" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_321b9ae3-ce09-4411-be28-1af87f523023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5a25fa65-be43-4ee0-b555-5715d67ecd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5a25fa65-be43-4ee0-b555-5715d67ecd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3ca8e07c-f9c7-4f65-9eaf-c90c10942628" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3ca8e07c-f9c7-4f65-9eaf-c90c10942628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bfc9bdfb-514c-402a-9855-c50a81bc1216" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bfc9bdfb-514c-402a-9855-c50a81bc1216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1251c57f-a194-472f-8d7f-0f87059a0926" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_CommonStockSharesIssued_1251c57f-a194-472f-8d7f-0f87059a0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_05e4614c-41f1-4409-9666-fd2b3e6abc61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_292d462a-babc-4896-a602-2fe6f3e6de8c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_05e4614c-41f1-4409-9666-fd2b3e6abc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f88581f7-4b2d-4bdc-b4b9-dd918d7d2fec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_Revenues_f88581f7-4b2d-4bdc-b4b9-dd918d7d2fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8e2b679-6960-4052-9ba6-8392d17fa37f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8e2b679-6960-4052-9ba6-8392d17fa37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_80c0815e-e732-484d-89f9-9f159150452f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_80c0815e-e732-484d-89f9-9f159150452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_210d43b0-2e23-4bc5-9f56-a7f78903b848" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_210d43b0-2e23-4bc5-9f56-a7f78903b848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a54d1431-0b1b-44b8-b059-47142f956130" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5688fce3-b5ed-4c19-a74d-859b1cfb9758" xlink:to="loc_us-gaap_OperatingExpenses_a54d1431-0b1b-44b8-b059-47142f956130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85ad2334-687e-4685-a9e8-706332f7f23c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_OperatingIncomeLoss_85ad2334-687e-4685-a9e8-706332f7f23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dece9ed2-a30a-4cfb-8906-b5a35550e3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dece9ed2-a30a-4cfb-8906-b5a35550e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d0fcfb9f-ec46-4c58-a6e9-a93f3036634d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dece9ed2-a30a-4cfb-8906-b5a35550e3bf" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d0fcfb9f-ec46-4c58-a6e9-a93f3036634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_81021b72-2380-43db-917b-e4dc75ae3a86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dece9ed2-a30a-4cfb-8906-b5a35550e3bf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_81021b72-2380-43db-917b-e4dc75ae3a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5b751ae3-d065-492c-8647-c051c5b45da4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dece9ed2-a30a-4cfb-8906-b5a35550e3bf" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_5b751ae3-d065-492c-8647-c051c5b45da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_34893c81-3b8b-46b1-9f68-dddaae644ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_34893c81-3b8b-46b1-9f68-dddaae644ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2c046852-9b2c-4cfe-a8ea-10ce7dae1878" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2c046852-9b2c-4cfe-a8ea-10ce7dae1878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_280b5d13-b48c-4438-8c75-0a157a6b1268" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_NetIncomeLoss_280b5d13-b48c-4438-8c75-0a157a6b1268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_bd1f9e95-8e2c-4626-a086-cc36a4e66fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_bd1f9e95-8e2c-4626-a086-cc36a4e66fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8cfc0f86-6dc6-4cab-8fc7-cc675ab3618f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8cfc0f86-6dc6-4cab-8fc7-cc675ab3618f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_cf5c9885-07d9-4eb0-977c-775863e67c92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_cf5c9885-07d9-4eb0-977c-775863e67c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_37a9fb5e-f4f1-402a-aa88-b3f64118d06a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_cf5c9885-07d9-4eb0-977c-775863e67c92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_37a9fb5e-f4f1-402a-aa88-b3f64118d06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_36999e60-785c-4b74-8d1b-af3c599c2c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8d884e7-dabe-4284-a565-be1444fa6bfc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_36999e60-785c-4b74-8d1b-af3c599c2c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_077c8524-d621-4361-a585-74d221b228b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_077c8524-d621-4361-a585-74d221b228b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd66e84c-49cb-4d62-9c55-1c65ccc5e778" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_077c8524-d621-4361-a585-74d221b228b0" xlink:to="loc_us-gaap_NetIncomeLoss_fd66e84c-49cb-4d62-9c55-1c65ccc5e778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_077c8524-d621-4361-a585-74d221b228b0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fa79f060-5890-4b77-be9b-a7fc8586f1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fa79f060-5890-4b77-be9b-a7fc8586f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_36b8e193-ec53-4c51-86c1-710f9e6d3f37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_ShareBasedCompensation_36b8e193-ec53-4c51-86c1-710f9e6d3f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_b847a784-e03b-4e66-8d3a-f9164449b883" xlink:href="mbx-20190930.xsd#mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement_b847a784-e03b-4e66-8d3a-f9164449b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a08aeb7b-571c-4382-b650-1655e454cc34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a08aeb7b-571c-4382-b650-1655e454cc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7f161ba2-ee9d-4158-b963-8c127ce3223f" xlink:href="mbx-20190930.xsd#mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7f161ba2-ee9d-4158-b963-8c127ce3223f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_dffec762-bb11-4fb7-9615-b4db4678c5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_dffec762-bb11-4fb7-9615-b4db4678c5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8166c075-ec09-451f-b8f0-8804df88ece4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8166c075-ec09-451f-b8f0-8804df88ece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_051e6785-18a4-424d-916d-ae1a1bd09535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_051e6785-18a4-424d-916d-ae1a1bd09535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30ada07e-0acd-4262-9c55-3dba26bac2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30ada07e-0acd-4262-9c55-3dba26bac2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ad90d954-ea33-4f11-a518-86a49564dd49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_275072ec-c425-4ee5-b32e-07c6e73f2c99" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ad90d954-ea33-4f11-a518-86a49564dd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c4e2ec0-b83b-4917-b31a-55e0ce9ea8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f86cd3a-26e7-4e4a-af6c-3643305054b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c4e2ec0-b83b-4917-b31a-55e0ce9ea8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e78957bf-bf7a-4d81-ba37-d4ca07f89358" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e78957bf-bf7a-4d81-ba37-d4ca07f89358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6fe0e1a4-1864-4527-b4bd-7463187da2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e78957bf-bf7a-4d81-ba37-d4ca07f89358" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6fe0e1a4-1864-4527-b4bd-7463187da2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88c34dfc-6c1f-49c1-be04-b4a91626edc4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e78957bf-bf7a-4d81-ba37-d4ca07f89358" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88c34dfc-6c1f-49c1-be04-b4a91626edc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5f82bb67-8459-4724-a64a-d0b172588a14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5f82bb67-8459-4724-a64a-d0b172588a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d6b1d932-a106-4b05-9b80-7cde0d1f3dae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d6b1d932-a106-4b05-9b80-7cde0d1f3dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f1ee867d-e17f-420f-9a6d-8864ff058df4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f1ee867d-e17f-420f-9a6d-8864ff058df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5142cf64-b74b-4a0b-ad4f-5e6a75ac0320" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0c9c54eb-eccf-4f70-b350-49637f939fe0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5142cf64-b74b-4a0b-ad4f-5e6a75ac0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9055c52e-065c-4fa1-8181-a2581e944c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9055c52e-065c-4fa1-8181-a2581e944c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa325239-dbd1-441e-b2d9-c1eb5adf7f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aa325239-dbd1-441e-b2d9-c1eb5adf7f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2490325b-44e9-49d1-a0a7-dc0421dd1bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2490325b-44e9-49d1-a0a7-dc0421dd1bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e09c8dcf-f1a3-4253-bde8-9b7584601453" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e09c8dcf-f1a3-4253-bde8-9b7584601453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd4d09d4-162e-45ac-9913-cfc5322f3121" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2244ebf3-0254-4e40-9740-9038d5e39ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:to="loc_us-gaap_InterestPaidNet_2244ebf3-0254-4e40-9740-9038d5e39ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_4938ee0b-35dc-40d4-be34-f73787cd858d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_4938ee0b-35dc-40d4-be34-f73787cd858d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_fc23eeae-3b8c-4068-bda6-3f35aa2c3420" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_fc23eeae-3b8c-4068-bda6-3f35aa2c3420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LeaseholdImprovementsPaidByLandlord_c665870d-b325-4f9b-8c0e-d67b3204669d" xlink:href="mbx-20190930.xsd#mbx_LeaseholdImprovementsPaidByLandlord"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:to="loc_mbx_LeaseholdImprovementsPaidByLandlord_c665870d-b325-4f9b-8c0e-d67b3204669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesIssuedInLeiuOfCash_1d1b1411-296f-4bb6-b26a-e5bd39d6d9b2" xlink:href="mbx-20190930.xsd#mbx_SharesIssuedInLeiuOfCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b6ff16d2-0919-4a1f-b3ce-cb003daba68c" xlink:to="loc_mbx_SharesIssuedInLeiuOfCash_1d1b1411-296f-4bb6-b26a-e5bd39d6d9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d79858b2-a24c-4070-937f-ecbce73058d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d79858b2-a24c-4070-937f-ecbce73058d3" xlink:to="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5fddd2d-09c9-40f1-84e7-3015542ad7b8" xlink:to="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_713a16e1-a4f1-4989-bc7d-5bb4745ef8be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_CommonStockMember_713a16e1-a4f1-4989-bc7d-5bb4745ef8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_39db7a28-fcdb-43f4-8f32-8d5545aee09b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_39db7a28-fcdb-43f4-8f32-8d5545aee09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f688320-fd3c-46ba-acb7-b1fc34721b47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_RetainedEarningsMember_4f688320-fd3c-46ba-acb7-b1fc34721b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_456c2b4e-b257-4a18-9736-a5324c6ba7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6995e91e-d159-495a-b3fc-a7ef1892f1d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_456c2b4e-b257-4a18-9736-a5324c6ba7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_69dfbb5a-dc21-4a07-beaf-bc938a5c03eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019IssuanceMember_4dc32f6f-6526-43e1-940e-43d98bc312c6" xlink:href="mbx-20190930.xsd#mbx_March2019IssuanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_March2019IssuanceMember_4dc32f6f-6526-43e1-940e-43d98bc312c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LincolnParkSaleMember_835174d1-de9c-4b91-97d7-b1bec480c878" xlink:href="mbx-20190930.xsd#mbx_LincolnParkSaleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_LincolnParkSaleMember_835174d1-de9c-4b91-97d7-b1bec480c878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_a01e21cc-f1f0-48d7-8cd9-1963b9acfef8" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_AprilOfferingsMember_a01e21cc-f1f0-48d7-8cd9-1963b9acfef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018IssuanceMember_4ba87168-9616-4120-b675-dc087d874d27" xlink:href="mbx-20190930.xsd#mbx_June2018IssuanceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_June2018IssuanceMember_4ba87168-9616-4120-b675-dc087d874d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenceRightsMember_476e5ba0-9c14-417a-ba68-b31b9cac942e" xlink:href="mbx-20190930.xsd#mbx_LicenceRightsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a0eab3f-3436-4b51-a867-671005e1ba24" xlink:to="loc_mbx_LicenceRightsMember_476e5ba0-9c14-417a-ba68-b31b9cac942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18091617-784d-48c3-a3d1-52a47ce45b57" xlink:to="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7faf1868-ebb0-43f0-9dad-a316a8ae6699" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e25fe320-83e4-4af9-ae54-c75301b4d966" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockholdersEquity_e25fe320-83e4-4af9-ae54-c75301b4d966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1590759c-b2c8-4b21-930b-b6f1c9a9602e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_SharesOutstanding_1590759c-b2c8-4b21-930b-b6f1c9a9602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b42158f5-41cd-4213-ba08-4fffb4776485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b42158f5-41cd-4213-ba08-4fffb4776485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f36e2be-0db9-45ab-b6d3-2c59b254b0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f36e2be-0db9-45ab-b6d3-2c59b254b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27a518f9-758a-40c3-897b-2ea4264a6b22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27a518f9-758a-40c3-897b-2ea4264a6b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52ea275-06d3-4b58-92e4-7af4a2042145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b52ea275-06d3-4b58-92e4-7af4a2042145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40403b99-c701-4735-87a2-17cb545e8039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40403b99-c701-4735-87a2-17cb545e8039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cbb05997-ebde-41af-9f1d-96855862a3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_NetIncomeLoss_cbb05997-ebde-41af-9f1d-96855862a3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_658bfc18-9855-4e8f-bb9d-5229a36c3e70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_658bfc18-9855-4e8f-bb9d-5229a36c3e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_3110d769-0993-4bb1-9a78-eed3d640fdcf" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised_3110d769-0993-4bb1-9a78-eed3d640fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_14f56972-3aa4-4d81-95bb-666de11431b2" xlink:href="mbx-20190930.xsd#mbx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_mbx_StockIssuedDuringPeriodSharesWarrantsExercised_14f56972-3aa4-4d81-95bb-666de11431b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef4e3002-f08c-44b3-888e-3f470034bb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_StockholdersEquity_ef4e3002-f08c-44b3-888e-3f470034bb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4960d88b-5ccb-46a6-b325-68d00c87347e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd7ab030-b77a-496b-bfb1-fac16da41fdb" xlink:to="loc_us-gaap_SharesOutstanding_4960d88b-5ccb-46a6-b325-68d00c87347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mbx-20190930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7705c684-47ff-4fbb-84ed-65856b43c063" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e96cebb1-c961-43d9-9daf-520ec991d5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7705c684-47ff-4fbb-84ed-65856b43c063" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e96cebb1-c961-43d9-9daf-520ec991d5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidity"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a13e605a-ab12-4814-bc57-48782676bab2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NatureOfBusinessAndLiquidityTextBlock_92bb1cef-9943-4aa4-a741-4e57a2d42209" xlink:href="mbx-20190930.xsd#mbx_NatureOfBusinessAndLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a13e605a-ab12-4814-bc57-48782676bab2" xlink:to="loc_mbx_NatureOfBusinessAndLiquidityTextBlock_92bb1cef-9943-4aa4-a741-4e57a2d42209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#NatureofBusinessandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df702b09-a13f-4348-957f-3feb712c5cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df702b09-a13f-4348-957f-3feb712c5cef" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cdca327d-034a-45d1-98e2-1cead83a8b47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AnimalLifeScienceMember_e5927a61-b48c-4b74-ba18-8601850f8f04" xlink:href="mbx-20190930.xsd#mbx_AnimalLifeScienceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6961a71d-5647-47dd-b98e-5044ecaec132" xlink:to="loc_mbx_AnimalLifeScienceMember_e5927a61-b48c-4b74-ba18-8601850f8f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_689217a5-109a-40f9-b9fc-a1d254b7eb8f" xlink:to="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_4ddcb6e0-1ee2-4f1e-a9f5-12ff938daddf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3587813c-9ce1-4c02-94b5-20a7940bb4dd" xlink:to="loc_us-gaap_EuropeanUnionMember_4ddcb6e0-1ee2-4f1e-a9f5-12ff938daddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:href="mbx-20190930.xsd#mbx_AuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:href="mbx-20190930.xsd#mbx_AuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_AuthorityAxis_5ae7764a-a862-4ac7-b133-d32e6e42769b" xlink:to="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FoodAndDrugAdministrationMember_a83d605d-2cec-4d78-b3a8-cc4c8eca0e12" xlink:href="mbx-20190930.xsd#mbx_FoodAndDrugAdministrationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_AuthorityDomain_444b86bb-b0fc-4571-b5c8-22fa8a3044b2" xlink:to="loc_mbx_FoodAndDrugAdministrationMember_a83d605d-2cec-4d78-b3a8-cc4c8eca0e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_20606e0a-a18f-416f-8261-440dff70f947" xlink:to="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ac684ec-6c04-4064-8b73-aaaa1d4041e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ac684ec-6c04-4064-8b73-aaaa1d4041e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfDrugTechnologies_985898b2-b168-474b-a947-956b62634725" xlink:href="mbx-20190930.xsd#mbx_NumberOfDrugTechnologies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberOfDrugTechnologies_985898b2-b168-474b-a947-956b62634725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugCandidates_6f3f4400-de91-49d4-ba3c-30e5b9b2c171" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugCandidates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofDrugCandidates_6f3f4400-de91-49d4-ba3c-30e5b9b2c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofDrugsinClinicalTrials_df9151e4-16ca-49f8-9728-f74d4d2bebfa" xlink:href="mbx-20190930.xsd#mbx_NumberofDrugsinClinicalTrials"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofDrugsinClinicalTrials_df9151e4-16ca-49f8-9728-f74d4d2bebfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberofClinicalTrials_ee50b5b6-8d04-4a94-93f2-089d1aea735f" xlink:href="mbx-20190930.xsd#mbx_NumberofClinicalTrials"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberofClinicalTrials_ee50b5b6-8d04-4a94-93f2-089d1aea735f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_NumberOfOtherDrugDevelopmentProjects_697dba7e-1a69-49cb-b92a-307408553c81" xlink:href="mbx-20190930.xsd#mbx_NumberOfOtherDrugDevelopmentProjects"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_NumberOfOtherDrugDevelopmentProjects_697dba7e-1a69-49cb-b92a-307408553c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MarketExclusivityExtensionPeriod_3e222180-b7e7-4d48-af8b-32deae3f2b1b" xlink:href="mbx-20190930.xsd#mbx_MarketExclusivityExtensionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d57bb04d-bcda-4a20-b2ea-9f2559d53443" xlink:to="loc_mbx_MarketExclusivityExtensionPeriod_3e222180-b7e7-4d48-af8b-32deae3f2b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8af743aa-d005-41bf-850a-5a55717c0224" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dc735f13-e1b9-4178-bf5f-cece14e8ae64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8af743aa-d005-41bf-850a-5a55717c0224" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dc735f13-e1b9-4178-bf5f-cece14e8ae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_84fd047a-a2d0-4f9c-8f25-0d20bd07fb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_84fd047a-a2d0-4f9c-8f25-0d20bd07fb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b156b567-2f5a-4866-9d35-1eaa81d69e05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b156b567-2f5a-4866-9d35-1eaa81d69e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_85db6384-0a21-4866-acd0-c104b29aab5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_UseOfEstimates_85db6384-0a21-4866-acd0-c104b29aab5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GoingConcernPolicyPolicyTextBlock_95d89338-825b-461c-a406-514652e6db69" xlink:href="mbx-20190930.xsd#mbx_GoingConcernPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_mbx_GoingConcernPolicyPolicyTextBlock_95d89338-825b-461c-a406-514652e6db69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cf92c2ad-deef-4728-bade-48de2135cde0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cf92c2ad-deef-4728-bade-48de2135cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f7540d22-293f-4253-bb6a-43759a25537e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f7540d22-293f-4253-bb6a-43759a25537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_55170864-9f53-4f2c-a0ab-5709f9b19d35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_55170864-9f53-4f2c-a0ab-5709f9b19d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock_a9737d3e-1e23-495f-aac9-ec95bc7369f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_LessorLeasesPolicyTextBlock_a9737d3e-1e23-495f-aac9-ec95bc7369f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMethodInvestmentsPolicy_aab8ef51-f968-4161-8666-c49c2a6d4eda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostMethodInvestmentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_CostMethodInvestmentsPolicy_aab8ef51-f968-4161-8666-c49c2a6d4eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9539a83a-6d5a-4d20-868e-e4e33eaec086" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9539a83a-6d5a-4d20-868e-e4e33eaec086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2b124bb7-1289-4e6a-ad69-575e98b8d1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2b124bb7-1289-4e6a-ad69-575e98b8d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3243fb0a-e425-4cd7-a3c8-00dd9584a4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3243fb0a-e425-4cd7-a3c8-00dd9584a4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d2a91e6-c9d3-425f-933b-123a553117b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f64c626a-b681-4385-807f-31c04e0ac65b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d2a91e6-c9d3-425f-933b-123a553117b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_53cef68b-15ab-4f0b-bacb-8afdd4280ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0fd62fe7-cbb3-4c80-8d63-e2528462258a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53cef68b-15ab-4f0b-bacb-8afdd4280ef2" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0fd62fe7-cbb3-4c80-8d63-e2528462258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b7839253-5930-4e6b-87f1-963f6b80bb55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53cef68b-15ab-4f0b-bacb-8afdd4280ef2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b7839253-5930-4e6b-87f1-963f6b80bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c5f8d3c3-2a65-48ad-b43b-22e4f4cbcbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53cef68b-15ab-4f0b-bacb-8afdd4280ef2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c5f8d3c3-2a65-48ad-b43b-22e4f4cbcbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_dfc71988-e7b0-45db-a0be-4ff546141e70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:to="loc_us-gaap_NumberOfOperatingSegments_dfc71988-e7b0-45db-a0be-4ff546141e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a1d576b-525c-404c-938c-31fe7843b2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2a1d576b-525c-404c-938c-31fe7843b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments_3d55207c-bc16-4e7f-9b7f-a23d73e361a6" xlink:href="mbx-20190930.xsd#mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:to="loc_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments_3d55207c-bc16-4e7f-9b7f-a23d73e361a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74ee5eed-d99d-4ec6-9700-b3b794b3ec2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74ee5eed-d99d-4ec6-9700-b3b794b3ec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4afc7d82-cc08-49cc-9792-419f930a9d93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb87fb3-a5d0-4b1b-9a69-1ad1d6196b74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4afc7d82-cc08-49cc-9792-419f930a9d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_000b15c9-11f0-454c-b733-8c2333614ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_000b15c9-11f0-454c-b733-8c2333614ebb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_VendorPrepaymentAndDeposits_21ce5acc-d7b1-40f3-842e-87d013751070" xlink:href="mbx-20190930.xsd#mbx_VendorPrepaymentAndDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:to="loc_mbx_VendorPrepaymentAndDeposits_21ce5acc-d7b1-40f3-842e-87d013751070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_4ad9cb18-5c38-44a9-9ce3-3078836dd80b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:to="loc_us-gaap_PrepaidInsurance_4ad9cb18-5c38-44a9-9ce3-3078836dd80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5a43d9fe-410c-4806-ace9-f893f45e9536" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5a43d9fe-410c-4806-ace9-f893f45e9536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_04eaad09-4e9d-4a2c-a027-2d5cb3e287db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_04eaad09-4e9d-4a2c-a027-2d5cb3e287db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9331baeb-6fb7-4b92-bae4-c8d2a7e33c53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_f9d2ec30-575e-4ad6-a081-890ca6479d5c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9331baeb-6fb7-4b92-bae4-c8d2a7e33c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d11ca03-7846-4532-801d-a742609cb891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d11ca03-7846-4532-801d-a742609cb891" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b30f7801-2087-43a5-aa91-ece0a71bd905" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfc310a1-5be1-4d2a-9615-13876b1b8d27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c0c547-da31-4c8c-996e-2edafec96d9f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfc310a1-5be1-4d2a-9615-13876b1b8d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4982f14-581b-48e6-8a01-f4b3b797343d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75b2a286-8b63-4ae9-8706-8e2d9dec5326" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75b2a286-8b63-4ae9-8706-8e2d9dec5326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac38f83b-af02-463d-a1e5-cbb0dd85e7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac38f83b-af02-463d-a1e5-cbb0dd85e7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b1c3f8b1-41e4-4a90-931d-b177fae7710d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894bd58f-b927-4824-9617-64b332c598f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b1c3f8b1-41e4-4a90-931d-b177fae7710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_718f797e-dacc-4456-b54b-e1c94a249c10" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_09b84b37-f81a-4bca-98d7-6f6b6c3929da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_771e3aec-ecf0-4b83-bbe0-73444074207e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_09b84b37-f81a-4bca-98d7-6f6b6c3929da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a65ec07e-9efa-4b84-9d06-9b77ee9f8b26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a65ec07e-9efa-4b84-9d06-9b77ee9f8b26" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3911331-5f5a-4d11-9c68-6721ff6606b5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e81fb93a-42c4-4fb8-a60a-eeecb2ed070a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bbd4da7-73c9-4333-89a5-d4617d684f11" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e81fb93a-42c4-4fb8-a60a-eeecb2ed070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_75916638-d19c-4159-b337-ace98097e5ea" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityCurrentMember_d4f9ce0c-16f2-4359-b3fb-cc89e820f603" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabilityCurrentMember_d4f9ce0c-16f2-4359-b3fb-cc89e820f603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityLongtermMember_1043a20c-2d0d-4803-b21c-f78a93cc1b6f" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityLongtermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabilityLongtermMember_1043a20c-2d0d-4803-b21c-f78a93cc1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabiltyMember_90ae52e6-9edf-4083-b382-318192da4c5d" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabiltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9d98f04c-01dc-44bb-8840-73db9737037d" xlink:to="loc_mbx_WarrantLiabiltyMember_90ae52e6-9edf-4083-b382-318192da4c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_55724f53-ec59-4ea8-af6c-a00009b36ec0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceb7fd2f-ec51-41da-96f4-cc738c33423d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618f8d64-1933-4571-9721-97a02552f202" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618f8d64-1933-4571-9721-97a02552f202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_e0b05852-3748-4212-acab-5ca3e055383f" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_e0b05852-3748-4212-acab-5ca3e055383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_96d1befb-9654-4be3-acf5-f2899d126219" xlink:href="mbx-20190930.xsd#mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises_96d1befb-9654-4be3-acf5-f2899d126219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_cee8fa9e-89a0-46d9-8d92-6e30dac08a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_cee8fa9e-89a0-46d9-8d92-6e30dac08a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_0336ca2e-3c42-4e3a-a4c8-e81fc2032608" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_0336ca2e-3c42-4e3a-a4c8-e81fc2032608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2728908-fa4e-44eb-89ae-c4096a8ebd01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_98156549-ab1a-4d0e-bdc3-713a2506401c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e2728908-fa4e-44eb-89ae-c4096a8ebd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5b1015f8-83e6-491e-bf17-77801c6c43e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_89e830b2-d88b-47fe-b69d-26e2cdf8057b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5b1015f8-83e6-491e-bf17-77801c6c43e1" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_89e830b2-d88b-47fe-b69d-26e2cdf8057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3145fcd5-5a4e-4b53-924c-29bb11626f90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_42028244-00c5-4048-b674-ad769e7ef89e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3145fcd5-5a4e-4b53-924c-29bb11626f90" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_42028244-00c5-4048-b674-ad769e7ef89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedClinicalTestingCurrent_00bdd181-f9a7-486e-84fe-5335b9403996" xlink:href="mbx-20190930.xsd#mbx_AccruedClinicalTestingCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_mbx_AccruedClinicalTestingCurrent_00bdd181-f9a7-486e-84fe-5335b9403996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_81dd4fbf-52bc-4fd1-b0c6-f9303aaf94cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_81dd4fbf-52bc-4fd1-b0c6-f9303aaf94cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_563f531f-7dfe-4987-9b09-4755900520d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_563f531f-7dfe-4987-9b09-4755900520d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_33734cc8-73b6-4187-af99-8be8e369a75c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_33734cc8-73b6-4187-af99-8be8e369a75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_31d23953-f114-473e-ad08-c334a0907503" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_31d23953-f114-473e-ad08-c334a0907503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedLicenseFeesAndSRACurrent_9f8fb05c-26a2-495b-9594-91b9db94674c" xlink:href="mbx-20190930.xsd#mbx_AccruedLicenseFeesAndSRACurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_mbx_AccruedLicenseFeesAndSRACurrent_9f8fb05c-26a2-495b-9594-91b9db94674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AccruedDrugManufacturingCost_fd815aab-d923-4560-9b0f-3652c7c0b539" xlink:href="mbx-20190930.xsd#mbx_AccruedDrugManufacturingCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_mbx_AccruedDrugManufacturingCost_fd815aab-d923-4560-9b0f-3652c7c0b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d5bb445e-7fe1-490a-b379-a85bc8e907ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea0a390-0dea-43d2-abef-584090f64d03" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d5bb445e-7fe1-490a-b379-a85bc8e907ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiability"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityAbstract_d6c3d42d-cfef-47b4-9058-97ba5c403deb" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock_8e53e8b9-bbf0-4157-a3ac-0d499ed47f64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_WarrantLiabilityAbstract_d6c3d42d-cfef-47b4-9058-97ba5c403deb" xlink:to="loc_us-gaap_ProductWarrantyDisclosureTextBlock_8e53e8b9-bbf0-4157-a3ac-0d499ed47f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityAbstract_8b29174f-45af-49ce-929f-7878f072fdb7" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ScheduleOfWarrantActivityTableTextBlock_da0e9166-684c-410a-83a2-16c0b21bc9e7" xlink:href="mbx-20190930.xsd#mbx_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_WarrantLiabilityAbstract_8b29174f-45af-49ce-929f-7878f072fdb7" xlink:to="loc_mbx_ScheduleOfWarrantActivityTableTextBlock_da0e9166-684c-410a-83a2-16c0b21bc9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ScheduleOfAssumptionsUsed1TableTextBlock_58772548-0fdf-4787-b69c-17d37e5d54dd" xlink:href="mbx-20190930.xsd#mbx_ScheduleOfAssumptionsUsed1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_WarrantLiabilityAbstract_8b29174f-45af-49ce-929f-7878f072fdb7" xlink:to="loc_mbx_ScheduleOfAssumptionsUsed1TableTextBlock_58772548-0fdf-4787-b69c-17d37e5d54dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityAbstract_76ee69e3-54c8-40f6-9aad-26c8f35c9ead" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_WarrantLiabilityAbstract_76ee69e3-54c8-40f6-9aad-26c8f35c9ead" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3796752c-8014-4d0b-93a7-070cd58543c8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_8484b831-879a-4053-b744-4a50397f5833" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:to="loc_mbx_AprilOfferingsMember_8484b831-879a-4053-b744-4a50397f5833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019RegisteredDirectOfferingsMember_334e3be9-ab93-4ef8-8980-91b49caf11c7" xlink:href="mbx-20190930.xsd#mbx_March2019RegisteredDirectOfferingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a59ae0e8-2f1b-4846-83bf-c301288730f1" xlink:to="loc_mbx_March2019RegisteredDirectOfferingsMember_334e3be9-ab93-4ef8-8980-91b49caf11c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25be4e38-6eeb-443e-97db-a478f02c7544" xlink:to="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_932f1611-03f2-427f-912e-c2ee41769e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:to="loc_us-gaap_WarrantMember_932f1611-03f2-427f-912e-c2ee41769e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8fdecb52-f958-4ea6-942b-34e97b21c064" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeea5b63-9198-4c0a-bbfc-510cd9be5e74" xlink:to="loc_us-gaap_CommonStockMember_8fdecb52-f958-4ea6-942b-34e97b21c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_138a8ad1-a991-45b3-8ba3-493f47219c8d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwitersMember_ea3225f3-80a8-4c98-a4c4-2b8a8b7917be" xlink:href="mbx-20190930.xsd#mbx_UnderwitersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fb63cb-acbb-4780-b7a8-0706d65675d5" xlink:to="loc_mbx_UnderwitersMember_ea3225f3-80a8-4c98-a4c4-2b8a8b7917be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ae96be7-a1d3-4590-83ab-fa7f94ccfdd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c82ad31-23b1-43b6-9a2f-69f665b58071" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c82ad31-23b1-43b6-9a2f-69f665b58071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ec021c4-ae39-4c54-9e65-73cda29f36aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ec021c4-ae39-4c54-9e65-73cda29f36aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5412bad3-332f-4637-bfc7-9eccf6875085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5412bad3-332f-4637-bfc7-9eccf6875085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f70bb21-5d6f-4efb-aad8-fe7a31bd37f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f70bb21-5d6f-4efb-aad8-fe7a31bd37f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b08b02e5-2dd8-4349-9c6d-d69e5ab1e90f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2815d774-0206-4a71-8774-a09899ce2e38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b08b02e5-2dd8-4349-9c6d-d69e5ab1e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WarrantLiabilityAbstract_f778d679-b6e4-49e7-943b-498295a3ca15" xlink:href="mbx-20190930.xsd#mbx_WarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_WarrantLiabilityAbstract_f778d679-b6e4-49e7-943b-498295a3ca15" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_744ce802-103f-439a-9591-41ee8d224e0f" xlink:to="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_710d31e3-0297-4bce-989c-16b1aabe8688" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8e85f15e-dc84-411a-bbb8-7ede264825d8" xlink:to="loc_us-gaap_WarrantMember_710d31e3-0297-4bce-989c-16b1aabe8688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:to="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d14bfc91-7011-4dd8-b4d4-2d3ec59f1d50" xlink:to="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4da9bb43-3049-45c6-bba9-6385ce2855ce" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:to="loc_srt_MinimumMember_4da9bb43-3049-45c6-bba9-6385ce2855ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99bd64f9-8768-4d7c-9101-e569917437e7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a93dc365-a788-4f48-b6fe-a87e6906f474" xlink:to="loc_srt_MaximumMember_99bd64f9-8768-4d7c-9101-e569917437e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd09028d-5121-47d7-9637-15229b811b66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b35da78-c919-4864-a10f-fcd2c58c1d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b35da78-c919-4864-a10f-fcd2c58c1d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5757a27e-0311-445a-98da-f8237f1b9ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5757a27e-0311-445a-98da-f8237f1b9ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_a1fe134e-952a-46a7-9844-09bc932c61dc" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_a1fe134e-952a-46a7-9844-09bc932c61dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_8f42dff3-282d-493d-a44d-63374834e5f4" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_8f42dff3-282d-493d-a44d-63374834e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65fc4eff-2bcb-406a-8d4b-4d58187db50e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0c42434b-3494-4133-b234-2093275d82a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65fc4eff-2bcb-406a-8d4b-4d58187db50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_05284b44-3a30-4997-a4b5-217c4f3bfce6" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_05284b44-3a30-4997-a4b5-217c4f3bfce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7858dfb9-ed00-4fbc-a7f4-981d979e0b73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7858dfb9-ed00-4fbc-a7f4-981d979e0b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_831cf080-ad98-4cc9-9545-8ce0ac670e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_831cf080-ad98-4cc9-9545-8ce0ac670e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_fd48d358-81ba-47a6-ae9e-da3a748a8410" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod_fd48d358-81ba-47a6-ae9e-da3a748a8410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a95abe70-d2f1-4982-bc1b-b0cbe7af358a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dc7d249c-ab55-4322-acd4-834f53d8f23b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a95abe70-d2f1-4982-bc1b-b0cbe7af358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_8429deb7-ef08-4851-bee9-5b50367ca2d5" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_8429deb7-ef08-4851-bee9-5b50367ca2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_eefc59d6-69a9-47e4-b9b0-6f78de903165" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_eefc59d6-69a9-47e4-b9b0-6f78de903165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4ee44b32-9c3e-49fd-959d-20545794332f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4ee44b32-9c3e-49fd-959d-20545794332f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_1e666b10-2b31-48f7-85ad-3880edd122e1" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_20ba6b2e-d133-48a5-8f89-03f146d1681d" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_1e666b10-2b31-48f7-85ad-3880edd122e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fafc04-e402-45e1-9f2d-955d05379c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8f82f9f8-ee82-4b80-b202-e70d390766ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8f82f9f8-ee82-4b80-b202-e70d390766ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_749aeffd-b5e5-4b6d-8fea-df9cbb4f3acc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_749aeffd-b5e5-4b6d-8fea-df9cbb4f3acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a345630c-2a34-41bb-8456-16a8976e290c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a345630c-2a34-41bb-8456-16a8976e290c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed254dc8-55be-494c-9591-f3cad039c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6562789a-c448-4044-bd97-31fae18d8de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed254dc8-55be-494c-9591-f3cad039c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:type="simple" xlink:href="mbx-20190930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_afe60b0b-5089-4f88-93c0-7e599d708538" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2f2ddbd6-6cf1-45a9-9b71-822430938cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_afe60b0b-5089-4f88-93c0-7e599d708538" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2f2ddbd6-6cf1-45a9-9b71-822430938cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db64ff52-04f1-4d61-8079-3bc3e984cbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15208fb7-4015-4c59-8b46-fd23bc212b62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db64ff52-04f1-4d61-8079-3bc3e984cbe0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15208fb7-4015-4c59-8b46-fd23bc212b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9ceec807-13c3-4e79-a4ec-d49afb601e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db64ff52-04f1-4d61-8079-3bc3e984cbe0" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9ceec807-13c3-4e79-a4ec-d49afb601e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ComponentsofShareBasedCompensationTableTextBlock_48005684-9e5d-49b6-9519-b34fee2ddecf" xlink:href="mbx-20190930.xsd#mbx_ComponentsofShareBasedCompensationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db64ff52-04f1-4d61-8079-3bc3e984cbe0" xlink:to="loc_mbx_ComponentsofShareBasedCompensationTableTextBlock_48005684-9e5d-49b6-9519-b34fee2ddecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6f09ead5-f149-4ad4-90cf-68e669f0eab0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6f09ead5-f149-4ad4-90cf-68e669f0eab0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5db22c07-824f-45bc-81db-3f81ac727e9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LincolnParkSaleMember_a6149849-215e-40df-9da4-39b0c1e23863" xlink:href="mbx-20190930.xsd#mbx_LincolnParkSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_LincolnParkSaleMember_a6149849-215e-40df-9da4-39b0c1e23863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AtMarketIssuanceSalesAgreementMember_4a7b8264-fe30-40ea-92c0-b3ee7bac1e84" xlink:href="mbx-20190930.xsd#mbx_AtMarketIssuanceSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_AtMarketIssuanceSalesAgreementMember_4a7b8264-fe30-40ea-92c0-b3ee7bac1e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SecuritiesPurchaseAgreementMember_915a4475-4590-4ed0-b3f3-9da511ddd50d" xlink:href="mbx-20190930.xsd#mbx_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_SecuritiesPurchaseAgreementMember_915a4475-4590-4ed0-b3f3-9da511ddd50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_June2018RegisteredDirectOfferingMember_8de348f6-0030-418a-8ffa-56d38947e194" xlink:href="mbx-20190930.xsd#mbx_June2018RegisteredDirectOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_June2018RegisteredDirectOfferingMember_8de348f6-0030-418a-8ffa-56d38947e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_March2019RegisteredDirectOfferingsMember_f412c9ba-6c5e-4fb5-813e-602709614500" xlink:href="mbx-20190930.xsd#mbx_March2019RegisteredDirectOfferingsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_March2019RegisteredDirectOfferingsMember_f412c9ba-6c5e-4fb5-813e-602709614500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_AprilOfferingsMember_bf4ce24d-a8c2-41da-a665-89bbbe7c30b4" xlink:href="mbx-20190930.xsd#mbx_AprilOfferingsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9945da67-a141-4c0e-b711-a975e87d7aaf" xlink:to="loc_mbx_AprilOfferingsMember_bf4ce24d-a8c2-41da-a665-89bbbe7c30b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_61e530cd-34c2-4b40-b5bd-d7ce999d50b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentSharesMember_104a5b21-d6fb-4d8c-bb7c-6ebc1d2a58f5" xlink:href="mbx-20190930.xsd#mbx_CommitmentSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:to="loc_mbx_CommitmentSharesMember_104a5b21-d6fb-4d8c-bb7c-6ebc1d2a58f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:href="mbx-20190930.xsd#mbx_TheWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5a305b12-fdc2-4feb-ae85-5ec9bbb91477" xlink:to="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantOneMember_eaa14e2b-f68c-4caf-bb67-16ff4d171108" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_GSKConsultingAgreementWarrantOneMember_eaa14e2b-f68c-4caf-bb67-16ff4d171108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_GSKConsultingAgreementWarrantTwoMember_7e5ebe81-2016-4d90-87fd-361a35c7b657" xlink:href="mbx-20190930.xsd#mbx_GSKConsultingAgreementWarrantTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_GSKConsultingAgreementWarrantTwoMember_7e5ebe81-2016-4d90-87fd-361a35c7b657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingAgreementWarrantThreeMember_c23b6d31-1235-4c11-ad5a-35207e68f0b6" xlink:href="mbx-20190930.xsd#mbx_ConsultingAgreementWarrantThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_TheWarrantsMember_e673590a-a465-4aad-8f23-fcdd8750e204" xlink:to="loc_mbx_ConsultingAgreementWarrantThreeMember_c23b6d31-1235-4c11-ad5a-35207e68f0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_59e7043e-4dfd-4f78-a299-3115e7849746" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_f0f9a6c2-8eae-457f-8437-0afe993bc1ba" xlink:href="mbx-20190930.xsd#mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember_f0f9a6c2-8eae-457f-8437-0afe993bc1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OppenheimerCoIncMember_d1eb75f2-3652-402e-869a-7721791c089a" xlink:href="mbx-20190930.xsd#mbx_OppenheimerCoIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_OppenheimerCoIncMember_d1eb75f2-3652-402e-869a-7721791c089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnderwriterMember_ade9c382-20ab-4cb8-807c-7bf5138ab3b3" xlink:href="mbx-20190930.xsd#mbx_UnderwriterMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3db85045-3a8c-4ad7-9f7a-a393b7d601fb" xlink:to="loc_mbx_UnderwriterMember_ade9c382-20ab-4cb8-807c-7bf5138ab3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a3624e1-3e20-4f39-b352-bd8db5cdd3f8" xlink:to="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ec84724-c6b9-434a-97ed-779e58b5d8a1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:to="loc_srt_MaximumMember_0ec84724-c6b9-434a-97ed-779e58b5d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2dbe00c4-9b85-42b4-b39f-1c3b720a3888" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82308ca1-e779-4b2a-aa7e-856753fb5fc7" xlink:to="loc_srt_MinimumMember_2dbe00c4-9b85-42b4-b39f-1c3b720a3888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_611685f1-610d-479a-b107-91d45bdf7c11" xlink:to="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8dab511b-b0aa-40f0-b43a-7fd371bbfc53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ada856c0-a867-497a-adad-b7bfd90ddb4e" xlink:to="loc_us-gaap_CommonStockMember_8dab511b-b0aa-40f0-b43a-7fd371bbfc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5a2b5289-b094-4422-999b-8df1e68f4f6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_StockPlanMember_9df7c5df-0a1b-4c71-80b2-881b21f90cfb" xlink:href="mbx-20190930.xsd#mbx_StockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_mbx_StockPlanMember_9df7c5df-0a1b-4c71-80b2-881b21f90cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f9b9870-89be-4870-a1e0-6444381cff52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f9b9870-89be-4870-a1e0-6444381cff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4355a54f-590c-429d-9eee-89eb09f71a91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9fa5060-5b35-449d-88b1-9a647a78d3ec" xlink:to="loc_us-gaap_WarrantMember_4355a54f-590c-429d-9eee-89eb09f71a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b481a001-2968-4963-bca3-48a8c868f818" xlink:to="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharesAuthorized_b1af8c65-5533-4e50-92a5-0b09033bc91a" xlink:href="mbx-20190930.xsd#mbx_SharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SharesAuthorized_b1af8c65-5533-4e50-92a5-0b09033bc91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c89efa6d-179d-4164-b534-035d0608c153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c89efa6d-179d-4164-b534-035d0608c153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c2b9cc99-0160-469c-873e-3614b43bb192" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c2b9cc99-0160-469c-873e-3614b43bb192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d85f6a0f-004c-43c8-ada5-de1adbd476d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d85f6a0f-004c-43c8-ada5-de1adbd476d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_d6bbdb3d-3b32-477a-8cf6-4330e40923f1" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction_d6bbdb3d-3b32-477a-8cf6-4330e40923f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3a88aa0-2152-4dd1-b96c-f22ef891214b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3a88aa0-2152-4dd1-b96c-f22ef891214b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_84dbdbc7-8b35-4050-94c5-b28e6890f0df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_84dbdbc7-8b35-4050-94c5-b28e6890f0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_56c0b9ae-15c1-4650-a89f-d260239e923c" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_56c0b9ae-15c1-4650-a89f-d260239e923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_29c39285-ea3c-404c-83d4-d295aeb567d3" xlink:href="mbx-20190930.xsd#mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds_29c39285-ea3c-404c-83d4-d295aeb567d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5d175249-2e22-4dfe-9a6c-6a3d6990d279" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5d175249-2e22-4dfe-9a6c-6a3d6990d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7112bc97-391b-4674-a003-3518aa95b97b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7112bc97-391b-4674-a003-3518aa95b97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_cc1d79ab-8eb7-455c-98d6-bb845f1b261b" xlink:href="mbx-20190930.xsd#mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue_cc1d79ab-8eb7-455c-98d6-bb845f1b261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef508d11-4ef7-4750-b800-d4fd131213ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef508d11-4ef7-4750-b800-d4fd131213ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_25c7d578-d737-48d0-a07e-7b1e37f0e059" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_25c7d578-d737-48d0-a07e-7b1e37f0e059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_114dfb61-56ac-4a94-b00a-50e5f1478f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_114dfb61-56ac-4a94-b00a-50e5f1478f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adad86d9-8712-412d-9d71-3fcb04d151e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adad86d9-8712-412d-9d71-3fcb04d151e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4bf4f03-2dfb-4f58-9d08-2b613b3677fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4bf4f03-2dfb-4f58-9d08-2b613b3677fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65008a68-7aff-45a1-abc8-3c0d650ef41f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65008a68-7aff-45a1-abc8-3c0d650ef41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d28cdb66-c31b-42b5-9f41-223abe4bc94f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d28cdb66-c31b-42b5-9f41-223abe4bc94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ba9695a-3b20-4586-a62b-452f7706f5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ba9695a-3b20-4586-a62b-452f7706f5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightAgreementPeriod_df2f1649-618f-4ecf-89f6-663e2f285bd8" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightAgreementPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightAgreementPeriod_df2f1649-618f-4ecf-89f6-663e2f285bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued_249607f9-0638-40d6-b9ae-621060092a3c" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightNumberofWarrantsIssued"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightNumberofWarrantsIssued_249607f9-0638-40d6-b9ae-621060092a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16277442-4249-4951-9336-e10ea087484f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16277442-4249-4951-9336-e10ea087484f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_49fc172c-5a15-4e9a-b96c-5fc71ce0e569" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_49fc172c-5a15-4e9a-b96c-5fc71ce0e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightVestingPeriod_aaf83513-2281-4669-9641-67eb19c0f479" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightVestingPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightVestingPeriod_aaf83513-2281-4669-9641-67eb19c0f479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassofWarrantorRightExpirationPeriod_bcb177af-7238-4d23-be0a-245335aca1a2" xlink:href="mbx-20190930.xsd#mbx_ClassofWarrantorRightExpirationPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassofWarrantorRightExpirationPeriod_bcb177af-7238-4d23-be0a-245335aca1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d42871a5-14b1-4f67-a4d7-eb19f0ff1181" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d42871a5-14b1-4f67-a4d7-eb19f0ff1181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightTerm_c0115c22-85d6-436f-952c-b95f63014c90" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightTerm"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassOfWarrantOrRightTerm_c0115c22-85d6-436f-952c-b95f63014c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ConsultingFees_9c79a7cc-3dd2-4479-861d-20bb18fd479b" xlink:href="mbx-20190930.xsd#mbx_ConsultingFees"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ConsultingFees_9c79a7cc-3dd2-4479-861d-20bb18fd479b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ec18e6f-0297-465c-bae0-3907e744ecd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ec18e6f-0297-465c-bae0-3907e744ecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6d0311dc-1949-427f-9fd4-1f302c59ede9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6d0311dc-1949-427f-9fd4-1f302c59ede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c11f9c54-c9d6-4f3e-a45c-b7993e1d3e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c11f9c54-c9d6-4f3e-a45c-b7993e1d3e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a349d383-014c-4fe1-9657-d207cf3cf45c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a349d383-014c-4fe1-9657-d207cf3cf45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod_407603a8-96a5-4836-a8f6-a62ae5003ff6" xlink:href="mbx-20190930.xsd#mbx_ClassOfWarrantOrRightInitialExercisePeriod"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_ClassOfWarrantOrRightInitialExercisePeriod_407603a8-96a5-4836-a8f6-a62ae5003ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitsSoldInPeriod_2f5c7efd-c2fa-435e-bee4-b902c7f9352b" xlink:href="mbx-20190930.xsd#mbx_UnitsSoldInPeriod"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_UnitsSoldInPeriod_2f5c7efd-c2fa-435e-bee4-b902c7f9352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ba811902-bf85-4923-85b8-9f615b6af618" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ba811902-bf85-4923-85b8-9f615b6af618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_UnitOfferingUnitPricePerShare_4efd9698-f492-4b5a-8441-3ae0c36ee172" xlink:href="mbx-20190930.xsd#mbx_UnitOfferingUnitPricePerShare"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f68fa4-5fe3-4a99-86a1-636033faf0c9" xlink:to="loc_mbx_UnitOfferingUnitPricePerShare_4efd9698-f492-4b5a-8441-3ae0c36ee172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofOptionActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d6163eb-6c8e-4b3e-b776-351fd65002ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d6163eb-6c8e-4b3e-b776-351fd65002ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2ee2a437-6f7d-460e-aed4-2af6588e777b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2ee2a437-6f7d-460e-aed4-2af6588e777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc9a09f2-0ff7-46c3-a42e-aa8beb2df20b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc9a09f2-0ff7-46c3-a42e-aa8beb2df20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04c6590a-042e-4c73-87fd-4826dafd6cca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04c6590a-042e-4c73-87fd-4826dafd6cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98f3a78b-55c1-429b-946e-7339a3c347f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c65f6a5-99cc-4880-9dde-c3f6b1869705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98f3a78b-55c1-429b-946e-7339a3c347f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f5e0727-2910-465d-a00b-af496428f5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f5e0727-2910-465d-a00b-af496428f5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_dd976da7-f588-45ce-a128-60f9cda245b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_dd976da7-f588-45ce-a128-60f9cda245b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bf1aec6f-7d59-4f2d-bfbf-56c5da61fa82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bf1aec6f-7d59-4f2d-bfbf-56c5da61fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_4d6fd2c4-6a1b-4cb1-8700-b11e0f2a8fd3" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_4d6fd2c4-6a1b-4cb1-8700-b11e0f2a8fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_031298cb-a0bc-4fc2-9de6-8eedca8fe164" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_031298cb-a0bc-4fc2-9de6-8eedca8fe164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e39aed3f-b14e-4ac7-bbf5-7c40c340b9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_d4700b16-d936-4220-90e9-510f3a27c002" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e39aed3f-b14e-4ac7-bbf5-7c40c340b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_dd600d85-7f01-437c-882a-564011290714" xlink:href="mbx-20190930.xsd#mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_dd600d85-7f01-437c-882a-564011290714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325cca9f-e69d-4685-8d80-3f95182fb929" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325cca9f-e69d-4685-8d80-3f95182fb929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d6f3823f-86b2-4ea2-a05b-3fccdc5286ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d6f3823f-86b2-4ea2-a05b-3fccdc5286ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca3fa79-e29f-4f71-a35f-f878e95a5a13" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca3fa79-e29f-4f71-a35f-f878e95a5a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d70ab4-f5c7-4101-ad9e-d3aefb1fb367" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d70ab4-f5c7-4101-ad9e-d3aefb1fb367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48a784a2-048c-4c60-a74d-fed4fb3b2fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2d6966fb-d2de-4009-b71d-ef549119e680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48a784a2-048c-4c60-a74d-fed4fb3b2fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4290f0e-3bff-43e5-aa7c-e602bd0d5418" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4290f0e-3bff-43e5-aa7c-e602bd0d5418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6384d822-cd21-4709-8a58-71fac9f711ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6384d822-cd21-4709-8a58-71fac9f711ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c46352d5-5a29-4efe-bc64-d1db786082c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c46352d5-5a29-4efe-bc64-d1db786082c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aaed2b53-f1f9-48b0-85a9-f5375c7de1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aaed2b53-f1f9-48b0-85a9-f5375c7de1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c2cd35b-2026-4151-b3d1-8240f9ebb550" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb61b294-fd0c-48dd-94a1-9c8c14cbd585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0c2cd35b-2026-4151-b3d1-8240f9ebb550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquitySummaryofAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_68a73ec2-a4d6-4079-93e0-864a15b9ec09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68a73ec2-a4d6-4079-93e0-864a15b9ec09" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:to="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_243bb974-8b74-4ae4-88e3-7ce4864baea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49276244-2e7f-4fa4-aed2-3ffff4ac59ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74ad45fc-e2b1-4bc5-921a-3ab8e7699667" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49276244-2e7f-4fa4-aed2-3ffff4ac59ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:to="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05842ca7-9fbd-493d-bba2-e011aa022f9f" xlink:to="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5c27ab4-c7b3-49db-ab6f-1a9a9e080eb5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:to="loc_srt_MinimumMember_d5c27ab4-c7b3-49db-ab6f-1a9a9e080eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_224f58a7-61dc-44d5-a1df-87f4eacea9de" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7320219-3621-45c6-951c-fd9942306a51" xlink:to="loc_srt_MaximumMember_224f58a7-61dc-44d5-a1df-87f4eacea9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40b5bc0a-1945-469a-8098-0a40da915222" xlink:to="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ee15d429-4a49-4eda-a4ff-591a8f8fe2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ee15d429-4a49-4eda-a4ff-591a8f8fe2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bb4b4b97-ea79-4b02-bacf-d2ce69f2de55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bb4b4b97-ea79-4b02-bacf-d2ce69f2de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_716b56ea-c5d6-4b92-9ed8-f6da491765e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_716b56ea-c5d6-4b92-9ed8-f6da491765e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ebedf878-6c20-477e-aa52-b4bc93d72b19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ebedf878-6c20-477e-aa52-b4bc93d72b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b74a55c-4142-4f92-a81c-ab0f50dd1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b74a55c-4142-4f92-a81c-ab0f50dd1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e897f3a7-46af-436b-ba88-e2a0c320af70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ae81d94-f833-435d-abb9-6dcd67d2ca4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e897f3a7-46af-436b-ba88-e2a0c320af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#EquityComponentsofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9da2840a-8933-48ce-ad48-c98fdf121307" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9da2840a-8933-48ce-ad48-c98fdf121307" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8c540580-260a-4033-87c1-b4778e031668" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e05b08-6f82-438d-8469-d308a60bd6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e05b08-6f82-438d-8469-d308a60bd6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a1ef325-2777-4098-9bc9-64dc5e89c21c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df9ab636-9d17-4000-9d64-234dd86c7af9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a1ef325-2777-4098-9bc9-64dc5e89c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20090869-9a37-494b-a4a8-9cc5bcfc20f2" xlink:to="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_081d4f9b-6894-4662-9052-d5455b0ed27f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94fa34c0-ddd9-42b7-bb2e-d672f41b1341" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_081d4f9b-6894-4662-9052-d5455b0ed27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7eb33eb9-5093-48e0-93c2-1b87d53e9840" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_442dde39-b5d8-4507-ad58-8845ff3fb10b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7eb33eb9-5093-48e0-93c2-1b87d53e9840" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_442dde39-b5d8-4507-ad58-8845ff3fb10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_360f1297-e5d2-4cbf-9600-227a6ba71e17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17e39469-4ffb-4b77-b72e-c5a9034292e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_360f1297-e5d2-4cbf-9600-227a6ba71e17" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17e39469-4ffb-4b77-b72e-c5a9034292e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ffa8850c-c94c-4aa6-8f2e-3e60eb3000ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_360f1297-e5d2-4cbf-9600-227a6ba71e17" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ffa8850c-c94c-4aa6-8f2e-3e60eb3000ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78323abd-eeed-4949-9640-dc237d4aae76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_544daf01-6ee2-45b7-832e-17f3274598b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78323abd-eeed-4949-9640-dc237d4aae76" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_544daf01-6ee2-45b7-832e-17f3274598b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d971606-6e30-47fd-a0b8-898032d2cf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_033a2793-e3a7-47e6-aab1-0c7ad9fc5543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d971606-6e30-47fd-a0b8-898032d2cf7c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_033a2793-e3a7-47e6-aab1-0c7ad9fc5543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0908158-3451-4026-a625-98ad95b1f0da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d971606-6e30-47fd-a0b8-898032d2cf7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0908158-3451-4026-a625-98ad95b1f0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70e642f3-56db-445f-a695-de196fbe7e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70e642f3-56db-445f-a695-de196fbe7e4c" xlink:to="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87d897df-c5b7-40a6-870a-4a5c5704076c" xlink:to="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5fa15689-0f9f-40eb-9c42-d6eb7dea27cf" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_232b0b3c-7c74-4582-a3b4-9c602b83cd33" xlink:to="loc_srt_MaximumMember_5fa15689-0f9f-40eb-9c42-d6eb7dea27cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_b0788c1b-a957-4de1-b61f-0271bedb71c0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember_469ebbff-dda1-4fe2-8e44-d5731533cd70" xlink:href="mbx-20190930.xsd#mbx_LeaseAgreementForCorporateOfficeSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_99e6dda0-a23e-488a-b05d-d3084d88b26f" xlink:to="loc_mbx_LeaseAgreementForCorporateOfficeSpaceMember_469ebbff-dda1-4fe2-8e44-d5731533cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_08e16f5a-aaf5-4ab0-a026-e24ba57ef25f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_IPXMemorialDriveInvestorsLLCMember_3df7c0da-62e5-42f6-95dc-95698b04ce15" xlink:href="mbx-20190930.xsd#mbx_IPXMemorialDriveInvestorsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_IPXMemorialDriveInvestorsLLCMember_3df7c0da-62e5-42f6-95dc-95698b04ce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OlympiaDriveWBellfortLLCMember_10e51109-d1eb-401a-952a-40ee76404c3f" xlink:href="mbx-20190930.xsd#mbx_OlympiaDriveWBellfortLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_OlympiaDriveWBellfortLLCMember_10e51109-d1eb-401a-952a-40ee76404c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_HoustonPharmaceuticalsIncMember_bc6edb6e-1894-4dc5-880d-0a2718d3e7e5" xlink:href="mbx-20190930.xsd#mbx_HoustonPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_HoustonPharmaceuticalsIncMember_bc6edb6e-1894-4dc5-880d-0a2718d3e7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MdAndersonMember_479db02f-b4fb-42f2-b34c-825b96801c57" xlink:href="mbx-20190930.xsd#mbx_MdAndersonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_MdAndersonMember_479db02f-b4fb-42f2-b34c-825b96801c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_DerminMember_6e46cb84-a4fa-4cb9-889b-89b480c0fd63" xlink:href="mbx-20190930.xsd#mbx_DerminMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_DerminMember_6e46cb84-a4fa-4cb9-889b-89b480c0fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WPDPharmaceuticalsMember_f94a7422-96b3-41fa-a950-46c89c5f1f8c" xlink:href="mbx-20190930.xsd#mbx_WPDPharmaceuticalsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e2c0a2c-d8ed-4852-8fc5-46964bfeb9e9" xlink:to="loc_mbx_WPDPharmaceuticalsMember_f94a7422-96b3-41fa-a950-46c89c5f1f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_c52e027c-4a2f-4ebe-ad27-9b3f0d4243d1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MdAndersonMember_d2355391-400c-45be-9b29-f26ca10fc819" xlink:href="mbx-20190930.xsd#mbx_MdAndersonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_90cc0d9c-6ca7-478e-b5c3-86832622f09f" xlink:to="loc_mbx_MdAndersonMember_d2355391-400c-45be-9b29-f26ca10fc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_41feed4a-e776-48ca-855c-e7bf16a8aabf" xlink:to="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_fda2223c-2691-42cd-aecc-1e6a84d99a26" xlink:href="mbx-20190930.xsd#mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_3e80282c-b2c7-4f7b-8906-00db8eb26b22" xlink:to="loc_mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember_fda2223c-2691-42cd-aecc-1e6a84d99a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ed6dd52-341f-4c35-b89c-c36f5c927232" xlink:to="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ae3373f1-f4f5-459a-ad2e-ac8320929123" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9551867b-bb40-48c2-a192-86e154982b1f" xlink:to="loc_us-gaap_LicenseMember_ae3373f1-f4f5-459a-ad2e-ac8320929123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_427d27aa-f2d7-4aa7-9aa1-8f328e02bce2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3d3fd9fa-53d6-4dcb-becf-203c8b709743" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ed7fe65-b658-43ea-acf9-b7685c0da40f" xlink:to="loc_us-gaap_SubsequentEventMember_3d3fd9fa-53d6-4dcb-becf-203c8b709743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_53462891-45c4-4585-94bb-02788ca1a566" xlink:to="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_WPDPharmaceuticalsMember_63c038b7-f515-443e-af84-d43cc43a1d35" xlink:href="mbx-20190930.xsd#mbx_WPDPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_19f0563e-7c62-4754-ab4b-d26340b3b475" xlink:to="loc_mbx_WPDPharmaceuticalsMember_63c038b7-f515-443e-af84-d43cc43a1d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:href="mbx-20190930.xsd#mbx_PeriodAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:href="mbx-20190930.xsd#mbx_PeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_PeriodAxis_d7f5b347-adf9-4f75-8bee-98340fa6eec5" xlink:to="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodOneMember_de85db21-80b3-4092-93fb-a6d5fa655f16" xlink:href="mbx-20190930.xsd#mbx_PeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:to="loc_mbx_PeriodOneMember_de85db21-80b3-4092-93fb-a6d5fa655f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PeriodTwoMember_91a2ec86-fb54-4579-b540-5b82032f3661" xlink:href="mbx-20190930.xsd#mbx_PeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_PeriodDomain_282f22b7-3fd1-494a-ac4e-579baca44937" xlink:to="loc_mbx_PeriodTwoMember_91a2ec86-fb54-4579-b540-5b82032f3661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:href="mbx-20190930.xsd#mbx_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesTable_ed14aaba-acef-403a-8a2a-282b9d966792" xlink:to="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_837fcc80-493b-47da-b6b5-51174b032ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_837fcc80-493b-47da-b6b5-51174b032ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_432101e6-9015-4b1b-8242-2614ef9311a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_432101e6-9015-4b1b-8242-2614ef9311a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_21ae1fad-64e8-40f3-83ab-89d96b0af1c9" xlink:href="mbx-20190930.xsd#mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_21ae1fad-64e8-40f3-83ab-89d96b0af1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfRentPayableByCoLessee_d364e7bc-6a2a-4a14-8182-47855332ec24" xlink:href="mbx-20190930.xsd#mbx_PercentageOfRentPayableByCoLessee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PercentageOfRentPayableByCoLessee_d364e7bc-6a2a-4a14-8182-47855332ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_5a0912c2-d82e-4711-8722-d7081bdc2901" xlink:href="mbx-20190930.xsd#mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee_5a0912c2-d82e-4711-8722-d7081bdc2901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_06b0e312-fd2c-4c9b-8e0a-2b24e1fb45ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_SubleaseIncome_06b0e312-fd2c-4c9b-8e0a-2b24e1fb45ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f7e0cb0e-a896-49d7-a84e-f6161eb65c46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseCost_f7e0cb0e-a896-49d7-a84e-f6161eb65c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_cc2b4c86-2d4e-471e-98c5-ca56ca2e6f00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_ShortTermLeaseCost_cc2b4c86-2d4e-471e-98c5-ca56ca2e6f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8d329e08-41c6-427e-b2e1-068d2f6f5eff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_VariableLeaseCost_8d329e08-41c6-427e-b2e1-068d2f6f5eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6914764d-5e89-4799-86ee-829537ae4076" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6914764d-5e89-4799-86ee-829537ae4076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d6b6b650-7656-49ea-89a6-e247e0856c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d6b6b650-7656-49ea-89a6-e247e0856c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f36cbbd4-825e-443b-9ad9-a70ef40a53e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f36cbbd4-825e-443b-9ad9-a70ef40a53e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_d75cceed-3bdf-4d6e-93e3-651b7aae349a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_d75cceed-3bdf-4d6e-93e3-651b7aae349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_45d56406-b74f-4585-968b-a471765fb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_45d56406-b74f-4585-968b-a471765fb6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_91a1d932-8d14-415e-8a1b-6239fd2e7834" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_91a1d932-8d14-415e-8a1b-6239fd2e7834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_160dfad0-2759-49c0-b308-b1c62d4bc68d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_160dfad0-2759-49c0-b308-b1c62d4bc68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3b1f4c8b-bd2d-4cff-adb3-239aad388442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3b1f4c8b-bd2d-4cff-adb3-239aad388442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicenseAgreementAnnualLicenseFee_cee16276-de12-4b06-8f53-c30c8789ef35" xlink:href="mbx-20190930.xsd#mbx_LicenseAgreementAnnualLicenseFee"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicenseAgreementAnnualLicenseFee_cee16276-de12-4b06-8f53-c30c8789ef35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_MilestonePaymentsLiabilities_496327e1-44ba-4048-ae50-bf0725af5b10" xlink:href="mbx-20190930.xsd#mbx_MilestonePaymentsLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_MilestonePaymentsLiabilities_496327e1-44ba-4048-ae50-bf0725af5b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_512f4c43-8984-431a-b291-446eec9d6cef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_PaymentsForRoyalties_512f4c43-8984-431a-b291-446eec9d6cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_041a5f46-164b-4e59-bcec-cc0cc274f1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_041a5f46-164b-4e59-bcec-cc0cc274f1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7078d3bc-90b6-4e64-a9c7-b2e7acf8d275" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7078d3bc-90b6-4e64-a9c7-b2e7acf8d275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_PaymentsForResearchAndDevelopmentAgreement_27b428bb-4b38-4939-aa17-356110b850e7" xlink:href="mbx-20190930.xsd#mbx_PaymentsForResearchAndDevelopmentAgreement"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_PaymentsForResearchAndDevelopmentAgreement_27b428bb-4b38-4939-aa17-356110b850e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensingAgreementTerm_241cc09b-813b-4f5a-8528-01c64174d2aa" xlink:href="mbx-20190930.xsd#mbx_LicensingAgreementTerm"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicensingAgreementTerm_241cc09b-813b-4f5a-8528-01c64174d2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4a5a3a2-a266-4f1f-8ed4-9a967b0a80a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4a5a3a2-a266-4f1f-8ed4-9a967b0a80a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_OptionRepurchasePayments_a69e900f-3923-4cd4-ad28-e271b141dbbd" xlink:href="mbx-20190930.xsd#mbx_OptionRepurchasePayments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_OptionRepurchasePayments_a69e900f-3923-4cd4-ad28-e271b141dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_e8c0dbc5-4fea-4569-a009-bf11e49f7f03" xlink:href="mbx-20190930.xsd#mbx_LicensedTechnologyFuturePaymentToRemoveCountry"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_LicensedTechnologyFuturePaymentToRemoveCountry_e8c0dbc5-4fea-4569-a009-bf11e49f7f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EquityDistributionCommitment_14cd3494-4761-4c28-bd92-77e01c49ad8b" xlink:href="mbx-20190930.xsd#mbx_EquityDistributionCommitment"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_EquityDistributionCommitment_14cd3494-4761-4c28-bd92-77e01c49ad8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab534414-1f13-4877-a685-311e1f2b2ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab534414-1f13-4877-a685-311e1f2b2ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_ResearchAndDevelopmentCommitment_b1ca97fd-62d4-4268-8e8d-227976279358" xlink:href="mbx-20190930.xsd#mbx_ResearchAndDevelopmentCommitment"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_ResearchAndDevelopmentCommitment_b1ca97fd-62d4-4268-8e8d-227976279358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_0d578a50-71d5-469a-912b-d76480f3ccd6" xlink:href="mbx-20190930.xsd#mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbx_CommitmentsAndContingenciesLineItems_01666189-90b6-45fd-996d-a383bab44bef" xlink:to="loc_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_0d578a50-71d5-469a-912b-d76480f3ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9d245e9-1f2d-447c-a2d3-9f047a0ef54d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_886f05cc-1680-4cf2-ae3c-1b80a0f4b895" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9d245e9-1f2d-447c-a2d3-9f047a0ef54d" xlink:to="loc_us-gaap_OperatingLeasePayments_886f05cc-1680-4cf2-ae3c-1b80a0f4b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9a6919ed-266f-4651-8d78-d728a7912bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9d245e9-1f2d-447c-a2d3-9f047a0ef54d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9a6919ed-266f-4651-8d78-d728a7912bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mbx-20190930.xsd#CommitmentsandContingenciesMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1600a70e-0cfe-4020-b9fa-9d871be63843" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1600a70e-0cfe-4020-b9fa-9d871be63843" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7f24a45a-118d-4ec1-bf26-ca0c70d64957" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7f24a45a-118d-4ec1-bf26-ca0c70d64957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b6229098-ff39-4252-ba7f-40e34650cc54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b6229098-ff39-4252-ba7f-40e34650cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b19382a3-94bd-4aaa-b45f-a6a5d53fce24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b19382a3-94bd-4aaa-b45f-a6a5d53fce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_934b3ea5-4b59-4cc1-9fe6-47debdf99bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_934b3ea5-4b59-4cc1-9fe6-47debdf99bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d38f50d5-d6ab-469b-aef9-c72d28b546c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d38f50d5-d6ab-469b-aef9-c72d28b546c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8f258dd-9e95-413d-821e-8ed88b2f459d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b8f258dd-9e95-413d-821e-8ed88b2f459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5573394-15bd-4c33-9ea2-576b240a3483" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5573394-15bd-4c33-9ea2-576b240a3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4a08e247-2aea-4d8e-9479-9e448508c1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4a08e247-2aea-4d8e-9479-9e448508c1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eca1a107-3189-4dec-b7bc-f4462382b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_021a6e73-cbf7-454b-9ac6-14f4d37a0eaa" xlink:to="loc_us-gaap_OperatingLeaseLiability_eca1a107-3189-4dec-b7bc-f4462382b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mbx-20190930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f86784e2-9f0d-43da-8b9e-50cae77a8741" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ba4c2ac0-f337-4162-a510-a5d9a0f2f160" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f86784e2-9f0d-43da-8b9e-50cae77a8741" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ba4c2ac0-f337-4162-a510-a5d9a0f2f160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>mbx-20190930_g1.jpg
<TEXT>
begin 644 mbx-20190930_g1.jpg
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M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
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M$0,1 #\ O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7S*57L)HY%:GWS6N5S?"CD14Z3+H\ Z(
M
M
M
M
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M\+'.3PEK\K9XRCG:T^.Y4Q"UOH41%<D;TXV5W=I$M)(U\$C&KX#.(YDZH
M
M
M
M
M
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MF]Q!WLYI'2*B?<MXE5&M3H:VC6IL1$0QP/8/%
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MDC3=QU-S1'1)@
M
M
M
M
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M'[^3%<;N9[O$I5J^65[GO=XW.55HG0FY$V(B(>.'H'F@
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MIN-96O(;S#W;%5B^4QU*\$C'(CXWHBU5CVM=3;2BH9E'.G2@
M
M
M
M
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M9E2+"\WNHUK5=2WN7;$]P>Y:LD<NZ"1RN6J)&^5:HDV(K<6@
M
M
M
M
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M.8]CDJUS7-54<U46J*BT5#[0^8^H
M
M
M
M
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M
M
M
M
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M%)6V%Q;3W28@UE5#DV%A-?,C43,2%$;>DR732DS[4),^A#\IYX+6%UQ<O9'
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M8-FS!H,P9?G9<X3<LXF/;]A6N1=K7M6K7L<B.8Y%:Y$5%0R0/'/;
M
M
M
M
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MRQ!\6R[A]G8PTHJ00QQ5_?*QJ*Y>E5<JJJ[555,H#Q#W@
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M -]IZ0?&?:
M
M
M
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MU$1$1.I$H?0'Y'[
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MR6NF<MT09S&FH
M
M
M
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MFQ%>ZG%([[Y[G.7I4RV/!.A
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MRKFV;L1%5?72P)1KEWOBX'^4YLKBP(*I%OP
M
M
M
M
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M:B-:B=2(B'VA\Q]0
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MO%K'<6[T5LEM<QT2:"1KD1R*UVUO$C5=&YCZ(CD-CAQYV@
M
M
M
M
M
M                                     'YVHD5AZ3)9C1V9$U;3DQ]I
MEMMZ6MEI$=E<EU"26^MIAM*$FLS-*"(B]!=!_;I'N:UCG*K&[D5=B56JT3HJ
MNW9TG\-CC:YSVM1'NIQ*B)5:)1*KTT38E>C8?H'\']@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\4DP7)^(_',3BMW3N9\7NHJ1->R-SN*>"-BT?(Q.%'*Y>*J)1%5-TA'))P
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M7:Y*THE5V&^(BXED
M                                              Q7NS=FL>.NL<FW
M'N/)ON/UOA_R-]T>1_(V09!\G?=!D%5BU1_Y1BU5=WTOUN^NXK'\!%=\/Q>]
M?:VE:T^YEO+>-9NQJ'+V7H?C&,7''V<?'''Q=G&Z5_ERN8Q*,8YWE.2M*)55
M1%\#-&:,"R9@4^9<RS_%L$MN#M)."23A[21D3/(B8^1:R/:WR6K2M5HU%5-
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M$KCN4KKXWA23.B5_9RQ>Z,1JN;PS1QOV(YNWAHM=BK13.8Y@ZL
M
M
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MN;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                          I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD
M9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^<1
MEC.53OJP[Y/=^;2%\49=FLH
M                                                    !%?YUWV9
M/)?^IK_,!JD3CRW=]&#?WOS&Z(#YG^XS'/[G_P PM"@>-4C(H      #IA<4
M?9;XU_0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J
M/I^U[^+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&
MV_T_;"_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
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M5K&YR4KLJ>Z'F'J@
M        !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\ "0%5.<3NEC]+V_P=P4C1
MI09<@            !T+O*DW@K?? KC_ )1-E%)R#%<6/5F4=5&N0BVUE)=Q
M*(_,7TZ.3+?'*Z!8+5Z>IS/3\;J0R8UURTF5M4L6LHV\-I//\9CZN&Y1)51/
M R1SXT_>&QG+_FE<VZ28/?RNXKRWM_BLO7QVRK"BN\+XVQR+^_ZR1(1&3*
M           %*WWA#?'\X7+K%],5TUUZET#@$&+8Q3<[H[.=;(1"RV\>92DS
M1\?$DX^VL_WQ.-+2?P=!H]RG97_1.0)\Q3-1+G%;MRM7I6"WK$Q%_P#-[=4\
M"HIF+SAYL_3.HL&687*MKA%FU')T)/<\,SU3_P GXNB]-45"!$6E*D
M      3\>[F^VWM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y3
M3<                                 *6_O&7MMZM_17PCZV]X#1KE"[
MM;[TY-YK9&9'.AWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[
MGL0_#VOG$98SE4[ZL.^3W?FTA?%&79K*
M
M  17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\ ,+0H'C5(R*
M     Z87%'V6^-?T Z<^KO'!C-GK_&^,^E;OSB0W"T^_P%@GHBS\WC,_#E3K
MR#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M "[E[O=[!MO]/VPOQ;P$9K\V7>C'Z*@^$G-1N3ONED]+W'P=N3G"LA:L
M                                                   UXW-RUXS<
M>FGE;HWGK37TQELG?D*[RFN/*Y#9I0OO@X?!=F958D2'$F?J\-WH2B,_A+KU
MN7<A9TS:Y$RYAE[=QJM.-D3NR3]]*Y$B;_">AQN9M0\C9.:JYGQ6QLY$2O9O
ME;VJI]["U5E=_!8N\B9W![POPZPKUJ'JK$MJ;KLF^_U6=%IHVOL0E=O4D]]K
MEKJ<KC>(?0R_\A7T3U,^A_%.><O\I>H6)<,F.7%CAL*[VJ]9Y4_@Q)V2^_I_
M]2O>8^<;3;"^*/ +?$,4G3<Y&);PK_#F7M4]X7_Z$7FUO>*^5.4'(BZGU7J/
M5%<]W^%+MD7VR,IB?&ZM>!9S9F-8TOM0?1?BTKG<?0R["ZD<V8%RB9&LJ/QV
M^O[^9-Z-X+>)>NK4223Q4F2GA('S!SFY^OZQY?P_#L/A7<K^TN94ZJ.<L47C
MK"M>BA'!LSS.^?>VE/EEG*7:<.-()2'8&"VT;5]<MA1G_J[L+6T/%&)#!I5V
MF3I+-9?OC4)AP7172O 43XA@=BYZ;G3M6Y=7K1;A951?%2G10A7'-==7<PJO
MZ0Q^_:Q=[8'I:MIU*VV;$BIXZUZ:FDMW?WN2V#MMD=U;9!:O$E+UG=V4RUL'
M4IZFE+LR>\_)<))J/H1J/IU$DVUK:V<206<<<4";FL:C6IXD:B(1==7=W?3+
M<7LLDUPN]SW*]R^-SE5?W3Y _<^<                    _7!GSJR6Q/K9
MDNOG1E^)&FP9#T27'7VFGO8D,+;>:7VJ,NJ3(^AC^)8HIHUBF:U\3MZ.1%1?
M&B[%/TBEE@D26!SF2MW.:JHJ>)4VH;>ZT\PKF]J)3!8+RBW)"BQ4-MQ:B]S"
MPS;'HR&B2E"&,;S=614#*"2@D]$QB(TET/T>@1_C.DVFF/HOZ3P3#G2.WO9$
MV&1:]<D/9O7^,2-@>L6J6753]%8]B38V[F23.GC2G5'/VD:?Q21O5/O"G-+#
M5QXVR<;U'N.M2M!RY5EC<W"<I=2@NAHBVF&V$'&HOB]3-1KI7SZ].WM+J1Q!
MCO*9ISB**_!YK_#INA&R)-$GC;,UTBT\$S?#4FG+_.+J=ABHS&X,.Q*#I5T;
MH)5\3H7-B2OAA=X*$G>G_>,.-N3^JP]S:?V?JB>]V(>L<:E4VS<7C*]!..R9
M2/N0R5MH_A)+-5*47P'U^$X5S!RAYQLN*3+N(65_$FYLB/MI%\")[K'7QRM0
MG3+G.?DF_P"&/,V&W^'S+O=$K+J)/"J^XRHG[V)RDL.EN?W#/D&<2/JKD5K2
M[N)Q-G%Q:VO$X;F;ZG$F9HCX=F;>/Y-*-DR[7#9BN(0HRZG\9/6"<QZ5:BY3
MXGX[A%[%;MWRM9VT*>.:%9(TKT5<BKZBE@\L:O::9QX68!C5C+<OI2)[^QF7
MQ0S)'*M.FC51.O:AN"(^)'
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M;_6WH\56YO>[6Q].0^:WI;KDO[T;_P! 3^=V)=(&<IIN
M                 %+?WC+VV]6_HKX1];>\!HURA=VM]Z<F\ULC,CG0[T;#
MT!!YW?$ XM25%     )>_(O^T?U%]ZNV?JVR00!S.=SV(?A[7SB,L9RJ=]6'
M?)[OS:0OBC+LUE
M                                            (K_.N^S)Y+_U-?Y@
M-4B<>6[OHP;^]^8W1 ?,_P!QF.?W/_F%H4#QJD9%       =,+BC[+?&OZ =
M.?5WC@QFSU_C?&?2MWYQ(;A:??X"P3T19^;QF?ARIUY!C[PC[!M1]/VO?Q;S
MX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER      !=R]WN]@VW^G[87XM
MX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M                            :]<D>5&B.).$1M@[\SN-A&/6-BJFI?\
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M$W<NV:5RIJ[A-R]W#9WDJV<O0BMN4[-E5Z$;-V3U5=B<)T%QD^;!@
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MM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y33<
M                     *6_O&7MMZM_17PCZV]X#1KE"[M;[TY-YK9&9'.A
MWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[GL0_#VOG$98SE4
M[ZL.^3W?FTA?%&79K*
M                                                17^==]F3R7_J
M:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H      #IA<4?9;XU_
M0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J/I^U[^
M+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&V_T_;"
M_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
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M'>)[.%R>!4-QLEYBAS;E+#<S04X+ZRBF5$]B][$5[/&Q_$Q?"U3- YPZ8
M       J ^\9[W^Z3=6FN/-7,=57ZQPV?GV41VE](J\IV%*;AU$64UUZKFTN
M,XXE]M73M2U<&1&9J41: \H65_B>6\1S;.U.UO;AL$:KO[*!*O5%ZGR2<*^&
M+P(9R<Z&;/CN9\,R; Y>QL;9UQ*B;NUN%HQ%3[ID4:.1>A)EIO4K>BX12D
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MQ[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                            I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWF
MMD9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^
M<1EC.53OJP[Y/=^;2%\49=FLH
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M;"<-/-/, TRP!<N9<6X=A[KA\RK,]KW\;VL:NUK&)2C$HE.O:;/CBCNP
M                                             "BUY\>9OYAYB>88
MZE;\E6M]=:LP6-'(GW#:^4L>3L9,6,A2"(R<?V"I?:UW)-;A^GO-1%ISRNX<
MW#]([>\5$:EY>7,ZKLV\,GQ>J^I!3;T)U4,IN;/$WXEK-<V2*KELK*U@1-NS
MBC^,T3QK<5V52J]=2// ^'G+#:"&7M?<;-Y99"D$TINUI]79G(HR1(0IR.MZ
M].G13QVWT(,T*<?2E9$?0S$M8IJ%D3!%5N+8SAD$B5\E]S"C]F^C./C6G31J
MT(<PG3?4''41V#X)BMQ$M/+9:S*S;M2LG!P)7HJY*]!N!AGDM>8_F9,/%Q_/
M%8#YH+U_,]@:WH39-:HW7QZ=65R,E;)#4CO,_43+HVM)=7"[#C_$>8W1_#JM
M_2W;RI[&&"X?7?N?V21[TIZ_I1=VTD?#.6/6K$Z._0_Q>%?937%M'3=O9VJR
M[EKZSH5/7;#9O%O=W>;=R3+V09OQ[P]A1$;\>=F.:6]JT:F%+2EN/1Z[FU;Q
MH?)*%]9J"(C-237T(CXN^YM]-;>K;2VQ:X=T*V*%C5V];[A')LVIY"]2T.YL
M.375&YHZ\NL'MF]*.FF>]-G4RW<U=NQ?+3K2IGN@]VOV;)2S]U/*?!*=2G(Q
M2"H-;9!DJ6FE$GUM;*K')\4-]Q@S5X:5$V3O0NY3?7T<K=<X^"L5?B.!W4B4
M6G'<1QU7HKPQRTKTKMIT(IUUIR28Z]$^/X_:1+5*]G;2243IIQ2Q5IT)LKTJ
MAEJK]VGQ=EM)7?+Z^L'2?[EKJ]*5].VJ-\3^"2U+V?>*0_Z%?PAK4GTE\3T>
MGP9^<J]<O^S9?B8VGLKQS]O75+9FSP4]4Z&#DAL&M_VK,<SW5]C9-8E.JBW3
M]OAKZA[ICW;?1:7V52N2&V7HR76SD-,8SA\9]U@ED;K;,AQ,IMAU;?4DK4TX
M23/J:5$70_,=SB9G5JHS![!'TV*LDJHB]%4V53P52O6AZS.2?*B/19,;Q!65
M2J)%"BJG2B+MHO4M%IU*>E_9P>+?].>_O_\ ;KO^10^+ZX.=_HS"OL7']L?;
M]2O(7TKB_P!FW_L#\D[W;[C2Y%=16[[WG$FGV>#(G,8#816^CB#<\6(QC%8Z
M]W-$I*>CZ.U1DH^I%VG^D7.%G)'HLV%88Z/I1JSM7U%61R)M^]7J\)^<O)5D
M=8U2#%\5;+T*Y+=R>&J)$U5V??)U[=QY.?[MEJ-R.::OD]L>'+[TFEZ?@>,V
M4<D$?QTG%CV]4X:U%\!^,1%_V&/OBYQL?1]9\$LW1]39Y&K]E6._T'GS<DN7
M7,I!CMZV3K=!$Y/L(]B_NF.KSW:1/20[C7,0R,B9]5@7FBR,C5W-ID'(MH&V
MB[2[>]2"3"/TD23/TFLO7MN<I=C;S+W75S+W[%&NM?$B^7X? >+=<D";76.9
M.JC7V/V:O;=^-4HSP>$PQDGNW7(2+XWW(<AM-7G:3_J_W24^;XKXJDMD<4GO
MDNLS+P">=ZI<-/B>&GXQ$L_BCH[/G#RF^GZ0PC$8MU>S?#+3KIQ.AK1-VZN[
M9O.9O>2C.,=?T;C.&2[Z=HR>*NS97A;-2J[]]$V[=QKSE7D ^8!CWB?)$336
M=]A]$GBNR5P_&+Q&D=S?W;X]AID7:X:_C]A]K:O1W=J5=;8\U>E-W3XP[$;6
MO]+;UIO_ *&2;Q;*[TZ*JG'8ARA:OV=?B[<,NZ?T5S2NU-W;QP]==M-B+TT1
M=4\U\J3S$,!2ZJ]XJ;'GDRCO66%+QO9*C(FD/=&D:ZOLJ4^OL<(NU!*5W=4]
M.Y)D7<X;KKI)BJHEKCMFVO\ 3=I;]--OQAD5/5Z-NXC_ !3E_P!9<(15N\OW
MKZ?T'9W/179\6DEKZG3LWHII[G&G=N:R<=9V3JS8^O7F'5,/-9Q@^38FXR^E
MPFE,NMWU7 4VZEU1)-)D1DH^GPB0<,S#@&-(CL&OK.[:J5189HY:IOJG YVR
MFTC?%<MYBP)RMQNPO;-R+14G@EB5%W47M&MVUV4,<#V#Q0
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MS?ZV]'BJW-[W:V/IR'S6]+=<E_>C?^@)_.[$ND#.4TW
M                "EO[QE[;>K?T5\(^MO> T:Y0N[6^].3>:V1F1SH=Z-AZ
M @\[OB <6I*B@    $O?D7_:/ZB^]7;/U;9(( YG.Y[$/P]KYQ&6,Y5.^K#O
MD]WYM(7Q1EV:R@
M                                           $5_G7?9D\E_ZFO\P&
MJ1./+=WT8-_>_,;H@/F?[C,<_N?_ #"T*!XU2,B@      .F%Q1]EOC7] .G
M/J[QP8S9Z_QOC/I6[\XD-PM/O\!8)Z(L_-XS/PY4Z\
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M45*HI=S"L6PO';"/%<&N(;K#9DJR6)[9&.3=L<U51:+L5*U145%HJ'K1\!Z
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M][M;'TY#YK>ENN2_O1O_ $!/YW8ET@9RFFX
M        4M_>,O;;U;^BOA'UM[P&C7*%W:WWIR;S6R,R.=#O1L/0$'G=\0#B
MU)44     E[\B_[1_47WJ[9^K;)! ',YW/8A^'M?.(RQG*IWU8=\GN_-I"^*
M,NS64
M                                   BO\Z[[,GDO_4U_F U2)QY;N^C
M!O[WYC=$!\S_ '&8Y_<_^86A0/&J1D4      !TPN*/LM\:_H!TY]7>.#&;/
M7^-\9]*W?G$AN%I]_@+!/1%GYO&9^'*G7@
M
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MOHU(9'>XS._J)EHBN5=T4B-DJO"SM**I,6*]%D@
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M);@;5I]2TTA;BOD/4V(4U&EHE=2;2SD=^WD^;M>"A1D79:))77JHC,DF5B\
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M1J5DK42S6[RE?PW+FMJ^+:R>/H]TA?21J5V(_A5CE]:YQLX.*.Z
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MYC6H?9XYCBR6&4%6J/HG;7*(M%2!';&LWHLSD5M=C&OV\-9-:N9' M-NTP#
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MJ9FYFS7F+.6*OQO,]W->8E)O?(M4:E57@8U*,C8BJO"R-K6-KL:AB<>Z<\
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MBIL5%1=J*B[%1=Q>V.2.:-LL3D=$Y$5%145%14JBHJ;%14VHJ;%0_0/X/[
MH=>>A]H_MW[U=3?5MC8U$Y8^Y[#_ ,/=><2&37-7WU8C\GM/-HR(03^5S
M  )^/=S?;;VE^BOF_P!;>CQ5;F][M;'TY#YK>ENN2_O1O_0$_G=B72!G*:;@
M       !ROQN&8'       7<O=[O8-M_I^V%^+> C-?FR[T8_14'PDYJ-R=]
MTLGI>X^#MR<X5D+5D5_G7?9D\E_ZFO\ ,!JD3CRW=]&#?WOS&Z(#YG^XS'/[
MG_S"T*!XU2,B@      .F%Q1]EOC7] .G/J[QP8S9Z_QOC/I6[\XD-PM/O\
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M%V0
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M$7Z?M;?C)"$<ZO\ ==C_ **N/@U).T7[VLN^E[;X1IT;1D$;1D6WG)Z)/>O
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MPS5K+'Q]J,@S%:\++NW1?6/5%X98T55<L,M%5BK56N1\:JY6<3I#A$A,@
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M3SS7,S[FY>Z2XD<KG.<JN<YSEJYSG+55<JJJJJJJJJU4_"/T/R
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M)?WHW_H"?SNQ+I SE--P        Y7XW#,#@      +N7N]WL&V_T_;"_%O
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M96%-B[H
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MG2B%=\>RYCV5[]V%YBL[BRQ!J5[.:-T;E3H<G$B<35Z'-JU>A5,<CUSQ0
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M5.O- _-,^SVY7?17/^<ZL2KH?WLX%\N;[5Q$6O?<[F#T>[VS3G=C6XQK
M   Z(GE9_9[<4?HK@?.=H,D=<.]G'?ESO:M-E-!.YW+_ */;[9QOX(J)=*FO
MO*O\=^)7WJ[=^=\ %\.3?]68]^'M?:3F>_.[^M,O?)[SV]N5B1=,HL
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MQH2S;W%O=PMN;5[);=Z5:YCD<UR=:.1514\**?0'Y'[
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MUS;7MM'>6<C);25B/8]CD<Q[')5KFN:JM<UR*BHY%5%1:HM#Z0_$_<
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MZVOH3<BCN/DB4N'+V1E-9*0MFVKV[1AV/40GT^ XN.Y+<0X@XBA2SF1UNO\
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M^0L6TVS==94Q;RY(51T<J(J-FA?MCE:FVG$FQS:KP2->SB56JIK(.T.&
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M1S=:AOS#G6/)5A)7!\';[HB>M?>2)5ZK38O91JV)*[6/69.E2 D6H*B@
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M,!Q_&<L8K%C> W$EMBD#JL>Q=OA146J.:Y-CF.16N38Y%38>+F'+N"9KPB;
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M\YU8E70_O9P+Y<WVKB(M>^YW,'H]WMFG.[&MQC6      !T1/*S^SVXH_17
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M27,;$LEDFRG?<3K65VUS%:OEV\BIO?&BHK741)&*CD3B1Z-BZ$VD#@
M7O?(NV8YL/R\]>U,F24N;JC,]@ZSE/&[XCQ-Q[O[MJF-(+O5X1P:#.(C#2>B
M>D=ML^A]>X\ON9S!4PG5J[N&)PQW]M!<HE-FUG8O5.OBDA>Y5V^4J^)-8N5/
M''8SHY9V[W<4N'W-Q;*M:K1']NQ%ZN&.=C439Y*)XUF#%?2QX
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M\TNG46<].Y<=M&(N.X(CKABHFUUO1/C,:^#@1)DV5XHD1*(YQ1:&G)E,
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MR'>XR\)-W;"JIZZ[+[:@3KS GV'/"FM9=G[Q8Y$L:]?>CMFXY6RY=LD^OH*
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MGR.5SE]5553<;"L,LL%PRWP?#6)%A]K R*)B;FQQM1C&^HU$0]2/A/O
M*W7O&6A(5_IC3O(ZM@-_=!KO,W=;9++8824B3AN<PIEI4/6$G]\J'C^4T7A1
MT'^]=NW3+]\8N'RA9JEM,QXAD^9R_%+NV2XC15V)-"J->C4ZY(GU<O5"WJ*4
M<Z&48KS+.&YU@8GQRRN5MI51-JPSM5[%<O5'+'1J=<[NLJ"#0 SE     )"_
M*NWL[Q]YVZ"RQZ647'\IRMG5F7DZM2(J\>V7TQ4Y$U2#)11J2ZGP[/K\!+@I
M,R-/4CB;7'*[<V:7XK8-;Q7<$"W,5-_:6_NM$\+V-?'XGJ3'H'FQV3]6,(Q!
MSN&SN+A+6:N[L[GW*KO Q[F2^-B=!T-1DJ;'&)-][:I]#Z4VKN:^)MRLUE@.
M49F[%<<\'Y2D453*FU].TY^Y)NK!MJ(R7PFZ\DOW1[V5L!N,T9DL<NVM4GO;
MJ.%%I7A1[D1SU\#&U<O@13GLVYAMLIY7Q#,UW18+&TEF5%6G$L;%<UB>%[D1
MB>%R',^S'++[/<NRK.LJG.6F3YID=YEF1V;O_BV-]D=G*N+B<[U,S\2783''
M%>GX5#9G#["UPJP@PRQ:C+*VA9%&U-S61M1C&IXFHB&'F)8A=XOB-QBM^]9+
MZZG?+(Y=[I)'*][E\;G*IYL?8?$     7I/(FT1'U)P5QS.)<-#&3[[R>_V/
M:/+093$X_"F.XCAD!;G0B7".IHEV3!%UZ?*BSZ]3,BS&YG\T/Q_4Z;#(W5LL
M*@9;M3H[14269WCXGI&[\$AJSRH939EW2F'%9&TO\7GDN7+T]FU5AA;^]X(U
MD;^%7K)G!74LP   $%OG_P"B(6Q^%\;;T:"VO)>/V<45VB>E*52DX;GMA7X/
MDM:V78IQ;#]W84TQWH9=B(!J/XI*,6<Y4\T2X/J,[ 'N5+/%K9[.'H[:!KIH
MW+X48V9B=:OIOH53YO<IQ8UIDW,;&(M]@]U&_BZ>QN'-@E:G@5[H7KU)'7=4
MI(C2<RZ     /UP)TRKG0[*ODNPY]=+CSH,MA9MOQ9D1Y$B-)967I0ZP\VE2
M3_<,A_$L4<T3H941T3VJUR+N5%2BHO@5-A^D4LD$K9X7*V9CD<U4WHJ+5%3P
MHNU#IZZFS=O9FJ]9['90VVUL#7^&9NTVRKO:;;RO'*V^0AI9D7<VA,\B2?3T
MD,5<>PU<%QR]P=RJKK2[FA6N_P!RD<S;_%-U<O8HW', L<::B(V\LX9T1-U)
M8VR;/XQ1Z\]#[1_;OWJZF^K;&QI=RQ]SV'_A[KSB0RRYJ^^K$?D]IYM&1""?
MRN8    !/Q[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I S
ME--P        Y7XW#,#@      +N7N]WL&V_T_;"_%O 1FOS9=Z,?HJ#X2<U
M&Y.^Z63TO<?!VY.<*R%JR*_SKOLR>2_]37^8#5(G'EN[Z,&_O?F-T0'S/]QF
M.?W/_F%H4#QJD9%       =,+BC[+?&OZ =.?5WC@QFSU_C?&?2MWYQ(;A:?
M?X"P3T19^;QF?ARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW
M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
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M4J.3X9>GI7U=%^2:_=)E?',+55X(;^&5$Z*S0JQ?L]@E=G0F_HLFBG)=H
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MLZUZT]5*G<X69781IG#@,+J3XK?QL<G7# BS/^Q*V!*=3M_0M)X:1&7X
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M3IE]3[%0><O %Q#3RRQZ)M9<.Q%J.7[F*X8YCE]65L">KOZZ8(T6,S
M           -ZN*_F/\ +CA_(A1=5;/L)V#QY#;TG5F<^-EFNY;2"Z+CQJ:;
M(1,QKU@B+Q'J:36R'.Q)*<422(1CGG1_(.H#'28Y9,;B:HJ)<PTBN$7K5Z)2
M2G0DS9&I5:(E25\@ZU:B:</;'@%^]^%-5%6UGK+;JG4C'+6*O2L+HW+1*JJ(
M6=>(7GU<:]VJK<2Y P3XX; DFU&3<6LY=SJ.XE*,D$XUF!1X\S$#>-*G%HN(
M[4&,CHD[!U0I9J!RMYRRTC[_ "H[],82E5X&MX+IB>&*JI+3<BQ.5[EV]DU"
M]&G/-KDC-"LP[.#/T+C#J)QO=QVCU\$U$6&N]4F:C&IL[9RDZ-5;55[60+JC
MLJ^YI[2*Q.K+:JF1K&LL8,EM+L:9 GQ''HLR+(:42D.-K4A:3(R,R%8IX)[6
M9UM<L?'<,<K7-<BM<UR;%1S5HJ*B[T5*H6LM[BWNX&75J]DMM(U'->QR.:YJ
M[4<UR*J*BIM146BGT!^1^P                            0?>95Y-^NN
M6+-YM_1K=+J_D634B?8-(81 P;;<DB-U3.6,14=E%ELE?7P[MAM1R%J-$YMX
ME(D1K+Z-\PV+Y#=%E_,RR7N4*HUJUXIK5-U8E7U\2=,+E\E-L2MHK'U9UNY:
M\%U";+F/*J16&<Z*YR4X8+M=])43^3E7HG:B\2[)4=5'LI>;,UCL#3><9#K;
M:.)7.$9SBTYRNO<<O8WJTV'(;/XKC:DJ<C3H,IOHY'E1W'8TIE2767%MJ2H]
M&,&QK"<Q89%C&"3QW.&3MXF2,6J*G^EKDW.:Y$<U:M<B*BH9E8Y@6,9:Q6;!
M,>MY;7%;=ZMDCD2CD7_0YJ[VN:JM<U4<U5144\&/4/)             ":;R
MF/-&M^&F7QM0[9FSKGC1G%XQZXXX[,FR]/7EB^33^98_#2;QNXS*<>\2[KF&
MS=<2GUN,2I"'&)E<M>=$;?43#US!@+6QYSMHEIL1$NV-2J0R+LI(E*0R*M$_
MDWT8J.CLYR]:\W.FF(MRYF%SY<CW4J<6U7+9O<M%FC3;6)56L\;4JM.T8BO1
M627AJ2[ILEIJK(L=M:Z]H+VNA6])=U$V/8U5O56,=N77V5;81''HLV#-BO)<
M:=;4I#B%$I)F1D8S0N;:XLKB2TNXWQ743U8]CT5KF.:M'-<U:*CD5%145*HN
MQ34ZUNK:^MH[VRD9+:2L:]CV.1S'L<E6N:Y*HYKD5%14545%JA]0?@?N
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M4VM5-J;=QX69N975#-N 766\8ELG89>1+'(C+=K7*U51=CD78NS>15"<B 0
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M+\6\!&:_-EWHQ^BH/A)S4;D[[I9/2]Q\';DYPK(6K(K_ #KOLR>2_P#4U_F
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M"-     "U![L]_SK?].'_'D4>YS/^F_^(?[B7YY'O^J/^&_[^6H!1TOP
M              &H//S3+G(#AER.U1%CG+ML@UC=V>-PR3WG,R_##8SC#8GP
MEV%*RK&X;9K+J:"5W$E1EVG(&E68DRIJ+@^.O7A@BO6-D7JBFK#,OJ12/6G3
MNJF\CG5W++LX:9XUE^-.*XFL7NC3KFAI/"GJRQL2O1OHNXYOHV#,5
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M;ADS-G]8W@^QY6WP5)3T1MOC6KF78MFS%8'[=WN;NT^SY.SJ6AT81D.;/
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M_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN        '*_&X9@<
M     !=R]WN]@VW^G[87XMX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H
M #IA<4?9;XU_0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O- _
M-,^SVY7?17/^<ZL2KH?WLX%\N;[5Q$6O?<[F#T>[VS3G=C6XQK       Z(G
ME9_9[<4?HK@?.=H,D=<.]G'?ESO:M-E-!.YW+_H]OMG&_@BHETJ:^\J_QWXE
M?>KMWYWP 7PY-_U9CWX>U]I.9[\[OZTR]\GO/;VY6)%TRBP    !OYY6GVA/
M%'Z5*_YMLQ%>M_=-COR%WMFDNZ"=\67_ $@WVKCHB#) V4        #G)>8W
M[>7+KZ?MD_C)-&OND'==@'HJW^#0Q<UH[VLQ>E[GX1QI8)&(Q     +4'NSW
M_.M_TX?\>11[G,_Z;_XA_N)?GD>_ZH_X;_OY:@%'2_
M  !S?^?>B?\ #9S%Y :@CQ40Z2@S^QML1CM-^&PSA&9-1\SPR,ST-3;GJ.-7
M\6.X:3Z>,RLNB3(TEL'I7FC]L=/<*S ]W%<RVC6RJN]9H56&95_?2,<Y/ J;
M]YBKJ[E/]B=2<8RXQO#:PWCGPHB;$@F1)H43][%(UJTZ47=N33\2 1P
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M=F/2K,+L$QMO:6CZNM[EK52*XC1?7-JJ\+VU1)(E571N5-KF.8]VFXD,C4
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M;S*LTR*N]>%[U8BK[%J)1$1$3<L1V26   %37WE7^._$K[U=N_.^ "^')O\
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ML%MJKE5/CSF,S=8M:R[C2B<?0RY8GW$M/*1$I'(CFT1O KI1!"1/
M  !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER
M  ;I^7)[>7$7Z?M;?C)"$<ZO]UV/^BKCX-23M%^]K+OI>V^$:=&T9!&T8
M !SZ?-ST2>@N?&\J:'!.%C6PKEG<F)]&TLL/UNRDN7=V4)A!FAB#6YS\KP&4
M)Z(0B(1))*>B2U?T"S1^U6EF&7$CN*\M(UM)>E4=;^0RJ]+G0]D]57:JNVU7
M:8^<Q.4_V1U<Q6VC9PV-Y*EY%T(K;FKW\*=#6S]M&B)L1&;$1-A&J)D(1
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M?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
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M2OB3AJO@J2CHG<_%-6\NRU1*XM;LV[O='I'3QKQ43PT.C,,A3:
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M2/IG"ORNW_M!_E]GWZ$Q?\CN/[,?X4>4GYM>_O['-B?R<#]NLD?3.%?E=O\
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MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\                    &FOF
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M,F!9MP>''LN7,5WA,[:LD8NSPM<BT<Q[5V/8]&O8M4<U%2ADL>,>X
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ME-R_==2^(]_*F*)@>:<-QI5HEGB%O/7J[*9DE=Z?<]:>,Z=@Q8-T@
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M6PI;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD9D<Z'>C8>@(/.[X@'%J2HH
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M)QTK]E43U2S/*5(QFLENURT<^QND3PKV?%3["*OJ%Z09C&K
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M !^';LJJ=-"UG)U.L.K,L:.1O:X/<-IL\JDMN^B?Q.+9MHU>BI=N&;!J*
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MARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW>V:<[L:W&-8
M    '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?]'M]LXW\$5$NE37
MWE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46     -
M_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M!SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_  :&+FM'>UF+TO<_".-+!(Q&(
M !:@]V>_YUO^G#_CR*/<YG_3?_$/]Q+\\CW_ %1_PW_?RU *.E^
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M+\L:FX3\0QN/@OXT7L+EB)VT+EZE]G&[V<3O)=O3A>C7MD[3#5G->E6,_I'
M9./#Y%3XQ:O5>QG:G6GL)&^PE;Y;=R\3%>QUZSAKS<TAS>UJWGNI;KP;>M1$
MC9UKRX=CLYE@=Q(9)SU.W@MK,Y=5)62RA6;!*AS4MK)"DNMO,M9AZB::YETT
MQE<+QZ.MN^JPW#$589V(N]CNAR;..-WELJE45JM<[5S335'*VJ6")BV7I:7+
M*)/;O5$F@>J;GMZ6+MX)6U8^BT5'-<UNX C\D<
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M)2W]XR]MO5OZ*^$?6WO :-<H7=K?>G)O-;(S(YT.]&P] 0>=WQ .+4E10
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M;MYPFJ&*,P73C'<3>M%BPFZ5NVGEK"]L:5VTJ]6I6BTKN4YKPV.,20
M.EEP[QMS#N)/%[%'D(1)QSCSIBFF=C+4<ESJ[76.19SRV67'FT.R)C:W%]%K
MZK49]RC/J>-FH5XF(Y]QN_;ZR;%KQZ;57R77$BM2JTV(E$38FSH0V]TWLEPW
M3S </<E'PX-9,78B>4VVC1RT152JJBJNU=J[UWE-OSWZU4'S%=A2C>)PKK =
M5V24$@TG'2UA\*G\%2C4KQ#4JI-SKT+T+Z=/1U/0[E>F272*T92G9W5RWQUE
M5]?_ !4]0S5YL8%BUFO)*U[6TM7>*D+64\/K*^J0XBPI6P     E#\FG836N
M_,7X^ORWT1ZW,)N7:]GFM:F_&=S#"L@K:!A)DXA!K=RPZ\B2HEDKX"+O[5%"
M?,1A+L7TAQ9L:5FMVQ3M\"131N>OJ1=INI]BJ$\<M.,MP;6?!WR+2"Y=-;N\
M*S02-C3?TR]GOKXJT5+_ *,J#7D      #0_S.-O1=)\#^3&8.R6X\^TUI<:
M]H.Y71]=_L\F]?UCL-LOC/2:YS(SF=.BDI;C*6LNQ*A*.BV7WYDU1P7#VHJQ
M,O63OZNSMO=W(O4CNSX/&Y$3:J$3:YYCCROI-CF).<B2R6+[>/K[2Z_V=JMZ
MU:LG'XFJJ[$4YUXUR,9P      +N7N]WL&V_T_;"_%O 1FOS9=Z,?HJ#X2<U
M&Y.^Z63TO<?!VY.<*R%JR*_SKOLR>2_]37^8#5(G'EN[Z,&_O?F-T0'S/]QF
M.?W/_F%H4#QJD9%       =,+BC[+?&OZ =.?5WC@QFSU_C?&?2MWYQ(;A:?
M?X"P3T19^;QF?ARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW
M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
M1[?;.-_!%1+I4U]Y5_COQ*^]7;OSO@ OAR;_ *LQ[\/:^TG,]^=W]:9>^3WG
MM[<K$BZ918     W\\K3[0GBC]*E?\VV8BO6_NFQWY"[VS27=!.^++_I!OM7
M'1$&2!LH        '.2\QOV\N77T_;)_&2:-?=(.Z[ /15O\&ABYK1WM9B]+
MW/PCC2P2,1B     6H/=GO\ G6_Z</\ CR*/<YG_ $W_ ,0_W$OSR/?]4?\
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MUX!JUA'N7#;9IMXT6YM57=T++"J[7PN7IVNC549)O:Y\D AXFL
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M[E%<\:E81EY[>*S?=-DGZNP@K-,BKN3B8Q6(J^R<U**JHB]',9 &TH
M%37WE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46
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M'*N1'91LI$_3V-(L:HB^5':(ON[U1-R2[(&HJ4<CI51:QJ4BAI29<
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MVSG;1HMQ;HM$>B43MX*K5T3EIQ-JKH7*C7*K58]\I@A GL
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MJJO2ILE;V\%I;LM;5C8[:)C6,:U*-:UJ(C6M1-B(B(B(B;D/H#\C]@
M   "#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M   W3\N3V\N(OT_:V_&2$(YU?[KL?]%7'P:DG:+][67?2]M\(TZ-HR"-HP
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M9/L,5AU,PJ/_ &*[X8+SA3UD[6TAE6G1+&WLW+L1'QMJJNE0K1BY12
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MOWM$9$[\,GC2T'*9DUV9-4&8W.SBP[!H'3N5?6]L]%BMVK]]57S-\,*^);R
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MXXHUK<6LS4M:UJ,U*6I1]3,_29B9$1&HC6I1$(155<JN<M7*?X'^G^
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MRG;C;DI*V,:IF9:]K&6VH>7LLL(-<J]P"*CME&HC4]2%U[B* VVY;[EAU:3
M\033S'Y:81=R5M'N79#.Y:K$JKN9.NUO0DW1[JJI2WFNT;7'\-74G+L5<9LX
MT2\8U-LUNU*),B)ODMTV.Z5@Z?<FHM/8:"F<
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ML6L9LY,<DJ3)CQ=3M&]8,*U0P5&2*R#-=M&GQF#=7<G;0HJJKH7+O2JNB<O
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MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\
M'\W6FI#3K#[3;S#S:VGF74)<:=:<2:'&G6UDI#C;B%&2DF1D9'T,?ZUSF.1S
M55'(M45-Z+UH?XYK7M5CT16JE%1=J*B]"E';SBO+:E\2-FO;GU11OJXX[1N9
M#S$>#'6J)JG-I[CLN5A4OP^Y,;'+3X[]&ZKM2ELG(9EW1VUOZ8<O>L4>?<%3
M+F.RI^U]C&B*KEVW4+:(DR=<C=C9DV[:2;GJC<L.9+1.33O'%S-E^)?V+OY5
M5$:FRTG=55@7JC=M= NRB<4>]B*^$P62*O
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MDY+,I+<8QBV=KAGN5M"VTA54V+)*J23*GWS&,C1?O9EZRVP*%&AH
M5-?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
M  GX]W-]MO:7Z*^;_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN
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MBS-G=T5_FEBH^*)OE6UJY**CDXD19IFKM1ZHC&+ZQKG-;(3YBK!;@
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M6     -_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M       !SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_!H8N:T=[68O2]S\(XTL$C
M$8@    %J#W9[_G6_P"G#_CR*/<YG_3?_$/]Q+\\CW_5'_#?]_+4 HZ7X
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M+=[9()&HYKFJCFN:Y*HYJI5%145%146BIM0_8/S/T
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MD:C4PF1G>$1_CD23)*NF.D?H[NI]>TK-Y;YPZ-;%F_"*NV5ELY/LT@F7U?\
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MVGN3,RV>:<+O,9DQ"RF22-LLMLZ-7(BI1Z,M&.5-O0]J^$F:%=2RX
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MNJWQ+]H8+&'XAVW9_%F2LKV_9<?'VLTU:=BWAX>&E75K5*2[I7HOE;2'X_\
MLU<8A/\ I'L.T^,OA?P]AVW!P=E!#2O;.XN+BK1M*46N_@BHET
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M:BI'<1HOKF[^%[:HDL2JKHW*FUS',>[382&1J
M       6Q/(=\Q%R^@0^$&X;TW;>EARI?'S(+25WO6%%"9?G6^K'Y#QDXX_C
M\9IR92DI2S]0)^(DT-Q8C2J)<T6D:6LKM2\O14MY'(E_&U-C7JJ-9<HB=$BJ
MC)MWE\,BU5\CDT&Y3=977<+=+<R2UN(FJN'R.7:Z-J*Y]JJKTQHBOAW^Y\4:
M4;'&U;/@I27K
M
M
M
M
M                              #7KDYQ?T]RYU5;ZAW1CA7>.V#B)U79
M1%MP\DQ*_CH<1!R7%+=3+[E5<PTNJ1W=JV7V''&'VW6''&U=9DO.V8,@X['F
M#+DW9W;$X7-7;'*Q?71RLJG$Q:(O0K51'-5KD14X[/61,MZBX!)ES,\/:V3U
MXFN39)#(GK98GT7@>VJIN5'-56/1S'.:M#7GCY?VY."&QU8YF\5S(M<Y!,F*
MUMM:LANMX_EM>TMQ;<&>GJ\F@S"%%(E3:QUQ2T>EQE;\<T/*U'TNU6R[JA@_
MQS#')#C$34^,6KE3M(G+[)N[M(E7UDB(B+N<C7U:F3&K.D&9=)\:^)8HU9L%
MF<OQ:[:B]G,U/8NW]G,U/7Q*JJF]JO91RZ'"4")@
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MR)-G!.U$7C:F](YDI)'O1*NCXE=&Y3?D162X
M
M
M
M
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ME/)C6#))?Y)<ZJ2HE9;9%78RY:U-R>M;.B(QRTXDC<Y&K#L+"%;@
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MJ*;#03PW,++FW<U]O(U'-<U45KFN2K7-5-BHJ*BHJ;%0_:/S/U
M
M
M
M
M
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M7PMG%;*[?)9U1.!.M;=ZHWH]R?&UJ48Y2P^*DER0
M
M
M
M
M
M -$^9_EV<;N<&/K9VAC'R+L*#7KAXMMW$T1Z[.J T$XJ)&ERC:5%RC'V7G#-
M5=8H>92E:S85'>43R9/TYU<SCII=H[!)^TPESZRVLM70OZU1*UBD5/YR-478
MG&CVIPK%&INC.2=4[-6X[!V6,,92*[BHV>/J15I26-%_FY$<E%7@5CEXDIT\
MVO*=Y0<,'[3)9U&O:VEHJW7H^W,#@2I4"K@)6KL5GV.I.3;8-(0WV>(\_P"/
M5&MQ*&IKJ^Y*="M-M=\DZBM99Q2_$<QNHBVL[D1SG?U$FQDR;Z(G#+1%5T34
MHJYMZH\OF>],WR7TL7Z0RPVJI=P-56M;_P#D1[7P+NJKN**JHC97+5$C!$U$
M$@                        &=^,V_\RXN[TUOO7!'5_+F 9%%LWZTY+L6
M+D="[W0\DQ6R<9ZK*MR6BD2(;QD1J0E[O3T6E)ES&<\J8=G;+%YEC%$_V:[A
M5J.HBK&]-L<K:^RC>C7IUTHNQ5.LR-F_$\AYKLLUX2O^U6<R.5M51)(UV21.
M5/8RQJYB]2+5-J(=(G5&S<2W1K3!-L8'8%9X?L/%J;+<?E_$)TZ^YA-3&X\Q
MI"UE&L8*G#8E,F?>Q(;6VKHI)D,><=P6_P N8S=8#BC.#$+2=\4B='$Q52J+
MTM=ZYJ[G-5%38IM;E_',.S-@=IF'"7]IAMY;LFC7IX7M1:*G0YM>%S=[7(J+
MM0R /)/8
M
M
M
M
M                              _PXVAU"VG4(<:<0IMQMQ)+0XA9&E:%
MH41I4A23Z&1^@R'^HJM5'-6BH?XJ(Y%:Y*M4A6YE>1[Q>Y(?*>7:F9:XX[5E
MKD3'+##ZEN5KG(9KO<ZHL@U\B3 A5KLA[T'*IW8"DJ6IUYF4KHD6/T[YE\[9
M/X+#'E7&,";1.&5U+B-$V>YST<KD1/8RH_<C6N8FTK%J7RLY$SKVF(Y>1,%Q
M]U55T+$6VD<NWW2WJUK55?90K'O5SFR+L*M?*WRR.7W$!<ZSV/K:3D>OX9OK
M+:NN/6\NP),5E:D^M6\V/#CVV)-N)(C3\L0X'?UZ(-?0Q=W(NM&G^H"-AP>\
M;#BKJ?[-<4BGJO0Q%56R_P#E/?3IH4+U T,U&TX5\^-63IL';7_:K:LT%$Z7
MN1J/A_\ .9'7HJ1_B5B(                        M=^[Q\OW[.JSKAEF
M5HZ\]0-3]GZ;5+>6LFZ63+8:V#A\0W#)MEJ%;36+B*PCN6XJ;8N'T2V0HKS:
MZ?MAGM=1<.8B-E5MM=T3V:(JP2KUJK4=$YR[$X(4WJ:!<F^H[Y[>[TSQ.15=
M"CKJSJNYBJB7$*=2->YLS&IM7CF=N0M"BDQ>\
M
M
M
M
M
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M"T7:G0M47:A[,><>F
M
M
M
M
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MO5J<#&(C$<YW B\2M1:<2HB4V/''G:@
M
M
M
M
M
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M*5\I5Z-GBV'2V>&X=A[>&PMX(&TI2-C6)15JJ>2B=.WQ[3T@^,^T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
<                                 #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812541504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Mar. 22, 2018</div></th>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 08, 2019</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease payments, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease payments, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease payments, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease payments, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payments to HPI over three-year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_PaymentsForResearchAndDevelopmentAgreement', window );">Payments for research and development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_LicensingAgreementTerm', window );">HPI out-licensing agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,785,000<span></span>
</td>
<td class="nump">$ 1,332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,816,000<span></span>
</td>
<td class="nump">$ 6,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,727,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,727,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,528,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount', window );">Employee agreements, termination benefits provided to key employees, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbx_WPDPharmaceuticalsMember', window );">WPD Pharmaceuticals | First Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ResearchAndDevelopmentCommitment', window );">Research and development commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbx_WPDPharmaceuticalsMember', window );">WPD Pharmaceuticals | After Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ResearchAndDevelopmentCommitment', window );">Research and development commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbx_MdAndersonMember', window );">MD Anderson | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_OlympiaDriveWBellfortLLCMember', window );">Olympia Drive W Bellfort, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease (in months)</a></td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent', window );">Operating lease, rent expense, annual increase in rent (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_PercentageOfRentPayableByCoLessee', window );">Percentage of rents payable by co-lessee</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee', window );">Percentage of Sub-lease income allocable to co-lessee</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_OptionRepurchasePayments', window );">Option repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_MdAndersonMember', window );">MD Anderson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_PaymentsForResearchAndDevelopmentAgreement', window );">Payments for research and development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_MdAndersonMember', window );">MD Anderson | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_PaymentsForResearchAndDevelopmentAgreement', window );">Payments for research and development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_DerminMember', window );">Dermin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_LicensedTechnologyFuturePaymentToRemoveCountry', window );">Future payment to remove Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_EquityDistributionCommitment', window );">Equity distribution commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbx_WPDPharmaceuticalsMember', window );">WPD Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_LicensedTechnologyFuturePaymentToRemoveCountry', window );">Future payment to remove Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mbx_LeaseAgreementForCorporateOfficeSpaceMember', window );">Lease Agreement For Corporate Office Space | IPX Memorial Drive Investors, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">66 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent', window );">Operating lease, rent expense, annual increase in rent (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | MD Anderson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_LicenseAgreementAnnualLicenseFee', window );">License agreement, annual license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | MD Anderson | Submission Of NDA And Receipt Of First Marketing Approval For Sale Of A Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_EquityDistributionCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Distribution Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_EquityDistributionCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_LicenseAgreementAnnualLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_LicenseAgreementAnnualLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_LicensedTechnologyFuturePaymentToRemoveCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensed Technology, Future Payment To Remove Country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_LicensedTechnologyFuturePaymentToRemoveCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_LicensingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_LicensingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_MilestonePaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_MilestonePaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_OptionRepurchasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Repurchase Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_OptionRepurchasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_PaymentsForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_PaymentsForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_PercentageOfRentPayableByCoLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Rent Payable By Co-Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_PercentageOfRentPayableByCoLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Sub-lease Income Allocable To Co-lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ResearchAndDevelopmentCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ResearchAndDevelopmentCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbx_WPDPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbx_WPDPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_PeriodAxis=mbx_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_PeriodAxis=mbx_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_PeriodAxis=mbx_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_PeriodAxis=mbx_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_OlympiaDriveWBellfortLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_OlympiaDriveWBellfortLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_DerminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_DerminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_WPDPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_WPDPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mbx_LeaseAgreementForCorporateOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mbx_LeaseAgreementForCorporateOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_IPXMemorialDriveInvestorsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_IPXMemorialDriveInvestorsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6805434048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,409<span></span>
</td>
<td class="nump">$ 7,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,177<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,586<span></span>
</td>
<td class="nump">7,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">11,148<span></span>
</td>
<td class="nump">11,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,398<span></span>
</td>
<td class="nump">19,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,188<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability - current</a></td>
<td class="nump">6,820<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,119<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - long-term, net of current portion</a></td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability - long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,423<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 and 75,000,000 shares authorized as of September 30, 2019 and December 31, 2018, 45,727,700 and 28,528,663 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">54,673<span></span>
</td>
<td class="nump">40,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociBeforeTaxAttributableToParent', window );">Accumulated other comprehensive income</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(35,763)<span></span>
</td>
<td class="num">(26,356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">18,975<span></span>
</td>
<td class="nump">14,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 30,398<span></span>
</td>
<td class="nump">$ 19,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, attributable to parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6815617568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>March 2019</div></th>
<th class="th"><div>Lincoln Park</div></th>
<th class="th"><div>April Offerings</div></th>
<th class="th"><div>June 2018</div></th>
<th class="th"><div>Licence Rights</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>March 2019</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Lincoln Park</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>April Offerings</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>June 2018</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Licence Rights</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>March 2019</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Lincoln Park</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>April Offerings</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>June 2018</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Licence Rights</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 17,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,469,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued for cash - sale of common stock</a></td>
<td class="nump">5,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(1,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Mar. 31, 2018</a></td>
<td class="nump">20,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,407)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,768,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">17,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,469,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(9,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2018</a></td>
<td class="nump">14,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,570)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,861,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2018</a></td>
<td class="nump">20,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,768,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued for cash - sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(5,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative translation adjustment</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Jun. 30, 2018</a></td>
<td class="nump">16,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,532)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,861,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(2,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative translation adjustment</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2018</a></td>
<td class="nump">14,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,570)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,861,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2018</a></td>
<td class="nump">14,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,356)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,528,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued for cash - sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,226<span></span>
</td>
<td class="nump">$ 883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
<td class="nump">$ 883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="nump">605,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(4,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative translation adjustment</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Mar. 31, 2019</a></td>
<td class="nump">14,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,397)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,409,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 14,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,356)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,528,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (9,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2019</a></td>
<td class="nump">18,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,763)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,727,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">14,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,397)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,409,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued for cash - sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(1,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative translation adjustment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">4,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Jun. 30, 2019</a></td>
<td class="nump">22,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,618)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,197,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued for cash - sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued for cash - sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(4,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Cumulative translation adjustment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2019</a></td>
<td class="nump">$ 18,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,763)<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,727,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790118000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Option Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning of period (in shares)</a></td>
<td class="nump">2,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(103,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, end of period (in shares)</a></td>
<td class="nump">3,781,000<span></span>
</td>
<td class="nump">2,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable, end of period (in shares)</a></td>
<td class="nump">993,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in dollars per share)</a></td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, exercised (in dollars per share)</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in dollars per share)</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding, end of period (in dollars per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, exercisable (in dollars per share)</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance (in dollars per share)</a></td>
<td class="nump">2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding balance (in dollars per share)</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), outstanding</a></td>
<td class="text">8 years 7 months 9 days<span></span>
</td>
<td class="text">9 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), exercisable</a></td>
<td class="text">7 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding balance</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631951936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is authorized to issue 105,000,000 shares of which 5,000,000 shares of preferred stock are authorized and 100,000,000 shares of common stock are authorized.</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is authorized to issue up to 5,000,000 shares of preferred stock. Its certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of September&#160;30, 2019, there was no preferred stock issued.</span></div><div style="text-indent:19pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Lincoln Park Transaction</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On October 4, 2018, the Company entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"). Pursuant to the terms of the Purchase Agreement, Lincoln Park has agreed to purchase from the Company up to $20.0 million of our common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, the Company filed with the SEC a registration statement to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, at the time the Company signed the Purchase Agreement and the Registration Rights Agreement, the Company issued 243,013 shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement and the Company may issue an additional 121,507 commitment shares pro-rata when and if Lincoln Park purchases (at the Company's discretion) the $20.0 million aggregate commitment. The commitment shares were valued at $337,788, recorded as an addition to equity for the issuance of common stock and treated as a reduction to equity as a cost of capital to be raised under the Purchase Agreement. During the three months ended December 31, 2018, the Company issued 1,399,153 shares to Lincoln Park which included 10,918 commitment shares, for $1.8 million. During the first quarter of 2019, the Company issued 605,367 shares, which included 5,367 commitment shares for $0.9 million. No shares were issued to Lincoln Park during the second quarter of 2019. During the third quarter of 2019, the Company issued 100,674 shares to Lincoln Park which included 674 commitment shares, for $0.1 million.</span></div><div style="text-indent:19pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:174%;">At Market Issuance Sales Agreements ("ATM")</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> In September 2017, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with Roth Capital Partners, LLC ("Roth") and National Securities Corporation ("National") (collectively, the &#8220;Agents&#8221;). Pursuant to the terms of the ATM Agreement, the Company was permitted to sell from time to time through the Agents shares of the Company&#8217;s common stock with an aggregate sales price of up to $13 million.  The Company agreed to pay a commission to the Agents of 3.0% of the gross proceeds of the sale of the shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company also provided the Agents with customary indemnification rights. In June 2019, the Company canceled the ATM Agreement. The Company did not sell any shares under this ATM Agreement in 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Subsequent to canceling the ATM Agreement with Roth and National, the Company entered into an At Market Issuance Sales Agreement (the &#8220;Opco Agreement&#8221;) with Oppenheimer &amp; Co. Inc. (the &#8220;Agent&#8221;) on July 23, 2019. Pursuant to </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">the terms of the Opco Agreement, the Company may sell from time to time through the Agent shares of the Company&#8217;s common stock, with an aggregate sales price of up to $15 million (the &#8220;Shares&#8221;). Any sales of Shares pursuant to the Opco Agreement will be made under the Company&#8217;s effective &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-3 (File No. 333-219434), which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the Opco Agreement, the Company may sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended. Sales of the Shares, if any, may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company&#8217;s Board of Directors or a duly authorized committee thereof. The Company or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to $15 million, or sooner if either the Company or the Agent terminate the Agreement pursuant to its terms. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the Agreement and reimburse the Agent for certain expenses. The Company has also provided the Agent with customary indemnification rights. The Company has not sold any shares under the Opco Agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Adoption of 2015 Stock Plan</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In 2015, the Board of Directors of the Company approved the Company&#8217;s 2015 Stock Plan, which was amended in 2017 and 2018. The expiration date of the plan is December&#160;5, 2025 and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants under the plan is currently 4,500,000 shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards, stock unit awards or stock appreciation rights. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for the nine months ended September&#160;30, 2019:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:34.818851%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782032%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Stock Options Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted Average Grant Date Fair Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,794,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9.43</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,115,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(25,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(103,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,781,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">993,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.79</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of the option grants has been estimated, with the following assumptions:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:59.549708%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.577778%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.577778%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.31</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation for the three and nine months ended September&#160;30, 2019 and 2018, are as follows (in thousands):</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:46.684211%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549708%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2019, 1,115,000 stock options were granted. Options granted during 2019 have an aggregated fair value of $1.2 million which was calculated using the Black-Scholes option-pricing model. As of September&#160;30, 2019, total compensation cost not yet recognized was $3.2 million and the weighted average period over which this amount is expected to be recognized is 2.51 years. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the "plain vanilla" method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because the Company does not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies combined with the Company's due to the lack of sufficient historical data of its stock price. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">During the nine months ended September 30, 2019, the Company granted 316,907 restricted stock units, which vest annually in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY0OTI2NzQ1NjEzNg_c203f143-78a7-490e-b73e-32b489147d7d">four</span> equal installments. The weighted average grant date fair value was $1.31 per unit. As of September&#160;30, 2019, total compensation cost not yet recognized was $0.4 million and the weighted average period over which this amount is expected to be recognized is 3.8 years. No restricted stock units were vested as of September 30, 2019 and no units were granted prior to 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Consulting Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In 2017, the Company entered into a consulting agreement for its investor relations operations. The consulting agreement initially covered a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzcyMQ_9e5789a7-6205-4556-8350-0fb32f1e123d">twelve</span> months from the commencement date of July 29, 2017 and was extended in April 2018 until March 31, 2019. Pursuant to the original consulting agreement, in exchange for the consulting services, the Company issued two warrants (collectively, the &#8220;Warrants&#8221;) to purchase 100,000 and 50,000 shares of common stock at exercise prices of $2.41 and $3.00 per share. Each of the Warrants vested over a 12-month period in equal monthly installments starting July 29, 2017, provided that the consultant was providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017 and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODM2NQ_0243ffb2-eae1-40d2-9343-bc1cb403c4d5">five</span> years from the initial exercise date. In connection with the first extension of the consulting agreement, the Company issued the consultant a 3-year warrant to purchase 100,000 shares of common stock at an exercise price of $3.00 per share vesting in four quarterly installments. In addition, the Company paid $20,000 to the consultant per quarter pursuant to the first amendment to the consulting agreement. On July 8, 2019, the Company amended the existing consulting agreement for additional cash payments, with a right to cease cash payments by issuing the consultant a fully vested <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTE4MQ_bd9f0e14-58b3-4547-8588-62c23121c211">three</span>-year warrant to purchase 150,000 shares of Company common stock, subject to NASDAQ listing of additional shares approval. On August 8, 2019, the Company elected to issue such warrant with an exercise price of $1.64. The Company recorded stock compensation expense for the non-employee consulting agreement of $0.1 million and $0.04 million for the three months ended September 30, 2019 and 2018, respectively, and $0.1 million for both the nine months ended September 30, 2019 and 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$9 million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale of 4,290,000 shares of common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common stock, pursuant to the Purchase Agreement, the Company also sold warrants to purchase 2,145,000 shares of common stock. The Company sold the common stock and warrants for aggregate gross proceeds of approximately $9.0 million. The net proceeds from the transactions was approximately $8.2 million after deducting certain fees due to the placement agent and transaction expenses. Subject to certain beneficial ownership limitations, the warrants became exercisable on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAzNTE_dc4c3f39-7e46-4a6e-916d-e8c0623716e3">six</span>-month anniversary of the issuance date at an exercise price equal to $2.80 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA1NTQ_b2561df1-708d-4b79-82bd-4bfa1c75f45e">five</span> years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$2.3 million Registered Direct Offering</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the Company entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $2.3 million. In connection with the offering, the Company issued 1,092,636 registered shares of common stock at a purchase price of $2.105 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase 0.65 of a share of common stock. The warrants have an exercise price of $2.02 per share, became exercisable six months from the date of issuance, and will expire five years from the initial exercise date. Roth Capital Partners LLC served as sole placement agent for the offering.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$5.25 million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with Oppenheimer &amp; Co. Inc. (the "Underwriter") relating to an underwritten offering (the "Offering") of 5,250,000 units (each a "Unit"), each unit consisting of (i) one share of the Company's common stock, and (ii) 0.5 of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $1.00 per Unit, and the Underwriter agreed to purchase the Units from the Company pursuant to the Underwriting Agreement at a price of $0.93 per Unit. The Warrants included in the Units are immediately exercisable at a price of $1.10 per share, subject to adjustments in certain circumstances, and will expire five years from the date of issuance. The net proceeds from the transaction was approximately $4.7 million after deducting the underwriting discount and estimated offering expenses payable by the Company.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">$15 million Registered Direct Offering</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company entered into subscription agreements (each a "Subscription Agreement") with certain institutional investors (the "Investors") for the sale by the Company of 9,375,000 units (each a "Unit"), each Unit consisting of (i) one share of the Company's common stock, and (ii) 0.5 of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $1.60 per Unit. The Warrants included in the Units are immediately exercisable at a price of $1.75 per share and will expire five years from the date of issuance. The net proceeds from the transaction was approximately $13.7 million after deducting the placement agent fees and estimated offering expenses payable by the Company.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Initial Public Offering Warrants</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Company's initial public offering completed in May 2016, the Company issued its underwriter a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjk1NQ_b57729a6-ddb3-4566-b0b4-be41f4b8b523">five</span>-year warrant to purchase 107,802 shares of common stock at an exercise price of $7.50 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6643060240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Basis of Presentation &#8211; Unaudited Interim Condensed Consolidated Financial Information -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a </span>fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These interim condensed unaudited consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December&#160;31, 2018 and December&#160;31, 2017 and notes thereto contained in the Form 10-K filed with the SEC on February&#160;21, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The company views its operations and manages its business in one operating segment. All long-lived assets of the Company reside in the United States.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_GoingConcernPolicyPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Going Concern -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of September&#160;30, 2019, the Company has incurred an accumulated deficit of $35.8 million since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of September&#160;30, 2019, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the Federally insured limits of $250,000.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Intangible Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development ("IPR&amp;D") asset, then no </span><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, if any, the IPR&amp;D assets will be amortized over their estimated useful lives.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if the Company believes indicators of potential impairment exist, using a fair-value-based approach.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net - Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Operating Leases Right-of-Use Assets</a></td>
<td class="text">Operating Lease Right-of-Use Asset - The Company determines if an arrangement is a lease at contract inception or during modifications or renewal of an existing lease. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company's operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheet. The Company has elected the practical expedient and will not separate lease components from nonlease components for its leases. The Company's operating leases are reflected in operating lease right-of-use asset ("ROU"), accrued expenses and current liabilities, and operating lease liability - long-term in the Company's condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 7 - Commitments and Contingencies - Lease Obligations Payable for additional information related to the Company&#8217;s operating leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMethodInvestmentsPolicy', window );">Cost Method Investments</a></td>
<td class="text">Cost Method Investment - Our cost method investment consists of an investment in a private company in which we do not have the ability to exercise significant influence over its operating and financial activities. The investment is tested for impairment quarterly.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments consist primarily of non-trade receivables, account payables, accrued expenses and a warrant liability. The carrying amount of non-trade receivables, accounts payables, and accrued expenses approximates their fair value because of the short-term maturity of such.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8211; Unobservable inputs for the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Loss Per Common Share</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting and warrants to purchase common stock were considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be antidilutive. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">For the three months ended September 30, 2019 and 2018, </span>approximately 14.7 million and approximately 6.5 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2019 and 2018, approximately 11.3 million and approximately 5.0 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Reclassifications - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;In July 2018, the FASB issued ASU No. 2018-11, Leases Targeted Improvements ("ASU 2018-11"). In March 2019, the FASB issued ASU. No. 2019-01, Leases ("ASU 2019-01"). ASU 2019-01 and 2018-11 assists stakeholders with implementation questions and issues as organizations prepare to adopt the new leases standard. The Company adopted this standard on January 1, 2019 and used the effective date of initial application using the modified retrospective transition method. Upon adoption there was no cumulative-effect adjustment to the opening balance of retained earnings as of January 1, 2019. Therefore, prior period financial information has not been adjusted and continues to be reflected in accordance with the Company's historical accounting policy. The standard establishes a ROU asset model that requires the lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. (see Note 7. Commitments and Contingencies - Lease Obligations Payable).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718) Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 affects all entities that enter into share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption permitted, but no earlier than an entity's adoption date of Topic 606. The adoption of this pronouncement did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) ("ASU 2018-13"). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  Early adoption is permitted upon issuance of this ASU. The Company is currently evaluating the impact that this standard will have, if any, on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the cost method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. An entity also may describe how such investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919352-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    " #V,VQ/F5R<(Q &  "<)P
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MENI_L^^V=O+)B<MQZ.IA_@T.;\/8-<LLSDI3?K\=JW8^7I?Y/\+D %P"\!X
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M-#%[R;7G@08/JH#5HX&R"H27R]!Z!!5@XNDMR,P"Y&Z0ND'I00'JAJLP23T
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M;41O@[&[+)OLZ+[3W_T'4$L#!!0    ( /<S;$\S.\GE/P(  +$'   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC97;CML@%$5_Q?('#/CN1(ZE)E75
M2JT43=7I,TE(; TV+I!X^O<%[+%LH,GDP=SV/JQ#$*?H*7OE%<;">VM(RS=^
M)42W!H ?*]P@_D0[W,J5,V4-$G+(+H!W#*.3-C4$A!"FH$%UZY>%GMNSLJ!7
M0>H6[YG'KTV#V-\M)K3?^('_/O%<7RJA)D!9=.B"?V+QJ]LS.0)3E%/=X);7
MM/48/F_\3\%Z%T!ET(J7&O=\UO=4*@=*7]7@VVGC0T6$"3X*%0+)YH9WF! 5
M27+\&8/ZTY[*..^_1_^BDY?)'!#'.TI^UR=1;?S<]T[XC*Y$/-/^*QX32GQO
MS/X[OF$BY8I$[G&DA.NO=[QR09LQBD1IT-O0UJUN^V$ES4:;VQ".AG R!/%=
M0S0:(L, !C*=ZF<D4%DPVGML^+<ZI"Y%L([D81[5I#X[O2:SY7+V5N:K MQ4
MG%&R'23A3!(N%3M;D0:3!,C])XC0"1%J?S3SKZ#;'SG]D?;'<W]@)#%(,BUI
MM00^06BH=H]4"Y;8R1+;+,9Q;0=),MLE@?IGT#S6+7@2)T]B\T0&3V+M8Y+<
M4RP84B=#:C/$!D/ZD.&>8L&0.1DRFR$Q&+(/W9%'J@5+[F3);9;48,FM; ,(
MG;?$5F9WK\G*B;2RD3(#:65M%"=9F&46D2T,\R3,TS1R$\DRX'R:H,V4FV\3
M_"B40_D?*C![.U4Q^X'8I6ZY=Z!"/L/ZL3Q3*K","I]DO$K6SVE \%FH;B;[
M;"@BPT#0;BR08*K2Y3]02P,$%     @ ]S-L3]<#+WP0!   GA,  !@   !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6R-F%N/XC@0A?\*ROMT7':N")":D-&N
MM"NU9K6[SVDP%TTN3))N9O_]YM8,<9U OT!BOCKVJ=AQX<6E*+]71ZWKV<\L
MS:NE=:SK\]RVJ^U19TGU5)QUWORR+\HLJ9O;\F!7YU(GNRXH2VTIA&=GR2FW
M5HNN[:5<+8JW.CWE^J6<56]9EI3_K75:7)8661\-WTZ'8]TVV*O%.3GHOW3]
M]_FE;.[LJ\KNE.F\.A7YK-3[I?5,\UC*-J C_CGI2W5S/6NMO!;%]_;F]]W2
M$NV(=*JW=2N1-%_O.M)IVBHUX_@QB%K7/MO V^L/]:^=^<;,:U+IJ$C_/>WJ
MX](*K-E.[Y.WM/Y67'[3@R'7F@WN_]#O.FWP=B1-']LBK;K/V?:MJHML4&F&
MDB4_^^]3WGU?!OV/,!P@AP!Y#6CZOA>@A@#U*\"Y&^ , <YG>W"' -?HP>Z]
M=\G<)'6R6I3%95;V\^&<M-..YF[SN+9M8_=TNM^:?%9-Z_LJ#!?V>ZLS(.L>
MD3<("3%F-H"Y$G8S@.LH)!K%6K)P.>X@X@0),@;Q4"6^KS(:J(+I4IV &@E(
M+.!  :<3<$8"RDAXSW@=DW>,D>[H(;%Y2,3WB)$1%QIQ028<+.!! 0]DPC4R
MT3/NS1BE'[C"G'X1YT@IR;@-Y_R /,;%G/,"0;?<R* /#?K H&<8]/G /9\/
M/ *<= )ND'..#[B8<RIPPTF# 308 (.^83!@';G$[7&*.+4!E.-S;QR3_J2S
M$#H+@;/ <!;R5+N"ISKBG'1#X(YS)'V0AAB P@NF+9+ ;WX!3+)WOV"=?<$V
M$8F-(G+"*D3OFYW8YHB_KFA* NY1SR1YOHC,?$FT4$&V..?Z"N2*<TJ,%^J0
M*="Q1\YTGO#^1@J8E*9)Q0</+'+JBT33X3-J,513T_;P[DM@^R5S^QV@1_8X
MA<QABKE[T.78&]Z0R07>'-.;"]:S\M$,!:04"NPYB P]!=[,D!3A],9*N'0@
M4#N063L0*!XD7SD1X)C#STG%=Z7&QG#)0*!F(+-F&"!O] S)07,4D!//$)"A
M ][S,23O/D-</!"H'LBL'@8HN.U,/)F[5#2!!:9)B$G'= @QY4W8PQ4$@1*"
MS!*"4 WA>$W)YID.017A!<T+/O1-DYQ4H5".,O]FQ$C35;[RU$0=+W$A(078
M6\,)";P]2^+9DL;,6P_0:.;Q+3,"&/&UL4%JZ*\ X.3T9)>X=I"@=I!F[3!
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M)LW3'$L-AS!0+5V33&%PJ5":$8M)")(V1G$W4I8Z7S:FH (8U &W(QDGAAU
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MH>>>9*+?.(YAX^AU\@>@(D/_ S84!+QZ :\>G19HP>PY7DE9^@%(H@DRT;P
M8 \*>%8.>O#LDS[5F[2(4F\$E'MTCTZAYSG*!XH=;Z:MLM0C@?@>7=FP^4$7
M*&2#-FM27X24X-%32OJ8WW/PVF#H6<+SC$ _(P$;T@+#O<!PC^I[>E/L.<.5
M52835X_T.12.<$W/CB,/0*DS6E.//4>XI><^T%1U"+4T90+9P"A/-] ,>B;,
M@(!PSQ&N,Q9[5.-7F363#F]>0+A_ <*]@'#? >'7GI.7?KKR-Z"Q]##_"8CH
MK4B'OKZ@OG)A9P0A$80NB2!PRJLL\W2"WG?4?0(ZJV,,0N"#D#1"EZ01>#ZP
M]"9OTB)*O1&21NB2- +(!E;1+3UME:4>"4DC=$D: 20$6D4W:U)?A*01NIPC
M D\'Z!P!9.P< 33H' %D\!R!/)/6AY"#0I=S1.A\CA@^^W#Y_GLWG^:;[XOU
MMO>UW.W*U>'#Y'=EN2NJ5K-?JO;NB_GMTXME<;?;_[KO;G/\OLOQQ:Y\N#Q^
MEV?X](6BJ_\!4$L#!!0    ( /<S;$\F96NP%0(  - %   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULC53;CILP$/T5Q >LN2<;$:1-ME$KM5*T5=MG
M!X:+UL;4=L+V[VL;AR4$K?8%V\,Y9SP73]HS_BIJ .F\4=**K5M+V6T0$GD-
M%(L'UD&K_I2,4RS5D5=(=!QP84B4H,#S$D1QT[I9:FQ'GJ7L+$G3PI$[XDPI
MYO]V0%B_=7WW:GAIJEIJ \K2#E?P$^2O[LC5"8TJ14.A%0UK'0[EUGWR-X=(
MXPW@=P.]F.P='<F)L5=]^%9L74]?" CD4BM@M5Q@#X1H(76-OU;3'5UJXG1_
M53^8V%4L)RQ@S\B?II#UUEV[3@$E/A/YPOJO8..)7<<&_QTN0!1<WT3YR!D1
MYNOD9R$9M2KJ*A2_#6O3FK6W^E?:,B&PA& D*-\?$4)+"-\)T8>$R!*BSQ)B
M2X@_2T@L(9D1T) LD_UG+'&6<M8[?.B?#NLV]3>)JF^NC::<YI\J@%#62Q9X
M08HN6LAB=@,FF&!\SQLQ2.F/3H(E)[O@3F#F8K^ \,);S/,2)KK%?%G"Q+>8
MPQ(F60XG7,Q9: 3"&X'5LD"T*! 9@>A&8#U+^H!)#*8UF/AQEK1[B!]."C-D
M[1Z4^*M9UNXQ03BKT.$>L_8>9T&C2==1X)69&<+)V;F5.N,3ZSB6G@+=M3/[
M3HVK8;J\RPRS[@?F5=,*Y\2D>A.F<TO&)*@K>@_J\=1JO(X' J74VY7:\V'(
M# ?).CL_T3C$L_]02P,$%     @ ]S-L3TB,TK.Q 0  T@,  !@   !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q]4]MNG# 0_17+'Q"#=YNV*T#*IHI:J956
MJ9H\>V&X*+:'VF9)_[ZV80E*45_PS'#.F8O'V8CFQ;8 CKPJJ6U.6^?Z V.V
M;$$)>X,]:/^G1J.$\ZYIF.T-B"J2E&0\26Z9$IVF119C)U-D.#C9:3@98@>E
MA/ES!(EC3E-Z#3QV3>M"@!59+QKX">Y7?S+>8XM*U2G0MD--#-0YO4L/QWW
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M-AYO-LZ_-L8#2MG=X JU^, 61T'M@_D1;3NMV>1XT\\OB"W/N/@#4$L#!!0
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M_H,MAH+:A>,G?S;3F$V&PW[^06SYQL4?4$L#!!0    ( /<S;$]"EO:&M0$
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U3VV[;, S]%4$?
M4"5*NF:!;:#I,&S !@0=MCTK-FT+U<63Y+C[^U&RZWFML1=)I'@.#RDJ&ZQ[
M\BU (,]:&9_3-H3NR)@O6]#"W]@.#-[4UFD1T'0-\YT#42605HQO-N^8%M+0
M(DN^LRLRVP<E#9P=\;W6POT^@;)#3K?TQ?$HFS9$!RNR3C3P#<+W[NS08C-+
M)348+ZTA#NJ<WF^/IWV,3P$_) Q^<2:QDHNU3]'X7.5T$P6!@C)$!H';%1Y
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M-WAVTYA-1K#]_(/8\HW+GU!+ P04    " #W,VQ/(?NZ>5H"  "C"   &0
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M;=SVG=VK>6#FP,AA>0O(^B 5?P%02P,$%     @ ]S-L3Q=;00*W 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL;5/;;MP@$/T5Q >$-;MQ
M5BO;4C95U4JMM$K5]IFUQS8*>%S Z_3O"]AQW=0OP SGG+DP9".:%]L"./*J
M56=SVCK7GQBS90M:V#OLH?,W-1HMG#=-PVQO0%21I!7CNUW*M) =+;+HNY@B
MP\$IV<'%$#MH+<SO,R@<<YK0-\>S;%H7'*S(>M' -W#?^XOQ%EM4*JFALQ([
M8J#.Z6-R.A\"/@)^2!CMZDQ")5?$EV!\KG*Z"PF!@M(%!>&W&SR!4D'(I_%K
MUJ1+R$!<G]_4/\;:?2U78>$)U4]9N3:G1THJJ,6@W#..GV"NYYZ2N?@O< /E
MX2$3'Z-$9>-*RL$ZU+.*3T6+UVF77=S'Z>8^G6G;!#X3^$(XQCAL"A0S_R"<
M*#*#(S%3[WL1GC@Y<=^;,CAC*^*=3]YZ[ZW@:9JQ6Q":,><)PU>89$$PK[Z$
MX%LASOP_.M^F[S<SW$?Z?DU/TFV!PZ; (0H<_BGQX5V)6YCCNR!LU5,-IHG3
M9$F)0Q<G>>5=!O:1QS?Y"Y^F_:LPC>PLN:+S+QO[7R,Z\*GL[OP(M?Z#+8:"
MVH7C@S^;:<PFPV$__R"V?./B#U!+ P04    " #W,VQ/"F]!L\8!   W!
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6QU5&%OVR 0_2N('U!LDK1-
M9%MJ.DV;M$E1IZV?B7VV4<%X@./VWQ>PZUDI^V*XX[UW=QSG;%3ZQ;0 %KU*
MT9D<M];V!T),V8)DYD;UT+F36FG)K#-U0TRO@56!) 6A27)+).,=+K+@.^DB
M4X,5O(.31F:0DNFW(P@UYCC%'XXGWK36.TB1]:R!7V!_]R?M++*H5%Q"9[CJ
MD(8ZQP_IX;CS^ #XPV$TJSWRE9R5>O'&]RK'B4\(!)36*S"W7. 1A/!"+HV_
MLR9>0GKB>O^A_C74[FHY,P./2CSSRK8YOL>H@IH-PCZI\1O,]>PPFHO_ 1<0
M#NXS<3%*)4SXHG(P5LE9Q:4BV>NT\BZLXW1"]S,M3J S@2Z$^Q"'3(%"YE^8
M946FU8CT=/<]\RU.#]3=3>F=X2K"F4O>..^EH+?[C%R\T(PY3ABZPJ0+@CCU
M)02-A3C23W0:IV^B&6X"?;.FI_NXP#8JL T"V[7 77)58@SSGR)WT2"[B "]
M"A+#;*Z"D%7C).@F/%F#2C5T85Q6WF4J'FAH_#_X-%(_F6YX9]!96?=\0I-K
MI2RX5)(;ETOKIG@Q!-36;^_<7D]O>3*LZN<Q)<N_HG@'4$L#!!0    ( /<S
M;$_$X:&YT@$  )P$   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;'54
M[V[;(!!_%<0#E(0D3AK9EII6TR9M4M1IW6=BGVU4,![@N'O[ 78]+Z-?#'?\
M_MQA(!V4?C4-@$5O4K0FPXVUW9$04S0@F;E3';1NI5):,NM"71/3:6!E($E!
MZ&J5$,EXB_,TY,XZ3U5O!6_AK)'II63Z]PF$&C*\QN^)9UXWUB=(GG:LAN]@
M?W1G[2(RJY1<0FNX:I&&*L,/Z^,I\?@ >.$PF,4<^4XN2KWZX$N9X94O" 04
MUBLP-USA$83P0JZ,7Y,FGBT]<3E_5_\4>G>]7)B!1R5^\M(V&3Y@5$+%>F&?
MU? 9IGYV&$W-?X4K" ?WE3B/0@D3OJCHC55R4G&E2/8VCKP-XS"N;.XG6IQ
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MVB[<P+T$7LMC(53 R^8-.N(W+'XT+TRNO%YE7U:XYB6M'88/"_<YF&U3A=>
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M6$"@ P(CP&O)U%8_I2)=+3B[.+Q]6U7:?!3D*9 /<]M,JF>G?I.[K>7L>15
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M.\0)J("9[23=OY]M'$J,F^5+;!_//7?W8.Z2GAE_$P6E,GBOJT8LPT+*=@&
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M>][-L^X@66MG->C_,&3_ %!+ P04    " #W,VQ/7]OV<1L"   :!@  &0
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M *56N/*&/JK6]X"YTV"*#@I72!BWO_-F4Y?%>E/G-"JN8H7@3Y,R[U 6H$"
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MO@:'_Z8H81R4R$%V91'H_[F\195ENOY_=^*Z%V$.X2AFU6*1U8V78]K7KCV
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MUO.2&@5]+'[TQ4'2[LC']? D#>F^>BC9/=8&P*.2T8"BL(:DY:AR+"A)&9_
M:&_9[88I0^0&>FS%1]WFIG:QA%M@[)>+5C1^ W8[^X(G?:BK<4XAE:-<R8R=
M(%$\[F]9%[-R=+P8KW(?8/[6K.>=3@JC&!E,:-FUHX^73*G>&?9QY0BDT'G/
M+FZ,#,E>BP^>*EP%?&(<>SN@(E<MOF(EA>@U[KMI/R7/DM/T?#R$_Q*Q&?\<
M_,7/]AN] _&?R,=S,CSO&9R?(<HPHMSFF!<='A,.K 35(@U5*VU\7!0;G<G"
MY>QZ09,2TH+0::LBMEX]KM>B7-"%^,HE% .$8+QP(?(LU-[&VQT;)O3(2&,S
M@CB7((54^YY!!N][9]"K+7-(/!:[M_5VRT858C$&Y<W/H.M@^IBS:&%O+,S%
M:]:MD#RTVXA/V'/%-4>)FQQVRO?WL2[*PC.L?D15NTIRC.:44Z]);!R4O%"3
M3+%<4O4,;7*B82QT)EZEP<VCP]=VK8L1 Z6:;QVNJG^T^^0MVB(^(7OO/F//
MHA3H3IGTNTGPFEP<'[<N#O[R,:>0"!L)(9%CWO!!=9]X3?IY^[^O(TV+>E^^
M<IB[S]LO8[WECLB"?S@:'S]W+_*_' 0BL(Y1$O[E][GB\>#SI]YH9L%/O(HE
M.1D8]_(>W/L__'Z^1Q#];[J>7<P 9G,^))8S&9\[UO/$Z\D?'])_GF^_G(<8
M6&!OC_P[?CE'L)SC$_>R_'/;U9RDPY.+8'CZ]_==3VIX=\W=;:CID'1>Y.Z(
M96]O1G&B;P337+DR]T7V-0-ESX5Q^4^E;#^5L[O'0H[<L?%(.S8&)41Z>C>:
MZZAQ[^@*EWS1QND,((U-70$!;;\!ZUEI@[NP(P#6N@81#_?$_6O@1OU5TK%<
M8SNTU>OA]0T%NZ+R]AS8Y**L@U>"T*-7TH)R*\"=Q\4Z/W\;^*5=FDE=,5'(
MS5U#NO[U@U:H'FY2+W /SM/ (G[Z_<L5FWC3NX#4F0+91DAJ(<7C.*L8TD7=
MD@9.Y&'H6!\UIS/GBBMA+-#HV,0"N=QC]_AT<*)/P[;9:3L^WL%:-D_HT_8$
MY'+C7/BB]BT%[0LE7=/KV)0[PII,9NMRFAX"^["S?@",!I,M #@9#/_[ D 8
M@'%!'R67J&>&@:R478WV:RV'2?G;$O(4M6QPV"I5W95O"(8V)5BJ@70FFQ52
MW8&OG">FC:L/1=D4?*,&R1]=;@?"]."59F0'0?U'S@]#(:L'M*7,^!D1 PKI
M6=$Q%P3QH6&9*2*Q^C+5:<,,#;)'6+O,0=2)$ ;E6<?A 4LE6+1S@TT4LMV'
M$AHX7,T=/B3&ZJY<0"(16\,.9OM!KI",R8-( \CMNQH<M(+:U69F6URN..A6
MXOR;H,F-Q"HC;C.(28O4F$9N$:'EN,@@<[2NCB@H0 BS-%4!EK9&B8G54 H3
M"U-:$3=O&ZS[  .__MIU-3G#I#$.(7)2$4X,X77!4Q*XI?96%X^[_@>BV1^X
M2(]K/]?XQ<IT'J*. VL)(:#U9,<\AQT==+9Y0$2! FA-UG]=E?#W5*9O-1PY
M%;/AY<T+7=3ES6>89$!/CX;CE%VG(!9^PA**R?GQ^+G+4,=WY3W- ]>2-.81
M]2! 4FEJ>;AD;>G!3-[@B.->3&Z=4!8)+0POCF;(+#"B$&LR!,GBM\"2::1V
MZ/G +I:CZ>'N K''"VLS UTV*B=;HS<\1[<W_56Q58;Z"+HUWV)=$)LCBR9V
M_$KWA=^IG.$AXC;QMPVH+Y+4AA_\#:O=Z@_[[8[[UG D"0:_N&BO/N*/<&_8
M%<5^4, 1S.9EV1%1B6XY.R>GOAMR$".D'G$6:ZDV"!O<*;3"PAM+0A*[D%KO
M&@O83@UMC$TLFZ.ARI%$[+C$[-V7"6_GN0?9=:VA4RF.($FUF81V44#/NJZ4
M[X.,R3*XD"(@4ACT*3]*25\M4&/*W&VY8>='H##I#?M$M<CAA2L;NG=X(-#"
M=P^>T^#>-!\=?:##7QP-_?!N(/P5!S+_=!(2S($(0 $)#<:RJKK#':V6VMN8
M=DRU=5S^%LW/CA'32ZS1Q#@N-@.P8K$M?]#8$Q*3LWK6*N*$KU+,4>%?P6NO
MQ?)&1K;CF*[[W&"2QI-I@1I; MIK'ST'33>6DRTX8 .H&L:AN;->4W4=9.,E
MZMC:3?)(= V?GZ0<'NLAMHPI,"57$7#B']N&6ALDL-0Y=G1/^Z0W2PGN:5%K
MCNEU6I'F,F,RDC;3"&*H8H5#?&R&2<)M9TJ+U\\=$: $$!NLAH$WZ>.'S^(H
MI)X1>O_DIG%(#]+#D _8[[KTO\<O1+0#4_89K;@F"_L\I?P?>89<0-,@.70,
M]6SP_1%$S^6^^X9DV^[[\"PEN!HAC;MK!C\*LST;G3\/J0'%/)5'.5S$ZA%6
M3_:.HQ?D1;_F<#'+_0WQ&)Z9.X__%"F=TY9RK0G&I>20>'(@"*DC$CTM\6AA
MT0<".Q5X(A99(;$E1IC77]EU+F%_;M$24I3!6#/-5>%[CJNC7!2^S<T4K@U>
M"0<-*_3^TU=&X6T!JQ+.YC+E'12Y4 ^&?DI-MM^,=YE1!\GK'@Z42NHGL:A"
M,=])87]H_#=*)QG$I\-3 8$^5U/4RLJ13M&3D,$@W6"ZUONY,R RGE >5'_=
MR3\GJ?5TOC,1-RJQCH?/ RXZ"2[":*)<0)H(>?';U$<FB=/8,DUD#R&)FZIO
M-:D/=6%+ $64FQ!=^;?KIFD10K[PN@#;FQHA55J"\HG8&]S[-L9JP8L>3*RH
M;H5]?1>&7W30M6@\QG*<=V'"!W3AG68IOC&&I.LHA 3YO&[O>!)I'8BK/H%(
M%(C^BE N7:#*E:&2\4"">5R1PYI4+DQZ9.ST, ZN#'?5"W_23S1/&S/,W>>\
M5):"4K$#MJ^;FC8C,2U/N7&1HG%D'=B2HFF"#MI?"UODKV@HU-9[B\XEWY:+
MGQHXN?S?#LC&5'_-#YZXA.3R22::_FQ1$Y3^78FCN@Z?W2AF]V?)Y!C]&!<G
M[AW@65C4F6]P55)JP!A>.KX8NW=X"Z/CXV0\/G._+O*[C+_#"@DYU67#?'%4
M*T>3L^1BU$G,L('KSB<T'#I_BAM::BG.547U!<1]8J'O) LSC=+1L5\:E;1<
M@@2+=0782L]TZGB4',-\[.UZFD6-?%XC4$R>)>/T^&2<M#&NXU3;^<)3T;$[
MP+Y%*&8 YG1\<IJ.+B;>\6*] V%EN)-4,J7]RT(E"EOU]&=T YZ?I"?Q%[V"
M^'-R=CQ.+^"@(J\YH?5G@.SX;)*>Q8<+PLI^IM,Z'A[#*L>[W@;!^C)I-LLE
M_CLL&/(''Q/GNND\T4^=V%J-5@ER0:/OG7OFABWS;)W2\_RH=7;T!^<1I5@I
M,LBS2_%7<?PDE^+X:;W9>?[1Y<N]E"RRC;:3/?PO9)G/;4?WME8[28_'I^D9
M(?UH<(*NS_'@G/]S?)X<#TXFR2]2'/8\'<,1(R;@NR/^S]D)?SGJ.'MGZ 8^
M!KEIB-J%^>3$#> _69%)*A8!U?U+_VNV%3DR<QW<W+*UT> <R-]@?)'\)7=:
MJRR;#5C?/^)E$XD'/4FE/%V9M^H):DT-YO9DC"/936[@2>RRRPV(>E>/T]/S
M,SHC]0]ROY3 (WA(YNPL.1!L1#D511$W(E?6EB@&%(!"V&023X_U%@@#O#^)
MXT;P-+E14D_%:A7 2 C?!I?HSC^L@)S?Y\42IN44^)?5@%LF^YP+JA]Z0-<0
M,\S]9>26/0YBFQ7^\^1TO MJ4C38I[ST 6$@/<\[,PMD&G/ $SS@\?'@M\(;
M(<@73\6;<7H*R#;<#V_$*B^[\A;Y[\<AN$L.?*D-)S 6KL(W.@SRV]/_;DBG
M976["."*V'81<'*Z\]IN14 +P;T04##E3!'PT[W+B)O;D/(\'E'N=513O%K3
M;VR_/&,ENA$]J0'0^9QFX^7Q57XQYH:MA_)0?,K]63S2'G[_3)[OR[B1K,1V
MQHTL/%3I-HWH^B^PM=_1S?2^HD*L8D6!W4A^=[YP0'AQ\\YB29@]'(;[%Y36
MK=P_)O/Q<NJB^7(TQP .UZB>'-J^3B)YI7T:-$=1Y[/P?<*:O^<UNNWI-<K"
M^E03)!Y1M9A1SC&[*^C35>42&Z5D6^93SL2ZS/F=6-%F;4S"-H5$=^9+  8E
M("F57LY#/Y'$NMO'I--ZX ^-7"?&IE:GL/EB@P(4+(5H'?7#,,*B>Y4K%K37
M]ROWI?"5/T-*XMP'QLQM-H*Q'GE>>UM)MZN6WX-IU*5](TW5-C,!E>87;+$;
M-[MB>DDI'S"D#\R,%=(D=+YYIZV9-:7:*AH!"["957O%.Z+,*D^[>N_''E0&
MH?(D^8&Z9 Q.A_ 72*^G_,,89=,?DK]X.%\,!\,A/[PX0VGTA^3LQ/UT+D]?
M!T=]^,BB]'@P(2"!8'R63 :C,?_CXCQYA:%]V*J#*WR*D/J#_Z.M++ZF2(7X
MKUMJY\L++6.5=(22-EG$LD!>)8[>XNI\(6)/5JY3 >,)'9\?%[GLB#]J?1AP
MJ? KJL,EH[+_88^%BTBV>XG<9QBE N8FXHF;5D!YQ(#IQF=*?%NAG<[-Q!$6
M,KY6:*ZEM5M>DQ.Y0X5-AR#3HPW[NC6IK#!W0=3:T2[U;&1-(@9S 4X899,$
MA0*@1UJ:4\G(Y)MWT5>I;<PF,W TIE0#IBIS;:/N3)&3Q\;@Y1+TQT8JC;@\
M67W\M2*&+2LY# ?SH8A?J92VDSN>8_3:+!>>8K<!T*.58[$ZK8SKX)1B.4QJ
MV$R5)BD7J@F ZV>4H_+-K+2V3<[=6K>:2[PKM8WJ+.,-7'0O_?@6,6E1)M<@
M!B2?C'SP ?YONJYP_./4. ]<>2>B33/-<':2GF\<PLK)M3ZXU <'SR5SO,[O
M"FX:;R#9^ORC?><COV-'(JX1;.)EMBK0+O:&NFUCGY/# _L"*H+71G933NS2
MA;HK3L,9J'TM/IL%,JZ3Q1TKI"O^;#STH8]4M&M3MU0.HPNH]&\N@+;F JF<
MUHO_M0E'1HKH+GW'7K>"-]:O+2C'WSI"WRN!'-#X)*^E;2&%\FRDP59N>V-<
M2@5UP7I?/8.<[DBH,BH$*BH*#!T<AA_SR9N/';2(O@QLLWOMVQW]S-WA)X!3
MMC,^1MO1I(_1M'>;-2W?E6OEZ3SN 4[Z83M8MPUPG1IU5+&'N$E6V@H?HS%F
M4)S9Z65*H'!'-8IE% -._J]YN!==)-#>K%U%"<T$=8Z3/*<GX27*[NZPE"Y7
M\I!Y7=N"UCHH1M 7;'@VF9RE9^?GJ:U?:S=%(5Y2:;F5,=05 ZAI0RY%P^@Z
M:(U'/PJGXU;L(9D*<9*@D:S@%A[;4/B5S2WL1*AWQ,<HEHW2R<5%.CIQ>-;&
M*]%N-5)W-$PO0!+M0),SXD$3=U6>@_7-B[I9MW,?HPLZ!;%M<GKFAFW-SP^[
MATFS#P<7?O;W57#0/43"D,L&FT1V$C1;8(ZD<,;A"L+;Z=GQGE#%-_M :FJS
M 8-?2S:QSP&_R5"KOO3>HL.#RT_O@ &VN]:>;6/3Y1Y#!_8=F,,_"=L3?<0>
M\LIL8;OKDF1#9KCX4/C\>VUU8&C^2R.\'A[H&_#!(18^]ID!=B5WN&UOA]M*
MV8-EAP!!X<A[RM6@TN6P-E"9YS;$U SH(J"C9BQ/J1J"LK-FB6PPFOA3MTJ#
M$2^PQP2C#?>,DOW*FF"HR6#X@R[JKJ:$(:RAFL_<4HGYNL(XM(D&RQIZPM.B
M_,B^B^4M53DVDU&8N0@HZFZ,M(N41/^9_90 ,MU0%]":6A_ER]*;QUCZ"X*_
MVJV*$5<7.J@]WU:(@433B)WL43>L>\5 "/LUU]9%"F!BP%$0H_F4)(2?>/RW
M"/Z;7KP/JVG5=_.V6&D/VS?&?5EI&.W$M4W:=H/"^;OEK?>]-4^X-.G^M\;E
M4H4=U&@J3R*P-Q(/X%V6J]:FPWVZD'I**/'7H[UL'Y<B4S?W^6(N,_<)Q7:I
M@:#HPI3L85$?K)NC27+X!@1OBM&:3"9'X]'%\>38M37#5+>EC46J?+R7;;J%
M4[O\%0G.W6!2S4J"D-U;0>"+?Y5R<-HJP'<WN/.]=O?$M!M5#MKH)=VGI10<
M5_%UM4RR4N=6BS;?0/6!Z(%EWJH/U.#C!N!]##C6JZY@*;^+R81@0A%BJ%;?
M**;1!\+;-4)*=!A"J\SUG)5Z2)C.E15$:ZSZ@98 &#-P%5'U?>D\0-<U:W1L
M81EDM8X.XPT<F:N-:.\7]V7@P9IUL9)*M)*;V[X"+\C(A.GW5$J)"@FC[V&&
M1,88O%C@6>>YFFU"<EW5_C!3@7C4 \:QZ;@YH.ZT7 D&QV$9P,VF6>6"QLYW
M&!Q(C./Q>GK>;Y.+%J60RJ+KW)=655Y[X^QM 4%S\XCU/O_;AM4!0]0HNJVI
MJA+CAEVCZW4/U,PBPA7:M:.*2 @30I\VL57">+J <;.'@!&1+O80+LCN$A<P
M]I4OVL.1I( KC4@*;=*$K6A\("^0UA.QH5TOX(BO2(PX8?H5NQRM!D&1'LON
M;K7&3DUS7R$W(K6<N5P3J3*!KL\LB$4FNRTN$,BB4Q8IY&)\XH@^90$:"Z0I
MD/P$H=>G^>-9<G=MU(,U(#R5(FR4I<4Y%-A8B]PH'NBZ6!^:>HQ.8V,D%\?-
M WE9_8?M$Y$F)*Y_%IO)>*F2_Y_JRFFLU%E&BK4.CS>17UF9@MP6G=IEKCA
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M#;I M=L</L&,4A1YY#AHZ  .#!H3$/.0!<5\;J6=<RV%'PC.@E6]$349Q]2
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M@GOA>:/_TN^S73'%$(BR"FG+/^@GTU:6[G28M'XE<.@2A<YQ\9LU!?3!_VY
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M$]?[7=J#KL,W+99( Y#9CQ&V%R?N'= OZHHKW"6W54G1U6-XZ?AB[-[A+8R
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MR5H2DY4C1NC6P7,#I((*"90^65TY,$C]Y,*!\\RA=SR,<"%M;5?!_:Z[Z9-
M[QF!A-)!X!PZ((DJI!26_$X[=K(%?PB!SEYM*ZVPD&@;S)=P3+"#+K(6,L-R
M*!/ 'DHBBG,C1Y*B-*,2E6>"2@FFC8R@0G!D-?09G:%I4TSI@_DBON1[W&T.
MW!QS)#X$1D5OZE5WYGAJOI6\R^:X=VD/XP45V0CUOM'+X=8WEP[?2YR3UOIM
M/@C0[*BJZ/8=)05GV"WFEP6# PLF$>KK@%)(\J3YS%5)-8 E!!LL%4EWD6\2
M52O<JOXZM?FAFN<GJ/FE][G '$M$=T7KNW_,N_R?%2^N_EZR_5>9"GY!C::_
MG8#(Y2F(#(]?Y.+Z^#6:%\B_%>EUK7&G_^YUWP$%ZX9017@GMR19AIT>\_R)
MX6?SKJ)[/7!LPII>H;5^[.[QZ]P,YZBAZMXLT09C.-H?C? @'&:M!HH8CO8G
MG)&&7=N"XXLZ^0Y02P,$%     @ ]S-L3SXE4!MJ P  (QD   \   !X;"]W
M;W)K8F]O:RYX;6S%F5M/VS 4@/^*E2<FK4OCM.4BBD2!;4@(T(K8X^0F+K5P
M[& [Y?+K.4Y4< 0ZVHOI4VO'B;^>).>S3P\?M;E?:'U/GBJI[#19.5<?I*DM
M5KQB]H>NN8(C2VTJYJ!I[E);&\Y*N^+<53*EP^$DK9A0R='AYEK7)@T;VO'"
M":V@TW?<"OYHWX_[)F$P8,UOV&*:#!/"&J=_"NFX.66._S*ZJ86ZFR990I;"
M6#?W<[<C*Z%$)5YXV;;L2C_^UD:\:.68G!=&2]F>Y0^T)\$,]JWGEALGBMY
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M=,G5\+LU([A]N%3V\1G#U+M[R)'2H3_%FN'Z< B'J;\1YFHIOOT!4$L#!!0
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M'NJS[E_\[ M02P$"% ,4    " #V,VQ/'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " #V,VQ/)^B'#H(   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( /8S;$_BSQ%W[@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( /8S;$^97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ]S-L
M3][\[MY) P   Q   !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( /<S;$_JKP;,CP,  /4/   8
M      "  78,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #W,VQ/,SO)Y3\"  "Q!P  &               @ $[$   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ]S-L3]<#+WP0!   GA,  !@
M             ( !L!(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( /<S;$^9*6&8)00  -43   8              "  ?86  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #W,VQ/F8Z.1HL(  !<
M-   &               @ %1&P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ ]S-L3R9E:[ 5 @  T 4  !@              ( !$B0
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /<S;$](C-*S
ML0$  -(#   8              "  5TF  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #W,VQ/9&83;; !  #2 P  &
M@ %$*   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ]S-L
M3U@>Y1NU 0  T@,  !D              ( !*BH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #W,VQ/'K[N++4!  #2 P  &0
M        @ $6+   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( /<S;$^V&; KLP$  -(#   9              "  0(N  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ]S-L3Y7/!I*T 0  T@,
M !D              ( !["\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #W,VQ/0I;VAK4!  #2 P  &0              @ '7,0
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /<S;$^CWG/
MLP$  -(#   9              "  <,S  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ ]S-L3R'[NGE: @  HP@  !D
M ( !K34  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #W
M,VQ/R6N_O<X!  "<!   &0              @ $^.   >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /<S;$\76T$"MP$  -(#   9
M          "  4,Z  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#
M%     @ ]S-L3PIO0;/& 0  -P0  !D              ( !,3P  'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #W,VQ/Q.&AN=(!  "<
M!   &0              @ $N/@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+ 0(4 Q0    ( /<S;$_OYA^6Q0$  #<$   9              "  3=
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ]S-L3XUB
MD%)1 @  )P@  !D              ( !,T(  'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"% ,4    " #W,VQ/2,I)Z'8"  !*"   &0
M    @ &[1   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M /<S;$_L!,F!"@(  /4%   9              "  6A'  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ ]S-L3V:+Y\\4 @  ]@8  !D
M             ( !J4D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #W,VQ/#.?\[C8#  #_#@  &0              @ 'T2P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /<S;$]C[E<<0P(
M &\'   9              "  6%/  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ ]S-L3]:] !5? P  Y@\  !D              ( !
MVU$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #W,VQ/
M6IM<H(($  !Q%P  &0              @ %Q50  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /<S;$];Y+M:;@D  $L^   9
M      "  2I:  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ ]S-L3Y$=ECI; P  )PX  !D              ( !SV,  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #W,VQ/KE&($F\"  "L"
M&0              @ %A9P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( /<S;$]-B<!:= (  #P(   9              "  0=J  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ]S-L3U_;]G$;
M @  &@8  !D              ( !LFP  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #W,VQ/>4\3$"\&  #>)0  &0
M@ $$;P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /<S
M;$\LMB!?Z0$  /0$   9              "  6IU  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ ]S-L3Y3(%FX4 @  A@8  !D
M         ( !BG<  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " #W,VQ/2GX4#2!V   JQ@$ %               @ '5>0  >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #W,VQ/OP:RN4T"  !>"P  #0
M            @ $G\   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /<S;$\^
M)5 ;:@,  ",9   /              "  9_R  !X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " #W,VQ/V=><1),!   D%P  &@              @ $V]@
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #W,VQ/IAQR
M7Y\!  "3%P  $P              @ $!^   6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     +@ N '0,  #1^0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6615692256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for the nine months ended September&#160;30, 2019:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:34.818851%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.782032%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.929308%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Stock Options Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted Average Grant Date Fair Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,794,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9.43</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Granted</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,115,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(25,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(103,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,781,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">993,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.79</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="text-indent:55pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of the option grants has been estimated, with the following assumptions:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:59.549708%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.577778%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.577778%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.040936%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.31</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ComponentsofShareBasedCompensationTableTextBlock', window );">Components of Share-Based Compensation</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation for the three and nine months ended September&#160;30, 2019 and 2018, are as follows (in thousands):</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:46.684211%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549708%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ComponentsofShareBasedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ComponentsofShareBasedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6610374944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_VendorPrepaymentAndDeposits', window );">Vendor prepayments and deposits</a></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Non-trade receivables</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,177<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_VendorPrepaymentAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vendor Prepayment And Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_VendorPrepaymentAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6814721968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,256,193<span></span>
</td>
<td class="nump">3,426,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares under warrants granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="nump">1,585,500<span></span>
</td>
<td class="nump">742,991<span></span>
</td>
<td class="nump">2,273,700<span></span>
</td>
<td class="nump">404,002<span></span>
</td>
<td class="nump">8,242,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (shares)</a></td>
<td class="nump">4,687,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings | Common Stock | Underwiters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (shares)</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings | Common Stock | Underwiters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_UnderwitersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_UnderwitersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6814825744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details) - Warrant - $ / shares<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Under Warrant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Under Warrant, balance at beginning of period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,426,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares under warrants granted (shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="nump">1,585,500<span></span>
</td>
<td class="nump">742,991<span></span>
</td>
<td class="nump">2,273,700<span></span>
</td>
<td class="nump">404,002<span></span>
</td>
<td class="nump">8,242,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of shares under warrant, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,413,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Number of shares under warrant, expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Under Warrant, balance at end of period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,256,193<span></span>
</td>
<td class="nump">3,426,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber', window );">Number of Shares Under Warrant, Vested and Exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,256,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod', window );">Range of Warrant Price Per Share, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Vested and Exercisable at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
<td class="text">4 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
<td class="text">4 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life, Vested and Exercisable at end of period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod', window );">Range of Warrant Price Per Share, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Vested and Exercisable at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk fee interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.55%<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod', window );">Range of Warrant Price Per Share, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of Warrant Price per Share, Outstanding, end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue', window );">Range of Warrant Price Per Share, Vested and Exercisable at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk fee interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.50%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options ExercisedI n Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631626048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Other Supplemental Cash Flow Information For Operating Leases</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other supplemental cash flow information for operating leases is as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.064327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The minimum lease payments are expected to be as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:74.023392%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.245614%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbx-20190930.htm": {
   "axisCustom": 2,
   "axisStandard": 18,
   "contextCount": 230,
   "dts": {
    "calculationLink": {
     "local": [
      "mbx-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mbx-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mbx-20190930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbx-20190930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbx-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mbx-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 422,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 1,
    "http://www.moleculin.com/20190930": 7,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 13
   },
   "keyCustom": 58,
   "keyStandard": 286,
   "memberCustom": 34,
   "memberStandard": 18,
   "nsprefix": "mbx",
   "nsuri": "http://www.moleculin.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.moleculin.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Warrant Liability",
     "role": "http://www.moleculin.com/role/WarrantLiability",
     "shortName": "Warrant Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Equity",
     "role": "http://www.moleculin.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Income Taxes",
     "role": "http://www.moleculin.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.moleculin.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Subsequent Events",
     "role": "http://www.moleculin.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Tables)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mbx:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Warrant Liability (Tables)",
     "role": "http://www.moleculin.com/role/WarrantLiabilityTables",
     "shortName": "Warrant Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mbx:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Equity (Tables)",
     "role": "http://www.moleculin.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Commitment and Contingencies (Tables)",
     "role": "http://www.moleculin.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mbx:NumberOfDrugTechnologies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "technology",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Liquidity (Details)",
     "role": "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails",
     "shortName": "Nature of Business and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mbx:NumberOfDrugTechnologies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "technology",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mbx:VendorPrepaymentAndDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mbx:VendorPrepaymentAndDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "id7d483fa5b8b4a508aa8033181369c0b_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "id7d483fa5b8b4a508aa8033181369c0b_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "iacbd36b98aa84664bebd964e031364e7_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details)",
     "role": "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "iacbd36b98aa84664bebd964e031364e7_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mbx:AccruedClinicalTestingCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mbx:AccruedClinicalTestingCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mbx:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "icfdda18b689c40d8a99d07a7fce046cd_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Warrant Liability - Narrative (Details)",
     "role": "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails",
     "shortName": "Warrant Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mbx:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i0ca157a098ae4304a258adc86a04a5b6_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details)",
     "role": "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
     "shortName": "Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mbx:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "id8e7189457f243459bd45d9722f2f29c_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mbx:SharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.moleculin.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ic650d629ddbe42bba07cd7284425b9cb_D20181004-20181004",
      "decimals": "INF",
      "lang": null,
      "name": "mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "id8ab107b4fc145aa9e410c1077fc257f_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Equity - Summary of Option Activities (Details)",
     "role": "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails",
     "shortName": "Equity - Summary of Option Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i267a7a9087cd4a01a174352734ebad88_D20190101-20190930",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Equity - Summary of Assumptions Used (Details)",
     "role": "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
     "shortName": "Equity - Summary of Assumptions Used (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i267a7a9087cd4a01a174352734ebad88_D20190101-20190930",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mbx:ComponentsofShareBasedCompensationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Equity - Components of Stock Based Compensation (Details)",
     "role": "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails",
     "shortName": "Equity - Components of Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mbx:ComponentsofShareBasedCompensationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Income Taxes (Details)",
     "role": "http://www.moleculin.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details)",
     "role": "http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails",
     "shortName": "Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Commitments and Contingencies - Minimum Lease Payments (Details)",
     "role": "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i658888d65697477c8bdf7f277240e630_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "i114bd5e9a8244f23bea013dccf03d439_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mbx:NatureOfBusinessAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Liquidity",
     "role": "http://www.moleculin.com/role/NatureofBusinessandLiquidity",
     "shortName": "Nature of Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mbx:NatureOfBusinessAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies",
     "role": "http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies",
     "shortName": "Basis of presentation, principles of consolidation and significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbx-20190930.htm",
      "contextRef": "ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Address"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mbx_AccruedClinicalTestingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Clinical Testing Current",
        "terseLabel": "Accrued clinical testing"
       }
      }
     },
     "localname": "AccruedClinicalTestingCurrent",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_AccruedDrugManufacturingCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Drug Manufacturing Cost",
        "label": "Accrued Drug Manufacturing Cost",
        "terseLabel": "Accrued drug manufacturing costs"
       }
      }
     },
     "localname": "AccruedDrugManufacturingCost",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_AccruedLicenseFeesAndSRACurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued License Fees And SRA Current",
        "verboseLabel": "Accrued license fees and sponsored research agreements"
       }
      }
     },
     "localname": "AccruedLicenseFeesAndSRACurrent",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_AnimalLifeScienceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Animal Life Science",
        "label": "Animal Life Science [Member]",
        "terseLabel": "Animal Life Science"
       }
      }
     },
     "localname": "AnimalLifeScienceMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_AprilOfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "April Offerings",
        "label": "April Offerings [Member]",
        "terseLabel": "April Offerings"
       }
      }
     },
     "localname": "AprilOfferingsMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_AtMarketIssuanceSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AtMarketIssuanceSalesAgreementMember",
        "terseLabel": "At Market Issuance Sales Agreement"
       }
      }
     },
     "localname": "AtMarketIssuanceSalesAgreementMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_AuthorityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Authority",
        "label": "Authority [Axis]",
        "terseLabel": "Authority [Axis]"
       }
      }
     },
     "localname": "AuthorityAxis",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mbx_AuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Authority",
        "label": "Authority [Domain]",
        "terseLabel": "Authority [Domain]"
       }
      }
     },
     "localname": "AuthorityDomain",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_ClassOfWarrantOrRightInitialExercisePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ClassOfWarrantOrRightInitialExercisePeriod",
        "terseLabel": "Warrants, initial exercise period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightInitialExercisePeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_ClassOfWarrantOrRightTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class Of Warrant Or Right, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTerm",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_ClassofWarrantorRightAgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ClassofWarrantorRightAgreementPeriod",
        "terseLabel": "Period of agreement"
       }
      }
     },
     "localname": "ClassofWarrantorRightAgreementPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_ClassofWarrantorRightExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ClassofWarrantorRightExpirationPeriod",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ClassofWarrantorRightExpirationPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_ClassofWarrantorRightNumberofWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ClassofWarrantorRightNumberofWarrantsIssued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofWarrantsIssued",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_ClassofWarrantorRightVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ClassofWarrantorRightVestingPeriod",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ClassofWarrantorRightVestingPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_CommitmentSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment Shares",
        "label": "Commitment Shares [Member]",
        "terseLabel": "Commitment Shares"
       }
      }
     },
     "localname": "CommitmentSharesMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Commitments and Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mbx_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Issued For Licence Rights Under Licence Agreement",
        "label": "Common Stock Issued For Licence Rights Under Licence Agreement",
        "terseLabel": "License rights expense settled in stock"
       }
      }
     },
     "localname": "CommonStockIssuedForLicenceRightsUnderLicenceAgreement",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_ComponentsofShareBasedCompensationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ComponentsofShareBasedCompensationTableTextBlock",
        "terseLabel": "Components of Share-Based Compensation"
       }
      }
     },
     "localname": "ComponentsofShareBasedCompensationTableTextBlock",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbx_ConsultingAgreementWarrantThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ConsultingAgreementWarrantThreeMember",
        "terseLabel": "Consulting Agreement Warrant Three"
       }
      }
     },
     "localname": "ConsultingAgreementWarrantThreeMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_ConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting Fees",
        "label": "Consulting Fees",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "ConsultingFees",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_DerminMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dermin",
        "label": "Dermin [Member]",
        "terseLabel": "Dermin"
       }
      }
     },
     "localname": "DerminMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount",
        "terseLabel": "Employee agreements, termination benefits provided to key employees, aggregate amount"
       }
      }
     },
     "localname": "EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_EquityDistributionCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Distribution Commitment",
        "label": "Equity Distribution Commitment",
        "terseLabel": "Equity distribution commitment"
       }
      }
     },
     "localname": "EquityDistributionCommitment",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exercises",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exercises",
        "negatedLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis, Transfer of Liability From Long-term To Current",
        "negatedTerseLabel": "Reclass of liability from long-term to current"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_FoodAndDrugAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Food and Drug Administration",
        "label": "Food and Drug Administration [Member]",
        "terseLabel": "Food and Drug Administration"
       }
      }
     },
     "localname": "FoodAndDrugAdministrationMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_GSKConsultingAgreementWarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GSKConsultingAgreementWarrantOneMember",
        "terseLabel": "GSK Consulting Agreement Warrant One"
       }
      }
     },
     "localname": "GSKConsultingAgreementWarrantOneMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_GSKConsultingAgreementWarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GSKConsultingAgreementWarrantTwoMember",
        "terseLabel": "GSK Consulting Agreement Warrant Two"
       }
      }
     },
     "localname": "GSKConsultingAgreementWarrantTwoMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_GoingConcernPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GoingConcernPolicyPolicyTextBlock",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbx_HoustonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "HoustonPharmaceuticalsIncMember",
        "terseLabel": "Houston Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "HoustonPharmaceuticalsIncMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_IPXMemorialDriveInvestorsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IPXMemorialDriveInvestorsLLCMember",
        "terseLabel": "IPX Memorial Drive Investors, LLC"
       }
      }
     },
     "localname": "IPXMemorialDriveInvestorsLLCMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "negatedLabel": "Operating lease, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_June2018IssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "June2018IssuanceMember",
        "terseLabel": "June 2018"
       }
      }
     },
     "localname": "June2018IssuanceMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_June2018RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "June2018RegisteredDirectOfferingMember",
        "terseLabel": "June 2018 Registered Direct Offering"
       }
      }
     },
     "localname": "June2018RegisteredDirectOfferingMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_LeaseAgreementForCorporateOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LeaseAgreementForCorporateOfficeSpaceMember",
        "terseLabel": "Lease Agreement For Corporate Office Space"
       }
      }
     },
     "localname": "LeaseAgreementForCorporateOfficeSpaceMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_LeaseholdImprovementsPaidByLandlord": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leasehold Improvements Paid By Landlord",
        "label": "Leasehold Improvements Paid By Landlord",
        "terseLabel": "Leasehold improvements paid by landlord"
       }
      }
     },
     "localname": "LeaseholdImprovementsPaidByLandlord",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_LicenceRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licence Rights",
        "label": "Licence Rights [Member]",
        "terseLabel": "Licence Rights"
       }
      }
     },
     "localname": "LicenceRightsMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_LicenseAgreementAnnualLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "LicenseAgreementAnnualLicenseFee",
        "terseLabel": "License agreement, annual license fee"
       }
      }
     },
     "localname": "LicenseAgreementAnnualLicenseFee",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_LicensedTechnologyFuturePaymentToRemoveCountry": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensed Technology, Future Payment To Remove Country",
        "label": "Licensed Technology, Future Payment To Remove Country",
        "terseLabel": "Future payment to remove Germany"
       }
      }
     },
     "localname": "LicensedTechnologyFuturePaymentToRemoveCountry",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_LicensingAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LicensingAgreementTerm",
        "terseLabel": "HPI out-licensing agreement term"
       }
      }
     },
     "localname": "LicensingAgreementTerm",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_LincolnParkSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lincoln Park Sale",
        "label": "Lincoln Park Sale [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkSaleMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_March2019IssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Issuance",
        "label": "March 2019 Issuance [Member]",
        "terseLabel": "March 2019"
       }
      }
     },
     "localname": "March2019IssuanceMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_March2019RegisteredDirectOfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Registered Direct Offerings",
        "label": "March 2019 Registered Direct Offerings [Member]",
        "terseLabel": "March 2019 Registered Direct Offerings"
       }
      }
     },
     "localname": "March2019RegisteredDirectOfferingsMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_MarketExclusivityExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market Exclusivity Extension Period",
        "label": "Market Exclusivity Extension Period",
        "terseLabel": "Market exclusivity extension period (years)"
       }
      }
     },
     "localname": "MarketExclusivityExtensionPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_MdAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MdAndersonMember",
        "terseLabel": "MD Anderson"
       }
      }
     },
     "localname": "MdAndersonMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_MilestonePaymentsLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "MilestonePaymentsLiabilities",
        "terseLabel": "Milestone payments liabilities"
       }
      }
     },
     "localname": "MilestonePaymentsLiabilities",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_NatureOfBusinessAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NatureOfBusinessAndLiquidityTextBlock",
        "terseLabel": "Nature of Business and Liquidity"
       }
      }
     },
     "localname": "NatureOfBusinessAndLiquidityTextBlock",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbx_NumberOfDrugTechnologies": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfDrugTechnologies",
        "terseLabel": "Number of core drug technologies"
       }
      }
     },
     "localname": "NumberOfDrugTechnologies",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_NumberOfOtherDrugDevelopmentProjects": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfOtherDrugDevelopmentProjects",
        "terseLabel": "Number of other drug development projects"
       }
      }
     },
     "localname": "NumberOfOtherDrugDevelopmentProjects",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_NumberofClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberofClinicalTrials",
        "terseLabel": "Number of clinical trials"
       }
      }
     },
     "localname": "NumberofClinicalTrials",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_NumberofDrugCandidates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberofDrugCandidates",
        "terseLabel": "Number of drug candidates"
       }
      }
     },
     "localname": "NumberofDrugCandidates",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_NumberofDrugsinClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberofDrugsinClinicalTrials",
        "terseLabel": "Number of drugs in clinical trials"
       }
      }
     },
     "localname": "NumberofDrugsinClinicalTrials",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbx_OlympiaDriveWBellfortLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Olympia Drive W Bellfort, LLC",
        "label": "Olympia Drive W Bellfort, LLC [Member]",
        "terseLabel": "Olympia Drive W Bellfort, LLC"
       }
      }
     },
     "localname": "OlympiaDriveWBellfortLLCMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "OperatingLeaseRentExpenseAnnualIncreaseInRentPercent",
        "terseLabel": "Operating lease, rent expense, annual increase in rent (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseRentExpenseAnnualIncreaseInRentPercent",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbx_OppenheimerCoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oppenheimer &amp; Co. Inc.",
        "label": "Oppenheimer &amp; Co. Inc. [Member]",
        "terseLabel": "Oppenheimer &amp; Co. Inc."
       }
      }
     },
     "localname": "OppenheimerCoIncMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_OptionRepurchasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option Repurchase Payments",
        "label": "Option Repurchase Payments",
        "terseLabel": "Option repurchase payment"
       }
      }
     },
     "localname": "OptionRepurchasePayments",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_PaymentsForResearchAndDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PaymentsForResearchAndDevelopmentAgreement",
        "terseLabel": "Payments for research and development agreement"
       }
      }
     },
     "localname": "PaymentsForResearchAndDevelopmentAgreement",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_PercentageOfRentPayableByCoLessee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of Rent Payable By Co-Lessee",
        "label": "Percentage of Rent Payable By Co-Lessee",
        "terseLabel": "Percentage of rents payable by co-lessee"
       }
      }
     },
     "localname": "PercentageOfRentPayableByCoLessee",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbx_PercentageOfSubLeaseIncomeAllocableToCoLessee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Sub-lease Income Allocable To Co-lessee",
        "label": "Percentage Of Sub-lease Income Allocable To Co-lessee",
        "terseLabel": "Percentage of Sub-lease income allocable to co-lessee"
       }
      }
     },
     "localname": "PercentageOfSubLeaseIncomeAllocableToCoLessee",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbx_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period",
        "label": "Period [Axis]",
        "terseLabel": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mbx_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period",
        "label": "Period [Domain]",
        "terseLabel": "Period [Domain]"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_PeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period One",
        "label": "Period One [Member]",
        "terseLabel": "First Two Years"
       }
      }
     },
     "localname": "PeriodOneMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_PeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period Two",
        "label": "Period Two [Member]",
        "terseLabel": "After Two Years"
       }
      }
     },
     "localname": "PeriodTwoMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_ResearchAndDevelopmentCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Commitment",
        "label": "Research and Development Commitment",
        "terseLabel": "Research and development commitment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitment",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Roth Capital Partners LLC and National Securities Corporation [Member]",
        "terseLabel": "Roth Capital Partners and National Securities Corporation"
       }
      }
     },
     "localname": "RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SaleOfStockFeesPaidPercentageOfGrossProceeds",
        "terseLabel": "Commissions paid, percentage of gross proceeds (percent)"
       }
      }
     },
     "localname": "SaleOfStockFeesPaidPercentageOfGrossProceeds",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction",
        "label": "Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction",
        "terseLabel": "Maximum amount of shares to be sold in transaction"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Sale Of Stock Number Of Shares Issued In Transaction Aggregate Price",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_ScheduleOfAssumptionsUsed1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Assumptions Used 1",
        "label": "Schedule of Assumptions Used 1 [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsed1TableTextBlock",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbx_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ScheduleOfWarrantActivityTableTextBlock",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbx_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SecuritiesPurchaseAgreementMember",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregated Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregated Fair Value",
        "terseLabel": "Shares granted, aggregate fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options ExercisedI n Period",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options ExercisedI n Period",
        "terseLabel": "Range of Warrant Price Per Share, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
        "negatedLabel": "Number of shares under warrant, exercised (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue",
        "terseLabel": "Range of Warrant Price Per Share, Vested and Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
        "negatedLabel": "Number of shares under warrant, expired (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber",
        "verboseLabel": "Number of Shares Under Warrant, Vested and Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms",
        "verboseLabel": "Weighted Average Remaining Contractual Life, Vested and Exercisable at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
        "verboseLabel": "Weighted average grant date fair value, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, exercised (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbx_SharesAuthorized": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/EquityNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "label": "SharesAuthorized",
        "totalLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "SharesAuthorized",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_SharesIssuedInLeiuOfCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares Issued in Leiu Of Cash",
        "label": "Shares Issued in Leiu Of Cash",
        "terseLabel": "Research and development expense settled in stock"
       }
      }
     },
     "localname": "SharesIssuedInLeiuOfCash",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodValueStockWarrantsExercised",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_StockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "StockPlanMember",
        "verboseLabel": "2015 Stock Plan"
       }
      }
     },
     "localname": "StockPlanMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember",
        "terseLabel": "Submission Of NDA And Receipt Of First Marketing Approval For Sale Of A Licensed Product"
       }
      }
     },
     "localname": "SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_TheWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TheWarrantsMember",
        "terseLabel": "The Warrants"
       }
      }
     },
     "localname": "TheWarrantsMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_UnderwitersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwiters",
        "label": "Underwiters [Member]",
        "terseLabel": "Underwiters"
       }
      }
     },
     "localname": "UnderwitersMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriter",
        "label": "Underwriter [Member]",
        "terseLabel": "Underwriter"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_UnitOfferingUnitPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unit Offering Unit Price Per Share",
        "label": "Unit Offering Unit Price Per Share",
        "terseLabel": "Unit offering (in dollars per unit)"
       }
      }
     },
     "localname": "UnitOfferingUnitPricePerShare",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbx_UnitsSoldInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Units Sold In Period",
        "label": "Units Sold In Period",
        "terseLabel": "Units sold in period (in units)"
       }
      }
     },
     "localname": "UnitsSoldInPeriod",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbx_VendorPrepaymentAndDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vendor Prepayment And Deposits",
        "label": "Vendor Prepayment And Deposits",
        "terseLabel": "Vendor prepayments and deposits"
       }
      }
     },
     "localname": "VendorPrepaymentAndDeposits",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vendor Prepayment And Deposits, Expansion Of Production Commitments",
        "label": "Vendor Prepayment And Deposits, Expansion Of Production Commitments",
        "verboseLabel": "Vendor prepayment and deposits, expansion of production commitments"
       }
      }
     },
     "localname": "VendorPrepaymentAndDepositsExpansionOfProductionCommitments",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbx_WPDPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "WPD Pharmaceuticals",
        "label": "WPD Pharmaceuticals [Member]",
        "terseLabel": "WPD Pharmaceuticals"
       }
      }
     },
     "localname": "WPDPharmaceuticalsMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_WarrantLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Warrant Liability [Abstract]"
       }
      }
     },
     "localname": "WarrantLiabilityAbstract",
     "nsuri": "http://www.moleculin.com/20190930",
     "xbrltype": "stringItemType"
    },
    "mbx_WarrantLiabilityCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "WarrantLiabilityCurrentMember",
        "terseLabel": "Warrant Liability Current"
       }
      }
     },
     "localname": "WarrantLiabilityCurrentMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_WarrantLiabilityLongtermMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "WarrantLiabilityLongtermMember",
        "terseLabel": "Warrant Liability Long-Term"
       }
      }
     },
     "localname": "WarrantLiabilityLongtermMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbx_WarrantLiabiltyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "WarrantLiabiltyMember",
        "terseLabel": "Warrant Liability Total"
       }
      }
     },
     "localname": "WarrantLiabiltyMember",
     "nsuri": "http://www.moleculin.com/20190930",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r99",
      "r131",
      "r133",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r100",
      "r131",
      "r134",
      "r246",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r132"
     ],
     "calculation": {
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Non-trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "auth_ref": [
      "r234",
      "r243"
     ],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.",
        "label": "Accrued Salaries",
        "terseLabel": "Accrued payroll and bonuses"
       }
      }
     },
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r25",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r139",
      "r141",
      "r169",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r120",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Sale of common stock, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r141",
      "r163",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociBeforeTaxAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, attributable to parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "AOCI before Tax, Attributable to Parent",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AociBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r232",
      "r238"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r35"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r142",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Payments to HPI over three-year period"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment in accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r23",
      "r65"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r66",
      "r72",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r58",
      "r65",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r200"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r80",
      "r128",
      "r129",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "verboseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "verboseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercised price per warrant (usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Common stock offered for each warrant (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrants, aggregate amounts (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r113",
      "r235",
      "r242"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.moleculin.com/role/EquityNarrativeDetails": {
       "order": 2.0,
       "parentTag": "mbx_SharesAuthorized",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 100,000,000 and 75,000,000 shares authorized as of September 30, 2019 and December 31, 2018, 45,727,700 and 28,528,663 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r180",
      "r183",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostMethodInvestmentsPolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the cost method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. An entity also may describe how such investments are assessed for impairment.",
        "label": "Cost Method Investments, Policy [Policy Text Block]",
        "terseLabel": "Cost Method Investments"
       }
      }
     },
     "localname": "CostMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.",
        "label": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r32",
      "r203"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent - long-term"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r95"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r36",
      "r39",
      "r185",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "verboseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "verboseLabel": "Warrant liability - current"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Warrant liability - long-term"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share - basic and diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r77",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of expected recognition of compensation cost (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Weighted average period of expected recognition of compensation cost for equity investments other than options (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation cost, net of estimated forfeitures, related to the Company's non-vested equity awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest (percent)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r63",
      "r116"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Gain from change in fair value of warrant liability",
        "terseLabel": "Gain from change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r188",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails",
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r192",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r188",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Pricesin ActiveMarkets forIdenticalAssets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r188",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant OtherObservable Inputs(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r188",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "verboseLabel": "Significant OtherUnobservable Inputs(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails",
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r190",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r190",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r190",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r186",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuances of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value - net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails",
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r186",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r72",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r197",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "terseLabel": "Loss on foreign currency transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r107",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r96",
      "r174"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "negatedTerseLabel": "income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.moleculin.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r57",
      "r59",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Other Supplemental Cash Flow Information For Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019 (remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of operating lease (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor, Leases [Policy Text Block]",
        "terseLabel": "Operating Leases Right-of-Use Assets"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r233",
      "r240"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r43",
      "r45",
      "r48",
      "r64",
      "r84",
      "r236",
      "r244"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Consolidated net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r209",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Minimum Lease Payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liability - long-term, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r207",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r215",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "Minimum lease payments, year one"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "Minimum lease payments, year five"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "Minimum lease payments, year four"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "Minimum lease payments, year three"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "Minimum lease payments, year two"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r29"
     ],
     "calculation": {
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r178",
      "r179",
      "r181"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5"
     ],
     "calculation": {
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Payments for royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.moleculin.com/role/EquityNarrativeDetails": {
       "order": 1.0,
       "parentTag": "mbx_SharesAuthorized",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid Expense and Other Assets, Current"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r105",
      "r106"
     ],
     "calculation": {
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance or sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r166"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Product Warranty Disclosure [Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r110",
      "r241"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r72",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r171",
      "r248"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r127",
      "r239"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails",
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r93",
      "r94",
      "r98"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from registered offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of units sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.",
        "label": "Schedule of Assumptions Used [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r142",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r146",
      "r154",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r33",
      "r76",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares under warrants granted (shares)",
        "verboseLabel": "Shares of equity investments granted in period other than options (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value for equity investments granted other than options (usd per share)",
        "verboseLabel": "Range of Warrant Price Per Share, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Under Warrant, balance at end of period (shares)",
        "periodStartLabel": "Number of Shares Under Warrant, balance at beginning of period (shares)",
        "terseLabel": "Warrants balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares Under Warrant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Range of Warrant Price per Share, Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Range of Warrant Price per Share, Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "periodEndLabel": "Weighted Average Remaining Contractual Life, Balance, ending (in years)",
        "periodStartLabel": "Weighted Average Remaining Contractual Life, Balance, beginning (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair Value Assumptions and Methodology"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk fee interest rate (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Total number of underlying shares of common stock available under 2015 Stock Plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of shares exercisable, end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r148",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares outstanding, end of period (in shares)",
        "periodStartLabel": "Number of shares outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r140",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)",
        "verboseLabel": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r159",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term (in years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average grant date fair value, outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value, outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Shares granted, contractual term",
        "verboseLabel": "Weighted average remaining contractual term (in years), outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r210",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "verboseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation, principles of consolidation and significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r120",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issued for cash - sale of common stock (in shares)",
        "verboseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r120",
      "r127",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r120",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issued for cash - sale of common stock",
        "verboseLabel": "Shares of common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r120",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r102"
     ],
     "calculation": {
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r212",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r211",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/EquityNarrativeDetails",
      "http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails",
      "http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding Basic and diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "325",
   "URI": "http://asc.fasb.org/extlink&oid=75025870&loc=d3e40691-111596"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "http://asc.fasb.org/topic&trid=2155896"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888428&loc=SL77919352-209981"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r249": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r251": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r252": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r253": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r254": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r255": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789919520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 6,820<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Pricesin ActiveMarkets forIdenticalAssets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant OtherObservable Inputs(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant OtherUnobservable Inputs(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 6,820<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6634282976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">income tax benefit</a></td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795349600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">45,727,700<span></span>
</td>
<td class="nump">28,528,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">45,727,700<span></span>
</td>
<td class="nump">28,528,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637138288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Sale of common stock, issuance costs</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6941265040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 04, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2017 </div>
<div>technology </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction', window );">Maximum amount of shares to be sold in transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue', window );">Shares granted, aggregate fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Shares granted, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 9 days<span></span>
</td>
<td class="text">9 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, net of estimated forfeitures, related to the Company's non-vested equity awards | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of expected recognition of compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassofWarrantorRightAgreementPeriod', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mbx_StockPlanMember', window );">2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Total number of underlying shares of common stock available under 2015 Stock Plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of expected recognition of compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of equity investments granted in period other than options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value for equity investments granted other than options (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Weighted average period of expected recognition of compensation cost for equity investments other than options (in years) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of equity investments granted in period other than options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_TheWarrantsMember', window );">The Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassofWarrantorRightNumberofWarrantsIssued', window );">Number of warrants issued | technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants, aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassofWarrantorRightVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassofWarrantorRightExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ConsultingFees', window );">Consulting fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantOneMember', window );">GSK Consulting Agreement Warrant One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants, aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantTwoMember', window );">GSK Consulting Agreement Warrant Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants, aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_ConsultingAgreementWarrantThreeMember', window );">Consulting Agreement Warrant Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants, aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_LincolnParkSaleMember', window );">Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">605,367<span></span>
</td>
<td class="nump">1,399,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_LincolnParkSaleMember', window );">Lincoln Park | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_LincolnParkSaleMember', window );">Lincoln Park | Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction', window );">Maximum amount of shares to be sold in transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
<td class="nump">10,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AtMarketIssuanceSalesAgreementMember', window );">At Market Issuance Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds', window );">Commissions paid, percentage of gross proceeds (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AtMarketIssuanceSalesAgreementMember', window );">At Market Issuance Sales Agreement | Roth Capital Partners and National Securities Corporation | Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice', window );">Aggregate sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AtMarketIssuanceSalesAgreementMember', window );">At Market Issuance Sales Agreement | Oppenheimer &amp; Co. Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice', window );">Aggregate sales price | $</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds', window );">Commissions paid, percentage of gross proceeds (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from registered offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightInitialExercisePeriod', window );">Warrants, initial exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants, aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_June2018RegisteredDirectOfferingMember', window );">June 2018 Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassofWarrantorRightExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightInitialExercisePeriod', window );">Warrants, initial exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from registered offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_UnitsSoldInPeriod', window );">Units sold in period (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_UnitOfferingUnitPricePerShare', window );">Unit offering (in dollars per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember', window );">March 2019 Registered Direct Offerings | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_UnitOfferingUnitPricePerShare', window );">Unit offering (in dollars per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price per warrant (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from registered offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_UnitOfferingUnitPricePerShare', window );">Unit offering (in dollars per unit) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember', window );">April Offerings | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares of common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassOfWarrantOrRightInitialExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassOfWarrantOrRightInitialExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassofWarrantorRightAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassofWarrantorRightAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassofWarrantorRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassofWarrantorRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassofWarrantorRightNumberofWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassofWarrantorRightNumberofWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ClassofWarrantorRightVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ClassofWarrantorRightVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SaleOfStockFeesPaidPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Maximum Amount Of Common Stock To Be Sold In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Aggregated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_UnitOfferingUnitPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unit Offering Unit Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_UnitOfferingUnitPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_UnitsSoldInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units Sold In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_UnitsSoldInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mbx_StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mbx_StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_TheWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbx_TheWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbx_GSKConsultingAgreementWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_ConsultingAgreementWarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbx_ConsultingAgreementWarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_LincolnParkSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_LincolnParkSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbx_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbx_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_AtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_OppenheimerCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_OppenheimerCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_June2018RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_June2018RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_March2019RegisteredDirectOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbx_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbx_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbx_AprilOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6636298480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not expect to pay any significant federal, state, or foreign income taxes in 2019 as a result of the losses recorded during the three and nine months ended September&#160;30, 2019 and the additional losses expected for the remainder of 2019 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of September&#160;30, 2019, the Company maintained a full valuation allowance for all deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded an income tax benefit for the three and nine months ended September 30, 2019 of $0.2 million resulting in a quarterly effective tax rate of 5.2% and an annual effective rate of 1.4%. The total income tax benefit is comprised of research and development tax credits recoverable, associated with Moleculin Australia Pty Ltd., (MAPL), a wholly owned subsidiary formed in June 2018, related to preclinical development in Australia for WP1732, an analog of WP1066. Aside from the Australia tax credit, the Company has recorded no income taxes for the three and nine months ended September&#160;30, 2019 and 2018. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants and valuation allowances on the Company&#8217;s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6615674192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid expenses and other current assets consist of the following (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.064327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vendor prepayments and deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-trade receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September&#160;30, 2019 and at December 31, 2018 (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:23.000000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.882353%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.117647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.235294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.823529%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liabilities</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Measured at Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">in Active</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Assets (Level 1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unobservable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 3)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of December 31, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Level 3 Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The table below (in thousands) of Level 3 liabilities begins with the valuation as of the beginning of the third quarter and then is adjusted for the issuances and exercises that occurred during the third quarter of 2019 and adjusts for balances for changes in fair value that occurred during the current quarter. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:56.918129%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Long-Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value - net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;The table below (in thousands) of Level 3 liabilities begins with the valuation as of December&#160;31, 2018 and then is adjusted for the issuances and exercises, and changes in fair value that occurred during the nine months ended September&#160;30, 2019. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:54.140351%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Long-Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,328)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,174)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,174)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value -  net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,059)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,059)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>mbx-20190930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mbx="http://www.moleculin.com/20190930"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mbx-20190930.xsd" xlink:type="simple"/>
    <context id="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7c85ac00e67c48559bae7aff48334e41_I20191108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2019-11-08</instant>
        </period>
    </context>
    <context id="i658888d65697477c8bdf7f277240e630_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id8ab107b4fc145aa9e410c1077fc257f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i114bd5e9a8244f23bea013dccf03d439_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i50a5d43efb884dd483ae1a865e745eba_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0dd2efefa5274aa1a8f2a55f0852dd1a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i67f67e63bde64896b6be0cd287af8360_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic74fa480b48548fcb3f47ebd9af912da_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1e191fc355f64d22a595d839903d46d5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib2c767c50b21430cbcb5d42f9d4fd136_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iaeb8fc5d43ae43fca34bb33ecfcdf46c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i31a8d3d8b10b4b7e8f4bd5b548ead03e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie983009200a54629a89ffbfa2cb7f380_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9dc0d29d80ec4048ad2f652630bde7da_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifbdd2af8e4d642e1b38acd3209e7555d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="idd0ff7a1031f4a39b51e586b6cd222d6_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5ded679e60bf43f8a1f4e944669f3068_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if283467953714adaa4dbed6b2b274c45_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifaafa1f6602348a5b935698ec678c979_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id3e2febc71144313af2aeac4c7380281_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if6b4e969450c437790071f03f750f80e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia0d0afcd4335499d9e893ac0fe43a745_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7acb7f4d36654d6aaa455805fd5c6315_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i978af72bda7f4cdd9be415879b75924c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia243c08879a44b0faf74e1d1174ed227_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0247f93d3c7f48b79cc2f61f28823bc3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0d99b3bb92ec4d6ba3098d7f73a6bceb_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1e90206e9605402a8453b05d60c725f1_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifcb6cf7dac114e15b0924f118be98bfc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i10dbdf0540504f7ab8fc60ae4a1261b0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6d43a3d31a684c7898dc1177b7e32f2c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5f0a67ae93e4a0fbe9ed5c48e3b8c58_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LicenceRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea6b42302d064af99a04ff7719b2ffe4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2a5d1f7a1ea941aeb1aebd6c4114bfb5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2a0b19ebdcf34ae2bd120ba45f2990ba_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85a013c63ce649f6adc0f00d0053d9e8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i511e28680ebf4b96856998ec784196c8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib5c10695ca664bf5ba8f73db1e940f69_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6198e1f6f1d940ba8beb2aa6c66ee4ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i66751d7b8a8046c5870329c2d7f9b432_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i698da61e696241338dc1d0d51f6ee26f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4b54a748ee7147f8960b4e3c01fda1b5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i73f912538dc243708b1c08523fce0322_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i7f3883a699ce4e02b970417d508d4ad7_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i3ca2487f82e44a2d874e72ac389555e3_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i7bb5c9e8ad114039be905d2ce6a2f928_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i1499fe2de067467d92d06bf6af15d71f_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i4c1a22242df74771b68a9b7d49a044ea_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i993b33833a034e6287f0b8bca653f504_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i019f3c2995584a11884f6a959327107e_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if668eee949014fecb89a24b65ff223a8_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018IssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i9e84c009114a45de864360cb755f97d2_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i81d7cce25b87468db25b99f7b4ec4a5f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ib11fd7e524cb4871884958f022962fd8_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ic74298b670ca4645ae764781cf988f36_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ie58e6bb80ae84986b925d657b40bd986_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iccf298971c424b638760ec464c4f3e3b_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i8f19c66cce8b4632acc641adacd87dc5_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i5a55ef48475e4201bc338d2dca5da777_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i773749c5e55246028373864551af9e8d_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i87044ed8d26543a698744dcd07920f10_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia7c13ec668974c76b242c324030b9a8d_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i4c5aeb81499c4d30a2c9a5f3456dba46_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i475cf3e6dd1a4bc68203346a5e4ddd00_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ia59c9518ea0244de9d05ecac711dafd4_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i6dc0cbeab3aa44b48883e4da0862b3bf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mbx:AnimalLifeScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibaa5d1878a8449bbbfb93f6bcb30609b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id4ec7928d44f45ea880ca27fb60483ae_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mbx:AuthorityAxis">mbx:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id7d483fa5b8b4a508aa8033181369c0b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibb53084bb5d5439da0fc3b7ce0bac811_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5dd7f29a819443ba880b572c77f75db8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i43ba623e5dc34281830bac2c5b222d0b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4d184260db97490785df4ce8f01a87f4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1bb96a49c87b43728767fc948cbd81a0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3e02f1d5e0b843aa9cefaba9fe3c4bd4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i010c1a26c61e446aadddfcdda2856af2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iacbd36b98aa84664bebd964e031364e7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i285e6798fd8943ccb8ce51b198c79b4c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6ffd58e0885541359bfea5e4d56a4af2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id3707bb56148497495ea24016f264a35_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib34e1490cda548bdaab67ad8ede83e51_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i833cbb966fe54a1dbf89b625b300e6a7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i57abc24e231945ddb977a7587f1bc971_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a7f1136ba8448bfa401f14716d6bdc5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i219719edc1b9438090dbeae77bf96672_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbx:WarrantLiabiltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icfdda18b689c40d8a99d07a7fce046cd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8704f5f266694aa9b6f1e5fc38343f5f_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i0764deeff02e4de2af7c0933afdb419b_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i828883bbb66748609912c14fccab2dc0_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ic7679c4528b848609353c11a6dc439fd_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i8fdd5e53f5094aada2975171e573b157_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i0ca157a098ae4304a258adc86a04a5b6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i08cab3276359415a9615b407edca1b58_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id58152a5a8294f01b352ea46be89ca0e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic4c5782835d042a38441551c941b2df0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3468782c8cf7406292dddbcdcb10f2e6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie3b3edd6398a45bfa280974c3f953e3e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibdddec1576174893ac672d9353477c60_I20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="ic4e01f1ab9534250ba00bf6fed63b50e_D20190425-20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-25</startDate>
            <endDate>2019-04-25</endDate>
        </period>
    </context>
    <context id="ifca03e3808584abfb0298f0b407b56ac_I20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwitersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="ia04057d9a2fc47f59c529617eb6148da_I20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="i0ff20b788d224ad3a44277ae0c89865e_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="idfa81cbdf3044194a501897570de6f30_I20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwitersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic650d629ddbe42bba07cd7284425b9cb_D20181004-20181004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="i2b95e4a080574cb187b7baa5845b5bc7_D20181004-20181004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="ie0294ca4bdf04a0a9eca45bd94dea472_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i38daafc04f49458db341d48f10e1fbe3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2af2bc87c2d14e3faa7aa256386e955c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6670a76fcc104cb499360b871805a581_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:LincolnParkSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9b480bb73120461ead91f6bfb97297dc_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:RothCapitalPartnersLLCAndNationalSecuritiesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i5395f33565804b6db870e49ee1f42631_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OppenheimerCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="i4bbdedafb3e34aa6ae001a6d102bb5ea_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OppenheimerCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i944e3ebf4e3447758b5f5ad06e16b8d3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mbx:StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic11172b4c23840729a0c55b50453ef6b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7c80993834594538b743751a71aac719_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i2c39d2de985d4affbdbb368f73d64943_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if80a49b1ac35464ca409df350165e50c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i84c2d53697dc4799b0f1c3663013ed3f_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9a7f681b9d1a4c9a9ea32d44511a7e37_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic732ea1178074f47a9dc97cb065ced73_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iac0f11dd922044268e807fecd4317991_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i13547ca083ed457da93a472804befa90_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i47d423e14ef8484ca70b7db69ffb12f3_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6a3d37009bad40bcbbe66bfb5272cfd4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie587b47ea845420dab0c9acddca354f8_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i76cfe79a8ccc44f1a1b37b902e2066fa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i29e6f95a02bb48c59456c43de158162f_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id6bbd1cc266d4e28b55786247b4551ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if6aba8c1ca904a9bbabe93cdea1880d0_D20170729-20170729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2017-07-29</startDate>
            <endDate>2017-07-29</endDate>
        </period>
    </context>
    <context id="i7b9663d77efe491f97c917d37bd60486_I20170729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-29</instant>
        </period>
    </context>
    <context id="icd06781e67be410c92ac95aa2495a7db_I20170729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:GSKConsultingAgreementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-29</instant>
        </period>
    </context>
    <context id="i2e838cce41cb48e980a2b72acf45b359_I20170729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:GSKConsultingAgreementWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-29</instant>
        </period>
    </context>
    <context id="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-29</startDate>
            <endDate>2017-07-29</endDate>
        </period>
    </context>
    <context id="ia621ad5cb56b4f519b43b8d05d571153_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:ConsultingAgreementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ice90c9c153c9457994fb3428ae482f66_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:ConsultingAgreementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i06a1277d53a849948a8725927997052c_D20190708-20190708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-08</startDate>
            <endDate>2019-07-08</endDate>
        </period>
    </context>
    <context id="id3cdb4704f2241f7bf6422f7e0974142_I20190708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-08</instant>
        </period>
    </context>
    <context id="i1792812536944689b19b7c33818e27e0_I20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-08</instant>
        </period>
    </context>
    <context id="i743b8f15d1954cd1977b8bf32aa43aa0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8aa13f97f5742a3afa1fb7e64d1af57_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbx:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i6cbda1bd25cd4cd7ab24c983a3515b9e_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i11095fb1fa8d4f1a99847b1a8454b970_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:June2018RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i63863dee744943d8b707c78817d930ed_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1617ea995ee541e797427260cfd1509c_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i31991190cd3e40a2857e50efaa21c859_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0db6bce61f314f58ae7094418825cba1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:March2019RegisteredDirectOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ied5f752a87a043319ef30dc7b1278714_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i676b8255b2e542be8196edfc27042486_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbx:AprilOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i816a05948bde4ad3ab07190983382b45_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i4d3b7c28de3e409ab196587e0ef6e3b9_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="ife26a4e6c9db456586eec4fb4d9b4058_I20180322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-22</instant>
        </period>
    </context>
    <context id="i32cccf3548364065976506f8bb9f0ce0_D20180322-20180322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-22</startDate>
            <endDate>2018-03-22</endDate>
        </period>
    </context>
    <context id="i7d2aeadcc3b7480899be3e16b8a13854_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i5b329d2fb15249cbabe0efe9cfb5aa8a_D20190831-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-31</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ia823a60ecb104dedb9bf6190868e582c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i86c8d7aea62b452da49a9315e073e07a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:OlympiaDriveWBellfortLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i664f42f1665c485c853202fc74ba4d18_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if1d94dee648346efb077db14d8fbd8ec_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0c55769a2d6349beb36762d47f51c0ae_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbx:SubmissionOfNDAAndReceiptOfFirstMarketingApprovalForSaleOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6a3bb46bfb304e42ab171f7dfca58b9c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0ec29135c33746a293feac556994b9e6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i490694ff28c945c0970bd1b5b00026d8_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia0f36e65608b4660897d32d69ff25cdb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb689274badf4dc5ba81def9e3ba4777_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2016-05-02</startDate>
            <endDate>2016-05-02</endDate>
        </period>
    </context>
    <context id="i2399e296e4074ad8812022575df5b89e_D20190430-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="iea85e97e50094e9d81434a25899adfb3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie435b286972e4f7ea765d0391fbceef7_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i03cfdc63ce24474c9076a3ed88c23973_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4cf0e3597d934e9c84c3d513f1c63b8c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i921f1f39a083428c9445130e7d4459eb_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i442d97ffc8c34dfdb6c0f85109bcfe82_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i4177a6893406483a97433eb0e53c41da_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5fd4d78cf6204458b1ee511c741627f6_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i84dd43168aa14c0ba971eed3e33aab51_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4aabb04846bf431c9fecd7123d274260_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i7b81d0dea25642c59af5126ab6197c98_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic1546f03b3854c86bdcc7ffe18a533ef_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idb95c8a4307d477fb7b1a627137efc1d_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="ic028dc6b564848f8a736e7c1a222fe61_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="i213f24715e7642f782c9022686a24919_I20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:DerminMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-08</instant>
        </period>
    </context>
    <context id="i13dfe851934d44768ccba995e1db6556_D20190219-20190219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-02-19</endDate>
        </period>
    </context>
    <context id="i892ca0d0325349b29aa4133a6747e7f1_I20190219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mbx:PeriodAxis">mbx:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="i73c05bdb824e4b5aa9eb2f176d9c0de9_I20190219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mbx:PeriodAxis">mbx:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbx:WPDPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="technology">
        <measure>mbx:technology</measure>
    </unit>
    <unit id="candidate">
        <measure>mbx:candidate</measure>
    </unit>
    <unit id="drug">
        <measure>mbx:drug</measure>
    </unit>
    <unit id="clinicaltrial">
        <measure>mbx:clinicalTrial</measure>
    </unit>
    <unit id="project">
        <measure>mbx:project</measure>
    </unit>
    <unit id="segment">
        <measure>mbx:segment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMC0xLTEtMS0w_8b8cf685-1f5f-42be-a997-c033603a190b">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMS0xLTEtMS0w_39651c65-69c6-43ad-9f92-90b656740229">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGFibGU6ZWFmMjViMmJjYTNlNDA3ZTkxZjU5NWY4YmI4M2Y0YzkvdGFibGVyYW5nZTplYWYyNWIyYmNhM2U0MDdlOTFmNTk1ZjhiYjgzZjRjOV8xMi0xLTEtMS0w_16c42b14-49e4-439a-b131-b3e54839f4cd">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGV4dHJlZ2lvbjpmMzZhZmFlNWE5Yjc0YWEwOWVkOWI0MWYzZjU3YTgyMF84Mg_66f10d07-fd36-4354-90a2-2284a3340239">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80L2ZyYWc6ZjM2YWZhZTVhOWI3NGFhMDllZDliNDFmM2Y1N2E4MjAvdGV4dHJlZ2lvbjpmMzZhZmFlNWE5Yjc0YWEwOWVkOWI0MWYzZjU3YTgyMF84Mw_c0218a15-4c47-4958-9224-bbd106ec48b3">0001659617</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY0OTI2NzQ1NjEzNg_c203f143-78a7-490e-b73e-32b489147d7d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mbx:ClassofWarrantorRightAgreementPeriod
      contextRef="if6aba8c1ca904a9bbabe93cdea1880d0_D20170729-20170729"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzcyMQ_9e5789a7-6205-4556-8350-0fb32f1e123d">P12M</mbx:ClassofWarrantorRightAgreementPeriod>
    <mbx:ClassofWarrantorRightExpirationPeriod
      contextRef="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODM2NQ_0243ffb2-eae1-40d2-9343-bc1cb403c4d5">P5Y</mbx:ClassofWarrantorRightExpirationPeriod>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="i06a1277d53a849948a8725927997052c_D20190708-20190708"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTE4MQ_bd9f0e14-58b3-4547-8588-62c23121c211">P3Y</mbx:ClassOfWarrantOrRightTerm>
    <mbx:ClassOfWarrantOrRightInitialExercisePeriod
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAzNTE_dc4c3f39-7e46-4a6e-916d-e8c0623716e3">P6M</mbx:ClassOfWarrantOrRightInitialExercisePeriod>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA1NTQ_b2561df1-708d-4b79-82bd-4bfa1c75f45e">P5Y</mbx:ClassOfWarrantOrRightTerm>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="i816a05948bde4ad3ab07190983382b45_D20160501-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjk1NQ_b57729a6-ddb3-4566-b0b4-be41f4b8b523">P5Y</mbx:ClassOfWarrantOrRightTerm>
    <mbx:LicensingAgreementTerm
      contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgxOQ_a802d1b7-06a0-4544-aeec-9aa89cbf575a">P3Y</mbx:LicensingAgreementTerm>
    <dei:DocumentType
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV84NA_51db8a03-7574-493e-a6e8-bf33350edd0b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8xMDk5NTExNjMwMDg4_9ff240c7-d7f6-44b2-8dd8-380a52c008df">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDk_4b1e23dc-e843-4249-8ef3-8ac01d60f825">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE4_a241b419-26e1-448d-843e-d11197e809ce">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEy_22618a2c-3a08-43ac-87db-943ddf54dc45">001-37758</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8wLTAtMS0xLTA_05bd9c02-f985-44a4-9b1a-46831c81bd7e">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8yLTAtMS0xLTA_0df36d13-6075-4cc4-be7e-5dce95f11484">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl8yLTQtMS0xLTA_3e62de46-b0d4-4720-9acd-1d94ad7f1d4e">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl80LTAtMS0xLTA_d5bfba2b-8831-42a6-ae52-61171c6b4714">5300 Memorial Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl80LTItMS0xLTA_3d1b2a0b-e379-4f66-aafd-1ad2ba183ea6">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTAtMS0xLTA_fed3e04b-4cca-42dc-96e4-445a3f892294">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTItMS0xLTA_edd679b5-2e36-43b2-96fa-31a9df03c2ba">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MzQ5YTNhZWQ2ZWZmNDNjZmJhZjYwYzM3NTkyN2ZlYmYvdGFibGVyYW5nZTozNDlhM2FlZDZlZmY0M2NmYmFmNjBjMzc1OTI3ZmViZl81LTQtMS0xLTA_8565cd85-de73-4762-89c9-28d062b427d4">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDA3_4bd96ad6-e583-401e-80e8-90dbd118daeb">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE5_bddac13f-dfed-4896-9175-30ad73312d2d">300-5160</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEz_dac009d8-9408-426e-99ba-ff44bd392db7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDA5_8376303d-e954-494a-afdd-b658126264be">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8wLTItMS0xLTAvdGV4dHJlZ2lvbjplYWEyNDAzYjNhMDY0NjYxYmUwYjEyZjk5OGYyZGYxYl8zMQ_5350472c-e4c5-4fee-abe7-463bafebb1f9">true</dei:EntitySmallBusiness>
    <dei:EntityFilerCategory
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8xLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTJiMGIxYTZiOTg0NmNmODhmZTMyZjRjZmZlMjk5Zl81_9e94e928-ba5b-415f-bfb7-4873d478881b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6ZTJhNjcxODQxYzUxNDVhMDkxZDQwODdiZDNiOTljM2YvdGFibGVyYW5nZTplMmE2NzE4NDFjNTE0NWEwOTFkNDA4N2JkM2I5OWMzZl8xLTItMS0xLTAvdGV4dHJlZ2lvbjoxMzM2ZmY3MTdjNjE0MmE1YmZiMDUxNDhlMjAzYjA0MF8yOQ_bc0b8982-0164-4e8f-83f3-e4808c207afd">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDEx_b96bc152-3c8c-4cce-9276-ce3b9ebcc7cc">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8yMDE0_47ebc022-1d04-4631-b751-f945666e1c30">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTAtMS0xLTA_9aea3db1-fadd-47b6-a404-dfcf98594068">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTEtMS0xLTA_6696516f-f362-46fb-b5d2-bde7e8db8846">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGFibGU6MTFiNGYxNDgxZDk0NDE4MTlmYmUxNWM4NzAwYTAwY2YvdGFibGVyYW5nZToxMWI0ZjE0ODFkOTQ0MTgxOWZiZTE1Yzg3MDBhMDBjZl8xLTItMS0xLTA_2d2b8033-d3d4-4225-bb42-67b74b87ffc4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7c85ac00e67c48559bae7aff48334e41_I20191108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xL2ZyYWc6MmE5YWI5YWM3MmYyNDMyNmFiNDRlNTg0ODRkOGExNzEvdGV4dHJlZ2lvbjoyYTlhYjlhYzcyZjI0MzI2YWI0NGU1ODQ4NGQ4YTE3MV8xOTUw_ca759fb7-62aa-4ff8-8663-32ff1845b923"
      unitRef="shares">45727700</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNC0xLTEtMS0w_bfdadb76-b532-4377-9f5c-f7b26aadbaa7"
      unitRef="usd">15409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNC0zLTEtMS0w_921ff6d5-40e8-4f7e-8772-1dfd6395d45d"
      unitRef="usd">7134000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNS0xLTEtMS0w_b187c732-6008-4a9e-9efa-b3a3679dd696"
      unitRef="usd">3177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNS0zLTEtMS0w_dcf4f5ef-dee7-4ce4-b045-a87c586cd4d4"
      unitRef="usd">840000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNi0xLTEtMS0w_24bf3997-e60d-4e5a-b0fb-4e4835d10bcf"
      unitRef="usd">18586000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNi0zLTEtMS0w_0e411368-71f6-41cd-92f5-46a715bf85fb"
      unitRef="usd">7974000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNy0xLTEtMS0w_d52a189b-880f-499d-8993-73d0d507d70b"
      unitRef="usd">358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfNy0zLTEtMS0w_262ec169-1ca6-4553-90dc-d8c6037cea04"
      unitRef="usd">463000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOC0xLTEtMS0w_6ee8bf7b-bb9d-4816-b910-a8ad6917b0f5"
      unitRef="usd">11148000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOC0zLTEtMS0w_0be550f6-53e9-4b32-b72e-3c1e3455fe18"
      unitRef="usd">11148000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfOS0xLTEtMS0w_29305dc8-13f9-42ad-85ce-dfa20b9e9942"
      unitRef="usd">306000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTAtMS0xLTEtMA_66056f2a-a960-42fe-8790-e726d1d30db0"
      unitRef="usd">30398000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTAtMy0xLTEtMA_516666cf-37eb-47fe-a311-198f28c9b0ef"
      unitRef="usd">19585000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTMtMS0xLTEtMA_f8a44b18-aaf3-46c1-a72e-d9b30f81fd93"
      unitRef="usd">3188000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTMtMy0xLTEtMA_d242a3bb-1eb6-49d8-b372-60de37156f00"
      unitRef="usd">1246000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTQtMS0xLTEtMA_2fffdae7-dba2-42bf-a177-4f9ae4c728ad"
      unitRef="usd">1111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTQtMy0xLTEtMA_7b1c59f8-7117-494d-804b-efec9e2bc0c7"
      unitRef="usd">2452000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTUtMS0xLTEtMA_81364296-ed9a-4d73-af08-46fdae9fe7b9"
      unitRef="usd">6820000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTUtMy0xLTEtMA_84fbe966-230b-4d89-8bae-8312ca446da6"
      unitRef="usd">180000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTYtMS0xLTEtMA_0c0dbee5-53f9-40a0-ac3f-c4fcbde5e577"
      unitRef="usd">11119000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTYtMy0xLTEtMA_382b6959-f8c6-4afe-b15a-01bce7c86088"
      unitRef="usd">3878000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTctMS0xLTEtMA_4ad26483-656a-4f58-88e0-de2fcecf8f98"
      unitRef="usd">304000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTgtMy0xLTEtMA_e879e2a0-0239-4ef8-be60-6a05b1951aa7"
      unitRef="usd">107000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTktMS0xLTEtMA_f3db1de0-b39f-488e-8074-2f062ceecbb7"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMTktMy0xLTEtMA_c1a65b8e-bb7d-4fe6-aa7a-c531f9279a2b"
      unitRef="usd">1328000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjAtMS0xLTEtMA_6d8e8d44-4d07-4fa5-80ea-292c96153bfc"
      unitRef="usd">11423000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjAtMy0xLTEtMA_04036a8e-233a-4021-a727-9576664bd68f"
      unitRef="usd">5313000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjEtMS0xLTEtMA_5e6153b5-6cbf-4141-9875-9dfedcc8422a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjEtMy0xLTEtMA_8787a052-a933-48a1-8c0a-f3de38afa233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzIx_65dffff2-bf22-4d47-9f03-2fb2c307a846"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzIx_fd20fa64-fcc7-4f39-a3a5-bdf8722ab934"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzM1_835eea53-16a3-48de-a73c-7a467dae2882"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzM1_ee2b9a3a-ef92-44ac-8183-dacbf4291f67"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_0cae8c65-9a15-4a05-9d19-ef460fbc24e3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_256c39fd-3dca-448e-9337-bd7035ab90b3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_65669ebf-28d5-4404-8853-fdd52a54787f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmExY2RmNWUyMjRmNzQyYzQ5YTc2ZWQyY2Y4NTE4MDA1XzU3_de1ad32e-ecf7-4fa6-86a2-daed3aceaee5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMS0xLTEtMA_6d0e40a3-c15b-42b8-9944-b8919db0ffce"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjMtMy0xLTEtMA_63a8733a-1ddb-40fc-b41e-72f6f0300833"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzE4_25c8af86-1f2e-474f-860a-01104d8b8405"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzE4_60de7885-8a7c-44d5-997b-1f2d7bc64dac"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzMy_68963527-bb77-4d48-98e3-95133ac2d940"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzQw_9ca7ff38-b7f8-4e1b-8bb2-d45c8ea3151b"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzEwNA_6bdc7fe5-7a60-4849-85de-667b642a4e76"
      unitRef="shares">45727700</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzEwNA_d0031ee2-7a63-46d1-bde8-6f81b8510eac"
      unitRef="shares">45727700</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzExMQ_074101d4-b584-43b3-8d52-41e1a7b167c7"
      unitRef="shares">28528663</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOmY4MjQ5MDljZjM2ZjRhYWY5YmM4MjRhYjA5MWM3MzQ3XzExMQ_309f6b66-04ee-40dd-8154-a8a11f1d0e9f"
      unitRef="shares">28528663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMS0xLTEtMA_43f3e35d-97b6-4d9b-9bb3-aef7774f9882"
      unitRef="usd">46000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjQtMy0xLTEtMA_f65e7900-2b81-4801-8773-e39fa12babaf"
      unitRef="usd">29000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjUtMS0xLTEtMA_f5b591e3-1e30-4428-8a52-f62687565e5b"
      unitRef="usd">54673000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjUtMy0xLTEtMA_037d54bf-2377-4a12-bca9-baab9f57f830"
      unitRef="usd">40564000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AociBeforeTaxAttributableToParent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjYtMS0xLTEtMA_cb3921a2-f83a-4749-949d-41b7872e2f7d"
      unitRef="usd">19000</us-gaap:AociBeforeTaxAttributableToParent>
    <us-gaap:AociBeforeTaxAttributableToParent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjYtMy0xLTEtMA_4ea8cb48-ca05-45d0-b246-bbf9d454aef3"
      unitRef="usd">35000</us-gaap:AociBeforeTaxAttributableToParent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjctMS0xLTEtMA_9cd7fecb-3f06-4c6e-8658-198444e0720b"
      unitRef="usd">-35763000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjctMy0xLTEtMA_878986ac-dff7-4b01-af84-58f28a6548fc"
      unitRef="usd">-26356000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjgtMS0xLTEtMA_a1f8a2fb-fede-4755-8055-9f4c5687627c"
      unitRef="usd">18975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjgtMy0xLTEtMA_43dae111-fe73-452b-93e7-3aa53c173f5e"
      unitRef="usd">14272000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjktMS0xLTEtMA_de97cbf3-23c0-4cbd-ba2b-8875cfd54530"
      unitRef="usd">30398000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xNi9mcmFnOjNlOGE2YmUxZmJlNDQ0ZWE4ZDIxZGFmNTAzYWRmZWYxL3RhYmxlOjRlNWRlZGY4YWMzZDQ1MDNhMTA0OWIyOTU3NWExODc4L3RhYmxlcmFuZ2U6NGU1ZGVkZjhhYzNkNDUwM2ExMDQ5YjI5NTc1YTE4NzhfMjktMy0xLTEtMA_d4e22bae-cc2c-4acd-a6d8-bff997593f1a"
      unitRef="usd">19585000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi0xLTEtMS0w_d217009e-a06c-425b-9dfd-f76aea83ca5e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi0zLTEtMS0w_ba27d546-d724-42ba-97e7-fce2b0b1c194"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi01LTEtMS0w_27cab1a1-1377-4405-835f-0709a33cfcd5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMi03LTEtMS0w_d2cac3c1-c633-474f-ae8c-7f64c410a38a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS0xLTEtMS0w_745615d6-6ef0-46ba-a78c-3060c2d79a20"
      unitRef="usd">2785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS0zLTEtMS0w_28bb8126-7660-4ccd-8383-7c84c116902c"
      unitRef="usd">1332000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS01LTEtMS0w_6c8fe3c7-6155-4296-b7ee-a790442b45fe"
      unitRef="usd">7816000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNS03LTEtMS0w_cee52483-678a-4041-9c28-a70a4df56e9e"
      unitRef="usd">6801000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi0xLTEtMS0w_9f027db7-1a66-4934-b322-4e382eea4426"
      unitRef="usd">1672000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi0zLTEtMS0w_d91fddad-b640-4691-b6e3-0f1631e7f1f3"
      unitRef="usd">1248000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi01LTEtMS0w_eed3716b-d197-4914-ab16-7df453791c12"
      unitRef="usd">4748000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNi03LTEtMS0w_21ccb9e0-ba58-47a7-9ff8-8b28bae6a31c"
      unitRef="usd">3859000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy0xLTEtMS0w_8b0695df-550b-49c2-b2c5-0db7ec5421e8"
      unitRef="usd">51000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy0zLTEtMS0w_0e4c9a97-c416-473d-ab7b-b25e10fd0765"
      unitRef="usd">11000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy01LTEtMS0w_5abc7b89-e58d-4ffd-b43b-a1f5436106f9"
      unitRef="usd">147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfNy03LTEtMS0w_979c6f8b-95f5-4c85-85a7-16c1648dc9cc"
      unitRef="usd">27000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC0xLTEtMS0w_c9eea410-f66d-4414-8ba3-4bac18c0c84c"
      unitRef="usd">4508000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC0zLTEtMS0w_530a783e-a5c4-4163-94f3-3ceb20568bbb"
      unitRef="usd">2591000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC01LTEtMS0w_73b7a3a5-e801-4515-a4a6-71eb5b78322f"
      unitRef="usd">12711000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOC03LTEtMS0w_05379d23-acf8-4ec1-853a-04c9b7eb5179"
      unitRef="usd">10687000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS0xLTEtMS0w_da491248-8b7b-4bf4-bf73-eb718e7c0983"
      unitRef="usd">-4508000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS0zLTEtMS0w_66618bea-a633-4806-8499-9fa0ba294fc2"
      unitRef="usd">-2591000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS01LTEtMS0w_4a308744-fe4d-4872-b908-b807772de980"
      unitRef="usd">-12711000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfOS03LTEtMS0w_05193aae-7d65-4d68-b73e-45baf9e64381"
      unitRef="usd">-10687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtMS0xLTEtMA_e08c2f33-3ea9-43d4-8570-e39fcd46d0a7"
      unitRef="usd">-124000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtMy0xLTEtMA_490d0078-7f4e-411e-a81d-c6f59e1422fe"
      unitRef="usd">-573000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtNS0xLTEtMA_5c4614a2-ffaa-4a5e-9f44-ca343e0c1414"
      unitRef="usd">-3059000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTEtNy0xLTEtMA_b49c76ae-7c27-48a6-a825-6a6f7ed6db9f"
      unitRef="usd">-1614000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItMS0xLTEtMA_39c37b5c-6c22-4b3d-90de-0e400dbd59a4"
      unitRef="usd">5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItMy0xLTEtMA_a66ee6bd-d5ba-4984-8404-21b87dd42710"
      unitRef="usd">-21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItNS0xLTEtMA_cee12729-2e64-45b3-bc39-949024eeb5f6"
      unitRef="usd">5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTItNy0xLTEtMA_412d9899-f455-4e09-b5db-e07273ebf7d5"
      unitRef="usd">-23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtMS0xLTEtMA_5dc1f2bd-07e5-45e2-b270-76a914ef2192"
      unitRef="usd">5000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtMy0xLTEtMA_fc3d4086-284d-443b-b175-efe27a1c45b4"
      unitRef="usd">1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtNS0xLTEtMA_78e6d44a-2e40-4b97-8efe-7e86ae240353"
      unitRef="usd">10000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTMtNy0xLTEtMA_c764b98b-77bc-4847-9c02-4f4731c77bdb"
      unitRef="usd">5000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtMS0xLTEtMA_4930c734-5974-4939-b8c6-f2e169e280d0"
      unitRef="usd">-4374000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtMy0xLTEtMA_0930947e-733a-430c-b407-27c61a8e3ee0"
      unitRef="usd">-2038000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtNS0xLTEtMA_a366fb4f-2a9c-4472-8312-4e43f1932f06"
      unitRef="usd">-9637000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTQtNy0xLTEtMA_5e763ed4-7234-4350-b08d-5f50d479d0c4"
      unitRef="usd">-9091000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtMS0xLTEtMTEzNA_94e512dc-bbaa-4239-b451-0f451c773b91"
      unitRef="usd">-229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtMy0xLTEtMTEzNw_c0bca9b9-b84e-4adf-9758-c2ad487aa194"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtNS0xLTEtMTE0OQ_8e0afe20-a2b3-41e7-ab8b-3b2eb9506231"
      unitRef="usd">-229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTUtNy0xLTEtMTE0OQ_2971d1cf-3bf6-41e9-b2a3-883d70c77098"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMS0xLTEtMTE1Mw_04ec1ae3-b2cb-4d4e-ac86-dbc9d44b72ce"
      unitRef="usd">-4145000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMy0xLTEtMTE1Mw_9a6b1abe-148f-4f32-a4ca-4b1bf06a0907"
      unitRef="usd">-2038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNS0xLTEtMTE1Ng_beea93ea-dad0-4878-8733-8b5b7cace53d"
      unitRef="usd">-9408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNy0xLTEtMTE1Ng_a19f63ae-f36f-4f25-b9e1-9c4fba698d8f"
      unitRef="usd">-9091000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMS0xLTEtMA_5342f74d-4d0f-44a6-8ed5-081d52ef992c"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtMy0xLTEtMA_bcec5026-7c5c-46ce-b21c-9ccbd5be1352"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNS0xLTEtMA_0b9bb060-2dbc-4116-a62e-8fb1643a393d"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTYtNy0xLTEtMA_c18324bb-f2d0-4afd-9cef-c949f7a14cd5"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctMS0xLTEtMA_59bb526b-0ffe-413c-b81e-03ee791a0f70"
      unitRef="shares">45464746</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctMy0xLTEtMA_1ea6f21e-008f-4ee9-82b6-9d84b0871b06"
      unitRef="shares">26861497</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctNS0xLTEtMA_8fe15be2-bca0-4bc1-9b3c-26a8096179b7"
      unitRef="shares">39034303</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTctNy0xLTEtMA_6b7cac4a-e38c-4585-b85e-60e9734bb3a2"
      unitRef="shares">25373634</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktMS0xLTEtMA_2aa8e154-12a6-4b58-957b-8faf64fd9076"
      unitRef="usd">-4145000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktMy0xLTEtMA_2519b77b-073c-4037-8f7c-16c64a62b8fe"
      unitRef="usd">-2038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktNS0xLTEtMA_3c16bfc8-4daa-43f8-935a-3d60c04309a3"
      unitRef="usd">-9408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMTktNy0xLTEtMA_f3671904-63f3-4dec-9b00-0e1fe9ab0def"
      unitRef="usd">-9091000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtMS0xLTEtMA_d198c995-8795-4db5-870a-a766868a1ee8"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtMy0xLTEtMA_6f033a20-86c4-4631-82fb-5c98b6951b99"
      unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtNS0xLTEtMA_4df5161f-5bf5-460a-950e-c238d98d078f"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjEtNy0xLTEtMA_2bc63cb8-96ca-44ef-836d-0f89f5b1d0be"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItMS0xLTEtMA_1ffcdf0a-d886-4b32-ba72-ef0cd1b9232a"
      unitRef="usd">-4148000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItMy0xLTEtMA_da9de453-836b-41cc-9b37-8d0fccee3b4e"
      unitRef="usd">-2023000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItNS0xLTEtMA_aa3a975c-6bfa-4ada-860f-3ae8f5231b17"
      unitRef="usd">-9424000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8xOS9mcmFnOjA5YzAyYTRjODEyNTQwYzQ5MjU3OTQxMTU0Mjg2MDRiL3RhYmxlOjkxOTc5ZTFjZDVjMDRhMjE4MzdhNWMzNDM1MTNmN2Q3L3RhYmxlcmFuZ2U6OTE5NzllMWNkNWMwNGEyMTgzN2E1YzM0MzUxM2Y3ZDdfMjItNy0xLTEtMA_33e367db-7dcd-4821-b908-7b9a8622da3b"
      unitRef="usd">-9070000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMy0xLTEtMS0w_1f314181-c1e0-4840-8340-708b94b2b3df"
      unitRef="usd">-9408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMy0zLTEtMS0w_d152d318-e6cd-4eb6-b2ad-7999a6d8ca50"
      unitRef="usd">-9091000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNS0xLTEtMS0w_fcd5dbff-aeaf-4ffe-9b95-8852b3a024b8"
      unitRef="usd">147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNS0zLTEtMS0w_3c36b8dd-00f0-4f85-8d3b-643837f98a6e"
      unitRef="usd">27000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNi0xLTEtMS0w_0b490bc4-f71e-4c80-87c3-aa088d60e67b"
      unitRef="usd">1155000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNi0zLTEtMS0w_c4112504-b9b8-412a-8da9-b1e56aa28ba2"
      unitRef="usd">825000</us-gaap:ShareBasedCompensation>
    <mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0xLTEtMS0xODY3_737abdb6-976f-49ef-ab73-2dba3f5a8f8a"
      unitRef="usd">490000</mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement>
    <mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0zLTEtMS0xODY3_43a05ee3-0475-4758-a11a-a172c564c077"
      unitRef="usd">0</mbx:CommonStockIssuedForLicenceRightsUnderLicenceAgreement>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0xLTEtMS0w_9e07e719-30e9-4e03-a0d2-12940ad105c6"
      unitRef="usd">-3059000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfNy0zLTEtMS0w_baffe250-d133-4784-9957-1067c58c2bdb"
      unitRef="usd">-1614000</us-gaap:FairValueAdjustmentOfWarrants>
    <mbx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOC0xLTEtMS0w_d2cc7ae1-a533-4b52-ab3e-4917d6daa5f9"
      unitRef="usd">10000</mbx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOS0xLTEtMS0w_3f3c8e0f-09a1-4b43-ad5e-36b44a5e255f"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfOS0zLTEtMS0w_e19bc3bb-5eec-4b00-a180-97fba9b7bd8a"
      unitRef="usd">23000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTEtMS0xLTEtMA_458dca0d-130c-42d7-8736-93b1f1f66a62"
      unitRef="usd">2337000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTEtMy0xLTEtMA_2f4ee905-d352-4504-89ff-22846c4cec3b"
      unitRef="usd">172000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTItMS0xLTEtMA_af16d70a-61df-4265-bf83-f9c35e0363a8"
      unitRef="usd">1942000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTItMy0xLTEtMA_a65eee03-1963-441b-ae5e-c43eff34d12d"
      unitRef="usd">-25000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTMtMS0xLTEtMA_228e8cd4-002c-4d18-b29e-d5e784188805"
      unitRef="usd">-1441000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTMtMy0xLTEtMA_810f1869-1edf-4ba9-b355-ac2d038f6b88"
      unitRef="usd">923000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMS0xLTEtNDM_23b5fb2d-c1cf-4e49-9e81-4a64d3ec2c3c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMy0xLTEtNDY_119697d5-bbe7-418a-8ff0-820f65e921cc"
      unitRef="usd">11000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMS0xLTEtMA_5e479839-e4a0-4947-a98b-1359c6e3e17f"
      unitRef="usd">-12521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTQtMy0xLTEtMA_41fe94b9-a6c9-4095-8592-f73b85c66675"
      unitRef="usd">-9093000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTYtMS0xLTEtMA_71763491-f503-435c-94cb-688f99eab92d"
      unitRef="usd">42000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTYtMy0xLTEtMA_6df56daf-f9ed-4e82-a978-00dd034a30b0"
      unitRef="usd">303000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTctMS0xLTEtMA_8795d44f-af35-4a8c-9480-1accfff14c4b"
      unitRef="usd">-42000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTctMy0xLTEtMA_446afb47-04c7-426a-a659-39217f66b071"
      unitRef="usd">-303000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTktMS0xLTEtMA_89fa5ff5-7f31-4d3d-861d-26ec6f5a405f"
      unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMTktMy0xLTEtMA_3c296ab0-27fc-4b2e-a85e-7b00c64601d7"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjAtMS0xLTEtMA_e18f46d4-bf5d-4833-bd92-233ae2e499cc"
      unitRef="usd">1557000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjAtMy0xLTEtMA_136de8d6-5178-414b-9846-60d7fd6e99ef"
      unitRef="usd">15000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjEtMS0xLTEtMA_d5df2e3c-57ad-46e2-87fd-fa990c9cd793"
      unitRef="usd">19292000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjEtMy0xLTEtMA_c428d56b-a894-4c39-b0d8-6860aee48460"
      unitRef="usd">10269000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjItMS0xLTEtMA_04279288-edc7-4b4a-93aa-95f7d721dc69"
      unitRef="usd">20854000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjItMy0xLTEtMA_c22b7fe0-b132-4d84-b6af-83f36e6f4074"
      unitRef="usd">10284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjMtMS0xLTEtMA_70c5a8dc-a928-46ba-97f5-dcc823c1a41e"
      unitRef="usd">-16000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjMtMy0xLTEtMA_958980f7-5c83-4423-8706-085c11cf9469"
      unitRef="usd">-2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjQtMS0xLTEtMA_e67f362f-5593-46fc-a998-7fdd4f0dd6b7"
      unitRef="usd">8275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjQtMy0xLTEtMA_bd5494f7-71d3-4b20-a4e4-a9e2696476f8"
      unitRef="usd">886000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjUtMS0xLTEtMA_ac61df52-c752-4651-a6cb-68392e1a0b5e"
      unitRef="usd">7134000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i114bd5e9a8244f23bea013dccf03d439_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjUtMy0xLTEtMA_a9d21113-00c7-4b66-a9cd-e95a8c3f6f35"
      unitRef="usd">7714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjYtMS0xLTEtMA_3e53c638-7557-45e2-949b-9feb641fcc3d"
      unitRef="usd">15409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjYtMy0xLTEtMA_42233f76-f877-4e25-be5d-9d361593de70"
      unitRef="usd">8600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjktMS0xLTEtMA_f9bd3236-296e-436a-8a82-9e19410849e3"
      unitRef="usd">1000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMjktMy0xLTEtMA_b9d4f7da-78f2-40c3-8d1c-e8658656ce58"
      unitRef="usd">3000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzAtMS0xLTEtMA_1b8612d3-4a48-47f1-9edd-f0f222a8bb0f"
      unitRef="usd">15000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzAtMy0xLTEtMA_91b905d3-97d2-49cc-890c-dc7784b2de4c"
      unitRef="usd">20000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzEtMS0xLTEtMA_22d1a78d-3028-47c1-a3b3-6efe438e637d"
      unitRef="usd">21000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzEtMy0xLTEtMA_3f5920a3-0f9f-44d0-8bdd-afed004ebcdc"
      unitRef="usd">136000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <mbx:LeaseholdImprovementsPaidByLandlord
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzMtMS0xLTEtNTE_49e2bbf3-d335-4630-946f-8adba3ff8145"
      unitRef="usd">0</mbx:LeaseholdImprovementsPaidByLandlord>
    <mbx:LeaseholdImprovementsPaidByLandlord
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzMtMy0xLTEtNTQ_996f27be-767b-471c-ba10-21a1dbc69ba5"
      unitRef="usd">82000</mbx:LeaseholdImprovementsPaidByLandlord>
    <mbx:SharesIssuedInLeiuOfCash
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzUtMS0xLTEtNTE2OA_ce942445-f96a-435c-ab2d-c8e1ba787e51"
      unitRef="usd">490000</mbx:SharesIssuedInLeiuOfCash>
    <mbx:SharesIssuedInLeiuOfCash
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yMi9mcmFnOjQ5ZmMzODZhNmJkYTRjOTA5NWNhN2U5ZTQ0MzNhYzE2L3RhYmxlOmJlZGVkNDU3NzAzNzRhYzI4MDU4YTVkZDliNmQwZWNhL3RhYmxlcmFuZ2U6YmVkZWQ0NTc3MDM3NGFjMjgwNThhNWRkOWI2ZDBlY2FfMzUtMy0xLTEtNTE2OA_943a3786-9075-489d-87b1-870e95864158"
      unitRef="usd">0</mbx:SharesIssuedInLeiuOfCash>
    <us-gaap:SharesOutstanding
      contextRef="i50a5d43efb884dd483ae1a865e745eba_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0xLTEtMS0w_6ab66d33-2d2c-41e6-83b0-8e629f79a13e"
      unitRef="shares">28528663</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i50a5d43efb884dd483ae1a865e745eba_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0zLTEtMS0w_f4d5dbea-6923-4ec1-9007-caa1ffa5f7a6"
      unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0dd2efefa5274aa1a8f2a55f0852dd1a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi01LTEtMS0w_782ae4bd-4424-488c-a893-1addd75b0c3d"
      unitRef="usd">40564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67f67e63bde64896b6be0cd287af8360_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi03LTEtMS0w_17f223f9-32d6-46fb-9a41-b181dc0e8312"
      unitRef="usd">-26356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic74fa480b48548fcb3f47ebd9af912da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi05LTEtMS0w_cbfe6190-2c22-4233-9bed-fe3825cb7beb"
      unitRef="usd">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMi0xMS0xLTEtMA_78c23f2c-0861-4d6e-8c00-28648b86884d"
      unitRef="usd">14272000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0wLTEtMS0wL3RleHRyZWdpb246Nzc1MDY5NWEyZDliNGQ0ZmFlMmUyOWE1ZGVmOWI0YTJfNzA_bf7c4487-a497-4667-a0ae-eb49feb99420"
      unitRef="usd">617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0xLTEtMS0w_98683cca-f817-4f9b-9a5b-6b13f720935b"
      unitRef="shares">5250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0c47ac0738244cceb70f12fd2ab7cbb8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0zLTEtMS0w_5b8497b8-720a-4f7e-901b-05fb05ab346e"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1e191fc355f64d22a595d839903d46d5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy01LTEtMS0w_1a80f534-da81-4fc7-96d8-f5c6b4ab9eb9"
      unitRef="usd">3221000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2c767c50b21430cbcb5d42f9d4fd136_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMy0xMS0xLTEtMA_d45725ab-4fd8-4ab8-8661-ef9fd7e5e2e5"
      unitRef="usd">3226000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iaeb8fc5d43ae43fca34bb33ecfcdf46c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC0xLTEtMS0w_4612647c-e800-486d-aeef-cc616bee5782"
      unitRef="shares">605367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i31a8d3d8b10b4b7e8f4bd5b548ead03e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC01LTEtMS0w_0dfd5129-fbdc-49f7-96b0-1c6098150c07"
      unitRef="usd">883000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNC0xMS0xLTEtMA_14ec95d5-0f07-4238-a477-f7e118ba0edd"
      unitRef="usd">883000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie983009200a54629a89ffbfa2cb7f380_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS0xLTEtMS0w_274bb8d9-faea-4afa-8c93-ca8068405ddb"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS01LTEtMS0w_bf6ae3fd-05f6-4069-a929-f3472fc01eef"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNS0xMS0xLTEtMA_60fd7e71-f34e-4ba7-86b7-8f3f5b2b2b24"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i59651a8e28d5494b93b05f3a0788ddf6_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNi01LTEtMS0w_10e6f41f-d8d5-40a4-9c94-3305d9662123"
      unitRef="usd">348000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNi0xMS0xLTEtMA_48f60c85-e429-4d5c-8286-0264987db45e"
      unitRef="usd">348000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9dc0d29d80ec4048ad2f652630bde7da_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNy03LTEtMS0w_10d33265-5f92-4990-a7f7-d411b159162f"
      unitRef="usd">-4041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNy0xMS0xLTEtMA_0cc27704-b508-488f-95a8-c370104e8fdb"
      unitRef="usd">-4041000</us-gaap:NetIncomeLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="ifbdd2af8e4d642e1b38acd3209e7555d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOC05LTEtMS0w_28f6a83f-ad2e-435c-81b8-9e8cda1ec54e"
      unitRef="usd">-11000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="ie5a58e1eac7f4e59a1d815fde2f7f9a8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOC0xMS0xLTEtMA_81864199-d9fb-413e-84ee-c854e71108a3"
      unitRef="usd">-11000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0xLTEtMS0w_f90683d0-193e-49c0-b1fc-1c9c7c07efa7"
      unitRef="shares">34409030</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i356b435b6d1c4d2b8a953e62fcabc8cf_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0zLTEtMS0w_e751c004-6772-4341-8b33-a9bb6a331b82"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd0ff7a1031f4a39b51e586b6cd222d6_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS01LTEtMS0w_303edd35-d204-4709-a0f3-991968901f51"
      unitRef="usd">45021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ded679e60bf43f8a1f4e944669f3068_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS03LTEtMS0w_a817f4a5-7531-49bc-9833-00f92091a5fd"
      unitRef="usd">-30397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if283467953714adaa4dbed6b2b274c45_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS05LTEtMS0w_dd0a78a6-6d7d-49b8-ae06-9406ec7a1842"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaafa1f6602348a5b935698ec678c979_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfOS0xMS0xLTEtMA_7714d3bc-b0c8-405f-a9af-49b3ecc7fdd2"
      unitRef="usd">14682000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjhjODY0NmNhYTk0YTQzZTFiOGJjYmU2NWJlMGVmMDllXzcw_122fea4f-4f51-4644-9d6d-94fc443be4e8"
      unitRef="usd">1300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMS0xLTEtMA_64907066-c48a-4107-a449-24ab971a01a2"
      unitRef="shares">9375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i88bda0d034ed4b4fa8acb1d2327008e6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMy0xLTEtMA_c14537b0-886e-42d4-a93d-a6832f229d78"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if6b4e969450c437790071f03f750f80e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtNS0xLTEtMA_7e0409c6-1687-4725-a3e1-fd78e8a0e4fa"
      unitRef="usd">3575000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia0d0afcd4335499d9e893ac0fe43a745_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTAtMTEtMS0xLTA_14abe4b3-da0e-4cfe-8628-39fa9037cf26"
      unitRef="usd">3584000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mbx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMS0xLTEtMA_ff116d1e-3627-4c71-bca3-48eb501ca82c"
      unitRef="shares">1413018</mbx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mbx:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="i1de75bc762564c3e9aef00659ec1524f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMy0xLTEtMA_7f61e38f-8421-4a39-b89e-b8a8b2874e98"
      unitRef="usd">2000</mbx:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <mbx:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtNS0xLTEtMA_b3dccf49-e86f-4156-a1c4-af0db683b457"
      unitRef="usd">4729000</mbx:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <mbx:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTEtMTEtMS0xLTA_fd7e23f0-678d-4ed6-a46a-0bbd60af0f4e"
      unitRef="usd">4731000</mbx:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i79f6b40ec0e74bca90c637abea4396f0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTItNS0xLTEtMA_5c1f4cd6-eae9-4426-bded-bf9f825113ab"
      unitRef="usd">318000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTItMTEtMS0xLTA_450b9127-ec37-4135-8900-cad13a70d17d"
      unitRef="usd">318000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7acb7f4d36654d6aaa455805fd5c6315_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTMtNy0xLTEtMA_563683d7-4741-4869-9cd9-d542b688e82e"
      unitRef="usd">-1221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTMtMTEtMS0xLTA_99e25877-1c84-45aa-83f6-f21942a234fc"
      unitRef="usd">-1221000</us-gaap:NetIncomeLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="i978af72bda7f4cdd9be415879b75924c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTQtOS0xLTEtMA_55222ba2-4e62-4b9d-be53-ea94941fa495"
      unitRef="usd">-2000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="id3e2febc71144313af2aeac4c7380281_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTQtMTEtMS0xLTA_6b392f93-824a-41c0-ab49-5bca89918774"
      unitRef="usd">-2000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMS0xLTEtMA_7fbebc40-7343-4d66-9dcf-b43f1dd22839"
      unitRef="shares">45197048</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4114d578188c44b2bc0dfb8d5e61a9e5_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMy0xLTEtMA_51d62d43-3774-4c56-a41b-c1a227f8532d"
      unitRef="usd">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia243c08879a44b0faf74e1d1174ed227_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtNS0xLTEtMA_d31d745b-4140-4ab1-b860-92be1f4311b3"
      unitRef="usd">53643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0247f93d3c7f48b79cc2f61f28823bc3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtNy0xLTEtMA_27f9faea-1cf1-4bab-8240-1a53c60fe360"
      unitRef="usd">-31618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d99b3bb92ec4d6ba3098d7f73a6bceb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtOS0xLTEtMA_b54d658a-d620-4d93-9fd5-a92d1b2fe25e"
      unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e90206e9605402a8453b05d60c725f1_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTUtMTEtMS0xLTA_67b6f9a9-09e5-47bd-913b-88f156ac9b2c"
      unitRef="usd">22092000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMC0xLTEtMjgwMC90ZXh0cmVnaW9uOjZlZmZiZDI0NDNkMTQ4YmE5ODhhM2Q5ZmI4YjFiYTM5XzM4NDgyOTA2OTcyOTg_813546ce-ab53-4b1b-a5fb-12ada9064d65"
      unitRef="usd">59000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifcb6cf7dac114e15b0924f118be98bfc_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMS0xLTEtMTI3_f9a42c07-cbdb-40a2-b128-499a9d7ed651"
      unitRef="shares">100674</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10dbdf0540504f7ab8fc60ae4a1261b0_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtNS0xLTEtMTMz_a8171316-6476-473d-93b8-93e2c73b4f1c"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTYtMTEtMS0xLTEzOQ_4954223c-9e9b-4856-98f5-5520864cd33e"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMS0xLTEtMjA0Mw_511b6fa7-cb2c-4f8c-9b78-4251472641e7"
      unitRef="shares">429978</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a3309111d944596a286d7ef57fd3ce6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMy0xLTEtMjA0Mw_4f01dc52-bbf1-4551-b3f4-dc46ec83198d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6d43a3d31a684c7898dc1177b7e32f2c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMjA0Mw_cb9c123d-d8f3-47b7-823e-ae2adc02e8fd"
      unitRef="usd">489000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic5f0a67ae93e4a0fbe9ed5c48e3b8c58_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTIwNDM_93499856-c6ee-4e97-8982-53dfb21a90bd"
      unitRef="usd">490000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iea6b42302d064af99a04ff7719b2ffe4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMTQz_857b92a3-0765-4467-bbff-fdc4043960ec"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTE0Mw_e0d0a6c4-e67f-4d00-9edf-c3ef2f852134"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2a5d1f7a1ea941aeb1aebd6c4114bfb5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtNy0xLTEtMTQ2_a04b9765-937f-4087-87a6-80f4be171436"
      unitRef="usd">-4145000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMTEtMS0xLTE0Ng_7338f545-ca45-42e2-84db-9fa04addbba6"
      unitRef="usd">-4145000</us-gaap:NetIncomeLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="i2a0b19ebdcf34ae2bd120ba45f2990ba_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktOS0xLTEtMTQ5_4ff72de4-f026-4461-8d61-f2ed3e320ef0"
      unitRef="usd">-3000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMTEtMS0xLTE0OQ_8d93108f-d98e-4f09-baca-8eba5e4c7fc5"
      unitRef="usd">-3000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i85a013c63ce649f6adc0f00d0053d9e8_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMS0xLTEtMTcy_1e2cae39-3869-4f03-b853-4751d87f4dd1"
      unitRef="shares">45727700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i85a013c63ce649f6adc0f00d0053d9e8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMy0xLTEtMTcy_5a5fe7b0-081c-4b62-820d-9bf0f9d1aaa0"
      unitRef="usd">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i511e28680ebf4b96856998ec784196c8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNS0xLTEtMTcy_30052a31-66cc-47cb-8d2d-b3ea16b2946d"
      unitRef="usd">54673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5c10695ca664bf5ba8f73db1e940f69_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNy0xLTEtMTcy_318f023b-3071-4392-b5b1-d6f7e41dc9ec"
      unitRef="usd">-35763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6198e1f6f1d940ba8beb2aa6c66ee4ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtOS0xLTEtMTcy_47ecb8ac-a44c-4116-ae89-b12945315397"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMTEtMS0xLTE3Mg_4b06fc07-20d1-4369-bee0-874a3f1a83b9"
      unitRef="usd">18975000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i66751d7b8a8046c5870329c2d7f9b432_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMS0xLTEtMA_60895e09-aa80-4768-816c-fc88e1bb4579"
      unitRef="shares">21469109</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66751d7b8a8046c5870329c2d7f9b432_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMy0xLTEtMA_8eb985c1-9aa1-4385-a151-de7dcde4774b"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i698da61e696241338dc1d0d51f6ee26f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNS0xLTEtMA_c7c5877c-36ad-44c5-871b-2dea1fca7f02"
      unitRef="usd">31577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b54a748ee7147f8960b4e3c01fda1b5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctNy0xLTEtMA_fe190316-1277-45e9-abd6-a22e3397189d"
      unitRef="usd">-14480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i114bd5e9a8244f23bea013dccf03d439_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTctMTEtMS0xLTA_a7bef673-9706-4ca0-8ec4-77682aa6bed7"
      unitRef="usd">17118000</us-gaap:StockholdersEquity>
    <mbx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMS0xLTEtMA_fcf0a5f9-6655-4d7e-a75a-426cff1409d8"
      unitRef="shares">9752</mbx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mbx:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtNS0xLTEtMA_a7046c27-9123-41a5-b2c9-f22d23de7131"
      unitRef="usd">15000</mbx:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <mbx:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTgtMTEtMS0xLTA_ad686866-b344-4272-9881-74db533b0aaf"
      unitRef="usd">15000</mbx:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMC0xLTEtMC90ZXh0cmVnaW9uOmQ0YzVjZTg0N2ZkNjQxZTQ4MjM5NzVkYjI5ZTI2OGRmXzcw_735c42c3-c157-453f-9f6d-1b18101f4ae4"
      unitRef="usd">809000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMS0xLTEtMA_078c66d7-d98d-4a29-9eb3-3413dc580ceb"
      unitRef="shares">4290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if5f353f4acae4b5393210da0f101e2f0_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMy0xLTEtMA_53447451-b69b-4379-825a-9b0968fe093a"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktNS0xLTEtMA_88dfa92c-7883-4444-bb38-331467347ca2"
      unitRef="usd">5117000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMTktMTEtMS0xLTA_d6b1621d-b918-4b62-9b1e-0b4081b141af"
      unitRef="usd">5122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if9038ec6da0a49479199f3606a7a2f64_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtNS0xLTEtMA_fe2c37fd-6036-4e4e-a027-1d43878bc272"
      unitRef="usd">242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjAtMTEtMS0xLTA_11ccc61a-354a-43bf-bd73-2250e150670f"
      unitRef="usd">242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7f3883a699ce4e02b970417d508d4ad7_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjEtNy0xLTEtMA_6a76cfeb-5223-4f42-ada6-5d05086e78dc"
      unitRef="usd">-1927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73f912538dc243708b1c08523fce0322_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjEtMTEtMS0xLTA_cf350ca7-f9b5-4fde-a624-9090a6c6629f"
      unitRef="usd">-1927000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3ca2487f82e44a2d874e72ac389555e3_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMS0xLTEtMA_592b4062-76fa-49e7-9a3b-e4045ff9c794"
      unitRef="shares">25768861</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ca2487f82e44a2d874e72ac389555e3_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMy0xLTEtMA_8925d30f-1e97-40e7-b226-695be4541a68"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bb5c9e8ad114039be905d2ce6a2f928_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItNS0xLTEtMA_94b2c04f-e9bf-4505-a672-04864a7db3c6"
      unitRef="usd">36951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1499fe2de067467d92d06bf6af15d71f_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItNy0xLTEtMA_f70ecbc0-0106-4208-b366-4d8c6b9aed03"
      unitRef="usd">-16407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c1a22242df74771b68a9b7d49a044ea_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItOS0xLTEtMA_f6f9546e-d6c3-427e-b396-77dcf074df09"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i993b33833a034e6287f0b8bca653f504_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjItMTEtMS0xLTA_3139b5e4-02ca-4dd1-a293-e55d61f9c95a"
      unitRef="usd">20570000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmMzY2NiYjhkYTFhOTQwN2RiZjg1YmIxYzE3ZWMzOGNhXzcw_7465cabb-4291-487e-8440-9e75195b8a7a"
      unitRef="usd">232000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMS0xLTEtMA_ebf3e46e-2a38-4f2b-9a70-2fb5dba6e8eb"
      unitRef="shares">1092636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f0ce1a25c3843ed98210fd6f4af6f54_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMy0xLTEtMA_65e5ca51-68d4-4e83-b085-ee45a390492e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i019f3c2995584a11884f6a959327107e_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtNS0xLTEtMA_04e0cbcd-1649-48a3-963c-52a9b783e83f"
      unitRef="usd">957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if668eee949014fecb89a24b65ff223a8_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjMtMTEtMS0xLTA_be92fc59-3feb-4e86-92e1-c66221a51afc"
      unitRef="usd">958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9e84c009114a45de864360cb755f97d2_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjQtNS0xLTEtMA_54518611-cd73-4ea3-a248-c05a15869d13"
      unitRef="usd">339000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjQtMTEtMS0xLTA_64aa0360-9ced-47e0-895a-607bac1a27c8"
      unitRef="usd">339000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i81d7cce25b87468db25b99f7b4ec4a5f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjUtNy0xLTEtMA_90488d8c-1f98-4f84-a6fd-2aebeb64f354"
      unitRef="usd">-5125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjUtMTEtMS0xLTA_06c404de-9b29-48c2-8b49-9cd2c2a7da7f"
      unitRef="usd">-5125000</us-gaap:NetIncomeLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="ib11fd7e524cb4871884958f022962fd8_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjYtOS0xLTEtMA_ca5d9800-e45b-4ff3-8805-246c30b905df"
      unitRef="usd">6000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjYtMTEtMS0xLTA_3995dc95-4c33-4443-8283-bf1ae51b3980"
      unitRef="usd">6000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="ic74298b670ca4645ae764781cf988f36_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMS0xLTEtMA_314879f1-056e-4b02-b7f0-21eafd22ba58"
      unitRef="shares">26861497</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic74298b670ca4645ae764781cf988f36_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMy0xLTEtMA_ddd0e5b1-697f-44f9-ba8f-7fc737fd5199"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie58e6bb80ae84986b925d657b40bd986_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctNS0xLTEtMA_073e7365-2ba4-4f6a-a969-e93084bbc2ad"
      unitRef="usd">38247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccf298971c424b638760ec464c4f3e3b_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctNy0xLTEtMA_c59ef3c3-e20f-4c0d-bb70-d145c2cdc2ae"
      unitRef="usd">-21532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f19c66cce8b4632acc641adacd87dc5_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctOS0xLTEtMA_febb7138-dd50-4a95-8d2d-7adab24f2887"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a55ef48475e4201bc338d2dca5da777_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfMjctMTEtMS0xLTA_43fc8376-7692-4b5e-873a-94c53f996800"
      unitRef="usd">16748000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i773749c5e55246028373864551af9e8d_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDctNS0xLTEtMTk1_3ad0b0a9-ad18-49a9-86af-283f4fc12aac"
      unitRef="usd">244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDctMTEtMS0xLTE5NQ_dd9f5251-59ea-48fb-b4eb-b6ba1966c7cb"
      unitRef="usd">244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i87044ed8d26543a698744dcd07920f10_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDgtNy0xLTEtMTk1_333d9596-cf3b-41ab-9f42-6d80bb02efbc"
      unitRef="usd">-2038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDgtMTEtMS0xLTE5NQ_fd2c53b5-a6e4-4c2f-ac0b-5dbdf8bed530"
      unitRef="usd">-2038000</us-gaap:NetIncomeLoss>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="ia7c13ec668974c76b242c324030b9a8d_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDktOS0xLTEtMTk1_5a5a2d08-15dd-4255-b3ed-d28ac4deaa3d"
      unitRef="usd">15000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNDktMTEtMS0xLTE5NQ_11f69c6b-4d5c-40a7-8dd6-eccc4b1160e3"
      unitRef="usd">15000</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMS0xLTEtMTk1_a68d4a54-a0da-41ca-9d22-020bec0e622b"
      unitRef="shares">26861497</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibb5f2ac1f0f44ff0b7d57846299709b7_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMy0xLTEtMTk1_d57f31c2-a0c5-4856-9fc9-952365935e77"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c5aeb81499c4d30a2c9a5f3456dba46_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtNS0xLTEtMTk1_8d9fb31b-b46c-4fe9-99a1-2b10bc04ab57"
      unitRef="usd">38491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i475cf3e6dd1a4bc68203346a5e4ddd00_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtNy0xLTEtMTk1_98a8ea9d-3b39-4291-bad6-0dcef3145206"
      unitRef="usd">-23570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia59c9518ea0244de9d05ecac711dafd4_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtOS0xLTEtMTk1_d5a40fd7-76ca-46d5-a4cd-2f11bd01083e"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e1c59f4061d4e3a8723d7f7a3f6e0de_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8yNS9mcmFnOjcwZDU0Njg0NmM5ZDRjZTA5MDA2ZDY5ZmU0ODZjYzFkL3RhYmxlOjYxYWM5MTI2ZTFiODQ5NzFhOWM4NDExZDM1YTMzNDgzL3RhYmxlcmFuZ2U6NjFhYzkxMjZlMWI4NDk3MWE5Yzg0MTFkMzVhMzM0ODNfNTAtMTEtMS0xLTE5NQ_e3d106a7-d9a9-4d89-bc58-43add290724a"
      unitRef="usd">14969000</us-gaap:StockholdersEquity>
    <mbx:NatureOfBusinessAndLiquidityTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfOTUxMQ_c5d64820-0a1b-40f1-8921-408a90c1e91c">Nature of Business and Liquidity&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, with its focus on the treatment of highly resistant cancers via the development of its oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI formed Moleculin Australia Pty. Ltd., (MAPL), a wholly owned subsidiary in June 2018, to begin preclinical development in Australia for WP1732, an analog of WP1066. This enables the Company to enjoy the benefits of certain research and development tax credits in Australia. In February 2019, the Company entered into an agreement with Animal Life Sciences, LLC ("ALI"), where the Company has granted a sublicense to ALI to research, develop, make, have made, use, offer to sell, sell, export or import and commercialize certain licensed products for non-human use and share development data. ALI issued to the Company a 10% interest in ALI. ALI converted into a corporation and became Animal Life Sciences, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Core Technologies - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;MBI has three core technologies with six drug candidates, all of which are based on discoveries made at MD Anderson. These core technologies are 1) Annamycin, 2) its STAT3 Immune/Transcription Modulators, or simply "Immune/Transcription Modulators" WP1066 portfolio and 3) its Metabolism/Glycosylation Inhibitor portfolio, WP1122. The Company&#x2019;s clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We have completed full enrollment and begun treating patients with WP1220, an analog of WP1066, for the topical treatment of cutaneous T-cell lymphoma ("CTCL"), a form of skin cancer, in a clinical trial approved by Polish regulators in January 2019. MBI is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors. With the approval of the Polish clinical trial in January 2019 for WP1220 for the treatment of CTCL, the Company now has three drugs in four clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company believes Annamycin is a "Next Generation Anthracycline" since it is designed to avoid the multidrug resistance mechanisms that typically defeat currently approved anthracyclines, as well as to be non-cardiotoxic, which is the dose limiting toxicity of all currently approved anthracyclines. Annamycin is currently in two Phase I/II clinical trials, and preliminary clinical data suggests that it may have the potential to become the first therapy suitable for the majority of relapsed or refractory AML patients regardless of gene mutations. Additionally, preclinical research in animal models at MD Anderson demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs. Coupled with research demonstrating that Annamycin is capable of accumulating in the lungs at very high levels, this suggests that Annamycin may be well suited to become a treatment for lung-localized tumors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;WP1066 is one of several Immune/Transcription Modulators that appear capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells ("TRegs") while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1&#x3b1;. These transcription factors are widely sought targets that may also play a role in the lack of efficacy of immune checkpoint inhibitors in certain resistant tumors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis and glycosylation. Its lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy ("2-DG") within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Drug Candidates&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; - Within the Company's core technologies, it currently has six drug candidates representing three substantially different approaches to treating cancer. Annamycin is a chemotherapy designed to inhibit the replication of DNA of rapidly dividing cells and is the Company's most mature drug candidate. Annamycin had been in clinical trials pursuant to an investigational new drug application or IND that had been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, the Company resubmitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which the FDA allowed to go into effect in September 2017. The Company has trials open in the US and Poland and is actively recruiting in both countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has five other drug development projects, two of which are also in clinical trials:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;WP1066 has an approved physician-sponsored clinical trial open for enrollment and dosing patients for the treatment of brain tumors and is also being evaluated for another physician-sponsored clinical trial for the potential treatment of pediatric brain tumors, as well as AML and pancreatic cancer,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;WP1220 is an analog of WP1066 for which Polish authorities in January 2019 approved the Company's Clinical Trial Application ("CTA") to study the topical treatment of CTCL, which study reached full enrollment in August 2019,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;WP1732, another analog of WP1066, is being evaluated along with WP1066 for the potential treatment of AML, pancreatic and other cancers, and MBI has begun pre-clinical work that it expects to generate sufficient data for an IND for an intravenous formulation of one of its STAT3 inhibitors, which filing is expected to be submitted in 2021, and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;WP1122 and WP1234 are being evaluated for their potential to treat brain tumors and pancreatic cancer via their ability to inhibit glycolysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Clinical Trials - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that patient recruitment for its Annamycin clinical trial in the US has been slow due to the high number of competitive clinical trials, combined with the FDA&#x2019;s requirement to set the initial dose level relatively low in comparison with previous Annamycin clinical trials. Additionally, the Company believes that patient recruitment for its clinical trial in Poland has been more successful than in the US due to a comparatively lower number of competitive clinical trials and the protocol there being approved to start at a significantly higher dose than in the US with fewer enrollment screening limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018, the physician sponsored WP1066 Phase I clinical trial for the treatment of glioblastoma and melanoma metastasized to the brain, which opened for recruitment in July 2018, began treating patients.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company completed full enrollment in a proof-of-concept clinical trial in Poland to study WP1220, a part of the WP1066 portfolio, for the treatment of CTCL. Polish authorities approved the Company's CTA  for this use in January 2019, and the trial began enrolling patients in March 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Licenses - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company has been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of MBI's drug technologies, as these intellectual property rights are owned in part or entirely by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, the Company filed new patent applications in July 2019 for formulation, synthetic process and reconstitution related to MBI's Annamycin drug product candidate, although there is no assurance that the Company will be successful in obtaining such patent protection. Such technology is also licensed from MD Anderson. Independently from potential patent protection, MBI has received Orphan Drug designation ("ODD") from the FDA for Annamycin for the treatment of AML and for WP1066 for the treatment of glioblastoma. ODD may provide tax and other benefits during product development, and if either product is approved, may lead to a grant of seven-year market exclusivity. Under that exclusivity, which runs from the date of the approval of the New Drug Application ("NDA") in the United States, the FDA generally (there are important exceptions) could not approve another product containing the same drug for the designated indication. The Company also intends to apply for similar status in the European Union ("EU") where market exclusivity could extend to 10 years from the date of Marketing Authorization Application ("MAA") approval. Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (which the Company believes Annamycin would be one), which would preclude approval of any other annamycin product, but there can be no assurance that such exclusivity will be granted. In April 2019, FDA approved the Company's request for Fast Track Designation for Annamycin for the treatment of relapsed or refractory AML. Fast Track Designation, the purpose of which is to expedite drug development and approval, is granted to drugs intended to treat serious conditions and where data demonstrate the potential to address an unmet medical need.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Moleculin, LLC -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; Prior to MBI's initial public offering, the Company acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.&lt;/span&gt;&lt;/div&gt;</mbx:NatureOfBusinessAndLiquidityTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6dc0cbeab3aa44b48883e4da0862b3bf_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTE1MA_122c485e-9ae4-43b3-b4bf-761f56c76112"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <mbx:NumberOfDrugTechnologies
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTI3MQ_6bbd69f3-24e9-4925-bb28-29c7fa3fa12b"
      unitRef="technology">3</mbx:NumberOfDrugTechnologies>
    <mbx:NumberofDrugCandidates
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMTI5Nw_b6c1a425-1860-450d-ae3e-50932dfd963f"
      unitRef="candidate">6</mbx:NumberofDrugCandidates>
    <mbx:NumberofDrugsinClinicalTrials
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMjM4Ng_2a41b68c-435b-4d66-9ac9-089cb69db38c"
      unitRef="drug">3</mbx:NumberofDrugsinClinicalTrials>
    <mbx:NumberofClinicalTrials
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfMjM5OA_35bfea61-4075-423f-80b9-54dbde8ceb6e"
      unitRef="clinicaltrial">4</mbx:NumberofClinicalTrials>
    <mbx:NumberOfOtherDrugDevelopmentProjects
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfNDgwMw_70379a2c-4749-4c92-ab06-f4e01b53be34"
      unitRef="project">5</mbx:NumberOfOtherDrugDevelopmentProjects>
    <mbx:MarketExclusivityExtensionPeriod
      contextRef="ibaa5d1878a8449bbbfb93f6bcb30609b_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfODg3MQ_cd7766b0-b4a5-40d5-989f-e9eb979144e4">P10Y</mbx:MarketExclusivityExtensionPeriod>
    <mbx:MarketExclusivityExtensionPeriod
      contextRef="id4ec7928d44f45ea880ca27fb60483ae_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zMS9mcmFnOjA2ZDAyYWJiZjJlMzQ2ODU4ZDZmNDk4ZGIyNTFkN2JiL3RleHRyZWdpb246MDZkMDJhYmJmMmUzNDY4NThkNmY0OThkYjI1MWQ3YmJfOTAwOA_f0ce6c19-c850-4edc-a093-34922276a625">P5Y</mbx:MarketExclusivityExtensionPeriod>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODg_b58526b6-6816-4f68-9704-5e887f96f74e">Basis of presentation, principles of consolidation and significant accounting policies&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Basis of Presentation &#x2013; Unaudited Interim Condensed Consolidated Financial Information -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These interim condensed unaudited consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December&#160;31, 2018 and December&#160;31, 2017 and notes thereto contained in the Form 10-K filed with the SEC on February&#160;21, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The company views its operations and manages its business in one operating segment. All long-lived assets of the Company reside in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Going Concern -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of September&#160;30, 2019, the Company has incurred an accumulated deficit of $35.8 million since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of September&#160;30, 2019, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the Federally insured limits of $250,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064327%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vendor prepayments and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Vendor prepayments includes approximately $1.7 million for the expansion of Annamycin production commitments on a commercial scale to be delivered in 2020, which will be used in clinical trials. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Intangible Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; - Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development ("IPR&amp;amp;D") asset, then no &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, if any, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if the Company believes indicators of potential impairment exist, using a fair-value-based approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Property and Equipment, net - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term. Accumulated depreciation on property and equipment was $0.2 million at September&#160;30, 2019, and $0.1 million at December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Lease Right-of-Use Asset - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is a lease at contract inception or during modifications or renewal of an existing lease. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company's operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheet. The Company has elected the practical expedient and will not separate lease components from nonlease components for its leases. The Company's operating leases are reflected in operating lease right-of-use asset ("ROU"), accrued expenses and current liabilities, and operating lease liability - long-term in the Company's condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 7 - Commitments and Contingencies - Lease Obligations Payable for additional information related to the Company&#x2019;s operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt; &#160;Cost Method Investment - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Our cost method investment consists of an investment in a private company in which we do not have the ability to exercise significant influence over its operating and financial activities. The investment is tested for impairment quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial instruments consist primarily of non-trade receivables, account payables, accrued expenses and a warrant liability. The carrying amount of non-trade receivables, accounts payables, and accrued expenses approximates their fair value because of the short-term maturity of such.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets of identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 &#x2013; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 &#x2013; Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. In the accompanying interim condensed consolidated financial statements as of September&#160;30, 2019, the fair value of this warrant liability is included in current liabilities for the February 2017 Issuance of Warrants, the February 2018 Issuance of Warrants, the June 2018 Issuance of Warrants, the March 2019 Issuance of Warrants, and the April 2019 Issuance of Warrants. Warrant liabilities will be shown as a current liability on the balance sheet when it is deemed more probable than not by management to be exercised within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September&#160;30, 2019 and at December 31, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.882353%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.117647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.235294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.823529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Measured at Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of warrant liability as of September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of warrant liability as of December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below (in thousands) of Level 3 liabilities begins with the valuation as of the beginning of the third quarter and then is adjusted for the issuances and exercises that occurred during the third quarter of 2019 and adjusts for balances for changes in fair value that occurred during the current quarter. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.918129%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.450292%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.865497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclass of liability from long-term to current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuances of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The table below (in thousands) of Level 3 liabilities begins with the valuation as of December&#160;31, 2018 and then is adjusted for the issuances and exercises, and changes in fair value that occurred during the nine months ended September&#160;30, 2019. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.140351%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Long-Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclass of liability from long-term to current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuances of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value -  net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Loss Per Common Share&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting and warrants to purchase common stock were considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be antidilutive. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;For the three months ended September 30, 2019 and 2018, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;approximately 14.7 million and approximately 6.5 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2019 and 2018, approximately 11.3 million and approximately 5.0 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Reclassifications - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Subsequent Events -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company&#x2019;s management reviewed all material events through the date these unaudited condensed consolidated financial statements were issued for subsequent events disclosure consideration, see Note 8 - "Subsequent Events".&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;In July 2018, the FASB issued ASU No. 2018-11, Leases Targeted Improvements ("ASU 2018-11"). In March 2019, the FASB issued ASU. No. 2019-01, Leases ("ASU 2019-01"). ASU 2019-01 and 2018-11 assists stakeholders with implementation questions and issues as organizations prepare to adopt the new leases standard. The Company adopted this standard on January 1, 2019 and used the effective date of initial application using the modified retrospective transition method. Upon adoption there was no cumulative-effect adjustment to the opening balance of retained earnings as of January 1, 2019. Therefore, prior period financial information has not been adjusted and continues to be reflected in accordance with the Company's historical accounting policy. The standard establishes a ROU asset model that requires the lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. (see Note 7. Commitments and Contingencies - Lease Obligations Payable).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718) Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 affects all entities that enter into share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption permitted, but no earlier than an entity's adoption date of Topic 606. The adoption of this pronouncement did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) ("ASU 2018-13"). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  Early adoption is permitted upon issuance of this ASU. The Company is currently evaluating the impact that this standard will have, if any, on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODk_add1d734-ab6d-4e43-b294-ce93fb0755be">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Basis of Presentation &#x2013; Unaudited Interim Condensed Consolidated Financial Information -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a &lt;/span&gt;fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These interim condensed unaudited consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December&#160;31, 2018 and December&#160;31, 2017 and notes thereto contained in the Form 10-K filed with the SEC on February&#160;21, 2019.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTc_8a4b8ba1-b3f3-403c-bac6-99cf526e80e8">Principles of consolidation - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The company views its operations and manages its business in one operating segment. All long-lived assets of the Company reside in the United States.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTczNw_993f9a7d-f190-4d4d-a2eb-b247997ef3ce"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDE_7fd54a10-b5c7-4b80-a3ae-f654685cfbac">Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.</us-gaap:UseOfEstimates>
    <mbx:GoingConcernPolicyPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDc_522f9b86-418d-49fc-8baf-ac600d978214">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Going Concern -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of September&#160;30, 2019, the Company has incurred an accumulated deficit of $35.8 million since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of September&#160;30, 2019, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&lt;/span&gt;</mbx:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzc2OA_f7e7be28-103a-478c-9174-4f2225363aa5"
      unitRef="usd">-35800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMDI_04924ac0-04b6-4f65-bb3e-160ef951cddb">Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the Federally insured limits of $250,000.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0NjI2MA_68adf6dc-a406-4fb4-9772-b27ddec74153">Prepaid expenses and other current assets consist of the following (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064327%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vendor prepayments and deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <mbx:VendorPrepaymentAndDeposits
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMS0xLTEtMS0zMTY2_d4b70bcc-1a61-4790-8084-f39368a71e82"
      unitRef="usd">1994000</mbx:VendorPrepaymentAndDeposits>
    <mbx:VendorPrepaymentAndDeposits
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMS0zLTEtMS0zMTY2_9c2d92b2-a791-4219-bef9-0d5ac590e773"
      unitRef="usd">238000</mbx:VendorPrepaymentAndDeposits>
    <us-gaap:PrepaidInsurance
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMi0xLTEtMS0zMTY2_1950ab60-5072-4934-8dfd-bb0f6a794aed"
      unitRef="usd">560000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMi0zLTEtMS0zMTY2_cf27aa1e-3563-481f-80b4-82f53e7c3fd7"
      unitRef="usd">171000</us-gaap:PrepaidInsurance>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMy0xLTEtMS0zMTY2_2d31ac5f-e9e5-44c3-9189-9e9f04ed1a5c"
      unitRef="usd">316000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfMy0zLTEtMS0zMTY2_a12e65da-4aa9-41af-b8d2-1f80919167e7"
      unitRef="usd">56000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNC0xLTEtMS0zMTY2_371aea54-8f2b-440f-a47f-0e705290c09a"
      unitRef="usd">307000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNC0zLTEtMS0zMTY2_be727b30-175d-4b03-a971-ab234b60c134"
      unitRef="usd">375000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNS0xLTEtMS0zMTY2_7bc7bf62-7965-46fb-bb5b-168f434d28f3"
      unitRef="usd">3177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM1ODk4YTAzNzk5NjQ3MGQ4MGI1ODg0NTEwZTE3ZWFmL3RhYmxlcmFuZ2U6YzU4OThhMDM3OTk2NDcwZDgwYjU4ODQ1MTBlMTdlYWZfNS0zLTEtMS0zMTY2_11041d5f-28ad-480b-bd2a-6e0f76839bbf"
      unitRef="usd">840000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <mbx:VendorPrepaymentAndDepositsExpansionOfProductionCommitments
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMjE5OTAyMzI3Mzk0OQ_ff40f08f-2f5e-4410-a945-34c0ea60cc02"
      unitRef="usd">1700000</mbx:VendorPrepaymentAndDepositsExpansionOfProductionCommitments>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMTE_565430ba-5ee9-4d73-9432-dcf032ff4fea">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Intangible Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; - Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development ("IPR&amp;amp;D") asset, then no &lt;/span&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, if any, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if the Company believes indicators of potential impairment exist, using a fair-value-based approach.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTQ_1f444ccd-8b1c-4e99-ba14-3a41cedbaf40">Property and Equipment, net - Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfNjYzNA_17b915b0-efcb-40c2-b56d-c644ac029aae"
      unitRef="usd">200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfNjY1OQ_11ffe4dd-c509-425d-b960-ab95d1cd4fe6"
      unitRef="usd">100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0NTMyOQ_cde06d67-c5b8-4301-8089-6e77279dee20">Operating Lease Right-of-Use Asset - The Company determines if an arrangement is a lease at contract inception or during modifications or renewal of an existing lease. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company's operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheet. The Company has elected the practical expedient and will not separate lease components from nonlease components for its leases. The Company's operating leases are reflected in operating lease right-of-use asset ("ROU"), accrued expenses and current liabilities, and operating lease liability - long-term in the Company's condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 7 - Commitments and Contingencies - Lease Obligations Payable for additional information related to the Company&#x2019;s operating leases.</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:CostMethodInvestmentsPolicy
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTA5OTUxMTY0ODE5Mg_3cea42ca-6cac-4323-9ffe-ccc5ef7ea0b0">Cost Method Investment - Our cost method investment consists of an investment in a private company in which we do not have the ability to exercise significant influence over its operating and financial activities. The investment is tested for impairment quarterly.</us-gaap:CostMethodInvestmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTU_ad884856-71e0-4728-9f02-7c935fa5edc2">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial instruments consist primarily of non-trade receivables, account payables, accrued expenses and a warrant liability. The carrying amount of non-trade receivables, accounts payables, and accrued expenses approximates their fair value because of the short-term maturity of such.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets of identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 &#x2013; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 &#x2013; Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTY_1b837f42-2a9d-41e2-94d3-9987170c2f2f">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September&#160;30, 2019 and at December 31, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.882353%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.117647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.235294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.823529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Measured at Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of warrant liability as of September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of warrant liability as of December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id7d483fa5b8b4a508aa8033181369c0b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS0yLTEtMS0w_67e85c7a-d2ac-4ae3-9618-7584f27073c5"
      unitRef="usd">6820000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibb53084bb5d5439da0fc3b7ce0bac811_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS00LTEtMS0w_60071136-fe4c-4940-8414-1635e8882f6f"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5dd7f29a819443ba880b572c77f75db8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS02LTEtMS0w_633d31d1-0044-4e3d-a667-de460d75bdb3"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i43ba623e5dc34281830bac2c5b222d0b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMS04LTEtMS0w_7f01128e-e3ed-48cb-bccf-e95eb9fe814e"
      unitRef="usd">6820000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i4d184260db97490785df4ce8f01a87f4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi0yLTEtMS0w_d8bfc1c4-fc73-45ab-a627-df2e885cc4cf"
      unitRef="usd">1508000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1bb96a49c87b43728767fc948cbd81a0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi00LTEtMS0w_2682d1cc-6f30-4a31-9b2c-19fc4027788e"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3e02f1d5e0b843aa9cefaba9fe3c4bd4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi02LTEtMS0w_ada82002-ba19-46bb-8281-1365b8a0827f"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i010c1a26c61e446aadddfcdda2856af2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmM0ZjFiOGIwMjA5YzQzM2Y5MTc1MDlhNzAzMGJkMGZkL3RhYmxlcmFuZ2U6YzRmMWI4YjAyMDljNDMzZjkxNzUwOWE3MDMwYmQwZmRfMi04LTEtMS0w_78a44e99-762c-45f9-89a9-7d08f572219e"
      unitRef="usd">1508000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTE_fec61090-a0f4-4750-b620-8c262fa78cb9">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below (in thousands) of Level 3 liabilities begins with the valuation as of the beginning of the third quarter and then is adjusted for the issuances and exercises that occurred during the third quarter of 2019 and adjusts for balances for changes in fair value that occurred during the current quarter. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.918129%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.450292%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.865497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclass of liability from long-term to current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuances of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;The table below (in thousands) of Level 3 liabilities begins with the valuation as of December&#160;31, 2018 and then is adjusted for the issuances and exercises, and changes in fair value that occurred during the nine months ended September&#160;30, 2019. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.140351%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant Liability Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Long-Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclass of liability from long-term to current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuances of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value -  net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iacbd36b98aa84664bebd964e031364e7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS0xLTEtMS0w_9bf9fded-51b3-4981-ad56-655c7b25a236"
      unitRef="usd">6944000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i285e6798fd8943ccb8ce51b198c79b4c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS0zLTEtMS0w_6f5b9981-82ae-4a97-af20-351e793c26fd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6ffd58e0885541359bfea5e4d56a4af2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMS01LTEtMS0w_117ac911-9b26-43b4-b1f0-aa6c5d938416"
      unitRef="usd">6944000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi0xLTEtMS0w_0791ed9f-0b41-42ce-9c50-855f26aca53d"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi0zLTEtMS0w_0c421e47-a2dd-4bf1-b178-99ad4aef39b0"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMi01LTEtMS0w_5de005ea-248c-435d-97d5-b3d1c9f0adaf"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy0xLTEtMS0w_846a4254-f6ba-4a84-9cd5-2d1eaf6318c5"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy0zLTEtMS0w_1cfbd901-0b40-4e14-81e0-7145f36d7f9a"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfMy01LTEtMS0w_79b8a9a0-1162-4191-b1c9-2d0dd5fad4c4"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC0xLTEtMS0w_8a7de3c0-2046-4472-98c0-0b1da8b30698"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC0zLTEtMS0w_fa0a9c34-bc87-40df-9f56-48c1fad837b2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNC01LTEtMS0w_d89c5ce8-6cfe-4f4d-b9b5-7ca864228306"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ib4ebb5ee1c344b10b9395783436cda59_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS0xLTEtMS0w_780c0545-c9d9-4557-b030-9ac654323f03"
      unitRef="usd">-124000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="idc3b90a3d784455e8f02c76588828f16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS0zLTEtMS0w_33f00c7a-b317-424d-a171-592387698ded"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i33a86dac56df4e0f9f709e78a0e4bc2d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNS01LTEtMS0w_b3cbc043-6cdf-411d-92c5-283eb14c6428"
      unitRef="usd">-124000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id3707bb56148497495ea24016f264a35_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi0xLTEtMS0w_3456624b-1dac-4557-8f4c-14e9e02f0172"
      unitRef="usd">6820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi0zLTEtMS0w_d2dfc163-52fd-4caa-9caf-937021701d4e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib34e1490cda548bdaab67ad8ede83e51_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOmY3MTMwYWUzMWI2MzQzMzNhNmUxNDU0YjI4MTcyNzU3L3RhYmxlcmFuZ2U6ZjcxMzBhZTMxYjYzNDMzM2E2ZTE0NTRiMjgxNzI3NTdfNi01LTEtMS0w_9bca2b47-bebb-46f4-a98f-42986ce96f84"
      unitRef="usd">6820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i833cbb966fe54a1dbf89b625b300e6a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS0xLTEtMS0w_f048c58d-bbb6-4d5e-8e0c-314f4af4b19c"
      unitRef="usd">180000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i57abc24e231945ddb977a7587f1bc971_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS0zLTEtMS0w_76e85b3e-1531-4e13-905c-f7363ea6502e"
      unitRef="usd">1328000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2a7f1136ba8448bfa401f14716d6bdc5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMS01LTEtMS0w_9f432bfb-43e1-4697-adea-6bd06cfdd0d5"
      unitRef="usd">1508000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi0xLTEtMS0w_4d75c5cb-e263-4ef8-b14f-b8114adda6ba"
      unitRef="usd">-1328000</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi0zLTEtMS0w_ddee387f-e716-41ac-a410-0273fcb0526f"
      unitRef="usd">1328000</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent
      contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMi01LTEtMS0w_af8ee37b-d506-44e0-bedc-0dc8272fbbd3"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy0xLTEtMS0w_a529a237-9b61-44bd-a9f8-2ef2ea545113"
      unitRef="usd">3174000</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy0zLTEtMS0w_d1284a5b-d7e2-4771-a0e1-c9c6cf550890"
      unitRef="usd">0</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
      contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfMy01LTEtMS0w_33cb4b78-06e5-47ae-9344-f3ec2a5ed3c7"
      unitRef="usd">3174000</mbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC0xLTEtMS0w_d5e08aa8-b979-490e-977a-6d16ea7da705"
      unitRef="usd">11545000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC0zLTEtMS0w_deea7493-4404-46b1-ae3e-23ddc52c5c4b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNC01LTEtMS0w_6e7bd3ac-0bbc-49e2-b493-4289c3f0bb7b"
      unitRef="usd">11545000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i095e4a970ba74e3d99ded030ad0dea1c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS0xLTEtMS0w_6ffab8cb-ac47-4ad5-9c51-4bf7b46b5919"
      unitRef="usd">-3059000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ic2649ffae48b4df9a7cd99170a80c4b4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS0zLTEtMS0w_0ff7f07b-593f-4286-9f50-66779ffec1a4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i219719edc1b9438090dbeae77bf96672_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNS01LTEtMS0w_4bf40078-acd0-4be8-915d-8128741464fd"
      unitRef="usd">-3059000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id3707bb56148497495ea24016f264a35_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi0xLTEtMS0w_4478bb38-b4de-44fe-bd22-10c22d243784"
      unitRef="usd">6820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i34bd77ed3e2b4258bf0719a1aaaab210_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi0zLTEtMS0w_947c3bf8-aacf-4e12-a113-5581d3357156"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib34e1490cda548bdaab67ad8ede83e51_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RhYmxlOjFkZmRhZDUyZjQ1MTRiMjhhOGU2ZTM1OGNlYWU3NjdmL3RhYmxlcmFuZ2U6MWRmZGFkNTJmNDUxNGIyOGE4ZTZlMzU4Y2VhZTc2N2ZfNi01LTEtMS0w_213a7507-0e42-4088-b196-46b6ff7bdc32"
      unitRef="usd">6820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcyMTI_3b78ff77-1203-46af-bc8b-da1a7e5c7d1d">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Loss Per Common Share&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting and warrants to purchase common stock were considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be antidilutive. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;For the three months ended September 30, 2019 and 2018, &lt;/span&gt;approximately 14.7 million and approximately 6.5 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2019 and 2018, approximately 11.3 million and approximately 5.0 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY1MQ_847448d7-943d-4cf2-addb-1832e1524767"
      unitRef="shares">14700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY2Nw_26add7b7-1077-42e2-abb8-1a00544539da"
      unitRef="shares">6500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzY4NA_f0a287f4-91c7-46ac-bd64-ce842e8a71aa"
      unitRef="shares">11300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMzI5ODUzNDkwMzcwMA_37246a4c-490b-43b5-8f45-8be41f65d62f"
      unitRef="shares">5000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxODc_0ecaebd1-722b-420a-ad2d-0ac2e4a15e26">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Reclassifications - &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.&lt;/span&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNC9mcmFnOmVmOGY4MjU0MTFmMzQ0YjM4OGEzYzYyMjFmNWVjNTkxL3RleHRyZWdpb246ZWY4ZjgyNTQxMWYzNDRiMzg4YTNjNjIyMWY1ZWM1OTFfMTcxOTk_2fbb4593-ee14-417d-ba96-315458ca16ca">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;In July 2018, the FASB issued ASU No. 2018-11, Leases Targeted Improvements ("ASU 2018-11"). In March 2019, the FASB issued ASU. No. 2019-01, Leases ("ASU 2019-01"). ASU 2019-01 and 2018-11 assists stakeholders with implementation questions and issues as organizations prepare to adopt the new leases standard. The Company adopted this standard on January 1, 2019 and used the effective date of initial application using the modified retrospective transition method. Upon adoption there was no cumulative-effect adjustment to the opening balance of retained earnings as of January 1, 2019. Therefore, prior period financial information has not been adjusted and continues to be reflected in accordance with the Company's historical accounting policy. The standard establishes a ROU asset model that requires the lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. (see Note 7. Commitments and Contingencies - Lease Obligations Payable).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718) Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 affects all entities that enter into share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption permitted, but no earlier than an entity's adoption date of Topic 606. The adoption of this pronouncement did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) ("ASU 2018-13"). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  Early adoption is permitted upon issuance of this ASU. The Company is currently evaluating the impact that this standard will have, if any, on its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RleHRyZWdpb246MGRjMGIyYzY5MGU4NDg5MTk2ZDU2ZjVjOWFjZWUzMmFfMTU5_d5e4666e-d3d3-474d-a4e3-f61583187a5f">Accrued Expenses and Other Current Liabilities&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities consist of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.649123%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll and bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued license fees and sponsored research agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued drug manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RleHRyZWdpb246MGRjMGIyYzY5MGU4NDg5MTk2ZDU2ZjVjOWFjZWUzMmFfMTYw_52f00c15-6cfd-4b38-a840-e4e248ac5afe">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities consist of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.649123%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll and bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued license fees and sponsored research agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued drug manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mbx:AccruedClinicalTestingCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMS0yLTEtMS0w_5ec0acd2-4aee-44fb-8f93-d9bd5fcdb675"
      unitRef="usd">349000</mbx:AccruedClinicalTestingCurrent>
    <mbx:AccruedClinicalTestingCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMS00LTEtMS0w_c867688a-b586-4c6c-a14a-0289a5110a75"
      unitRef="usd">95000</mbx:AccruedClinicalTestingCurrent>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMi0yLTEtMS0w_e4c03694-c8ab-4654-ba11-2bdce7fc22f0"
      unitRef="usd">249000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMi00LTEtMS0w_e2608865-c90d-493d-9633-31c0a97d2fb5"
      unitRef="usd">492000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMy0yLTEtMS0w_2941f871-5c13-4c09-8206-0bc6568465c0"
      unitRef="usd">144000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfMy00LTEtMS0w_475126d1-8971-4413-9ed8-7f713bb8436c"
      unitRef="usd">227000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNC0yLTEtMS0w_f65613bd-f60c-43e6-8fcb-197a3b6116c4"
      unitRef="usd">137000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNC00LTEtMS0w_cabef318-a4f9-48fa-b1c4-a7058b543dfa"
      unitRef="usd">91000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNS0yLTEtMS0w_50e59df6-de08-4ca5-9456-86bca9e8be97"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <mbx:AccruedLicenseFeesAndSRACurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNi0yLTEtMS0w_1690ef76-d97d-4ccf-ade0-8a0961362226"
      unitRef="usd">91000</mbx:AccruedLicenseFeesAndSRACurrent>
    <mbx:AccruedLicenseFeesAndSRACurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNi00LTEtMS0w_2cdb7517-4429-427f-a042-44555c0046b6"
      unitRef="usd">1147000</mbx:AccruedLicenseFeesAndSRACurrent>
    <mbx:AccruedDrugManufacturingCost
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNy0yLTEtMS0w_7019f678-6947-48e6-8e11-04c94e4d52c3"
      unitRef="usd">41000</mbx:AccruedDrugManufacturingCost>
    <mbx:AccruedDrugManufacturingCost
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfNy00LTEtMS0w_5240925b-afcc-4680-b743-9de284dcda2d"
      unitRef="usd">400000</mbx:AccruedDrugManufacturingCost>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfOC0yLTEtMS0w_1f3a51ae-8c2e-4185-a303-9bf53e579be0"
      unitRef="usd">1111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF8zNy9mcmFnOjBkYzBiMmM2OTBlODQ4OTE5NmQ1NmY1YzlhY2VlMzJhL3RhYmxlOmNjYTc2ZmFhNDIwOTQ2ZWRiNDQyNThiMTAyYmY0OGY3L3RhYmxlcmFuZ2U6Y2NhNzZmYWE0MjA5NDZlZGI0NDI1OGIxMDJiZjQ4ZjdfOC00LTEtMS0w_de18db47-ea84-413c-84ae-122bd8bf3e4b"
      unitRef="usd">2452000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyDisclosureTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzMw_e924f407-b0ee-4a13-a072-9313bb85d082">Warrant Liability &lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As of September&#160;30, 2019, the Company had 10,256,193 warrants outstanding consisting of 5,250,000 warrants issued in April 2019; 1,585,500 warrants issued in March 2019; 742,991 warrants issued in June 2018; 2,273,700 warrants issued in February 2018; and 404,002 warrants issued in February 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;A summary of the Company's warrant activity during the nine months ended September&#160;30, 2019 and related information follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.035088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.187135%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.602339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.964912%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.105263%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares Under Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range of Warrant Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,426,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,242,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,413,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,256,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,256,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As discussed in Note 5, in connection with the offering that closed on April 25, 2019, the Company issued warrants to purchase 4,687,500 shares of its common stock (each a "Warrant"). The warrants are immediately exercisable at a price of $1.75 per share and expire five years from the date of issuance. In connection with the offering, the Company issued Oppenheimer &amp;amp; Co. Inc. a warrant (the "Underwriter Warrant") to purchase up to 562,500 shares of its common stock with an exercise price of $1.75 per share. The Underwriter Warrant expires on April 23, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As discussed in Note 5, in connection with the offering that closed on March 29, 2019, the Company issued warrants to purchase 2,625,000 shares of its common stock (each a &#x201c;Warrant&#x201d;).  The warrants are immediately exercisable at a price of $1.10 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance.  In connection with the offering, the Company issued Oppenheimer &amp;amp; Co. Inc. a warrant (the &#x201c;Underwriter Warrant&#x201d;) to purchase up to 367,500 shares of its common stock with an exercise price of $1.10 per share. The Underwriter Warrant expires on March 27, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The basis of value of the warrant liability is fair value, which is defined pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 to be &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#x201d;. The Company uses the Black-Scholes option pricing model (&#x201c;BSM&#x201d;) to determine the fair value of its remaining warrants outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The risk-free interest rate &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Where appropriate, the Company used the historical volatility of peer entities combined with the Company's due to the lack of sufficient historical data of its stock price during the years 2017 to 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The assumptions used in the BSM models for its outstanding warrants are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.362573%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380117%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.070175%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.918129%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380117%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.723977%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjg_644a6eea-0c6a-4185-a26f-bef52d539353"
      unitRef="shares">10256193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8704f5f266694aa9b6f1e5fc38343f5f_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTA2_1c770beb-f6c7-4753-a0ce-fc8790dce0ca"
      unitRef="shares">5250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0764deeff02e4de2af7c0933afdb419b_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQw_196b86a9-a873-45e0-a0e4-074b2f49b7b4"
      unitRef="shares">1585500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i828883bbb66748609912c14fccab2dc0_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTc0_20ec4d2a-8ff2-4bee-b91d-64fdbe9e028c"
      unitRef="shares">742991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic7679c4528b848609353c11a6dc439fd_D20180201-20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjA3_70df5fcb-ee02-4533-8fd7-c4086df8e89c"
      unitRef="shares">2273700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8fdd5e53f5094aada2975171e573b157_D20170201-20170228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjQ4_333707c8-418f-479d-a7af-9d4298d32b35"
      unitRef="shares">404002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <mbx:ScheduleOfWarrantActivityTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzNg_4fa5c035-39f7-4578-b336-67754df6e687">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;A summary of the Company's warrant activity during the nine months ended September&#160;30, 2019 and related information follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.035088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.187135%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.602339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.964912%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.105263%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares Under Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range of Warrant Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,426,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,242,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,413,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,256,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and Exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,256,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mbx:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0ca157a098ae4304a258adc86a04a5b6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS0xLTEtMS0w_bb8d8a1e-f185-42a6-8f6a-f64157797caf"
      unitRef="shares">3426711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i08cab3276359415a9615b407edca1b58_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS0zLTEtMS0w_a65345ba-b835-4b9e-9fa3-28a997c7563f"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id58152a5a8294f01b352ea46be89ca0e_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS01LTEtMS0w_0cc6fee5-2973-4b22-9826-283d2d5a56f3"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0ca157a098ae4304a258adc86a04a5b6_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS03LTEtMS0w_316ad337-f770-4168-8742-9d8e81403d22"
      unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMS05LTEtMS0w_1c3df4cd-edab-489a-8e29-ddc01d1bd381">P4Y6M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi0xLTEtMS0w_c3e5ace2-4ab0-41c2-a9bd-cd8d38b1c0d6"
      unitRef="shares">8242500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi0zLTEtMS0w_0a39974c-b5b3-4b66-8024-aaaeceafbda9"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi01LTEtMS0w_6a225edf-89d5-48b5-83da-dad72f8e656e"
      unitRef="usdPerShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMi03LTEtMS0w_b53a0530-caa6-45f5-a1db-6671bf99238f"
      unitRef="usdPerShare">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy0xLTEtMS0w_bb1b7be8-0242-4b91-8397-54af29a0f6b2"
      unitRef="shares">1413018</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod
      contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy0zLTEtMS0w_0d299f51-86ce-4c1c-8d21-6f3483530bd7"
      unitRef="usdPerShare">1.10</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod
      contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy01LTEtMS0w_3ca0a61c-c71b-4f4e-88ca-f698cb27f3bf"
      unitRef="usdPerShare">1.50</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfMy03LTEtMS0w_6509a437-1f33-4e7d-8fe1-e71d5a69389e"
      unitRef="usdPerShare">1.10</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedINPeriod>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNC0xLTEtMS0w_7a6928ad-688e-4693-91d2-e760278ca4c3"
      unitRef="shares">0</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS0xLTEtMS0w_644a6eea-0c6a-4185-a26f-bef52d539353"
      unitRef="shares">10256193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3468782c8cf7406292dddbcdcb10f2e6_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS0zLTEtMS0w_c79d56a0-3262-4f1f-a6a6-dcc6ee45efb0"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie3b3edd6398a45bfa280974c3f953e3e_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS01LTEtMS0w_18c33f36-1ef6-47cb-b569-be573ca776ec"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS03LTEtMS0w_d7773755-ee43-4514-acb8-57a1b7e5dcc5"
      unitRef="usdPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNS05LTEtMS0w_f0897920-49fb-439b-bc4d-25153273c507">P4Y3M14D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber
      contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy0xLTEtMS0w_3eab78cb-f96a-4362-b60d-a37ee655727c"
      unitRef="shares">10256193</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue
      contextRef="i3468782c8cf7406292dddbcdcb10f2e6_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy0zLTEtMS0w_0d7d5a55-6417-472a-8c0a-163a1bd16f30"
      unitRef="usdPerShare">1.10</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue
      contextRef="ie3b3edd6398a45bfa280974c3f953e3e_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy01LTEtMS0w_9ff3576e-6e59-4125-b661-54006e241fc6"
      unitRef="usdPerShare">2.80</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue
      contextRef="icfdda18b689c40d8a99d07a7fce046cd_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy03LTEtMS0w_c57f1a9f-9c84-4bd0-b722-7f6f6e0e3aae"
      unitRef="usdPerShare">1.89</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjQ0ODkzYTA1YjQzYzRlZDI4NDVhZDBmZDI1ZjdhN2Q4L3RhYmxlcmFuZ2U6NDQ4OTNhMDViNDNjNGVkMjg0NWFkMGZkMjVmN2E3ZDhfNy05LTEtMS0w_3969e362-96a9-4fce-9f4f-b402fa4659c7">P4Y3M14D</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibdddec1576174893ac672d9353477c60_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNTM2_c43eec6e-a61e-4d41-a7b9-5d11794a4c7c"
      unitRef="shares">4687500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjQx_2d492476-07e6-4bb3-9e81-793a2647da93"
      unitRef="usdPerShare">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic4e01f1ab9534250ba00bf6fed63b50e_D20190425-20190425"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfNjY1_b0ce45d6-61ce-428a-b343-734bf267ff2d">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ifca03e3808584abfb0298f0b407b56ac_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfODI2_30e5c267-a1a1-455f-bcc9-344efedc9c68"
      unitRef="shares">562500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib2a4b8d7f8ff4d62b958613b6ab257f5_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfODgy_828dcb41-cb2e-465f-90e5-e2a0841429dd"
      unitRef="usdPerShare">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia04057d9a2fc47f59c529617eb6148da_I20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTA3NQ_4eda6415-a263-4c8b-80a4-1a049a8ec135"
      unitRef="shares">2625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia04057d9a2fc47f59c529617eb6148da_I20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTE4MQ_685531ad-184e-4965-8567-a92acbbf1fc6"
      unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0ff20b788d224ad3a44277ae0c89865e_D20190329-20190329"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTI1NA_f68b5139-1b0a-44b8-ab5f-65d113f4a294">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idfa81cbdf3044194a501897570de6f30_I20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQxNg_ee3896fe-a390-4ea9-b477-075670fa4b35"
      unitRef="shares">367500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idfa81cbdf3044194a501897570de6f30_I20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMTQ3Mg_63bb5f75-a4b6-438f-b5b5-156357cac85a"
      unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ScheduleOfAssumptionsUsed1TableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RleHRyZWdpb246ZTMxYWY2ZDFiZTU1NGVkNGEzM2YwOWIxODk1MGQwNDRfMjYzNw_9b129ab7-901e-418c-b0fa-c09ea4ec5e49">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The assumptions used in the BSM models for its outstanding warrants are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.362573%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380117%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.070175%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.918129%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.380117%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.723977%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mbx:ScheduleOfAssumptionsUsed1TableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS0xLTEtMS0w_611a391a-920d-493b-b0ca-6bbd2390a8e4"
      unitRef="number">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS0zLTEtMS0w_ee48606e-2088-4c1d-81fa-01ceb2229080"
      unitRef="number">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS01LTEtMS0w_05e6189b-65ae-4036-9347-5ff5cbcf13d3"
      unitRef="number">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMS03LTEtMS0w_a8be3209-c348-46d5-8e63-7bfd30f5c6ae"
      unitRef="number">0.0251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi0xLTEtMS0w_bbfe08cb-71d4-47d4-8826-cba762be5db9"
      unitRef="number">0.9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi0zLTEtMS0w_ead403c0-efb1-4158-83ae-da70b2e3c0b8"
      unitRef="number">0.9750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi01LTEtMS0w_7c5cd16c-1a57-48a9-ba2b-14ad5186b747"
      unitRef="number">0.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMi03LTEtMS0w_70080488-06ae-4383-9045-71d00b3e10f7"
      unitRef="number">0.8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id973543b0ebb4fcaa9fea4f88381a12d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy0xLTEtMS0w_170c7bcb-5360-46de-97d2-66f391dc6873">P2Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic4c5782835d042a38441551c941b2df0_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy0zLTEtMS0w_74ef8038-60c2-40dc-93e1-f04235e76592">P4Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if0cd39cea47648aab3a8c2a2319efba4_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy01LTEtMS0w_6cd9b405-1e87-463e-95ef-012efb9074db">P3Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idb85e5a2b5114447a1229d11667e382b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfMy03LTEtMS0w_0afe54a3-b507-43ef-ba17-0339b10dff53">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id8e7189457f243459bd45d9722f2f29c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfNC0xLTEtMS0w_bcfddeb2-5256-4746-80c8-09c15db7ab53"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic8f55cc9d4be4111a189a4a16ccd728d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80MC9mcmFnOmUzMWFmNmQxYmU1NTRlZDRhMzNmMDliMTg5NTBkMDQ0L3RhYmxlOjEwNDcyODZhMjQ0NDRlY2I5MjZmYWJkYWMzNmYzOGUyL3RhYmxlcmFuZ2U6MTA0NzI4NmEyNDQ0NGVjYjkyNmZhYmRhYzM2ZjM4ZTJfNC01LTEtMS0w_0a068492-310d-4d6f-91c1-84f928d9421f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNzA_c90f3c4c-8910-4af5-a0e3-8c7c4e6948e4">Equity&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is authorized to issue 105,000,000 shares of which 5,000,000 shares of preferred stock are authorized and 100,000,000 shares of common stock are authorized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is authorized to issue up to 5,000,000 shares of preferred stock. Its certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of September&#160;30, 2019, there was no preferred stock issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:19pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Lincoln Park Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 4, 2018, the Company entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"). Pursuant to the terms of the Purchase Agreement, Lincoln Park has agreed to purchase from the Company up to $20.0 million of our common stock (subject to certain limitations) from time to time during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, the Company filed with the SEC a registration statement to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, at the time the Company signed the Purchase Agreement and the Registration Rights Agreement, the Company issued 243,013 shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement and the Company may issue an additional 121,507 commitment shares pro-rata when and if Lincoln Park purchases (at the Company's discretion) the $20.0 million aggregate commitment. The commitment shares were valued at $337,788, recorded as an addition to equity for the issuance of common stock and treated as a reduction to equity as a cost of capital to be raised under the Purchase Agreement. During the three months ended December 31, 2018, the Company issued 1,399,153 shares to Lincoln Park which included 10,918 commitment shares, for $1.8 million. During the first quarter of 2019, the Company issued 605,367 shares, which included 5,367 commitment shares for $0.9 million. No shares were issued to Lincoln Park during the second quarter of 2019. During the third quarter of 2019, the Company issued 100,674 shares to Lincoln Park which included 674 commitment shares, for $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:19pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:174%;"&gt;At Market Issuance Sales Agreements ("ATM")&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; In September 2017, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Roth Capital Partners, LLC ("Roth") and National Securities Corporation ("National") (collectively, the &#x201c;Agents&#x201d;). Pursuant to the terms of the ATM Agreement, the Company was permitted to sell from time to time through the Agents shares of the Company&#x2019;s common stock with an aggregate sales price of up to $13 million.  The Company agreed to pay a commission to the Agents of 3.0% of the gross proceeds of the sale of the shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company also provided the Agents with customary indemnification rights. In June 2019, the Company canceled the ATM Agreement. The Company did not sell any shares under this ATM Agreement in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Subsequent to canceling the ATM Agreement with Roth and National, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;Opco Agreement&#x201d;) with Oppenheimer &amp;amp; Co. Inc. (the &#x201c;Agent&#x201d;) on July 23, 2019. Pursuant to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;the terms of the Opco Agreement, the Company may sell from time to time through the Agent shares of the Company&#x2019;s common stock, with an aggregate sales price of up to $15 million (the &#x201c;Shares&#x201d;). Any sales of Shares pursuant to the Opco Agreement will be made under the Company&#x2019;s effective &#x201c;shelf&#x201d; registration statement (the &#x201c;Registration Statement&#x201d;) on Form S-3 (File No. 333-219434), which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Under the Opco Agreement, the Company may sell Shares through the Agent by any method that is deemed an &#x201c;at the market offering&#x201d; as defined in Rule 415 under the Securities Act of 1933, as amended. Sales of the Shares, if any, may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company&#x2019;s Board of Directors or a duly authorized committee thereof. The Company or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to $15 million, or sooner if either the Company or the Agent terminate the Agreement pursuant to its terms. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the Agreement and reimburse the Agent for certain expenses. The Company has also provided the Agent with customary indemnification rights. The Company has not sold any shares under the Opco Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Adoption of 2015 Stock Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2015, the Board of Directors of the Company approved the Company&#x2019;s 2015 Stock Plan, which was amended in 2017 and 2018. The expiration date of the plan is December&#160;5, 2025 and the total number of underlying shares of the Company&#x2019;s common stock available for grant to employees, directors and consultants under the plan is currently 4,500,000 shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards, stock unit awards or stock appreciation rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity for the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.818851%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782032%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,794,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(103,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,781,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the option grants has been estimated, with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.549708%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.577778%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.577778%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation for the three and nine months ended September&#160;30, 2019 and 2018, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.684211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.865497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549708%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the nine months ended September 30, 2019, 1,115,000 stock options were granted. Options granted during 2019 have an aggregated fair value of $1.2 million which was calculated using the Black-Scholes option-pricing model. As of September&#160;30, 2019, total compensation cost not yet recognized was $3.2 million and the weighted average period over which this amount is expected to be recognized is 2.51 years. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the "plain vanilla" method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because the Company does not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies combined with the Company's due to the lack of sufficient historical data of its stock price. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;During the nine months ended September 30, 2019, the Company granted 316,907 restricted stock units, which vest annually in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY0OTI2NzQ1NjEzNg_c203f143-78a7-490e-b73e-32b489147d7d"&gt;four&lt;/span&gt; equal installments. The weighted average grant date fair value was $1.31 per unit. As of September&#160;30, 2019, total compensation cost not yet recognized was $0.4 million and the weighted average period over which this amount is expected to be recognized is 3.8 years. No restricted stock units were vested as of September 30, 2019 and no units were granted prior to 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Consulting Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2017, the Company entered into a consulting agreement for its investor relations operations. The consulting agreement initially covered a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzcyMQ_9e5789a7-6205-4556-8350-0fb32f1e123d"&gt;twelve&lt;/span&gt; months from the commencement date of July 29, 2017 and was extended in April 2018 until March 31, 2019. Pursuant to the original consulting agreement, in exchange for the consulting services, the Company issued two warrants (collectively, the &#x201c;Warrants&#x201d;) to purchase 100,000 and 50,000 shares of common stock at exercise prices of $2.41 and $3.00 per share. Each of the Warrants vested over a 12-month period in equal monthly installments starting July 29, 2017, provided that the consultant was providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017 and expire &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODM2NQ_0243ffb2-eae1-40d2-9343-bc1cb403c4d5"&gt;five&lt;/span&gt; years from the initial exercise date. In connection with the first extension of the consulting agreement, the Company issued the consultant a 3-year warrant to purchase 100,000 shares of common stock at an exercise price of $3.00 per share vesting in four quarterly installments. In addition, the Company paid $20,000 to the consultant per quarter pursuant to the first amendment to the consulting agreement. On July 8, 2019, the Company amended the existing consulting agreement for additional cash payments, with a right to cease cash payments by issuing the consultant a fully vested &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTE4MQ_bd9f0e14-58b3-4547-8588-62c23121c211"&gt;three&lt;/span&gt;-year warrant to purchase 150,000 shares of Company common stock, subject to NASDAQ listing of additional shares approval. On August 8, 2019, the Company elected to issue such warrant with an exercise price of $1.64. The Company recorded stock compensation expense for the non-employee consulting agreement of $0.1 million and $0.04 million for the three months ended September 30, 2019 and 2018, respectively, and $0.1 million for both the nine months ended September 30, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;$9 million Registered Direct Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale of 4,290,000 shares of common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common stock, pursuant to the Purchase Agreement, the Company also sold warrants to purchase 2,145,000 shares of common stock. The Company sold the common stock and warrants for aggregate gross proceeds of approximately $9.0 million. The net proceeds from the transactions was approximately $8.2 million after deducting certain fees due to the placement agent and transaction expenses. Subject to certain beneficial ownership limitations, the warrants became exercisable on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAzNTE_dc4c3f39-7e46-4a6e-916d-e8c0623716e3"&gt;six&lt;/span&gt;-month anniversary of the issuance date at an exercise price equal to $2.80 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA1NTQ_b2561df1-708d-4b79-82bd-4bfa1c75f45e"&gt;five&lt;/span&gt; years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;$2.3 million Registered Direct Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2018, the Company entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $2.3 million. In connection with the offering, the Company issued 1,092,636 registered shares of common stock at a purchase price of $2.105 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase 0.65 of a share of common stock. The warrants have an exercise price of $2.02 per share, became exercisable six months from the date of issuance, and will expire five years from the initial exercise date. Roth Capital Partners LLC served as sole placement agent for the offering.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;$5.25 million Registered Direct Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with Oppenheimer &amp;amp; Co. Inc. (the "Underwriter") relating to an underwritten offering (the "Offering") of 5,250,000 units (each a "Unit"), each unit consisting of (i) one share of the Company's common stock, and (ii) 0.5 of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $1.00 per Unit, and the Underwriter agreed to purchase the Units from the Company pursuant to the Underwriting Agreement at a price of $0.93 per Unit. The Warrants included in the Units are immediately exercisable at a price of $1.10 per share, subject to adjustments in certain circumstances, and will expire five years from the date of issuance. The net proceeds from the transaction was approximately $4.7 million after deducting the underwriting discount and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;$15 million Registered Direct Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, the Company entered into subscription agreements (each a "Subscription Agreement") with certain institutional investors (the "Investors") for the sale by the Company of 9,375,000 units (each a "Unit"), each Unit consisting of (i) one share of the Company's common stock, and (ii) 0.5 of a warrant to purchase one share of common stock (each a "Warrant"). The public offering price of the Units was $1.60 per Unit. The Warrants included in the Units are immediately exercisable at a price of $1.75 per share and will expire five years from the date of issuance. The net proceeds from the transaction was approximately $13.7 million after deducting the placement agent fees and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Initial Public Offering Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the Company's initial public offering completed in May 2016, the Company issued its underwriter a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjk1NQ_b57729a6-ddb3-4566-b0b4-be41f4b8b523"&gt;five&lt;/span&gt;-year warrant to purchase 107,802 shares of common stock at an exercise price of $7.50 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mbx:SharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTI_3034bf95-3538-4ecb-97ac-727d1ca15e18"
      unitRef="shares">105000000</mbx:SharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzE_b1b81a3c-c986-4178-864c-7f66692e8828"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE5_8488c425-bcac-4dfc-8aa7-716b92c4f549"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjIz_3f79a171-ef70-41a6-a294-a0fa5dcff5f9"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODAx_6cb067ca-c2ae-4d6f-becc-81523f93e2b5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction
      contextRef="ic650d629ddbe42bba07cd7284425b9cb_D20181004-20181004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE4OQ_13c9bcb0-a78e-4c34-86f2-79b8d983b80c"
      unitRef="usd">20000000.0</mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2b95e4a080574cb187b7baa5845b5bc7_D20181004-20181004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTY5Mw_3bd42837-d5bd-493b-886e-53db65fe4f9e"
      unitRef="shares">243013</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTg2Nw_f203be41-8670-44b8-b633-813d3591eb3d"
      unitRef="shares">121507</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction
      contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTk2Ng_76abfbdc-18ed-4b89-9c70-47f23aa01270"
      unitRef="usd">20000000.0</mbx:SaleOfStockMaximumAmountOfCommonStockToBeSoldInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i788a186a009d4f408a1b4fdbf1af2269_D20181004-20181004"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjAyOA_67995a5e-ea0c-4add-8611-e19fa41d4bd4"
      unitRef="usd">337788</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie0294ca4bdf04a0a9eca45bd94dea472_D20181001-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjI2OA_c2fcbcc7-c1f8-4909-bea9-9ecfe82dddf1"
      unitRef="shares">1399153</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjMwOQ_5b98320d-8f08-4688-9c83-13fe1ce3c588"
      unitRef="shares">10918</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iec7a4aa1091e4aa39dd490228661c8b5_D20181001-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjMzNA_f90c0846-a30f-4d0e-bb8a-7d16695b1e48"
      unitRef="usd">1800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idbbeab36cd054ed4a096131a1540547e_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjM5MQ_8a1a5594-29d3-4ea8-a52b-bbe00f74ff1f"
      unitRef="shares">605367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQxNw_a71c05fe-48f7-492b-982c-d58e7c32cc5c"
      unitRef="shares">5367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iad3878a50b5f4df48cd39bbbefb615fc_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQ0Mg_c9ba130a-e1b5-4af0-95b2-cfbd274dd1cc"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i38daafc04f49458db341d48f10e1fbe3_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjM_5d4097af-7fc9-4aa1-b75c-e5ab04fb49fd"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2af2bc87c2d14e3faa7aa256386e955c_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjQ0Ng_6f9b2482-4fbe-4ae5-bec7-87f53496ad35"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if07593791c6b4d6b80ab745e6c608f55_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgwMA_03779b62-dd3e-451f-82e7-4e4ea248aaec"
      unitRef="shares">100674</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6670a76fcc104cb499360b871805a581_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgwNQ_b4c49231-d9ea-44c1-ab32-7cfd3a323559"
      unitRef="shares">674</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6670a76fcc104cb499360b871805a581_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5NjgxOQ_825c3710-a055-4972-b305-0b69d4b3fd62"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice
      contextRef="i9b480bb73120461ead91f6bfb97297dc_I20170930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjk4Ng_61f67473-90ea-48ff-9128-88ffb1717455"
      unitRef="usd">13000000</mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice>
    <mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds
      contextRef="i5395f33565804b6db870e49ee1f42631_D20170901-20170930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzA0Nw_5bf6903f-8ed8-434d-81b0-03e7aa9418fd"
      unitRef="number">0.030</mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds>
    <mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice
      contextRef="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzgzMA_5109b0f0-c6af-4000-9fd5-dc0f98f32c71"
      unitRef="usd">15000000</mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice>
    <mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice
      contextRef="i52b7a8aed09e4e4fa1c6908468b66fd6_I20190723"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTAwOQ_55cf87cc-a1b2-4594-9c4b-fa9b2d6344d5"
      unitRef="usd">15000000</mbx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice>
    <mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds
      contextRef="i4bbdedafb3e34aa6ae001a6d102bb5ea_D20190723-20190723"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTE1NQ_e844fe51-3a52-47f7-ba85-4f442c8a9887"
      unitRef="number">0.030</mbx:SaleOfStockFeesPaidPercentageOfGrossProceeds>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i944e3ebf4e3447758b5f5ad06e16b8d3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNTc4NQ_d1dbdd31-3c06-4db4-a33f-6c7f580d40c3"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjQ_66b8ee6b-ca19-4abf-9aee-85a91cbe4cce">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity for the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.818851%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.782032%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.929308%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,794,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(103,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,781,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS0yLTEtMS0w_63a17ada-46bd-4943-aa71-a668505b0457"
      unitRef="shares">2794000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS00LTEtMS0w_27357532-f54c-4e45-b699-0a65bc0367d7"
      unitRef="usdPerShare">1.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS02LTEtMS0w_3dcda4ff-dd39-4262-851b-6fd471a48e89"
      unitRef="usdPerShare">2.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic11172b4c23840729a0c55b50453ef6b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS04LTEtMS0w_b525a23a-7ecb-4fa4-89a0-6586b98f7c49">P9Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMS0xMC0xLTEtMA_6de67049-5a4e-4bd8-b80b-201e8d1fad7c"
      unitRef="usd">21200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi0yLTEtMS0w_56e31a05-49d0-430b-9801-9cb940655609"
      unitRef="shares">1115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi00LTEtMS0w_d2e15d98-0b16-4ed4-8172-40e26ba2a1c6"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMi02LTEtMS0w_115077b1-c40d-460d-b06e-02cdf8680a69"
      unitRef="usdPerShare">1.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy0yLTEtMS0w_72d9afc4-12e8-43f7-9121-0e118d45860f"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy00LTEtMS0w_340d981e-5b04-471e-9aef-7103c5dee657"
      unitRef="usdPerShare">0.13</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfMy02LTEtMS0w_29a489c9-6927-4b01-97d9-fd8108796f53"
      unitRef="usdPerShare">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0yLTEtMS04NjQ_0aa100d2-440e-404e-8082-667f25f02d9d"
      unitRef="shares">103000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC00LTEtMS04NjQ_4503a6a3-76f4-4b6d-bbaa-2335c0343ed5"
      unitRef="usdPerShare">1.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC02LTEtMS04NjQ_302fadcd-14f0-4cba-b0df-551ace73292d"
      unitRef="usdPerShare">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0yLTEtMS0w_76fc9ffb-a676-44c1-9288-ef2c29ae601e"
      unitRef="shares">3781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC00LTEtMS0w_d76e33ef-a362-4c7a-ba17-ef5d6bb6d8f9"
      unitRef="usdPerShare">1.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC02LTEtMS0w_007aafac-ff40-4fcc-a541-db309a04b02f"
      unitRef="usdPerShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC04LTEtMS0w_747456af-c76e-44c9-b22c-afaa925756b5">P8Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNC0xMC0xLTEtMA_57149de2-f1a6-41d4-a3fa-43c874c1b2a3"
      unitRef="usd">900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi0yLTEtMS0w_ca683c5d-18ce-45ab-95de-2e600fea3c1d"
      unitRef="shares">993083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi00LTEtMS0w_6e7fe95c-9749-41bb-b0b9-80217e0417b7"
      unitRef="usdPerShare">2.28</mbx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi02LTEtMS0w_c77af90c-1b9a-456a-bc6a-58d6e00049d8"
      unitRef="usdPerShare">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi04LTEtMS0w_c9fdbcf4-7f44-4d03-b525-967e246800a4">P7Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjYyZjI5ZGI3Zjk4MzQwYjA5NmExZGM4YTE5YjIwMGI0L3RhYmxlcmFuZ2U6NjJmMjlkYjdmOTgzNDBiMDk2YTFkYzhhMTliMjAwYjRfNi0xMC0xLTEtMA_5e7c7998-bd0d-4619-a496-c6ef91b9cdfd"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjc_fbf29108-7b4e-4dba-870f-2d8a3fdeadfc">&lt;div style="text-indent:55pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the option grants has been estimated, with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.549708%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.577778%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.577778%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.040936%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi0xLTEtMS0w_5a5df09f-4130-46c9-921b-59bff2eab9b2"
      unitRef="number">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi0zLTEtMS0w_8e0defc1-beda-4140-82fb-60ef2298e80b"
      unitRef="number">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi01LTEtMS0w_9dc72285-9c09-4e6d-953e-cec6ba932436"
      unitRef="number">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMi03LTEtMS0w_9ceb1755-ac14-4ae6-9f82-b0747429a1d5"
      unitRef="number">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy0xLTEtMS0w_468eb76a-6515-44bc-b093-1b18f3db0e63"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy0zLTEtMS0w_eba71353-501f-4cdb-a5ba-986833dcc898"
      unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy01LTEtMS0w_3ef986f4-ad8f-441e-a537-6bb9ecf7447a"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfMy03LTEtMS0w_240a8cd2-4a33-4171-acbc-c464862656ad"
      unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2c39d2de985d4affbdbb368f73d64943_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC0xLTEtMS0w_e02929df-e96f-4d0f-b35a-02c432418b23">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if80a49b1ac35464ca409df350165e50c_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC0zLTEtMS0w_2ed5381e-4854-4805-bac2-6d4627044843">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i84c2d53697dc4799b0f1c3663013ed3f_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC01LTEtMS0w_81479427-e74e-437d-a809-5a1532f7051b">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a7f681b9d1a4c9a9ea32d44511a7e37_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNC03LTEtMS0w_ca3076d0-ed59-4d67-9463-6a8251528270">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i267a7a9087cd4a01a174352734ebad88_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNS0xLTEtMS0w_6be61682-5b57-4925-9e67-a8d7cbcbc21c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7c80993834594538b743751a71aac719_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhhZDI4ZjgyZDI3NTQ1M2M5MWQ1ZGE2MDE4YjhkNjAyL3RhYmxlcmFuZ2U6OGFkMjhmODJkMjc1NDUzYzkxZDVkYTYwMThiOGQ2MDJfNS01LTEtMS0w_d21330e8-4e39-47a2-9b77-81c261f2eac0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <mbx:ComponentsofShareBasedCompensationTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMxNjI_f13616ab-82f1-4ed9-97b3-8e9fb40c7456">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation for the three and nine months ended September&#160;30, 2019 and 2018, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.684211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.865497%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549708%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mbx:ComponentsofShareBasedCompensationTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic732ea1178074f47a9dc97cb065ced73_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi0xLTEtMS0w_2f819c2c-2b7a-44fd-bf2c-aefb972902d4"
      unitRef="usd">430000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac0f11dd922044268e807fecd4317991_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi0zLTEtMS0w_ae73970a-8671-4bde-a13d-7b66ca941bf9"
      unitRef="usd">207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13547ca083ed457da93a472804befa90_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi01LTEtMS0w_a3162880-0a7a-4413-8d0c-94fe2a9953be"
      unitRef="usd">1003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47d423e14ef8484ca70b7db69ffb12f3_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMi03LTEtMS0w_41c68b62-dfbc-4764-80e8-28d617c49490"
      unitRef="usd">709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a3d37009bad40bcbbe66bfb5272cfd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy0xLTEtMS0w_800c35ae-30ff-4509-85f6-d5548377b13d"
      unitRef="usd">59000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie587b47ea845420dab0c9acddca354f8_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy0zLTEtMS0w_afe79969-c9f2-4cdf-8089-6b680db90271"
      unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76cfe79a8ccc44f1a1b37b902e2066fa_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy01LTEtMS0w_3ac2fe1e-6844-4e9d-8df4-da4f6cc4b5db"
      unitRef="usd">152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29e6f95a02bb48c59456c43de158162f_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfMy03LTEtMS0w_4d90d726-fe17-4e20-a4a8-d62af910d316"
      unitRef="usd">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC0xLTEtMS0w_a6421e91-ab9f-4952-ac74-ec4a04b05be9"
      unitRef="usd">489000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC0zLTEtMS0w_5bcea531-c4f4-4d1a-9787-a4fba5e35d39"
      unitRef="usd">244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC01LTEtMS0w_53ddb249-3095-456d-8e49-782f11c24242"
      unitRef="usd">1155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RhYmxlOjhkYjk2MmU3NjU1YzRhMGM4YjI1M2Q0M2MwMmFhMjNhL3RhYmxlcmFuZ2U6OGRiOTYyZTc2NTVjNGEwYzhiMjUzZDQzYzAyYWEyM2FfNC03LTEtMS0w_6ee7280d-606f-4c8d-ba60-901fde98edc2"
      unitRef="usd">825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjM3MQ_b2e5ed09-7017-45a4-8b94-65a2e2e98107"
      unitRef="shares">1115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <mbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjQ5NA_bd99cf39-3f15-4c4c-991c-41a50c549e10"
      unitRef="usd">1200000</mbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjYyMQ_e64e62b1-a2af-485b-8119-94d68d8ff991"
      unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNjcxMQ_d7d2cea8-2d73-40e0-b86a-ac02127f93ba">P2Y6M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc1Mg_9006b442-6c34-4bff-ad3e-ecbb01c4b835"
      unitRef="shares">316907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc1OQ_ffd1d6af-4a53-4f8c-a94f-09047092a7ef"
      unitRef="usdPerShare">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id6bbd1cc266d4e28b55786247b4551ba_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc3Mw_c23cfe4b-0c62-4907-90b9-2ca6b6f0318f"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic57217d230e04a20b1fbbbb0a4621df8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzI5ODUzNDg5Nzc4Nw_4c25915b-5e1f-4282-8ae6-162252747fe8">P3Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <mbx:ClassofWarrantorRightNumberofWarrantsIssued
      contextRef="i7b9663d77efe491f97c917d37bd60486_I20170729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzkzMg_afecfcb9-2b01-48a7-9530-6b0021bbafe2"
      unitRef="technology">2</mbx:ClassofWarrantorRightNumberofWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icd06781e67be410c92ac95aa2495a7db_I20170729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzk4Nw_2d17e100-629b-46da-b625-12192820c296"
      unitRef="shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i2e838cce41cb48e980a2b72acf45b359_I20170729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfNzk5NA_4322fd5d-9721-4262-a6d1-19a156610449"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icd06781e67be410c92ac95aa2495a7db_I20170729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA0Mg_998e87ba-da41-4db3-9c71-33dfc509fdb6"
      unitRef="usdPerShare">2.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2e838cce41cb48e980a2b72acf45b359_I20170729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA0OQ_9737a9d0-4a1a-4f1d-9e71-4e6d2a470293"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ClassofWarrantorRightVestingPeriod
      contextRef="idc5aa471439641b3b4d6875d29e5a8fc_D20170729-20170729"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODA5OA_c8295b92-9135-4253-a03c-40329a6c38c2">P12M</mbx:ClassofWarrantorRightVestingPeriod>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="ia621ad5cb56b4f519b43b8d05d571153_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODc0Nw_6efdd43b-5286-4fb2-b930-14ddf294605d">P3Y</mbx:ClassOfWarrantOrRightTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ice90c9c153c9457994fb3428ae482f66_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODc3NQ_0c88831e-4aee-48de-9807-7ea759c3205c"
      unitRef="shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ice90c9c153c9457994fb3428ae482f66_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODgyNQ_b8e32b5a-2994-4b6f-bad0-f3c7f9eb18e3"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ConsultingFees
      contextRef="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfODkwOA_59a78e52-eb2f-4641-8965-9e3d50997f1a"
      unitRef="usd">20000</mbx:ConsultingFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id3cdb4704f2241f7bf6422f7e0974142_I20190708"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTIwOQ_ebf79d52-a023-47bf-9c07-cdf7cd379c5a"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1792812536944689b19b7c33818e27e0_I20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTYzMg_25f26e2b-4514-4039-96d9-850911c3138b"
      unitRef="usdPerShare">1.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i743b8f15d1954cd1977b8bf32aa43aa0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjc0ODc3OTA4ODkwNQ_3e9d6106-2100-49e3-bfab-1d2e862c3467"
      unitRef="usd">100000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="if8aa13f97f5742a3afa1fb7e64d1af57_D20180701-20180930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjE5OTAyMzI3NTA2MQ_d580eae6-2fca-406b-a6e0-fe633f715e62"
      unitRef="usd">40000.00</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i6e27fabf4fc542bbaa7e3bc5b51667d3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMjE5OTAyMzI3NTA3MQ_c1b7894c-9e14-4c72-811d-02da795399fe"
      unitRef="usd">100000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTYzNw_c824f425-3fd7-44f1-a9aa-d80307808ece"
      unitRef="usd">9000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTc5Ng_6c07d966-0a5a-462d-b528-6931d07e1a55"
      unitRef="shares">4290000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTg1Mg_960b5a9c-064f-4add-a821-c54ee822988b"
      unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="if6871d1b35e04a7aa6aaa1fdcf78e40d_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfOTk5Mw_37e5c33d-b8e5-42a2-a4e4-8cc1ecc56c6d"
      unitRef="shares">2145000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAxMTM_84a312f8-b669-4f69-a0bb-369aaaf70a1e"
      unitRef="usd">9000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9571c0eecef94c34bbe012427346e7c0_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTAxNzQ_8ac43c1d-106b-439b-9f6f-185aac38e8c7"
      unitRef="usd">8200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6cbda1bd25cd4cd7ab24c983a3515b9e_I20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA0MjM_38044303-1233-4d0e-8b78-472eda2ea34a"
      unitRef="usdPerShare">2.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA3MDI_ae62ecb8-2ed1-4007-819d-6cd2c860b73c"
      unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i4f88662ffea74014aaef95dd483389a6_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA5MDg_2d704eb4-8dda-4576-96ae-cfdea2c9d08b"
      unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTA5NjQ_7484a3c7-6903-4a53-a9e3-c55930c9108c"
      unitRef="shares">1092636</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEwMjQ_907edb7a-9b38-440f-a770-82bf8bdd444d"
      unitRef="usdPerShare">2.105</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEyMDg_11ff64dc-a596-4859-8281-1e099740a0a9"
      unitRef="shares">0.65</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i11095fb1fa8d4f1a99847b1a8454b970_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEyNzg_7479e095-da05-4c0f-9dd5-5e6c4636abe8"
      unitRef="usdPerShare">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ClassOfWarrantOrRightInitialExercisePeriod
      contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEzMTE_e0102772-7817-4855-8c6a-b5181b632f27">P6M</mbx:ClassOfWarrantOrRightInitialExercisePeriod>
    <mbx:ClassofWarrantorRightExpirationPeriod
      contextRef="i45c85daacc8249d797ec5f08971c894c_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTEzNTc_f682ca5e-3d9b-4ef1-9aeb-81656e5d9a6f">P5Y</mbx:ClassofWarrantorRightExpirationPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE0NzA_c0b779b2-4f2a-4bcb-8cf9-a6846e4749c8"
      unitRef="usd">5250000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <mbx:UnitsSoldInPeriod
      contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE3MDM_45080fb9-e93e-484d-8cbb-09b26a8208e6"
      unitRef="shares">5250000</mbx:UnitsSoldInPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1617ea995ee541e797427260cfd1509c_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE3NTc_89f86af0-7ef2-4e16-be2f-0e5227eb35db"
      unitRef="shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE4MDY_27dd6eb5-e6c7-456f-9dd5-e4c54f636dcd"
      unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <mbx:UnitOfferingUnitPricePerShare
      contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTE5MjM_75869fd4-0f7f-47c3-8d25-81d145b30dc3"
      unitRef="usdPerShare">1.00</mbx:UnitOfferingUnitPricePerShare>
    <mbx:UnitOfferingUnitPricePerShare
      contextRef="i0db6bce61f314f58ae7094418825cba1_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIwNTU_2e637a66-be3e-4c23-a07b-5ab618299322"
      unitRef="usdPerShare">0.93</mbx:UnitOfferingUnitPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i31991190cd3e40a2857e50efaa21c859_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIxNDU_247363ac-4bbb-4011-a40e-91c6387f94c9"
      unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIyMjQ_19a77926-2dcb-4ba4-9d13-513a16931add">P5Y</mbx:ClassOfWarrantOrRightTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i63863dee744943d8b707c78817d930ed_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTIzMTA_179e2aa1-77bf-4498-8d13-f2b1701a191f"
      unitRef="usd">4700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI0MTI_d63e1a62-eda6-4e12-9625-f98e29b044ae"
      unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI2Mjc_78ab277a-cc2b-46ce-b771-c8ec6a598de0"
      unitRef="shares">9375000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ied5f752a87a043319ef30dc7b1278714_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI2ODE_0d86d30f-ca9c-4069-ab34-8154954505ab"
      unitRef="shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i676b8255b2e542be8196edfc27042486_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI3MzA_29f64d95-1857-4d64-90f1-b5d6f658f512"
      unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <mbx:UnitOfferingUnitPricePerShare
      contextRef="i676b8255b2e542be8196edfc27042486_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI4NDc_d899d073-b912-49f6-8da7-ff6166a92e0e"
      unitRef="usdPerShare">1.60</mbx:UnitOfferingUnitPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i676b8255b2e542be8196edfc27042486_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI5NDE_c46c9b9a-0e92-4483-84d0-9e46374158cb"
      unitRef="usdPerShare">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbx:ClassOfWarrantOrRightTerm
      contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTI5NzA_9a87f490-8de6-4ce6-9f67-c89316a6dac2">P5Y</mbx:ClassOfWarrantOrRightTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3f2e683c912a4654bad597a5b8965e22_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMTMwNTY_1414ec7a-dfcf-402d-95d9-e6e5e406d325"
      unitRef="usd">13700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i816a05948bde4ad3ab07190983382b45_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjE4Mw_8ccb4d36-f30c-43ba-b8be-87b25d9f0929"
      unitRef="shares">107802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4d3b7c28de3e409ab196587e0ef6e3b9_I20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80My9mcmFnOmJjYmEyOTU3ZTg5ZjQxNWViNTFiNDAyYjYzZmMyMjRiL3RleHRyZWdpb246YmNiYTI5NTdlODlmNDE1ZWI1MWI0MDJiNjNmYzIyNGJfMzg0ODI5MDcxMjE5MA_73bf81d8-2e1e-4d0d-b12e-923d0a6bd264"
      unitRef="usdPerShare">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMTYzMA_8b746fbb-ee38-4f5d-99c1-b5638a759828">Income Taxes&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not expect to pay any significant federal, state, or foreign income taxes in 2019 as a result of the losses recorded during the three and nine months ended September&#160;30, 2019 and the additional losses expected for the remainder of 2019 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201c;more likely than not&#x201d; that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of September&#160;30, 2019, the Company maintained a full valuation allowance for all deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded an income tax benefit for the three and nine months ended September 30, 2019 of $0.2 million resulting in a quarterly effective tax rate of 5.2% and an annual effective rate of 1.4%. The total income tax benefit is comprised of research and development tax credits recoverable, associated with Moleculin Australia Pty Ltd., (MAPL), a wholly owned subsidiary formed in June 2018, related to preclinical development in Australia for WP1732, an analog of WP1066. Aside from the Australia tax credit, the Company has recorded no income taxes for the three and nine months ended September&#160;30, 2019 and 2018. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants and valuation allowances on the Company&#x2019;s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwMA_e279321c-16c0-4ce2-a2d5-ec6fde8374dd"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwMA_fddf56b4-3374-41db-bec9-dfcbd88dc80c"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYwNw_49a50be4-cd64-4b48-ada7-e2ddc22421d3"
      unitRef="number">0.052</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfMzI5ODUzNDg4NjYxMw_8463779a-984b-48da-a23e-f28603489144"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56c0a8ba16714ef5bc65fa126910cacb_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfOTI0_f8e96955-b19b-463b-8232-18965ae28665"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf38acab08a44ad2bcca7d40c09d70b1_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80Ni9mcmFnOjQxNjA2MzhhNTkyYjQwN2JiNDU3MDhiNzgzMjEyYjMwL3RleHRyZWdpb246NDE2MDYzOGE1OTJiNDA3YmI0NTcwOGI3ODMyMTJiMzBfOTI0_fffdc90c-a033-4d18-83cb-78925c49d39e"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTQyOTM2NTExODE5Nzg_668d6f58-2154-4ec0-a612-b1786d36023e">Commitments and Contingencies&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the commitments and contingencies elsewhere in these notes, see below for a discussion of our commitments and contingencies as of September&#160;30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;Lease Obligations Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of use asset and a lease liability for all leases at the commencement date based on the present value of the lease payment over the lease term. In March 2018, the Company entered into a Lease Agreement (the &#x201c;Lease&#x201d;) which it uses for its corporate office space and headquarters. The term of the Lease began in August 2018 and will continue for an initial term of 66 months, which may be renewed for an additional 5 years. The Company is required to remit base monthly rent which will increase at an average approximate rate of 3% each year. The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the Landlord. The leased space is located in Houston, Texas. The corporate office lease is classified as an operating lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company entered into an Amended Lease Agreement (the "Lab Lease") which it uses for lab space. The term of the Lease began in September 2019 and will continue for an initial term of 35 months, with no further right or option to renew. The Company is required to remit base monthly rent which will increase at an average approximate rate of 3% each year.  The Lab Lease is classified as an operating lease. In August 2019, the Company entered into a sublease with Houston Pharmaceuticals, Inc. ("HPI"). The Company has granted HPI access to all of its Lab Lease space and HPI has agreed to pay the Company 50% of the Company's rent payable under the Lab Lease less 50% of any benefits from any sublease or other lab service agreement the Company may receive from its Lab Lease. Although HPI has access to the Company's Lab Lease space, it is the intent of the parties that they equally share the Lab Lease space for research purposes. The Company recorded approximately $3,400 in sublease income from the related party for the three and nine months ended September 30, 2019, respectively. Sublease income is recorded as other income on the Company's condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded lease costs of $0.02&#160;million and $0.03 million for the three and nine months ended September&#160;30, 2019, respectively. The Company made an accounting policy election not to apply the recognition requirements to short-term leases. The Company recognizes the lease payments for short-term leases in profit or loss on a straight-line basis over the lease term, and variable lease payments in the period in which the obligation for those payments is incurred. The Company recorded total expenses for its short-term leases of $0.01 million and $0.04 million for the three and nine months ended September&#160;30, 2019, respectively. The Company recorded lease costs for variable lease payments of $0.01 million and $0.02 million for the three and nine months ended September&#160;30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Other supplemental cash flow information for operating leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064327%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The minimum lease payments are expected to be as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.023392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.245614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the prior lease guidance, future minimum lease payments at December 31, 2018 under long-term leases for the five years ending December 31, 2019 through 2023 and thereafter are as follows (in thousands): $48, $53, $54, $55, $56, and $5, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, the weighted average remaining lease term is 4.42 and 2.84 for the Lease and Lab Lease, respectively, and the weighted average discount rate is 9.6%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses an incremental borrowing rate based on a peer analysis using information available at the commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. During the nine months ended September&#160;30, 2019, in addition to the initial adoption of the lease standard, the Company amended its Lab Lease which required additional right of use assets and liabilities to be recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"&gt;MD Anderson&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under agreements associated with Annamycin, the WP1122 Portfolio, and the WP1066 Portfolio, which includes WP1732, all described below, the Company is responsible for certain license, milestone and royalty payments over the course of the agreements. Annual license fees can cost as high as $0.1 million depending upon the anniversary. Milestone payments for the commencement of phase II and phase III clinical trials can cost as high as $0.5 million. Other milestone payments for submission of an NDA to the FDA and receipt of first marketing approval for sale of a license product can be as high as $0.6 million.  Royalty payments can range in the single digits as a percent of net sales on drug products or flat fees as high as $0.6 million, depending upon certain terms and conditions. Not all of these payments are applicable to every drug. Total expenses under these agreements were $0.1 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.2 million and $0.2 million during the nine months ended September&#160;30, 2019 and 2018, respectively. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;WP1122 Portfolio&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#x201c;IntertechBio Agreement&#x201d;) have been assigned to MBI. Therefore, MBI has obtained a &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;WP1066 Portfolio&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#x201c;Moleculin Agreement&#x201d;) have been assigned to MBI. Therefore, MBI has obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, MBI must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement.  Annual Maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights the Company has obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;MBI entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#x201c;HPI&#x201d;), pursuant to which it granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#x201c;HPI Out-Licensing Agreement&#x201d;). Under the HPI Out-Licensing Agreement the Company was required to make quarterly sponsored research payments totaling $0.75 million for the first twelve quarters following the effective date, of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding the Company's obligation to make the foregoing payments, the HPI Out-Licensing Agreement did not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of $1.0 million to HPI within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgxOQ_a802d1b7-06a0-4544-aeec-9aa89cbf575a"&gt;three&lt;/span&gt; years of the effective date of the HPI Out-Licensing Agreement ("HPI Option Repurchase Payment") MBI regained all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly sponsored research payments. The option repurchase payment was paid on April 30, 2019 for $1.0 million and, accordingly, the HPI Out-Licensing Agreement was terminated. The $1.0 million payment was accrued and expensed under "Research and development" in the second quarter of 2018. Total expenses related to HPI were $0.0 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.1 million and $1.2 million for the nine months ended September&#160;30, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, MBI entered into a license agreement with MD Anderson covering a new group of molecules recently discovered in connection with research it has been sponsoring there called WP1732, a part of the WP1066 Portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sponsored Research Agreements with MD Anderson&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, MBI amended its Sponsored Laboratory Study Agreement with MD Anderson where it was extended to the end of October 2018. In December 2017, MBI extended this Agreement until the end of October 2019 for total payment amount of $0.3 million spread over that period of time. In September 2018, the Company extended this Agreement until the end of October 2020 for total payment amount of $0.4 million spread over that period of time. In June 2019, the Company amended the Agreement to support the continuation of the project for total payment amount of $0.4 million. In October 2019, the Company amended the agreement until the end of October 2021 for a total additional payment amount of $0.4 million. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were $0.2 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.4 million and $0.3 million, for the nine months ended September&#160;30, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"&gt;Other Licenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Dermin&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In 2015, the Company obtained the rights and obligations for certain patent and technology development and license agreements with Dermin sp. z o.o. (&#x201c;Dermin&#x201d;). In connection with such agreements, certain intellectual property rights related to Annamycin, our WP1122 portfolio, and the Company's WP1066 portfolio were licensed to Dermin and Dermin was granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property. With respect to Annamycin, the license is limited to the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany; provided that the Company has the right to remove Germany from the list of covered territories with a $0.5 million payment. With respect to WP1122, the license is limited to the countries of Belarus, Russia, Kazakhstan, Uzbekistan, Turkmenistan, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. With respect to WP1066, the license is limited to the countries of Belarus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. In each case, Dermin agreed to pay a royalty for the sale of any licensed product in the licensed territories and agreed to pay all out-of-pocket expenses incurred in filing, prosecuting and maintaining the licensed patents for which the license has been granted in the licensed territories. Dermin also agreed to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In July 2019, Dermin assigned its rights under the foregoing license agreements to an affiliated entity, Exploration Invest Pte Ltd. (&#x201c;Exploration&#x201d;). On July 30, 2019, the Company and Exploration entered into a License Modification Agreement pursuant to which the Company agreed to issue Exploration shares of Company common stock valued at $0.5 million (based on the greater of the closing price of the common stock on the date of the agreement or the 10-day average closing price prior to the date of the agreement) in exchange for the modifying the license agreements to: (i) limit the licensed territory solely to Poland; and (ii) limit the patent rights and technology rights licensed to Exploration to the patent rights and technology rights that existed on the date the original license agreements were entered into with Dermin&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;. On August 8, 2019, the Company issued 429,978 shares of Company common stock to Exploration to satisfy this commitment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;WPD Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio to WPD Pharmaceuticals sp. z o.o. (&#x201c;WPD&#x201d;) (the &#x201c;WPD Agreement&#x201d;). WPD is affiliated with Dr. Waldemar Priebe, one of the Company's founders and largest shareholder. Under the WPD Agreement, the Company granted WPD a royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Germany, Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Armenia, Azerbaijan, Georgia, Slovakia, Czech Republic, Hungary, Uzbekistan, Kazakhstan, Greece, Austria, Russia, Netherlands, Turkey, Belgium, Switzerland, Sweden, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland (&#x201c;licensed territories&#x201d;), provided that the Company has the right to buyback Germany from the licensed territories by making a payment $0.5&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On July 30, 2019, the Company entered into the aforementioned July 30, 2019 agreement with Dermin that satisfied the foregoing buyback right, and as such, Germany is no longer considered part of the licensed territories.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In consideration for entering into the WPD Agreement, WPD agreed that it must use Commercially Reasonable Development Efforts to develop and commercialize products in the licensed territories. For purposes of the WPD Agreement, the term &#x201c;Commercially Reasonable Development Efforts&#x201d; means the expenditure by or on behalf of WPD or any of its affiliates of at least: (i) $2.0&#160;million during the first two years of the agreement on the research, development and commercialization of products in the licensed territories; and (ii) $1.0&#160;million annually for the two years thereafter on the research and development of products in the licensed territories. This license is subject to the terms in the prior agreements entered into by the Company with Dermin and MDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;WPD is actively seeking Polish government grants for research involving licensed drug candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to approval of the WPD Agreement, the Company's board of directors received a fairness opinion from Roth Capital Partners, LLC that stated that it was their opinion that the consideration the Company will receive from WPD pursuant to the WPD Agreement is fair, from a financial point of view, to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Animal Life Sciences&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio in the field of non-human animals to ALI (the &#x201c;ALI Agreement&#x201d;). ALI is affiliated with Dr. Waldemar Priebe, one of its founders and its largest shareholder. Under the ALI Agreement, the Company granted ALI a worldwide royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of non-human animals under the licensed intellectual property. This license is subject to the terms in the prior agreements entered into by the Company and MDA. Under the ALI Agreement, the Company has the right to name an observer to ALI's board of directors.  On August 8, 2019, the Company named its Chairman and CEO Walter V. Klemp to that position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Since ALI and WPD are beginning the process to develop and commercialize products using the sublicensed intellectual property rights, the Company is currently unable to predict whether ALI and WPD will be successful in developing such products or when the Company may recognize royalty revenues related to such products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has agreements with certain employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately $0.9 million using the rate of compensation in effect at September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ife26a4e6c9db456586eec4fb4d9b4058_I20180322"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzkz_5c490bec-eb6f-4567-8492-e0d16f78580a">P66M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ife26a4e6c9db456586eec4fb4d9b4058_I20180322"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODM2_7e8fcb56-a8fe-49a0-8db8-f44480cb5d67">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent
      contextRef="i32cccf3548364065976506f8bb9f0ce0_D20180322-20180322"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTY1_96e0d1a4-cd91-4526-a0f1-de0cad8eb3c6"
      unitRef="number">0.03</mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7d2aeadcc3b7480899be3e16b8a13854_I20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0MTY3NQ_a5c522d6-d0eb-4780-89c3-3972fac9c181">P35M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent
      contextRef="i5b329d2fb15249cbabe0efe9cfb5aa8a_D20190831-20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0MjY0NQ_0fc4347b-b90a-4000-ad84-5dca127ad181"
      unitRef="number">0.03</mbx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent>
    <mbx:PercentageOfRentPayableByCoLessee
      contextRef="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTM0Mw_935aa486-4604-4321-aff0-7995fb1bad41"
      unitRef="number">0.50</mbx:PercentageOfRentPayableByCoLessee>
    <mbx:PercentageOfSubLeaseIncomeAllocableToCoLessee
      contextRef="iedab1f6591a5425bb20b5c8eea9fff3f_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTA5OTUxMTY1NzcwMw_81360027-a6de-4bd7-ad83-0250eddfb598"
      unitRef="number">0.50</mbx:PercentageOfSubLeaseIncomeAllocableToCoLessee>
    <us-gaap:SubleaseIncome
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTMzOA_afab2e73-f751-46f0-b07f-b83e158a0e32"
      unitRef="usd">3400</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ia823a60ecb104dedb9bf6190868e582c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjE5OTAyMzI4NTMzOA_da9e588a-20ac-480b-9da8-633364e9d6ce"
      unitRef="usd">3400</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseCost
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI3MA_59d0d5df-8d6d-4791-b759-0f9249fd144e"
      unitRef="usd">20000.00</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI3Nw_49350868-4e32-4974-8bae-4589368c967c"
      unitRef="usd">30000.00</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTc0Ng_64464334-9372-440a-adb4-e75c94c573fa"
      unitRef="usd">10000.00</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTc1Mw_16009917-a0fa-46e9-aa07-87c127766ce9"
      unitRef="usd">40000.00</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTg4NA_45d852b1-a0b9-423d-981c-263493ce75b2"
      unitRef="usd">10000.00</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTg5MQ_db7dc8dd-c0db-4ae2-a0eb-c47de6e87405"
      unitRef="usd">20000.00</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTA5OTUxMTY1ODE0Ng_eaea5745-01f3-4f30-81b1-2b533fec3be7">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Other supplemental cash flow information for operating leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.064327%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.969591%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfMy0xLTEtMS00NjQ1_45c451b6-726c-4c20-93f8-da78e6e0322f"
      unitRef="usd">20000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfMy0zLTEtMS00NjUw_641cb1c8-31ae-4db7-8e5e-a1f63c814704"
      unitRef="usd">41000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if88cf89ea5f347dca4f2117c860f54fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfNS0xLTEtMS00NjQ1_0bf3de8f-645e-439a-8509-38fb41abedcb"
      unitRef="usd">212000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmRkMmI0ODhjMmY2NzRhZGViNGIwYjBlNDEwZjYwYmMyL3RhYmxlcmFuZ2U6ZGQyYjQ4OGMyZjY3NGFkZWI0YjBiMGU0MTBmNjBiYzJfNS0zLTEtMS00NjUw_840ed9d6-6d19-49ca-af2e-f9c9f42af7e8"
      unitRef="usd">321000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTU3MDE_7c7a0708-ecef-4209-a3ef-afdf785a5d80">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The minimum lease payments are expected to be as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.023392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.245614%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMS0yLTEtMS0w_374045b7-15c2-4588-8120-e17d1c89cd6d"
      unitRef="usd">33000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMi0yLTEtMS0w_157b08c8-90dc-4924-b74c-524f09609d62"
      unitRef="usd">135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfMy0yLTEtMS0w_c03cbed8-adc7-4318-bb63-3bcf80529eb8"
      unitRef="usd">138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNC0yLTEtMS0w_efbdec72-6390-407f-857e-b65ace55ac5a"
      unitRef="usd">105000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNS0yLTEtMS0w_8d2e536b-e63b-4f09-80db-f6bd5c64f092"
      unitRef="usd">57000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNi0yLTEtMS0w_fa735311-8516-4d9b-b953-3dd0f3c99a23"
      unitRef="usd">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfNy0yLTEtMS0w_1c5a357a-a171-4cfe-b0a4-2453db1260e0"
      unitRef="usd">478000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfOC0yLTEtMS0w_7a36d74e-7fc4-4157-9e45-7d4d9b33be53"
      unitRef="usd">74000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RhYmxlOmEwMWIxZTJhMjgzMDRlNjJhM2YwN2JmOTRkYmRhNjgxL3RhYmxlcmFuZ2U6YTAxYjFlMmEyODMwNGU2MmEzZjA3YmY5NGRiZGE2ODFfOS0yLTEtMS0w_a4410f03-63d1-473b-8959-d9c668225de0"
      unitRef="usd">404000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIxNA_d85449fe-63ab-4877-8353-566fadc56af1"
      unitRef="usd">48000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIxOA_9e1d7d62-5ded-41ed-90bb-5ebb4cbfcc0a"
      unitRef="usd">53000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIyMg_984616ed-ca27-498a-a917-4c8ca51627ec"
      unitRef="usd">54000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIyNg_aaf274e3-5a93-47c4-9c9e-4af28aa7f446"
      unitRef="usd">55000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIzMA_a0929542-ff0a-492e-9cd8-fb40eae583af"
      unitRef="usd">56000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="id8ab107b4fc145aa9e410c1077fc257f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjIzOA_5518dac4-b5bb-43e2-8346-305d40c3d60e"
      unitRef="usd">5000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjMyNA_591dbf99-44f7-4091-a13f-c78ebd78f622">P4Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i86c8d7aea62b452da49a9315e073e07a_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzAzODI1OQ_4717493d-b748-4a99-b63e-95a6843b1e92">P2Y10M2D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i658888d65697477c8bdf7f277240e630_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMjM3MA_c8f69f08-f7d2-4ba8-94a2-35c1220b563f"
      unitRef="number">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <mbx:LicenseAgreementAnnualLicenseFee
      contextRef="i664f42f1665c485c853202fc74ba4d18_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzM1MA_7e4eb228-826c-42cf-814c-a84f562715e1"
      unitRef="usd">100000</mbx:LicenseAgreementAnnualLicenseFee>
    <mbx:MilestonePaymentsLiabilities
      contextRef="if1d94dee648346efb077db14d8fbd8ec_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzQ4Nw_7535b724-21b1-4387-bc71-eb6d4271a523"
      unitRef="usd">500000</mbx:MilestonePaymentsLiabilities>
    <mbx:MilestonePaymentsLiabilities
      contextRef="i0c55769a2d6349beb36762d47f51c0ae_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzY0MA_b6015420-57d1-4d0b-86c6-4c313511b300"
      unitRef="usd">600000</mbx:MilestonePaymentsLiabilities>
    <us-gaap:PaymentsForRoyalties
      contextRef="i6a3bb46bfb304e42ab171f7dfca58b9c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzc2MA_d8f2cffc-d786-4187-a89a-f7e65ae69a58"
      unitRef="usd">600000</us-gaap:PaymentsForRoyalties>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0ec29135c33746a293feac556994b9e6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzkwOA_1725b81b-88dd-413a-bb1a-3084befc5005"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i490694ff28c945c0970bd1b5b00026d8_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzkxNQ_f76b9f59-28fb-4c4c-a8f4-c3a6fbf45a5d"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia0f36e65608b4660897d32d69ff25cdb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzk4Nw_dbfd2740-a598-4e4a-9c4f-347190f5fa56"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb689274badf4dc5ba81def9e3ba4777_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzk5NA_1c3a70b4-357e-4d56-ab61-f5d5852c9b24"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjM4MA_5b7ac80f-0937-4e18-bc98-8dbf1abf6d15"
      unitRef="usd">750000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="iab9e0d5eb1bd44fd9de408b8fc5b2adb_D20160502-20160502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgwMg_78cd4663-63f1-4585-a3a5-6bb6ddf6d4e9"
      unitRef="usd">1000000.0</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <mbx:OptionRepurchasePayments
      contextRef="i2399e296e4074ad8812022575df5b89e_D20190430-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzMwMQ_a3f80335-87db-4026-8f42-c6103f1f15a9"
      unitRef="usd">1000000.0</mbx:OptionRepurchasePayments>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="i282c9d75b4dc468ea50e64d7ebc11d35_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzM3NA_8fe8feea-bc19-4dc1-9163-0274a6306485"
      unitRef="usd">1000000.0</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iea85e97e50094e9d81434a25899adfb3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzUwOQ_6c7f039b-210f-44d3-a747-d21f087931c2"
      unitRef="usd">0.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie435b286972e4f7ea765d0391fbceef7_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzUxNg_b1a7fe4f-f35c-4d6c-9da1-9cceb0496275"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i03cfdc63ce24474c9076a3ed88c23973_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzU4OA_f8a18537-8220-4b11-81c9-b7e7e9af2abd"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4cf0e3597d934e9c84c3d513f1c63b8c_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNzU5NQ_abad0fca-e29d-4f8f-bb37-15fb3d26aa58"
      unitRef="usd">1200000</us-gaap:CostOfGoodsAndServicesSold>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="i921f1f39a083428c9445130e7d4459eb_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODIxMw_4836eac3-3540-4873-93ec-38e320b8f065"
      unitRef="usd">300000</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="i442d97ffc8c34dfdb6c0f85109bcfe82_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODQ4NA_0dd9333d-4025-4c7e-a446-446bd494ef04"
      unitRef="usd">400000</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="i4177a6893406483a97433eb0e53c41da_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc2OQ_4a2485f6-96a3-4405-ba9a-16a2cb95afcc"
      unitRef="usd">400000</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <mbx:PaymentsForResearchAndDevelopmentAgreement
      contextRef="i5fd4d78cf6204458b1ee511c741627f6_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfODc5NjA5MzA0NDE4Mg_3ccf8923-3597-4027-872d-8b5156e94f4d"
      unitRef="usd">400000</mbx:PaymentsForResearchAndDevelopmentAgreement>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i84dd43168aa14c0ba971eed3e33aab51_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTAzOA_1ed951b1-c582-4fff-a1f8-ecf67e403b1c"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4aabb04846bf431c9fecd7123d274260_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTA0NQ_dc5c957e-d4ac-46d6-b6ae-186ba6c903d3"
      unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7b81d0dea25642c59af5126ab6197c98_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTExNw_4ff54d2d-6912-441a-8e3b-4ce5939a87d2"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic1546f03b3854c86bdcc7ffe18a533ef_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfOTEyNA_a091d0ff-b96e-455e-9c81-40252a0200ca"
      unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <mbx:LicensedTechnologyFuturePaymentToRemoveCountry
      contextRef="idb95c8a4307d477fb7b1a627137efc1d_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTAyNjE_691da09f-31f1-40a4-9b1c-5c4db2e8aaaf"
      unitRef="usd">500000</mbx:LicensedTechnologyFuturePaymentToRemoveCountry>
    <mbx:EquityDistributionCommitment
      contextRef="ic028dc6b564848f8a736e7c1a222fe61_I20190730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTE0MTM_9576b8f9-7691-4dca-8476-3ef1bc8ac52b"
      unitRef="usd">500000</mbx:EquityDistributionCommitment>
    <us-gaap:CommonStockSharesIssued
      contextRef="i213f24715e7642f782c9022686a24919_I20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMzI5ODUzNDkwNjQ4MA_38ce5429-9efb-46c4-a36b-ad5e6d3fdd83"
      unitRef="shares">429978</us-gaap:CommonStockSharesIssued>
    <mbx:LicensedTechnologyFuturePaymentToRemoveCountry
      contextRef="i13dfe851934d44768ccba995e1db6556_D20190219-20190219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTI5NjU_ffffa5b3-df95-4b4d-8711-b024e4e4d8b4"
      unitRef="usd">500000</mbx:LicensedTechnologyFuturePaymentToRemoveCountry>
    <mbx:ResearchAndDevelopmentCommitment
      contextRef="i892ca0d0325349b29aa4133a6747e7f1_I20190219"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTM1MTk_eaf66c27-37d1-4a2c-8934-3c9a3e51264d"
      unitRef="usd">2000000.0</mbx:ResearchAndDevelopmentCommitment>
    <mbx:ResearchAndDevelopmentCommitment
      contextRef="i73c05bdb824e4b5aa9eb2f176d9c0de9_I20190219"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTM2Njc_31315e48-544c-43e5-9cd0-41297de34070"
      unitRef="usd">1000000.0</mbx:ResearchAndDevelopmentCommitment>
    <mbx:EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfMTU2NDA_0517f6f6-a890-4810-a115-d7287082a246"
      unitRef="usd">900000</mbx:EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie36ed57bd37e4c75940041563288d6d1_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF81Mi9mcmFnOjRlNWUwOGRjNjEwYjQzMDJiMTRhNmJiNjcyYjcwZWRmL3RleHRyZWdpb246NGU1ZTA4ZGM2MTBiNDMwMmIxNGE2YmI2NzJiNzBlZGZfMTI1_fa32cfd1-592b-466a-b0fe-3d368e014592">Subsequent EventsIn addition to the subsequent events discussed elsewhere in these notes, no other events occurred.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787329984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (35,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments', window );">Vendor prepayment and deposits, expansion of production commitments</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares) | shares</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vendor Prepayment And Deposits, Expansion Of Production Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_VendorPrepaymentAndDepositsExpansionOfProductionCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6616379824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_AccruedClinicalTestingCurrent', window );">Accrued clinical testing</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued payroll and bonuses</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_AccruedLicenseFeesAndSRACurrent', window );">Accrued license fees and sponsored research agreements</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_AccruedDrugManufacturingCost', window );">Accrued drug manufacturing costs</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="nump">$ 2,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_AccruedClinicalTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_AccruedClinicalTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_AccruedDrugManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Drug Manufacturing Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_AccruedDrugManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_AccruedLicenseFeesAndSRACurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_AccruedLicenseFeesAndSRACurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640646560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_WarrantLiabilityAbstract', window );"><strong>Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warrant Liability</a></td>
<td class="text">Warrant Liability <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As of September&#160;30, 2019, the Company had 10,256,193 warrants outstanding consisting of 5,250,000 warrants issued in April 2019; 1,585,500 warrants issued in March 2019; 742,991 warrants issued in June 2018; 2,273,700 warrants issued in February 2018; and 404,002 warrants issued in February 2017.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">A summary of the Company's warrant activity during the nine months ended September&#160;30, 2019 and related information follows:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:37.035088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.011696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.187135%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.602339%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.964912%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.105263%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares Under Warrant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Range of Warrant Exercise Price per Share</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,426,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.53</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,242,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,413,018)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,256,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.29</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Exercisable at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,256,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.29</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 5, in connection with the offering that closed on April 25, 2019, the Company issued warrants to purchase 4,687,500 shares of its common stock (each a "Warrant"). The warrants are immediately exercisable at a price of $1.75 per share and expire five years from the date of issuance. In connection with the offering, the Company issued Oppenheimer &amp; Co. Inc. a warrant (the "Underwriter Warrant") to purchase up to 562,500 shares of its common stock with an exercise price of $1.75 per share. The Underwriter Warrant expires on April 23, 2024.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 5, in connection with the offering that closed on March 29, 2019, the Company issued warrants to purchase 2,625,000 shares of its common stock (each a &#8220;Warrant&#8221;).  The warrants are immediately exercisable at a price of $1.10 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance.  In connection with the offering, the Company issued Oppenheimer &amp; Co. Inc. a warrant (the &#8220;Underwriter Warrant&#8221;) to purchase up to 367,500 shares of its common stock with an exercise price of $1.10 per share. The Underwriter Warrant expires on March 27, 2024. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The basis of value of the warrant liability is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. The Company uses the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of its remaining warrants outstanding. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The risk-free interest rate </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Where appropriate, the Company used the historical volatility of peer entities combined with the Company's due to the lack of sufficient historical data of its stock price during the years 2017 to 2019. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The assumptions used in the BSM models for its outstanding warrants are as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:51.362573%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.380117%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.070175%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.918129%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.380117%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.723977%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">75.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.37</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.57</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.12</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.98</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6636397728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn addition to the subsequent events discussed elsewhere in these notes, no other events occurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>230</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureofBusinessandLiquidity</Role>
      <ShortName>Nature of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/Basisofpresentationprinciplesofconsolidationandsignificantaccountingpolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/WarrantLiability</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/Equity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureofBusinessandLiquidityDetails</Role>
      <ShortName>Nature of Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/NatureofBusinessandLiquidity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesNarrativesDetails</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies- Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueofWarrantLiabilityDetails</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BasisofpresentationprinciplesofconsolidationandsignificantaccountingpoliciesFairValueMeasurementDetails</Role>
      <ShortName>Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Warrant Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails</Role>
      <ShortName>Warrant Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityAssumptionsUsedandSummaryofWarrantLiabilityDetails</Role>
      <ShortName>Warrant Liability - Assumptions Used and Summary of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Equity - Summary of Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquitySummaryofOptionActivitiesDetails</Role>
      <ShortName>Equity - Summary of Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Equity - Summary of Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquitySummaryofAssumptionsUsedDetails</Role>
      <ShortName>Equity - Summary of Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Equity - Components of Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityComponentsofStockBasedCompensationDetails</Role>
      <ShortName>Equity - Components of Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentandContingenciesOtherSupplementalCashFlowInformationForOperatingLeasesDetails</Role>
      <ShortName>Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mbx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Commitments and Contingencies - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsandContingenciesMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mbx-20190930.htm">mbx-20190930.htm</File>
    <File>a2019q3ex311-xnextgen.htm</File>
    <File>a2019q3ex312-xnextgen.htm</File>
    <File>a2019q3ex321-xnextgen.htm</File>
    <File>a2019q3ex322-xnextgen.htm</File>
    <File>mbx-20190930.xsd</File>
    <File>mbx-20190930_cal.xml</File>
    <File>mbx-20190930_def.xml</File>
    <File>mbx-20190930_lab.xml</File>
    <File>mbx-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mbx-20190930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640474480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_WarrantLiabilityAbstract', window );"><strong>Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">A summary of the Company's warrant activity during the nine months ended September&#160;30, 2019 and related information follows:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:37.035088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.011696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.187135%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.602339%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.964912%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.105263%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares Under Warrant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Range of Warrant Exercise Price per Share</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Life (Years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,426,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.53</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,242,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,413,018)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,256,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.29</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Exercisable at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,256,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.29</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_ScheduleOfAssumptionsUsed1TableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The assumptions used in the BSM models for its outstanding warrants are as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:51.362573%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.380117%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.070175%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.918129%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.380117%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.723977%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">75.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.37</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.57</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.12</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">to</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.98</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ScheduleOfAssumptionsUsed1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Assumptions Used 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ScheduleOfAssumptionsUsed1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6615857888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Other Supplemental Cash Flow Information For Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6807443680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 08, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Address</a></td>
<td class="text">5300 Memorial Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,727,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808454960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,408)<span></span>
</td>
<td class="num">$ (9,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement', window );">License rights expense settled in stock</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liability</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(1,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss on foreign currency transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,337)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,441)<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,521)<span></span>
</td>
<td class="num">(9,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock, net of issuance costs</a></td>
<td class="nump">19,292<span></span>
</td>
<td class="nump">10,269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,854<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">8,275<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">7,134<span></span>
</td>
<td class="nump">7,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">15,409<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accrued liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_LeaseholdImprovementsPaidByLandlord', window );">Leasehold improvements paid by landlord</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_SharesIssuedInLeiuOfCash', window );">Research and development expense settled in stock</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued For Licence Rights Under Licence Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_CommonStockIssuedForLicenceRightsUnderLicenceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_LeaseholdImprovementsPaidByLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leasehold Improvements Paid By Landlord</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_LeaseholdImprovementsPaidByLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_SharesIssuedInLeiuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued in Leiu Of Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_SharesIssuedInLeiuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633711664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Assumptions Used (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (percent)</a></td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637066080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation, principles of consolidation and significant accounting policies</a></td>
<td class="text">Basis of presentation, principles of consolidation and significant accounting policies<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Basis of Presentation &#8211; Unaudited Interim Condensed Consolidated Financial Information -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These interim condensed unaudited consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December&#160;31, 2018 and December&#160;31, 2017 and notes thereto contained in the Form 10-K filed with the SEC on February&#160;21, 2019. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Principles of consolidation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The company views its operations and manages its business in one operating segment. All long-lived assets of the Company reside in the United States. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. </span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Going Concern -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of September&#160;30, 2019, the Company has incurred an accumulated deficit of $35.8 million since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of September&#160;30, 2019, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the Federally insured limits of $250,000. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.064327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vendor prepayments and deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">238&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-trade receivables</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Vendor prepayments includes approximately $1.7 million for the expansion of Annamycin production commitments on a commercial scale to be delivered in 2020, which will be used in clinical trials. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Intangible Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development ("IPR&amp;D") asset, then no </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, if any, the IPR&amp;D assets will be amortized over their estimated useful lives.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if the Company believes indicators of potential impairment exist, using a fair-value-based approach.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Property and Equipment, net - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term. Accumulated depreciation on property and equipment was $0.2 million at September&#160;30, 2019, and $0.1 million at December&#160;31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Operating Lease Right-of-Use Asset - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is a lease at contract inception or during modifications or renewal of an existing lease. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company's operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheet. The Company has elected the practical expedient and will not separate lease components from nonlease components for its leases. The Company's operating leases are reflected in operating lease right-of-use asset ("ROU"), accrued expenses and current liabilities, and operating lease liability - long-term in the Company's condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 7 - Commitments and Contingencies - Lease Obligations Payable for additional information related to the Company&#8217;s operating leases. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> &#160;Cost Method Investment - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our cost method investment consists of an investment in a private company in which we do not have the ability to exercise significant influence over its operating and financial activities. The investment is tested for impairment quarterly.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments consist primarily of non-trade receivables, account payables, accrued expenses and a warrant liability. The carrying amount of non-trade receivables, accounts payables, and accrued expenses approximates their fair value because of the short-term maturity of such.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 3 &#8211; Unobservable inputs for the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. In the accompanying interim condensed consolidated financial statements as of September&#160;30, 2019, the fair value of this warrant liability is included in current liabilities for the February 2017 Issuance of Warrants, the February 2018 Issuance of Warrants, the June 2018 Issuance of Warrants, the March 2019 Issuance of Warrants, and the April 2019 Issuance of Warrants. Warrant liabilities will be shown as a current liability on the balance sheet when it is deemed more probable than not by management to be exercised within one year.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September&#160;30, 2019 and at December 31, 2018 (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:23.000000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.882353%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.117647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.235294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.823529%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liabilities</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Measured at Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">in Active</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Assets (Level 1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unobservable Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(Level 3)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrant liability as of December 31, 2018:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The table below (in thousands) of Level 3 liabilities begins with the valuation as of the beginning of the third quarter and then is adjusted for the issuances and exercises that occurred during the third quarter of 2019 and adjusts for balances for changes in fair value that occurred during the current quarter. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:56.918129%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Long-Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value - net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;The table below (in thousands) of Level 3 liabilities begins with the valuation as of December&#160;31, 2018 and then is adjusted for the issuances and exercises, and changes in fair value that occurred during the nine months ended September&#160;30, 2019. The ending balance of the Level 3 financial instrument presented above represents our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:54.140351%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant Liability Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Long-Term</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Warrant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Liability</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclass of liability from long-term to current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,328&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,328)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,174)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,174)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuances of warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value -  net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,059)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,059)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Loss Per Common Share</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting and warrants to purchase common stock were considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be antidilutive. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">For the three months ended September 30, 2019 and 2018, </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">approximately 14.7 million and approximately 6.5 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2019 and 2018, approximately 11.3 million and approximately 5.0 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their antidilutive effect.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Reclassifications - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A reclassification was made to the prior period financial statements to conform to the 2019 presentation. Such reclassification did not affect net loss as previously reported. Historically, "Deferred compensation - related party" was a separate line item on the balance sheet. Management believes that this balance is best shown included in "accrued expenses and other current liabilities," and, as such, a reclassification was made to the balance sheet for the period ended December 31, 2018 to include "deferred compensation - related party" in with "accrued liabilities and other current liabilities." Additionally, interim disclosures pertaining to stockholders' equity are shown for current and comparative year-to-date periods, with subtotals for each interim period.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Subsequent Events -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The Company&#8217;s management reviewed all material events through the date these unaudited condensed consolidated financial statements were issued for subsequent events disclosure consideration, see Note 8 - "Subsequent Events".</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;In July 2018, the FASB issued ASU No. 2018-11, Leases Targeted Improvements ("ASU 2018-11"). In March 2019, the FASB issued ASU. No. 2019-01, Leases ("ASU 2019-01"). ASU 2019-01 and 2018-11 assists stakeholders with implementation questions and issues as organizations prepare to adopt the new leases standard. The Company adopted this standard on January 1, 2019 and used the effective date of initial application using the modified retrospective transition method. Upon adoption there was no cumulative-effect adjustment to the opening balance of retained earnings as of January 1, 2019. Therefore, prior period financial information has not been adjusted and continues to be reflected in accordance with the Company's historical accounting policy. The standard establishes a ROU asset model that requires the lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. (see Note 7. Commitments and Contingencies - Lease Obligations Payable).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718) Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 affects all entities that enter into share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption permitted, but no earlier than an entity's adoption date of Topic 606. The adoption of this pronouncement did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) ("ASU 2018-13"). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  Early adoption is permitted upon issuance of this ASU. The Company is currently evaluating the impact that this standard will have, if any, on its financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791739728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following components (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.649123%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical testing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and bonuses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal and professional fees</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued license fees and sponsored research agreements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued drug manufacturing costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6635914368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following components (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.649123%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical testing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and bonuses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal and professional fees</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued license fees and sponsored research agreements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued drug manufacturing costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640714160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the commitments and contingencies elsewhere in these notes, see below for a discussion of our commitments and contingencies as of September&#160;30, 2019. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Lease Obligations Payable</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of use asset and a lease liability for all leases at the commencement date based on the present value of the lease payment over the lease term. In March 2018, the Company entered into a Lease Agreement (the &#8220;Lease&#8221;) which it uses for its corporate office space and headquarters. The term of the Lease began in August 2018 and will continue for an initial term of 66 months, which may be renewed for an additional 5 years. The Company is required to remit base monthly rent which will increase at an average approximate rate of 3% each year. The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the Landlord. The leased space is located in Houston, Texas. The corporate office lease is classified as an operating lease.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company entered into an Amended Lease Agreement (the "Lab Lease") which it uses for lab space. The term of the Lease began in September 2019 and will continue for an initial term of 35 months, with no further right or option to renew. The Company is required to remit base monthly rent which will increase at an average approximate rate of 3% each year.  The Lab Lease is classified as an operating lease. In August 2019, the Company entered into a sublease with Houston Pharmaceuticals, Inc. ("HPI"). The Company has granted HPI access to all of its Lab Lease space and HPI has agreed to pay the Company 50% of the Company's rent payable under the Lab Lease less 50% of any benefits from any sublease or other lab service agreement the Company may receive from its Lab Lease. Although HPI has access to the Company's Lab Lease space, it is the intent of the parties that they equally share the Lab Lease space for research purposes. The Company recorded approximately $3,400 in sublease income from the related party for the three and nine months ended September 30, 2019, respectively. Sublease income is recorded as other income on the Company's condensed consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recorded lease costs of $0.02&#160;million and $0.03 million for the three and nine months ended September&#160;30, 2019, respectively. The Company made an accounting policy election not to apply the recognition requirements to short-term leases. The Company recognizes the lease payments for short-term leases in profit or loss on a straight-line basis over the lease term, and variable lease payments in the period in which the obligation for those payments is incurred. The Company recorded total expenses for its short-term leases of $0.01 million and $0.04 million for the three and nine months ended September&#160;30, 2019, respectively. The Company recorded lease costs for variable lease payments of $0.01 million and $0.02 million for the three and nine months ended September&#160;30, 2019, respectively.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other supplemental cash flow information for operating leases is as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.064327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.969591%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The minimum lease payments are expected to be as follows (in thousands):</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:74.023392%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.245614%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the prior lease guidance, future minimum lease payments at December 31, 2018 under long-term leases for the five years ending December 31, 2019 through 2023 and thereafter are as follows (in thousands): $48, $53, $54, $55, $56, and $5, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the weighted average remaining lease term is 4.42 and 2.84 for the Lease and Lab Lease, respectively, and the weighted average discount rate is 9.6%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses an incremental borrowing rate based on a peer analysis using information available at the commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. During the nine months ended September&#160;30, 2019, in addition to the initial adoption of the lease standard, the Company amended its Lab Lease which required additional right of use assets and liabilities to be recorded.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MD Anderson</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under agreements associated with Annamycin, the WP1122 Portfolio, and the WP1066 Portfolio, which includes WP1732, all described below, the Company is responsible for certain license, milestone and royalty payments over the course of the agreements. Annual license fees can cost as high as $0.1 million depending upon the anniversary. Milestone payments for the commencement of phase II and phase III clinical trials can cost as high as $0.5 million. Other milestone payments for submission of an NDA to the FDA and receipt of first marketing approval for sale of a license product can be as high as $0.6 million.  Royalty payments can range in the single digits as a percent of net sales on drug products or flat fees as high as $0.6 million, depending upon certain terms and conditions. Not all of these payments are applicable to every drug. Total expenses under these agreements were $0.1 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.2 million and $0.2 million during the nine months ended September&#160;30, 2019 and 2018, respectively. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WP1122 Portfolio</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#8220;IntertechBio Agreement&#8221;) have been assigned to MBI. Therefore, MBI has obtained a </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WP1066 Portfolio</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#8220;Moleculin Agreement&#8221;) have been assigned to MBI. Therefore, MBI has obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, MBI must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement.  Annual Maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights the Company has obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">MBI entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), pursuant to which it granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#8220;HPI Out-Licensing Agreement&#8221;). Under the HPI Out-Licensing Agreement the Company was required to make quarterly sponsored research payments totaling $0.75 million for the first twelve quarters following the effective date, of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding the Company's obligation to make the foregoing payments, the HPI Out-Licensing Agreement did not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of $1.0 million to HPI within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YmI5MDU2NWJhZjQzNGFhOTc4NTQyMWIwN2Q0ZDI0L3NlYzphNWJiOTA1NjViYWY0MzRhYTk3ODU0MjFiMDdkNGQyNF80OS9mcmFnOjQ1NjRhMzE3NGU2NzRlMzM5MmMzNmE0MmUzMDZiMTE3L3RleHRyZWdpb246NDU2NGEzMTc0ZTY3NGUzMzkyYzM2YTQyZTMwNmIxMTdfNjgxOQ_a802d1b7-06a0-4544-aeec-9aa89cbf575a">three</span> years of the effective date of the HPI Out-Licensing Agreement ("HPI Option Repurchase Payment") MBI regained all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly sponsored research payments. The option repurchase payment was paid on April 30, 2019 for $1.0 million and, accordingly, the HPI Out-Licensing Agreement was terminated. The $1.0 million payment was accrued and expensed under "Research and development" in the second quarter of 2018. Total expenses related to HPI were $0.0 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.1 million and $1.2 million for the nine months ended September&#160;30, 2019 and 2018, respectively. </span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, MBI entered into a license agreement with MD Anderson covering a new group of molecules recently discovered in connection with research it has been sponsoring there called WP1732, a part of the WP1066 Portfolio. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sponsored Research Agreements with MD Anderson</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2017, MBI amended its Sponsored Laboratory Study Agreement with MD Anderson where it was extended to the end of October 2018. In December 2017, MBI extended this Agreement until the end of October 2019 for total payment amount of $0.3 million spread over that period of time. In September 2018, the Company extended this Agreement until the end of October 2020 for total payment amount of $0.4 million spread over that period of time. In June 2019, the Company amended the Agreement to support the continuation of the project for total payment amount of $0.4 million. In October 2019, the Company amended the agreement until the end of October 2021 for a total additional payment amount of $0.4 million. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were $0.2 million and $0.1 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $0.4 million and $0.3 million, for the nine months ended September&#160;30, 2019 and 2018, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Other Licenses</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Dermin</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In 2015, the Company obtained the rights and obligations for certain patent and technology development and license agreements with Dermin sp. z o.o. (&#8220;Dermin&#8221;). In connection with such agreements, certain intellectual property rights related to Annamycin, our WP1122 portfolio, and the Company's WP1066 portfolio were licensed to Dermin and Dermin was granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property. With respect to Annamycin, the license is limited to the </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany; provided that the Company has the right to remove Germany from the list of covered territories with a $0.5 million payment. With respect to WP1122, the license is limited to the countries of Belarus, Russia, Kazakhstan, Uzbekistan, Turkmenistan, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. With respect to WP1066, the license is limited to the countries of Belarus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Ukraine. In each case, Dermin agreed to pay a royalty for the sale of any licensed product in the licensed territories and agreed to pay all out-of-pocket expenses incurred in filing, prosecuting and maintaining the licensed patents for which the license has been granted in the licensed territories. Dermin also agreed to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In July 2019, Dermin assigned its rights under the foregoing license agreements to an affiliated entity, Exploration Invest Pte Ltd. (&#8220;Exploration&#8221;). On July 30, 2019, the Company and Exploration entered into a License Modification Agreement pursuant to which the Company agreed to issue Exploration shares of Company common stock valued at $0.5 million (based on the greater of the closing price of the common stock on the date of the agreement or the 10-day average closing price prior to the date of the agreement) in exchange for the modifying the license agreements to: (i) limit the licensed territory solely to Poland; and (ii) limit the patent rights and technology rights licensed to Exploration to the patent rights and technology rights that existed on the date the original license agreements were entered into with Dermin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">. On August 8, 2019, the Company issued 429,978 shares of Company common stock to Exploration to satisfy this commitment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">WPD Pharmaceuticals</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio to WPD Pharmaceuticals sp. z o.o. (&#8220;WPD&#8221;) (the &#8220;WPD Agreement&#8221;). WPD is affiliated with Dr. Waldemar Priebe, one of the Company's founders and largest shareholder. Under the WPD Agreement, the Company granted WPD a royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Germany, Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Armenia, Azerbaijan, Georgia, Slovakia, Czech Republic, Hungary, Uzbekistan, Kazakhstan, Greece, Austria, Russia, Netherlands, Turkey, Belgium, Switzerland, Sweden, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland (&#8220;licensed territories&#8221;), provided that the Company has the right to buyback Germany from the licensed territories by making a payment $0.5&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On July 30, 2019, the Company entered into the aforementioned July 30, 2019 agreement with Dermin that satisfied the foregoing buyback right, and as such, Germany is no longer considered part of the licensed territories.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In consideration for entering into the WPD Agreement, WPD agreed that it must use Commercially Reasonable Development Efforts to develop and commercialize products in the licensed territories. For purposes of the WPD Agreement, the term &#8220;Commercially Reasonable Development Efforts&#8221; means the expenditure by or on behalf of WPD or any of its affiliates of at least: (i) $2.0&#160;million during the first two years of the agreement on the research, development and commercialization of products in the licensed territories; and (ii) $1.0&#160;million annually for the two years thereafter on the research and development of products in the licensed territories. This license is subject to the terms in the prior agreements entered into by the Company with Dermin and MDA.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">WPD is actively seeking Polish government grants for research involving licensed drug candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prior to approval of the WPD Agreement, the Company's board of directors received a fairness opinion from Roth Capital Partners, LLC that stated that it was their opinion that the consideration the Company will receive from WPD pursuant to the WPD Agreement is fair, from a financial point of view, to the Company.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Animal Life Sciences</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On February 19, 2019, the Company sublicensed certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio in the field of non-human animals to ALI (the &#8220;ALI Agreement&#8221;). ALI is affiliated with Dr. Waldemar Priebe, one of its founders and its largest shareholder. Under the ALI Agreement, the Company granted ALI a worldwide royalty-bearing, exclusive license to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of non-human animals under the licensed intellectual property. This license is subject to the terms in the prior agreements entered into by the Company and MDA. Under the ALI Agreement, the Company has the right to name an observer to ALI's board of directors.  On August 8, 2019, the Company named its Chairman and CEO Walter V. Klemp to that position.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since ALI and WPD are beginning the process to develop and commercialize products using the sublicensed intellectual property rights, the Company is currently unable to predict whether ALI and WPD will be successful in developing such products or when the Company may recognize royalty revenues related to such products.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employment Agreements</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with certain employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately $0.9 million using the rate of compensation in effect at September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001659617-19-000169-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001659617-19-000169-xbrl.zip
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M)4< <-=0G_<OR.BU?_\K\S*,7B-HKF!U&L+PH%EQ-Z2^X16';W]A9ZTC6W?
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M/(2G%U9T2B@W7GR'N?SUMZ7=O>WC?P%02P,$%     @ ]S-L3X\?Y0* !0
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M%'*&R&@%8HJ:[[I"EQ#*0M*-00H.8#07PN]-O^_786* &==]%]AG.!J8T?+
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MN:3I%#F_KI]4\T@I%UPA9H4'88H"TP$,+$8$Q=,-Q'JV@;B$;/$4A/*KDJX
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MA98OL<)$R1(GBG^X<7E*#>F!X$8UAOU.[AN)369'9C[7Y4/5V.W<SD>=HA%
M, Z\IU2U\ X[V6L(Y@G!P!0+.#^>=FV_T_CMTD;8Y4-@>NXY #>=7"IT6M-&
M&05_A)E9#4KJVV%>;*:8:;*?;RQ?7!SRI]A-'[P@UJIBR96I-7,*;E<A0ROI
M/DPK.+3A^-N]D];&P<G^QA?4VMADS7:GN]?]=-+:;;+6V?JWO3;\^2YOT#^!
M<:/]HTVX[YLOV^T/J-D^.-G>W<_WV_"^9P>TN?'G(?PYNI:X_*Q-,-1;<#6
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MT*^B^*R"^.P7+ERN]*P "CTN">!Q8G2WZVPU!*S&.!\2MWG,-C]VS5  YBL
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M0 9N/(O%GI9;.SC!#-%LP]%L[AY!1+,YH=F4+]!8T$E*3SA(2F1PAMB"9,2
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M@OK"(]Z[1S2X$*BFA*<Z.X Q3;SF0&P.3$OAA:O1;OJ,-ZJ]-((Z@CJ"^D)
M_9$A4P3UA0=*=X\BLX++$$CF-87)YU24=,@D.NFR\4S&.@V:/A,:0;T9595K
MV)7PK]'G0VKY<A?^/5P+' Q:O;/A8.B[];I_;'WUW\_?BRG<DB>V@++?A\><
MF@'_=Z+_>$OFZW>G,V3(7(G*[EA2]L]. O0/\H@6#B9R@@SQ&(:(UQST1>M7
M7 ="<X:B]HM(@F5 J  PCGF:31TKH[:EEMM&WN2)99?@W^,L-@H-L7?BIN+H
M(UW=B*/-P]&)ILW ZT*+!3AI+2L#<,3RH(E+5A:3R;!0QRAPO6TUVY;NYBP%
MQ%'$4<31^^#H([W+B*.-P]$I-[3-P%0 3D+T=2)W9,2%HI1R[0LC:F9<,%L[
MPFU3(;<%%8BCB*.(HP_"T4<Z=!%'FX>C$WU4CTI4I2<@;"12657L>@5$4W!&
MR!"$YT4?5=O"B&TM;@;U$$<752FC;DV"7\38KR>YED74,."2X9+ADBUER3#H
M=>]*F5_GW$KT<<O4@$69:Q;&8SKU-D-=Q[:@:ZR-_ST=9>/>6V!*$L:])C(H
M2YPR@=CLLY8YE8W3"VD)NI[MK1O@L$!<;X*(KAZN8T/)U</UB9>%*^:"*4!.
MC8A$4F$*I)M(F(Y:>LV#S;"09I*(ZXCKB.L-PG5L_[ARN#X5A121Z9"C)3+5
M><$B%WU=*$]$TC12*:CS8B&M'Q'7$=<1UQN$Z]@X</5P?:*O9U',+$<ET2*+
M NX0B0N4$@HL@RN[FF Q30/7$]>QB]:]5NY@>#QNGW7:AV/H#MH?H=4>G>_6
M#[6[UC]_;%KMZ*9^_[(E9?D7<"6(*(_X_:L5 4[MCU>7-/K8=C=!=_BCNWFR
M[WD:KA^A;Q^W[YS53KL+Y"JT3T=:\"^]?OEWMQ7/^GWHQO/6L.^[@XZONL>7
MXU?N:=DYDBN1"+FLR.IUM7W$\\^G:7ZLQ5]N]?/+G3ZL&SV^SMUN.IQL^V[Z
M<#88GA2I+0; 03[TGW_K]4<O#(?]=C@;^M"!P]YOOGP,#B*>R2SX\'(Z/)N8
ML]$Y1:PI/V0*]1'UQ!NMK;:> =BMG9NYYF@2K(*K!W%R'F/6YQ"H1'1<(72<
M2B7/5 C/*;$Z2B*U8,3R'(B*S@;M% O.;>VPFYDKRTXA1XQ$C%S=J!^BY>J@
MY53H4*:LF&:9J)"++JF+&ND4!1*YL,G91$V=2\.>N.$2 B4"98.5R3E$T1 >
M5P@>IS+FBMT@8K#$Z3ITN5@2Q J=",W6%:.")1IJQMS-\!LJDQB#F^/*7<.*
MT4R;!HZCO'SE\JN^6[35@&5MY+#*^RUCDZBT\95!MU#M%7$B.\[$CJ^F'=$L
MYYAR,1F2M;5.2' 2O.$$,HV)!<<%]^,ZH4:-5IC/T6L(A&UX]VYDHP8=B=5C
MHZ74,R$;S9&-)K9:\BZ!5*)::(%(%FNV9"UQ2C37TR""'%<W\2<.C2(;(1LA
M&RW]2*P>&RVE"@O9:'YL-!58\5YX9U0D.F1/I$^>5!.7" \V*RY88&94D]6L
M"47(1LA&R$;(1LNJ'4,VFB,;36PC(8IN85(@)L5$I.6,!$<M,<%YJSE/7H11
M)9FAR$8+CG[]:Q2MO4J7OZ,.0.ARF5.K5N._[7S>L-H /D*YKV[TUML:WT4L
MMP;]1M[$&X"6C[7JS7?/BRRUNKUA^<QAKT"F/TOM.B&JP&79G,'XT4@X?7TZ
MM[N^&]N^4VZH/%'#](-G-Y=CA&%'](CSK7NM$AE ).79>BY_')R=G/C^:/]O
MO/6T-VC7D_MC'VJZP$?XZ5,[#8_'I1N7=REKA\:II[=N_P0?RFV=#>&GRX-&
M[W[/_2^X<7LMOZI8F?IYW)_ W7L@H0_^;^)SN;T??>>3/Q]L_>O:*GQS><>W
MOO,_H?^OG=N^LKF'Q-R^<*W67J\#\:R\U/JY70Y(/-YN%=:^1=I7ZKZ>?SG8
MSZ</]ILOQ[G5RZWG?G#<^J73^S18\;O]H>S>\+AW-O#=-/CGJM_,%WA^P)W<
M=C2;NP(/H]^"PN_;W2O-28]UHY$*\M5OC,P_?S;L_73YQ%B;&CUSJ7Z5&^GX
MTP'\>/7@AF4ZK</4ZT_MP6G'G__8[HZN?/2]ET#I[#/AF&5B!)>7.4&7EW0)
MI<_&4/J5(CI^49OR=FJLO?M7OOG^;[\HGE%J)'</?#]]QK[UHBJ?+/D#W_[M
M"^?/K+)6WO?]W\G'NJ> /VDJJWM4=MAW+_CR9"\@6\P\63?G<K0*,W>'QX/6
MRW+V"G/!:6&N /V6H-OW<(A='=-B!\)W*KEO_=45$*/')1D^3HSNM&MO=;\U
M4L9J .(AGM7'[/0<E@W%8.YB8-<XH??)UFUD/.1J/+1ROW?2ZIU"O]CJW?>M
MZG7[6*QO&"R@K\[3GJ@5;S(RK\59D0XDR_:/UAD4\\YLQ]Z'F]O[$'O:7D6L
MSO?:5Q&KU^K=R=[%P8MWQ_LG__OW*')UN*OV_]H_WN=_J'>'K\OG[!^_O7C)
MOT2L3OZW\^[??_Z]_^(/L7^Q>[%?O^?BE2S7*M\>_OGWNQ>=]O[)ZT_ORF=\
M';%Z>U)>_^LUW3^,8N_%GBCW]&'OP_M/^X?'Y?I___O@KU?\W8N?.V_Y+_E+
M)M\;^NF(9<$DLXQ$!I1(*RFQHOPPU 8G P\B9>QHN\J5J8CJ31#1U4-U[&B[
M:JA^\075$U,\"68)Z)J% $&3P'TBQCGG=;+1*XK];+&6]FE7;E(\/PKG]Z'@
M2VQWH-6]-$#JL_5QK#;Z68T"MKO+,M"7;0.OT/>OB)D]G68Q_09]XPU$-[3Y
MYPLX+:>F/6I%T?+=U/(GM?W$!7;_?.)&)',P::\K-M,[61YWX++7R.[4AJ*^
M,X.^\Z4"H.H[.2:50L[$@\]$Y@S$A=JWTZIBP7K*9;!;.TP:;!^RNH8L(ELC
M6RPALLT?V2:6G(A"!YL2H333@FRV@%H2@6@IK##96:]KK2T"VYK;<C,HLXPW
M5)M],^S%OTGPXSSNDU/H#A:@R,Y6"+%N<#\'1?;>SKLWQ[X//]?M?3ZUNXC]
MLV!_>TJKI4$Z&J(DV3 @,EI*K(F">$_KYE'0)A2M=INI1?18?M@Y:CK\+]N7
M@D#75+T6T6P>:#;19*-DC"LJ27#!$LFX+YJL=R0P4-I[;H/G6SN6(Y8U295]
MN#U_4S-MR,K]VHZUY*@UNJA!"SZ?COXY@.&P,PY!#*JB>B=-H/NA"8[5D_"Y
MUK"?]+HCL^+58' &Z9=>?[2[$7X?;>X?W017S^R^[\.HI@PA?!8(GR0+?3YX
M\58<&6%\2$$39W0FTD$F/AA!> I>9.5MMK45I;M9WHX>B:=VM3X"2!JR',N_
M@.\,MD3P7ZZ./NV,N(!^+_G!,5+"HBGAXAHE2.&I A"$2J-(^6.)9\R7'X9'
MI66DQE2DLYSQGY 6&J3=+]=1S65#'=7_]L4(&%4+Q6/??5^G<+>R;_=;'WWG
M#&I+@D^^W_?=8:O3]J'=:0_/T8>];@4&OY0-_[/N]R2-[2#_-=YW3$U]H WQ
MZ<@!-6"8(X*"(Q*H()XF3A@ON^H3HRKJK1VQ395K4H.L56$)]&>O"^@M)?\>
M0>\)M.1/1\'G#%Q1DI@014.VDCBG#&%4FZALY"&-(GF:-:I'[:J 'CJ^[[5R
M!U\RZSO@![!=<^_1T=%4C77BTWC5C?VZ82]@_/>K[I>=_+7^>^38.,A_#&!W
M, !T9LP"TP?/IW33Q&,T'ACQJL)T4)SX((!(QTS9->]5KA.MG[ASZWJZ+S"!
MN,G8=NF<0U_<*OKB&JMPU"+>5B'*/)ZVVXJ7XW9;P\F\W1M=2-!\;$B<_5NA
MEB_VXIUSE.O>_PQUYQO447XU5)+IRB:11;1 ,Z'.LZ*22$%\4D"$#E)Z58Q*
ME1<96UE/ Q*]9FL">W// D6 >Q* F[C&@+D010A$ <0"<)027S:&.).#=Z$P
M6,TGNF62(&+;*CK'&IMY]'P4Z1U\U8&B^E,&H\K[JTCO@[M1+,*PW<3O;Y8M
M-DM>Q&4:A&AJ]XDQF-S\^5L?3GT[765.C\]';W@,_4L+;WAY<# IHMDNYGN'
M!6]ZH"]EX.58!%#]F:53UV7NW.7$,*ELBIXFP@0M"A!/AE@C-'$BL,RRUE[S
M.DU9B)M%WA@;1--N8P!O[K8=HMJ\46TR!Y%G">"H(DDH3F2M^[,N9\*YE3K*
M"+'.062&(Z:MK4DW0RJP;&K/BO'J[\98KJ-8@J?^O Y2PM9K*Q.YF%&OO=KI
MW\8;C10P$P6\FE9L?6:Z$+,GFJ5<3KA6)&0K2'91**!""U^;LFT[>9,$,!"-
M616KCWK+2O=%D'MBD)OHN5XK@%K$P)P61$H6B <%)$I1%$\A$^.I6.\WFUI@
MRMB*9=DT-G)QTT%;SG?_#+[IH)T*9V "3E/]L[/7;]R*]546?IWL-\+]3'"_
M-ZW3<F[!QB0)I3R2@NZ6!.Z ) 7&2F:MI:KJM(4(T+&!SMKU0K]F^6H1V!X/
M;!,]UC*:F=6.,*C&>JB-V812Q$>>J+!9!UN,=8=Y.(W29M>Q2&VDIG9Z=2F@
M?S*MJ+:P6&T%'*YWI8K?4L56MWJ_U[VT21#)'XKDK[^HJ/LO]HZX""H'7B2$
MQ0+E(!UQ8!F17LLD(/(H(K;C0<\KPM^B5%4$NOD!W?D5T+T]8LQI9Y(B(8 A
MQ?KVQ.9,B>4T:P6.LUB CMVTQ!'CT $[YWGJWQUAV PO:^CU$_1'WU 6KS7H
M==JI56]X-6"]\?[7(@K/BR3\UN]];"=(/Y__441BJE_#[A=Y0.1_H(J[MWND
M0!IGA2,@/27224.\LX$PH5S4(("97("?;RO>*#?L]T]?HW -';0;"9S+&OR-
MP/FT*G.M-6 9G R.>!T=D;2.R%2.DVQ$L"IJK8T:SP6_Z>=%W&R8)KV\(DSS
M9$6858O.G=ZGP;C];KO[$09SF04^TV+=*6_WP/LFE48V>G%6Q+B<)8G=-C2)
M_;>S?CSV@U'GZMS^7(Q4K,]<!?OSNHKTFS^O_5@'A[W=^-^S=A^*LE34H^'Y
M;QW?'>YVT\OR["F.,YA917H[;5L:9K20CI&LJ"!2J$B<C(%H:[-SX(.K"9VW
MI*QC>@]:CQL#;G,/FB"X/1VX3>P_G;+2R6>2'20BP7+BG;&$TI2HD%[00+=V
M!&V4];<JZ+9>-M[BHB6W&7G-R/1YC*FS>I@^SX#)O9Q[KZXV'IU[#P3W.*VY
M6N-4DC*30LZ*2&^KYFHI83[&(O1,1AF>7G-]@A/6*/C"5*!-Q<>GJ]!$?'PZ
M?)P*?DCM<Y"&T,)NM1[=$Z^5(\)Q9K+6@1JV .5W P%R15R]38M^Y';7=^,\
MHA\S+=:BHQ^+\/8T;G&:92PVMAJD4&+9G71Y(. S]&-[',<8U!&_K=[ID\X0
MV.S,Z/E',"YW\Y>RF:,1S0?C[7MYN:\)U9N9U)N_KYE_+GN5LR(F"T9D$HE8
MS1+A&J+.RDM:)P7<;$2!R=!HY6T4K#WQ%'H$NR<#NXDM)R)WNFPAX2;7J0$<
MB+<*B F41BTU90E'SF^*W39#BHYJZLCYNQ7=RU'SF*S3;$WWWIG.T[QP.5GY
MBA+0O3<3)7S8G=9_@=DL=9(D9)6(M$*0D!PG7 @/'*1SHVK ;:5N]E'''A:8
MP+-1@#?__!U$M3FBVD3194(G*!Q$%#.62"8#<59JHFDR.6EP#FJIVR+,^O6$
MM&8Y8N>AXVJZ$CKNH$!"U6]C[^2DUQW[<T<CZ>N3[<'@S'<CE%<'3ZWZ;K8W
M9%FJ[ZO+'7Y5+JWM.[^=A4X['N0,_;*8R!@S,<:U>4))I<Q!1**,+WJP!DYL
MH8HB8\[1Z&(R3A3&<-O<8=]U= 9O./S-V1F,\+<<^)LHS%%RFY0.Q%LGB8S"
MD4"3)=IJZ@%D49YI@3^ZS;5#^&N0TKS.C8%.+S/[6N'\UJR>AC<'6IETSH;J
MO7?D=_YR)0F8W_E Y+\V;XA*;ES9/0*IYG<&Z8D3OOQ0V23#68K:;>UPNFV5
M;)R[9"WR/#?6/;Q1R+E(E1F1\^F0<TIGYCR8#)0$)CB1R4H2M,_$BEQ84F=)
MC1SKS!:1<V44ZC6L'7U9#.0X<A##YWCLN^^AU?=#:(T?#UH%N$;Z=IUW-'H
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MY*4Z>'%\O,=?EVM_)=^6^R[7HOYS4:_M_7E9'U[6L/S]_L@RH:2.0'Q0@LC
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MO^NA0_OCP3-]-ISI418$61!D0?!T!(&U\]/Y*(6PG_LPM,.L"F0)D"7 TY0
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M!\\:^_Z9PF_^^P3;TW^/]=]J_O+T#_SZ\[]AK#!N^N;]X;L_/KTY^H,?O#N
ML?S[_>MW^\4;&-_+7_\\_>_/]N-;P0K+J67(DB*F'[* 5"@=(H9(6/O M>=;
MN_*2LZUK#17O]23YP]8X[B\DMY)^L2DL!S-/7U4Y''?37;KTPF$A;5DZ@9R2
M#G%-%5+>,,1XS*0I)+;>;.WR;:KP-G!5[Y(R'HH"TH/\O"P"OTO$X=ODWX:C
MT!L,KXLB+BLBUQ1QRY,,!5A8@A<$F5(9!#JE0I(6&BF#52F#QXKIK=T[L+2R
M:,NBK=>B[=N#J=^JV66I]TU2KQ->E=(%K:A%0DJ&./R'C&$2P:+Q4C NK*8@
M];8)Z=]YWRSYLN3K;P I,W-FYLS,F9DS,S^,&&?62>_7$N]$/5UI2$F)0T81
MB;@I*5CAQ"-L.);$$$YBU!.44GH'R?^/5/3E$UY?6P,;&5WY2+33,S^N=.2Z
M?,ZK9_K*D\A6R-E;F>TSVV>V?S!L?Q\G=FZ4WQ,3!A*Z/^N ^Y_^?^;#:CCS
M?_GIAZ'UM;K_I[>3XW%Z2M+\L\)_$X7_W5[7"1T\M4P$ATK,2L0]]TAC*A!Q
MG$DAC:6";NU2GH_Z9@GZM"5H5APRVV>VSVR?V?XIL'WO\^&SOGQW^G+704Z(
MM;8D&K&":\29"<@XP1"E!?:DP*7 (2O,O7:6WV/'OENCW+/).)6[2YUCXS&?
MT:2J^M&L[T'(^QR]S]'[S,R9F3,S9V;.S)R9N0>=641@4C)=*F4]]Y@:)3 G
MPA58.JZ=N(9=>?,6+8=^MC^VDU/_&^B/V5"\D:'XHMN=I=2BM,$;5-!8/"UP
MBK33)2H<A@4LO9#.;NV2;44O9O??8W.6+.:RF,N8G9DY,_/78?:W^X(S9M\M
M9G>=NS:P ELM4%"F -!V'NF2<J2PPKJT94E5R*#=)U]N;Q*?Q6W1\9]Z%*L=
M;0\.]-2>#!C9'D31T<>\YXW]5QZ&H+]9F1UF->52!$D]YYHZ*;@75%LF55$4
MGJ7>1M]:72>]^.5\5LWT.-(K%]*YD73?[Q;2*10U')<4B3)HQ)472&EFD.>8
M%R$H*Q3?VJ7%MBCEMBQ)SP-X5V^VOL-![[(C[@F';B V>["0W[-5WIUL@)Z#
MRT4CXNN094/=HMP:[YO@8^G0DXH6CN& B%<"<0SP82@M4:D*XWG!B2XEP$>9
M82/#1H:-#!MWGX=H3&&5E]H1PC%3QBM<.&I]J6E05&Z&C=QL]>X0I7/V1G%#
M+>8!>64"X@4ND"X%19C+DFOA#+/EUBXKMU61C9&,*AE5,JK<0TB#<*6"I\[C
M4O!2.$4=+DTH=2"%$R1LAI6;1S(ROGP[OBPMEB"PM\9BA$GLY4VQ1(:5\)N3
MMC1*>X?9UBXIMSF^W7!&AI8,+1E:G@:TW !9N"6:4LJI"X(+04PIM3+"<:4Q
MYUY?SV#Y[*<3IZN3C"7?'4M>=NH$E$$5O/3(E9;%;D@>L$252 AG Q;<!:P6
M>3_96,F(DA$E(\J=(XI2S# F&=.8<5]2*0(VTEA=%BP4F&<76!]@I9MQQ0A3
MIO <86HU6":.($T50[XH7$F"LJK06[L4;Q?B#EK;/'%8>2!G;7,/OB&5U"HG
M"L.=Y:7TNL"^Y$YX8PEQK&CR3'F;9UHRG'OP]40 'GRA!]_!Y]?T</CZW<G[
MUT>1+G\ /?X<OGEW'.GVZ?7G%^S-WP>?7_YZ>%+WX.-E8;4QH) K@K@$K5QR
MCI'RHB"J,%*+*#W9Q6($N0??K28'\H"M!^NVL$QRYIT"NP@'5P:NP9(J^!7[
M,_?@Z\,N75J_W@3FH_5+-9.(!VJ0T@(C&DSAC"Z]C#WXR#96=+MD=Y "\D@3
MQ/-!F <I B]Q[7V;_,L]^.Y(Q'7.JQ8>5(F"H%(ZCKB7#!DL"^0]+S13F"OJ
M0<1ET99%V],6;9BHP"Q5JB@DUX1(R4.I5:$8%00+GT5;+T1;)\\*<X^ML0Z1
MDBNPDC1#JF06%32&FR0#61>V=E61V^QEX?88A5L^C9^9.3-S9N;,S'UCYIMT
MY2A+Z;U77&'"@[=&*DVY*8L0*&5:9K6S%VIG-[9IO*+!%@JQ6 <*3.H2@1%-
M4*PC00G8VCK8J'?*K'?V)V#9FX(2N9/>0Y'BN47"8TIERVR?V3ZS?6;[[Y&.
MZ"6W&"M"N.:% P60LQ);(XHB*.'H[63IY,X@=Z7N_]'U,A>\(+(DH-['=B#<
M:X9B&0]D<:%)(4OE"-O:94SU/(TQ2] L0;/BD-D^LWUF^\SVF>WO4%^^GZSV
MK"_?G;[<=8^77&L,]A!2UCO$A<=(JD*C$@M@+J*IL#(KS+UVEN=.>CFFF0/T
M.4"?F3DS<V;FS,R9F3,S]["$G21.  EH8:0 N](9^$VI( SWENLB7,.NS%UY
M[M)0?-4M8Z<PE]))BTA0\?"EY$B7P2&JO?&FY($5?&NWV":TR$UYLIA[7&(N
M8W9FYD?#S#?![._@"\Z8?;>8W77NXM)RS)U'RM!XYLY2) U72%E'+=7":1$R
M:/?)E_OX$Y^?S4_G(ST;?O"#V52/JU&*] ST(DB4,Z![IJ4\B;A,#FUGML]L
MG]D^LWUF^\SVF>TSVV>V[Q';W\!G8P@)3OB"<FNX%+$TDBIDP)2JD@9W\S/J
M2XOM:&FP+9/Z#OWL93C2G^KDO/VQG7I=^>>^_IG]-S?RW[SNMGNPNG!*8HP\
M+PSB(3 D)2X0Y:5EV,3&@F%KM^^]3K-PS,*Q-\+QNR<W9^%XE\)QI6F!4H6S
MJD#<,H8XYR =:2R8&8CV!3$,1&>6CCWV==]CWK*X+<K]4X]B1?[MP;_F8S]@
M>'L0Q4@_$I=OT*?G04GY2VN_6\&IDJ84V&I>\D)[47(AB0U*RL#*I@G-MY5\
M3R]^.9]5,SV.],K5W6\DSVVWNCLC8*RH0! N2H^XP109$3"BQ.O@*#6ZD%N[
MM-R6)=GFJG]E0A]^YYE;R=OX:JGS_9J;W=J >[",W[.=V2TQ?,_AXZ*1\'78
ML:&X7^Y2]DT L<Q =<YA7QB"2B4"Z/M!(:-E0")8P41P!5$* "(#0P:&# P9
M&&X#&'PA?6F,Q-I+KF1I%"U<60C#L7'P]V9@R)TM[PXSNDT'!/."E04"\X&C
MV"(":54JY!7#DAMCJ79;NTQN4YYQ(^-&QHV,&[>21V]M (M""6)Y+!?.I"BQ
MMV!;6!Z89V8S<-P\?3XCR+<CR-+JL(7R@5F&/,5@=5CLD#$"(T=X8:EU@" >
MK ZR75S2W_,><^@S>&3PR.#16_"XR;GI0)0M2Z"&-+QD5%M;<J*=MDX*9XOL
MC;HS7.CDY@0/,$"81,X5&'&M"B0==4C PAC* Y52W$GT.>-"QH6,"T\0%PI=
M%#YPR47A.4" L8Q%$12S!K40(CNC^@ 9W8PESH*53)1(E(HB;@J/I& :*6X+
M%I0J)<9;NZ3<%KQ_W8@>/G#DX[JY3]']$S0?8'D,.=I?2YN]Z5"/OEX[N*?7
MMDN0MWS>\GG+YRV?M_QWM..$8((K6_BBH+S$%"P$)DM>Q,ZDRDO7'$D1[9$4
ME>OM/R ;\/!Y)R'AZ#UYR[3#!FN%M",2<06_R5('!.L>>+"$:FVW=BGG^>#*
M=\</^@WX\?!%TN6,\P2X(J-85ERSX.G-]LN")PN>+'BRX,F")PN>WK',#>*O
MI<5:&DU*0;@/A;%E$32AI2+8:FNRW?[0[?9E[/9%<?C'6^=4*&A!4*&\1EP&
M@PSW\$\)3*#*T@IKLN7>ZWAM;I67Z^'?E:[Y2(N>WV-SAQR!R1LY;^2\D?-&
MSALY;^2;^GL>(Z=<U\/S&%8^"Y!;.9HK!>;<.^EH67"F2R4%Y\XZ+!3%@>!K
MN'%RBZN[],L<+X_GIGP*QIPJ5(EL8 9QH@U2@5-4.HF-P=0'$_,IMC&[F%.?
M>UQE<,G@DL$E:Z=9@&0!D@5(_[33[Q!DS-KIW6JG:U'#X*@MF"F0+CU'W-*
MM,4&%<ZX((UW!2Q9UD][%"3L[U&2W(.U[[(])Z[EHUXY/I&W?-[R><OG+9^W
M?-[R><OG+9^W?-[R><OG+?^PMOP-W+1:6,*\+4NI!+>B-)13RRC'L4VO_HH:
M#KFMZ-VY;-\OZ[K&A()"%YHZ+!$IG$,<. (9YAUR5&K+G=>:N:U=4N13'OFT
M8CZMV./8X1-@F7L\K9@1ZBX1:BVH2$@HE2T-XJZPB&,MD'2N1-Y:RPT!(>M9
MQJ@^!QD?=?/KO_S9S)\:/WTP';";;YIW,?C23>9FY!]M?VQCBD"U)0$'SD/
M1KA"2%Y2I016IJT>KG)_['L3^T=[R_[8T3#1I71<%QQI[#3BQ&JD'*4(4VR\
MQ;ZDU#S0#MG7VWY]AXE\HNY>'5MWAL;?#49ZP,:][,QQ$W'0<_"]:(E]'?+F
M?DZW :_=@T2P"H$12P%>;8&X+$JD@E5(%925A6*%%^*!]1?/L)IA-<-JAM6G
M *O<%MH;2;A2ECN&-;5*%X'QHG1&\W(SK.9V6'>'N"NET*53P3 2RZB5%O'@
M 6R5)H@:@HW%7)M"I.[L7)&,NAEU,^IFU,VHVZ\#BEP4-C!?.D<T-[:4%#/&
M2UUX[IS#>#/LYL[V]X&_78M722V]5@XQPQ3B5!%DM"L1=M:#*<P+BDNP>-EV
M(7"?SB9FZ,W0FZ$W0^\CA-Z;Y)P6RJJ"@ 3'E'/GE<.%M]H*0IP.CF<_\IVA
MZDK^J"LTQ\$))$JK$2]=@32W#M% B'&88,D\H&JV:#.L9EC-L)IAM5^P2CVQ
MA0H<E\1QS[04E#D1A&:A]-CY[$?N ^*NY<-ZY@@NM4 N]M/D3BID;"$19\",
M5&%!N=[:)7Q;E2KC[GUDS_YCIF'@\-,-/^S^%_S3#K)#).MA'T[79W'-5Z^.
M]\MSNX(PH^'8HY/Z;T*3!*NGM3:YASF5O[P?:&LGIS"P<^"?P7@R@V?.)B 5
M]=P-8QL1D(C.CZOZMV5WD3 <Z[$%W0 F!!^D5D4[-R?'[G^9Z3]V-]YW-JE2
MTZ*?IKX^8/#SQZ&;G< $8?S-7'@!D^U\O'7Y$[2!P<]G_N=F"^'-]UP<+:J\
M1?!IE!,_5?/34ST][^6*BE52=O\]F2X%V;%'9NKU>Z0#3.\G/?JHSZNM?ZQ0
MX8ODW;QZRS5,Z/46OZ5RZUHLT3\BB\N)?# 9>3N'+P;_',*&L2?;@_VQ_0KN
M[]6L#MN]/SOQ@U>+_?]LL?]7N@O]LMC_?RWV_W??_NF^87S_["=6PC0Z#XJG
MBX:AG[MP$SBT.X*1RW;$@^%_LC-HM.C#^:F?#NVJVNQ9Z5TAC&/"<RL*!53B
MI"@9E=*5CJ3S90J3^GR9JO7G6BT^-9]^.M2S^=2_#/^<5_#JJMH;N]^&H!H#
M.YX?P4O^.0*5^7YUX\\'"]TXZL![YZ_AWC?O_C4Z^/P'A>OYF^=O3D%OY6]^
MW3\_!)WUD/YK"'KNR/_?/\_?_.W.#.7EP?,W[P^>_PMTWW^='IR^ EWX-8SM
MY/WAZ6O\$GZ^?K=/#O[^@\'WX>71JT\'?[RUA2NYI!AA30SB.! D%27PF]0*
M6^(5L;4-,QS/O=N;)=^@<(0IZ3DE/'"AF*4%9Y*+DGI+X7H/!L=9W&W3N0<Q
MD,@_F(1!NP #/7:#Q1*T.G.S]&N;%[YK7E_7$4RK=/405H>L""NE%8)[HKE6
M7I4E5Z&TCF$#*KR\!*T?D9!XX-,Z O0 "7]:#;8._KF_-9A,!UL149[56N;6
M]F#KHX__3N93^!%Y"ZSAK8$&IIM'F#GQ4P_0"D T]<%/XR\; '< +Q@,@3\'
M%KY+UA0HH\=^<':BP?ZV?IY,K$&CX&[#6([U&";C!CK>]1R4RH_QO78R/9M,
M&XX=#_XU'YW'HVI L(_#V<E@.*O HK?S:@#?Q[G,0'=*1UOC-CF!V</U4U\-
MX^&FV<#&DV_3:O!AJ-/5SG_PH\E9>WU\VF0<%^'X?."F\^-X@TNP6@$]1J-X
MT<>3H3U)-$D=/N.+1T,;<7B@CZ>^QMMZ=$<)KD$WGH*F>QYO!BD)\_OKO )<
MCG<:?Z)'(7X3AW.P\WQG $(5KH?OGJ7!#IXE6-YNWOO1+VD/3SIXOKB^IGET
M;\"@ELNR!PPY!=[4@]]GYSN#WV9N9WOPP\'>[[_]"%."ITY&0*+)QS'<5<U-
M!9($P*VF]=BG8X';\67&'\-G9U/?+N@*\59>!&,8_/T[$8Q&)H+_:2!HG"-\
MB,MR!^@"K.''T=:L!AT.C._QXW>3\_2A\6,?TI*$ 1!BIN$EL)1>3R/]@3F[
M YCI3P,[]2Y>WQW,#K#CX!=OIO,XJPAJVRMO3,2%J0_'D:#CY1+6*[@WCJXA
M$+'!#_ZR0P\K ISPVV_/!C]L[?VVO_5C7!=XP,HS3V!ACJ? ;Y&;(U%;_H!7
MP$WU_JGGL=U.8GMPJM_[;;CW@X=?'?P*6P[V16@6N_*CT7;SK_\$>V(6]^_P
M-/T6J0%;"<1^U/M@&RT(UKS:P<I-W-RF[3(%8W*,3N8@1N)+TMWI^.$*18'K
M@7IQO,.J OG?ZI_M+/5@H[]N/(_'2M=<=J6SV!JO#=.:<\.EE,QSI[$LJ6$F
M))>=6G?9T76W7.V*._"SDWA@_8.O#[*_!/Z=5B?#L]^!!/ WB)J%MP[1)Z:2
M'!R]( =[;PFEELO"(Z5C36MF&#+<!"1*$HK2P@]"06.\F#3RO^)N *:NZGW]
MVW[-!K":T36VV"PKLCGRD/$6EFK#GDFH\#T@]:$;)ALT]V<3V']' *#C"#]#
M>!Q:D*MWFD1$FBCE-DJ 63N1\ZWO8(%L/MH<#;/HQO\XF;K*CU>,E22$7H;G
M@.-=NO;E>/,]B(5]!I9*:8PK56"(<J\05[1 QE")J+(B:!;+C9BMW=D)X. %
MR1"W?-0A.UR:8'(C'RSTIWMF@TEB@V<+;>XI,T%Q^/&M*2T8<+#T1)88\0([
MI#WSJ !*4Q><*EG8VJV&GRZRP WT8C>L[ 0P(_))U&D&>K:JL8*"7/E+F"H^
MA?P(%\(ZGMOA>'M ?TS:^5]'>T=LL']Z"KKI/U))&SL=GB6>.P#]9J1GDVD5
MK8E!!:H1*+9;5UR[U2BE@ZA'A<EH.$E0QNK7@9JA#7Q8G?[CU]&YG53G31'^
M_?')T SA <O[MN.3 '/3K%HM*16D%#]7"S-H4)M!D8CU-#MS3+HR;#QMS^/E
M40..GO]J-G?#Z->'MUTP<:+W_2R1>QH-@[A*$U!TM9W/0(\\!VUNZ 8C/W_O
M3X<Z$6;OX+<TQ7K>Z:U?IA'HUM-C/XM#,=.H4\[FIXG*,,%8*&@6O4RUK1*?
M"\_?&?SM:TTVVG<CGZ(2<V 3/YZ"N9'&7BL,Q_-Q/9_X]#/XL32>8'R4XDLM
MB.TE+29GB:HK-(&YZ[&?@%%XA"PHS(/1^>G9"6 =*.W/CI[]MI4LGR@^XM75
M>YA2/?[MJ.\L359X:O2BZC/0G3_ %,SYX/?(#"= Z>.&?Y*AI,<+ZV)I^8ZJ
M:,P<PVI'A6FCY00CB!'"2/+XS?KF&H[M:!X#B(,)S'=Z->L#*G^,<];7X=X*
M5BK2.I*RGJ8>M<9H,]4U8JQ-M[7U8*4NY\]([U6+:SSY^&7=(=*@%W!1#<?/
MFMD?Q<D_8=1X=\ /C]]2S8DII05CHHA5K<H2; NK$);*FE(YPZ3=J#K4(@_X
M9[.RT! [<=J]<T!>^G;IBY=[;V'!@]=E=&B+ G'* I+8*%1P9YR7UIO2;^V&
MR7QZB=*X(D*N%XM^9$;?!3N*%*U'MI6+QH^&@ O54B.H':A;AS"7P:]^[!M3
M>Z^K(\03.@!=H*W$JYV/YW5J7XW^$*$_2M[3^6@V3,C2>D+AAE/0M_08L"%Z
MX$ OFYTG) 65R7E8Z1F@Z'0*](0/%@"XHIVL8DWR$":_DM53-YS,)I^&MG5:
M#FLOGYN LC<:G@X3VJ<K&K=H5"&O?-_.*F66UT>5Y.-D\#N@BA_L_V-_?YWC
M:E\V('!\^3ABUQ**]2RZZ(Z/?35K* &D/-7GM?X2AWTVF<%[(OBE2<:6:^GS
M,)Q6L_C;5)^=PS.&*7EF 8.G^MUDVLQO@Y865;&%T@,Z!5!N%*,Z<,<QK#<L
MW"PM>9SZ0D<8G6^O*!,+EVC476K7R^G$^5&UIFW#NI["HV;3%"1.,UWEM#CX
MZ&@$#AH&>'1-V].T%C"]Z8?AAUH!2&[28WAO%7M3M7H4D!I4O<$8II%Z5L4L
MAJIUN0.[S> O7247?^-)',W'QS"U9Y,YW.AJK6\QF^5H$[-<&*[59VG$D7NL
M;<I<PI7#\?+9D0)@?IRG0 !HP:!U55$9@=M7EWSYY+CRP,B)K>.2UJ-M5EUW
M=)NXS/$E:#2QR>7J&KWXHGC[.A'61WG5V$K#&"9)I*^ IE/@BBO4TIK*L*]A
M;;LK!Y)YN7#I$9$!SB:-L[PF:-2[A[7&6K."'_AI=*\/(L!\:+;8GZU*?@Y:
M_S-8O@JT_2/XM-KZ,8HA>&%2R3M/>N_/4[@']AJ8,+.5L8>T15<4\#.4K,_M
M@44'YS:)E/^[_PLB__L_%"]^;HW92Q^3++V/0]B5("@F<Z!H8U0UE(E<ET9W
M-HJ_#<!*\@M.AH6/$_0A;DJ;)MO0RIYX^_YL,DP!F%:EC_=UPB5-Y&L3;U[%
M?H\.>)>AT!9X6V.ML<I2LAT\.P9,DLH:@U*?SL"0GJW!P;SR259W:!\E=S2U
M1N?5L([.'W<MKYW!/BSYR&MW'=="-)XCG5K/0I3[DP_ 1?')@\E9=#U$Y3G%
MS<#HC<&B&IGF/DJOL^@ B9)YL8UF^GV<GG8?=(J1-+;><#J(;AKGSWQ<2M .
M8!S'H[F-@ W@GJ*TTU9$GWA0T4\ 0^,FVTGKL S+)2:.'+G(5UK2JT7&]LF@
MGD_.89=2]/S7N$GAX<"S]5P;A:(C*_SX)*8U-1( :!_FHW&#EI=NA.\EB/O&
MTAL""-%B'2P]G+V-'0Q0\CDTTJW9A/^GNN@%W(Z:V%++BSZ#:OAIW44"O'<6
MV6_<@ /8GBF.':7>L-9GAS&&FGQ.4;'4P"PU<[9^IUI%V5E7O.&ZTTFKWG4U
MZX;%TOCA[2,0RVGG B,^/]Q+^IX^&[KT:MBNZ14)D*(\&%9K\SZ=5!$ 4FK/
MZMRZ(SK1T5WF4Q+$FG8[.)M/JWD2\BF$/4Q1T>&Q;GQ*49BE!\/TEV.=#O8/
MG]?HLWAV&"[TL#C&7Y[O[0R>SQ,4ZP4.=9U7"P V$;7.ID-X;'I5<U%TJ25U
M*[[K8S03_#1JX*!6 5Z"I(A_MH2$<29766?T\7T=!VG7C01K/C=P<QUDCW.,
M[X@B1G<M@=IK=1/7:53*4P;!,6SVZ.02K1G3T"1:*Y./-2L<3^I@*("SMRE<
MNJRJ'&]=<08G%F[6#&@S;A'^U5^),WZ?C.*/ADD2:7W*7K'3^;#5;0UP)&R5
M^7@6O>K9E+X4T;_H7@01\ [6ZM[CDB^C:(E"^_ER0_U>C^WI>IL.GQ]_//CX
M5F FE*86<<$5XE91I TN4> >$U,PXQG?V@VP02YZFVH_>5<*I0W?+'NT_SY.
M5N-5C5VP+E=_6LN>7TN@_#[;+1^CN.$^ESTY1G%I.NW7I\<B(CO'DM/AUH<D
M?6.<DY8_]U3I7#TSS'>*9-\VSHP(%M&CU3H=ST[ =K-#/4;)$3&)=L]:$"R!
M=]0IUN*9#K9B-XYYJ=K1C:$NP#Y*H#K:ZS_HT;P^QQ5UF7$MSJXQJ/9E'7=E
M][5GW@WU+)X(6 WB=GRX;63X0EQW^UK:0F;A^V#A&'D=5I=%R1-'U"C7Q'+U
M?'82?=(QQ6(]D+O@_U7KI(V"#5(8;+#7,2%B,'T/[/;H,Y[-W?GF@'P=!*Z'
M4E\*WX)Y=3$K8$7Q5IGO[GU\&_FNR>ZNQ=/%! U@R75Y!I? WVUN1\N@7Q!9
M((]6DDRB;*K?U^3QUW&=-AFQSB8YFWJTD(R@?K]?!'7\I[.H ":SK8ZF14]!
M]*H.VWSG1N8N3<EHHX%.],&/8SI)5/#GHX5EVOC EWE)2]]3R^U@42?#K6K>
MWH83!DOC%5B>8DKJN62&O^_Q;63XZ)1L\J8HXW6BVR6(7;M35V*&B:DOXO[%
M]*GF6 K<KPTP3NW8;;U-2[_R4[3Z-V5-K\!3KW.F+XWU)]G4Z(NMIV<17HR"
M9>D!O)B(U?B.:MD'&FDUFGP<N-I?%[]+4<_Z+$9RDL/+_6R8@K,7 N3PI1F.
MU[Q_B^S%J?^?^7!:GXM)9U%JGQT\(_%X'=B/QO:@-6-'YX,XFCCN%#P8Q@AT
M>C8(Z _#*$TW3>U"M'OV592[2*_&P;:@UVGT.%=S:WU5@2(2']GUR;G6\UG/
MH#,MH.>UR)JV>0*XZ60V ?9*V0*MW%AJ7%&!TO$8SRR>%UJ)O\<UC.Z,2.&U
M\25J!A]'T]&@*I I?AR?GS(MFOR!?/!BX[[<7_/9RIKA%A;78&EQ-6I+XU[>
M9("MZ##'H^'$C'0UB^FGD1U.88.,XQ^7940DC&AUAVAE-J#2Y>_.*4@8*B@]
M^I(4VL<:^]J\AEVS845B;$Y!3LF^L <G <'_[ 0P^&RV66XL[)Q%9C*0>SIK
M\V77\\BW-R?$[EQFD&TRP([V!LV30(N,Q_76++?MA92I!UQS1#W-%6\$W'>0
M@K0I3_G)90)<T"#JE);?Z@.2/54=+J8)+M"K/6$ZG9SKT>P<&0\H.S[>CD;/
MR,5DDWA0U([F*4MKU$YS87/I6>NV6A[6&J0J556-XDT:87VZ XPL8,;D55^-
MT>H4STQL.?.C$=@X<V!"8.4S/YTM'ABUY?J,<4R%U_7AU:@A3R.DFO,+QT(Z
MVD%Z:1/2C9F.U6 \&41;,AJ",6^A3LU/IWD_#:M6#C9.?QAMA,#MP0G@]H<Z
M(+FD9AWQ3.D>#3V6#HZJ*VKK3/>. ;@]J,['\*BHOL-K;%N- 41US%L;SN;)
M3.Q0LB;AVKR:8[G+H&\\3P-"87Y\TB@+]7QU5<VG:?YUMF9G#A^'HU%M4BXT
M&7CZQ,0,H'1^9 Y[_@)!=@9_Q<\[:]_Z(1='AL-T<KJZ,/OC-D<DZB;I^Z6E
M<PG-6],<B.*'4;:]G)Y%)>9Y'9V)JD[K2WKY_/G6C_4CVSAKI/B27)=*T]9E
MV1Q#Z#H5-L+PS@#>E5*NFG2:='A\Z5Q8G#MW\VGBI6:).M&D6N8.P\ /:_=L
M<\EP*<:WTQM2JD]2(M-V;5/FQN@\9L*=ZNE[/UOLTF$\H/\J$KM>Y,[GK4XP
MG0-;+H@4^:6%G_7C&U'@)#*ONNP.GT>77:M$CE."8RH35&TOZ%Y[1V+JQ \U
M"\;=6Y\TCW. 8?F4W5;]&"/1(Q=KD[7S7GJL6\8&\=8P8GQ^%4\()\YOUZEE
M@R0;7#/2U;AY$Z #]G+)?:-39E.H3WD-1WJ:*IW-JW9>+^91_ "?P033K%^\
M2DF <2X7:=Y, N#*URC_I0HZ1NO"$2FDEIPK8TPPBH726,-PB96Y-$Z\'A@&
MQHKKWXT*'Z1AO5B.ZD4<3@7#KWNS/[$X\,OGQ_&LJG5"E*7!R'!=((Y=@914
M 7GEC1**<.YY]PA[6_EF$,E[R4:IJ1QY<:_6O#XW*?4K>^1@+^Z1=D/M1/,@
MFG^^M47C'EED;-;[^A*N@M=]B9$<]U8H*AWG@1=>2XFMIB*8$G/)M,^,])W*
M,^U]?+GW-F#K2TL4LK+ B'MGD0:2(L85I524NJ3%UFZQB8]BR0S_L7LT(:H,
M,4$L60H1 ),._\,R4>@+QSH^)GEC8I:E_W%1V"5]F!+[YVY5G,?'M'[V]AF-
M> 4#<#YK% 50(>HS&.O*0E( NJS9:@R-"IEJI.R=38>CQJ!(24Z7FR/1$Q0+
M0T22_!+S^X^F,2_L>0?+KP';FU.O=C8\M3'*Y].SZ E9I&\,V_3<6/G%7\SZ
M2 E5#2E34*+5FN&N]D!:%/N-"9X<M57<)_,JE=<<UHI@?$P-'RE*T#E)<?&$
MB'9N6BN#@_D8C'PP]%WBDK$'4F?7;6O4+$H4U?5T4&^MK\'O*:]QH<&W7L^S
M5-BGKM"3#*^5ZC@V>4P[E9CJ:3:;'71BD##'K;\U:9/C^@T[%VZI3:Q!78LZ
M"82+%:?JYW2/^]0G[\?'*^9=+!TU;0R[JNNV^'WIMECLK%18JS[)GPXTU<<Y
MFN#7-0Y/[%PG@6I1>)%OW=1;U;^<I0U1"GIK51D7Q<J73N,]F])#8>6CD\D"
M+/6E-./ALP;[3_]]^O+7U_S@W:M8-OP4L!^_?G? 7_[ZXO/KSZ_/X;[3P[__
M_>[PZ/VG=>Q_\_=K_N;=,>@&?WPZ^/LU8/^?PX//Q_SUT>&[PW?[,,;7Y,W?
M!^3ET2_AX,A^ D7RK2ED04M3HE*2$O%02J0$YJCP4HJ@RB"X7R]T6#A-@S0J
M%%IP:PIEB<<N..N]Q-B*]=J,_]3QP$?,LZF3T1O0 E =VW@NKCZFL"C3VI9,
MZCC[4[GG>N$ 4.J5^XJ*CE</?'6B7&.A S5!%X$')F.#&NMT"7]@27R9*SHN
MIW6[>SBQT,NPMG_/ZW^?]AY^_Q:T*N($XTB;TH$"SQDR5'%D/9C?!HNB,!?V
ML-?*>A:HCKL=<R4#!ZL1%Z8LJ,(4K^_A/@%'K7HLI,KO':DR2&%9\G.G$O1^
MS.$=GEY=$7I_7)N0\3$]UKBB\V>E^OVRZ/VPF>H-BM\W?MG:$5O7T4^'NY,;
M'>1U?;8M1H/@E5.7#*=:+>M(Y*4@7[K'X/L8.727^M.2>S))"CWX(>6\X)]?
M[?RU,_AU;^_W]#?Y^<?:J[P8\W"Y/(V+\>*@TF&9^<BWTSINE+*J]?RMCN(O
M4"7;"!-<_^)3//9_G!35TV%5)8]'O*L9X5\OGBW&UA[(CHE+46/\)9[T)AC]
M4=?YB5TR1GX@.Z=OX]/^0O^],]A+@P;"-3Z3\X&;)#=A?9S6MV&%.HM@R9.U
M+W<RJU>I23M([OT%Z1+)VJ#>Y<T.$O]\&\N$^70\K&**(NC,,:J11JQ=1(/Z
MBA_B0YIP \QD'.<0\Q_BB;7ZD.7BVH61#XRVW3)+/&G:Z-*P3?2QKQW+8Q^=
M^#&X5Y]E6F#6NB9P]:&$?+;@AEJ"ZO/9@BL5M37T"ZZD%LL@L.!<EJ41P9A2
M,AQ*X95F&U>MGWI<C0R7D^9*H-\->CA=;N_:!57-1YT<_59(G"4O:=7J\;5W
MK/ZJO26&0Z(L:[?J,-4@J4,7'Q8!F?47I.R#Z$]L*P5<%$LKK5VN$%#52>M%
MG,884TJT&K^;C^O3;@ND:!]XZ3.:D2Y\%NF3YS"KF M3J\R,;*=,DR29+_U*
MI*^:]C311Q8/H]=!GR4RMM#Q_];/F +>1/]"6Z&Y?C*MGQR3%-;EVPU*R/91
MH7OHE>4W.#ANV3)ZUK6;LST$8W\K-3?2:((,"PQQS"P"3BB14C84M 1;W\MU
M1+",8VH=9<9;+HPU#E"!EL(97SA&^;H]]/MFY\4FQT2/ &/)F1<!XTI*Q"H%
M7S!";J))MAKOK'G<_#+)&U7]6/CR\FK\H$^/1C5>V#:LI$?1)&A23*/WM3[_
MVC5MFG)7C8&RLGZQM$#C#D[U/FHQ7?EEF[$F$286WSB>#UV;>G/JFT(#BRX$
M"\6\5KO; 7X8^H]5W5'AK*E<5@^V5G;KKTS;Q^1+90$K?QPI>2\'MEL)M#BT
M7<]E?/Q7/:C^G-2^!T'T^?#C6Z584%HX%(#&B#OND*;>('B<4$KXP"Q(DLGX
MLH/:+2T'S0K7;!XSN] H90OIJO(7-TLL:N3\I3;WMRD,3R@$=R>P_:KR+\.+
M6..K+KG]U/;'^<'S%V]%< 77H/J:P@H$H(V19MJC4!:\E(4-P D7')>.6 DV
M6HEEP:5S$DP:!J:<85B9$$V]5:!^58?$%Z2.KKT'C<]7$J!V$=:^NT5(<M94
M$[\^-C<.IJKC@8F0%ENQ#/R"FBF)H*KFIW766U/,KJ[XTM0 FJ2^&/IT@>Z-
MZ(JWCH;U::[D@IM=2-S;Z+'<].B8[9!2>9O\Q.5UR5&9[-?H@4N)N*T56N>X
MU:60VKRHF$FQF.7.X&!)@^3:BG'D2)CS114[$+F5C\ZPQ?&5L^E0KWCA+@EB
M-=UIQK/II"W%&;-?E]764D6_*ZC=MJ!JI/ZE*W^Y+[ SK=-X0J!.'NP&WM[-
MW7%[("!EV3?YO"DOIBW.O=VDX+2T2 E@-0\LQMZI%OC3\L"GZ39K6RA#L?E5
M\L16L:O/./K94FY.O.C#)/KKT@% H,3$#A,'+VWZ#G5:HG3(V1E.D[>2!@X3
M@X&WA[-C)F4DZMJQU$4QK84K(\Q39:KZEEK%:UX0:=]F/D_"S-?%,\^'?A0K
M,DV3ESD&1-ODF%3+2%>3U/>IL^#-/HA%:D\3,]5OG,QGL>AF5VE<+F+-ANG4
M>]H8-9<$':ML?6RKB\$GBU%<]N:F$54[ASCZ>KO4;O>5_5/OG$C>>.NTGLXE
M^VBY4[_ KI<SZE)\KW-[F,2*4VG3Q7ELQW>T%>&KGP;)N14/H:Y0-1U=AND/
MXYQK<;0]^*A3Y<R&-:K8XAS5[1K2,3:P(M(8&Q&S4AT"=O8TMH%:B)\DH_2G
M;]"ZTCGFV]:Z;J\=YJ\36))G\=C0=)QCM:W*8]\6E 9E9(DXD0YQ%2R21@>D
M;8FQ4T)2<L'7T#_E.*WNH%G>7@9+FWJ*1S=6>RZ)?L;8V^ X3=DV4S8Q^+R(
M7$7,6>O6E])(6\VU]@G4S>>B:=]1@&(;F)-8[C9]T56'&OG6Q,Y <YC6FFP+
MF:U+H:,?7O19KX\[U4%O3JD,YF=-]EI[HG[M?AAU?5*F$WCSJ<5<2[I4JGPY
MS35O1GKT+#Y@46AG.@E-*?#EM:"/):!;G#1M7.AX^Y(3B_'$#"@2\Y2II\?+
M^M8^]CR,]2K2B_YSH\=D7KGUYGN%E%&F%:427 @KC0LB4"$HQ[YD^/+F>ZC8
M2HH2_+;B+(F.$C>9-1>NFWU_^MKW_T)/X[&/:F\Y_.?UZ!=.D_*I2<C/EL9L
M=.&%\50B@IE&7$B+%!$<\4 I+5C)M"ZV=EFQ(R]Z34!NC.)B-V7_Q\U9G$%]
MLKT^BW/N9XL2)VY0^TP^^,B]26-98<N5D_8=-2N63[7#,SWSB[+XL>AZ=1)%
MQ4FMI'^1HU.1]45U%=A"8=YX.<]&>AP=G)VME))?8RI['+[QYY-F:XWC,:E8
M-+0-FK7J]U0/JY5"KP,WF9M94T6_M2K6NS!URFHL-O1%"=*^Z^O\O>N)#E%(
M==(&FI/>\9A@+)W>#"B92".0F<DF:05=O&CJ6D?80K.\_.*N7*V+BD>42"<"
M%I*M"1JNGD^(\VQJ_U]%E,5=45>NO'_?[5T4U[>IP9N.+^JFJ,1BA(U<;1.F
MJ]C\%)9L(6?A@^-(E$:43AN+"[3YJ4/QT.AY^X[ME6ZG3;[,Z>)P3P,ZL^G0
MU*<PD]9;,W;5&G* RB-MFOZ5T0A+^?S'L<X0[+"E<[U.M:Z5[^53F@:TL5Q[
MR\[UYIC/X+-JD'(WNO-/H=%)6#6SX<;$[XN"[9WS&A_J$.V&Y[2G/;0]B<=+
M.@<++LT3Z7&D?X/ZE2.E7Q4I!1[<&[OX(S;*!:,P<E$V2PZ>[[_%7%&N+4:8
MFY0&'AM?,H^ SWQ0!;'.F75/+*6:QO9&UDG*&9.:*U]:RYB26);R0@II)'P2
M#>F7SA(\<(?LE71H Z;+JANM!S'FS36-V$=#((A;1D&31VLR'1X/(WZD&N@U
M?B4E/59R/X61G"0IF!KCK+E/TR&;.D-MT2\ R.Z79-\9U*<>F]9&;>I=U!!2
M&Z +%L>J)AYASH+8/Z\?O RZSE:2-A?'_9-%$\]'5PNWUB_>-=FB<-T\:O2I
M+D_Z_C]I@;=A$7/8ZD8R]/=HM YC+FO'$Y7*:0^>U>T"P-I*UF<O:WK<"1 \
M;TYZ/9M4L^J9/@.+-#4I:F@'&)$(5M/I.1CHHTGDSJ>+$7O%RZ-7GPZ.7F/X
MCA[LO2VE=J&,!X4YCG!A.%)@+R-#A0/+5\""L'6XT-C34FC%9 C<!Z>E*157
MSH.5K0.V%S-L:DY>\:DVZFG#R8T?I4DV7@2-%A[A'Y),F\PKN+7Z\:<OGQBZ
M/3&R>B.HXB#349,LW"3C70HL5U)L][]J7TKSLN;)J3JCGL\F[:M2G9GZ$Q-M
MIBE*^OU9Y7]J?^G.,-[_<Y<$<=>"R1#[+_TT'*?]FM[;).\JM:-4E -IZ\ZF
M\/^N'5*3WKM3?_>/F;OX92%V<,D9%9LO^>+]7_Y2[$C)0$!\Y?UXYPMWXAU5
MJD)]\8JO??%-!_Z/1/>:]K"HD1W_ORW8@S<3Z^M<  ;G+*H'S6<USZZ5 >V4
M6ZT9C=0LW8[YDM&TU\\F9S_1LT^+^YL]$3^Z^8";A/IO&7(7"*] K2]#WBH\
M7G,N6[O+6GNMJV@A6#83,R_M0UC:-CU\T":-KZSL%;OW:XCZ']9Z'\)W7??[
M)N*__=C%MO)1,SCONIK269QJ?;/<&?4:5(TO $H-DA-T$&=WD:X]H.)_WBZ=
M$L=\-:%J?JN![;X)=?LQ)':-T%&,IM>,__N"[\%$>=XP_2)>Q!ZF67+R^O33
MZ.4IF!K/WX/YL??Y\//[XO#='^S@US_XP:_[\/DQ/CQZ\?'-T0OVYN]?3MM[
MX%WS-_15^?KS*_[RZ.3DX/D!>WGTGAX^MQ_?/#_^^/H=?/[\#W)P],_1P9$;
MO?[[33CX"W_Z[>C%#'Y^!G.&OG7<"&RL123U[Q8*(XDE1X$I!D:.(%[2K5VR
MK12_$&Y:\\+V=C/U1.Q<3JX%VM'-"LT-Z7(%EO5$MES.-M]K[KU:^8S+&9?O
M"9>=U(9@87BPA!=:*\\)MO")")86(B1<EH0RLH[+&7QO 7P_KX"OLM0I:BC2
M0@'X4J*0\4$A[ IM"X6]$&QKE[*+F1X9>K\5>F_!XKQ]O\-]T[%U2:=H58QV
M74.;N15*/GSUYRY,J]6H3[-X^^W:9=E]$]D]7#.<B"JP-B5&!184<<4XDBXX
M9 P.)<ASKKW;VBU*?/NR^[OLEE[)F2M,I7OU_=XW;>Y_ .VR9-'?=^T]B_[O
M(_I7U78+X*LU\8@5)4-<DH D-B#_:2B8%Y8%)[9VB2!9]/=557^,P:'#R1C-
MIMKYIJ-*S%"X$!+Z3E+Z47HD[UXE;\JY5G\N%NS0SYHTM2RC;R*CS]?4<^H8
MT;9(W4 *Q+EE2!&ID/(J8.X=T87=VF6D[)UKI9>RY>L5\L<H:>]_ +>J@C]Q
MX?Z]E.XLW+^?<%]5P#6AOBR<1AQ6!W&B S+2442"Q(HH4@HOHN\ER_;^:-R/
MWS&3<N:S5^3A:-]IP1K72'-<)(OGFXOGPV=KNC<31'M=<"0#-:![XX T%P%A
M+W"LN6RQTJ![8Y'](]DUGO7R# +WJ:5G$/A>(+"JHQLOJ# ,(R(*A[C!#&DE
M"-*&,FY*6*K8U(V)(H- 7U7VQ^BZ.9K,4@?Z:QZM[&'F9O--\RH&7\;B-B.?
M\SIO@8P/%!QO\33&6DBY@<S5(^,90+\"0-=/9@ACA0DE14*5!>)E,,B8PB!2
MRL 9=U0&!@"Z3<0=V%'WLNUZ(K[RN8U\;B.C?T;_!X/^WSEK+$/\]X/X51N9
M$,R)*P*B4H.-+#% O*,:E1X'44JFC E;NY+?00YQ!OB+UO0_4I&7R_IHWJ!N
MXD,OL[6A0M4EE0B:HJ95W?SA4RHU/SJ_BTK$W^$4.0@Y/8X-;U^&WZ<3-T]#
M36UP9ZNMG)Y<5>)W+PH8V_G!YWUV\/D]?OG'VQ X#EB"V J%1QS !6G%"\2X
MQ5Z7V%H<SXSO7+1+%@6*V[Z7OB5[:H@\AJ4ZM\/4.:)9@E3+M5F#N@[YLKAK
MO21-<3_G8UNHIE<SQ12WQ<E3(7*S[)E@@9N;1A?PC&KGBF)Z#Z[Y0(O>OTXF
M+LX=F'Q_T>NA!N]<\O/@Z,7;HBPXPT:CPGN%N!,,*<XH<C9@1H')@]?K-=P4
MAY6A#"<!1;V7I0@%+5Q@GFA6A/YW+ECR0E,'L;=%$ =HL+_>I*2N"AJ&L:_;
M(&[XNA^*/HT-CC['+KFI&',4+;%D<WP<BH\>G/K9R<0-8@7I^.UPVFG*4G=%
M2H4^_=B'X6QGL!]B;?WU'BFQ;/DP[NIA&*;"V_5%J&T2$[OCZ"G(G/^M3\]^
M;MONI&K./VSM__YG^OCYUH_UTU(UT?%@/,EMO.^0JPCN<Q_O*_MRK\DC0;W#
M3 F09(:[PD@M62&D* 4-5#FYJ;+BE7*LUU7!-RQM(P5TT^0:8']B[7PZB"W'
M1G5MX,Z.'%:IK='(SWS:[TWSK+:AUF(OUP6VEO>!E02OB;=K ]]-QMYM-U7[
MZRX<"TE5ZQT?I\/9S(_1)(1%4Y"5)BEU(7_0;&#KITK"0_AR.$TO&TVJNEM3
M;.J]TIN[VZ?AEZ1-3:JZP6I<A:;*/S PS."2<OC#.);S>MP+P;0^\J54O51L
M@D(5YJ-:"N]\#P/GD9I*W<K7/G;B:MIF7.CS *MZH2M7 TY-B>JZJ]9[W_3$
M:&IE=]H!V.'4SD]CVPO;=GIHNGK%+A_#J *O]%;KKN$@<5%LYE&WJ_?-7TMN
M])^&52R;?3A9-#KK?%U=/H%E/Z$.=#;="2-)FJ*U]3QCP[748LZ[G4O0/V(]
MC#RUUX#1=H:6FIS _\:Q+UO3G"A2R_C9Q_CNYIMX<Q6Y?[7+Q2BV2:C:B<<6
M(MW>=!=(L-VH&3IU5T.INUK3*2W9OK#IUC;$%S'\"6V1^VE\ !8]L-?L_/>1
M3D9_++V?A/F3-X0^O3SZXRT)G'-K'9*&6,2]4L#,A".F.;'>&0WV_KKB$;17
M01EJ*2XX(<P0RFD96%0_2ATN]#YHER!MR@7]MP=CT*IC(?8'W0#A2F+L_N9!
M.IQ,1B[*DBD(_:;;3)A/P9293_UV:DQPUG17<H-J$F8?DVDS]9U6/['[:E5?
M$;]PL2-GH[!<T_+9 ."M&%Y58G8&EP]\S>A:/+LZB0UII^W#+GE5\(/&]3/U
MIWH8>X -1O$==2.G2WH=[*TT.&OFFSQ&R4^TY*HE 3^"978W#="NG2ZQTN=L
M.0GX'110^ 6DTEY'?=THL9ZL'_+P'7R_]Y8(HTAA,/+!&L2QI<@4)8B$DL?V
M+51I#=(&[]#-OD?81!O[DD4^N@GG?&6H+7/.W7(.>0DH1T+PW &K%%@A#L8N
M,JK$2!M5.&(=3ZW#\<[%J@U=SFG+6#>,T]2RSN;/O>EVOWFPV:<)IIZ\7[O3
MIN3HX!QXWCJ/2U<*X'DC$6= 1XFE0J4';!/*>4\O:'9.1;^X-EK!FBAO).B
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MY4(Q6B*3!$9@Q"F0CNB)Y6V\2*LT7[+2?.)XD99QO@@=.O.( +,$V50:&&?
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MBNKGZQ;I[K"DQ9U>9=*<??YJV<=Z*K+5=-0/( 4Q?S8:]"<.I<*&*B"D)ME
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M:)/!(BJN$H$98EB?VTZHIZ5X-[^S7DY+44]!,3<_YW=TS^PIG0^*O[Y!9SK
MI;:6:H>=Y48J1^"W('@4S'J38_R62L?<POY]W.7XR1_$,.[&[71^)>[D!?KS
M+K7=DSU!$\:>""1]"HCG)&%6<XQ 9"G7U@N;XEE)]2"EE"CO2,SAH-()P@V!
M>YD,R1NZU#MWEX4WW2H0IZ+HP]%T?Z#?[?9/*LIQ!.RV<C]7]'D\A$<-?WWU
MX@CBY73BG#)MC\4]Y+$XUI!C<5<.)PP?6(F3E ZR2MIP,9!>#XP7WG>MFGKS
M/V4NADD;ZQ:5V73L>-2?-+%**U%^4N>A@/GKVN-A?#7YY5RBG_DUFZ<M=(;'
M77OZJM,K)ZQ\;SV@QJP9DP6A'-8ZD7#=I'K(UZKOSN3GJ+X4:DU"MRB[_)(K
M[\=KY*HO!</&\#O>?N6+B5KCY7\OO>'7)(AN0NG!IK;F45+0U IHF=-G+UO6
M['9J;SRUYX*MVU)[MQ_$"5OW@+;EUOJHRAK2M*HG3S9MEZ?6>NE)!&]9=>+Z
M@5K2Q(!2:)U])D(:Q55.1Q&22E0IRG&4[(HLN)4[Y<A]?U4OJ[?UJMJI%E7M
M+FM.!K^[^5&J#'Y'6X>[.YY^.7I_L+7QX61[YR/]\OFOSM8&/'OGH+.YLWZZ
M>[2+MW_?96<S^.W2K8.M'U^.=C^_@S:MBZV-+]TOOW_ \!RR_?N'[YL;?W2@
MK_S+84B;G_#I-(.?B!Y;'RCB-I;IV1W2R3 4#)@YR0<GE5AYP_CY\BS/7>#J
MIJNE(7JEF:6O6A!H0>"I2G]HZPA6CB=/N+#61$ZPS[DUDJ="I1($-*&,M"#P
M)"" IR#@M512:XN<T!)Q+SVRA%N$J396$()M!@'S!#7+?SH,> RCJDX.^1*-
MJF-[.NAWNU6\4;\W'L;AG2#U$8;HH:M)GF_BTE>3?$*382X@(@O.)]NU@TX<
MUE"QW@M;_9YO<>/VN-&9,QXB]YA)PY$';$=<"HZ<)011%WS,L$X37GE#G\1X
MN-MR:922NX>)T.JSANNS^[+?5I\]FCZ;\>!()=9:"N0-#H@;%I"1C"%&/+9&
M!9H<\&!N:*O/&D1W7_ >0AGDTS2?T4,!P@LLE_X,!+<,&ST?7=CZ1.Z !:=S
MW)8:3I)6! E/& *B:Y"F6"*<4_A*#637XYP]F#?.*=)(C=9,]W>KRIK$;5M5
M]I"J;$9KN1*$RD"0-J#/. =]9F+02"5%F'.:,^G!3*?G\Z"WJJSUXCX"K>W&
M?5OY<(\'_12'PS*]8I%BZ\U]F0CQP-[</^>DYGUL$>(N"+'U=H[L)I@9@(*
MDL0><18ETLD[1(RRS$E"I.<YN/\I$.)E.CY:5?9"5-D#.W);5?8@JFPNEL&Z
MF!C1R/)D$-?)(D<\1U9AH9W@+"2[\L:05I,UB.N^0!?N]G&9)*6W?R[-&9J<
MVFR](2\1(![,L3L1H#)%W;1B>0L0=P"(A8AG'(4)2:(0L4;<6X$,%T!XI?.
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M&@[XH/,^=R0$8>X-CSP(ZMG*&_X4Y/=E>DM:'?9"=-@#GM9O==@#Z+ 9O16
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MUC !^WBR1X!G:&D-LEHQQ$7$(&"1(ZRXHXD;!_9W=AX*+5;%#05LLPS%OXN
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M"E+:JJ5;J:4[N6I;M;04:FGFHE4\)HV91A)[BC@.'AG@F"C!G#,1E12&YOI
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MKW=.\.@3#D)X*;EZA-)(LU*A&?M!7?5&PWZZF!&TV?D//^PEPL"0LBZG]2&
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M\*D#PA-LQ>#@+<O-D*C=X )TKU3>LI:"QM.<@1&!T( 3ZCHH'8Q0&>ND9O?
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MO 6MEXH8,[-"P80#&UJ!(YS65N_]$ETV61 U ZQGL$)J:V$$7##CDC LJ]H
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MG,4P-;6&4DMM_;54=\6XT_9,NJ?(_0>EGHU%\0:*V;\\!F:G;<)FM]%A[;L
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M=KU!K?ZTHOB5>*QB-G2HHF,*_;CS4S$_#J=C$-3'__CY:P'S\H6 9,>] 6E
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M<+B=<0_XN1L51HI[K>G.WDG_GL+;PJUPI%<,E[W!PH4)IGMX"OB<!A]ZH^$
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M/7M[G=L()[S-Y7.UKWO%3=ZZ@\:U5M!8Z^>!.S/;Z6R>9KK(3J?UH'<=SMP
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M(F'[I6 -,=%GZGQ6D1:/F+X^^&0A81]Y"R!A_\.,U-K\^W9;I)QK0V83!=P
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M&,BLM/!\)/-+3WKCA0=.!Y->_YJ;U0:DXD";*82?9X6WH #0S*VK#!<E>4@
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M'WXY!_Y1$_L(' +CSANF.FBZ<:#[85Y'K77!?659KRSR474DV3I1[O&)4-?
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M![1I7T7A>K9MQ<D=_Q"FM"E,J)A6O0B.17$::J/#-$QF1<S@@?<VQW*4I:J
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MTOVHWJ_VFLWDGE!&67=>WZ30?K;%$1C(M!UOQ[;CO6$JQ'%<EMSR5CYW,DE
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M\*)EZ,%[N H_G:LXIJD^DHJ7INC[![=MYXYZTNL[>;P7K8[6(]GN()WEQ4+
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M:1[E85][G7[(DHB.R3AM!6=G1S!A/Y =U^6LP2X?L'2 QK!P.4@U,+&?>WI
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M8P!X%?]Z3DUQLD2QD(I;DO0P.=(*'\0[/:($N]4M#0)7'FVP?AA&D9B7PN$
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MJH6ICU?>;"X32[ATSL'2+QQEP8EI2G@H[E_G8&N;3ZUPS)R>+?%N!<71"A3
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M8+3NZ+?>('X>BOCI+$?\O.YE@QG]SZ@<)W_]_U!+ P04    " #W,VQ/"=7
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M>^_+69[W)R[IBWE_N2QFCTFM%9+&%*^HIK9OQJ_=K#M:'JW&/[M<MLE+<MM
MK=^7C86L5);X"H8!X(;2L', 2YC$ "9 XH0'R8@4&6,QKC0Q/'DF,@VBS5&.
MFP+<-W#?:)RW<.2[<LK4Z_RB&Y  _P.^GX#4.5OE2=*^7*Q#@5CE$J')&<:M
M,DHVB>MWASR&=%!3!EY-"=R3=:NED3952D'X_O-\8@- C+[<UTHID1+A>IDD
ML=(ZY;7503<I=-@2YQC23>/CW8YV?!BR(7M@XL#::!TE6DE\)WS4),@@25!2
M<AY*F5B3)/?62,=4]3D^PFUMRP>AW(OYLI\H&8(NA>EF=1N(#9%XH0+125IN
M7$A2-#D>>%N@8RH@'1WAMK;DP_ -H]6)4BJ@].4$BL3*A9ZIW.D@B-8<P:*&
M/&UR\OVV0,=4>SH^OFUKR7OGVV%>0'\.E>7H5$!2F*0,ZL5F4FXW+J=K6P!K
M@(4F-<X[H1U3%>NHF+>[35L?/[Q+UF%R9?%OF%S!H1XPO7)5T/M.L,A@C<"E
MD62#+RDNDJ4^-B?"@J+>ZFBL?= 5I^F4^/LL8<1=&O-+GV[$CQX>E>_*X2]&
M":\(=:IT)1KT3FFBA!H% <HA(:E)<^Q.:+_+M,HVO-MJ2JQBTWKM:.M!3I2E
M,0J72#1:$<D8+^D=1KC)/AN)_H).+0AV Y[O,D.R#X5JV*7MNOEN&0;X]Q*%
M??ZI2+S#>GCM$576N=N!7=R,.=5(^1)0R[_\\']02P,$%     @ ]S-L3SK"
MHG6720  C_4" !0   !M8G@M,C Q.3 Y,S!?9&5F+GAM;.V]:W<;.9(F_'U^
MA=_:KR^Z<+_TZ9X]+KO<ZUU7V<=V=<]^X@D  9M3%%-#4K[,K]\ 2<D214E)
M,I.D:/><<>E"93Z(> !$ ''YV__\<C9Z\@DGTV$S_OM/XB_\IR<X3DT>CC_\
M_:<_WK]@_J?_^>__]F]_^_\8^X]?WKYZ\KQ)%V<XGCUY-D&887[R>3C[^.1?
M&:=_/BF3YNS)OYK)G\-/P-B_S__H67/^=3+\\''V1'(15G\[^:N*0H(MDLD@
M"M/H$O,I96:3=BBMXJ#+___AKS9F S8CD\X"T]HK!D4&EKCS27#KI;?SAXZ&
MXS__6O^),,4G-+CQ=/[MWW_Z.)N=__7GGS]__OR7+W$R^DLS^?"SY%S]?/GI
MGY8?_W+K\Y_5_-,BA/#S_+=7'YT.UWV0'BM^_H_?7KU+'_$,V' \G<$X?7L!
MO3[/KO[P.AKS\^*7]-'I\*_3^=^_:A+,YNIY< A/[OQ$_8Y=?HS5'S$AF1)_
M^3+-/_W[OSUYLI <3-*D&>%;+$^67_[Q]N5MI,/Q[.<\//MY^9F?830BQ/,G
MS+Z>X]]_F@[/SD=X^;./$RQWHK\<<@5E*IS_49_V\\Z8/A*02;J(R.BG.*X$
M[Q#CNJ?OCOGJ62QC@8O1K$/$MY_=*=[F#(9="OC6HSM .W\0.\.SB),NH=YX
M[C6<ER!7$=9'GM'/T@5]["^I.?MYCN]9\ZD-KK/XA=7%E ?%Y^]?_-VU]Y*"
MA^-A73->T;?+/ZZOV (!?IGA.&/^Z<DP__VG84B8I44A,BA=C <5-1<8E8@B
M*+ #7YR,1G*6/22FC7.TH/O"5 A:ET ?3&HG&1&8\10S?3%M1L-<-Z%?8%37
MUW<?$6?3K03XX$.[D>YFV%=$[[V64D3'G>6:HP//302=E-8B!F\&$HRVJ&AY
M!RN8YA)8=!I9LDHG$7(IO/0J^C<P(=/@(\Z&"5IL"%OHX>8;]J.4>T:UHB$)
MR5I#['>8M4@!K)2Y6"VA<">0#Y03W*/-I)+ F0XQ,/I_8-F!QB2U5DEVK:%W
M,_JWFFS3IKRF36MN2TQA3!\Z.Y_@Q[K*?L)7S;2SF;/!&WO3X+:C7M&H-JJD
MDKFGR:1CTM'*G)5SG+Y1PLB!M@FBR)KLUQ*8%K3PQ:(<(PLU&"P>%<<^-?H,
MIA]?C)K/O2COV\/WHJ<[QK*J$@V!@U-*T7Q)6@4,W!I4TF724BR#S!%!<<&$
M!E*$H&THD)_ /(B8(H3B@^U3)>]F3?KS8S/*Y%7]^E\7P]G7/G2SYBU[4=)#
MHUO1EA"N1.1.&D1-FY3/-J>H?8"D2BYF4(2@30L+<U$JIJV/#&B?8[Y(TA,*
M@U;/'93+H8V:=..%H^H>-5=6RP@BCN8_'5Q,V0> \\$5?)(%OJ0OIP-7H AO
M/<,8:2%6A;.0(3-0PH('M#:$M=;@W!(L,(US<W#Y!C(+A?\91[/IY4^J,CTC
M#BX\K/]Q-Y2%UK8?W,MQ(D]\BL]Q\=^7X]L:>MN,1B^:R6>8Y$&AO29R1<N4
M<^1)!QMIP8J"%4C"9M"BY-C'R#?$>5,LW^C\='(IH*55OZ797\\J.F7)K-F?
M7A;<H/']]*29T./^_A/?E4:WP0U0FD++*F=>H68::'\#-)HE9VAUC3H':_N9
M(^M7MGV2H5?M-9V*_C89Q,YD^$@F[_3UQ:R>6]6CP($P@3L3$HLR>::C%(QV
M*AJD+=7.#9;+]=[SKEQ817+B5-A)\+>9(#M9%EY.IQ>8GU],"- ;G R;_$\8
M7>#O^'G^F^D@:BF,+X:,K909?:-8!$YP2RE1.V>U-[VM% ^A.W'&=*Z@VRQ2
M/;%HP?9O*$U1%F5$QC,YQMI I7E63"83HC0Z<M@GC5;@?9<\VD5%MXFD^UR.
MYK][?3[W\W_]@I,T)"]F(!T8X6G_=,:33'A2S <7F43R,JP&&Z7<]]*T%NEW
M2:^.%'>;::;7)6L]XF@(FW2&\3HC=#2>!4GFFX.B07):=?7^EZ\?7.M:=;?)
M9G<EV]/\GQ?3V?R Y7WS-.>Y,F#T!H;YY?@9G ]G,)K#KY>W\Q-,'$_G)YIO
MD40W'<[P'4X^#1,NAOH64_-AH=+Y#!MHKKF*(9 #0?S13AGF'4@F7(I&&_1<
M]7+<T?? 3IO(1T6+V[1WN]+^=YR1.)NS^3'\(,7(30B.8<Q8CVT+"T5D%JPW
MQEL)*O9R,'4#Q6D3:GN!W]:^WU7[SR[.+D;$UD_X?@+CZ6A.W&^4)ZRORWOX
MLJ#NJI0&UOA8$BDT$%BFT1<68\C,2!E V:30\3[8LA/JTV;7_A1ZFXUA6S:>
MQ2\/&Z?_@@F-:';-8%!"\.QL8#R$:C"0B (XSQ"SRE;SDE-YX(9GNS>?)H7V
MH(4UQZ1;'YK? W=A9=Z&*G0Q-CC)%(!F.GN":F)DUMJ,0F@EHMR>,'>\];LC
M2Q?27T.4W0_4UQSQ%XV*<\D*]XEI'<F_]1Z9*MIQKHC,'@YQN]+%;0'ID6?O
M(S,I1:8M6!:5-,SZS'GR3FEWB-N"'6Z.WT,<X4!X'H05CCFO,],^*08J"]JC
M0+N$VD3C>KTUGL/H<%9?B]OM_4)T!UFNN^)ZLHC"_&L:-33#__[3;'*!WW[8
MC&?X9?;K:/["O_\TQ0_UB\[HL)@XU>-JQM4]>_IE.!T44W+.,M-NE *CW4<P
MK]$QQ84Q6D)VT??*CG6H.B3+/0'5]Y!G"VW?19R=I=[#5>D*IN?S;;(5J,%*
MB'>7E%B+JDMKX*XX]7N(L+OVFKY$OS=>T/)H, B:0<(0N&" -L:2&#BD=35(
M<K][62+VR(<;>0"'I\,F$N^!!@3GK%G8P+_-3>>!$PJ$1<% T^AT\('%Y,C/
MC5$[74-&8R^VT2TD^W<..M#0ZI'#3N+M(8SJCE/:)3@5<G0@/2LIQVH^:>:+
MDLQG8K<!1!YZ.>*\%]4I\* [L?>P!KS%&8T/\Z\P&9-/,EVBTL5Z7V.\2E;D
M -H(#%)T+(J2R$&2@@C;!QG6PSD%%G0@Z!Y"J)ZFM#@8Q?QZ]A$G-Q(0%L?Q
MET"-33)J9%$:QS34PU"G+ .CI$Z$V^74R_+0%N$ID*0?=?01-'41I\,\A,G7
M=S#"UXO ^[F59$,N,=*@<Y*TQP$G+B,4VNB"\F 25]C+-G(GHE-P,CN1=A\1
MF-_@_ YG].7\<@52E>_5='@889_>YL,0#^1Z=J/35:;THY ^PK@?1BJ!(]#:
MR92FE4U'0X:SMXY9)S@W*")(?4J4><@[/11C-M%#ATRI5RF_T9,^UHNF>IU2
MLUXOM[^<E"RV,&LD05+D4P7-D;[*P=?L1YE6TC_6WEC=\?@#Y/=TK(6F6Q%V
MZ(Q62*^&9,J,QF]@\F<=^!*05T8X35MBQD"F< P$R.5J"D=,VM>[&=]"IVL?
M?E(:W5U\'<_2I^>3X>AU*3BYYMD %RA%2JR(PLG@R;760@Y,!*MB@%2PM%'G
MNF>?E#9W%EZ'=EW%\[\OQE@WQM7E(H)WPI*;885=YI);9VC+X=YE3\R3KH4Z
MUS_]I!3:@0 []-@6"T9" O*VEKJZ.GAP%DT$SD(2FN X<E.!T-5B*2%!"GHU
M:>Z.U?;6HT]*F;N*[LX\D[_]O"(>6M7_W&?>?R_U4#9YY8$J K2OF&(@<ZLL
MD2-SFITR%ATM3=:D0HQD/@V<#D6C3BQ#DDPC6.8A.&; Y:R#U,KM4C'E=YA=
M3+ IOUQ,AV.<U@(AKX8TAKQ=U89[']>%,MKC7:W;Q$$)$369HX9DYGQ"$8PR
M3FBR6A(.$(M-W%@68BKDX&!BP&V@>9QDT<69[%-/@GY>SVU'VU0P:?/4OL6^
M%OUJS9(, HVK-0RY]LYZ(X4RJ7BB?/)6#C2XHD2QK)@:H%9*9A XK7><%E0.
M+I@L=JR"\6;2Y(LT>SDNS>0,ED)8QO5DXV*D"4CN; 964UY8E @L%&E,R$9I
MK?HX!K@'4S<7\+_A[&,--OZ$BR#DUY_'M$I]')Z_P0GM.C/X@(-:M<EKXCOQ
MGV3/K68^.L6 _B>RYII4U]^E? N$^]_MN^+*^COZKI72L>O\^T45SNOR?'+Q
MX3VFC^-FU'P8XG10R]>0WR[)WR-31#L=:9)JQX*QT4I;[Y),"WONKN<_?C5W
M)KV.G><%IF:.Z5F-#*TVS'1@BRI:<U[=^1HKD#49F2HQQ<GV#%$FX41K?:X^
M_92TN9/D.O:=KR.BS?@9?:9:F>\G0QC1.$L01J!FPJ8:3U[JG5V]^2??C^S+
MB+' ABJ]]9+3T^QN<NS8D[X$MH((T?!H(IG_N6X(M'2PH(IDW(<L ,$ITR;C
M9OW33TNE.TBNPYH-US>#^4U[9=IS_(2CYKSN^B2!_\0TJU<K+D=PR 14?R.D
MR&*00(N)T]P;HY)OOPS?_ZY3TG.'4NVP?L+R.N1/G/WZ)8W(7?I$!M^OU1NJ
M%W"++)V!0BFE\#7K!QVC%<4S*#XR)3,"$C>CB"TT_M![3D/;G4JSA^(%M<A]
MOJBG@[='OXC+D-QRBQP8"%^8%K8P+VN%8LUS*8Z7T$^DVX/(]I5)TY<[U:WH
M#YUE,YW,KHUHO:MX^Z>(]3QZ?D>?<H):!I9QI4F4)@L6/$HF$D+V"GR[B$K"
M<8UC]-TJOW8%>K!PJ6[ITAQ ;1TZAA7W7;B6-QIMD&T06-6*6/=#VF\@U7Y5
MV_2JE_TRQP8KP(G,C-6T)[M,ZSM!9(9KC0DP"=6F[-C1,N:..*IC)<PFZN@Z
M<&,\/(/1JV'!=VF(W^ZJT03I:I^&J&O^=W3U"(5TZRUIV/#B"]<M;. ['K\_
MT[=KZ3?=BJ[#L^$YN2_O/?^!S8<)G'^L?O8B0- '*1P8)GBH]>I*H$'6F'21
M:UU$A]&7SHR/NU"<H&71B< [/(.<@UH8NM<A75*]!:BN+88[T1S 6.A&6TU?
MHN[8"+@;G#+>>:%JYPDDDB<N6=#1D/K !<UK;$-^I/J_;^O?H_HWD7 ?^=T7
MD^8<8?S'F(1R%>Z;4Z1%C@DDDT47@0Q"H3'+4H+R&7)NLP5L?I%\&\M^]_^.
MM+1Z6;RCB#N^%GYZ0>;-A.R<.:$-8"V;#37$C8! JE' 2K&L)%K4TMG55-[U
MYMOUAY[6[KV;S#J^5+H"LN1E&RCK]^G[U7B(C7='0:]3UPY2ZMI]6H&DM8[>
MQL@B+_/V@N0%F.29E 4\*/(H6M51VXO"[M@I^]/7)L+I6$\OFB8_'>=Z&_4T
MGY'XIK-%S[7+:'NOLN4F,YF0H&578WG!LY1T\N0$<A1M]/; :_:W[>TL_J8?
MV=VYZ74;#/T+3(?3IIQ/<%H#MNKSSB?#<1J>CY!^GJY"A6M1AG&>#C^,AX7L
M OIL2LW%>#8<?SBG3Z0:]W0#>JNXSTY?WT6 :'_R6(DD+1Y<R9)S[E&#$U[-
MHTFM(V,*.*A!34Y7LJ8_6,%KM0--EK8HQ,2@M><6$C<[Q/%V.= WQT& -\=*
MA/7R62$$5\E:*!" 2XTJ!U6"L1(<>I.T<@,P6F9;\]542C40P+# E:DUE:33
M(OLB=PGL[G+ <V/ST'18@C@V,JR3S0H5T//(#:>=HG!RC6B+" &) R(Y$0#,
MP!@35*!MB=QM).-=&^8+,2.9(+A5&&.&(Z'"[[6&:ZTE/=T^.Z!?/,=&D <D
MMKIL1+(XP5@.8,E2D1%5HE6$:U6CAH /O!="8T[,ZWH3(VL752T2B\5[+)AC
M4KLDWG2Z3D[P'(;YUR^U_P'6Y(Q%99>+24U#>CJ=XNQ(6+0)TF/CU]927EVE
M<M8I18C>*,TSDF'"D]8YA*(]H!K4LR%BI&:T/\6:"P,L>*5929P33ZT(:9<V
MYEW*Y 4,)_,"Y4U9%IU^-80X'.V4U+1G@,?&LTUENKJP69EC2*E>$6K(*4;:
MUB(7M)Y9*64<Q%*$#F!8M(:<;3*)672&,P5*2S**=$RX8ZK5U1 6L^)IS19;
M#('&]QO"]&*"^?7X+8EQ4E/2Z0._-^/)Y;=S:;[Z5G39"50U'P]3352/7C$:
M%&=.T0[.G9:\GVK:G8YBU_/VYS@9?IIO;U>P7I=O/[RBR("'Z'54CA4OH&8O
MUM4C.V:+C3:I($/NI:YZ6X#[#TH]'!M73_1[46(/53R[D-CBX)P<].*"PYJ^
M7*O\&UILC(X,10H:)'ECHI<V-9V-8%\ALL=#TL,H_]#!M[=&_\O7Y5CK4U],
M\+\N<)P6Q]51\>(\D4YR[YA6M)<"!/(J$Y+I)F(.O)>$V1;8#G6%=B#2W$7=
MCI37P[WY%<1U )?GZ&T@]EG/L 7&PQ0T[%R_=_&G8^4<B$=))9Z,=C255 T^
M\(F%8)%)S% P!9M#+_$8!^// ]4-CX$^F^AD3[297JW*R_NV5)(2' 0SL0:M
M9 FUH)1A0GEGHXC^5AVN_GBS"NZ [D-76FW!FIU4TJ=#\,O7JR__UQ GM>[C
MUU<U^W(^>5 '+XO0S'@1F?98BQ61G@OY,I$V=:55FZB_70RC>^#]L(TZ5F$/
MU9[73H;;>)?3K@W8?1M*=Z(]N,G4F=K;+&"=ZFQ?&^&=H'W0,9O:DC5(L@J\
MU'7Y=<P2:"63";[TZ_$=CF#M;:KCX-<FJNJ35R_'YQ>SZ5P"XK(WCXD2I*>A
M1ZMJB;G O./T+<H<,B:CI.V51;<Q'8<YU9$V[^+-CJKHTYZZ!DU>1KLEY8M7
MD4'ADFFK,JO%\UAM5YZS-^BBV!=+Y/?)DFU4L:>U1"VA19%4\9%\@5JE2$/@
M+"B1613.E1I.*WB_IO9M3-\;2[91Q9TF\_&&IZX3\I%=[J]!=K2W^@])<;5
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MYBN:-!$)GF<6D4:O%;+@<F2@G2]<)F=T/P[4?:B^<R.T,X7U<':Z@FDYA]J
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M!R91UMVS( M NZ<%E6T(/$MW7+FU#PSH,9/RJ)1]F\3A8"1>6PYT/C\'KK9
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M*4&I< C=L<2IF44)T3V%^M+19+QP&>E[LS;/ ^88P_(?[:;LK%]^ZVBTW,?
M)HVS)W:GXJU._=@[1D*RN08;WN77:6@+;H<MX3T<MX";=H&,LCU'NR!Q0YA0
MX?@D'E2(P=3%%/KEI7O*4%ZPI&R!OPJ!K6ILC%WN">R[C09@'(V9RF*[L /Z
M0."(VTSL^'_B,[L'USHOAMLV+JF[!R<V^^\G*+,)"7Z33OJ^>V_(-1V1]"P[
M,6E-6-HN$9@3PY?T\OU=_IKQM4=5>\;EG$N]F^]D;O42L-/&,C W=F;Z&K?6
M_9P%O\!A,)5N*00'IBGJIAT3690UJUT&XQ.'+O T[V!=],UOC @EL9%' DI
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M+Q4/$.J1Q:$K#J)944TC*4\6ML62U#?@Q(5Q>)'%XK(CL7ICHW;]6QZ\CKO
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M]<#16KQ2C*5Z7%%U?5)M$Z"F)JDB*HT+!?&7.0FD)DRX.;=.$ZHOWB:U8);
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MU#,VY6U,0Y[:[HG)I>$B?C$/K3;XT4?O[>1G*G-%DGL-H=<CD,I@>'#V(+:
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M.DDJNK,^_&U/_('TA.!!0[A50+CAI$*DE4PXG!T?.^).M7JH7*I2TI>M(:+
MZ_<Z/WE$:EB]+(E"@U;7?@$BO),N V[@4MV"+(^6PZDE.L=XZ&]@C&,B3,,*
MEF[%MU6GT\%)-9X&$X0N(LNW<KK??5A'Q@*U5'I<BR?/;@&,OJ",A5KQS 1:
MFXE';"JQXPD-<8][Y&SHH^)3.#\MQ291AZOQK5BA.]R<3TOTA/K L)QX:"T8
M5 Z? !L4^51=D4B9V#64WU)XK%/3 /G)M6_0Y>3.2&'/!H]EB!AS<J$0,Z-/
M/@5(/8AF\)W\/U,Z_]]#D!=:R?*[L#&2,8728#B>V2&1Z >9<""?,$UZ&6>R
M[A Z%)+:V_<, -BG>7Y1KU)7"DW'M&\IF86#,8/2W'@OCZPO4&29^^2(2GVZ
M>A@*PDY1/ P<1ZV.![T^9_[/_D[Z/_@?_ ]^OCJ+?$A/&$H'?TJ9(*Z+GKW]
M/-M<UC:)/TOO$8X^(QH1*+X]/Y$@17>6#B]T% >:<W5PZ$T,:K#JJIX&%,2[
M<_BVT=SL)LS2M0YQJI=L F(Z83B&+:XL>G&>M,J(8K-PK+:>Y$H ]H-@0H>[
MTUB;8%X*EO5,RN9()0=5.A<JQ8RCVVP057?2Q] IG:XW5 1+!6_!/S#'Q;('
MFN!R5EWZ-X(\E&:-+TA/W?=D%9??'HSY6E\BKDBFQIXJL+,<.!-BLIMEL"=?
M3P=6[8:S4N:919G+\#V<>TF7RW773KC(BKVJ A^<3,?TOR<$*\JGGP\\.OGM
MPG/&6"&]^4BLDZQ+]>_+R%>>TNZO+/N\[[N]7K;;=;YT15)7]J<@=<6UZ5)F
MQ2!OZ%[V0=;7@0(%D59Y>P4S[T2=%8&+/L2-75UF@TW[4_H]/',&6<EE:*#4
M22;+WO-_W,V'TQJXRM?9C/'SU4"[?9'O [T[9*ED8V9+\2<]5R3NIK^>)[P?
MQ4/D0\^W.E84UQ6RL[2#[,("OO;0J?2>O3E'3NC3O=7:5A:>CDR0<%RZ)7G8
M0)1L*>F.SO2\0+-.VAPSWN12H,ZL4+RDR\WK>#2$I\C9)[LMO)I?8$-*9_HY
MV157T_+4X#".O:TD7=8%3F_0)C.KY)\ZF6,?4016_*U[<C-/:IC^/;]-B3&_
M4-'@.@/<Q9N&Y@8C:^'WWY H9;%^=#TFK$I)+^@7(XU?_YXYUY;<2XC4A&0#
M,ZQ(I%>A8"\E';YG%U\SGL2%2?=F*(UW<;<J1.TLC6L<J!]'\Z9$#Y?7VXQ/
M4E>JZVQ]$21NV%'4M AV$DR5UVR5*,E!5$.JBU!Z0VXQ[B5@,8HN;13$79 5
M,9_XA(G&+6J^@DW2)I<LU1##G<.*Q!S5(Y40@X7%RN@Z;P WAH5>X1^C3LG\
M-V<".?_HF 75;_-F]5N<I2[>7LR5+YT<W)=8\5*09OZ#<YCTHD- <(9I=UBB
M:DPVD#CK?9+!SR,C7IE_]NODD_)B*%7UOH>>X^7+OH_ISD7;M\;80L;>$-<_
ME-/7\:4^FH_OMKU@'V%X%UKYI"\YN$WP.Z<C7["+$Y^U.].^"ZF(ZF(QU&\4
M@IQ0@F  !Q,"1ONS+W?4!$VSPL[=*2.FA^NR:.HC8L4VD/WSF7?&JP*BM!\C
MZGPPX4"PUA!Y%^>_VXOH3#IG?QJ](R!1/";[ACCK2IM!X+DM7O*[T;2&)0O4
M!D<)+TLN7[:XIL<59=&-T:>.O5E8_9!UNTXKCGH2Q6KSX*?19Z'-3[I]@MM_
MK*YX\/\TFHH-_N3 A718>2G'VFJ4KI0(A*#1RE+#/XW6$5+]83H7=JY#F3A=
MB?MI=")6:AM9-O_F[A-4@(LV%4)*$E:DI&1ZXU^UIM&+O_D;H?!'A[49?=[G
M\[S++!94N)^_>58U;CC(5P"&7I'T54]UR,'XJ!S3_ V##'H$Z>B4Y0SJZ:.]
MZMCO6;C [JH+J^V=9"D="'!\VX6>Q#\XKJ:D3!U3VXDT?E:.$"KZ\GC;;[0[
M'%NLM0Z<]/#5,ZVJD5EP6YHJCPB TZ+*W5F/<5.>JI/E?CL]+O042"6S,O6A
M</"X2UADN/5_PRE$:HB7L,4NE&&[:I@6NIH6#IJ8=R6FF51VQ9]_",@X>OX!
M;#7*?*+,!_8.%"!LE\UCSW\Q#%"@:0PLS8/KU"7NSHBE80L1A^;O%YZT=3#;
M,3.X[7BYU1N>(.JBU(6BO1,62Y^AP$"+&Z*V4?<Y7NDMF_8HM'W4<'XXI'V7
M;6Z3S5IS%P!=A'0>UG3!AG 0,2J]/UV1_&.[8+?X6[C"(O^O*_:[0JV[$;P+
MU.V5IN;>W<G]%L^U$J#5YJ7"--VBQC<]X+#PF0(H$WN(CDEY(C&3<E-T+W"Z
M^(6^LA+I[/BT9=*P94W?M\8:U([J)/I'DP2/^20.7*P"R(-@(ANI7J8+GIUI
M&K20:G^^R$/V\B9*@$S:&) JV"E^( *,B50!<#OK*XT'[NPR6[Z5NMNEQ=5F
M>C<CHZE2IU:6\>QTPZRXN:ZW\MEV(PYIR?\+<[QK-V_$M+RL7\WH?#K"1B[C
M<8486TQ!MZ^$L%TZR-6TU&FG1 O@@>D?>G8>6@SJGT_9J;2JPTMB<.-ICY=$
MHKU[:&_<U?06GP[0NV><1J%0F6CAX2<%F7D"C3T#E1&_ /-'U;-S+?[1IQ2&
M?S\.S/ZO.PY"MW:VXU+U4$:41)D7RUG>R3(TAY+XFF#W%%N!"7\P79/IL0+'
MLH?19GW#G<,HGK9GR]WX4W9;!]!C>)JPLW7G./I573YQOC:U=0*4D:OK^]"0
MU:SM_J+M*+S:#<R%$\]^MKBQG2AR25&[I5M_//,X7IH]V([7?+455M<@HD)_
MR)I6$QII%E&E)Q7]:NW3?T,I_]=PG31PCOG59$S!IO]Q3=9]B6X7/V$_[N"0
M7S'I\]X:S'F;EP^_Y=H/O>7_TU\E1&:ICQ@RY1$BZLZ)#+X/X,C8B,7$PFAM
MK@F?11-E^FX>W40D/V^I6T>>\L_+:1%_RD,3F:5EV][L<)L. $\Y[Q(2-Q7'
M8UCA-5L72[?]<AU!;1.DTY]L;F>%$>\^Y&+66J>3HC#8.*L=W3S03L*RMV=1
MBZ[JX+@9QC=ZPKG>Y1'8VC],FEL>FCY/-7583E17#SNE908A*92/<SUT =7*
M&#1Z0U]_O+#IL9XK-#:N?<)*W\,9J*\_&1&!4E):TY_ZUV^EU^[)!YS-GA1\
M.PAM+DO><(P)6M8WNG\WJOFAA@].)B]YF0)IIE'"1?X=:B ?MY:''JXI<"CL
M[D34H*Y(M->@0L:ID7;O3)H\RT8VS3,2U!:4_'-==#O,]G^>ERF5A\$:S&];
MEIRV!-P9Z_6L#C7-)VTNUG+H*>/SV//7$ISH;&WL_VK(+^?^=4U$?XU]P[[+
MZGT?S-3,$1SZO3. L%]CFG24$[QZ]WRKM?Y/_7I:_VYVW#,Y:S<G^M7L&[;(
M5Q_].ECV$H]KVE^<@5O;JD@SKH[[72>3:7K* (E#__J36V,V-GA2H;#IP&M@
MM%KUZ4,[F<Q6!3+X"GFB"$K[].-V_/1)U;L=9;/4[O^&//O%\&0L,$4VZ3*_
MN?=6$64,W_3^J]F9\_;57T^RMD08+E>N2 2KGC&)J7;^]CO[C7R:QX&)QV/[
M-PKDRW8^1TVLG[M$G1IL][-)W-=I_F3$B>8]GQ%1>*B_WBET%!+X%B:?A=N>
MGPG@G>5J7.U:+;JDN(YQ#Y_F#4JJ.99Y$YNC3EKW9S/XE[:._&\1+Q0<!=H:
M?K%M%C=;[5@ME*=P!]7);"7J:$P%,-9)M510E_RO[4YV1B=Y7E++K[12MIB^
M%1.GH5NRZ]_=3;>?US3L.BI,T%=MU8KKP2_X22=9A 0F&GFQA&N,6W[5<E.8
M:N^0F[4LQ 08CB<ROONR$Z4]?]\_N!ZUB<1+G.CHZTR+;LONB7[CJ)$8CMO%
MZW0AA.J3QK]4"*PP:6@+)J25\O/C8Q(Z.;_"-S<VM[?9.0L0^DHLEGY"F.0V
MZH'KK>34"<;0XWH^;SYG:K:"T*H\&D0VO=7D4JX1G^Z9H&69.UP_5"<*H^>G
M.\T..>:"C$J@4Y'))T>^?@OW/453Q ?'0V:]H<E>'ZO?A#/F/>UIX7O-<]/8
M.^TN8(<BYMS:\_M@?__9PR4[ Q<0]3(]O9+%]S+(FO/L.-LTO!Z?]-EHFV)Y
M5L41K$OP/YL,5H0=C@5M1_$RJC6E#7_1LN^Z6-26!>KEA;IM>UC\%CYPS5BN
MC"RLJ(T\IX53#^R4%L]6(>9-2Y_1>#^;IVA_8Z-.MJ\"$!3;]O^P]YY!;6Y+
MVBC>WHX88\" 26:3,YB<P29G3! "A,"  (, &3 BP[8Q.9D<1+#)2&00(@E,
MSCF+9'+.(#)<[S,U9T+-F6_FJ[EUZU9-_VXMK?5T]]//J^IWJ70],:_"?OAL
MHW42>IG^O67^J"36$G!-Y;_HPJ9L=\90 G"GEY;PW%A8;W+S/1S[/"-DZ2T=
MV*+BTS\EZM6VX:@2L2]D\_A^_I<D6$9SYDG0L-D=^MW(].E8PV@NCR23XMQ5
M(T8=3WCMAEU&DVTWV*51H#;!R"%_%+S7  !H1;%412R8+8BUXGT/^?Y(DU-#
M1%$[WLW>2)FP<4& OFM\!"H-SZA3*[(,ZT2?IH37DB3"\@J\2@\]XG"-.R\:
M&(_SRB#<TYOH2ZGG)UJ^OJY'_K'7B?=;##<OV?JOTT"T?0W4%T'AY:<1YZ%;
M16DRWY84*!XU1&*L(G>X@ 9[SE%83.9.*$1DWD9N1V341V6@;F00^\+CS<@X
MVI<_V)+7%?ZARWXT+\3!#&^7SM2;D<:CZA+M4#I#%)$[Q[Z;CC[(F>98S#P;
M2+M4,IF^"7,O.2.INB7@O8N_^&Y;LC2YUFA\U7DE4TN==19X9X_23T860NP^
MG1S1)5=XPO9BI871++CU"<@.J*H;P:J9PM(YC8_X(Z8A$&*/JL;^;K6?N,;'
M+@$OS!8]&X%L?:SJURY-B#";E36L&1JM].0^@_^^?H$@'P%N%RW%WA(\VD;Y
M+,LH5N8U&"[MQJ?&DTK]5E3>C]3'!8\MTG3'NW[4C@GN^<Z,V%GWT;BXD-JH
MD>I^JG#6P!,B[.F.(&QH>]'MN['QIK_*Q:ZD_8,WS\90\\:4-IWIQ<T:$G(A
MZV');,[.'1LL!+?;?R$?J;-;<VQ[$L,<ESC8>VW^->//A1,A(4<WID&EQ0:2
MQ9E#J/6*6<CJ(\-X,S/KB>UUM:I5:2Q4$ZOB556_9XHFX7->UC9F'3>M07@:
M1*)C;72!-K,<J?P#'FPJ:D -3 3"(%H:N-$A4*_, ;2E\:7"3V41\R*9S)Q<
MS[ Y@P/5EQZ(?JT*+K)K?ZJR>+_"4$-L"?3G+<&5)A:0*$EEK'A+@!=C92#U
M W(+G/A,6"Y<]YU,E1M&U=_]P1U;L9+HIG5G=G;V%%RTI+E_Z6.3YS?S4A/A
MNK=/-H*INR6@HO/\Z-*R5'*N-P:2N *_FFYL,N%T]=.FE8;B*9M,IY^N7JK
M; _B6[=O"8CL([=N/AM=Q)YU+>3B%F3L&DR-+I(U*;F$4^_ZV,H1B\!/C5E8
M\W2[:'HF1ZN13-\2BG/SB#B83W22F<,[[H6\MRXR5T&Y?C*MS1C<-_D(M&F;
MY_%1VYFJ_[J/]1VJ!^OP"-X+X[J6Z'(8T6RD@NB?V%8X+CF7%GTOQ&OH(HJK
M6 DSY$4B#A,#K"JI]/7,><G4W#,R2],GOB3JJPJ[KJO)9#R,/. FHVK*F++
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M3$Q,ZY;7T-0.IA1DI"*2$Z:X)7_E8HQ'O0PNTL_,W%%47-<SJ%*^?^:*(>,
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M&E&1=W@U:]T*XRC6L$;8QR34\Q$Q@Q])/Z *79]+L&0O\/IDWED\5Z:0L L
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MC'_<$A"76^P4X_:*9]=JS#,$VY_G;PM2M3F,B<+=7"J<]5P@"CDB>JXBCJ)
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M"X0H13IEJB8H4R7J%S#[&( EGFTXPXTSQ%:]N,L<N!C2\9"($F=.-#(?!5#
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MB3HHBURUR,[*O/&=RFO\.Q66*']/509\,=G3F%1YII3!I/2"24G?>E9JT (
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M-K0"M."?2(S=",?X3Z\*JA6EU*2)K? MHYJ8>D\1YE:ZK@$1^C"(X5OT#[0
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M46"G0>JGS3,>@V9F+6).? &!A9TB="5W!+8' ZTI]*%&@Q!H:0_8 $@Q60J
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M,<HJ&# J;RB3.JR)#C05V/N8>_O=[<;-'M-B45YR;[1(&I-"ZNP9-U .TR9
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M*O,\;$?/_LK0\@/!LC-F4V[WN!Y&8R&NLU/P^$QZ)OFUZ5.K\<)LRKIS9Z3
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M.D6QMOK)%>J@S2ND!:4K$E<XY6X(KEBYB[JYU:HU*Z6]2<D[:Q!DL3-<Y &
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M,!43A3@70 ,@JC[LTT)%$J926"F**/>M(J_G+]O+[^K]:LP$^@\@:B$EY:_
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ME/9I-N%J.?A,9FNC5SA!LKG#J"6_7(P@MZG),,W7H*Z8Y_R.SKCO$ZK(92B
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M09@,EDM1X]*QXW45/FHP=PX$47&AR"4KFW1L'&-_=E*.$I""E8UAQ09()\/
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M",]RJLV^%6/='O59MMTWPG#4#]%VV!CGL65)(13CY\R'XV+._OJ51[6G8?+
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MG@SL9T_+NPJ9GM('>Q#R7-#=K8+&1:2G;+:.SE4(N+8RPTGBO<8_>@+23#A
MD!F@=C"_& Y3TLY35EZ!7HDM7.87L^I&Y X$A#[^^KSC:WWFJGV.65U,[X6Z
M,$+P%<E@;)(6R&5TX<;V_2E0"C">JMXW;H+,GXXY9>@&K"6,Q92EO<W\_!=D
MR9#%>(2I#LTS0_78"O'6+N/CQECOKR DJ4:%]]RF2V)<2ML#DJ7'SU1!PV!H
MS0Y%L4(',$SJ:M<EN9.)1I'U#'_<O_ W]9_<DO4-2#S7?)LFIKEI6PJJ&'X
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M#-D5UVLS>Y7Y8U+SX=SKR%VK<)44@OE6*%70GZ.S_;-PAB3\ $53O[+\EA+
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M%NIFL5.DX,MT[*7%/PT:^^,C'SF9,B33P4)6*:N2=9B:#=[GBK><A^O4--&
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M(IPU)JL_HN\4* HW]309/,:PF--[:=M(W%E*3KF.Y2A[#DTE0MHW=Z=9'CU
MV>K%H3=7+%8L[&-A"66^=J@Q>3 1"+10#7G_EQ-GT<7:WN,-B=H6KSQ+O4X_
MW-8/3C/V\P:$$ O%\%"!VF9_J3M-7QRW8YSV=D[Y7?8V-0AVJ ")=L:_4N03
MRH^I7<>:/#;$&VGVDN+LW:,V^)R40%X&^L*.GM'@_43PO2S3WNYGWJWLREYH
M.+41V7%0QCNY:9V/*[E5G6&]..>11E^:KAOCKN!JI[Z,\OSUL]VZ0;HG-@I$
M&AV?P,WI=,U@"6KXEGV!<U#;'_]S"NFWFB##H.B))W'>7WL>6;(*^?1Z0#2C
MWXHUOTZ($3YP:;NZF6O"7*5T% =IN=Y>*9X2,MF&.;Q_;AUUE]5!+OP6J/<[
M'6_K3=K2&3O@W6;4E"PLR_-@/ E!'0)LN&1)P!;,VA 'I5]6D="O?*C&@>[
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M!%LLZ=_JWLL<49 @D;E)L5;Q_JYR<+VQ+<YE@=A\4TDAIO+I59D*7J]Q,N!
MT<1:5]!1S:$13TZ0:/'B!+VY#IZI/7W90XPX4<='^KIH_F:]<8(U5WGMWI0
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MRS/LK*12*L&^%,H K^#NF NV&!F'EU\HRV629?)QL?^K O]0[:,?K>2ZV@H
M!+9A2'6T*79--]&B'@W"=17^F:S+# _KV-,[VZ+8)$,4RDH.%UMPE\R9=.4\
M'JEX5I C,.\#\(.N%T>N:;>-O*/U@I48EMFU#A%[I&^Q(J^T4Q+,8R#:)HY^
M=.;I!(-69.0P]J"_#CL;JA4'[!\ F<-]H;+,ZRMR1'@X-W@[0M0+L/U04#M
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MJG2!"2MANG3OX#6?1[H4]<&Z)AEC%9I19U_<1T?$1I\B12!%60A1D G(9!K
M($$BUM.S#&568? #VIZ;4M70F\.DK52I%?S^9--7]X;URM 8'(^_3&1'[RAA
M)P,X\[R*9-W\U$M*KKR<65]R?L2 W%*-2G+3BDDOKEOZ^.&V27E/8I-E2IG]
M:G.>1VDUHW&D.X(K(6/!)466Y:<L6IO?PM*^PD"%N"PI4'YBQ:.)W3&KLYM]
MJ8W[C:S"=!P2+O70W[]]Y9'2D97JX$557!JL0(,%&JV_@@,.G'1E8NIYPG09
MF>Q,>9*9R?(6-[$0<KEX59]9>K,L.%W]NW[MW^C?% M&<9S$:013H;!9AZ80
MX]A4(4D)%2S,.+,JO]S1QMR\F@8FJ' " Q242.T^_BXZNS]Z3R2-_+$/X,?Z
M$[=@X.!D%(V744C^E_O\Z\_Z;N-@$/-#^>&W_(JN)T_RR5N8UGSJ-I?.(/>[
MUIZJ0G*^RN^_[UWR(!4("Q)#I"% Q,,4DB0.82AEJ@*:!3%Q6BF> //<).A\
MZN_2.VFA?\8L\!>ZWFXV-K,.'5DN1\L$?_PZC%/!<[J^FFTV^ NP?]Q\\-W]
M,&I&^)ZF!XYJ)DSC2[[2=Q1FB]0<@-S*0P&50\FC0-",AFD ,>,"(BEC2 B1
M4 0L0DF @R1TJF5EW?+<1I@*K.,(8DVSY3@P!GECJWD+\S^!"C4PL%L5H48J
M!.5,EU=!M6Y\6EETY>1$W)P?,#06_$Z]VNSN/TG^96VTSVRTD4QFF$8""I3&
M)J9"0*H8ADI/KG%,0Q&%5KN=78W,37A:\>"Y_E2$A@NV+;RN8>%G:.U?6?-!
MULA"<PFBS^#PRP3TAH>?N77B /'+X$]#Q#NN]>5Q''(D9$%"*14PT_-?B%))
M(97:V4@"1%3*DX0DRBUR\W)C\UM5?SH^2B]>ANOTT@M=S^%'W&ZWFR7;;<L<
M3MM<3P-'V]WK)VE<[^&99E&]5O?[!Y[F+&</G;W*'^ARO<!4$*,B4&*3%ER$
MU)1.5!!C25#& I6EECMS%JW-3T,ZCD=6D'T<*:VIMI,43_2-K"E7\.;G8.E3
M1D8_6EHW]_R'2Y_:;76\].B681KR:;E=R3OU=BV67Y=B1U?E.>D(R3 5.(!Q
ME"8091F!+! !)!G"H4@XC^+,98WC;"MSFU:4(,V[?X YZ/CY>4KM5.)JHD;6
MAP$<.>M")P<^%>%\0Y-J0:>MQRK0??'0D.JJK.9[NA2_RNV"24;2+,H@XBR%
M*#:)]QGFD,F((!)'"8NL-NLO/']NWWQYG*F,D%-ZI&M*);L&1#^ET.Y+OX*8
MD;_Q?4E@ \TD&.>KG3"GNU[2Q^66KLICNLU%-^"0[/&6;_6+Z3O^^2Q-?D.=
MGS8Q<53S6?M. YC/7S9PZ6''"CVOUA/#UU_U_WS23ZE]V0QG<8PB"B-).40)
MQ9"%6@@X3^(,$Z2"5#AM;EQJ:6Y"<  *2J3 0!TX6;A,K^7J@P_2QEY\&,:7
M^R)#'Q=>UQ@N-C;M$D.?S2<K#+TW#,\^8U8]7U+M<@BZE<6"XU"R,$%0*&PB
M?I'2_H&>([" BS +)0TR[II]YFD3<U.&PVY#N=' ]T#=L\\<<6F[R7 -0Y-L
M,1P#])M]YKSQ%MEGCFZ<//O,>>#GLL]<N-+]J_UEN=)>0KZ6=1!%T3Z41S&)
M"4Y"B%&$(0H(AB;7#-1.?A:F7 _](;;]=KL:FML7O,=JSEU725:=3S_VDMO_
M,?NB;.1/N@NFGP_;AHB.S[OS]LD^<ALCVI^ZU?7N0?>OU]OE]GL=O/]!EB4*
MUO<F)^RN6. X%83+ .H^US-ZQ0)(!<L@#C/%5,))**T&Z[Z&YO;!5UCW1]OV
M:$$%USX&OY/=[B_>)V<C?_%#Z7(*R;?AXHJX_,['3Q:<;V-D.T+?ZGI_.>C>
M%L5.BH4,I%1!'$**,8$HT_-[EB"F:0VB, M(%!.G:L&7FYJ;,!SEG;NI,\V!
M98G6;^ZYFFR[*;\?"D?6B4LYYRJ@X^:;>TK&V+GFZM:>/<_<4ZMM<LP=W3%,
M.U[5SS45JE[J_RZWK7)%*9$T9F4F^%! %!*D=211D%*!6< 4EY&54V'3V-ST
MH\%:5N]KUXIRDXM.?NT$PQ=K(TO&GK"RMEP%=)P:4#:$^)2-SO8F%0X;RX^E
MP^J>H;.1UP]R<Z_]F+]M\C^V7\R)#[K^OB"("2DB 7&@?0T4*@E)%$C-;X)2
M'"FNQ<-M,G*VG;E)1NU<-UA!!1;4:%VG(N>IM9V)7$W8-!,15ZX&S$,ZF;AZ
M&G+^Z1//0CI-/)V$=%\^S(_8G]YJK774Y8K%W5$EXI.ZQ4_+%A\.!N&,X0 '
M% JL,JTC4D%,50AY(DD4\2 @0>CB?XP!<FXB])%_D6)71>Z\DU]U5\56Z<JF
MZU4[K^>Y^VID_6L7BF]9V!2-%R!?G]:"/RT@?U0_'GS^5/YME!-E8_:(3W=M
M%)R3NGEC,GWL'H[:UK"QY(/<TN5:BM=TL]9-:SAFZVR1R##%/#8EY$,]&L21
MA#@2!&8<92EF/*,Q=8MS/]^0BTI,EGQJ][!;T:W6!>W.+_G2,6[M J-V2GP]
M2R-K:0,0- C!YPJC1_'K)L&G?%UH:5(!ZK;V6$)ZKAXF K_*K8G8?+_)OR[U
M9/+%]]\**=ZNWZZ_RL*LG!\B$!<B(JF(.84!-?74I/X?C ("182H0BGB$L>+
M;;ZE*SM9L&_:R?G; Q@Q1D-NJ\H'.Y,79+G6_U=C!K0_8O/:?K"3DW'8'5EB
M#+%E '$#V^1@^>FWBN4_@SWX40)CW1GSJ4<.K4^J4>ZL'.O6@"<\^^3XG1;:
MMUOY4"S,QA[C"=."%S"3/0M!%J ,:K^(X9!B%2FG\/TQ0,YM<CS.K.O9YM2'
MEV'R.?6@+OY!Y]3&5E :.\_9]$E?S'0V?<#YH\ZF3Y@><39]VM:PP:?. ON1
MKNA&HVDR1J]%:R,R,M'<,8^@2HF>6C/.391W!+E*LD@(&LG Z1"H19MS&QJ:
MI,2/]+MN<U6FRV/Y6CO2C@ZS#=]V<NV9Q9'5MR&P@>M/*AUX\*E\-LU.*F0.
M/!SKDLNMPV3F;WDN_EBN5OJ9;]=;_6(LM:Q52>K?YZLE_W[8 %"AC&-3UEC&
M+( H$@@2(C&D4F)&B5G*<RK;8]_TW$3G !?0$J^;U#AP;J<XXS YLO TH$O)
M;C':E+VHD(//]7]'V1MQ)\ZG4CFT/JE@N;-RK%L#GG!%BJXJHN[5SKAH[^5F
MF8LJTNY7^4?Y)SWI#DF8R""%29":4AC:1R+*G(G#+!42DT1&3N5\[)J=G6Q5
M,;3F''VYV@A!0:L=9YX_/.@I4U7J>7",K65GT(!D!*,0XE"%)LPHA1BQ!"+)
M8B)0FJ62#,B=YK4[)LJC5D7G'G? M;'.EOU@-[;XYW;D<:4$7$<\@PHRJ# W
MX= W0..NKO#H[KH1Y3WQ6G_+TR=ALV;C;$(V^[NO*)/ ^E->L^.4UW=5EFOM
M@YL59RG^+DVR)RENM6K0>_DWDP'J%=W*_:K"(I RTQH70*5,R80D51 +;"*B
MLB#4@Q!/5+QXK&S<TLW64O8F,\#E\SXV8[POO8$-:(4;W)<)T<P)7:#,HN+7
M:E$QWVV+K3F[N[Z_ 4S>+]=FO]/(;H6U5%J1K_0DJS"_JE37572G>YM4JJ=;
M)(TA"[F>B*4TAC2F*<PRGJ8H"10E:?TVO5Z+'_]=:HR8V9LD3<76'_4=LAS\
M9_E6C.U 7%_+HS*_/$91V7\#]J]830%X_4UN^+*0X/UFR3W6QYZ^S[S7])@&
M_?2E/2;ME;,5/J9%X)X=H\Z?V6S#V&:%[KIU1LK2I&S=8[3)^FS/D:BKB94=
M.SI73UH;CS,_"2WZ#.Y(9G'QULD26?2!;R>QZ+UVX&YDSI<OI,HW\A/]ULY@
M_BFO\I<ON$RR4$4(IB:=!1(JA#C2$I\RACA7*@NDTQ);;XMS6UUK1_OF90%G
MKG5V([]HJ5U^E6"YUO^^/,X/I-UR2](GF6-O2-Z]?*MG:08LT&AO+B3,][A/
M:4N.UUW*WD:GW:.TY>!DA]+ZQJ$'W3?+KWJ(^7IP+^[4X9=[G5N$)%8,9P1F
MB<F+B4@&"=(BQ(*,IDQ@2C+'BARV3<]O7?G-?LI:)L7;0]XGU7*LUF'="79J
M- :Q(XO2 =W!>6N7;+PQ)V&+XO!'G\?FW=CR>X3>LNV)C].[,7)ZM-[Q_H$^
MTWJ[%,O5SCSSHPDA*\/*JF3-4KS19IF)V*YRH.]4<PSCO=R4\[#;AWRG!_B$
MI2R)4P0#L\2'XDQ!0J,8<J;]+"EHI/_/R:_R@6IVOI<V"C96@6)OUO ]-#^=
M9^F=3=TE8WMP+7O P2#06 3,)PU:-IE1:G\(3)M5+:UISZ^TS*.GYY-HK]Z@
M%V#3>HP^N3SQ*KT^?&AHB9[*F06.._5FN:9KOJ2K]WFQ+%?-7(N5]3]J1M_O
M'J[Y+O> 08-XI%)E]A3YW3NW:'?BG7-[)D[WS1WN'?99O'YX7.7?I?XL-U^7
M7)ZO&[U?*RX7D(M/Y@QE^^\O\V+[:[[]=UD&S]^O3<&*<L^_7FM>T#2E.(HB
M2+,,040%AI@K D5"<1:E7.I9GHO7,PGJN7E%OZTW>YSE8M1^)XOGIB[(6I9?
MN#DU]U N6^EIO)++[:Z,D=G(:BUKFX/M%]FD^/FG JSS-:QXJDL_ EKRY>9@
M3?,>V>GS[-Z.D06^L1?4!H-+6YZM'<QJ:U._%T^V1+7!X+NLSEY5)M]4J2?K
M+5"/\563=I+/(68:X)..49/VQ?$@-VWCPT;)?<FE=U(C*][LC*C^LEPO'W8/
M37KQ5SM9'^A8!(B(.(H5E(PF$&')(<FR"&(98"Y1) ER.EKAUOS<QJT:*%@9
M\/N* #=::.@&Y&O'/13'KK ;,<8C>&3I/]0"JY#?@ H[:$AOT(-79E7S5W/J
MXM,?<J5G\K_DZ^T7CX(^C$.?RNR(8%*)'<;.L58.?(I[X,;?<MW(2V/:9ET=
M\3@^RA0SK)WW*(4)$RE$$5:0($Q@'"=!G/&8!L1*XZQ:FYNDE8!!C=@^U*.?
MU?ZX&*]<C:Q.O5C]1(-84](1%M+_C,GB0ZS-:0>*V-\TS -Z)XM"RJ?Z\T&N
MY1]T]4EN'A89REB4:6]'27,D2R4"$IIR&& A(Y8%/(F=DI3WM#<W03B,PZ67
M8Z;;)59@<I67VQ;&VW'=M>@CW<ZY\4CER'I1(6U7.'U7L5G#!9^Z,K\[>RR6
MQ/AT4?J:G-0GL;3_V FQO<V?T.RW<%L^SH('(4,T0##+J(E0XP'$E*20HE"F
M*>68TM0EWYQMPT[2,T&VN7(N?#2YNEYFSE(^7&^N)?*YA*<5'?)^/W'5V,<5
MH2ZVQE:CLVT_NRQU,6*C3YWW#RV[4-<8QCS1FL,BF&J'$B*LO1XB*(%,A)PQ
MI03/8K<Z"_.LV%P7"W KT7S"5K>&7,/!V*OLEN8/*(YPJ<#RP&H(4Y90OF3$
M:;V#JPHD[W=$Z4K>J7)EMRKEJO_1*L/T=OUI0]>%R;*:KQ?ZN\M"I1",LT#I
M.4F&("88P8BH-)14*IE8E5\=TOC</MY#4>7=>KDM0)&OKDE)X-(-ED$5(Y$[
M=G!%G7*C+M!VH/E)J3:3!+B%WV.<Q0#6O,9;N+0_;=S% &9.XB^&/&.@L-4%
M0^H63C; 6@?[BOIDWXOCDWUEU8D%"U48:\<#4JU_$'%J@N:I*).R")&%68BD
MD^KY0C8W26S7:+$Y)%QTGA*NBWY8ND7^N]U299^C,\>6X&G[T5VC?7/N5<"]
M@9M6W7US>B+]WAL8-?+@[?K-\JO\=[/&O$A3%"0\2Z%* V*.3DE(6<R@H@3C
M. P9R\@(T0<M"'-3^LX(!*51CQ*"T.X3KV$( YF>2RA"N8!F/&)C!2C-F#P*
MX0R%SQ")T$8QQVB$,RP-C$@X]Z0KTGQUR?$E-=X?#KO5SOM#%1;V85G\_F8C
M-3PM0[+8?J#;!OPB-OD,@S2!24(S[4>C3+O0,H8A22E#D4G&[53V<"K@<Q-?
M Q4HC55_\A58H-\8>0,>:EWX2;]"7!L[)+O2%"^"I6<]P^X=V_&^/K/2X<@M
M:)E_ \J7QC  &@K A_*EJ5GPG%]IPG[SGEUI"NS3YU::L$?.9E::LOUA ^';
M-=^8,?>5K/[[=ETN5'W)5_H9Q>OR*,>'?+5ZDV\,N 6GDB0"4TA)&D&41@0R
MW3V0,T13F4D2IX'+>.;8_MR&I08^^*DQX,_&)VW;\$^@LL)M7'+M%[OA942V
M1QXE'(@&GXT)H+;!XQ+,0/9\:K4KA$DE=R _Q\HY]#%#-^!OA=!O:E$>D[S;
ME!7DM+F+C 4L-N788A0QB#"/( Y9")- "!1E"4=V*^!]#<U-TNH=ZAJL.;FE
MX;INTU_@U';;_GJFIMG&?TJ2?N] @]7GQGXW&U=O]%]X_,0;_]U&G@8"]%P_
MSOY9^S!875'R>[D^VRJ((T(4HS" *M1>$N(J@Q1A#)E*,0ME$F3,Z=36]9#F
M)C ?=P\/=//=;+14N)M"JXXNDH?.\K/=Y;<+GFFZ?71$]V;?*?56UCBU=OQ1
M.^5VE@6J6>UCV;/HNH'E\.1ABJR%_5%NMM_?ZY?8U#@S[M^CF2N?G"0+.,^D
M65ZE40A1$*201(+"$"'%D8AB19W*'MHV/#=U;7"7%;3VH,N\#F[R:LV\G8B.
MP>?(4ME O@$EZ&-&IZA%YLJ:3Q6T;GM2K7-EY%C1G.]_]C+A+^F*FQ3"^L?V
MB@^BF)& 8)C@-(9(RQLDB4PAUHYFN7//W"*T1D<\-Z4<I\3T#6A9_VS5Q"^\
M,W92/:LW862-G^ E&&T]<K)^FFD-\@N@?]2"Y-U],&)U\IZ&!RZE['23_[G3
M ^OKK_I_/NFGW'Y;%@N6B"Q1F,),F/*.PIQS(E$*J9!AG$1QR$*W@(CS[<QM
ML#G !"5.8(""SP:J:[#O!6(MUS*NIVOL!8HA3+DO/'3SX'4UX4)3TRX1=-M[
M,N_ON?S:Y57MA8L=W[Y=JWSS4"I/%7].$ZJGZS&"4D:JWG1A&,,PX!%7G$>,
M.26V[FUQ=CK1"D.O(8,6YFO/!USBW74AU .;8\O(E41>L9390\XX*Y67&GVF
MA<@>#BZO,_;=.$QY?I5_W')N$D";NK&;?*U_Y%7<_?D42@%*6("P@+&()$01
M89"9,,XH25,6<:PRMU.?K@#FIDO:8RP#[O8V@*=&N F2<W?8Z=.8)(\L5Z;X
M]$5RIUEK',J>3SUSQC"IO UEZ%CM!C_'/07?M04>ZX*D1H+[Z\?&/$ A81A&
MF2 0R4!!&B8"JDC/Z@B+61PBNW)+4T-W48)IRC795A^6!RNO*C<\^<O2+>ES
M?@&FV*&?R&P_J1.?HZ,ZLC!."F>RA([/07([-^2SM.\>T_FJKD!;)E4H:UQ\
MD(_Y9KM(,(_26,4P"!+MT2>202I)#)E,0R0RQF*:V,9S7FID;EY[@Q,<@((*
MJ7U YT5"NP7<%TTCB^T AIPB./LHN")Z\^*C)XO<[#.N';79>ZV[;ZMUZ*$.
M0:I2J;S)-^^6>I[*Y0<C,,5O:_V@^C>W]QM9RM0B8!2%2"60TUA E(94:T 2
M0Y7$48R1Y"FWRK0V',+<9*+$5TBP*2%KE_*Q_&<AM]M5E7:HV';E6?;5,_TN
MX?A\CZPWE0%UK&6=UDG; &K(H+("E&;L?[DW9/0>L*\6/WY/3%1+?J0><7*@
MKR.SPQ4>^.#)G-KK#&^[IU<^:6B:8>WLFJHQQX< PC1 F,=0X$3I(08C[6O2
M")*0<R8)BP5Q2IYRH9VYC2-W987[C[O'QU7)+EV!E[3X MZL\C^>;+Z8[^LX
MTX=KMN'SS-LM%'O@<^1QHLX<;#".&H#?PX3?/,'GFYHX+7"GO:=9@+LOOS(X
M]+;0/E9QNQ;=03SZ@E]S4[>O%=/S;KF6;[?RH5@@'A$N90)%K *(I"ERKW0/
M*$4Q$U+/>2.KB>THZ.8F4>UXO\J^,JR[/_3/7-4VLXH%'!C@Z:7?[:3NV7IS
M9('TW)'@LS$2E%:.$:+ID_U1PC&] 'R>T$N?W%X,L_3:R- @AJUQI\JSKD**
M%]]_*TSZV+JHKVZ[.H"E@;W,S=;B3O^N]K+,\:RF/#5/4LP")B!3)(8H"!G$
M)(XACE @.&4<\]!NE\XOL/GMP97.J]+.:U%5IU>-08#N+?JK:^2#ESZTC8>8
MNE]&CY+85C.*QB23&.HG8Q58KO\,]H:!@V7&AVYL P?C1JE7[I=OOW$57I!-
M'&WAD\W3& RO3Q^P>KVB19&KOU.S@Z;?JW*58K\P\5YNEKE8X(Q&B$JN^U.:
M--PX@"Q**:0BB91(,".A53RL;8-S<]<K5":&DPY8 [5AV&+-V3-O8Z\P6\#U
MM&KI0$S7&J7-8Z9;D70PZLGZH\M][FKQOLIN2>_-4?P=>U<E1N+Y@[Q=F5XR
MJQ/YR[RJ6K2(2,R0B!$401Q!) 6"F*D$IA$FBJ0IY_9E59U:GJ%^U.#+O.X[
M!JOLS<O2 $ ;"\ V!SS7?S1&V"N,6Z_T2\UH7(^L.2V:[]HT5]C!'CSXE&MW
M;&2:[?>P1J-[HJTKO[0[:?\@ZCH& ;?G338:##*S/2P,>\"@\4$/,'=K^8LT
M)6866!*>8672 >B9/J)<Z!$ I9 H3%(1QA39.XY'SYZ;QK]9;@I3CS[OR0+?
MRYF5/@]E8GP%-HZRA@8^5^ LSXB=(\))08<2,IU&UL1X$[YS%G=+VY,[IA2O
M<U"/Y.GL)>X"5#N^^Q*9[_+UO2E;7;]2"8M0R#,$@P1CB$)&(*,"0Q6&RF39
MU/\K;/6HNZFYR5.-]E $%AB\L+,(M2N[_<KEC[.1A:P;J)]OV(Z,CD^ZYP&3
M?>%VAK0_>,L[KBPS]+J*("P6/)%1S"6'*3>?/0XEQ(CJV6BLHBA!..!<N937
M/FG!Z6N?K(YVOH]MJ6,I'3>*3XFT6_"_BIZ1/^Q#O,_K/DZ&U^LYMGN4<CS[
M1IZGVLZQC1>+Z9Q<.%*MG(NER^J3'^7YCN+MNG(VC@Y_U,="Y/O-DLM%(!A+
M:$A@2C(&D8@E)"D-84*3B#/]BI'$;[D<?]CGYG<TX,"C07?5V<#G>!.D" C"
M,H8L"T.(6)I!&D4,"B0E3<. H2QUVZ6>Z;OP3,=)Y9/7XZ8Z7BK%#_>>V V,
M,^W[D8?<Z^N8WASR05<,F,,@%0<W8/].U32 O>241$Q87<E_[TU:8,DC_'G5
M6/+?+\YEED: ,,R-,M$&YO]-PMFO=&6@?9#%5C]9MV?^<+L63W_1NG+!F(K#
M*(QA1O0+A@@SJ15$" ,9QEAR+-,X63R6-GS<TLW6;DB\"I.+T!TC&SEFR\1X
M<O.#/,"] 70+F+Q?KM=F$I(K\-B]%SY"+T8"I8)*!0E&,419G$*2( HIB@33
M\V33QW4OOEZ+6?9A@^NY>E"NQ?/TG9VC,5EOC.PZ&&0W5:S=ZW8/'+"#?3\=
M_ZYU@S\?P NQ/D?UZP!-.DY[X>YXY/7ST($+C>:@F1GP-_*+'O.77^L]U3?Y
M1@_@ZY>[S4:N^??RK+D)U=4>P5J4_ZK2W-Z*_]@56^,*_"JW=^H3_?8^WY1_
MV&J\;+>M]F7?:[_!'(HE6<PITU/1)*00I3*!>CA6$"D2!ZFD<>2V*#$I^KDM
M2]1& EY;";8'PQP722=]"2P78.?:M6,O[I8G/Y\8WD2A_/0N+XH_WX"FXQL.
M0(N$<AAIT0 ./-P $_2M1WS-A<F#MZG^WJ+#Q&Y5A'A<4'Z.?O2Z6#VI =,N
MA#]'WYPLLC\+B(F+W=M,D<]D=@M2' HJ8AARS"%"@IJ]_A3B,)$<I5DJ>.1Y
MZ=:O!3_ \NV%;("3KN)Z?FT\K>0^WZLP@]5<CXNYY27 D $.9VTG7-,=IQ\G
M7=?U;,*\UG;'Z1_G]=V18+@'P+W)<Z''^%>;W?VM>%BNE^:$F,%0QVBI(*0\
MD%*/BI$I?$(SR$Q G%0HH$K%/)76$7 ];<UOSI>+TL4W@,%3Q/8Q<'T$]P?!
M>:1M9*WO8FQ @&\?=?8!OQXIG"@ >-#+YQ1.:,E)1SQAWQ,F"RBT-*4=46A[
MR\#<Y<7M;OLEWRS_2ZNC4#S%/(QA@E(MH7&406)2N"*AU30),\)B:1-->.[A
M<PLDK/ !N@=8^O2E'U^XIO1N<]BODM<P,X4+W(+F,7WU&8/[4DRW;YDV#?09
ML">IFL]=<\7ZP169G^]VVV*K%7BYOC]RP#[(![HTV['FC+TY3[^C*Q,8'RTB
M%8H0$P(I9PRB(,(0JXQ#CM,HH6F:X80Y!P).:\/<O+!:4>HE@AO #WC!UOHT
MPG.^%*F@F*0LAFF2AA!%)H6W"JDI^9U0G&:I4MF A:7YOA;/M+BT:;"?O"/E
M(/3='+/[\PW(#\;/_]UQ6%V:[_OP ZTPM9@XL[BT9P.TZ "=9Z*&K3 ]3U]Z
M7V6:V(SI5YJ>IY_.KC8]$Q1/&81^W9E9U_ZW194,>4$5"T3&"8R5S" R)3:Q
M$ 3*F% J,Q(E27!5(J'S[<[-!ZI0FNWD/VJ<8%D"O3*KT 76^R=;(W$Y=G28
M/>H14PUUT^2:<>C"TYXW\5"WB;WYAWIN'QC(G!?;7Z2>6XJWZZ^RVL2NZ]8M
M9!RG*5$"XM3(##&IRK*(0\%)*,-("6)6:.RG;1UMS4U:RE3=%5;0 NL8HMK!
MK9T'ZXFQL07D/%G3%+JTH,AKH&A'<].&@?;;?1+D:7&+SZ"4A0RU9D2(018G
M3/LI#&LIB1248<*R%&,:I-A'[,C\9N%EZ8IZ4L5;2'T$;5P56S$CV;@T01T[
M+&&ZZ($Y;/*[[<5?J0/[T^IE:JQZ3E4L,DHH0IC"0.(4HBC*($L$@HD,* ^3
M&"%FE<&PNYFY^1"'' G\*/7T(:/$:D"UE LDVZG"]=2-K I'E61NFC6I,1),
MG.5@E"P33UMZGE039ZV]F&_B_-7NZQKUQM7V^^VW9;&0&&=<F>/_&3%G+AB!
MA"4I%#01(4%<1,BJO,G)D^?V\>_!@<\&GD-XQU/"^A<=!M,P\H?LBP'[<);!
M3$P4O++'YV<9Y:RY'0LE3Z^?;"GD+,SV8L?Y"]R4IMAL%Q]U_Y7KNG^3^?V&
M/GY9<KHJ7Z&0A!E5*((J"I@YZ:4@SA35TQ(9J"A5F4BL5*>SE;DI4!N?TR?8
MS66W('EC:&1Q<B''^J.T,K[#O=#WMUP+_:]CMZ*[@4F^:"L;FZ_;[N)A4XW7
MNXUVH^GZM_4A\E$J1:.44YB:NFDHR/0G+E ()8X9)22@S*UXVIDVYO:5-Q!!
MB=%M(G&.0KM9Q)7$C/QQ/^6D/\+6>0+18;[/V<.Y9B:=.G38>3QOZ+K4?=+P
MMX__^V6^+G8K,Q/9UUVH-SX.J8TSFIJRWP)2'NMQ'<M(SR:8@"3E42RYC"*,
M;6<3=DW.[?/7J,$!]J&2,6@2U7:E2AY*>_^<Q#^98_L#5H#]^.UNY'0X])8/
MFLS3=S.L/05PO'/BD[,FU<7V^]MUL=V4T\2B/"_\Z0M=UY$BO^;E?HKL/Y+T
M(5^MWN0;\]1%0IA"<2@AQXAJ]<H(Q(EB95WI1"C.:*:\IL><UKZY2>70!'<_
MQ+MTS9;0#_&&/-->E$.P9,41:)$$JD0:6TW3(91RSY3M*=U1BAO.]$V8Q8'>
MD4R<P5[@L_>OMP/!(\.\LA+\V_7C;EN\DU_E*JY]9B:R)*01AR%-B1[L<0))
MA%-3TTWP-$D0)=PM%**CM1G&0RSOUTNUY.64Q'35;^N<%7+SM<SY4UGP4VD"
MB!TS6W2R3FF0H(1!'J8Q1"G/-.M$NU@D3J*(IUE@-T'TS/DDQ[1;)=4KM#>@
M)M@?OW9NAR?61G8!.@@;80G)@I-1*L.?:>YYZKQ?MOMBU?:.6]P$6\CEXO5Z
M:[:<A-#O4/%2_WBW^93_L5Z8R'JI@@0F$8D@4B&!1.A)FDQ)%K LRYBP.JO8
MT<;<I**""6J<-^!EUQ:E-9'=VN")GK%7DL\PH]\P8&!>KP46'!PTH&A$H)#\
M+_?YUY_UW>;[)^:'<FVH]=EW/7F2S]W"M.8SM[ETZ.?]9KF2FY?:V[O/-]\7
ME&E?RQR;":59<!$20Q;%")I(5,JYDHFR2OUYX?DS_:Q+C* !Z?I=/V70]IL>
MS,LTW[,E)0,^Y+.&7_T1/WWJQ!_P69-./][SEPV;2+W8%<NU48+\@2W7Y9S0
M+ \OA:R2D92I%Y7<;.1^(J@_*#W=J\_$W*Z%^<',+1:$I@K%)(198 ZQA"B
M5&4*2J[G8XB$,@Z=\OUZQ#8WP6BB_4P.UO_Y_BW(OY:K5QLIH3DE/BA-N\^N
MM)MM/%,'C:Q<C56@9=8->&(8:%G66HZLC0.5=67RI,8^?].9$4CW.?WQ"6_2
MZ=((O!Y/K\9H8F!(3_GX9K7;-A3ER4TS^F+K#W",U?OS-GL-/7G:PK11)V>M
M.PDX.7_5P,1D0]($]*Y!O_[VN-1?39.O<A%E'"49$C"B&8((TP22.-'S#Z$B
MG"5QEN%PL9;WVHGJ*1<S*6ZK;XI4WU0;_7B?UN'@?Y5"#>S6NJ^;+  WIDZK
M,>"*)&N3O _]<33SZN,)MV*GL-ECOKDINZ@OD=TD6*;-D#<EO2>I]R9MW'WX
M>K?DIF1!*VS*9*)9$,XIP22&,L@(1'&:0AIQ"?4 1,(@E9FD5LO8EYN8V^RU
MG+'N],O4H 5T'PUIGQ&O@])^N;Z>J)&U]3Q /T+8;7R':EVX<3*)Z0;>UH.>
M*Z^,&GCQ_=V2LN5**T>9_Z4\;D,"&2*AW44EI( HHP0R)#-(:4B3) NI3/B@
M'>QSK<WMD]XC!"5$IU-,=O0Z;F!?2]KHG[<37\,WK;MX&&7;^FR#S[-QW67[
MQ:WKSIN&Z495HN@3_?9J6?!57NPVTG'II.,),WJIZ\IC&B8XX!QE6<6"#Y\O
M=U=SD[[:%G8?O]@VMPQ8BI%\MUENE[)XK]^>+]JKW@^T=< 1H2F*<19!0DW^
M )DJB"F.82 XE6F6AI3%MFYM;VMS&PX/@$&#^'#BQV&!HY=EBX4)G]R-O:#0
MA]730H M)5T3^-YG3#?QMC7GR839^J9KQCQ3@_)L64^$>1I+%L(@BLU>+XX@
MCC&&(DA9$), 98S;E)2P:\Y)'B8H,F%*:VHI+@"3*M=#Y)9^<TTMU,.OBUOA
M@[5I/(NJINF%*J0W#9MZK//M:?11Y-_9N-CB,_@;?=:?=SEZ[QIX-I"NY)TJ
ML_;]JM^8.]6J]?DJ-]F>%RR51&680<$#LZ*&,&0D4##!.-7>AY*A=$IBUM_D
M[/P/C=ALNI28P><*I.-TW()H.Y7Q2]_8+H@;<^['N:S)\'K"JK_5:0\]6;-P
M<@[)_LZA:99/B@LWI8(7-$ )(9%V4R*3Q2#*8CV[83&,,:<BIJ$,D\S%:^EH
M:VXNR],:X\9Y<<VP?)E6.QGQ1-;(^M%9B[U=4GWL4NH6=/G-MGRYN8FS+??:
M?9IMN?^6@<Y*DU+IW7(MW^H?BP51A)"$"RB1-!G.< :IX$I3&@2<(Q'BQ*H>
MZ>4F9N>,- C!9X,1E"!=G9%3(BV=CZOH&=O9<&/&W=FX:+Q7Y^*TE6F=B8M6
MGC@/EZ\<>F[E@[PO*V^NM\8=660XT&Z R,R9M,34SZ.0)!F%&8X$TQ][((55
MII!+#<SMVZZ/:1Q  H/2]>C*$8G=7[8/:D;^KAU9&7!ZY;SI5Q]?.7KLQ.=7
MSAMU>H#EPG7/4V5SG[Z@_O>;?*/DTB:=P8+Q),(L8#"BG&BQ" -(9("@(CS,
M HG2.*53%ML<;LK<9.FDM&)9?1,(DZ]%F=/C7ZO3XZJQL Q %?EJ13>%.3U3
M!:,ZYC=XQE?)TAGZ(5Z0L9TNC]46]X0TOP)[2FR3!LVG\.+UO3NG^HM76/-#
ME6&\OM=\5V/T@&C@TIV)U[EKJJ[=M6NQW:G#AN=+NEI)\>+[:\J_/+UV@>(0
M"2Y2&#.F1^0P"R'#:0;C( XBE229B(E3';5K$<UM8-5OQ(.6RJ)<'<^5DN;P
MAAY%@=30FV,=[J<Y_/6@Y5KBE/TR]HIC&4"8JWTB6=T;)48]/.U/W[0"4BJC
MS AGS#JYR^,*I"^2O:Y37@UJVM5,7QR>K'EZ>_#,SO%)OBU/NM8Y0\WR>K_[
M'"B4$9YA*),T@ CKZ1A-4P1YBGG"L@#'J=6B["RMF]L8\L$0T1:L,JLK>*^5
MJB3F!OQ;Y5.; _ M0P'= JE_I>^L\AM<-6F;95<]]T'#L5^O*:9V<^+F!SBX
M>$V7/]<!QT&8_^\X"'E-=TUV8/(JD.[^Q-D:W&8,6:[OZP/< F=*"97!D'$!
MD4Q"/<!S!+,DR*)(14D464WL[)J;VXA;@W-*"V1);/^ Y9>N*293G6#]2+H]
M*1T::_&0R43/WJ"V"CG<-6Q)J#H'VI1#89A3R4@,8T9#B.(X@ 0G!*9,1EG$
MLTPAIR.:3YX^MX^^!N>V /.4+[O%E,$LC/PMU[A&2 E\UF*?JQ1/&YATQ>&L
M;<>K!^<O<H^AN-4>A#!>Q)L5O5]0*4C&>0(3%2J(.$D@"16'B,0TII)09A\\
M\>3)<_LT]^" 06<?+?&4KOXPB<$DC/QE6MKO%!=QUM8K B*>/F^R2(BS9K1#
M(,Y?X/[IF=R]MQM)7^9"+D@<<4[#&)*8!1 ASB$1B$"6)A%""N$86;G'QP^>
MVX=79H4VX(!!9__A/2&K_[L;2L'8SJV=]4Z?W3E3K_CJGCQNLH_NG!'M;^[L
MWP>&&^U8L11+NOG>.LE0)KB(6<*)5 JF29+JT8_&D#&1PE#JCQ)'. RE4_K;
MBRW-[:,\.G(S('/(95(MXV)\4#7VVJ8+2^ZQ(WT,> WMN-C8M)$7?3:?!$;T
MWN"^=O5VS;6P%/*5K/[[=GWW6*9S7=^_,_\N9\1WZK="WA:%W"Y0DF:*4)-1
M(=#_0W$ 6:A5(HLQ)BP-"4^H?69*Q]:M/H=)\TONX8*5P7L#UM(AOX(K^?V+
M76,0.MD1ZQ(Q^*G!_F?PUE3#:PA^5Q%<6@!S!7\S.2V,$>/Q+7)>KC&7:]//
MQ?L3$#\4_TXKD@,9[%B>='WB9&N5 TUM+UP.?<1 IY%_D6)GAAS]M-U#M<^B
MGRT^E0?KY;?M"VW;[XLT2% H](!+8ZY=R$2&4+]V,10J2H(T0ZE*$B<7TJ[=
MV3F4-6SC+K6  X/<T;&T)-[2S?1/Y]A.9P>3X',)&QC<H 3NTQ]UH\JK=VK9
M]+2^JAL?)YZKX^U#3\.]U./DAJ[>KH7\]K_E]P7+9!82/9V-4I1 %"JLO56>
MP2S2DUTN@R055B=<+K8P-^FI3W[5*$$)$VB<KB?BCHGL7W.ZFIZ1I<29F0&G
MXBY8?_6QN./G3GPN[H)9IP?C+EWH/BVM8CD^R,<Z.5A3<&A!8TE4&@60QTS/
M/Q.:0,8%@6F*,5:)_MBIU2I55R-S^Z@KG&"S!PH>*Z3V,Y^+?/9/*7VP-/*W
M71-TP-@<F+),$M+)D/TDT =3$\WV!C#F-)OKHZ)CVG;QULGF9WW@VQ.QWFN'
MS;C*H+9;SC<[*9I\P"8<?K<IT^L)3#$+L-+LQ2:0A :015A %' 9!C04D0Q<
M)EK=S<U-#VN@(#>HW294/;S:S:/\L36V+AJ@H*&K!?4&U&#]S9CL2/$Y4>II
M<=+YD9WUQ],BR[N&28A^[NYAMS*+X&4[9[(,-:F2XR3%3,^2PI1E$!%!(<DX
MAC&G.*:8ZY^=3AU:MSQ#86F @^K;Z4BGY28\]KUAIT&C<#RR'-W>O7Q[(>_8
M"$%RS@SYU";[QB>5*6=.CA7+_0'N<[\Z&O=0!J&2P_KS"%C ,I[$$%,A(0I-
M:6Z!"8QPPF4:Q((Q;#L![&QI;N+4G%9KE>[H&<,=F>V?"GKC:V2AZ<3I9X)C
M147'+*?[_LFF.E9FM.<[=C<,\UB.SNCL3P.;<T!WNVVQI6NQ7-^_H,62WZ[%
MJ^5JIZ]>) D.&$XY9.8$+<JHA#C+%*1Q1CA/,IQ2IUVG83!F)Q?'*8AXG3JA
MJH.9'PP!I27E:5=1V0)^&I0]86#_V3D\X_?*V*)TG(ZGE1VAZI.6&3>M3JE-
M\><974>E3S=I()))?:;KV#IVH*Y\VA4YYE[T'[9\<2&C3@O8AWRU>I-OS!\7
M)$Q"@K) ^UXJ@B@0,20!11!%DD6Q#)7(W%+)C@)S;L)\_-D/R/'FOROM-/CY
M.VADC?:9FZUE+/ALS 6UO3[#%$;M$._IU/PCG3Y5VFALGTV#-EYK ]+F7 KB
M"(^BD;($Q1E/%>1I&$,DS1YM%J4PDH1&*A0BY9EU-AO+1N>F\M?'@#E1WC]W
M'X/(L=6X*_HK=(G_&DZL_>[O& 1/M!O<3;2G)#*.]'3E=K%]U'0I5QR->Y()
MQ?7>P75E]/2_/#)2^9VWN^V7?+/\+ST#ETQ1%9#,U, SASH4A9BB%&(1<R1%
M$&E??J$G+"RW3CQYN367][_=YGBO_Y.DDG0/](HTDAU<VWG:GO@;6:!KXDJ8
M-\TJQ@&IUV(R?71X+B9SL;FIB\GTV7VFF$SO+5>6G[\5_[$KMF9<VB=P+!8B
M%EQ)G,(T2$U@7HHA4UD*DYC&.& "!3&V.QAFU9[55S#I4;"_42T7I@L!_U)F
M&#3_W.=Z-T-KDYYVU2R>#ZQ/?Y9_LR>6R3B#82)C4W30G)[7_$N2R3#C<1!D
MD<MBS/7L3^AM/S/W=IKNC=&15?V0&QX<D+;R97H($72BQ*>R=S<XJ;9;V7ZL
M[G8WN>E[L=DNWF]RL>/;XG8M/LK-UR6715UC,^0LC@@+8)K$9;TP 7&@.,Q"
MR:- 8<43J\E\9RMSTY,::+G]4B-UK&+:36JW8'BC:F2A&,22M498L="A#?K^
MEB[H?QUK0G<#DVB!E8V-!MA=/+!<NIYZ4@VU22JP%HVHO,DW34MWFY<KNGPH
M%BJ6,F5*0L2#"")!,20HU3_)+(IEEFHWQ"E@T*GUN6E%E1"#MW<+Y+=']]1W
M;EU@YW*,1NS(RM+@/B0<,1K38"\+/C3H3>& "K_'HNM#:/-:@]T)P+0EV8=P
M<U*A?=!#AIX*_?A%KE9F$X6NOR\D8E@BRJ%$:0I1IBBD*&(P4T&0!(%")+0Z
M0';^\7,3I_K48PD1U!A=SX(^H:];=ZXG961A<>)CP G0<V9???SSR4,G/OMY
MSJ#3@Y]GKYHX5N4P-3HLHS>YP/\M7^G'F&G_![J5ORS7RX?=PX*%E 5,"<BB
M.-92(!AD(48PR5)& H8#*IQ.44T'?6XR<P!Y QXJB."G1ZF?OMX.*6(X3?_;
M^5#S[-6QMUZO#X1I+R,="+@!#07@P $P)-R FH89A,<,[KI9A,RXH_\QPF@&
M]XJWT)KA"(8-AKIMLP=LIOOE,4&Z*FZ9*3W,;<^J=CQA1G+3H"RG>0U.\+E!
MZC%BSH(/G]]P5W.3?G06=A]_)3:W#(Q%H,47_53S'U/.Y2M=F2/S[_/5DG\_
MA-Z@C"JI8CU)"TT86:K2RE&3G.$P4VF6I;%3,4R;5N?F61FTY5=1_M#"[1B1
M8,6X96R";Q['CE*X1.$-J$"#S_5_1TDEYD27UR@&JX:GC6=PX>(DLL'IYB$Y
MAYYD4-0/?UVMX]ZNUSN3U:A)M6C^]+Z:W"Q8@*,4,:D[(140,19!G$429AD7
M@C(4"6)=V&D(@+GIU4E"W/)T=[T@?J,_0V,)6#;)1I?KZH*?J![[@=N,<7"?
M=<O<%#TQLN(-@>\K[\]PXCIS @UX[(3Y@H8;_327T!7/&1C3E6_D\GY=G>+5
M,JIG0(7V[_2\QN2X>"&5_OLG^FV14A5F 1401TFB98Y0B%.)(0X%#PC+4)@X
M'?6R;'=NZF; @7QM-J ,?,!K_&![,,#1,[/M 3O?; 1>1]:J&C%H((,69F!
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MM8=:__:-E M%,QDK3"$.,A-CAK%VO@6'*@H9R400*8EL5Q;Z&IN;9M7( &T
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M)"*0*,D@IDI:/UXS*'F:()XB1B/DW>]O_]E3LU"WX@66QSH%V^6<HBO &)B
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MH7W1.<F,H5($G28:0,:I<6TE&OC-">=9&V#(*0S:8KG5Q R])^PW)UUW6X9
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MQ:[@:U6>5*Q+'A*D<LY)#%"22=-F2YM\7 H(9ZE0<7G80V11O[8^%7Q;V'D
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M.IKG^I^?__-T^B7,B)W5T?I%6"Z_3N?'_Q%FISCQAG,5R"W/23A0.4EPM,A
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M>:_6TY--PM?I'(UT"EBHHQHK]2'1RDB<J2A\"+&-B;Y.QKCY]4:H.4#2(^=
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M\,.=D+8S5>-L9,,H?M%:"R,G 7Z=D_1_F]:'G0\?"U((74@H+%333?8[J*1
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MMN%!<T'^4,DZ&9TB1\D#1%&OE:IZ&\EGD^Y7[[?4D^\!8II5Q8[S4.-HX0\
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M2P$"% ,4    " #W,VQ/4,$B_F\(   L+P  &0              @ $
M83(P,3EQ,V5X,S$Q+7AN97AT9V5N+FAT;5!+ 0(4 Q0    ( /<S;$]ETP A
M= @  !(N   9              "  :8(  !A,C Q.7$S97@S,3(M>&YE>'1G
M96XN:'1M4$L! A0#%     @ ]S-L3X\?Y0* !0  _AH  !D
M ( !41$  &$R,#$Y<3-E>#,R,2UX;F5X=&=E;BYH=&U02P$"% ,4    " #W
M,VQ/2DYM)8P%  !D&P  &0              @ $(%P  83(P,3EQ,V5X,S(R
M+7AN97AT9V5N+FAT;5!+ 0(4 Q0    ( /<S;$_10%[_$@$" $]Z%P 0
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M2P$"% ,4    " #W,VQ/^?ZY\9VR 0 $!P( $P              @ '*D (
M;6)X+3(P,3DP.3,P7V<Q+FIP9U!+ 0(4 Q0    ( /<S;$_U4Z)4H<$  /H^
M"  4              "  9A#! !M8G@M,C Q.3 Y,S!?;&%B+GAM;%!+ 0(4
M Q0    ( /<S;$_;9)RQJ'(  &\J!0 4              "  6L%!0!M8G@M
F,C Q.3 Y,S!?<')E+GAM;%!+!08     "P + .$"  !%> 4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6636871328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NatureOfBusinessAndLiquidityTextBlock', window );">Nature of Business and Liquidity</a></td>
<td class="text">Nature of Business and Liquidity<div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, with its focus on the treatment of highly resistant cancers via the development of its oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI formed Moleculin Australia Pty. Ltd., (MAPL), a wholly owned subsidiary in June 2018, to begin preclinical development in Australia for WP1732, an analog of WP1066. This enables the Company to enjoy the benefits of certain research and development tax credits in Australia. In February 2019, the Company entered into an agreement with Animal Life Sciences, LLC ("ALI"), where the Company has granted a sublicense to ALI to research, develop, make, have made, use, offer to sell, sell, export or import and commercialize certain licensed products for non-human use and share development data. ALI issued to the Company a 10% interest in ALI. ALI converted into a corporation and became Animal Life Sciences, Inc. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Core Technologies - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">MBI has three core technologies with six drug candidates, all of which are based on discoveries made at MD Anderson. These core technologies are 1) Annamycin, 2) its STAT3 Immune/Transcription Modulators, or simply "Immune/Transcription Modulators" WP1066 portfolio and 3) its Metabolism/Glycosylation Inhibitor portfolio, WP1122. The Company&#8217;s clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We have completed full enrollment and begun treating patients with WP1220, an analog of WP1066, for the topical treatment of cutaneous T-cell lymphoma ("CTCL"), a form of skin cancer, in a clinical trial approved by Polish regulators in January 2019. MBI is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors. With the approval of the Polish clinical trial in January 2019 for WP1220 for the treatment of CTCL, the Company now has three drugs in four clinical trials.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company believes Annamycin is a "Next Generation Anthracycline" since it is designed to avoid the multidrug resistance mechanisms that typically defeat currently approved anthracyclines, as well as to be non-cardiotoxic, which is the dose limiting toxicity of all currently approved anthracyclines. Annamycin is currently in two Phase I/II clinical trials, and preliminary clinical data suggests that it may have the potential to become the first therapy suitable for the majority of relapsed or refractory AML patients regardless of gene mutations. Additionally, preclinical research in animal models at MD Anderson demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs. Coupled with research demonstrating that Annamycin is capable of accumulating in the lungs at very high levels, this suggests that Annamycin may be well suited to become a treatment for lung-localized tumors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">WP1066 is one of several Immune/Transcription Modulators that appear capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells ("TRegs") while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1&#945;. These transcription factors are widely sought targets that may also play a role in the lack of efficacy of immune checkpoint inhibitors in certain resistant tumors.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company is also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis and glycosylation. Its lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy ("2-DG") within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Drug Candidates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> - Within the Company's core technologies, it currently has six drug candidates representing three substantially different approaches to treating cancer. Annamycin is a chemotherapy designed to inhibit the replication of DNA of rapidly dividing cells and is the Company's most mature drug candidate. Annamycin had been in clinical trials pursuant to an investigational new drug application or IND that had been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, the Company resubmitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which the FDA allowed to go into effect in September 2017. The Company has trials open in the US and Poland and is actively recruiting in both countries.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has five other drug development projects, two of which are also in clinical trials:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1066 has an approved physician-sponsored clinical trial open for enrollment and dosing patients for the treatment of brain tumors and is also being evaluated for another physician-sponsored clinical trial for the potential treatment of pediatric brain tumors, as well as AML and pancreatic cancer,</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1220 is an analog of WP1066 for which Polish authorities in January 2019 approved the Company's Clinical Trial Application ("CTA") to study the topical treatment of CTCL, which study reached full enrollment in August 2019,</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1732, another analog of WP1066, is being evaluated along with WP1066 for the potential treatment of AML, pancreatic and other cancers, and MBI has begun pre-clinical work that it expects to generate sufficient data for an IND for an intravenous formulation of one of its STAT3 inhibitors, which filing is expected to be submitted in 2021, and </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">WP1122 and WP1234 are being evaluated for their potential to treat brain tumors and pancreatic cancer via their ability to inhibit glycolysis.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Clinical Trials - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company believes that patient recruitment for its Annamycin clinical trial in the US has been slow due to the high number of competitive clinical trials, combined with the FDA&#8217;s requirement to set the initial dose level relatively low in comparison with previous Annamycin clinical trials. Additionally, the Company believes that patient recruitment for its clinical trial in Poland has been more successful than in the US due to a comparatively lower number of competitive clinical trials and the protocol there being approved to start at a significantly higher dose than in the US with fewer enrollment screening limitations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the physician sponsored WP1066 Phase I clinical trial for the treatment of glioblastoma and melanoma metastasized to the brain, which opened for recruitment in July 2018, began treating patients.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company completed full enrollment in a proof-of-concept clinical trial in Poland to study WP1220, a part of the WP1066 portfolio, for the treatment of CTCL. Polish authorities approved the Company's CTA  for this use in January 2019, and the trial began enrolling patients in March 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Licenses - </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company has been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of MBI's drug technologies, as these intellectual property rights are owned in part or entirely by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, the Company filed new patent applications in July 2019 for formulation, synthetic process and reconstitution related to MBI's Annamycin drug product candidate, although there is no assurance that the Company will be successful in obtaining such patent protection. Such technology is also licensed from MD Anderson. Independently from potential patent protection, MBI has received Orphan Drug designation ("ODD") from the FDA for Annamycin for the treatment of AML and for WP1066 for the treatment of glioblastoma. ODD may provide tax and other benefits during product development, and if either product is approved, may lead to a grant of seven-year market exclusivity. Under that exclusivity, which runs from the date of the approval of the New Drug Application ("NDA") in the United States, the FDA generally (there are important exceptions) could not approve another product containing the same drug for the designated indication. The Company also intends to apply for similar status in the European Union ("EU") where market exclusivity could extend to 10 years from the date of Marketing Authorization Application ("MAA") approval. Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (which the Company believes Annamycin would be one), which would preclude approval of any other annamycin product, but there can be no assurance that such exclusivity will be granted. In April 2019, FDA approved the Company's request for Fast Track Designation for Annamycin for the treatment of relapsed or refractory AML. Fast Track Designation, the purpose of which is to expedite drug development and approval, is granted to drugs intended to treat serious conditions and where data demonstrate the potential to address an unmet medical need.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Moleculin, LLC -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> Prior to MBI's initial public offering, the Company acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NatureOfBusinessAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NatureOfBusinessAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6641046416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining three months)</a></td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6807576624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,785,000<span></span>
</td>
<td class="nump">1,332,000<span></span>
</td>
<td class="nump">7,816,000<span></span>
</td>
<td class="nump">6,801,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,672,000<span></span>
</td>
<td class="nump">1,248,000<span></span>
</td>
<td class="nump">4,748,000<span></span>
</td>
<td class="nump">3,859,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,508,000<span></span>
</td>
<td class="nump">2,591,000<span></span>
</td>
<td class="nump">12,711,000<span></span>
</td>
<td class="nump">10,687,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,508,000)<span></span>
</td>
<td class="num">(2,591,000)<span></span>
</td>
<td class="num">(12,711,000)<span></span>
</td>
<td class="num">(10,687,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liability</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">573,000<span></span>
</td>
<td class="nump">3,059,000<span></span>
</td>
<td class="nump">1,614,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before taxes</a></td>
<td class="num">(4,374,000)<span></span>
</td>
<td class="num">(2,038,000)<span></span>
</td>
<td class="num">(9,637,000)<span></span>
</td>
<td class="num">(9,091,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">229,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,145,000)<span></span>
</td>
<td class="num">$ (2,038,000)<span></span>
</td>
<td class="num">$ (9,408,000)<span></span>
</td>
<td class="num">$ (9,091,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (usd per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding Basic and diluted (shares)</a></td>
<td class="nump">45,464,746<span></span>
</td>
<td class="nump">26,861,497<span></span>
</td>
<td class="nump">39,034,303<span></span>
</td>
<td class="nump">25,373,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="num">$ (16,000)<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,148,000)<span></span>
</td>
<td class="num">$ (2,023,000)<span></span>
</td>
<td class="num">$ (9,424,000)<span></span>
</td>
<td class="num">$ (9,070,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6657161632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Components of Stock Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6615898544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>drug </div>
<div>technology </div>
<div>project </div>
<div>clinicalTrial </div>
<div>candidate</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NumberOfDrugTechnologies', window );">Number of core drug technologies | technology</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NumberofDrugCandidates', window );">Number of drug candidates | candidate</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NumberofDrugsinClinicalTrials', window );">Number of drugs in clinical trials | drug</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NumberofClinicalTrials', window );">Number of clinical trials | clinicalTrial</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_NumberOfOtherDrugDevelopmentProjects', window );">Number of other drug development projects | project</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_AuthorityAxis=mbx_FoodAndDrugAdministrationMember', window );">Food and Drug Administration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_MarketExclusivityExtensionPeriod', window );">Market exclusivity extension period (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_MarketExclusivityExtensionPeriod', window );">Market exclusivity extension period (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mbx_AnimalLifeScienceMember', window );">Animal Life Science</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_MarketExclusivityExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market Exclusivity Extension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_MarketExclusivityExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NumberOfDrugTechnologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NumberOfDrugTechnologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NumberOfOtherDrugDevelopmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NumberOfOtherDrugDevelopmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NumberofClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NumberofClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NumberofDrugCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NumberofDrugCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_NumberofDrugsinClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_NumberofDrugsinClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_AuthorityAxis=mbx_FoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_AuthorityAxis=mbx_FoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mbx_AnimalLifeScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mbx_AnimalLifeScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808395648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation, principles of consolidation and significant accounting policies - Fair Value Measurement (Details) - Fair Value, Inputs, Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant Liability Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 6,944<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(3,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">6,820<span></span>
</td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant Liability Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant Liability Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">6,944<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(3,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 6,820<span></span>
</td>
<td class="nump">$ 6,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabilityCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabilityCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabilityLongtermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabilityLongtermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabiltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbx_WarrantLiabiltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>